<SEC-DOCUMENT>0001043961-17-000009.txt : 20170518
<SEC-HEADER>0001043961-17-000009.hdr.sgml : 20170518
<ACCEPTANCE-DATETIME>20170518143441
ACCESSION NUMBER:		0001043961-17-000009
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20170331
FILED AS OF DATE:		20170518
DATE AS OF CHANGE:		20170518

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TRANSGENOMIC INC
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36439
		FILM NUMBER:		17854543

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		4027385480

	MAIL ADDRESS:	
		STREET 1:		12325 EMMET STREET
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tbio-20170331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA5C428EDC1D456C0B01133C926F101E4"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;_______________________________</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM </font><font style="font-family:inherit;font-size:18pt;font-weight:bold;">10-Q</font><font style="font-family:inherit;font-size:18pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;_______________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Mark One)</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended March 31, 2017</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OR</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from _____ to _____</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: 000-36439</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;_______________________________</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">TRANSGENOMIC, INC.</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;_______________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:47%;"></td><td style="width:5%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">91-1789357</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12325 Emmet Street, Omaha, Nebraska</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">68164</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(402) 452-5400</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;_______________________________</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x </font><font style="font-family:inherit;font-size:10pt;">No&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;Yes&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x </font><font style="font-family:inherit;font-size:10pt;">No&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:46%;"></td><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-top:4px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of April 30, 2017, the number of shares of common stock outstanding was </font><font style="font-family:inherit;font-size:10pt;">26,863,062</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><hr style="page-break-after:always"><div><a name="s2446C485322952F2AE8B8B1956C96911"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC.</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:83%;"></td><td style="width:7%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Page&#160;No.&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;I.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s58FC984C4593510A830C0B0E623D5627"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s58FC984C4593510A830C0B0E623D5627"> 3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s661EC54BDAF25216B8348D358CC6926C"><font style="font-family:inherit;font-size:10pt;">Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s661EC54BDAF25216B8348D358CC6926C"> 3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC5AF5E288626586C8AC933D58343880F"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets at March 31, 2017 (Unaudited) and December 31, 2016</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC5AF5E288626586C8AC933D58343880F"> 3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s11780AA2483F52848F22E7F7B0E6AAA6"><font style="font-family:inherit;font-size:10pt;">Unaudited Condensed Consolidated Statements of Operations for the Three Months Ended March 31,&#160;2017 and 2016</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s11780AA2483F52848F22E7F7B0E6AAA6"> 4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s82066475AB3C526281100C7F8653A575"><font style="font-family:inherit;font-size:10pt;">Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31,&#160;2017 and 2016</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s82066475AB3C526281100C7F8653A575"> 5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBA54661FC72D5558B5BFB1A1EC03F533"><font style="font-family:inherit;font-size:10pt;">Notes to Unaudited Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;2.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBD797332F2DF511C815F4DC7DC9815B0"><font style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBD797332F2DF511C815F4DC7DC9815B0"> 22</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;3.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s08425E8FA6D4503EA7A74A7384042AF4"> 26</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;4.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1DC49D17F43552258D10FA86A0020A89"><font style="font-family:inherit;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1DC49D17F43552258D10FA86A0020A89"> 27</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;II.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8926D75C802E5A2291EB5963AD32C4D4"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8926D75C802E5A2291EB5963AD32C4D4"> 28</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB66B232CD6C75035BE9523D31105BFCB"><font style="font-family:inherit;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB66B232CD6C75035BE9523D31105BFCB"> 28</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1A.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE4DF711E6A045119A93D789A468CE3B6"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE4DF711E6A045119A93D789A468CE3B6"> 29</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;6.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s29C797C4B1B353D2B5726FB424170B33"><font style="font-family:inherit;font-size:10pt;">Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s29C797C4B1B353D2B5726FB424170B33"> 30</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s7698DB28155955F487B63962D98DED99"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7698DB28155955F487B63962D98DED99"> 31</a></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;2</font></div></div><hr style="page-break-after:always"><div><a name="s58FC984C4593510A830C0B0E623D5627"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I. FINANCIAL INFORMATION</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div><a name="s661EC54BDAF25216B8348D358CC6926C"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements</font></div></td></tr></table><div><a name="sC5AF5E288626586C8AC933D58343880F"></a></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Dollars in thousands, except share data)</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT ASSETS:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">279</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">567</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">495</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PROPERTY AND EQUIPMENT, NET</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER ASSETS:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangibles, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,259</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT LIABILITIES:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current maturities of long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,368</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,814</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,509</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,541</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,129</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,824</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LONG TERM LIABILITIES:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">582</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,872</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,609</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCKHOLDERS&#8217; DEFICIT:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock, $0.01 par value, 15,000,000 shares authorized, 214,705 shares issued and outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $0.01 par value, 150,000,000 shares authorized, 26,863,062 shares at March 31, 2017 and 26,446,927 shares at December 31, 2016 issued and outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital  </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206,342</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205,877</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(227,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(225,493</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,643</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,259</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See notes to unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;3</font></div></div><hr style="page-break-after:always"><div><a name="s11780AA2483F52848F22E7F7B0E6AAA6"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Dollars in thousands, except per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:73.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NET SALES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">658</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COST OF GOODS SOLD</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">505</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OPERATING EXPENSES:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,754</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OPERATING LOSS FROM CONTINUING OPERATIONS</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,555</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,243</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER INCOME (EXPENSE):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(247</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(169</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant revaluation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(280</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INCOME TAX EXPENSE (BENEFIT)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LOSS FROM CONTINUING OPERATIONS</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCOME (LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAXES</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NET LOSS </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,762</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PREFERRED STOCK DIVIDENDS</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET LOSS FROM CONTINUING OPERATIONS AVAILABLE TO COMMON STOCKHOLDERS</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,484</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET INCOME (LOSS) FROM DISCONTINUED OPERATIONS AVAILABLE TO COMMON STOCKHOLDERS</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NET LOSS AVAILABLE TO COMMON STOCKHOLDERS</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,762</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,657</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BASIC AND DILUTED LOSS PER COMMON SHARE  FROM CONTINUING OPERATIONS </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BASIC AND DILUTED INCOME (LOSS) PER COMMON SHARE FROM DISCONTINUED OPERATIONS </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BASIC AND DILUTED LOSS PER COMMON SHARE  </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,779,835</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,323,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See notes to unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;4</font></div></div><hr style="page-break-after:always"><div><a name="s82066475AB3C526281100C7F8653A575"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Dollars in thousands)</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br>&#160;March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CASH FLOWS USED IN OPERATING ACTIVITIES:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,762</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less income (loss) from discontinued operations, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from continuing operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash flows used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation and change in liability of stock appreciation rights</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for losses on doubtful accounts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant revaluation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on settlement of lease termination</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">358</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,967</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,230</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(587</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities, continuing operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(130</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,312</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) operating activities, discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(612</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,924</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CASH FLOWS USED IN INVESTING ACTIVITIES:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CASH FLOWS (USED IN) PROVIDED BY FINANCING ACTIVITIES:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal payments on capital lease obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of preferred stock and warrants, net of costs of $219</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal payments on debt</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(550</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash flows (used in) provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,728</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NET CHANGE IN CASH AND CASH EQUIVALENTS</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">444</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CASH AND CASH EQUIVALENTS AT END OF PERIOD</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUPPLEMENTAL CASH FLOW INFORMATION</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid during the period for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initial valuation of warrant issued in conjunction with Private Placement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,827</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion of convertible promissory notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt settled with issuance of preferred stock and warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See notes to unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;5</font></div></div><hr style="page-break-after:always"><div><a name="sBA54661FC72D5558B5BFB1A1EC03F533"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div><a name="s138E68534ED05D70B466E466272FB2C8"></a></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.  BUSINESS DESCRIPTION</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Description</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transgenomic, Inc., and Subsidiary, (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, the &#8220;Company&#8221; or &#8220;Transgenomic&#8221;) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and integrated diseases through our proprietary molecular technologies and clinical and research services. A key goal is to bring our Multiplexed ICE COLD-PCR (&#8220;MX-ICP&#8221;) product to the clinical market through strategic partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring and treatment of cancer.</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MX-ICP is technology proprietary to Transgenomic. It is a reagent that improves the ability to detect genetic mutations. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital PCR. By enhancing the level of detection of genetic mutations and suppressing the normal or wild-type DNA, several benefits are provided.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, our operations were organized and reviewed by management along our major product lines and presented in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;business segments: Laboratory Services and Genetic Assays and Platforms. Beginning with the quarter ended September 30, 2015, our operations are now organized as </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;business segment, our Laboratory Services segment, and during the fourth quarter of 2015, we began including a portion of our Laboratory Services segment as discontinued operations, this has continued through March 31, 2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our current Laboratory Services business consists of our laboratory in Omaha, Nebraska, which is focused on providing genetic analytical services related to Oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing service technologies, including our proprietary MX-ICP technology. Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;) as a high complexity laboratory and is accredited by the College of American Pathologists.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed consolidated balance sheets, statements of operations and statements of cash flows for all periods presented reflect our former Genetic Assays and Platforms activities and Patient Testing business as discontinued operations (See Note 3 - &#8220;Discontinued Operations&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Going Concern</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America applicable for a going concern, which assume that we will realize our assets and discharge our liabilities in the ordinary course of business. We have incurred substantial operating losses and have used cash in our operating activities for the past few years. As of March 31, 2017, we had negative working capital of </font><font style="font-family:inherit;font-size:10pt;">$20.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and we were also not in compliance with our loan agreement due to the fact that events of default existed, including our failure to make certain required monthly interest payments to the lenders. The Company&#8217;s ability to continue as a going concern is dependent upon a combination of completing its planned merger with Precipio Diagnostics, LLC (&#8220;Precipio&#8221;), generating additional revenue, improving cash collections, potentially selling underutilized assets and/or product lines related to discontinued operations and, if needed, raising necessary financing to meet its obligations and pay its liabilities arising from normal business operations when they come due. Following the planned merger, Transgenomic will change its name to Precipio, Inc. (&#8220;New Precipio&#8221;). On February 17, 2017, Transgenomic received written notification from the staff of Nasdaq that, as a result of Transgenomic&#8217;s inability to maintain certain Nasdaq continued listing requirements, Nasdaq had determined to delist Transgenomic&#8217;s shares from Nasdaq.  Accordingly, trading in Transgenomic&#8217;s shares was suspended, and on February 22, 2017, Transgenomic&#8217;s shares began trading on the OTCQB exchange under the ticker &#8220;TBIO&#8221;.  As discussed below upon completion of the merger, the New Precipio common stock will be required to meet the Nasdaq listing standards.  As a result of the merger, New Precipio is expected to meet Nasdaq's initial listing requirements.  In addition, at the time of the merger the Company intends to execute a reverse stock split. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern for the next twelve months from the date of issuance of these condensed financial statements. These condensed consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. There is no assurance that the Company will complete the merger in a timely manner or at all. The merger agreement is subject to many closing conditions and termination rights. The Company </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">also cannot be certain that additional financing, if needed, will be available on acceptable terms, or at all, and its failure to raise capital when needed could limit its ability to continue its operations.</font></div><div style="line-height:174%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Merger Agreement</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 12, 2016, Transgenomic, New Haven Labs Inc., a wholly owned subsidiary of Transgenomic (&#8220;Merger Sub&#8221; and, together with Transgenomic, the &#8220;Transgenomic Parties&#8221;), and Precipio entered into an Agreement and Plan of Merger (as amended by the Merger Agreement Amendment (as defined below) the &#8220;Merger Agreement&#8221;) pursuant to which Precipio will become a wholly owned subsidiary of Transgenomic (the &#8220;Merger&#8221;), on the terms and subject to the conditions set forth in the Merger Agreement. On February 2, 2017, Transgenomic, Merger Sub and Precipio entered into a First Amendment to Agreement and Plan of Merger (the &#8220;Merger Agreement Amendment&#8221;), which provided for, among other things, the revision of the exchange ratio set forth in the Merger Agreement, the waiver and removal of certain closing conditions and the authorization of certain actions taken by each of Transgenomic and Precipio since the date the Merger Agreement. The parties expect the Merger to close in the second quarter of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the effectiveness of the Merger (the &#8220;Effective Time&#8221;), (i)&#160;the outstanding common units of Precipio will be converted into the right to receive approximately </font><font style="font-family:inherit;font-size:10pt;">160.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock of New Precipio (&#8220;New Precipio common stock&#8221;), together with cash in lieu of fractional units, which will result in Precipio common unit holders owning approximately </font><font style="font-family:inherit;font-size:10pt;">52%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the issued and outstanding shares of New Precipio common stock on a fully diluted basis, taking into account the issuance of shares of convertible preferred stock of New Precipio (&#8220;New Precipio preferred stock&#8221;) in the Merger and the private placement as discussed below (the &#8220;fully diluted New Precipio common stock&#8221;) and (ii)&#160;the outstanding preferred units of Precipio will be converted into the right to receive approximately </font><font style="font-family:inherit;font-size:10pt;">24.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of New Precipio preferred stock with an aggregate face amount equal to </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(based upon the purchase price of the new preferred stock of New Precipio in the new preferred stock financing), which will result in the Precipio preferred unit holders owning approximately </font><font style="font-family:inherit;font-size:10pt;">8%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the fully diluted New Precipio common stock.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon completion of the merger, New Precipio will be required to meet the initial listing requirements to qualify its shares for listing and begin trading of its shares on Nasdaq. These initial listing requirements are more difficult to achieve than the continued listing requirements.&#160; Pursuant to the Merger Agreement, Transgenomic agreed to use its commercially reasonable efforts to cause the shares of Transgenomic common stock being issued in the merger to be approved for listing on Nasdaq at or prior to the effective time of the merger. Based on information currently available to Transgenomic, Transgenomic anticipates that its stock will be unable to meet the </font><font style="font-family:inherit;font-size:10pt;">$4.00</font><font style="font-family:inherit;font-size:10pt;">&#32;(or, to the extent applicable, </font><font style="font-family:inherit;font-size:10pt;">$3.00</font><font style="font-family:inherit;font-size:10pt;">) minimum bid price initial listing requirement at the closing of the merger unless it effects a reverse stock split. On October 31, 2016, the stockholders of Transgenomic authorized the Transgenomic Board to effect a reverse stock split of the shares of Transgenomic common stock at a ratio of between one-for-ten to one-for-thirty, such ratio to be determined by our Board of Directors (the &#8220;Reverse Split Proposal&#8221;).  The Reverse Split Proposal was described in detail in our definitive proxy statement filed with the Securities and Exchange Commission on September 22, 2016, as supplemented on October 13, 2016.&#160; In addition, often times a reverse stock split will not result in a trading price for the affected common stock that is proportional to the ratio of the split.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s0568297D3C6E5EDB8C53AB58E70AE5DB"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are presented in conformity with GAAP. Supplemental cash flows from discontinued operations are presented in Note 3 - &#8220;Discontinued Operations&#8221;. We have evaluated events occurring subsequent to March 31, 2017 for potential recognition or disclosure in the condensed consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2016. The accompanying condensed consolidated financial statements as of and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 13, 2017. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2017.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risks and Uncertainties.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements.  The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise specified, book value approximates fair value. The common stock warrant liability is recorded at fair value.  See Note 8 - &#8220;Fair Value&#8221; for additional information.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents and Other Current Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less. Other current assets as of March 31, 2017 of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;include prepaid assets of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and other receivables of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Cash.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits.  We have not experienced any losses on such accounts as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense in continuing operations related to property and equipment was less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for each of the three month periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. Depreciation expense during each period includes depreciation related to equipment acquired under capital leases. </font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense for intangible assets was less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the three month periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. Amortization expense for intangible assets is expected to be </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for each of the years ending December 31, 2017, 2018 and less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for each of the years ending December 31, 2019, 2020 and 2021.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">-year contractual terms. Unvested awards as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;had vesting periods of up to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;years from the date of grant. None of the awards outstanding at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;are subject to performance or market-based vesting conditions.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2016, we recorded compensation expense for all stock awards of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, within selling, general and administrative expense. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the unrecognized compensation expense related to unvested stock awards was less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;year.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in our stock awards outstanding as of March 31, 2017 were fully vested stock appreciation rights (&#8220;SARs&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">to purchase </font><font style="font-family:inherit;font-size:10pt;">83,333</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock. The SARs were issued solely to our executive officers and vested over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;years from the date of grant. </font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Sales Recognition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:66px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is realized and earned when all of the following criteria are met:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persuasive evidence of an arrangement exists;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delivery has occurred or services have been rendered;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The seller&#8217;s price to the buyer is fixed or determinable; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collectability is reasonably assured.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;In our Omaha, Nebraska laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year.  At each of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue were </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales from Patient Testing laboratories are reported as part of discontinued operations (See Note 3 - &#8220;Discontinued Operations&#8221;) and are recognized on an individual test basis and, since collectability is not reasonably assured, are recognized when cash is received. There are no deferred net sales associated with our Patient Testing services. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loss Per Share.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period.  Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to </font><font style="font-family:inherit;font-size:10pt;">4,425,218</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">12,970,881</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock have been excluded from the computation of diluted loss per share at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, because the effect is anti-dilutive due to the net loss.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers. This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year.  As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company adopted ASU No. 2016-09 as of January&#160;1, 2017. The adoption of this guidance does not have a material effect on the Company&#8217;s financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August&#160;2016, FASB issued ASU No.&#160;2016-15</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">Classification of Certain Cash Receipts and Cash Payments.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">ASU No.&#160;2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No.&#160;2016-15 is effective for fiscal years </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">beginning after December&#160;15, 2017, and for interim periods within that fiscal year. We do not believe ASU No.&#160;2016-15 will have a material effect on our financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, FASB issued ASU No.&#160;2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business.  ASU No. 2017-01adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within those fiscal years. The Company does not believe ASU No. 2017-01 will have a material effect on its financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC544C8679BDF5188BBCD98A9A7B60296"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.  DISCONTINUED OPERATIONS</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;In March 2016, we halted testing services in our Patient Testing laboratory in New Haven, Connecticut. As a result of this action, as of December 31, 2015, our Patient Testing business met the criteria to be reported as discontinued operations. The related assets, liabilities, results of operations and cash flows for the Patient Testing business are classified as assets held for sale, liabilities held for sale and discontinued operations for all periods presented.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results of the discontinued operations consisted of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three months ended     March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,183</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,025</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss) from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on settlement of liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At March 31, 2017 and December 31, 2016, the Company had assets of the discontinued operations of less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;which were classified as assets held for sale in the condensed consolidated balance sheets.</font></div><div><a name="s643495F990FA55B0A1F8384873CD770E"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;DEBT</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dollars&#160;in&#160;Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revolving Line of Credit</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term Loan</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible Promissory Notes </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,368</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,814</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,368</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,814</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net of current maturities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revolving Line of Credit.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6.25%</font><font style="font-family:inherit;font-size:10pt;">&#32;or (b) the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wall Street Journal</font><font style="font-family:inherit;font-size:10pt;">&#32;prime rate plus </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3%</font><font style="font-family:inherit;font-size:10pt;">. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;">6.75%</font><font style="font-family:inherit;font-size:10pt;">. As discussed below under </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Additional Terms</font><font style="font-family:inherit;font-size:10pt;">, the interest rate is subject to increase if there is a default under the Loan Agreement. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20,000</font><font style="font-family:inherit;font-size:10pt;">&#32;on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line.  In addition, a fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.5%</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum is payable quarterly on the unused portion of the Revolving Line.  The Revolving Line matures on November 1, 2017.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Term Loan.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">We received </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;under the Term Loan on the Effective Date.  Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">9.1%</font><font style="font-family:inherit;font-size:10pt;">.  As discussed below, the interest rate is subject to increase if there is a default under the Loan Agreement.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will pay the Lenders an additional final payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$120,000</font><font style="font-family:inherit;font-size:10pt;">, at maturity or prepayment of the Term Loan, which has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the total outstanding balance under the Term Loan.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Additional Terms.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement contains affirmative and negative covenants.  Under the Loan Agreement, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders&#8217; consent.  Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of March 31, 2017, we were not in compliance with the Loan Agreement, as amended, due to the fact that events of default existed, including our failure to make certain required monthly interest payments.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">&#32;and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. At March 31, 2017, our applicable interest rates have been increased by </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;&#32;&#32;Convertible Promissory Notes. </font><font style="font-family:inherit;font-size:10pt;">The Notes accrue interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;">&#32;per year and matured on December 31, 2016. </font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revolving Line and Term Loan.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 13, 2013 (the &#8220;Effective Date&#8221;), we entered into a Loan and Security Agreement with affiliates of Third Security, LLC, a related party, (the &#8220;Lenders&#8221;) for (a) a revolving line of credit (the &#8220;Revolving Line&#8221;) with borrowing availability of up to </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">, subject to reduction based on our eligible accounts receivable, and (b) a term loan (the &#8220;Term Loan&#8221; and, together with the Revolving Line, the &#8220;Loan Agreement&#8221;) of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">. From the Effective Date through 2015, there were a number of amendments to the Loan Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2016, we entered into an eighth amendment to the Loan Agreement (the &#8220;Eighth Amendment&#8221;). The Eighth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) extended the maturity date of the Loan Agreement until November 1, 2017, and (d) provided for the repayment of an overadvance of </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;">&#32;previously provided by the Lenders to us pursuant to the Loan Agreement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2016, the overadvance that existed at December 31, 2015 was repaid to the Lenders and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was received from certain of the Lenders and another lender affiliate in connection with the equity offering made on January 6, 2016.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 6, 2016, we entered into a ninth amendment to the Loan Agreement (the &#8220;Ninth Amendment&#8221;). The Ninth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) amended the prepayment terms of the Loan Agreement, (c) provided for the reduction of amounts available under the Revolving Line upon the prepayment or repayment of certain amounts by us, (d) removed the minimum liquidity ratio and minimum net revenue financial covenants applicable to us under the Loan Agreement, (e) amended the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent of the Lenders, and (f) capitalized certain amounts owed by us to the Lenders and added such overdue amounts to the outstanding principal amount of the Revolving Line. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 2, 2017, we entered into a termination and tenth amendment to the Loan Agreement (the &#8220;Tenth Amendment&#8221;). The Tenth Amendment, among other things, (i) provides that the Lenders will waive specified events of default under the terms of the Loan Agreement until the effective time of the Merger (or the termination of the Merger Agreement in accordance with its terms), (ii) provides for the conversion of all outstanding indebtedness owed to the Lenders under the Loan Agreement (the &#8220;Outstanding Indebtedness&#8221;) into shares of Transgenomic common stock and preferred stock (collectively, the &#8220;Conversion Shares&#8221;) effective as of the closing date of the Merger and (iii) the termination of the Loan Documents (as defined in the Loan Agreement) and the termination and release of all security interests and liens of the Lenders in the Collateral (as defined in the Loan Agreement) in each case immediately following the conversion of the Outstanding Indebtedness into Conversion Shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effectiveness of certain provisions in the Tenth Amendment, including provisions relating to conversion of the Conversion Shares and termination of the Loan Documents, is conditioned on, among other things, the consummation of the Merger, and, in the event that the Merger is not consummated, these provisions in the Loan Agreement Amendment will terminate.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Tenth Amendment, the Lenders have agreed to convert the outstanding principal and accrued interest under the Loan Agreement into (i) approximately </font><font style="font-family:inherit;font-size:10pt;">10.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of New Precipio common stock immediately prior to the effectiveness of the Merger at a price equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">&#32;per share and (ii) </font><font style="font-family:inherit;font-size:10pt;">24.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of New Precipio preferred stock. As of March 31, 2017, the outstanding amount owed under the Loan Agreement was approximately </font><font style="font-family:inherit;font-size:10pt;">$7.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of principal and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of accrued interest. The issuance of the Conversion Shares is subject to the approval of the Transgenomic stockholders in accordance with NASDAQ Capital Market listing rules.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Promissory Notes.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 31, 2014, we entered into an Unsecured Convertible Promissory Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;) with an accredited investor (the &#8220;Investor&#8221;), pursuant to which we agreed to issue and sell to the Investor in a private placement an unsecured convertible promissory note (the &#8220;Initial Note&#8221;). We issued the Initial Note in the aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;">&#32;to the Investor on December 31, 2014. Pursuant to the terms of the Initial Note, interest accrued at a rate of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;">&#32;per year and the Initial Note was set to mature on December 31, 2016. The Initial Note has been converted in full into </font><font style="font-family:inherit;font-size:10pt;">502,786</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock, in accordance with the terms of the Initial Note. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 15, 2015, we entered into the Note Purchase Agreement with </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;">&#32;accredited investors (the &#8220;Additional Investors&#8221;) and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, notes (the &#8220;Additional Notes&#8221;) in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$925,000</font><font style="font-family:inherit;font-size:10pt;">.  We also issued, to our placement agent for the Notes, a convertible promissory note in an aggregate principal amount equal to </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the proceeds received by us, or </font><font style="font-family:inherit;font-size:10pt;">$46,250</font><font style="font-family:inherit;font-size:10pt;">&#32;(the &#8220;Agent Note&#8221;).  The Additional Notes and Agent Note have the same terms and conditions as the Initial Note.  As of December 31, 2016, </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of the aggregate principal amount of the Additional Notes and Agent Note, and accrued interest thereon, had been converted into an aggregate of </font><font style="font-family:inherit;font-size:10pt;">281,023</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On the Maturity Date, the then outstanding aggregate amount owed on the Additional Notes and Agent Note of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, including accrued interest, became due. Pursuant to the terms of the Initial Note, our failure to pay any principal or interest within </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">&#32;days of the date such payment is due will constitute an event of default (the &#8220;Prospective Event of Default&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 10, 2017, the Additional Investors and our placement agent executed a waiver of the Prospective Event of Default, pursuant to which, they agreed to waive the Prospective Event of Default on the condition that the Company and the Additional Investors enter into definitive documentation evidencing the terms for an extended maturity date of the Additional Notes and the Agent Note on or before January 16, 2017 (the &#8220;Waiver Deadline&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2017, all but one Additional Investor exercised their conversion rights relating to their respective Additional Notes, including the Agent Note, and converted an aggregate principal amount of&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.4</font><font style="font-family:inherit;font-size:10pt;">&#32;million, and accrued interest of less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, into </font><font style="font-family:inherit;font-size:10pt;">416,135</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock. The Waiver Deadline was extended with respect to the remaining Additional Investor who did not exercise conversion rights (the &#8220;Non-Converting Investor&#8221;) so that the parties could continue to discuss a resolution of the Prospective Event of Default relating to such Non-Converting Investor&#8217;s Additional Note with an outstanding principal amount due of </font><font style="font-family:inherit;font-size:10pt;">$0.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 17, 2017, the Non-Converting Investor agreed to extend the Maturity Date of its Additional Note pursuant to an amendment to the Additional Note (the &#8220;Amendment&#8221;). The Amendment provides that two-thirds of the outstanding principal amount of the Additional Note must be paid upon the earlier to occur of the close of the Company&#8217;s merger with Precipio Diagnostics, LLC or June 16, 2017 (such applicable date, the &#8220;Deferred Maturity Date&#8221;).&#160; The remaining one-third of the principal amount outstanding on the Additional Note must be paid on the six month anniversary of the Deferred Maturity Date (the &#8220;Extended Maturity Date&#8221;).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFCF0EFA125FC56ACB15E803B2744FA39"></a></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.  CONTINGENCIES</font></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to a number of claims of various amounts that arise out of the normal course of our business.  In addition to the claims described in this Note, we are delinquent on the payment of outstanding accounts payable amounting to approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;with certain of our vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, the Board of Regents of the University of Nebraska (&#8220;UNMC&#8221;) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;owed by us to UNMC.  A </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. We and UNMC entered into a settlement agreement dated February 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to UNMC in installments over a period of time. As of March 15, 2017, the initial payment due to UNMC under the settlement agreement is delinquent. We and UNMC are currently in discussions to extend the date of the initial payment due to UNMC.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, on April 13, 2016, Fox Chase Cancer Center (&#8220;Fox Chase&#8221;) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the &#8220;Court of Common Pleas&#8221;), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the &#8220;License Agreement&#8221;), as well as the assignment of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc. (&#8220;IDT&#8221;) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the &#8220;IDT Agreement&#8221;). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase&#8217;s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney&#8217;s fees.&#160; Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by us as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;On June 23, 2016, the Icahn School of Medicine at Mount Sinai (&#8220;Mount Sinai&#8221;) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;owed by us to Mount Sinai for services rendered. We and Mount Sinai entered into a settlement agreement dated October 27, 2016, which included, among other things, a mutual general release of claims, and our agreement to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to Mount Sinai in installments over a period of time. A </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.  Effective as of February 1, 2017, we and Mount Sinai agreed to amend the terms of our settlement agreement to extend the date of the initial payment due to Mount Sinai.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 19, 2016, Todd Smith (&#8220;Smith&#8221;) filed a lawsuit against us in the District Court of Douglas County Nebraska, alleging breach of contract and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;owed by us to Smith for costs and damages arising from a breach of our obligations pursuant to a lease agreement between the parties.  On April 7, 2017, we entered into a settlement agreement with Smith related to the early termination of our lease for our Omaha, Nebraska facility. The agreement included, among other things, a mutual general release of claims, and our agreement to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to Smith in installments over a period of time. A </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;liability has been recorded and is reflected in accrued expenses at March 31, 2017. The accrued </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">liability includes </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;recorded as a net loss on the settlement and is included in other expense in our condensed consolidated statements of operations for the three months ended March 31, 2017. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 21, 2017, XIFIN, Inc. (&#8220;XIFIN&#8221;) filed a lawsuit against us in the District Court for the Southern District of California alleging breach of written contract and seeking recovery of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.27 million</font><font style="font-family:inherit;font-size:10pt;">&#32;owed by us to XIFIN for damages arising from a breach of our obligations pursuant to a Systems Services Agreement between us and XIFIN, dated as of February 22, 2013, as amended and restated on September 1, 2014. On April 5, 2017, the court clerk entered default against us. On May 5, 2017, XIFIN filed an application for entry of default judgment against us. A </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and Science Park Development Corporation (&#8220;SPDC&#8221;) entered into that certain Lease dated as of December 31, 2011, as modified by the First Amendment to Lease dated as of June 18, 2013, as further modified by a letter agreement dated as of February 2, 2015, as modified by the Second Amendment to Lease dated as of June 26, 2015 (the &#8220; SPDC Lease&#8221;).   In November 2016, SPDC alleged that we defaulted on our obligations under the SPDC Lease.  Specifically, SPDC alleges that we failed to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in rental payments due under the SPDC Lease and that we vacated a portion of the leased premises in violation of the terms of the SPDC Lease.  We and SPDC entered into a settlement agreement dated March 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to SPDC in installments over a period of time. This liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CPA Global provides us with certain patent management services.  On February 6, 2017, CPA Global claimed that we owe approximately </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for certain patent maintenance services rendered.  CPA Global has not filed claims against us in connection with this allegation.  A liability of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 9, 2016, counsel for Edge BioSystems, Inc. (&#8220;EdgeBio&#8221;) sent a demand letter on behalf of EdgeBio to us in connection with the terms of that certain Asset Purchase Agreement dated September 8, 2015 (the &#8220;EdgeBio Agreement&#8221;). EdgeBio alleges, among other things, that certain customers of EdgeBio erroneously remitted payments to us, that such payments should have been paid to EdgeBio and that we failed to remit these funds to EdgeBio in violation of the terms of the EdgeBio Agreement.  On September 13, 2016, we received a demand for payment letter from EdgeBio&#8217;s counsel alleging that the balance due to EdgeBio is approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.  A liability of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 17, 2017, Jesse Campbell (&#8220;Campbell&#8221;) filed a lawsuit individually and on behalf of others similarly situated against us in the District Court for the District of Nebraska alleging we have a materially incomplete and misleading proxy relating to a potential merger and that the merger agreement&#8217;s deal protection provisions deter superior offers.&#160; As a result, he alleges that we have violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9 promulgated thereafter.&#160; Although we intend to defend the lawsuit, there can be no assurance regarding the ultimate outcome of this case.  Given the uncertainty of litigation, the legal standards that must be met for, among other things, class certification and success on the merits, we are unable to estimate the amount of loss, or range of possible loss, at this time that may result from this action. In the event that a settlement is reached related to these matters, the amount of such settlement may be material to our results of operations and financial condition and may have a material adverse impact on our liquidity.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s09676B274D5F5C00AB0FF3E3E9234E83"></a></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.  INCOME TAXES </font></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annually, we file U.S. Federal, state and foreign income tax returns.&#160; All U.S. Federal and most state loss carryforwards remain subject to adjustment in the event of an income tax examination.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense from continuing operations was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;for both the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2016. We maintain a full valuation allowance on our net deferred tax assets,&#160;having concluded that we are not more likely than not going to realize the benefit of our deferred tax assets, including our net operating loss carryforwards.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC9A664B01E8E57049440E15FCE0B2641"></a></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.  STOCKHOLDERS&#8217; DEFICIT</font></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock.</font></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">150,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock authorized for issuance.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2016, we entered into a Securities Purchase Agreement (the &#8220;SPA&#8221;) with certain accredited investors (the &#8220;2016 Investors&#8221;), pursuant to which, on January 8, 2016, we sold to the 2016 Investors, and the 2016 Investors purchased from us (the &#8220;January 2016 Offering&#8221;), an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of units (the &#8220;Units&#8221;) consisting of (a) an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,365,243</font><font style="font-family:inherit;font-size:10pt;">&#32;shares (the &#8220;A-1 Preferred Shares&#8221;) of our Series A-1 Convertible Preferred Stock (the &#8220;A-1 Preferred&#8221;), and (b) warrants (the &#8220;2016 Warrants&#8221;) to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,773,929</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock, with an initial value of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">. The gross amount of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;included </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of cash proceeds and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of debt settled with the issuance of preferred stock and warrants. Each Unit was sold to the 2016 Investors at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$0.93</font><font style="font-family:inherit;font-size:10pt;">&#32;per Unit. The A-1 Preferred Shares are convertible into shares of our common stock at an initial rate of 1-for-1, which conversion rate is subject to further adjustment as set forth in our Certificate of Designation of Series A-1 Convertible Preferred Stock, which was filed with the Secretary of State of the State of Delaware on January 8, 2016 (the &#8220;Series A-1 Certificate of Designation&#8221;). We determined there was a beneficial conversion feature (&#8220;BCF&#8221;) in connection with this issuance and valued the BCF at </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">.&#160; The holders of the A-1 Preferred were able to convert at any time following the issuance.&#160; Accordingly, we recorded a dividend totaling </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during 2016 related to this beneficial conversion, which was recorded against additional paid in capital. Pursuant to the terms of the Series A-1 Certificate of Designation, the holders of the A-1 Preferred Shares will generally be entitled to that number of votes as is equal to the product obtained by multiplying: (i) the number of whole shares of our common stock into which the A-1 Preferred may be converted as of the record date of such vote or consent, by (ii) </font><font style="font-family:inherit;font-size:10pt;">0.93</font><font style="font-family:inherit;font-size:10pt;">, rounded down to the nearest whole number. Therefore, every </font><font style="font-family:inherit;font-size:10pt;">1.075269</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of A-1 Preferred will generally initially be entitled to one vote. In May 2016, </font><font style="font-family:inherit;font-size:10pt;">2,150,538</font><font style="font-family:inherit;font-size:10pt;">&#32;of the A-1 Preferred Shares were converted into </font><font style="font-family:inherit;font-size:10pt;">2,150,538</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock. At March 31, 2017, there were </font><font style="font-family:inherit;font-size:10pt;">214,705</font><font style="font-family:inherit;font-size:10pt;">&#32;A-1 Preferred Shares outstanding.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrants were immediately exercisable upon issuance, have a term of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;years and have an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.21</font><font style="font-family:inherit;font-size:10pt;">&#32;per share of our common stock. Each 2016 Warrant includes both cash and &#8220;cashless exercise&#8221; features and an exchange feature whereby the holder of the 2016 Warrant may exchange (the &#8220;Exchange Right&#8221;) all or any portion of the 2016 Warrant for a number of shares of our common stock equal to the quotient obtained by dividing the &#8220;Exchange Amount&#8221; by the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged (the &#8220;Exchange Price&#8221;). Under the 2016 Warrants, the &#8220;Exchange Amount&#8221; is based upon a Black Scholes option pricing model, and the aggregate Exchange Amount under all of the 2016 Warrants will be </font><font style="font-family:inherit;font-size:10pt;">$1.4</font><font style="font-family:inherit;font-size:10pt;">&#32;million, subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged. Each 2016 Warrant provides that the number of shares that may be issued upon exercise of the Exchange Right is limited to the number of shares that may be purchased pursuant to the terms of the 2016 Warrant, unless we have previously obtained stockholder approval or approval from The Nasdaq Stock Market LLC to issue any additional shares of our common stock (the &#8220;Additional Shares&#8221;) pursuant to the Exchange Right (the &#8220;Required Approvals&#8221;). For any Exchange Right exercised more than </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">&#32;days following the issuance of the 2016 Warrants, if we have not obtained either of the Required Approvals, we will be required to pay the 2016 Warrant holder an amount in cash for any Additional Shares that we cannot issue without the Required Approvals based on the Exchange Amount.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrants further provide that, to the extent the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged is less than </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, the Exchange Price will be deemed to be equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, and, in addition to issuing shares of our common stock based on this Exchange Price, we will be required to pay to the 2016 Warrant holder an amount in cash equal to the product obtained by multiplying (a) </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">&#32;minus the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the 2016 Warrant holder by the Company in such exchange at an Exchange Price equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">. Therefore, if the Required Approvals are obtained, based on the Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$1,436,882</font><font style="font-family:inherit;font-size:10pt;">&#32;(which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of the issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the 2016 Warrants will be </font><font style="font-family:inherit;font-size:10pt;">2,873,765</font><font style="font-family:inherit;font-size:10pt;">. In addition, if, for example, assuming an Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$1,436,882</font><font style="font-family:inherit;font-size:10pt;">, the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrants are exchanged is </font><font style="font-family:inherit;font-size:10pt;">$0.25</font><font style="font-family:inherit;font-size:10pt;">, we would be required to pay to the 2016 Warrant holders cash in an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$718,441</font><font style="font-family:inherit;font-size:10pt;">&#32;in addition to issuing the 2016 Warrant holders </font><font style="font-family:inherit;font-size:10pt;">2,873,765</font><font style="font-family:inherit;font-size:10pt;">&#32;shares. During the year ended December 31, 2016, </font><font style="font-family:inherit;font-size:10pt;">1,006,419</font><font style="font-family:inherit;font-size:10pt;">&#32;of the 2016 Warrants were exchanged for </font><font style="font-family:inherit;font-size:10pt;">1,613,353</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock and cash due of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">. As of March 31, 2017 and December 31, 2016, the </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;due to a 2016 Investor is included in other current liabilities on our condensed consolidated balance sheet.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the terms of the SPA, we amended that certain Series A Warrant to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,161,972</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock previously issued by us to an affiliate of one of the 2016 Investors on July 7, 2015 (the &#8220;Original Warrant&#8221;), as previously reported by us on our Amendment No. 1 to Current Report on Form 8-K/A, filed with the SEC on July </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7, 2015 (as so amended, the &#8220;Amended Warrant&#8221;). The Amended Warrant amends the Original Warrant to provide that the Amended Warrant is subject to the same terms and conditions as the 2016 Warrants and, therefore, includes both cash and &#8220;cashless exercise&#8221; features and an Exchange Right whereby the number of shares issuable pursuant to the Exchange Right is equal to the &#8220;Amended Warrant Exchange Amount&#8221;, which is based on a Black Scholes option pricing model, and will be </font><font style="font-family:inherit;font-size:10pt;">$941,197</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment to the extent that the risk-free U.S. treasury rate fluctuates between the date of issuance of the Amended Warrant and the date the Amended Warrant is exchanged. The Amended Warrant is exercisable for up to </font><font style="font-family:inherit;font-size:10pt;">1,161,972</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock in the event we have obtained either of the Required Approvals with respect to the Amended Warrant. In the event the Amended Warrant holder exercises the Amended Warrant more than </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">&#32;days following the issuance of the Amended Warrant, if we have not obtained either of the Required Approvals, we will be required to pay the Amended Warrant holder an amount in cash for the shares of our common stock that we cannot issue under the Amended Warrant pursuant to such exercise without the Required Approvals based on the Amended Warrant Exchange Amount.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Amended Warrant also provides that, to the extent the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is less than </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, the Exchange Price will be deemed to be equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, and, in addition to issuing shares of our common stock based on this Exchange Price (assuming receipt of the Required Approvals), we will be required to pay to the Amended Warrant holder an amount in cash equal to the product obtained by multiplying (a) </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">&#32;minus the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the Amended Warrant holder by us in such exchange at an Exchange Price equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">. Therefore, if the Required Approvals are obtained, based on the Amended Warrant Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$941,197</font><font style="font-family:inherit;font-size:10pt;">&#32;(which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the issuance of the Amended Warrant and the date the Amended Warrant is exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the Amended Warrant will be </font><font style="font-family:inherit;font-size:10pt;">1,882,395</font><font style="font-family:inherit;font-size:10pt;">. In addition, if, for example, assuming an Amended Warrant Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$941,197</font><font style="font-family:inherit;font-size:10pt;">, the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is </font><font style="font-family:inherit;font-size:10pt;">$0.25</font><font style="font-family:inherit;font-size:10pt;">, we would be required to pay to the Amended Warrant holder cash in an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$470,599</font><font style="font-family:inherit;font-size:10pt;">&#32;in addition to issuing the Amended Warrant holder </font><font style="font-family:inherit;font-size:10pt;">1,882,395</font><font style="font-family:inherit;font-size:10pt;">&#32;shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with entering into the SPA, we also entered into a Registration Rights Agreement, dated January 8, 2016, with the 2016 Investors. Pursuant to the terms of the Registration Rights Agreement, we were required to file with the SEC a registration statement to register for resale the shares of our common stock issuable upon conversion of the A-1 Preferred Shares and the shares of our common stock issuable upon exercise of the 2016 Warrants and the Amended Warrant by January 25, 2016. We filed the required registration statement with the SEC on January 25, 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Craig-Hallum (the &#8220;Placement Agent&#8221;) served as the sole placement agent for the January 2016 Offering. In consideration for services rendered as the Placement Agent in the January 2016 Offering, we (1) paid to the Placement Agent cash commissions equal to approximately </font><font style="font-family:inherit;font-size:10pt;">$140,000</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">7.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the gross proceeds received in the January 2016 Offering, excluding any proceeds received from Third Security, LLC or any of its affiliates; (2) issued to the Placement Agent, for a price of </font><font style="font-family:inherit;font-size:10pt;">$50</font><font style="font-family:inherit;font-size:10pt;">, a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year warrant to purchase up to </font><font style="font-family:inherit;font-size:10pt;">107,527</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.21</font><font style="font-family:inherit;font-size:10pt;">&#32;per share (the &#8220;Agent Warrant&#8221;), which is subject to the same terms as the 2016 Warrants except that the Agent Warrant was not exercisable until July 8, 2016 and does not contain the Exchange Right; and (3) reimbursed the Placement Agent for reasonable out-of-pocket expenses, including fees paid to the Placement Agent&#8217;s legal counsel, incurred in connection with the January 2016 Offering, which reimbursable expenses did not exceed </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The January 2016 Offering and the payment of all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock in the form of shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">$1.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share of our common stock discussed under &#8220;-Conversion of Preferred Stock&#8221; below required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale (the &#8220;2012 Private Placement&#8221;).  The exercise price of these warrants decreased to </font><font style="font-family:inherit;font-size:10pt;">$4.39</font><font style="font-family:inherit;font-size:10pt;">&#32;per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">2,188,177</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">3,239,827</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 31, 2016, we issued to a vendor an aggregate of </font><font style="font-family:inherit;font-size:10pt;">78,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock and, on June 14, 2016, we issued to a second vendor an aggregate of </font><font style="font-family:inherit;font-size:10pt;">64,153</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock. Such shares of common stock were issued to the vendors in lieu of an aggregate cash amount of approximately </font><font style="font-family:inherit;font-size:10pt;">$89,000</font><font style="font-family:inherit;font-size:10pt;">&#32;owed by us to such vendors for services previously performed by such vendors. We issued the shares to the vendors in transactions exempt from registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The offering of the shares to the vendors did not involve a public offering, and no general solicitation or advertisement was made in connection with the offering of the shares to the vendors.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 7, 2016, we entered into an At the Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with Craig-Hallum, as sales agent, pursuant to which we may offer and sell, from time to time, through Craig-Hallum, up to </font><font style="font-family:inherit;font-size:10pt;">$3,500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of shares (the &#8220;Shares&#8221;) of our common stock. Any Shares offered and sold in the offering will be issued pursuant to our effective shelf registration statement on Form S-3 (File No. 333-201907) and the related prospectus previously declared effective by the SEC on February 13, 2015, as supplemented by a prospectus supplement, dated June 7, 2016, that we filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The number of shares eligible for sale under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the ATM Agreement, we will pay Craig-Hallum a placement fee of </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the gross sales price of the Shares, unless Craig-Hallum acts as principal, in which case we may sell Shares to Craig-Hallum as principal at a price to be agreed upon by us and Craig-Hallum. We will also reimburse Craig-Hallum for certain expenses incurred in connection with the ATM Agreement, and agreed to provide indemnification and contribution to Craig-Hallum with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The ATM Agreement was terminated during the fourth quarter of 2016 and at the time of termination we had sold </font><font style="font-family:inherit;font-size:10pt;">1,177,849</font><font style="font-family:inherit;font-size:10pt;">&#32;shares.&#160; The average sales price per common share was </font><font style="font-family:inherit;font-size:10pt;">$0.42</font><font style="font-family:inherit;font-size:10pt;">&#32;and the aggregate net proceeds from the sales totaled </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">. We did not sell any shares under the ATM Agreement during the three month periods ended March 31, 2017 and 2016.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The sale of shares under the ATM Agreement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the 2012 Private Placement.  The exercise price of these warrants decreased to </font><font style="font-family:inherit;font-size:10pt;">$4.23</font><font style="font-family:inherit;font-size:10pt;">&#32;per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">3,262,088</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">3,362,276</font><font style="font-family:inherit;font-size:10pt;">.  The </font><font style="font-family:inherit;font-size:10pt;">3,362,276</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants issued in the 2012 Private Placement expired in February 2017.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrants.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we did not issue any warrants, no warrants were exercised and </font><font style="font-family:inherit;font-size:10pt;">3,362,276</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants expired. During the three months ended March 31, 2016, we issued warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">2,933,106</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock and no warrants were exercised. The warrants issued in the three months ended March 31, 2016 included </font><font style="font-family:inherit;font-size:10pt;">1,051,650</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants issued due to repricing requirements of the Private Placement and </font><font style="font-family:inherit;font-size:10pt;">1,881,456</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants issued in connection with the January 2016 Offering.  Warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">3,334,011</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock were outstanding at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrant Holder</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issue&#160;Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">374,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,780</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.24</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.66</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,161,972</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,527</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,334,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in January 2013. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with a private placement which was completed in October 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in February 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in July 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were originally issued in connection with the offering in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table><div style="line-height:174%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock Series A.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Board of Directors is authorized to issue up to </font><font style="font-family:inherit;font-size:10pt;">15,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. The authority of the Board of Directors includes, but is not limited to, the determination or fixing of the following with respect to shares of such class or any series thereof: (i)&#160;the number of shares; (ii)&#160;the dividend rate, whether dividends shall be cumulative and, if so, from which date; (iii)&#160;whether shares are to be redeemable and, if so, the terms and amount of any sinking fund providing for the purchase or redemption of such shares; (iv)&#160;whether shares shall be convertible and, if so, the terms and provisions thereof; (v)&#160;what restrictions are to apply, if any, on the issue or reissue of any additional preferred stock; and (vi)&#160;whether shares have voting rights. The preferred stock may be issued with a preference over the common stock as to the payment of dividends.  We have no current plans to issue any additional preferred stock. Classes of stock such as the preferred stock may be used, in certain circumstances, to create voting impediments on extraordinary corporate transactions or to frustrate persons seeking to effect a merger or otherwise to gain control of the Company. For the foregoing reasons, any additional preferred stock issued by the Company could have an adverse effect on the rights of the holders of the common stock.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;29, 2010, we entered into a transaction with the Third Security Investors, pursuant to the terms of a Series A Convertible Preferred Stock Purchase Agreement (the &#8220;Series A Purchase Agreement&#8221;), in which we: (i)&#160;sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,586,205</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series A Preferred Stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$2.32</font><font style="font-family:inherit;font-size:10pt;">&#32;per share; and (ii)&#160;issued Series A Warrants to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,293,102</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series A Preferred Stock having an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.32</font><font style="font-family:inherit;font-size:10pt;">&#32;per share (the sale of Series A Preferred Stock and issuance of the Series A Warrants hereafter referred to together as the &#8220;Financing&#8221;). The Series A Warrants may be exercised at any time from December&#160;29, 2010 until December&#160;28, 2015 and contain a &#8220;cashless exercise&#8221; feature.  The gross proceeds from the Series A financing were </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;">.  The </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of costs incurred to complete the Series A financing were recorded as a reduction in the value of the Series A Preferred Stock.  We used the net proceeds from the financing to acquire the FAMILION family of genetic tests from PGxHealth, a subsidiary of Clinical Data, Inc. Until the November 2011 modifications, the Series A Preferred Stock met the definition of mandatorily redeemable stock as it was preferred capital stock that was redeemable at the option of the holder through December 2015 and was reported outside of equity. The Series A Preferred Stock was to be accreted to its redemption value of </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;">. Until the November 2011 modifications, the Series A Warrants did not qualify to be treated as equity and, accordingly, were recorded as a liability.  A preferred stock anti-dilution feature is embedded within the Series A Preferred Stock that met the definition of a derivative.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Series A financing, we filed a Certificate of Designation of Series A Convertible Preferred Stock (the &#8220;Series A Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware, designating </font><font style="font-family:inherit;font-size:10pt;">3,879,307</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our preferred stock as Series A Preferred Stock. As of December 31, 2013, the Series A Preferred Stock, including the Series A Preferred Stock issuable upon exercise of the Series A Warrants, was convertible into shares of our common stock at a rate of 4-for-1, which conversion rate is subject to further adjustment as set forth in the Series A Certificate of Designation. Giving effect to the reverse split of our stock in January 2014, the conversion rate was adjusted to 1-for-3. Certain rights of the holders of the Series A Preferred Stock are senior to the rights of the holders of our common stock. The Series A Preferred Stock has a liquidation preference equal to its original price per share, plus any accrued and unpaid dividends thereon. The holders of the Series A Preferred Stock are entitled to receive quarterly dividends, which accrue at the rate of </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the original price per share per annum, whether or not declared, and which shall compound annually and shall be cumulative. In any calendar quarter in which we have positive distributable cash flow as defined in the Series A Purchase Agreement, we are required to pay from funds legally available a cash dividend in the amount equal to the lesser of </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;of such distributable cash flow or the aggregate amount of dividends accrued on the Series A Preferred Stock.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Generally, the holders of the Series A Preferred Stock are entitled to vote together with the holders of common stock, as a single group, on an as-converted basis. However, the Series A Certificate of Designation provides that we shall not perform some activities, subject to certain exceptions, without the affirmative vote of a majority of the holders of the outstanding shares of Series A Preferred Stock.  The holders of the Series A Preferred Stock, along with the holders of the Series B Preferred Stock, also are entitled to elect or appoint, as a single group, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#160;directors of the Company.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Series A financing, we also entered into a registration rights agreement with the Third Security Investors (the &#8220;Registration Rights Agreement&#8221;). Pursuant to the terms of the Registration Rights Agreement, the Company has granted certain demand, &#8220;piggyback&#8221; and S-3 registration rights covering the resale of the shares of common stock underlying the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A Preferred Stock issued pursuant to the Series A Purchase Agreement and issuable upon exercise of the Series A Warrants and all shares of common stock issuable upon any dividend or other distribution with respect thereto.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2011, we entered into a transaction with the Third Security Investors, pursuant to an Agreement Regarding Preferred Stock (the &#8220;Amendment Agreement&#8221;), in which the Third Security Investors agreed to (i) waive their rights to enforce the anti-dilution and redemption features of the Series A Preferred Stock and (ii) at the next annual stockholders&#8217; meeting, vote to amend the Series A Certificate of Designation to remove the anti-dilution and redemption features of the Series A Preferred Stock.  In exchange, the Company issued shares of common stock to the Third Security Investors having an aggregate market value of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the Amendment Agreement, the values of the Series A Preferred Stock and Series A Warrants, including the Series A Preferred Stock conversion feature and Series A Warrant liability, were reclassified into stockholders&#8217; equity as of the date of the Amendment Agreement.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock Series B.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 5, 2014, we entered into a Series B Convertible Preferred Stock Purchase Agreement (the &#8220;Series B Purchase Agreement&#8221;) with affiliates of Third Security, LLC (the &#8220;2014 Third Security Investors&#8221;), pursuant to which we, in a private placement, sold and issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,443,297</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our Series B Preferred Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;">&#32;per share (the &#8220;Series B Preferred Stock&#8221;), at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$4.85</font><font style="font-family:inherit;font-size:10pt;">&#32;for an aggregate purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">.  Each share of Series B Preferred Stock issued pursuant to the Series B Purchase Agreement was initially convertible into shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;">-for-1, which conversion rate was subject to further adjustment as set forth in the Certificate of Designation of Series B Convertible Preferred Stock.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Series B financing, we also entered into a Registration Rights Agreement, dated March 5, 2014, with the 2014 Third Security Investors, pursuant to which we granted certain demand, &#8220;piggy-back&#8221; and S-3 registrations rights covering the resale of the shares of common stock underlying the Series B Preferred Stock issued pursuant to the Series B Purchase Agreement and all shares of common stock issuable upon any dividend or other distribution with respect thereto.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Series B financing required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement.  The exercise price of the warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$12.96</font><font style="font-family:inherit;font-size:10pt;">&#32;per share to </font><font style="font-family:inherit;font-size:10pt;">$11.73</font><font style="font-family:inherit;font-size:10pt;">&#32;per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">1,097,600</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">1,212,665</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Conversion of Preferred Stock - Series A and Series B.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2016, the Company entered into a Conversion Agreement (the &#8220;Conversion Agreement&#8221;) with the holders (the &#8220;Preferred Holders&#8221;) of all of the Company&#8217;s outstanding shares of Series A Convertible Preferred Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;">&#32;per share (the &#8220;Series A Preferred Stock&#8221;), and Series B Preferred Stock, pursuant to which, among other things, the Preferred Holders: (a) elected to convert all of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock into shares of our  common stock, in each case in accordance with the terms thereof, and (b) agreed that all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock would be paid by the Company in shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">$1.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share of our common stock (collectively, the &#8220;Conversion&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The outstanding shares of Series A Preferred Stock were convertible into shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;">-for-3, and the outstanding shares of Series B Preferred Stock were convertible into shares of our common stock at a rate of 1-for-1. Prior to the entry into the Conversion Agreement, there were </font><font style="font-family:inherit;font-size:10pt;">2,586,205</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series A Preferred Stock outstanding, which were converted into </font><font style="font-family:inherit;font-size:10pt;">862,057</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock, and </font><font style="font-family:inherit;font-size:10pt;">1,443,297</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series B Preferred Stock outstanding, which were converted into </font><font style="font-family:inherit;font-size:10pt;">1,443,297</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock, for an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,305,354</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock issued upon conversion of the Series A Preferred Stock and Series B Preferred Stock (the &#8220;Conversion Shares&#8221;). At the time of the entry into the Conversion Agreement, there were </font><font style="font-family:inherit;font-size:10pt;">$3.7</font><font style="font-family:inherit;font-size:10pt;">&#32;million in accrued and unpaid dividends on the outstanding shares of Series A Preferred Stock, which were converted, in accordance with the Conversion Agreement, into </font><font style="font-family:inherit;font-size:10pt;">3,681,590</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock, and </font><font style="font-family:inherit;font-size:10pt;">$0.8</font><font style="font-family:inherit;font-size:10pt;">&#32;million in accrued and unpaid dividends on the outstanding shares of Series B Preferred Stock, which were converted, in accordance with the terms of the Conversion Agreement, into </font><font style="font-family:inherit;font-size:10pt;">793,235</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock, for an aggregate of </font><font style="font-family:inherit;font-size:10pt;">4,474,825</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock issued pursuant to the accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock. Therefore, in connection with the full conversion of the Series A Preferred Stock and Series B Preferred Stock, plus the conversion of all accrued and unpaid dividends thereon, we issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;">6,780,179</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock to the Preferred Holders on January 6, 2016.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following the conversion of the shares of Series A Preferred Stock and Series B Preferred Stock into common stock, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series A Preferred Stock or Series B Preferred Stock remain outstanding.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock Dividends.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;undeclared dividends for the three months ended March 31, 2017. For the three months ended March 31, 2016, we had undeclared dividends.  In accordance with the FASB&#8217;s Accounting Standards Codification Topic 260-10-45-11, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings per Share</font><font style="font-family:inherit;font-size:10pt;">&#8221;, these dividends were added to the net loss per share calculation.</font></div><div><a name="s063F905723BB5010A62FCDF2E852BF5D"></a></div><div style="line-height:120%;padding-left:30px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:30px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.  FAIR VALUE</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities;</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2&#8212;Observable inputs other than those included in Level&#160;1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets;&#160;and</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3&#8212;Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our long term debt book value approximates fair market value due to the variable interest rate it bears. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrant Liabilities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2012 Warrant Liability</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2012 Warrant Liability represents the fair value of the </font><font style="font-family:inherit;font-size:10pt;">3.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants issued in February 2012 (as adjusted pursuant to the terms of the 2012 Warrants). We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated Statement of Operations. Management does not believe that this liability will be settled by a use of cash. The 2012 Warrants expired in February 2017 and, as such, the 2012 Warrant Liability no longer exists at March 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2012 Warrant Liability is considered a Level 3 financial instrument and is valued using a Monte Carlo simulation model.  This method is well suited to valuing options with non-standard features, such as anti-dilution protection.  A Monte Carlo simulation model uses repeated random sampling to simulate significant uncertainty in inputs.  Assumptions and inputs used in the valuation of the common stock warrants are broken down into four sections: Static Business Inputs; Static Technical Inputs; Simulated Business Inputs; and Simulated Technical Inputs.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 Warrant Liability</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrant Liability represents the fair value of the </font><font style="font-family:inherit;font-size:10pt;">1.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants issued in January 2016, of which, </font><font style="font-family:inherit;font-size:10pt;">0.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants remain outstanding as of March 31, 2017. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated Statement of Operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrant Liability is considered a Level 3 financial instrument and is valued using a binomial lattice simulation model.  This method is well suited to valuing options with non-standard features.  Assumptions and inputs used in the valuation of the common stock warrants include; our equity value, which was estimated using our stock price of </font><font style="font-family:inherit;font-size:10pt;">$0.56</font><font style="font-family:inherit;font-size:10pt;">&#32;as of March 31, 2017; volatility of </font><font style="font-family:inherit;font-size:10pt;">115%</font><font style="font-family:inherit;font-size:10pt;">; and a risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">1.66%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2017 and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:  &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.6953125%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,446</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB9F7C49859DD5341A4138C0E208BBB15"></a></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.  STOCK OPTIONS </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Options.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity under our 2006 Equity Incentive Plan (the "Plan") during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:71%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">738,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62,739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">675,287</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.73</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,957</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSGENOMIC, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we did not grant any options to purchase shares of our common stock.  Options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">14,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock were granted during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">661,914</font><font style="font-family:inherit;font-size:10pt;">&#32;options that were vested or expected to vest with an aggregate intrinsic value of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;with a remaining weighted average contractual life of </font><font style="font-family:inherit;font-size:10pt;">7.2</font><font style="font-family:inherit;font-size:10pt;">&#32;years.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Appreciation Rights (</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">SARs</font><font style="font-family:inherit;font-size:10pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">83,333</font><font style="font-family:inherit;font-size:10pt;">&#32;outstanding and exercisable SARs shares were vested or expected to vest. All outstanding SARs were issued solely to our chief executive officer. The weighted-average exercise price of these SARs was </font><font style="font-family:inherit;font-size:10pt;">$4.32</font><font style="font-family:inherit;font-size:10pt;">&#32;per share and the aggregate intrinsic value was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;with a remaining weighted average contractual life of </font><font style="font-family:inherit;font-size:10pt;">6.5</font><font style="font-family:inherit;font-size:10pt;">&#32;years. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC48F44AFBAEE587A9FE90AFCF60815F2"></a></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.  SUBSEQUENT EVENTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 13, 2017, Transgenomic completed the sale of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$1.15 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of promissory notes (the &#8220;Bridge Notes&#8221;) in a bridge financing pursuant to a securities purchase agreement (the &#8220;Purchase Agreement&#8221;). Transgenomic may receive additional investments of up to </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in connection with the bridge financing. The financing is intended to help facilitate the completion of Transgenomic&#8217;s merger with Precipio, which is expected to close during the second quarter of 2017. Transgenomic received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$1,031,000</font><font style="font-family:inherit;font-size:10pt;">&#32;from the sale of the Bridge Notes.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Bridge Notes have an annual interest rate of </font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;">&#32;and a </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">-day maturity. Transgenomic may repay the Bridge Notes at any time in cash upon payment of a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;">&#32;premium. In connection with the issuance of the Bridge Notes, Transgenomic issued warrants (the &#8220;Bridge Warrants&#8221;) to acquire </font><font style="font-family:inherit;font-size:10pt;">1.15 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Transgenomic common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, subject to anti-dilution protection. The Purchase Agreement provides certain piggyback registration rights for the holders of the Bridge Warrants for a period of six months after the closing of the bridge financing.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the bridge financing, Transgenomic agreed to loan </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the net proceeds from the sale of the Bridge Notes to Precipio pursuant to a promissory note (the &#8220;Precipio Note&#8221;) with an original principal amount of up to </font><font style="font-family:inherit;font-size:10pt;">$561,500</font><font style="font-family:inherit;font-size:10pt;">&#32;upon substantially the same terms and conditions as the Bridge Notes. The payment of the Precipio Note is subordinated to the payment by Precipio of its secured </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;bank debt pursuant to a subordination agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aegis Capital Corp. acted as placement agent for the bridge financing and received a placement agent fee of </font><font style="font-family:inherit;font-size:10pt;">$84,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and warrants (the &#8220;Aegis Warrants&#8221;) to acquire </font><font style="font-family:inherit;font-size:10pt;">168,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Transgenomic common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. The Aegis Warrants are identical to the Bridge Warrants except that the Aegis Warrants do not have anti-dilution protection.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sBD797332F2DF511C815F4DC7DC9815B0"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div></td></tr></table><div style="line-height:120%;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s54FBD4A4BEE7571092DC0969FBA35D02"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward-Looking Information</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Quarterly Report on Form 10-Q, including this Management&#8217;s Discussion&#160;and Analysis, contains forward-looking statements. These statements are based on management&#8217;s current views, assumptions or beliefs of future events and financial performance and are subject to uncertainty and changes in circumstances. Readers of this report should understand that these statements are not guarantees of performance or results.  Many factors could affect our actual financial results and cause them to vary materially from the expectations contained in the forward-looking statements. These factors include, among other things: our expected revenue, income (loss), receivables, operating expenses, supplier pricing, availability and prices of raw materials, insurance reimbursements, product pricing, sources of funding operations and acquisitions, our ability to raise funds, sufficiency of available liquidity, future interest costs, future economic circumstances, business strategy, industry conditions, our ability to execute our operating plans, the success of our cost savings initiatives, competitive environment and related market conditions, expected financial and other benefits from our organizational restructuring activities, actions of governments and regulatory factors affecting our business, retaining key employees and other risks as described in our reports filed with the Securities and Exchange Commission. In some cases these statements are identifiable through the use of words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative versions of these terms and other similar expressions.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements we make are not guarantees of future performance and are subject to various assumptions, risks and other factors that could cause </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">actual results to differ materially from those suggested by these forward-looking statements. Actual results may differ materially from those suggested by the forward-looking statements that we make for a number of reasons, including those described in Part II, Item 1A, &#8220;Risk Factors,&#8221; of this Quarterly Report on Form 10-Q and in Part I, Item 1A, &#8220;Risk Factors,&#8221; of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, which we filed with the Securities and Exchange Commission on April 13, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following discussion should be read together with our financial statements and related notes contained in this Quarterly Report on Form 10-Q and with the financial statements, related notes and Management&#8217;s Discussion&#160;and Analysis included in our Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, which we filed with the Securities and Exchange Commission on April 13, 2017.  Results for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;are not necessarily indicative of results that may be attained in the future.</font></div><div><a name="sED2E74A321525401B9880AE6F2AF7405"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transgenomic, Inc. (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, the &#8220;Company&#8221; or &#8220;Transgenomic&#8221;) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and integrated diseases through our proprietary molecular technologies and clinical and research services. A key goal is to bring our Multiplexed ICE COLD-PCR (&#8220;MX-ICP&#8221;) product to the clinical market through strategic partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring and treatment of cancer.</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MX-ICP is technology proprietary to Transgenomic.  It is a reagent that improves the ability to detect genetic mutations by 100 - 400 fold over existing technologies. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital PCR.  By enhancing the level of detection of genetic mutations and suppressing the normal, or wild-type, DNA, several benefits are provided.  It is generally understood that most current technologies are unable to consistently identify mutations that occur in less than approximately 5% of a sample.  However, many mutations found at much lower levels, even as low as 0.01%, are known to be clinically relevant and can have significant consequences to a patient: both in terms of how they will respond to a given drug or treatment and how a given tumor is likely to change over time. More importantly, in our view, is the ability to significantly improve the level of detection while using blood, saliva and even urine as a source for DNA, rather than depending on painful, expensive and potentially dangerous tumor biopsies.  We believe that this is an important advancement in patient care with respect to cancer detection, treatment and monitoring and can result in significant cost savings for the healthcare system by replacing invasive procedures with the simple collection of blood or other bodily fluids.  By broadening the types of samples that can be used for testing and allowing all sequencing platforms to provide improved identification of low level mutations, MX-ICP has the potential to make testing more readily available and more patient friendly, enable genetic monitoring of disease progression, effectively guide treatment protocols, and reduce the overall cost of diagnosis and monitoring while significantly improving patient outcomes.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing service technologies, including our proprietary MX-ICP technology.  ICE COLD-PCR is a proprietary ultra-high sensitivity platform technology with breakthrough potential to enable wide adoption of personalized, precision medicine in cancer and other diseases. It can be run in any laboratory that contains standard PCR systems. MX-ICP enables detection of multiple known and unknown mutations from virtually any sample type, including tissue biopsies, blood, urine, saliva, cell-free DNA (&#8220;cfDNA&#8221;) and circulating tumor cells (&#8220;CTCs&#8221;) at levels greater than 1,000-fold higher than standard DNA sequencing techniques. It is easy to implement and use within existing workflows. Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;) as a high complexity laboratory and is accredited by the College of American Pathologists.</font></div><div style="line-height:120%;text-align:justify;padding-left:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following discussion should be read together with our financial statements and related notes contained in this Quarterly Report.  Results for the three months ended March 31, 2017 are not necessarily indicative of results that may be attained in the future.</font></div><div style="line-height:120%;text-align:justify;padding-left:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s02247D078B44507FB8C75AC3A156F9C2"></a></div><div style="line-height:174%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">First Quarter 2017 Overview and Recent Highlights </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Below is a summary of our most recent business activities:</font></div><div style="line-height:174%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leading Clinical Laboratory Services Provider LifeLabs Selects ICE COLD-PCR (ICP) as Its Mutation Enrichment Platform - In January 2017, we announced a licensing agreement with leading Canadian laboratory services provider LifeLabs, which has selected our ICP technology as its mutation enrichment platform for cancer testing. LifeLabs intends to use ICP with tissue samples and is receiving a three-year non-exclusive license to the ICP technology in Canada. The three-year renewable agreement also allows LifeLabs to benefit from technology improvements and additional product launches during its term.</font></div></td></tr></table><div><a name="sB92C9FF2F73F575EBCD2B156441E6983"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Uncertainties</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have historically operated at a loss and have not consistently generated sufficient cash from operating activities to cover our operating and other cash expenses. We have been able to historically finance our operating losses through borrowings or from the issuance of additional equity. At </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents of less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">. Our ability to continue as a going concern is dependent upon a combination of completing our planned merger with Precipio, generating additional revenue, improving cash collections, potentially selling underutilized assets and/or product lines related to discontinued operations and, if needed, raising necessary financing to meet our obligations and pay our liabilities arising from normal business operations when they come due. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2106A1E7B29E52508F7052A16B11175E"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Continuing Operations for The Three Months Ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">2016</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Sales. </font><font style="font-family:inherit;font-size:10pt;">Net sales were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Net Sales</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">658</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales increased by $0.4 million, or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">179%</font><font style="font-family:inherit;font-size:10pt;">, during the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to the same period in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">. The increase in total net sales for the current year period reflects higher sales of our contract laboratory services due to a new contract that did not exist in the prior year period. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of Goods Sold.</font><font style="font-family:inherit;font-size:10pt;">&#32;Cost of goods sold includes material costs for the products that we sell and other direct costs (primarily personnel costs, rent, supplies and depreciation) associated with the operations of our laboratories. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Gross Profit.</font><font style="font-family:inherit;font-size:10pt;">&#32;Gross profit and gross margins were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Margin %</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross Profit (Loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(269</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(114</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit was $0.2 million, or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">30%</font><font style="font-family:inherit;font-size:10pt;">&#32;of total net sales, during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">first</font><font style="font-family:inherit;font-size:10pt;">&#32;quarter of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, compared to negative $0.3 million, or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">(114)%</font><font style="font-family:inherit;font-size:10pt;">&#32;of total net sales, during the same quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">. The increased gross profit during the three months ended March 31, 2017 as compared to the same period of 2016 is due to increased revenues, along with a slight decrease in cost of goods sold which resulted from lower personnel costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, General and Administrative Expenses.</font><font style="font-family:inherit;font-size:10pt;">&#32;Selling, general and administrative expenses primarily consist of personnel costs, marketing, travel costs, professional fees, facility costs and bad debt provisions. Our selling, general and administrative costs decreased by </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to $</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the three month period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to the same period in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">. This decrease was due to lower personnel costs, lower professional fees and lower stock compensation costs in the first quarter of 2017 as compared to the first quarter of 2016. These decreases were partially offset by increased costs related to our pending merger and an increase of approximately $0.4 million related to charges incurred as part of a settlement agreement for the early termination of our facility lease for our Omaha, Nebraska facility. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses.</font><font style="font-family:inherit;font-size:10pt;">&#32;Research and development expenses primarily include personnel costs, intellectual property fees, patent costs, outside services, laboratory supplies and facility costs and are expensed in the period in which they are incurred.  For the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, research and development expenses totaled </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to $0.3 million for the three months ended March 31, 2016.  The decrease was a result of lower personnel costs and lower laboratory </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;24</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">supply costs during the three months ended March 31, 2017 as compared to the same period in 2016.  Research and development expenses totaled </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">114%</font><font style="font-family:inherit;font-size:10pt;">&#32;of net sales during the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Income (Expense).</font><font style="font-family:inherit;font-size:10pt;">&#32;Other expense for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;includes interest expense of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for interest related to our debt.  We also recorded expense of less than $0.1 million and income of $0.3 million for the three months ended March 31, 2017 and 2016, respectively, for the revaluation of common stock warrants, which was due to the change in fair value of the common stock warrant liability. The income and expense associated with the change in fair value of the warrants is a non-cash item. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Discontinued Operations for The Three Months Ended March 31 2017 and 2016</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;In March 2016, we halted testing services in our Patient Testing laboratory in New Haven, Connecticut. As a result of this action, as of December 31, 2015, our Patient Testing business met the criteria to be reported as discontinued operations. The related assets, liabilities, results of operations and cash flows for the Patient Testing business are classified as assets held for sale, liabilities held for sale and discontinued operations for all periods presented.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues and net loss of the discontinued operations consisted of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:71.2890625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three months ended     March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) from discontinued operations, before tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of tax</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC30789FA14765CEF910C6F2B7EE58F95"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our working capital positions at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;were as follows:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets (including cash and cash equivalents of $59 and $110, respectively)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,129</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,824</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,305</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,562</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,329</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,233</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had cash on hand of less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">. Our ability to continue as a going concern is dependent upon a combination of completing our planned merger with Precipio, generating additional revenue, improving cash collections, potentially selling underutilized assets and/or product lines related to discontinued operations and, if needed, raising necessary financing to meet our obligations and pay our liabilities arising from normal business operations when they come due. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern. There is no assurance that we will complete the merger in a timely manner or at all. The merger agreement is subject to many closing conditions and termination rights. We also cannot be certain that additional financing, if needed, will be available on acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue our operations.</font></div><div><a name="sB8A7E2A1217553958030D4361FF3B3BB"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Analysis of Cash Flows - </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">2016</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Change in Cash and Cash Equivalents.</font><font style="font-family:inherit;font-size:10pt;">&#32;Cash and cash equivalents decreased by less than $0.1 million during the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, compared to an decrease of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. These amounts include cash provided by discontinued operations of $0.1 million and cash used in discontinued operations of $0.6 million, for the three months ended March 31, 2017 and 2016, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Cash Flows From Continuing Operations</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows Used in Operating Activities.</font><font style="font-family:inherit;font-size:10pt;">&#32;The cash flows used in operating activities of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;included a net loss of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and a decrease in accrued expenses of $0.6 million. These were partially offset by an increase in accounts payable of $2.0 million and non-cash adjustments of $0.4 million. The cash flows used in operating activities in the first </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;months of </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;included the net loss of </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and a decrease in accrued expenses and other liabilities of $0.5 million. These were partially offset by an increase in accounts receivable of $1.2 million.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows Used in Investing Activities.</font><font style="font-family:inherit;font-size:10pt;">&#32;Cash flows used in investing activities for continuing operations were zero and less than $0.1 million for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2016, respectively.   </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows Provided by Financing Activities.</font><font style="font-family:inherit;font-size:10pt;">&#32;There were no cash flows provided by financing activities for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;other than capital lease payments of less than $0.1 million. Cash flows provided by financing activities during the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;totaled $1.7 million which included net proceeds of approximately $1.8 million from our Unit issuance and $0.5 million from borrowing on our debt. These proceeds were partially offset by payments on our debt of approximately $0.6 million</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s7984B62521D55B43A938E1E51FA0FDA7"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At each of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations and Commitments</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no material changes to our contractual obligations outside the normal course of business as compared to those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on April 13, 2017 except for the following.</font></div><div style="line-height:120%;padding-left:48px;padding-top:12px;text-align:justify;text-indent:32px;"><font style="padding-top:12px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:16px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Our debt decreased by $0.4 million resulting from the conversion of convertible promissory notes into shares of our common stock in January 2017.  See Note 4 - Debt to our accompanying condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-left:48px;padding-top:12px;text-align:justify;text-indent:32px;"><font style="padding-top:12px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:16px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Our operating lease obligations decreased from approximately $1.3 million to approximately $0.6 million as the result of a settlement agreement we entered into on April 7, 2017 related to the early termination of our lease for our Omaha, Nebraska facility.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s941822D9BD345E378A75D8AB949F67B2"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Estimates</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounting policies used in the preparation of our consolidated financial statements may involve the use of management judgments and estimates. Certain of our accounting policies are considered critical as they are both important to the portrayal of our financial statements and require significant or complex judgments on the part of management. Our judgments and estimates are based on experience and assumptions that we believe are reasonable under the circumstances. Further, we evaluate our judgments and estimates from time to time as circumstances change. Actual financial results based on judgments or estimates may vary under different assumptions or circumstances. Our critical accounting policies are discussed in our Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, filed with the Securities and Exchange Commission on April 13, 2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s873604EE1FC45F32B5D58BA2F747F621"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please refer to our Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, filed with the Securities and Exchange Commission on April 13, 2017.  There have been no changes to those accounting pronouncements listed except as noted in Note 2 - &#8220;Summary of Significant Accounting Policies-Recent Accounting Pronouncements&#8221; in the Notes to Unaudited Condensed Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFC270D9930F952548F614B88FE343229"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Impact of Inflation</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not believe that price inflation or deflation had a material adverse effect on our financial condition or results of operations during the periods presented.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s08425E8FA6D4503EA7A74A7384042AF4"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the information required under this item.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1DC49D17F43552258D10FA86A0020A89"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;font-size:10pt;text-indent:-48px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Controls and Procedures.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management performed, with the participation of our Chief Executive Officer and Interim Chief Financial Officer, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).  Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Interim Chief Financial Officer, to allow timely decisions regarding required disclosures. Based on the evaluation, our Chief Executive Officer and Interim Chief Financial Officer concluded that, as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, our disclosure controls and procedures were effective at the reasonable assurance level. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have evaluated the changes in our internal control over financial reporting that occurred during the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and concluded that there have not been any changes that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;27</font></div></div><hr style="page-break-after:always"><div><a name="s8926D75C802E5A2291EB5963AD32C4D4"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II. OTHER INFORMATION</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div><a name="sB66B232CD6C75035BE9523D31105BFCB"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to a number of claims of various amounts that arise out of the normal course of our business.  In addition to the claims described in this Item 1, we are delinquent on the payment of outstanding accounts payable amounting to approximately $0.6 million with certain of our vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, the Board of Regents of the University of Nebraska (&#8220;UNMC&#8221;) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of $0.7 million owed by us to UNMC. A $0.4 million liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. We and UNMC entered into a settlement agreement dated February 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay $0.4 million to UNMC in installments over a period of time. As of March 15, 2017, the initial payment due to UNMC under the settlement agreement is delinquent.  We and UNMC are currently in discussions to extend the date of Transgenomic&#8217;s initial payment due to UNMC.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;In addition, on April 13, 2016, Fox Chase Cancer Center (&#8220;Fox Chase&#8221;) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the &#8220;Court of Common Pleas&#8221;), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the &#8220;License Agreement&#8221;), as well as the assignment of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc. (&#8220;IDT&#8221;) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the &#8220;IDT Agreement&#8221;). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase&#8217;s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney&#8217;s fees.&#160; Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by us as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 23, 2016, the Icahn School of Medicine at Mount Sinai (&#8220;Mount Sinai&#8221;) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of $0.7 million owed by us to Mount Sinai for services rendered. We and Mount Sinai entered into a settlement agreement dated October 27, 2016, which included, among other things, a mutual general release of claims, and our agreement to pay approximately $0.7 million to Mount Sinai in installments over a period of time. A $0.7 million liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.  Effective as of February 1, 2017, we and Mount Sinai agreed to amend the terms of our settlement agreement to extend the date of the initial payment due to Mount Sinai.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 19, 2016, Todd Smith (&#8220;Smith&#8221;) filed a lawsuit against us in the District Court of Douglas County Nebraska, alleging breach of contract and seeking recovery of $2.2 million owed by us to Smith for costs and damages arising from a breach of our obligations pursuant to a lease agreement between the parties.  On April 7, 2017, we entered into a settlement agreement with Smith related to the early termination of our lease for our Omaha, Nebraska facility. The agreement included, among other things, a mutual general release of claims, and our agreement to pay approximately $0.6 million to Smith in installments over a period of time. A $0.6 million liability has been recorded and is reflected in accrued expenses at March 31, 2017. The accrued liability includes $0.4 million recorded as a net loss on the settlement and is included in other expense in our condensed consolidated statements of operations for the three months ended March 31, 2017. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 21, 2017, XIFIN, Inc. (&#8220;XIFIN&#8221;) filed a lawsuit against us in the District Court for the Southern District of California alleging breach of written contract and seeking recovery of approximately $0.27 million owed by us to XIFIN for damages arising from a breach of our obligations pursuant to a Systems Services Agreement between us and XIFIN, dated as of February 22, 2013, as amended and restated on September 1, 2014. On April 5, 2017, the court clerk entered default against us. On May 5, 2017, XIFIN filed an application for entry of default judgment against us.  A $0.3 million and $0.2 million liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and Science Park Development Corporation (&#8220;SPDC&#8221;) entered into that certain Lease dated as of December 31, 2011, as modified by the First Amendment to Lease dated as of June 18, 2013, as further modified by a letter agreement dated as of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2, 2015, as modified by the Second Amendment to Lease dated as of June 26, 2015 (the &#8220; SPDC Lease&#8221;).   In November 2016, SPDC alleged that we defaulted on our obligations under the SPDC Lease.  Specifically, SPDC alleges that we failed to pay approximately $0.4 million in rental payments due under the SPDC Lease and that we vacated a portion of the leased premises in violation of the terms of the SPDC Lease.  We and SPDC entered into a settlement agreement dated March 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay approximately $0.4 million to SPDC in installments over a period of time. This liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CPA Global provides us with certain patent management services.  On February 6, 2017, CPA Global claimed that we owe approximately $0.2 million for certain patent maintenance services rendered.  CPA Global has not filed claims against us in connection with this allegation.  A liability of approximately $0.2 million has been recorded and is reflected in accrued expenses at December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 9, 2016, counsel for Edge BioSystems, Inc. (&#8220;EdgeBio&#8221;) sent a demand letter on behalf of EdgeBio to us in connection with the terms of that certain Asset Purchase Agreement dated September 8, 2015 (the &#8220;EdgeBio Agreement&#8221;). EdgeBio alleges, among other things, that certain customers of EdgeBio erroneously remitted payments to us, that such payments should have been paid to EdgeBio and that we failed to remit these funds to EdgeBio in violation of the terms of the EdgeBio Agreement.  On September 13, 2016, we received a demand for payment letter from EdgeBio&#8217;s counsel alleging that the balance due to EdgeBio is approximately $0.1 million.  A liability of approximately $0.1 million has been recorded and is reflected in accrued expenses at December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 17, 2017, Jesse Campbell (&#8220;Campbell&#8221;) filed a lawsuit individually and on behalf of others similarly situated against us in the District Court for the District of Nebraska alleging we have a materially incomplete and misleading proxy relating to a potential merger and that the merger agreement&#8217;s deal protection provisions deter superior offers.&#160; As a result, he alleges that we have violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9 promulgated thereafter.&#160; Although we intend to defend the lawsuit, there can be no assurance regarding the ultimate outcome of this case.  Given the uncertainty of litigation, the legal standards that must be met for, among other things, class certification and success on the merits, we are unable to estimate the amount of loss, or range of possible loss, at this time that may result from this action. In the event that a settlement is reached related to these matters, the amount of such settlement may be material to our results of operations and financial condition and may have a material adverse impact on our liquidity.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The outcome of legal proceedings and claims brought against us are subject to significant uncertainty.  Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess of management&#8217;s expectations, our financial statements for such reporting period could be materially adversely affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results.</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:21px;text-align:justify;text-indent:29px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><a name="sE4DF711E6A045119A93D789A468CE3B6"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk Factors</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As disclosed in &#8220;Item 1A. Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2016, there are a number of risks and uncertainties that may have a material effect on the operating results of our business and our financial condition. There are no additional material updates or changes to our risk factors since the filing of our Annual Report on Form 10-K for the year ended December 31, 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;29</font></div></div><hr style="page-break-after:always"><div><a name="sD010ECA23B795A588D03FF2FB239DE24"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.            &#160;&#160;&#160;&#160;Unregistered  Sales of Equity Securities and Use of Proceeds</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s29C797C4B1B353D2B5726FB424170B33"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6.</font></div></td><td style="vertical-align:top;padding-left:90px;"><div style="line-height:120%;text-align:right;font-size:10pt;text-indent:-90px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibits </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibits</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Amendment to Agreement and Plan of Merger, dated as of February 3, 2017, by and among the Registrant, New Haven Labs Inc. and Precipio Diagnostics, LLC (incorporated by reference to Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K filed on February 2, 2017).</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Waiver Letter Agreement by and among the Registrant, Potomac Capital Partners, L.P., MAZ Partners LP, David Wambeke and Craig-Hallum Capital Group LLC, dated as of January 10, 2017 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on January 17, 2017).</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Amendment to Unsecured Convertible Promissory Note by and among the Registrant and MAZ Partners LP, dated as of January 17, 2017 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on January 20, 2017).</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination and Tenth Amendment to Loan and Security Agreement, dated as of February 3, 2017, by and among Third Security Senior Staff 2008 LLC, as administrative agent and a lender, the other lenders party thereto and the Registrant (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on February 2, 2017).</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Promissory Note, dated February 2, 2017, between the Registrant and Precipio Diagnostics, LLC (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed on February 3, 2017).</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities Purchase Agreement, dated as of April 13, 2017, by and between the Registrant and the investors set forth on Schedule A attached thereto (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on April 17, 2017).</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Promissory&#160;Note, issued by the Registrant to certain investors, dated as of April 13, 2017 (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed on April 17, 2017).</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Warrant to Purchase Common Stock, issued by the Registrant to certain investors, dated as of April 13, 2017 (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K filed on April 17, 2017).</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Precipio Diagnostics, LLC Subordinated Promissory Note, issued by Precipio to the Registrant, dated as of April 13, 2017 (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Current Report on Form 8-K filed on April 17, 2017).</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subordination Agreement, dated as of April 13, 2017, by and between the Registrant and Webster Bank, National Association (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Current Report on Form 8-K filed on April 17, 2017).</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Paul Kinnon, President, Chief Executive Officer and Interim Chief Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002, as amended.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Paul Kinnon, President, Chief Executive Officer and Interim Chief Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, as amended.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;30</font></div></div><hr style="page-break-after:always"><div><a name="s7698DB28155955F487B63962D98DED99"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s2446C485322952F2AE8B8B1956C96911"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:6%;"></td><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TRANSGENOMIC,&#160;INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;18, 2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/</font><font style="font-family:inherit;font-size:8pt;">S</font><font style="font-family:inherit;font-size:10pt;">/ PAUL KINNON</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paul Kinnon</font></div><div style="padding-bottom:1px;text-align:center;text-indent:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">President, Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;31</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>tbio-ex311_20170331x10q.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1190B4B3F6E856BDBBBFC6BC2FDF45EB"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1 </font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Paul Kinnon, certify that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Transgenomic, Inc. (the Registrant);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and I have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known to me by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent function):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:41.40625%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ PAUL KINNON</font></div><div style="padding-bottom:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paul Kinnon</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">President, Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">May&#160;18, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>3
<FILENAME>tbio-ex321_20170331x10q.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCD05D824784F5EBE9E1C24B3A8FB9C45"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1 </font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION 1350 </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the accompanying Quarterly Report on Form 10-Q of Transgenomic, Inc. for the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, I, Paul Kinnon, Chief Executive Officer and Interim Chief Financial Officer of Transgenomic, Inc., hereby certify pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Such Quarterly Report on Form 10-Q of Transgenomic, Inc. for the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in such Quarterly Report on Form 10-Q of Transgenomic, Inc. for the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, fairly presents, in all material respects, the financial condition and results of operations of Transgenomic, Inc.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:41.40625%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ PAUL KINNON</font></div><div style="padding-bottom:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paul Kinnon</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">President, Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">May&#160;18, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A signed original of the certification required by Section&#160;906 has been provided to Transgenomic, Inc. and will be retained by Transgenomic, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>4
<FILENAME>tbio-20170331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:04180d9294f34771afeb525abccf34c3,x:352462cb10814db4b252ff197d508e3e-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:tbio="http://www.transgenomic.com/20170331" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="tbio-20170331.xsd" xlink:type="simple" />
	<xbrli:context id="FD2017Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Apr.30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb.2_dei_LegalEntityAxis_tbio_PrecipioMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbio:PrecipioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-02</xbrli:startDate>
			<xbrli:endDate>2017-02-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb.2_dei_LegalEntityAxis_tbio_PrecipioMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbio:PrecipioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-02</xbrli:startDate>
			<xbrli:endDate>2017-02-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Sep29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct31_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct31_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementBusinessSegmentsAxis_tbio_PharmacogenomicServicesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tbio:PharmacogenomicServicesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementBusinessSegmentsAxis_tbio_PharmacogenomicServicesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tbio:PharmacogenomicServicesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_TitleOfIndividualAxis_us-gaap_ExecutiveOfficerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">tbio:GeneticAssaysandPlatformsandPatientTestingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">tbio:GeneticAssaysandPlatformsandPatientTestingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_LongtermDebtTypeAxis_tbio_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tbio:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LongtermDebtTypeAxis_tbio_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tbio:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q1March13-2013_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_tbio_ThirdSecurityLlcAndAffiliatesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">tbio:ThirdSecurityLlcAndAffiliatesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-03-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Jan20_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsidiarySaleOfStockAxis_tbio_AgentNoteMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tbio:AgentNoteMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_LongtermDebtTypeAxis_tbio_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tbio:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Dec.31_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsidiarySaleOfStockAxis_tbio_AdditionalNotePrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tbio:AdditionalNotePrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Jan.13_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsidiarySaleOfStockAxis_tbio_AgentNoteMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tbio:AgentNoteMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan06_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb.2_dei_LegalEntityAxis_tbio_PrecipioMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertibleCommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbio:PrecipioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-02</xbrli:startDate>
			<xbrli:endDate>2017-02-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb.2_dei_LegalEntityAxis_tbio_PrecipioMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbio:PrecipioMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_tbio_WallStreetJournalPrimeRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">tbio:WallStreetJournalPrimeRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsidiarySaleOfStockAxis_tbio_AdditionalNotePrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tbio:AdditionalNotePrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_dei_LegalEntityAxis_tbio_PrecipioMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbio:PrecipioMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Jan.13_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsidiarySaleOfStockAxis_tbio_AgentNoteMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tbio:AgentNoteMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-13</xbrli:startDate>
			<xbrli:endDate>2017-01-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Jan15_us-gaap_SubsidiarySaleOfStockAxis_tbio_AdditionalNotePrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tbio:AdditionalNotePrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb.2_dei_LegalEntityAxis_tbio_PrecipioMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbio:PrecipioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-02</xbrli:startDate>
			<xbrli:endDate>2017-02-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q1March13-2013_us-gaap_LineOfCreditFacilityAxis_tbio_ThirdSecurityLlcAndAffiliatesMember_us-gaap_LongtermDebtTypeAxis_tbio_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">tbio:ThirdSecurityLlcAndAffiliatesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tbio:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-03-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Jan20_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsidiarySaleOfStockAxis_tbio_AdditionalNotePrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tbio:AdditionalNotePrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_dei_LegalEntityAxis_tbio_PrecipioMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbio:PrecipioMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jan.17_us-gaap_DebtInstrumentAxis_tbio_AdditionalNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tbio:AdditionalNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-17</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct.27_us-gaap_LitigationCaseAxis_tbio_MountSinaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:MountSinaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-27</xbrli:startDate>
			<xbrli:endDate>2016-10-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_LitigationCaseAxis_tbio_CPAGlobalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:CPAGlobalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Feb25_us-gaap_LitigationCaseAxis_tbio_UNMCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:UNMCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-02-25</xbrli:startDate>
			<xbrli:endDate>2016-02-25</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Dec.19_us-gaap_LitigationCaseAxis_tbio_SmithMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:SmithMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-19</xbrli:startDate>
			<xbrli:endDate>2016-12-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_LitigationCaseAxis_tbio_XIFINInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:XIFINInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LitigationCaseAxis_tbio_XIFINInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:XIFINInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_LitigationCaseAxis_tbio_SmithMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:SmithMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb.6_us-gaap_LitigationCaseAxis_tbio_UNMCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:UNMCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-06</xbrli:startDate>
			<xbrli:endDate>2017-02-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Nov.30_us-gaap_LitigationCaseAxis_tbio_ScienceParkDevelopmentCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:ScienceParkDevelopmentCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-11-30</xbrli:startDate>
			<xbrli:endDate>2016-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2June23_us-gaap_LitigationCaseAxis_tbio_MountSinaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:MountSinaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-23</xbrli:startDate>
			<xbrli:endDate>2016-06-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_LitigationCaseAxis_tbio_MountSinaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:MountSinaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb.6_us-gaap_LitigationCaseAxis_tbio_CPAGlobalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:CPAGlobalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-06</xbrli:startDate>
			<xbrli:endDate>2017-02-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Sep.13_us-gaap_LitigationCaseAxis_tbio_EdgeBioSystemsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:EdgeBioSystemsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-13</xbrli:startDate>
			<xbrli:endDate>2016-09-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Apr.7_us-gaap_LitigationCaseAxis_tbio_SmithMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:SmithMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-07</xbrli:startDate>
			<xbrli:endDate>2017-04-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb.21_us-gaap_LitigationCaseAxis_tbio_XIFINInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:XIFINInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-21</xbrli:startDate>
			<xbrli:endDate>2017-02-21</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_LitigationCaseAxis_tbio_UNMCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:UNMCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_LitigationCaseAxis_tbio_EdgeBioSystemsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:EdgeBioSystemsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar.6_us-gaap_LitigationCaseAxis_tbio_ScienceParkDevelopmentCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:ScienceParkDevelopmentCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-06</xbrli:startDate>
			<xbrli:endDate>2017-03-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LitigationCaseAxis_tbio_EdgeBioSystemsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:EdgeBioSystemsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LitigationCaseAxis_tbio_MountSinaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:MountSinaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LitigationCaseAxis_tbio_UNMCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:UNMCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LitigationCaseAxis_tbio_CPAGlobalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">tbio:CPAGlobalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersJanuary2021TwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:VariousInstitutionalHoldersJanuary2021TwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersDecember2020OneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:VariousInstitutionalHoldersDecember2020OneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersFebruary2020Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:VariousInstitutionalHoldersFebruary2020Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_AffiliatesofThirdSecurityLLCJanuary2021Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:AffiliatesofThirdSecurityLLCJanuary2021Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersJanuary2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:VariousInstitutionalHoldersJanuary2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersApril2020Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:VariousInstitutionalHoldersApril2020Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_AffiliatesofThirdSecurityLLCJanuary2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:AffiliatesofThirdSecurityLLCJanuary2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersJanuary2021OneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:VariousInstitutionalHoldersJanuary2021OneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_tbio_AttheMarketOfferingAgreementMember_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:AttheMarketOfferingAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbio:CraigHallumCapitalGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan.8_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-08</xbrli:startDate>
			<xbrli:endDate>2016-01-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan.8_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:A2016WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesAWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:SeriesAWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan06_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesA1WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:SeriesA1WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-06</xbrli:startDate>
			<xbrli:endDate>2016-01-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan.8_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2010Q4Dec29-2012_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2010-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_tbio_AttheMarketOfferingAgreementMember_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:AttheMarketOfferingAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbio:CraigHallumCapitalGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4Nov_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-11-01</xbrli:startDate>
			<xbrli:endDate>2011-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesAWarrantsMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:SeriesAWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2010Q4Dec29-2012_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2010-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1January_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbio:CraigHallumCapitalGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-06</xbrli:startDate>
			<xbrli:endDate>2016-01-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q1Mar5_tbio_WarrantyHoldersAndIssuanceAxis_tbio_ThirdSecurityLlcAndAffiliatesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:ThirdSecurityLlcAndAffiliatesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-03-05</xbrli:startDate>
			<xbrli:endDate>2014-03-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2June7_us-gaap_ClassOfWarrantOrRightAxis_tbio_AttheMarketOfferingAgreementMember_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:AttheMarketOfferingAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbio:CraigHallumCapitalGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-01</xbrli:startDate>
			<xbrli:endDate>2016-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_SubsidiarySaleOfStockAxis_tbio_OfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tbio:OfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan.8_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-08</xbrli:startDate>
			<xbrli:endDate>2016-01-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:A2016WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2June14_us-gaap_CounterpartyNameAxis_tbio_VendorIIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbio:VendorIIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-14</xbrli:startDate>
			<xbrli:endDate>2016-06-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan.31_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbio:CraigHallumCapitalGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q1Mar5-2014_tbio_WarrantyHoldersAndIssuanceAxis_tbio_ThirdSecurityLlcAndAffiliatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:ThirdSecurityLlcAndAffiliatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-03-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-01</xbrli:startDate>
			<xbrli:endDate>2016-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:A2016WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q1Jan24-2013_tbio_WarrantyHoldersAndIssuanceAxis_tbio_ThirdSecurityLlcAndAffiliatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:ThirdSecurityLlcAndAffiliatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-01-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-06</xbrli:startDate>
			<xbrli:endDate>2016-01-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD_us-gaap_ClassOfWarrantOrRightAxis_tbio_AttheMarketOfferingAgreementMember_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:AttheMarketOfferingAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbio:CraigHallumCapitalGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q1Mar5-2014_tbio_WarrantyHoldersAndIssuanceAxis_tbio_ThirdSecurityLlcAndAffiliatesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:ThirdSecurityLlcAndAffiliatesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-03-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan.8">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-08</xbrli:startDate>
			<xbrli:endDate>2016-01-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan06_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesAWarrantsMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:SeriesAWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesAWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:SeriesAWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2010Q4Dec29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-12-29</xbrli:startDate>
			<xbrli:endDate>2010-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesAWarrantsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:SeriesAWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May31_us-gaap_CounterpartyNameAxis_tbio_VendorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbio:VendorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-31</xbrli:startDate>
			<xbrli:endDate>2016-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:A2016WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-06</xbrli:startDate>
			<xbrli:endDate>2016-01-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-06</xbrli:startDate>
			<xbrli:endDate>2016-01-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1January_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbio:CraigHallumCapitalGroupLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_tbio_AttheMarketOfferingAgreementMember_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:AttheMarketOfferingAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbio:CraigHallumCapitalGroupLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:A2016WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-06</xbrli:startDate>
			<xbrli:endDate>2016-01-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:A2016WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3July7_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesAWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="tbio:WarrantyHoldersAndIssuanceAxis">tbio:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:SeriesAWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-07-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2010Q4Dec29_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-12-29</xbrli:startDate>
			<xbrli:endDate>2010-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan.31_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">tbio:CraigHallumCapitalGroupLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2June14">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-14</xbrli:startDate>
			<xbrli:endDate>2016-06-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan06_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-06</xbrli:startDate>
			<xbrli:endDate>2016-01-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2010Q4Dec29_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-12-29</xbrli:startDate>
			<xbrli:endDate>2010-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tbio:SeriesA1ConvertiblePreferredStockandWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-06</xbrli:startDate>
			<xbrli:endDate>2016-01-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-06</xbrli:startDate>
			<xbrli:endDate>2016-01-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q1March5_us-gaap_ClassOfWarrantOrRightAxis_tbio_ThirdSecurityLlcAndAffiliatesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tbio:ThirdSecurityLlcAndAffiliatesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-03-05</xbrli:startDate>
			<xbrli:endDate>2014-03-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tbio:A2016WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tbio:A2016WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q1Feb28_us-gaap_FairValueByLiabilityClassAxis_tbio_A2012WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tbio:A2012WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-02-01</xbrli:startDate>
			<xbrli:endDate>2012-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1January_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tbio:A2016WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_FairValueByLiabilityClassAxis_tbio_A2012WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tbio:A2012WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByLiabilityClassAxis_tbio_A2012WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tbio:A2012WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByLiabilityClassAxis_tbio_A2012WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tbio:A2012WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_FairValueByLiabilityClassAxis_tbio_A2012WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tbio:A2012WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByLiabilityClassAxis_tbio_A2012WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tbio:A2012WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByLiabilityClassAxis_tbio_A2012WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tbio:A2012WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tbio:A2016WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tbio:A2016WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tbio:A2016WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tbio:A2016WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tbio:EquityIncentivePlan2006Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tbio:EquityIncentivePlan2006Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tbio:EquityIncentivePlan2006Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tbio:EquityIncentivePlan2006Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Apr.13_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-04-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Apr.13_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-13</xbrli:startDate>
			<xbrli:endDate>2017-04-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Apr.13_dei_LegalEntityAxis_tbio_PrecipioMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbio:PrecipioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-04-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Apr.13_dei_LegalEntityAxis_tbio_AegisCorpMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbio:AegisCorpMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-04-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Apr.13_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-13</xbrli:startDate>
			<xbrli:endDate>2017-04-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Apr.13_dei_LegalEntityAxis_tbio_AegisCorpMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbio:AegisCorpMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-13</xbrli:startDate>
			<xbrli:endDate>2017-04-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Apr.13_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-04-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Apr.13_dei_LegalEntityAxis_tbio_PrecipioMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">tbio:PrecipioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-04-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="investor">
		<xbrli:measure>tbio:investor</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="Director">
		<xbrli:measure>tbio:Director</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="operating_segment">
		<xbrli:measure>tbio:operating_segments</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2017Q1YTD" id="Fact-77E2FA7438E055B2B5868E367106435D">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2017Q1YTD" id="Fact-C7BEBAF7E37357CF9D9F6891FFC81A2A">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2017Q1YTD" id="Fact-2D844C58D6B65F97904A0635AD41E5FA">Q1</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2017Q1YTD" id="Fact-7B127109A24B53D6B45A2B14CB45BB76">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q1YTD" id="Fact-D58282200EFD56E5A65221A4081357B7">2017-03-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q1YTD" id="Fact-C86911E45FD65724AA3BD73D3EE10FB5">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q1YTD" id="Fact-FBF0DD49DA645629B9E0362B7FC2475F">0001043961</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2017Q2Apr.30" decimals="INF" id="Fact-5362D9BD7742573F92CF81470B94A0E7" unitRef="shares">26863062</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2017Q1YTD" id="Fact-B1475BD6F5BC5AB8B69950DF23497405">Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2017Q1YTD" id="Fact-EB17C316FD83579181998CC517F6D774">TRANSGENOMIC INC</dei:EntityRegistrantName>
	<tbio:AdditionalShorttermLoanMaximumAmountAuthorized contextRef="I2017Q2Apr.13_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-FD0E64AAE931F7DD45A5F2C6CBB8B1DC" unitRef="usd">100000</tbio:AdditionalShorttermLoanMaximumAmountAuthorized>
	<tbio:CashPaymentPortionofStockWarrantsExercised contextRef="FI2017Q1_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesAWarrantsMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-FF4D9517BE065E9E81DBBA98B028B30A" unitRef="usd">470599</tbio:CashPaymentPortionofStockWarrantsExercised>
	<tbio:CashPaymentPortionofStockWarrantsExercised contextRef="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-CCF223F86DB559D8A2A209C0E7B1805A" unitRef="usd">718441</tbio:CashPaymentPortionofStockWarrantsExercised>
	<tbio:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights contextRef="D2012Q1Feb28_us-gaap_FairValueByLiabilityClassAxis_tbio_A2012WarrantLiabilityMember" decimals="-5" id="Fact-C410676AE9A55B02980D0C5F17F2E691" unitRef="shares">3400000</tbio:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights>
	<tbio:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights contextRef="D2016Q1January_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember" decimals="-5" id="Fact-DCB4A0B3787A5AAAABF5C623D983AEB2" unitRef="shares">1800000</tbio:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights>
	<tbio:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights contextRef="D2017Q2Apr.13_dei_LegalEntityAxis_tbio_AegisCorpMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-821787A7D24CEF1815B2F2F3AB13B349" unitRef="shares">168000</tbio:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights>
	<tbio:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights contextRef="D2017Q2Apr.13_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-D47A50DFA5419EB1DED3F2D5863AE953" unitRef="shares">1150000.00</tbio:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights>
	<tbio:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights contextRef="FD2017Q1YTD" decimals="INF" id="Fact-5FDDEEE9096F540FACB474695B3155F5" unitRef="shares">2933106</tbio:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights>
	<tbio:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights contextRef="FD2017Q1YTD_us-gaap_SubsidiarySaleOfStockAxis_tbio_OfferingMember" decimals="INF" id="Fact-4F6BF24631E0543E89ACF4A2DCDAD6B3" unitRef="shares">1881456</tbio:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights>
	<tbio:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights contextRef="FD2017Q1YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-29B4E39737F05BE4A3A0F3BFF58533C0" unitRef="shares">1051650</tbio:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights>
	<tbio:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights contextRef="FD2017Q1YTD_us-gaap_TitleOfIndividualAxis_us-gaap_ExecutiveOfficerMember" decimals="INF" id="Fact-28F40CC934635B0BBF5D8E6B702ABEE5" unitRef="shares">83333</tbio:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights>
	<tbio:ClassofWarrantorRightExchangePriceofWarrantsorRights contextRef="FI2017Q1_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesAWarrantsMember" decimals="2" id="Fact-90CA018DF70351BDB868484D38A18B66" unitRef="usdPerShare">0.50</tbio:ClassofWarrantorRightExchangePriceofWarrantsorRights>
	<tbio:ClassofWarrantorRightExchangePriceofWarrantsorRights contextRef="FI2017Q1_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesAWarrantsMember" decimals="INF" id="Fact-CE31AF5560325F2B8583A51EB0E557E5" unitRef="usdPerShare">0.50</tbio:ClassofWarrantorRightExchangePriceofWarrantsorRights>
	<tbio:ClassofWarrantorRightExchangePriceofWarrantsorRights contextRef="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember" decimals="INF" id="Fact-914C2A912CA35D1F9E315015AA672602" unitRef="usdPerShare">0.50</tbio:ClassofWarrantorRightExchangePriceofWarrantsorRights>
	<tbio:ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment contextRef="D2016Q1Jan06_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesA1WarrantMember" id="Fact-B5AE8577CE7E5F3A997E61D8C973FED4">P90D</tbio:ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment>
	<tbio:ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment contextRef="FD2017Q1YTD_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesAWarrantsMember" id="Fact-359F4C51F70C53DBB79B1827A8E10695">P90D</tbio:ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment>
	<tbio:ClassofWarrantorRightExerciseTerm1 contextRef="D2016Q1January_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember" id="Fact-5992D8FEBD275960B373FA13E393A98B">P5Y</tbio:ClassofWarrantorRightExerciseTerm1>
	<tbio:ClassofWarrantorRightExerciseTerm1 contextRef="FD2017Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember" id="Fact-9933F3CFEF0C5877B1BD823D5E436A53">P5Y</tbio:ClassofWarrantorRightExerciseTerm1>
	<tbio:ClassofWarrantorRightNumberofIssuedWarrantsExpired contextRef="FD2017Q1YTD" decimals="INF" id="Fact-7AB92F4DDFF0FCF8672CF865EB30C332" unitRef="shares">3362276</tbio:ClassofWarrantorRightNumberofIssuedWarrantsExpired>
	<tbio:ConvertibleNotesNumberOfSecuritiesCalledByNote contextRef="I2010Q4Dec29-2012_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-3C8F8A42C7F09F3D3399F37AB29B72C8" unitRef="shares">1293102</tbio:ConvertibleNotesNumberOfSecuritiesCalledByNote>
	<tbio:DebtConversionConvertedInstrumentInterest contextRef="FI2017Q1_dei_LegalEntityAxis_tbio_PrecipioMember" decimals="-5" id="Fact-0134699435F2D3BFA01FE99C743A325F" unitRef="usd">800000</tbio:DebtConversionConvertedInstrumentInterest>
	<tbio:DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease contextRef="FD2017Q1YTD_us-gaap_LongtermDebtTypeAxis_tbio_TermLoanMember" decimals="INF" id="Fact-484529AED4255516BC36F1A267D17432" unitRef="number">0.05</tbio:DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease>
	<tbio:DebtInstrumentDebtDefaultPeriod contextRef="FD2016Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" id="Fact-4B386130782397334E360D6262EAF9FF">P10D</tbio:DebtInstrumentDebtDefaultPeriod>
	<tbio:DebtInstrumentFutureDebtExtinguishmentCosts contextRef="FD2017Q1YTD_us-gaap_LongtermDebtTypeAxis_tbio_TermLoanMember" decimals="-4" id="Fact-7342896A0CC658E093DB5F250D9E5F78" unitRef="usd">120000</tbio:DebtInstrumentFutureDebtExtinguishmentCosts>
	<tbio:DebtInstrumentNumberofAdditionalAccreditedInvestors contextRef="I2015Q1Jan15_us-gaap_SubsidiarySaleOfStockAxis_tbio_AdditionalNotePrivatePlacementMember" decimals="INF" id="Fact-482CC73837455483A71C11A9FC9D780D" unitRef="investor">7</tbio:DebtInstrumentNumberofAdditionalAccreditedInvestors>
	<tbio:DebtInstrumentPremiumFeePercentage contextRef="I2017Q2Apr.13_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-2CBD3194362B86F4A8D4F2D2CDB57892" unitRef="number">0.2</tbio:DebtInstrumentPremiumFeePercentage>
	<tbio:DebtInstrumentPrepaymentPenaltyPercent contextRef="FD2017Q1YTD_us-gaap_LongtermDebtTypeAxis_tbio_TermLoanMember" decimals="INF" id="Fact-22E4D3A1B91950309396A8EE92571BF7" unitRef="number">0.01</tbio:DebtInstrumentPrepaymentPenaltyPercent>
	<tbio:DelinquentAccountsPayable contextRef="FI2017Q1" decimals="-5" id="Fact-079365C21B9744B9E46DE9BA75DE6737" unitRef="usd">600000</tbio:DelinquentAccountsPayable>
	<tbio:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense contextRef="FD2016Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-9D78BBBD379E550DAD1B7ADFD9208847" unitRef="usd">68000</tbio:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense>
	<tbio:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense contextRef="FD2017Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-5364480A0DEE529E95F8C6C0359D7F0D" unitRef="usd">0</tbio:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense>
	<tbio:DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense contextRef="FD2016Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-53578C7EB9825C6BA0CF7765343722D1" unitRef="usd">1025000</tbio:DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense>
	<tbio:DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense contextRef="FD2017Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-338D2187F3385C20BC786737EDEB839F" unitRef="usd">-65000</tbio:DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense>
	<tbio:DividendsPreferredStockCashNotDeclared contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-B9C26E4D809C98C6C287F8B031A6AF86" unitRef="usd">0</tbio:DividendsPreferredStockCashNotDeclared>
	<tbio:GainLossOnStockWarrantsRevaluation contextRef="FD2016Q1YTD" decimals="-3" id="Fact-38365E2BC02A54B497998617432747F5" unitRef="usd">321000</tbio:GainLossOnStockWarrantsRevaluation>
	<tbio:GainLossOnStockWarrantsRevaluation contextRef="FD2017Q1YTD" decimals="-3" id="Fact-1F5752F69D1B5AAB81C189CBB2A1B1B9" unitRef="usd">-33000</tbio:GainLossOnStockWarrantsRevaluation>
	<tbio:InitialFairValueofWarrantsIssued contextRef="D2016Q1Jan.8" decimals="-5" id="Fact-C293045C1A71E1BB9790F31BF49A7092" unitRef="usd">1800000</tbio:InitialFairValueofWarrantsIssued>
	<tbio:InitialFairValueofWarrantsIssued contextRef="FD2016Q1YTD" decimals="-3" id="Fact-309813067BFE59E1886D521DA17BADBD" unitRef="usd">1827000</tbio:InitialFairValueofWarrantsIssued>
	<tbio:InitialFairValueofWarrantsIssued contextRef="FD2017Q1YTD" decimals="-3" id="Fact-CC0036CC7516551AB8AD9EF906767A3F" unitRef="usd">0</tbio:InitialFairValueofWarrantsIssued>
	<tbio:InterestIncomeAndExpenseNet contextRef="FD2016Q1YTD" decimals="-3" id="Fact-2E8FC0545E9C5F31949661693149F5B6" unitRef="usd">-169000</tbio:InterestIncomeAndExpenseNet>
	<tbio:InterestIncomeAndExpenseNet contextRef="FD2017Q1YTD" decimals="-3" id="Fact-952C5F46BED8526980F932698F065FE5" unitRef="usd">-247000</tbio:InterestIncomeAndExpenseNet>
	<tbio:LoantoRelatedPartyPercentage contextRef="I2017Q2Apr.13_dei_LegalEntityAxis_tbio_PrecipioMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-330419A81A6BD957F681F2DD3D418F3E" unitRef="number">0.5</tbio:LoantoRelatedPartyPercentage>
	<tbio:LossContingencyDeferredPayment contextRef="FI2017Q1_us-gaap_LitigationCaseAxis_tbio_SmithMember" decimals="-5" id="Fact-666E3B8EB95DC9DAC4BBFDBA28E9F204" unitRef="usd">400000</tbio:LossContingencyDeferredPayment>
	<tbio:NumberOfDirectors contextRef="FI2017Q1_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="INF" id="Fact-A031BE5B90D9A1AC8E31F384E04352A5" unitRef="Director">2</tbio:NumberOfDirectors>
	<tbio:OtherIncomeExpense contextRef="FD2016Q1YTD" decimals="-3" id="Fact-8985644F538D52F9A4180528512FFD36" unitRef="usd">152000</tbio:OtherIncomeExpense>
	<tbio:OtherIncomeExpense contextRef="FD2017Q1YTD" decimals="-3" id="Fact-F9169D5606C1502DB2D396FE93B89B34" unitRef="usd">-280000</tbio:OtherIncomeExpense>
	<tbio:PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds contextRef="D2016Q1January_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember" decimals="INF" id="Fact-CA25BC5BBA365227948CC34034CBE86D" unitRef="number">0.07</tbio:PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds>
	<tbio:PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares contextRef="D2016Q1January_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember" decimals="INF" id="Fact-EFA5B5EBF1A05CF5B20AED75FEDB89A0" unitRef="shares">107527</tbio:PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares>
	<tbio:PercentageofInitialNote contextRef="I2015Q1Jan20_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsidiarySaleOfStockAxis_tbio_AgentNoteMember" decimals="2" id="Fact-504F90D085C73519EE7DE9AFB364F13F" unitRef="number">0.05</tbio:PercentageofInitialNote>
	<tbio:PlacementFees contextRef="D2017Q2Apr.13_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-D950A09476C4073D3E5FF2EB09CEC6A9" unitRef="usd">84000</tbio:PlacementFees>
	<tbio:PlacementFeesPercentageofGrossSalesPrice contextRef="I2016Q2June7_us-gaap_ClassOfWarrantOrRightAxis_tbio_AttheMarketOfferingAgreementMember_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember" decimals="INF" id="Fact-868361F50D355658B2643CD386880B14" unitRef="number">0.0325</tbio:PlacementFeesPercentageofGrossSalesPrice>
	<tbio:PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent contextRef="I2017Q2Jan.17_us-gaap_DebtInstrumentAxis_tbio_AdditionalNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="4" id="Fact-82BF52BA6A71F8D74FAF0D959B058F10" unitRef="number">0.3333</tbio:PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent>
	<tbio:PreferredStockDividendRateCompoundPercentageMaximum contextRef="FD2017Q1YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-C28B7855C608C4A5593CF384007BB3C9" unitRef="number">0.5</tbio:PreferredStockDividendRateCompoundPercentageMaximum>
	<tbio:ProceedsFromtheSalesofDebtInstrument contextRef="D2017Q2Apr.13_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-DD6E926A88EC04645050F2C9CCC869D5" unitRef="usd">1031000</tbio:ProceedsFromtheSalesofDebtInstrument>
	<tbio:ProceedsfromIssuanceofCommonStockandWarrantsNet contextRef="D2016Q1Jan.8_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember" decimals="-5" id="Fact-FCFF14133063DA6DC148F32127E86CE6" unitRef="usd">2000000</tbio:ProceedsfromIssuanceofCommonStockandWarrantsNet>
	<tbio:Proceedsfromissuanceofcommonstockandconvertiblenotes contextRef="D2010Q4Dec29" decimals="-5" id="Fact-FD338058B4AC5F2B83AFF37B749F1854" unitRef="usd">6000000</tbio:Proceedsfromissuanceofcommonstockandconvertiblenotes>
	<tbio:RequiredCumulativePaymentonPrincipalPerAmendmentPercent contextRef="I2017Q2Jan.17_us-gaap_DebtInstrumentAxis_tbio_AdditionalNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="4" id="Fact-BAC022ED3A96712FCFEF0D8718AA6466" unitRef="number">0.6667</tbio:RequiredCumulativePaymentonPrincipalPerAmendmentPercent>
	<tbio:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber contextRef="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" decimals="INF" id="Fact-BD2BBCDAB6BC58F49CBB54B8346C523B" unitRef="shares">83333</tbio:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
	<tbio:StockIssuanceCostsReimbursableExpenses contextRef="D2016Q1January_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember" decimals="INF" id="Fact-2758F423C1B85C4F95D06C24FF54D9C2" unitRef="usd">50000</tbio:StockIssuanceCostsReimbursableExpenses>
	<tbio:StockWarrantExchangeAmount contextRef="FI2017Q1_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesAWarrantsMember" decimals="0" id="Fact-652AB86AEEA85D1C8EE59002FC97B0D3" unitRef="usd">941197</tbio:StockWarrantExchangeAmount>
	<tbio:StockWarrantExchangeAmount contextRef="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember" decimals="0" id="Fact-ADE4D8F7C6DE52FD8474C47FFCF5F404" unitRef="usd">1436882</tbio:StockWarrantExchangeAmount>
	<tbio:StockWarrantExchangeAmount contextRef="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember" decimals="-5" id="Fact-7603FFFE3BA755589B61F7566C26ED05" unitRef="usd">1400000</tbio:StockWarrantExchangeAmount>
	<tbio:StockWarrantsSettledwithCash contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-F0CBEB03AB69C08FA5B5F3581FD1E9C5" unitRef="usd">500000</tbio:StockWarrantsSettledwithCash>
	<tbio:StockWarrantsSettledwithCash contextRef="FD2017Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-E95622CB1D4FFD3C7643F35891AB5520" unitRef="usd">500000</tbio:StockWarrantsSettledwithCash>
	<tbio:StockholdersEquityNoteConversionRatio contextRef="D2014Q1Mar5_tbio_WarrantyHoldersAndIssuanceAxis_tbio_ThirdSecurityLlcAndAffiliatesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-B37DAC7E5449055D40F7F3888901E5E0" unitRef="number">1</tbio:StockholdersEquityNoteConversionRatio>
	<tbio:StockholdersEquityNoteConversionRatio contextRef="D2014Q1March5_us-gaap_ClassOfWarrantOrRightAxis_tbio_ThirdSecurityLlcAndAffiliatesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-0FD3B742BF05535495300BEEE63422B2" unitRef="number">1</tbio:StockholdersEquityNoteConversionRatio>
	<tbio:StockholdersEquityNoteConversionRatio contextRef="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember" decimals="INF" id="Fact-8F6865A782205B70AB58F1A4A4E2359E" unitRef="number">1</tbio:StockholdersEquityNoteConversionRatio>
	<tbio:StockholdersEquityNoteConversionRatio contextRef="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="4" id="Fact-D5031117EFDC519DB68FEBF3AFC3A554" unitRef="number">0.3333</tbio:StockholdersEquityNoteConversionRatio>
	<tbio:StockholdersEquityNoteConversionRatio contextRef="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-82449F24F60B5DB6A3AADB3F7FFBE146" unitRef="number">1</tbio:StockholdersEquityNoteConversionRatio>
	<tbio:StockholdersEquityNoteConversionRatio contextRef="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-54991483E484FFEB1C01F38A82B2FB5F" unitRef="number">1</tbio:StockholdersEquityNoteConversionRatio>
	<tbio:StockholdersEquityNoteConversionRatio contextRef="FD2014Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-BDB77DE2876DC7645108F37E63F30B72" unitRef="number">4</tbio:StockholdersEquityNoteConversionRatio>
	<tbio:StockholdersEquityNoteReverseStockSplitConversionRatio contextRef="I2016Q4Oct31_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="1" id="Fact-178DE498BE79C4CB0573E91DA7C0B2AA" unitRef="number">0.1</tbio:StockholdersEquityNoteReverseStockSplitConversionRatio>
	<tbio:StockholdersEquityNoteReverseStockSplitConversionRatio contextRef="I2016Q4Oct31_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="4" id="Fact-B2CA087CEFE3F30C8707E91DD4ED30BC" unitRef="number">0.0333</tbio:StockholdersEquityNoteReverseStockSplitConversionRatio>
	<tbio:WorkingCapitalDeficiency contextRef="FI2017Q1" decimals="-5" id="Fact-70DAC75A63D45B22B633C66ABF89DEEA" unitRef="usd">-20600000</tbio:WorkingCapitalDeficiency>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-B0D35571DBEF5F3AB2E079A5AEC57052" unitRef="usd">6541000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-5935C4A446655682873A06B7BB3C2821" unitRef="usd">8509000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-0F4278BD683A5E7D83137FCA47C9A217" unitRef="usd">225000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-94F3EE7C812F52B1BC72C88DDB2FC212" unitRef="usd">279000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-B9584FD88D7952A9B713AAA09249F6C6" unitRef="usd">3546000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-E7667456AD1A53D29902B6C855390700" unitRef="usd">3398000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2016Q4" decimals="-3" id="Fact-5E885BA8703654BC9A20763BDBE5C0CE" unitRef="usd">205877000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q1" decimals="-3" id="Fact-EE250F3EDE08561D9313A7DEEB78C864" unitRef="usd">206342000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2016Q1YTD" decimals="-5" id="Fact-B4836450215AD5AF10E7F9B32C3DA381" unitRef="usd">100000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q1YTD" decimals="-5" id="Fact-3273AC17E3E8513997AF5527FEADD130" unitRef="usd">100000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q1YTD" decimals="INF" id="Fact-4B7B2AF74E135293BA58B4229062F634" unitRef="shares">12970881</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1YTD" decimals="INF" id="Fact-135DEDACB9FA5CE2A2F871968E651251" unitRef="shares">4425218</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-3" id="Fact-5F2E72B4A12F5D1D9C0147EE03523303" unitRef="usd">1259000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q1" decimals="-3" id="Fact-FF0DF1900C995BC882B78CFBEAAB6CE6" unitRef="usd">1229000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-0E3484CB28555074AF165D7BAB01680F" unitRef="usd">495000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-5C6648CF82BD572981B4B3D8C13AB1E6" unitRef="usd">567000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-12389464AA95537BBE2F2D52FC042706" unitRef="usd">31000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-2A7435CECF6D50CDBA7C9DEA9DFC4238" unitRef="usd">24000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2017Q1_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember" decimals="-5" id="Fact-B377A72D71935459C9A61C2AEDAD5B25" unitRef="usd">100000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-4F56E0A95BA451F380D11A7B185770B0" unitRef="usd">444000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q1" decimals="-3" id="Fact-091E1662DA845A70ADFF9D3821175E97" unitRef="usd">222000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-3E9E77B1B88F5817A52AE79E488562F0" unitRef="usd">110000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q1" decimals="-3" id="Fact-3016AF7B2E565A5582FE5B72CF061BB1" unitRef="usd">59000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q1YTD" decimals="-3" id="Fact-89F72D8584345F85877CDD92A8744C7D" unitRef="usd">-222000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q1YTD" decimals="-3" id="Fact-D08FBA82925956D1A8105991C1AE6A56" unitRef="usd">-51000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="FD2016Q1YTD" decimals="-3" id="Fact-665610394F995045A019FC65FF8F4923" unitRef="usd">-612000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
	<us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="FD2017Q1YTD" decimals="-3" id="Fact-D94CC00490205468B2225509E3C4168E" unitRef="usd">80000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_AffiliatesofThirdSecurityLLCJanuary2018Member" decimals="INF" id="Fact-F40CBB9A48BE50E8A8B9A9E494870BD4" unitRef="usdPerShare">9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_AffiliatesofThirdSecurityLLCJanuary2021Member" decimals="INF" id="Fact-FAB11609EEE45D7C9D6D71CC0D012D84" unitRef="usdPerShare">1.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersApril2020Member" decimals="INF" id="Fact-A8C019165A385D81BAAA9E7B2E7EE773" unitRef="usdPerShare">4.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersDecember2020OneMember" decimals="INF" id="Fact-8AF647C96AD655A3AD50CEA37A9D8718" unitRef="usdPerShare">1.66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersFebruary2020Member" decimals="INF" id="Fact-A296A47572E85906B0EEDE77322A1829" unitRef="usdPerShare">2.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersJanuary2018Member" decimals="INF" id="Fact-38C380E003055514BED8167BDE0D54FF" unitRef="usdPerShare">9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersJanuary2021OneMember" decimals="INF" id="Fact-F538B3ECC6B55B56B3055C7EE79575A2" unitRef="usdPerShare">1.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersJanuary2021TwoMember" decimals="INF" id="Fact-30CF2C5FF30855059B175B5DA9F1B23F" unitRef="usdPerShare">1.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_tbio_AttheMarketOfferingAgreementMember_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember" decimals="INF" id="Fact-3CB6C75C89A551A287E1BFBAC5336638" unitRef="usdPerShare">4.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q1_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesAWarrantsMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-E04FBBA6F5D25CF28B545A69FAC3FDDE" unitRef="usdPerShare">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember" decimals="INF" id="Fact-95A18435D9155C83A71253624C6A8AC1" unitRef="usdPerShare">1.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-8DAF322651F958CCA84F2A72C05FC831" unitRef="usdPerShare">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2010Q4Dec29-2012_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-CE9FEA3A56057F65CD80F37B02776983" unitRef="usdPerShare">2.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2010Q4Dec29-2012_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-960410D4DB8CFA072FA0F37A62FF4C76" unitRef="usdPerShare">2.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2013Q1Jan24-2013_tbio_WarrantyHoldersAndIssuanceAxis_tbio_ThirdSecurityLlcAndAffiliatesMember" decimals="INF" id="Fact-079E4F0E4F2C57E7B20404F424793010" unitRef="usdPerShare">12.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2014Q1Mar5-2014_tbio_WarrantyHoldersAndIssuanceAxis_tbio_ThirdSecurityLlcAndAffiliatesMember" decimals="INF" id="Fact-9C4DC1A8D02557C2924709BC542772DA" unitRef="usdPerShare">11.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q1Jan.31_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember" decimals="INF" id="Fact-2FF32945488B5221AC986765691DAADB" unitRef="usdPerShare">4.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q1Jan.8_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-50134AE9B86E56FBB6779C1110ABD38B" unitRef="usdPerShare">0.93</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-E6105B1C394D5A719C5C12E5C6BE4E6F" unitRef="usdPerShare">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q2Apr.13_dei_LegalEntityAxis_tbio_AegisCorpMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-D0A191D59B4CAD4C2812F2F415DAD3BA" unitRef="usdPerShare">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q2Apr.13_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-F860472518A20018F4EEF2D7648B71FA" unitRef="usdPerShare">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="I2016Q1Jan.8_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C8E0AF1BA11E5516922EF329590DD37E" unitRef="shares">0.93</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="I2016Q1Jan.8_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-F8FCDEE757B1551FB3BBC3AB3488866F" unitRef="shares">1.075269</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q1_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesAWarrantsMember" decimals="INF" id="Fact-7E7E0AAF60EA5E61BB08BC22DF73231F" unitRef="shares">1161972</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q1_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesAWarrantsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-EB72130A87B8574FB7AC3EE2A9F59A90" unitRef="shares">1882395</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q1_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-8633EB3221B751DCB894102A69F63A52" unitRef="shares">2873765</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2013Q1Jan24-2013_tbio_WarrantyHoldersAndIssuanceAxis_tbio_ThirdSecurityLlcAndAffiliatesMember" decimals="INF" id="Fact-71A27FD687A85CE088122AF6CF24240A" unitRef="shares">1097600</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2014Q1Mar5-2014_tbio_WarrantyHoldersAndIssuanceAxis_tbio_ThirdSecurityLlcAndAffiliatesMember" decimals="INF" id="Fact-E2AF4FAA174E5369BD2131CD868B1987" unitRef="shares">1212665</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2015Q3July7_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesAWarrantsMember" decimals="INF" id="Fact-D2F750662F625CDD9500BB6CD33EF875" unitRef="shares">1161972</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2016Q1Jan.8_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-7089B7B819A65F76BDD1608B822D466D" unitRef="shares">1773929</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2016Q1Jan06_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_ClassOfWarrantOrRightAxis_tbio_SeriesAWarrantsMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-FA8184B61E21531A963FFB1162D402F1" unitRef="shares">1882395</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-3FD53329466A506597332442389CA372" unitRef="shares">3334011</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_AffiliatesofThirdSecurityLLCJanuary2018Member" decimals="INF" id="Fact-3DBCEB93EA855DAA9BCA91362E5343B2" unitRef="shares">250000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_AffiliatesofThirdSecurityLLCJanuary2021Member" decimals="INF" id="Fact-62ECA2FDFAF8559C9E9E209CC1CF82C6" unitRef="shares">161026</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersApril2020Member" decimals="INF" id="Fact-DCA5895C207A5821946D6A1101C05168" unitRef="shares">374618</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersDecember2020OneMember" decimals="INF" id="Fact-9DCE7697FE5A57A791B9F3E82D88EB3B" unitRef="shares">122433</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersFebruary2020Member" decimals="INF" id="Fact-3E1C696B181351C6A972806C902EC8CE" unitRef="shares">714780</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersJanuary2018Member" decimals="INF" id="Fact-9B9EC4EC559C587C9DF9B75ECEB22A07" unitRef="shares">441655</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersJanuary2021OneMember" decimals="INF" id="Fact-8870EBC9275454CBA40670C1062F97EB" unitRef="shares">1161972</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_tbio_WarrantyHoldersAndIssuanceAxis_tbio_VariousInstitutionalHoldersJanuary2021TwoMember" decimals="INF" id="Fact-2C83B707235A57B58F10171B088DBE4E" unitRef="shares">107527</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q1_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember" decimals="-5" id="Fact-39E7E328F183A135778DE9ED0695FFF6" unitRef="shares">800000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommonStockDividendsShares contextRef="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-596338F916AA5120977CF019C5D95BF6" unitRef="shares">3681590</us-gaap:CommonStockDividendsShares>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-1F275DF84E2753939DC60FEF8C8F4723" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q1" decimals="INF" id="Fact-A69A42F1F61B562A9EB4BF9E2EA4E443" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-51D73058943A5C5892E98754CD1B66C9" unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q1" decimals="INF" id="Fact-8867DD3469795F90BC804EEB79F3E419" unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2016Q2June7_us-gaap_ClassOfWarrantOrRightAxis_tbio_AttheMarketOfferingAgreementMember_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember" decimals="INF" id="Fact-B5856A4FA9F65A2FB3FB58E697474A09" unitRef="shares">3500000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-A2ACD6F415645211BBAD21A9DBA723C5" unitRef="shares">26446927</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_tbio_AttheMarketOfferingAgreementMember_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember" decimals="INF" id="Fact-72C203376B3254C694657708567C9E38" unitRef="shares">1177849</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q1" decimals="INF" id="Fact-7107EE3C0C505CE697983B1DA2FFE6E6" unitRef="shares">26863062</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-FF35913F0E175C27B416575C723FC3EA" unitRef="shares">26446927</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q1" decimals="INF" id="Fact-B791DB4F3F3E5FBDB54482955FE57258" unitRef="shares">26863062</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-631BA3669160560593EA4C06FA144C0F" unitRef="usd">264000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2017Q1" decimals="-3" id="Fact-4B7C4B1368FA5C97BD5DF1AD3963CC0A" unitRef="usd">268000</us-gaap:CommonStockValue>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="D2017Q1Feb.2_dei_LegalEntityAxis_tbio_PrecipioMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-74BB67A9EABEDB830F92E918487B633B" unitRef="usd">3000000</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2016Q1YTD" decimals="-3" id="Fact-0C353721178556318AA52AFABA3FB905" unitRef="usd">199000</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2016Q4YTD" decimals="-5" id="Fact-2C235940A9A0B9AA517DF321541F2D54" unitRef="usd">200000</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2017Q1YTD" decimals="-3" id="Fact-6DFDA134EB8852EC8A773CA7B050366A" unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A4D3CBD4C3535B94A7BFB74E0EB96C58" unitRef="shares">862057</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-4F5F1B4D4C8A5033B08CF5EEF4D463E8" unitRef="shares">2586205</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-0D3B0E5623D4552386774AAD0610740D" unitRef="shares">1443297</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-65543F6C8C8D5CCFB3DF2D80C8A203DF" unitRef="shares">1443297</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2016Q1Jan06_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-DFD7E75A77925F888F9CA0B47E56B266" unitRef="shares">2305354</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2016Q2May_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-9F9273C4E53F5CEFA55880B295D12E06" unitRef="shares">2150538</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2016Q2May_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-5E5D12496B935C31AD60E601DB1CCB22" unitRef="shares">2150538</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2017Q1Feb.2_dei_LegalEntityAxis_tbio_PrecipioMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-064758D1C625F8965BF9E91798EC05B7" unitRef="shares">160600000</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2017Q1Feb.2_dei_LegalEntityAxis_tbio_PrecipioMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-C0EB93B6F12E7741B6C4E917FDC375DE" unitRef="shares">24100000</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember" decimals="INF" id="Fact-07BDCF75B6FA5E4502DBF357A68F3108" unitRef="shares">1006419</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_tbio_A2016WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-EB78648B20AAE20B2589F357D3CD0EC6" unitRef="shares">1613353</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2016Q1YTD" decimals="-3" id="Fact-98280E6D502C512FADDBBCE0B027D6ED" unitRef="usd">505000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2017Q1YTD" decimals="-3" id="Fact-9023038B532A580FA415F1FC88FD25DB" unitRef="usd">459000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2016Q4" decimals="-3" id="Fact-0EE8716B782E5B7A8EC1211A507C9497" unitRef="usd">7814000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2016Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="-3" id="Fact-E4FFD1003FE151D2B4B8AF6CC4077EB5" unitRef="usd">3243000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_tbio_TermLoanMember" decimals="-3" id="Fact-8134F533ECA55F1EAB2539D01ADFA678" unitRef="usd">4000000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="-3" id="Fact-7CF82E5D0E865864B946EA9C0FAEED76" unitRef="usd">571000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q1" decimals="-3" id="Fact-3EB17AF9CB50590B924E962DD5C85049" unitRef="usd">7368000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q1_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="-3" id="Fact-AE06E7EA669A5FDC82FDC5A1C4E3D513" unitRef="usd">3243000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q1_us-gaap_LongtermDebtTypeAxis_tbio_TermLoanMember" decimals="-3" id="Fact-BE0F8FDEFACD55F08842FAAA6DD32964" unitRef="usd">4000000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q1_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="-3" id="Fact-328EED228A0D5C8ABBEBA91CACB903B5" unitRef="usd">125000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="FD2016Q1YTD" decimals="-3" id="Fact-455AD66FF36252319A3A81B18872E2E8" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="FD2016Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsidiarySaleOfStockAxis_tbio_AdditionalNotePrivatePlacementMember" decimals="INF" id="Fact-655CBD3BDED95566942A385755793CBE" unitRef="usd">400000</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="FD2017Q1YTD" decimals="-3" id="Fact-0821300461AD5EE5B46132DD17D2A5BA" unitRef="usd">499000</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="FD2017Q1YTD_dei_LegalEntityAxis_tbio_PrecipioMember" decimals="-5" id="Fact-6899464182E66A16B1F4E99BFD5DACC8" unitRef="usd">7200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="D2016Q4Dec.31_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsidiarySaleOfStockAxis_tbio_AdditionalNotePrivatePlacementMember" decimals="INF" id="Fact-F7034D4CA8CF528389A680992740092B" unitRef="shares">281023</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="D2017Q1Feb.2_dei_LegalEntityAxis_tbio_PrecipioMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertibleCommonStockMember" decimals="-5" id="Fact-3010DA872C43F41AFEA9E99A44EF5A81" unitRef="shares">10400000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="D2017Q1Feb.2_dei_LegalEntityAxis_tbio_PrecipioMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-5" id="Fact-5FD5155D16F17F9ADBD3E99B90D48F2D" unitRef="shares">24100000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="D2017Q1Jan.13_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsidiarySaleOfStockAxis_tbio_AgentNoteMember" decimals="INF" id="Fact-ECA5C4ECF60B68C99F92E9B2CBF348AA" unitRef="shares">416135</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="FD2017Q1YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-D79122B3CC9F5EEEA64A9EFA0321956C" unitRef="shares">502786</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="FD2017Q1YTD_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_tbio_WallStreetJournalPrimeRateMember" decimals="INF" id="Fact-30AA232998E35710AEB3D64382F6FB11" unitRef="number">0.03</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2014Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-E843150E702E5EB1B14ADC42D16B87F4" unitRef="usd">750000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2013Q1March13-2013_us-gaap_LineOfCreditFacilityAxis_tbio_ThirdSecurityLlcAndAffiliatesMember_us-gaap_LongtermDebtTypeAxis_tbio_TermLoanMember" decimals="INF" id="Fact-87487D6AA57853EFB4E4C7D968214D12" unitRef="usd">4000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2015Q1Jan20_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsidiarySaleOfStockAxis_tbio_AdditionalNotePrivatePlacementMember" decimals="INF" id="Fact-D94364E824595E8B801408BD531E40D8" unitRef="usd">925000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2015Q1Jan20_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsidiarySaleOfStockAxis_tbio_AgentNoteMember" decimals="INF" id="Fact-974C5A3501A8740877CBE9AFE67D7FC1" unitRef="usd">46250</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2016Q1Jan06_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-2A3B6927203350829DDD322F7E0892F4" unitRef="usd">750000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2017Q1Jan.13_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsidiarySaleOfStockAxis_tbio_AgentNoteMember" decimals="INF" id="Fact-58792A7276116A54D150E9B2A5F1636B" unitRef="usd">446250</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2017Q2Apr.13_dei_LegalEntityAxis_tbio_PrecipioMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-E85BB80B84CEA98444BDF2E0DFBDD000" unitRef="usd">561500</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2017Q2Apr.13_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-1B4AF4E0FBEF08710B42F283C2783CCB" unitRef="usd">1150000.00</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="FI2017Q1_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="4" id="Fact-D70F0E598D1750BDB9456A27477C827F" unitRef="number">0.0675</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2014Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-35AA45C13EC35BBCA6B12D435E91CA4F" unitRef="number">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-61D21988A8B1504A90CAFF7848A38B4F" unitRef="number">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q1_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="INF" id="Fact-4376870078035B78AD92682B2D06D117" unitRef="number">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2017Q2Apr.13_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-11CBBC52690FE8E0DA58F2CCC306EAA9" unitRef="number">0.04</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentTerm contextRef="D2017Q2Apr.13_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-87770853348A18F5780EF2CF40E9DCA5">P90D</us-gaap:DebtInstrumentTerm>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-BDE3A142B1EA5799A57C4332052F6172" unitRef="usd">170000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q4_us-gaap_StatementBusinessSegmentsAxis_tbio_PharmacogenomicServicesMember" decimals="-5" id="Fact-1850EBD568B511AE88E8E94BD18CE963" unitRef="usd">200000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-05F4BE6E58E2554EAAABCE12B7CC30F9" unitRef="usd">133000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q1_us-gaap_StatementBusinessSegmentsAxis_tbio_PharmacogenomicServicesMember" decimals="-5" id="Fact-831A296C98425FC8874BE293E6E4FEFF" unitRef="usd">100000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:Depreciation contextRef="FD2016Q1YTD" decimals="-5" id="Fact-3A748C5772295498900F691685EC51D1" unitRef="usd">100000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2017Q1YTD" decimals="-5" id="Fact-3E9036B23413501590D6C6CB102D679C" unitRef="usd">100000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q1YTD" decimals="-3" id="Fact-65A9A3044BE25016BD400DE8434B4830" unitRef="usd">83000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q1YTD" decimals="-3" id="Fact-0DF7665E14405ED883E973A6FD6E11FF" unitRef="usd">48000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="FD2016Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-8ABE8EA67C50559BB4A3A5DC82A9799E" unitRef="usd">-1173000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
	<us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="FD2017Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-C7EDB2CD675F50659CEBF2F4F8CD5BA6" unitRef="usd">73000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
	<us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax contextRef="FD2016Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-3B18D630060A54469A74BB3654D2FFD2" unitRef="usd">-1173000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax>
	<us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax contextRef="FD2017Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-16EAB9D2BE6351EC9A8E99DB3D7C4D10" unitRef="usd">118000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax>
	<us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="FD2016Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-358AD725630A5A4B81C0DEDF20D7DB2A" unitRef="usd">0</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
	<us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="FD2017Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-47576F5528B4567BB144DE23C58660D1" unitRef="usd">0</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="FD2016Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-C7ACF493D7FB5006ADCD742692038AC5" unitRef="usd">1183000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="FD2017Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-6992CFE75D695B82A732FCDF546700B5" unitRef="usd">15000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef="FD2016Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-63B54814B69B58269F9E8FCC2B7126AD" unitRef="usd">-80000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef="FD2017Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-31F9D718B37E5CB4A9A633DB6D14261C" unitRef="usd">53000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="FD2016Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-B2832E5E23305BD5940F338639F7FD00" unitRef="usd">1103000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="FD2017Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-EFBA4DA9D82C5F9EB48187FE02DABA75" unitRef="usd">68000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
	<us-gaap:Dividends contextRef="D2016Q1Jan.8_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-5" id="Fact-32B15B6154DA26BEC6A1F3222CFC98CF" unitRef="usd">400000</us-gaap:Dividends>
	<us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="I2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-AD3CC7C36EDA55598FB33B195369AD08" unitRef="usd">3700000</us-gaap:DividendsPayableCurrentAndNoncurrent>
	<us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="I2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-3A5745955ADC5B0C90BB1E4DB211B8DE" unitRef="usd">800000</us-gaap:DividendsPayableCurrentAndNoncurrent>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q1YTD" decimals="2" id="Fact-13C7E8F535C959FA94442EEAAD06DC20" unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q1YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember" decimals="2" id="Fact-77E51A9D70FE579AAB55E9170E768D36" unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q1YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember" decimals="2" id="Fact-66F1E5A5481F53D5B847AECC968AE829" unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q1YTD" decimals="2" id="Fact-C5D454A5D4B153E795CF2072CCEBE3CD" unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q1YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember" decimals="2" id="Fact-62EDE4B730605E059B96F680497E8FF1" unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q1YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember" decimals="2" id="Fact-1CD86AEF58CE59E1BA09D46693212FFD" unitRef="usdPerShare">0.00</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-A28827987FEF56CB99E7C7D8F17069EA" unitRef="usd">224000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-6289DAE33AE0536FB89F55159A871159" unitRef="usd">192000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="FI2017Q1" decimals="-5" id="Fact-663397120C3C589BA190904B151E58D8" unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2016Q1YTD" decimals="-3" id="Fact-18F5342763F2557A817A857D0C9F46F9" unitRef="usd">-321000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2017Q1YTD" decimals="-3" id="Fact-A22170586C295D14B27F185FC09151F1" unitRef="usd">33000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q1YTD_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember" decimals="2" id="Fact-50DA4D99CAFC50A18CAEADA9E3A99B32" unitRef="number">1.15</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q1YTD_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember" decimals="4" id="Fact-7BD7E52CABD25DBD80DA397D7338F4E8" unitRef="number">0.0166</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2016Q1YTD_us-gaap_FairValueByLiabilityClassAxis_tbio_A2012WarrantLiabilityMember" decimals="-3" id="Fact-1FCBEDF3F5F1583A879C2700E2CF6B13" unitRef="usd">330000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2016Q1YTD_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember" decimals="-3" id="Fact-D24651D2CCD05909995AD2B4EB6D56E3" unitRef="usd">-9000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2017Q1YTD_us-gaap_FairValueByLiabilityClassAxis_tbio_A2012WarrantLiabilityMember" decimals="-3" id="Fact-EC67794B666F54C392E75B07B2A6247F" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2017Q1YTD_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember" decimals="-3" id="Fact-EEA53D6F567D6870AC9CE9EEB1E6E4ED" unitRef="usd">-33000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2016Q1YTD_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember" decimals="-3" id="Fact-AB19AAD4567D55FA9B26FF325D34FF24" unitRef="usd">1437000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2017Q1YTD_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember" decimals="-3" id="Fact-CBE881300EEBEB2FB562E9EEAFDF9D39" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2015Q4_us-gaap_FairValueByLiabilityClassAxis_tbio_A2012WarrantLiabilityMember" decimals="-3" id="Fact-08E9AADE78DB568E8B47F63F200A14E2" unitRef="usd">350000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2015Q4_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember" decimals="-3" id="Fact-FFD0F726D40858E6AEDF673E113DC7BA" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2016Q1_us-gaap_FairValueByLiabilityClassAxis_tbio_A2012WarrantLiabilityMember" decimals="-3" id="Fact-AD8089A286BF5A97A0293E0B5E749345" unitRef="usd">20000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2016Q1_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember" decimals="-3" id="Fact-2A1CA18C5A9F5A0FBA8F13B2B722B3AD" unitRef="usd">1446000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2016Q4_us-gaap_FairValueByLiabilityClassAxis_tbio_A2012WarrantLiabilityMember" decimals="-3" id="Fact-C23766C1242C56E1B9FB385C405F1E93" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2016Q4_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember" decimals="-3" id="Fact-D539320B510208EF4B0CE9EEACC0D52C" unitRef="usd">582000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q1_us-gaap_FairValueByLiabilityClassAxis_tbio_A2012WarrantLiabilityMember" decimals="-3" id="Fact-D15B513EACD6527394FFBB1721928A6E" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q1_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember" decimals="-3" id="Fact-D736D39126A289B9F40CE9EEB3E80F27" unitRef="usd">615000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="FI2017Q1" decimals="-5" id="Fact-BA85DB9171D4551288E3B21330AB6E44" unitRef="usd">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="FI2017Q1" decimals="-5" id="Fact-AE1F27F5A04450A096124C12EFB5591C" unitRef="usd">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="FI2017Q1" decimals="-5" id="Fact-65054EBA0A925AB783B67386178D0D16" unitRef="usd">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="FI2017Q1" decimals="-5" id="Fact-B30F1084D31A597193258B4F93517433" unitRef="usd">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="FI2017Q1" decimals="-5" id="Fact-B0152969C5EA1EA6867FE985B5030661" unitRef="usd">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:GainLossOnContractTermination contextRef="FD2016Q1YTD" decimals="-3" id="Fact-D40E1C5C0489C1443065FDA1151BEA77" unitRef="usd">0</us-gaap:GainLossOnContractTermination>
	<us-gaap:GainLossOnContractTermination contextRef="FD2017Q1YTD" decimals="-3" id="Fact-40C5A4B684C127C94AA6FDA1151BC0A1" unitRef="usd">-358000</us-gaap:GainLossOnContractTermination>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2016Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-915D81E378BA59D7B77AE6B149CF2630" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2017Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-288F70B1ABD8504D9303995669330CB0" unitRef="usd">-45000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GrossProfit contextRef="FD2016Q1YTD" decimals="-3" id="Fact-14738EBE2904524C87DFDBD22F329A22" unitRef="usd">-269000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q1YTD" decimals="-3" id="Fact-8450D2921D1D5B13BC5EF4C5C22DF7B1" unitRef="usd">199000</us-gaap:GrossProfit>
	<us-gaap:IncomeLossFromContinuingOperations contextRef="FD2016Q1YTD" decimals="-3" id="Fact-321CBEA0CF4E5D66A4B943718736A23D" unitRef="usd">-2091000</us-gaap:IncomeLossFromContinuingOperations>
	<us-gaap:IncomeLossFromContinuingOperations contextRef="FD2017Q1YTD" decimals="-3" id="Fact-076161B0F791548586FE272098C1F513" unitRef="usd">-1835000</us-gaap:IncomeLossFromContinuingOperations>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2016Q1YTD" decimals="-3" id="Fact-869F76817F765249A3217E14AF21EA3E" unitRef="usd">-2091000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2017Q1YTD" decimals="-3" id="Fact-6AE5B7444F9F53BFAD42D558840E58FF" unitRef="usd">-1835000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="FD2016Q1YTD" decimals="-3" id="Fact-65EFC242F9AF56A5B39627021E4C5DA6" unitRef="usd">-1173000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="FD2016Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-E03CA3C54B7C51E1BF22E4D5C6B18111" unitRef="usd">-1173000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="FD2017Q1YTD" decimals="-3" id="Fact-82070AD11B715B87A8C200EE8EC7D8CD" unitRef="usd">73000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="FD2017Q1YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tbio_GeneticAssaysandPlatformsandPatientTestingMember" decimals="-3" id="Fact-C56B499FA2B950E8969BF52B99309327" unitRef="usd">73000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q1YTD" decimals="-3" id="Fact-B22D920F418452AA8747D0B3D6F12711" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q1YTD" decimals="INF" id="Fact-B21DE7C4CBBB53AAA2EEAA0E9A1527BA" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q1YTD" decimals="-3" id="Fact-C1E8ACD046375EB08404856699E72473" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q1YTD" decimals="INF" id="Fact-8E0C8BDBAEA259E7BC37F718A35F3827" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2016Q1YTD" decimals="-3" id="Fact-EEA4ED3E8AD95A30AE133091FA1557BD" unitRef="usd">1230000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q1YTD" decimals="-3" id="Fact-F3BE71413D7850339691BBD0D89763FF" unitRef="usd">1967000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q1YTD" decimals="-3" id="Fact-C824B125AFE4591C96F15ADB93FB2351" unitRef="usd">-73000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q1YTD" decimals="-3" id="Fact-1C3E4B39438859CF98F003F599650506" unitRef="usd">55000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="FD2016Q1YTD" decimals="-3" id="Fact-C1A2DC59B10B54A591D2BB6F1136ECD4" unitRef="usd">17000</us-gaap:IncreaseDecreaseInInterestPayableNet>
	<us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="FD2017Q1YTD" decimals="-3" id="Fact-686B05E0850D5D07A677B46388F8B4FE" unitRef="usd">0</us-gaap:IncreaseDecreaseInInterestPayableNet>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2016Q1YTD" decimals="-3" id="Fact-08BC186F6DF652D38D66B2F3138E8666" unitRef="usd">-6000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2017Q1YTD" decimals="-3" id="Fact-F6D68496496C53D8B9DBDE82004E23A9" unitRef="usd">-9000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="FD2016Q1YTD" decimals="-3" id="Fact-AC182E0074185E4B9638ABEFDF6C777E" unitRef="usd">-481000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="FD2017Q1YTD" decimals="-3" id="Fact-9BAC32478E585DC7B4B4F55F4C083AD8" unitRef="usd">-587000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2016Q1YTD" decimals="-3" id="Fact-15E3061F04E250AF8C5A9FEA1A03DCF7" unitRef="usd">-41000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2017Q1YTD" decimals="-3" id="Fact-92641FCFD69B5AB09AFAC7AB62E6D23A" unitRef="usd">45000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2016Q4" decimals="-3" id="Fact-9AD3B2AA8D945394AD1B57473F55D576" unitRef="usd">562000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2017Q1" decimals="-3" id="Fact-247BF11946D95220B60FC7DC2FD9F865" unitRef="usd">531000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestPaid contextRef="FD2016Q1YTD" decimals="-3" id="Fact-A42D9C835FCA5B189F5F4FF0E23E672B" unitRef="usd">0</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2017Q1YTD" decimals="-3" id="Fact-E74C941534D25E32944E279EDF1A5466" unitRef="usd">0</us-gaap:InterestPaid>
	<us-gaap:InterestPayableCurrentAndNoncurrent contextRef="I2017Q1Jan.13_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsidiarySaleOfStockAxis_tbio_AgentNoteMember" decimals="-5" id="Fact-14B7C1BB6CA8C5DC5411F9D9E5F0FE93" unitRef="usd">100000</us-gaap:InterestPayableCurrentAndNoncurrent>
	<us-gaap:InventoryNet contextRef="FI2016Q4" decimals="-3" id="Fact-899A143A345055F08A696635E70809B5" unitRef="usd">24000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2017Q1" decimals="-3" id="Fact-BA90E3AAB36154469D07C40C84F707B3" unitRef="usd">15000</us-gaap:InventoryNet>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-3" id="Fact-54C1EC5C7954564FA57482102D53CC68" unitRef="usd">20609000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2017Q1" decimals="-3" id="Fact-A1FCC76463255075879E62C5788BD42E" unitRef="usd">21872000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-F8B88B0A7555559CBB6DB9AAFB8A38A2" unitRef="usd">1259000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q1" decimals="-3" id="Fact-CDD8F3AE7C4958DDB4938E02F7F7F6EB" unitRef="usd">1229000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-21E814D3613E5499A8B495AFF9E4827A" unitRef="usd">19824000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-97443BE8F3C3564AA11828236054B356" unitRef="usd">21129000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LineOfCreditFacilityCommitmentFeeAmount contextRef="FD2017Q1YTD_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="INF" id="Fact-77287D45E6BE5452B03511C3701B74B4" unitRef="usd">20000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
	<us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity contextRef="I2013Q1March13-2013_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LineOfCreditFacilityAxis_tbio_ThirdSecurityLlcAndAffiliatesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="INF" id="Fact-A659A8049B6D511884DD9E7A66CD4A5B" unitRef="usd">4000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage contextRef="FD2017Q1YTD_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="INF" id="Fact-B3FAD4A052335D62BE0F33C40577109E" unitRef="number">0.005</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
	<us-gaap:LongTermDebt contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="-5" id="Fact-3A3D33773187EB2D9A37E9B1E7468DA5" unitRef="usd">600000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="I2017Q1Jan.13_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_SubsidiarySaleOfStockAxis_tbio_AgentNoteMember" decimals="-5" id="Fact-D92E2B93586527BD7A22E9B2F9EE55F2" unitRef="usd">100000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-CF5755D29070572F840803F52EE7179D" unitRef="usd">7814000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-3972C2D4DACD52EB94EE4FD7034926CD" unitRef="usd">7368000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-99B538E277A05D1582EC44C864FDB160" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2017Q1" decimals="-3" id="Fact-5244B76C2F155A82A442AFEBF36EF331" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtPercentageBearingVariableInterestRate contextRef="FI2017Q1_us-gaap_LongtermDebtTypeAxis_tbio_TermLoanMember" decimals="3" id="Fact-18A1E533993851CB89A5EAC1DDF9F694" unitRef="number">0.091</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2016Q4_us-gaap_LitigationCaseAxis_tbio_CPAGlobalMember" decimals="-5" id="Fact-437615F612CD5ECD9946E9C571FA1B0A" unitRef="usd">200000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2016Q4_us-gaap_LitigationCaseAxis_tbio_EdgeBioSystemsInc.Member" decimals="-5" id="Fact-0685EC11116F776D49E3E9C727E835E5" unitRef="usd">100000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2016Q4_us-gaap_LitigationCaseAxis_tbio_MountSinaiMember" decimals="-5" id="Fact-8079930FA3405D88B30F62C07EB24605" unitRef="usd">700000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2016Q4_us-gaap_LitigationCaseAxis_tbio_UNMCMember" decimals="-5" id="Fact-8B9E97801AC45286810CD15CEEC13D05" unitRef="usd">400000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2016Q4_us-gaap_LitigationCaseAxis_tbio_XIFINInc.Member" decimals="-5" id="Fact-7829EF71B68C25896043E9C041ED936F" unitRef="usd">200000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2017Q1_us-gaap_LitigationCaseAxis_tbio_CPAGlobalMember" decimals="-5" id="Fact-DEBBE4FA8CF129A1EB09E9C516E81977" unitRef="usd">200000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2017Q1_us-gaap_LitigationCaseAxis_tbio_EdgeBioSystemsInc.Member" decimals="-5" id="Fact-7BCCA4219AD78DE09E72E9C6CC8B5FAA" unitRef="usd">100000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2017Q1_us-gaap_LitigationCaseAxis_tbio_MountSinaiMember" decimals="-5" id="Fact-A60BB6820AD65CF5BDF99387ADF2B46C" unitRef="usd">700000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2017Q1_us-gaap_LitigationCaseAxis_tbio_SmithMember" decimals="-5" id="Fact-B5A4BFCA128CECD57BB7FDB5C76A2ED6" unitRef="usd">600000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2017Q1_us-gaap_LitigationCaseAxis_tbio_UNMCMember" decimals="-5" id="Fact-46E2CDDF38D0562EB4F66F31872FF4F0" unitRef="usd">400000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2017Q1_us-gaap_LitigationCaseAxis_tbio_XIFINInc.Member" decimals="-5" id="Fact-9ED195E361003575EB00F8BA9B53DCF5" unitRef="usd">300000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyDamagesAwardedValue contextRef="D2016Q4Oct.27_us-gaap_LitigationCaseAxis_tbio_MountSinaiMember" decimals="-5" id="Fact-2B8CF77266A811361236E9BEBBAE9882" unitRef="usd">700000</us-gaap:LossContingencyDamagesAwardedValue>
	<us-gaap:LossContingencyDamagesAwardedValue contextRef="D2017Q1Feb.6_us-gaap_LitigationCaseAxis_tbio_UNMCMember" decimals="-5" id="Fact-E0313F8CD34180A969E3E9BDA0A34AB1" unitRef="usd">400000</us-gaap:LossContingencyDamagesAwardedValue>
	<us-gaap:LossContingencyDamagesAwardedValue contextRef="D2017Q1Mar.6_us-gaap_LitigationCaseAxis_tbio_ScienceParkDevelopmentCorporationMember" decimals="-5" id="Fact-30E1B68D86B435F40C8BE9C3E98FA09F" unitRef="usd">400000</us-gaap:LossContingencyDamagesAwardedValue>
	<us-gaap:LossContingencyDamagesAwardedValue contextRef="D2017Q2Apr.7_us-gaap_LitigationCaseAxis_tbio_SmithMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-8FB6B7EE703F22298E41FDB392DB3D7F" unitRef="usd">600000</us-gaap:LossContingencyDamagesAwardedValue>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2016Q1Feb25_us-gaap_LitigationCaseAxis_tbio_UNMCMember" decimals="-5" id="Fact-1FF2A97FD83756EE8A20EC87A74878D3" unitRef="usd">700000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2016Q2June23_us-gaap_LitigationCaseAxis_tbio_MountSinaiMember" decimals="-5" id="Fact-64745DF9691A529EB3F43FF0E68A88BF" unitRef="usd">700000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2016Q3Sep.13_us-gaap_LitigationCaseAxis_tbio_EdgeBioSystemsInc.Member" decimals="-5" id="Fact-65D26189723AAA8CFC20E9C694326779" unitRef="usd">100000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2016Q4Dec.19_us-gaap_LitigationCaseAxis_tbio_SmithMember" decimals="-5" id="Fact-7FDE9948A29FE9560F07E9BF7A44C850" unitRef="usd">2200000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2016Q4Nov.30_us-gaap_LitigationCaseAxis_tbio_ScienceParkDevelopmentCorporationMember" decimals="-5" id="Fact-DC23D2A8D41D4A301C33E9C363C765F9" unitRef="usd">400000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2017Q1Feb.21_us-gaap_LitigationCaseAxis_tbio_XIFINInc.Member" decimals="-4" id="Fact-F43E18757EB41A66489AE9BFB80B819D" unitRef="usd">270000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2017Q1Feb.6_us-gaap_LitigationCaseAxis_tbio_CPAGlobalMember" decimals="-5" id="Fact-6392A9F6B7EA76D758ABE9C47889E2B4" unitRef="usd">200000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q1YTD" decimals="-3" id="Fact-C17D93B038BF5C28B40DB231803B5E50" unitRef="usd">1728000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q1YTD" decimals="-3" id="Fact-BA13E6AA19CA5893AC7D268FD38CC760" unitRef="usd">-1000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q1YTD" decimals="-3" id="Fact-4B0C9214474E5E81A3F5568AF41157E8" unitRef="usd">-26000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q1YTD" decimals="-3" id="Fact-2F7E15BB99CE5C9585FFDC0FC031FAC6" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q1YTD" decimals="-3" id="Fact-A75EBDA1D4E35928BC6CF50BADED547D" unitRef="usd">-1924000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q1YTD" decimals="-3" id="Fact-0336565425825CF4AF286B867E96BD5B" unitRef="usd">-50000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2016Q1YTD" decimals="-3" id="Fact-21223DAA09A45302836FC5103FBBCFBF" unitRef="usd">-1312000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2017Q1YTD" decimals="-3" id="Fact-70DE3DB4EA055723948BFD63C5C0BE78" unitRef="usd">-130000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q1YTD" decimals="-3" id="Fact-5324F75CA8B75A6C923C27CDE71D7C7B" unitRef="usd">-3264000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1YTD" decimals="-3" id="Fact-7B656774AD72548F85011A94EE6A385A" unitRef="usd">-1762000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2016Q1YTD" decimals="-3" id="Fact-80CF626C68675ED2BB9E3F0A3C2C6DCE" unitRef="usd">-3657000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2016Q1YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember" decimals="-3" id="Fact-75459E3CBFEA5C7DAB0F81D62594F564" unitRef="usd">-2484000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2016Q1YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember" decimals="-3" id="Fact-D1175CE26FED52D9B8DA0DB16483B15E" unitRef="usd">-1173000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q1YTD" decimals="-3" id="Fact-57C8B0265064575E8642E57D6D2F8EF5" unitRef="usd">-1762000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q1YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember" decimals="-3" id="Fact-DFA1F94556C25EB585BFF04CA34E2015" unitRef="usd">-1835000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q1YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember" decimals="-3" id="Fact-2D4A0ED530345155AEFBDEF0DC75EBEB" unitRef="usd">73000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NumberOfOperatingSegments contextRef="D2015Q3Sep29" decimals="INF" id="Fact-F36B38451DE45C4BB20855604F52B8CE" unitRef="operating_segment">2</us-gaap:NumberOfOperatingSegments>
	<us-gaap:NumberOfOperatingSegments contextRef="FD2017Q1YTD" decimals="INF" id="Fact-C3E46B670D9F514DB48C4100275F0887" unitRef="operating_segment">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:OperatingExpenses contextRef="FD2016Q1YTD" decimals="-3" id="Fact-D5F0B05F6AEE5395BA5C4460AAFE8223" unitRef="usd">1974000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q1YTD" decimals="-3" id="Fact-65146C52F11A56758745E4AAC68599CB" unitRef="usd">1754000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q1YTD" decimals="-3" id="Fact-8412968B20C85F01921AD955D29D638B" unitRef="usd">-2243000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q1YTD" decimals="-3" id="Fact-D80239559E3554F98FCC1C6F0CCCF56B" unitRef="usd">-1555000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OtherAssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-BFA84DB9A1085731A240B23985540CA3" unitRef="usd">105000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2017Q1" decimals="-5" id="Fact-7F77CE6500945CA18CF55A1C5ACB4EDE" unitRef="usd">200000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-1F0108E32BC05EA391D32DF19D35D688" unitRef="usd">190000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-47BF3C6DB9595D478928CDAAE45B2632" unitRef="usd">58000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q1" decimals="-3" id="Fact-22CEA727FFD15DFE9E8BBD086D53EF25" unitRef="usd">4000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-B9685EF6B1235FE8AEADB6750D505941" unitRef="usd">1529000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2017Q1" decimals="-3" id="Fact-FC29D7BC1F09506DA6B13F12D3B92D0E" unitRef="usd">1529000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-FF51131E87DF54A381AE27013F2410A7" unitRef="usd">203000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q1" decimals="-3" id="Fact-1E4FAB7420CC59D89DE8F55E79DC8E6F" unitRef="usd">128000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherReceivablesNetCurrent contextRef="FI2017Q1" decimals="-5" id="Fact-B2FEB59A8C855561876063D9516823ED" unitRef="usd">100000</us-gaap:OtherReceivablesNetCurrent>
	<us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement contextRef="D2016Q1January_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember" decimals="INF" id="Fact-C250A717CA0857B39983A7304FE23450" unitRef="shares">3239827</us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement>
	<us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement contextRef="D2016Q1January_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-AB0CDE0BD6B6596894C7F61AA2D964D1" unitRef="shares">2188177</us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement>
	<us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_tbio_AttheMarketOfferingAgreementMember_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember" decimals="INF" id="Fact-18504499085FEBF261F8F36872556E6D" unitRef="shares">3362276</us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement>
	<us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_tbio_AttheMarketOfferingAgreementMember_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-E7EDE93965885311872F5C024429C4CC" unitRef="shares">3262088</us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2016Q1YTD" decimals="-3" id="Fact-84C48C47B8F750B389D13755486734C5" unitRef="usd">7000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2017Q1YTD" decimals="-3" id="Fact-0E804AA1195D5EA6900395F93974225B" unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2010Q4Dec29_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-5" id="Fact-BA9C0389B74C9EF44538F37BB6E75F08" unitRef="usd">200000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2016Q1January_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember" decimals="-4" id="Fact-180373F282F95680A8384B2AAE6F2940" unitRef="usd">140000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2016Q1YTD" decimals="-3" id="Fact-E6266B85938AA26A84E1F98D33EBE6A0" unitRef="usd">219000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q1YTD" decimals="-3" id="Fact-A7B579F50BC652BFB863BD803A74BBF9" unitRef="usd">19000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q1YTD" decimals="-3" id="Fact-CC2318E0DD4850FE93FE7D5FC4EE0936" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockDividendRatePercentage contextRef="FD2017Q1YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-3517B353734448C6E8C9F3820810EE18" unitRef="number">0.1</us-gaap:PreferredStockDividendRatePercentage>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2016Q1YTD" decimals="-3" id="Fact-4E3246BAF5BC5DC6B3696301DF382E72" unitRef="usd">393000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2017Q1YTD" decimals="-3" id="Fact-A98077F186075E119646744592C7F50E" unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-17B75EDDEB6F5AC384A106F19391DEE2" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q1" decimals="INF" id="Fact-8F5FFE8206445EB1909A9EC38C604553" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="I2014Q1Mar5-2014_tbio_WarrantyHoldersAndIssuanceAxis_tbio_ThirdSecurityLlcAndAffiliatesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-146DF4D1E057513D946A5321557F257B" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="I2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-3D6C4C38907A5E9888814EF9B5638A94" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-AD758FA1B1BF5A499B61B3EA423E34DD" unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q1" decimals="INF" id="Fact-2BB4BD2F50AD58798E439B90E7761260" unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-C670F6B9BC21BBB5467EF37CCE6BFDB0" unitRef="shares">3879307</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-706B587673515CC8819B23DDAEC2E38F" unitRef="shares">214705</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q1" decimals="INF" id="Fact-C084490023D8503B8A07775FCE253E11" unitRef="shares">214705</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-AF4EEE0EB3945D709F9B24DCDE03B18F" unitRef="shares">214705</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q1" decimals="INF" id="Fact-1DE020E368E05089BA48420A0D3F1EE7" unitRef="shares">214705</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q1_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-87752DD0B4E1543AA1BD2D9C026DCE40" unitRef="shares">214705</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="I2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-07A523F0EC705604BC63A87E93E89723" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="I2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-397147A9DE2A5FC19B91BAD77408B49C" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-5A2CEFC68F2F59E3AAFE3CB9DED5830A" unitRef="usd">2000</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q1" decimals="-3" id="Fact-851FF5441B465904A19A9792C40995F9" unitRef="usd">2000</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseCurrent contextRef="FI2017Q1" decimals="-5" id="Fact-015E0E4D5B5F5B489AEFAEA48EFE2C05" unitRef="usd">100000</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2016Q4QTD_us-gaap_ClassOfWarrantOrRightAxis_tbio_AttheMarketOfferingAgreementMember_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember" decimals="-5" id="Fact-BDE3C274E44B54F5A4FCD8B9D1E40397" unitRef="usd">500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2017Q1YTD_us-gaap_LongtermDebtTypeAxis_tbio_TermLoanMember" decimals="-5" id="Fact-8A93CFBEF8B35C56AB10EA64C411A4BB" unitRef="usd">4000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="FD2016Q1YTD" decimals="-3" id="Fact-2FC4892BA44A57ACB6FB1997ED77A53F" unitRef="usd">1779000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="FD2017Q1YTD" decimals="-3" id="Fact-C0500A21E1E358E89D7FCB3061F34A9E" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2016Q1YTD" decimals="-3" id="Fact-CA3542074D175E648D4C98FEFF841E48" unitRef="usd">500000</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2017Q1YTD" decimals="-3" id="Fact-B0E7CD1203D256D2A81CB811D3F01D56" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-3" id="Fact-609376D9A6F85811835D585B765156E1" unitRef="usd">144000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q1" decimals="-3" id="Fact-D670C28170EA5633A6E0B5CD650055F2" unitRef="usd">127000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="FD2016Q1YTD" decimals="-3" id="Fact-C25894A272C45D569873E70954B32CFF" unitRef="usd">21000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="FD2017Q1YTD" decimals="-3" id="Fact-07B79AB4594A5545A267C4DD31D669E5" unitRef="usd">1000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="FD2016Q1YTD" decimals="-3" id="Fact-F286C8A6520F5F41B97F3A2C06A8CA3E" unitRef="usd">1000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
	<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="FD2017Q1YTD" decimals="-3" id="Fact-A6C2385288DE56F8AE91F482607A968E" unitRef="usd">1000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
	<us-gaap:RepaymentsOfLongTermLinesOfCredit contextRef="FD2016Q1QTD_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="-5" id="Fact-AB96DA1BB79FE19BF2DEE99944CC589F" unitRef="usd">200000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
	<us-gaap:RepaymentsOfNotesPayable contextRef="FD2016Q1YTD" decimals="-3" id="Fact-FAA05DD4BD555416B7CBA334081FF24B" unitRef="usd">550000</us-gaap:RepaymentsOfNotesPayable>
	<us-gaap:RepaymentsOfNotesPayable contextRef="FD2017Q1YTD" decimals="-3" id="Fact-7AE29A5223425BE9AA5A7C3DA2E7D72E" unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q1YTD" decimals="-3" id="Fact-C2F09D565C0C5736B824D9B207A91875" unitRef="usd">270000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q1YTD" decimals="-3" id="Fact-A40065A0C7205084ADD1BAD3D7F04063" unitRef="usd">134000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-3" id="Fact-37FA50CC9FC353AA9A66143D0A8D6D23" unitRef="usd">-225493000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q1" decimals="-3" id="Fact-31D73186C02F51F9AE24D90069119A0A" unitRef="usd">-227255000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction contextRef="D2017Q1Feb.2_dei_LegalEntityAxis_tbio_PrecipioMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="2" id="Fact-8F654A7C5A9AF8802F6DE917C498CC1A" unitRef="number">0.52</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
	<us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction contextRef="D2017Q1Feb.2_dei_LegalEntityAxis_tbio_PrecipioMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="2" id="Fact-7B5640A0A963801FB88FE918846D2BC6" unitRef="number">0.08</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
	<us-gaap:SaleOfStockPricePerShare contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_tbio_AttheMarketOfferingAgreementMember_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember" decimals="INF" id="Fact-639A7F4CA3F55149AA29AAE637FCFA53" unitRef="usdPerShare">0.42</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2016Q1Jan.31_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember" decimals="2" id="Fact-D5B047E662E35A9FBC6CC165A14DC280" unitRef="usdPerShare">1.21</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SalesRevenueNet contextRef="FD2016Q1YTD" decimals="-3" id="Fact-F20D71B326B2570B945AFED5C8B64976" unitRef="usd">236000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2017Q1YTD" decimals="-3" id="Fact-7C2090F0589C57C5B115048C80AA529B" unitRef="usd">658000</us-gaap:SalesRevenueNet>
	<us-gaap:SecuredDebt contextRef="I2017Q2Apr.13_dei_LegalEntityAxis_tbio_PrecipioMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-DA0A9E548EDF12D34491F2E4D34E815D" unitRef="usd">500000</us-gaap:SecuredDebt>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2016Q1YTD" decimals="-3" id="Fact-CB5405A0FC0F51C7B216D513BEE29105" unitRef="usd">1704000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q1YTD" decimals="-3" id="Fact-6AF8EEC4AC4A5681A8046BD38892A635" unitRef="usd">1620000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q1YTD" decimals="-3" id="Fact-42C78027537E5D53B67602FF25CD36F6" unitRef="usd">110000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-52154CA9EBAF52E3BCDE232F0EF01257" unitRef="usd">100000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q1YTD" decimals="-3" id="Fact-7343ADF6E37D5354A236D26EBDA48741" unitRef="usd">-24000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="INF" id="Fact-65A01194A1645049BAC4D27F7D799CCD" unitRef="usd">0</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-B5554DC0073E5EAD9765709B858690E5">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2017Q1YTD_us-gaap_TitleOfIndividualAxis_us-gaap_ExecutiveOfficerMember" id="Fact-55003C94D350572ABE9BFBD976EED6A6">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" decimals="2" id="Fact-9BD37A27AE3551A89BCDF83068111554" unitRef="usdPerShare">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="FD2017Q1YTD" id="Fact-5DED37AD6D5E5815B52C516509A0B4FA">P1Y0M0D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" id="Fact-A5586F4F0EFE2992CFA4E9E1E3EFD96D">P6Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member" decimals="INF" id="Fact-4BCC411536B559E1B69E60989B756C78" unitRef="shares">547957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member" decimals="2" id="Fact-978AFAF94A07544DBF901E5482D95633" unitRef="usdPerShare">4.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member" decimals="INF" id="Fact-D5E1F41CCC0151C493A9A36033B6424F" unitRef="shares">62739</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2016Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member" decimals="INF" id="Fact-5114AB43E0505C6CABFB0DEF8EEAC0DA" unitRef="shares">14000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member" decimals="INF" id="Fact-C8825ADBFE905D66A410E6536B5872A3" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member" decimals="INF" id="Fact-255413A97AA95B84AF544D5123220AB2" unitRef="shares">738026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member" decimals="INF" id="Fact-ABF1D8E5FB835C6BBAAF1E68C09BB057" unitRef="shares">675287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member" decimals="2" id="Fact-CAB2071330E65D24964B3275DF188398" unitRef="usdPerShare">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member" decimals="2" id="Fact-F97F879573BE54998BAF9957C6AE0B96" unitRef="usdPerShare">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member" decimals="INF" id="Fact-777B8FA4C5B958B2AB36091F49BF15D2" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member" decimals="INF" id="Fact-45C5740742B45CCBADC873D4572D6C26" unitRef="shares">661914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member" decimals="2" id="Fact-3645E5C631BE5BA68AE4FB01E4C19BB3" unitRef="usdPerShare">2.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member" decimals="2" id="Fact-2D09F331DA895973B2F3F6531CB4B910" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharePrice contextRef="FI2017Q1_us-gaap_FairValueByLiabilityClassAxis_tbio_A2016WarrantLiabilityMember" decimals="INF" id="Fact-B5F36396FC06543B9365209AA8591E20" unitRef="usdPerShare">0.56</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2014Q1Mar5-2014_tbio_WarrantyHoldersAndIssuanceAxis_tbio_ThirdSecurityLlcAndAffiliatesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-FA3ED119404F530B84AFC2B5ADF4FA8A" unitRef="usdPerShare">4.85</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2016Q1Jan.31_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember" decimals="INF" id="Fact-EA0536A41A075656A18CCF3F5031BACD" unitRef="usdPerShare">50</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2016Q1Jan.31_us-gaap_CounterpartyNameAxis_tbio_CraigHallumCapitalGroupLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-74BEA560A86853ADBC8B6A0A9FBD307C" unitRef="usdPerShare">1.00</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2017Q1Feb.2_dei_LegalEntityAxis_tbio_PrecipioMember" decimals="INF" id="Fact-C25BCAC9F489F4DEF8A5E99B11438AAE" unitRef="usdPerShare">0.50</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="FI2017Q1_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" decimals="INF" id="Fact-BE88D0C69DC25CB6949F334558BF3D8E" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="FD2017Q1YTD" id="Fact-8C5004A4FDCF5000BA2E8349347F3B4D">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_tbio_EquityIncentivePlan2006Member" id="Fact-95D0AE809A26715ED516E9DABA0C517C">P7Y2M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharesIssued contextRef="I2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-8C7B47C0F8775000A68A1941980A1BDC" unitRef="shares">6780179</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="I2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-EA5EAC00E6C854898B311353524EDDCE" unitRef="shares">4474825</us-gaap:SharesIssued>
	<us-gaap:StockDividendsShares contextRef="D2016Q1Jan06_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-5364664F394A5EA09D0E78162A0E1458" unitRef="shares">793235</us-gaap:StockDividendsShares>
	<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="D2016Q2June14_us-gaap_CounterpartyNameAxis_tbio_VendorIIMember" decimals="INF" id="Fact-19309AC4F11B58F68F7F39376001EC6F" unitRef="shares">64153</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="D2016Q2May31_us-gaap_CounterpartyNameAxis_tbio_VendorMember" decimals="INF" id="Fact-8A1CD5BD5E79500C8C4717FEDDBDBDAD" unitRef="shares">78000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2010Q4Dec29_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-453AB71C3B51AEF2037AF379E9C29B39" unitRef="shares">2586205</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2014Q1Mar5_tbio_WarrantyHoldersAndIssuanceAxis_tbio_ThirdSecurityLlcAndAffiliatesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-66AD08BE20A0561A930A025A4C6E596B" unitRef="shares">1443297</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2016Q1Jan.8_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-AEDA993201A05B7E979117950FF86CD6" unitRef="shares">2365243</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="D2016Q2June14" decimals="-3" id="Fact-DCE5586917255AE3A438A639B9B55DA5" unitRef="usd">89000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="D2014Q1Mar5_tbio_WarrantyHoldersAndIssuanceAxis_tbio_ThirdSecurityLlcAndAffiliatesMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-5A752454072454ACA81BBF411B1BE4AC" unitRef="usd">7000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="D2016Q1Jan.8_tbio_WarrantyHoldersAndIssuanceAxis_tbio_SecurityPurchaseAgreementMember" decimals="-5" id="Fact-C37E0735D097FD512EFDF32103DA51D0" unitRef="usd">2200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-85A91CC40A4B5AE6B1947248F54CB203" unitRef="usd">-19350000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q1" decimals="-3" id="Fact-6BE707A239ED50A19B9F55E6831F61FA" unitRef="usd">-20643000</us-gaap:StockholdersEquity>
	<us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="D2011Q4Nov_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-448E45884D86EA329466F386CCB9F6A1" unitRef="usd">300000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2016Q4" decimals="-3" id="Fact-78C395F9DC625455AAC7D16AB4A6CFF1" unitRef="usd">582000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2017Q1" decimals="-3" id="Fact-072ECEC5EC4F5CF9A60FC2A99B7DC328" unitRef="usd">615000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q1YTD" decimals="0" id="Fact-1D450ADEE78A58048035EB9B03FFA223" unitRef="shares">20323333</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q1YTD" decimals="0" id="Fact-4AA083F8F3A95D6DA07EB78373FAD85C" unitRef="shares">26779835</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<tbio:ConcentrationOfCashPolicyPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-2BA88E402CD850A6A0577744BD5665B8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Concentrations of Cash.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</tbio:ConcentrationOfCashPolicyPolicyTextBlock>
	<tbio:RisksAndUncertaintiesPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-98D8BF9AA3BE5EBFAB4F69C15E058424">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Risks and Uncertainties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements.  The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</tbio:RisksAndUncertaintiesPolicyTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-B94E669FED6159CFB963B49EF8577DAE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying condensed consolidated financial statements are presented in conformity with GAAP. Supplemental cash flows from discontinued operations are presented in Note 3 - &amp;#8220;Discontinued Operations&amp;#8221;. We have evaluated events occurring subsequent to March 31, 2017 for potential recognition or disclosure in the condensed consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The condensed consolidated balance sheet as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2016. The accompanying condensed consolidated financial statements as of and for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) on April 13, 2017. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="FD2017Q1YTD" id="Fact-4A9CC0E7AD2653559DB3FBDE19360C27">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;BUSINESS DESCRIPTION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Business Description&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Transgenomic, Inc., and Subsidiary, (&amp;#8220;we&amp;#8221;, &amp;#8220;us&amp;#8221;, &amp;#8220;our&amp;#8221;, the &amp;#8220;Company&amp;#8221; or &amp;#8220;Transgenomic&amp;#8221;) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and integrated diseases through our proprietary molecular technologies and clinical and research services. A key goal is to bring our Multiplexed ICE COLD-PCR (&amp;#8220;MX-ICP&amp;#8221;) product to the clinical market through strategic partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring and treatment of cancer.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;MX-ICP is technology proprietary to Transgenomic. It is a reagent that improves the ability to detect genetic mutations. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital PCR. By enhancing the level of detection of genetic mutations and suppressing the normal or wild-type DNA, several benefits are provided.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Historically, our operations were organized and reviewed by management along our major product lines and presented in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; business segments: Laboratory Services and Genetic Assays and Platforms. Beginning with the quarter ended September 30, 2015, our operations are now organized as &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; business segment, our Laboratory Services segment, and during the fourth quarter of 2015, we began including a portion of our Laboratory Services segment as discontinued operations, this has continued through March 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our current Laboratory Services business consists of our laboratory in Omaha, Nebraska, which is focused on providing genetic analytical services related to Oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing service technologies, including our proprietary MX-ICP technology. Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments (&amp;#8220;CLIA&amp;#8221;) as a high complexity laboratory and is accredited by the College of American Pathologists.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our condensed consolidated balance sheets, statements of operations and statements of cash flows for all periods presented reflect our former Genetic Assays and Platforms activities and Patient Testing business as discontinued operations (See Note 3 - &amp;#8220;Discontinued Operations&amp;#8221;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Going Concern&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America applicable for a going concern, which assume that we will realize our assets and discharge our liabilities in the ordinary course of business. We have incurred substantial operating losses and have used cash in our operating activities for the past few years. As of March 31, 2017, we had negative working capital of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and we were also not in compliance with our loan agreement due to the fact that events of default existed, including our failure to make certain required monthly interest payments to the lenders. The Company&amp;#8217;s ability to continue as a going concern is dependent upon a combination of completing its planned merger with Precipio Diagnostics, LLC (&amp;#8220;Precipio&amp;#8221;), generating additional revenue, improving cash collections, potentially selling underutilized assets and/or product lines related to discontinued operations and, if needed, raising necessary financing to meet its obligations and pay its liabilities arising from normal business operations when they come due. Following the planned merger, Transgenomic will change its name to Precipio, Inc. (&amp;#8220;New Precipio&amp;#8221;). On February 17, 2017, Transgenomic received written notification from the staff of Nasdaq that, as a result of Transgenomic&amp;#8217;s inability to maintain certain Nasdaq continued listing requirements, Nasdaq had determined to delist Transgenomic&amp;#8217;s shares from Nasdaq.  Accordingly, trading in Transgenomic&amp;#8217;s shares was suspended, and on February 22, 2017, Transgenomic&amp;#8217;s shares began trading on the OTCQB exchange under the ticker &amp;#8220;TBIO&amp;#8221;.  As discussed below upon completion of the merger, the New Precipio common stock will be required to meet the Nasdaq listing standards.  As a result of the merger, New Precipio is expected to meet Nasdaq's initial listing requirements.  In addition, at the time of the merger the Company intends to execute a reverse stock split. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern for the next twelve months from the date of issuance of these condensed financial statements. These condensed consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. There is no assurance that the Company will complete the merger in a timely manner or at all. The merger agreement is subject to many closing conditions and termination rights. The Company also cannot be certain that additional financing, if needed, will be available on acceptable terms, or at all, and its failure to raise capital when needed could limit its ability to continue its operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:174%;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Merger Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October 12, 2016, Transgenomic, New Haven Labs Inc., a wholly owned subsidiary of Transgenomic (&amp;#8220;Merger Sub&amp;#8221; and, together with Transgenomic, the &amp;#8220;Transgenomic Parties&amp;#8221;), and Precipio entered into an Agreement and Plan of Merger (as amended by the Merger Agreement Amendment (as defined below) the &amp;#8220;Merger Agreement&amp;#8221;) pursuant to which Precipio will become a wholly owned subsidiary of Transgenomic (the &amp;#8220;Merger&amp;#8221;), on the terms and subject to the conditions set forth in the Merger Agreement. On February 2, 2017, Transgenomic, Merger Sub and Precipio entered into a First Amendment to Agreement and Plan of Merger (the &amp;#8220;Merger Agreement Amendment&amp;#8221;), which provided for, among other things, the revision of the exchange ratio set forth in the Merger Agreement, the waiver and removal of certain closing conditions and the authorization of certain actions taken by each of Transgenomic and Precipio since the date the Merger Agreement. The parties expect the Merger to close in the second quarter of 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon the effectiveness of the Merger (the &amp;#8220;Effective Time&amp;#8221;), (i)&amp;#160;the outstanding common units of Precipio will be converted into the right to receive approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;160.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock of New Precipio (&amp;#8220;New Precipio common stock&amp;#8221;), together with cash in lieu of fractional units, which will result in Precipio common unit holders owning approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the issued and outstanding shares of New Precipio common stock on a fully diluted basis, taking into account the issuance of shares of convertible preferred stock of New Precipio (&amp;#8220;New Precipio preferred stock&amp;#8221;) in the Merger and the private placement as discussed below (the &amp;#8220;fully diluted New Precipio common stock&amp;#8221;) and (ii)&amp;#160;the outstanding preferred units of Precipio will be converted into the right to receive approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of New Precipio preferred stock with an aggregate face amount equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (based upon the purchase price of the new preferred stock of New Precipio in the new preferred stock financing), which will result in the Precipio preferred unit holders owning approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the fully diluted New Precipio common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon completion of the merger, New Precipio will be required to meet the initial listing requirements to qualify its shares for listing and begin trading of its shares on Nasdaq. These initial listing requirements are more difficult to achieve than the continued listing requirements.&amp;#160; Pursuant to the Merger Agreement, Transgenomic agreed to use its commercially reasonable efforts to cause the shares of Transgenomic common stock being issued in the merger to be approved for listing on Nasdaq at or prior to the effective time of the merger. Based on information currently available to Transgenomic, Transgenomic anticipates that its stock will be unable to meet the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (or, to the extent applicable, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) minimum bid price initial listing requirement at the closing of the merger unless it effects a reverse stock split. On October 31, 2016, the stockholders of Transgenomic authorized the Transgenomic Board to effect a reverse stock split of the shares of Transgenomic common stock at a ratio of between one-for-ten to one-for-thirty, such ratio to be determined by our Board of Directors (the &amp;#8220;Reverse Split Proposal&amp;#8221;).  The Reverse Split Proposal was described in detail in our definitive proxy statement filed with the Securities and Exchange Commission on September 22, 2016, as supplemented on October 13, 2016.&amp;#160; In addition, often times a reverse stock split will not result in a trading price for the affected common stock that is proportional to the ratio of the split.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-89CAEBECF39E573D9D94F5589BF7AD86">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash and Cash Equivalents and Other Current Assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-0FF3CE166FB552AF8FE7664EC97FC79E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;CONTINGENCIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are subject to a number of claims of various amounts that arise out of the normal course of our business.  In addition to the claims described in this Note, we are delinquent on the payment of outstanding accounts payable amounting to approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with certain of our vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 25, 2016, the Board of Regents of the University of Nebraska (&amp;#8220;UNMC&amp;#8221;) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; owed by us to UNMC.  A &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. We and UNMC entered into a settlement agreement dated February 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to UNMC in installments over a period of time. As of March 15, 2017, the initial payment due to UNMC under the settlement agreement is delinquent. We and UNMC are currently in discussions to extend the date of the initial payment due to UNMC.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition, on April 13, 2016, Fox Chase Cancer Center (&amp;#8220;Fox Chase&amp;#8221;) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the &amp;#8220;Court of Common Pleas&amp;#8221;), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the &amp;#8220;License Agreement&amp;#8221;), as well as the assignment of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc. (&amp;#8220;IDT&amp;#8221;) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the &amp;#8220;IDT Agreement&amp;#8221;). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase&amp;#8217;s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney&amp;#8217;s fees.&amp;#160; Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by us as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; On June 23, 2016, the Icahn School of Medicine at Mount Sinai (&amp;#8220;Mount Sinai&amp;#8221;) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; owed by us to Mount Sinai for services rendered. We and Mount Sinai entered into a settlement agreement dated October 27, 2016, which included, among other things, a mutual general release of claims, and our agreement to pay approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Mount Sinai in installments over a period of time. A &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.  Effective as of February 1, 2017, we and Mount Sinai agreed to amend the terms of our settlement agreement to extend the date of the initial payment due to Mount Sinai.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December 19, 2016, Todd Smith (&amp;#8220;Smith&amp;#8221;) filed a lawsuit against us in the District Court of Douglas County Nebraska, alleging breach of contract and seeking recovery of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; owed by us to Smith for costs and damages arising from a breach of our obligations pursuant to a lease agreement between the parties.  On April 7, 2017, we entered into a settlement agreement with Smith related to the early termination of our lease for our Omaha, Nebraska facility. The agreement included, among other things, a mutual general release of claims, and our agreement to pay approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Smith in installments over a period of time. A &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; liability has been recorded and is reflected in accrued expenses at March 31, 2017. The accrued liability includes &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recorded as a net loss on the settlement and is included in other expense in our condensed consolidated statements of operations for the three months ended March 31, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 21, 2017, XIFIN, Inc. (&amp;#8220;XIFIN&amp;#8221;) filed a lawsuit against us in the District Court for the Southern District of California alleging breach of written contract and seeking recovery of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.27 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; owed by us to XIFIN for damages arising from a breach of our obligations pursuant to a Systems Services Agreement between us and XIFIN, dated as of February 22, 2013, as amended and restated on September 1, 2014. On April 5, 2017, the court clerk entered default against us. On May 5, 2017, XIFIN filed an application for entry of default judgment against us. A &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We and Science Park Development Corporation (&amp;#8220;SPDC&amp;#8221;) entered into that certain Lease dated as of December 31, 2011, as modified by the First Amendment to Lease dated as of June 18, 2013, as further modified by a letter agreement dated as of February 2, 2015, as modified by the Second Amendment to Lease dated as of June 26, 2015 (the &amp;#8220; SPDC Lease&amp;#8221;).   In November 2016, SPDC alleged that we defaulted on our obligations under the SPDC Lease.  Specifically, SPDC alleges that we failed to pay approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in rental payments due under the SPDC Lease and that we vacated a portion of the leased premises in violation of the terms of the SPDC Lease.  We and SPDC entered into a settlement agreement dated March 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to SPDC in installments over a period of time. This liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;CPA Global provides us with certain patent management services.  On February 6, 2017, CPA Global claimed that we owe approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for certain patent maintenance services rendered.  CPA Global has not filed claims against us in connection with this allegation.  A liability of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On March 9, 2016, counsel for Edge BioSystems, Inc. (&amp;#8220;EdgeBio&amp;#8221;) sent a demand letter on behalf of EdgeBio to us in connection with the terms of that certain Asset Purchase Agreement dated September 8, 2015 (the &amp;#8220;EdgeBio Agreement&amp;#8221;). EdgeBio alleges, among other things, that certain customers of EdgeBio erroneously remitted payments to us, that such payments should have been paid to EdgeBio and that we failed to remit these funds to EdgeBio in violation of the terms of the EdgeBio Agreement.  On September 13, 2016, we received a demand for payment letter from EdgeBio&amp;#8217;s counsel alleging that the balance due to EdgeBio is approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  A liability of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 17, 2017, Jesse Campbell (&amp;#8220;Campbell&amp;#8221;) filed a lawsuit individually and on behalf of others similarly situated against us in the District Court for the District of Nebraska alleging we have a materially incomplete and misleading proxy relating to a potential merger and that the merger agreement&amp;#8217;s deal protection provisions deter superior offers.&amp;#160; As a result, he alleges that we have violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9 promulgated thereafter.&amp;#160; Although we intend to defend the lawsuit, there can be no assurance regarding the ultimate outcome of this case.  Given the uncertainty of litigation, the legal standards that must be met for, among other things, class certification and success on the merits, we are unable to estimate the amount of loss, or range of possible loss, at this time that may result from this action. In the event that a settlement is reached related to these matters, the amount of such settlement may be material to our results of operations and financial condition and may have a material adverse impact on our liquidity.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-30192214A9EA56A199BFEE2C312091EF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-91C2B2A876225357885B09D28E548DEE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;DEBT&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Dollars&amp;#160;in&amp;#160;Thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revolving Line of Credit&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Term Loan&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible Promissory Notes &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(3)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;571&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,368&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,814&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current portion of long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,368&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,814&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term debt, net of current maturities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revolving Line of Credit.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;6.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or (b) the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Wall Street Journal&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; prime rate plus &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;3%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The current interest rate is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.75%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As discussed below under &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Additional Terms&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the interest rate is subject to increase if there is a default under the Loan Agreement. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$20,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line.  In addition, a fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;0.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum is payable quarterly on the unused portion of the Revolving Line.  The Revolving Line matures on November 1, 2017.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Term Loan.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under the Term Loan on the Effective Date.  Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;9.1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  As discussed below, the interest rate is subject to increase if there is a default under the Loan Agreement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We will pay the Lenders an additional final payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$120,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, at maturity or prepayment of the Term Loan, which has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the total outstanding balance under the Term Loan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Additional Terms.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Loan Agreement contains affirmative and negative covenants.  Under the Loan Agreement, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders&amp;#8217; consent.  Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of March 31, 2017, we were not in compliance with the Loan Agreement, as amended, due to the fact that events of default existed, including our failure to make certain required monthly interest payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. At March 31, 2017, our applicable interest rates have been increased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;   Convertible Promissory Notes. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Notes accrue interest at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year and matured on December 31, 2016. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revolving Line and Term Loan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On March 13, 2013 (the &amp;#8220;Effective Date&amp;#8221;), we entered into a Loan and Security Agreement with affiliates of Third Security, LLC, a related party, (the &amp;#8220;Lenders&amp;#8221;) for (a) a revolving line of credit (the &amp;#8220;Revolving Line&amp;#8221;) with borrowing availability of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, subject to reduction based on our eligible accounts receivable, and (b) a term loan (the &amp;#8220;Term Loan&amp;#8221; and, together with the Revolving Line, the &amp;#8220;Loan Agreement&amp;#8221;) of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. From the Effective Date through 2015, there were a number of amendments to the Loan Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 6, 2016, we entered into an eighth amendment to the Loan Agreement (the &amp;#8220;Eighth Amendment&amp;#8221;). The Eighth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) extended the maturity date of the Loan Agreement until November 1, 2017, and (d) provided for the repayment of an overadvance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$750,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; previously provided by the Lenders to us pursuant to the Loan Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the first quarter of 2016, the overadvance that existed at December 31, 2015 was repaid to the Lenders and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was received from certain of the Lenders and another lender affiliate in connection with the equity offering made on January 6, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June 6, 2016, we entered into a ninth amendment to the Loan Agreement (the &amp;#8220;Ninth Amendment&amp;#8221;). The Ninth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) amended the prepayment terms of the Loan Agreement, (c) provided for the reduction of amounts available under the Revolving Line upon the prepayment or repayment of certain amounts by us, (d) removed the minimum liquidity ratio and minimum net revenue financial covenants applicable to us under the Loan Agreement, (e) amended the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent of the Lenders, and (f) capitalized certain amounts owed by us to the Lenders and added such overdue amounts to the outstanding principal amount of the Revolving Line. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 2, 2017, we entered into a termination and tenth amendment to the Loan Agreement (the &amp;#8220;Tenth Amendment&amp;#8221;). The Tenth Amendment, among other things, (i) provides that the Lenders will waive specified events of default under the terms of the Loan Agreement until the effective time of the Merger (or the termination of the Merger Agreement in accordance with its terms), (ii) provides for the conversion of all outstanding indebtedness owed to the Lenders under the Loan Agreement (the &amp;#8220;Outstanding Indebtedness&amp;#8221;) into shares of Transgenomic common stock and preferred stock (collectively, the &amp;#8220;Conversion Shares&amp;#8221;) effective as of the closing date of the Merger and (iii) the termination of the Loan Documents (as defined in the Loan Agreement) and the termination and release of all security interests and liens of the Lenders in the Collateral (as defined in the Loan Agreement) in each case immediately following the conversion of the Outstanding Indebtedness into Conversion Shares.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The effectiveness of certain provisions in the Tenth Amendment, including provisions relating to conversion of the Conversion Shares and termination of the Loan Documents, is conditioned on, among other things, the consummation of the Merger, and, in the event that the Merger is not consummated, these provisions in the Loan Agreement Amendment will terminate.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Tenth Amendment, the Lenders have agreed to convert the outstanding principal and accrued interest under the Loan Agreement into (i) approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of New Precipio common stock immediately prior to the effectiveness of the Merger at a price equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share and (ii) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of New Precipio preferred stock. As of March 31, 2017, the outstanding amount owed under the Loan Agreement was approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of principal and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of accrued interest. The issuance of the Conversion Shares is subject to the approval of the Transgenomic stockholders in accordance with NASDAQ Capital Market listing rules.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Convertible Promissory Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December 31, 2014, we entered into an Unsecured Convertible Promissory Note Purchase Agreement (the &amp;#8220;Note Purchase Agreement&amp;#8221;) with an accredited investor (the &amp;#8220;Investor&amp;#8221;), pursuant to which we agreed to issue and sell to the Investor in a private placement an unsecured convertible promissory note (the &amp;#8220;Initial Note&amp;#8221;). We issued the Initial Note in the aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$750,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the Investor on December 31, 2014. Pursuant to the terms of the Initial Note, interest accrued at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year and the Initial Note was set to mature on December 31, 2016. The Initial Note has been converted in full into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;502,786&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock, in accordance with the terms of the Initial Note. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 15, 2015, we entered into the Note Purchase Agreement with &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;seven&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; accredited investors (the &amp;#8220;Additional Investors&amp;#8221;) and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, notes (the &amp;#8220;Additional Notes&amp;#8221;) in an aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$925,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  We also issued, to our placement agent for the Notes, a convertible promissory note in an aggregate principal amount equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the proceeds received by us, or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$46,250&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (the &amp;#8220;Agent Note&amp;#8221;).  The Additional Notes and Agent Note have the same terms and conditions as the Initial Note.  As of December 31, 2016, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$400,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the aggregate principal amount of the Additional Notes and Agent Note, and accrued interest thereon, had been converted into an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;281,023&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On the Maturity Date, the then outstanding aggregate amount owed on the Additional Notes and Agent Note of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, including accrued interest, became due. Pursuant to the terms of the Initial Note, our failure to pay any principal or interest within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; days of the date such payment is due will constitute an event of default (the &amp;#8220;Prospective Event of Default&amp;#8221;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 10, 2017, the Additional Investors and our placement agent executed a waiver of the Prospective Event of Default, pursuant to which, they agreed to waive the Prospective Event of Default on the condition that the Company and the Additional Investors enter into definitive documentation evidencing the terms for an extended maturity date of the Additional Notes and the Agent Note on or before January 16, 2017 (the &amp;#8220;Waiver Deadline&amp;#8221;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 13, 2017, all but one Additional Investor exercised their conversion rights relating to their respective Additional Notes, including the Agent Note, and converted an aggregate principal amount of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million, and accrued interest of less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;416,135&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock. The Waiver Deadline was extended with respect to the remaining Additional Investor who did not exercise conversion rights (the &amp;#8220;Non-Converting Investor&amp;#8221;) so that the parties could continue to discuss a resolution of the Prospective Event of Default relating to such Non-Converting Investor&amp;#8217;s Additional Note with an outstanding principal amount due of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 17, 2017, the Non-Converting Investor agreed to extend the Maturity Date of its Additional Note pursuant to an amendment to the Additional Note (the &amp;#8220;Amendment&amp;#8221;). The Amendment provides that two-thirds of the outstanding principal amount of the Additional Note must be paid upon the earlier to occur of the close of the Company&amp;#8217;s merger with Precipio Diagnostics, LLC or June 16, 2017 (such applicable date, the &amp;#8220;Deferred Maturity Date&amp;#8221;).&amp;#160; The remaining one-third of the principal amount outstanding on the Additional Note must be paid on the six month anniversary of the Deferred Maturity Date (the &amp;#8220;Extended Maturity Date&amp;#8221;).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2017Q1YTD" id="Fact-5A9E207B162E511EA2FF196B1959DA0A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;STOCK OPTIONS &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock Options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes stock option activity under our 2006 Equity Incentive Plan (the "Plan") during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at January&amp;#160;1, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;738,026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(62,739&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;675,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;547,957&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we did not grant any options to purchase shares of our common stock.  Options to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;14,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock were granted during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;661,914&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options that were vested or expected to vest with an aggregate intrinsic value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with a remaining weighted average contractual life of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock Appreciation Rights (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8220;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;SARs&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8221;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; outstanding and exercisable SARs shares were vested or expected to vest. All outstanding SARs were issued solely to our chief executive officer. The weighted-average exercise price of these SARs was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.32&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share and the aggregate intrinsic value was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with a remaining weighted average contractual life of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="FD2017Q1YTD" id="Fact-1BB480D514385AC38F791469E1F93680">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes stock option activity under our 2006 Equity Incentive Plan (the "Plan") during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at January&amp;#160;1, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;738,026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(62,739&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;675,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;547,957&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
	<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-550C628AB3D85A1AADC813FE1B0E211E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;DISCONTINUED OPERATIONS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; In March 2016, we halted testing services in our Patient Testing laboratory in New Haven, Connecticut. As a result of this action, as of December 31, 2015, our Patient Testing business met the criteria to be reported as discontinued operations. The related assets, liabilities, results of operations and cash flows for the Patient Testing business are classified as assets held for sale, liabilities held for sale and discontinued operations for all periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Results of the discontinued operations consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.5%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Three months ended     March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;(Dollars in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost of goods sold&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,183&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross profit (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Operating income (loss) from discontinued operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss on settlement of liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income (loss) from discontinued operations before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax expense &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income (loss) from discontinued operations, net of taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At March 31, 2017 and December 31, 2016, the Company had assets of the discontinued operations of less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which were classified as assets held for sale in the condensed consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-8CAE875567FD56498A2ABFFA1C19A276">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Loss Per Share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period.  Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2017Q1YTD" id="Fact-C841EAC7E15759E4B961E26A0C3118F3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Dollars in Thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Beginning balance at January 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total (gains) or losses:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Recognized in earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at March 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the three months ended March 31, 2017 and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:  &amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.6953125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Dollars in Thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Beginning balance at January 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;582&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total (gains) or losses:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Recognized in earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at March 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,446&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-469DA3F82B745C30ADAA5F496774471D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unless otherwise specified, book value approximates fair value. The common stock warrant liability is recorded at fair value.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-9D76208A14F05452B7C3293C7B2FB9AC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:30px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;FAIR VALUE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;1&amp;#8212;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;2&amp;#8212;Observable inputs other than those included in Level&amp;#160;1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets;&amp;#160;and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;3&amp;#8212;Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Debt.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our long term debt book value approximates fair market value due to the variable interest rate it bears. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Common Stock Warrant Liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;2012 Warrant Liability&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The 2012 Warrant Liability represents the fair value of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants issued in February 2012 (as adjusted pursuant to the terms of the 2012 Warrants). We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated Statement of Operations. Management does not believe that this liability will be settled by a use of cash. The 2012 Warrants expired in February 2017 and, as such, the 2012 Warrant Liability no longer exists at March 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The 2012 Warrant Liability is considered a Level 3 financial instrument and is valued using a Monte Carlo simulation model.  This method is well suited to valuing options with non-standard features, such as anti-dilution protection.  A Monte Carlo simulation model uses repeated random sampling to simulate significant uncertainty in inputs.  Assumptions and inputs used in the valuation of the common stock warrants are broken down into four sections: Static Business Inputs; Static Technical Inputs; Simulated Business Inputs; and Simulated Technical Inputs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Dollars in Thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Beginning balance at January 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total (gains) or losses:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Recognized in earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at March 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;2016 Warrant Liability&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The 2016 Warrant Liability represents the fair value of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants issued in January 2016, of which, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants remain outstanding as of March 31, 2017. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated Statement of Operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The 2016 Warrant Liability is considered a Level 3 financial instrument and is valued using a binomial lattice simulation model.  This method is well suited to valuing options with non-standard features.  Assumptions and inputs used in the valuation of the common stock warrants include; our equity value, which was estimated using our stock price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.56&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of March 31, 2017; volatility of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;115%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; and a risk-free interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.66%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the three months ended March 31, 2017 and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:  &amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.6953125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Dollars in Thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Beginning balance at January 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;582&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total (gains) or losses:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Recognized in earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at March 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,446&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-3FB06AC074E653B0A179707F2392F95F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;INCOME TAXES &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Annually, we file U.S. Federal, state and foreign income tax returns.&amp;#160; All U.S. Federal and most state loss carryforwards remain subject to adjustment in the event of an income tax examination.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax expense from continuing operations was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for both the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and 2016. We maintain a full valuation allowance on our net deferred tax assets,&amp;#160;having concluded that we are not more likely than not going to realize the benefit of our deferred tax assets, including our net operating loss carryforwards.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-BD9DD67579955E9E9CFAF304D87AA94A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-09, Revenue from Contracts with Customers. This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year.  As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company adopted ASU No. 2016-09 as of January&amp;#160;1, 2017. The adoption of this guidance does not have a material effect on the Company&amp;#8217;s financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August&amp;#160;2016, FASB issued ASU No.&amp;#160;2016-15&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Classification of Certain Cash Receipts and Cash Payments.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ASU No.&amp;#160;2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No.&amp;#160;2016-15 is effective for fiscal years beginning after December&amp;#160;15, 2017, and for interim periods within that fiscal year. We do not believe ASU No.&amp;#160;2016-15 will have a material effect on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2017, FASB issued ASU No.&amp;#160;2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business.  ASU No. 2017-01adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December&amp;#160;15, 2017, and interim periods within those fiscal years. The Company does not believe ASU No. 2017-01 will have a material effect on its financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-23E36E60D2A15D97A1E4E9E2886E444D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Net Sales Recognition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:66px;text-indent:-36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue is realized and earned when all of the following criteria are met:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Persuasive evidence of an arrangement exists;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Delivery has occurred or services have been rendered;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The seller&amp;#8217;s price to the buyer is fixed or determinable; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; In our Omaha, Nebraska laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year.  At each of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net sales from Patient Testing laboratories are reported as part of discontinued operations (See Note 3 - &amp;#8220;Discontinued Operations&amp;#8221;) and are recognized on an individual test basis and, since collectability is not reasonably assured, are recognized when cash is received. There are no deferred net sales associated with our Patient Testing services. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfDebtTableTextBlock contextRef="FD2017Q1YTD" id="Fact-8E19447E63585E4BBB6D168546CDAAE7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Dollars&amp;#160;in&amp;#160;Thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revolving Line of Credit&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Term Loan&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible Promissory Notes &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(3)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;571&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,368&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,814&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current portion of long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,368&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,814&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term debt, net of current maturities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revolving Line of Credit.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;6.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or (b) the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Wall Street Journal&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; prime rate plus &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;3%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The current interest rate is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.75%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As discussed below under &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Additional Terms&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the interest rate is subject to increase if there is a default under the Loan Agreement. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$20,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line.  In addition, a fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;0.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum is payable quarterly on the unused portion of the Revolving Line.  The Revolving Line matures on November 1, 2017.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Term Loan.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under the Term Loan on the Effective Date.  Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;9.1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  As discussed below, the interest rate is subject to increase if there is a default under the Loan Agreement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We will pay the Lenders an additional final payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$120,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, at maturity or prepayment of the Term Loan, which has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the total outstanding balance under the Term Loan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Additional Terms.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Loan Agreement contains affirmative and negative covenants.  Under the Loan Agreement, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders&amp;#8217; consent.  Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of March 31, 2017, we were not in compliance with the Loan Agreement, as amended, due to the fact that events of default existed, including our failure to make certain required monthly interest payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. At March 31, 2017, our applicable interest rates have been increased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;   Convertible Promissory Notes. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Notes accrue interest at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year and matured on December 31, 2016. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
	<us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="FD2017Q1YTD" id="Fact-E5AA23F10D245BB2927D2D1E13D113B6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Results of the discontinued operations consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.5%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Three months ended     March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;(Dollars in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost of goods sold&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,183&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross profit (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Operating income (loss) from discontinued operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss on settlement of liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income (loss) from discontinued operations before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax expense &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income (loss) from discontinued operations, net of taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
	<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="FD2017Q1YTD" id="Fact-28823F01546A5F0594DAE407FB15E9E5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrant Holder&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Issue&amp;#160;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Underlying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Various Institutional Holders&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;441,655&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Affiliates of Third Security, LLC&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;250,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Various Institutional Holders&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;April 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;374,618&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Various Institutional Holders&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(3)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;February 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;714,780&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Various Institutional Holders&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(4)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;122,433&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Various Institutional Holders&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(5)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,161,972&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Affiliates of Third Security, LLC&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(6)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;161,026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Various Institutional Holders&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(6)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107,527&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,334,011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with an offering which was completed in January 2013. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with a private placement which was completed in October 2014.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with an offering which was completed in February 2015.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with an offering which was completed in July 2015.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were originally issued in connection with the offering in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2017Q1YTD" id="Fact-8C718092391C52D598CD3B5CD533F29E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock-Based Compensation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year contractual terms. Unvested awards as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; had vesting periods of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years from the date of grant. None of the awards outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are subject to performance or market-based vesting conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2017Q1YTD" id="Fact-C6F89662E5AE52D098C5EB2461F78C9D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying condensed consolidated financial statements are presented in conformity with GAAP. Supplemental cash flows from discontinued operations are presented in Note 3 - &amp;#8220;Discontinued Operations&amp;#8221;. We have evaluated events occurring subsequent to March 31, 2017 for potential recognition or disclosure in the condensed consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The condensed consolidated balance sheet as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2016. The accompanying condensed consolidated financial statements as of and for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) on April 13, 2017. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Risks and Uncertainties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements.  The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unless otherwise specified, book value approximates fair value. The common stock warrant liability is recorded at fair value.  See Note 8 - &amp;#8220;Fair Value&amp;#8221; for additional information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash and Cash Equivalents and Other Current Assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less. Other current assets as of March 31, 2017 of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; include prepaid assets of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and other receivables of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Concentrations of Cash.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits.  We have not experienced any losses on such accounts as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Property and Equipment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation expense in continuing operations related to property and equipment was less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for each of the three month periods ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Depreciation expense during each period includes depreciation related to equipment acquired under capital leases. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangible Assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization expense for intangible assets was less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the three month periods ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Amortization expense for intangible assets is expected to be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for each of the years ending December 31, 2017, 2018 and less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for each of the years ending December 31, 2019, 2020 and 2021.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock-Based Compensation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year contractual terms. Unvested awards as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; had vesting periods of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years from the date of grant. None of the awards outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are subject to performance or market-based vesting conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and 2016, we recorded compensation expense for all stock awards of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, within selling, general and administrative expense. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the unrecognized compensation expense related to unvested stock awards was less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which is expected to be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Included in our stock awards outstanding as of March 31, 2017 were fully vested stock appreciation rights (&amp;#8220;SARs&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock. The SARs were issued solely to our executive officers and vested over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years from the date of grant. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Net Sales Recognition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:66px;text-indent:-36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue is realized and earned when all of the following criteria are met:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Persuasive evidence of an arrangement exists;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Delivery has occurred or services have been rendered;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The seller&amp;#8217;s price to the buyer is fixed or determinable; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; In our Omaha, Nebraska laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year.  At each of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net sales from Patient Testing laboratories are reported as part of discontinued operations (See Note 3 - &amp;#8220;Discontinued Operations&amp;#8221;) and are recognized on an individual test basis and, since collectability is not reasonably assured, are recognized when cash is received. There are no deferred net sales associated with our Patient Testing services. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Loss Per Share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period.  Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,425,218&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,970,881&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock have been excluded from the computation of diluted loss per share at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, because the effect is anti-dilutive due to the net loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-09, Revenue from Contracts with Customers. This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year.  As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company adopted ASU No. 2016-09 as of January&amp;#160;1, 2017. The adoption of this guidance does not have a material effect on the Company&amp;#8217;s financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August&amp;#160;2016, FASB issued ASU No.&amp;#160;2016-15&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Classification of Certain Cash Receipts and Cash Payments.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ASU No.&amp;#160;2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No.&amp;#160;2016-15 is effective for fiscal years beginning after December&amp;#160;15, 2017, and for interim periods within that fiscal year. We do not believe ASU No.&amp;#160;2016-15 will have a material effect on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2017, FASB issued ASU No.&amp;#160;2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business.  ASU No. 2017-01adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December&amp;#160;15, 2017, and interim periods within those fiscal years. The Company does not believe ASU No. 2017-01 will have a material effect on its financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-86381942992A50ABBF3FBABD8DDD5DCF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;STOCKHOLDERS&amp;#8217; DEFICIT&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Common Stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;150,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock authorized for issuance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 6, 2016, we entered into a Securities Purchase Agreement (the &amp;#8220;SPA&amp;#8221;) with certain accredited investors (the &amp;#8220;2016 Investors&amp;#8221;), pursuant to which, on January 8, 2016, we sold to the 2016 Investors, and the 2016 Investors purchased from us (the &amp;#8220;January 2016 Offering&amp;#8221;), an aggregate of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of units (the &amp;#8220;Units&amp;#8221;) consisting of (a) an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,365,243&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares (the &amp;#8220;A-1 Preferred Shares&amp;#8221;) of our Series A-1 Convertible Preferred Stock (the &amp;#8220;A-1 Preferred&amp;#8221;), and (b) warrants (the &amp;#8220;2016 Warrants&amp;#8221;) to purchase up to an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,773,929&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock, with an initial value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The gross amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; included &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of cash proceeds and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of debt settled with the issuance of preferred stock and warrants. Each Unit was sold to the 2016 Investors at a purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.93&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per Unit. The A-1 Preferred Shares are convertible into shares of our common stock at an initial rate of 1-for-1, which conversion rate is subject to further adjustment as set forth in our Certificate of Designation of Series A-1 Convertible Preferred Stock, which was filed with the Secretary of State of the State of Delaware on January 8, 2016 (the &amp;#8220;Series A-1 Certificate of Designation&amp;#8221;). We determined there was a beneficial conversion feature (&amp;#8220;BCF&amp;#8221;) in connection with this issuance and valued the BCF at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160; The holders of the A-1 Preferred were able to convert at any time following the issuance.&amp;#160; Accordingly, we recorded a dividend totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during 2016 related to this beneficial conversion, which was recorded against additional paid in capital. Pursuant to the terms of the Series A-1 Certificate of Designation, the holders of the A-1 Preferred Shares will generally be entitled to that number of votes as is equal to the product obtained by multiplying: (i) the number of whole shares of our common stock into which the A-1 Preferred may be converted as of the record date of such vote or consent, by (ii) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.93&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, rounded down to the nearest whole number. Therefore, every &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.075269&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of A-1 Preferred will generally initially be entitled to one vote. In May 2016, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,150,538&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the A-1 Preferred Shares were converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,150,538&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock. At March 31, 2017, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;214,705&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; A-1 Preferred Shares outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The 2016 Warrants were immediately exercisable upon issuance, have a term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years and have an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.21&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share of our common stock. Each 2016 Warrant includes both cash and &amp;#8220;cashless exercise&amp;#8221; features and an exchange feature whereby the holder of the 2016 Warrant may exchange (the &amp;#8220;Exchange Right&amp;#8221;) all or any portion of the 2016 Warrant for a number of shares of our common stock equal to the quotient obtained by dividing the &amp;#8220;Exchange Amount&amp;#8221; by the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged (the &amp;#8220;Exchange Price&amp;#8221;). Under the 2016 Warrants, the &amp;#8220;Exchange Amount&amp;#8221; is based upon a Black Scholes option pricing model, and the aggregate Exchange Amount under all of the 2016 Warrants will be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.4&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million, subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged. Each 2016 Warrant provides that the number of shares that may be issued upon exercise of the Exchange Right is limited to the number of shares that may be purchased pursuant to the terms of the 2016 Warrant, unless we have previously obtained stockholder approval or approval from The Nasdaq Stock Market LLC to issue any additional shares of our common stock (the &amp;#8220;Additional Shares&amp;#8221;) pursuant to the Exchange Right (the &amp;#8220;Required Approvals&amp;#8221;). For any Exchange Right exercised more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; days following the issuance of the 2016 Warrants, if we have not obtained either of the Required Approvals, we will be required to pay the 2016 Warrant holder an amount in cash for any Additional Shares that we cannot issue without the Required Approvals based on the Exchange Amount.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The 2016 Warrants further provide that, to the extent the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged is less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Exchange Price will be deemed to be equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and, in addition to issuing shares of our common stock based on this Exchange Price, we will be required to pay to the 2016 Warrant holder an amount in cash equal to the product obtained by multiplying (a) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; minus the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the 2016 Warrant holder by the Company in such exchange at an Exchange Price equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Therefore, if the Required Approvals are obtained, based on the Exchange Amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,436,882&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of the issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the 2016 Warrants will be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,873,765&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In addition, if, for example, assuming an Exchange Amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,436,882&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrants are exchanged is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.25&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we would be required to pay to the 2016 Warrant holders cash in an aggregate amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$718,441&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in addition to issuing the 2016 Warrant holders &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,873,765&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares. During the year ended December 31, 2016, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,006,419&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the 2016 Warrants were exchanged for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,613,353&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock and cash due of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As of March 31, 2017 and December 31, 2016, the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; due to a 2016 Investor is included in other current liabilities on our condensed consolidated balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In accordance with the terms of the SPA, we amended that certain Series A Warrant to purchase up to an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,161,972&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock previously issued by us to an affiliate of one of the 2016 Investors on July 7, 2015 (the &amp;#8220;Original Warrant&amp;#8221;), as previously reported by us on our Amendment No. 1 to Current Report on Form 8-K/A, filed with the SEC on July 7, 2015 (as so amended, the &amp;#8220;Amended Warrant&amp;#8221;). The Amended Warrant amends the Original Warrant to provide that the Amended Warrant is subject to the same terms and conditions as the 2016 Warrants and, therefore, includes both cash and &amp;#8220;cashless exercise&amp;#8221; features and an Exchange Right whereby the number of shares issuable pursuant to the Exchange Right is equal to the &amp;#8220;Amended Warrant Exchange Amount&amp;#8221;, which is based on a Black Scholes option pricing model, and will be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$941,197&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, subject to adjustment to the extent that the risk-free U.S. treasury rate fluctuates between the date of issuance of the Amended Warrant and the date the Amended Warrant is exchanged. The Amended Warrant is exercisable for up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,161,972&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock in the event we have obtained either of the Required Approvals with respect to the Amended Warrant. In the event the Amended Warrant holder exercises the Amended Warrant more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; days following the issuance of the Amended Warrant, if we have not obtained either of the Required Approvals, we will be required to pay the Amended Warrant holder an amount in cash for the shares of our common stock that we cannot issue under the Amended Warrant pursuant to such exercise without the Required Approvals based on the Amended Warrant Exchange Amount.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Amended Warrant also provides that, to the extent the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Exchange Price will be deemed to be equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and, in addition to issuing shares of our common stock based on this Exchange Price (assuming receipt of the Required Approvals), we will be required to pay to the Amended Warrant holder an amount in cash equal to the product obtained by multiplying (a) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; minus the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the Amended Warrant holder by us in such exchange at an Exchange Price equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Therefore, if the Required Approvals are obtained, based on the Amended Warrant Exchange Amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$941,197&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the issuance of the Amended Warrant and the date the Amended Warrant is exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the Amended Warrant will be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,882,395&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In addition, if, for example, assuming an Amended Warrant Exchange Amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$941,197&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.25&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we would be required to pay to the Amended Warrant holder cash in an aggregate amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$470,599&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in addition to issuing the Amended Warrant holder &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,882,395&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with entering into the SPA, we also entered into a Registration Rights Agreement, dated January 8, 2016, with the 2016 Investors. Pursuant to the terms of the Registration Rights Agreement, we were required to file with the SEC a registration statement to register for resale the shares of our common stock issuable upon conversion of the A-1 Preferred Shares and the shares of our common stock issuable upon exercise of the 2016 Warrants and the Amended Warrant by January 25, 2016. We filed the required registration statement with the SEC on January 25, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Craig-Hallum (the &amp;#8220;Placement Agent&amp;#8221;) served as the sole placement agent for the January 2016 Offering. In consideration for services rendered as the Placement Agent in the January 2016 Offering, we (1) paid to the Placement Agent cash commissions equal to approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$140,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the gross proceeds received in the January 2016 Offering, excluding any proceeds received from Third Security, LLC or any of its affiliates; (2) issued to the Placement Agent, for a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year warrant to purchase up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107,527&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.21&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share (the &amp;#8220;Agent Warrant&amp;#8221;), which is subject to the same terms as the 2016 Warrants except that the Agent Warrant was not exercisable until July 8, 2016 and does not contain the Exchange Right; and (3) reimbursed the Placement Agent for reasonable out-of-pocket expenses, including fees paid to the Placement Agent&amp;#8217;s legal counsel, incurred in connection with the January 2016 Offering, which reimbursable expenses did not exceed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The January 2016 Offering and the payment of all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock in the form of shares of our common stock at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share of our common stock discussed under &amp;#8220;-Conversion of Preferred Stock&amp;#8221; below required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale (the &amp;#8220;2012 Private Placement&amp;#8221;).  The exercise price of these warrants decreased to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.39&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share and the number of shares issuable upon exercise of the warrants increased from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,188,177&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,239,827&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On May 31, 2016, we issued to a vendor an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock and, on June 14, 2016, we issued to a second vendor an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64,153&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock. Such shares of common stock were issued to the vendors in lieu of an aggregate cash amount of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$89,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; owed by us to such vendors for services previously performed by such vendors. We issued the shares to the vendors in transactions exempt from registration under the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The offering of the shares to the vendors did not involve a public offering, and no general solicitation or advertisement was made in connection with the offering of the shares to the vendors.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June 7, 2016, we entered into an At the Market Offering Agreement (the &amp;#8220;ATM Agreement&amp;#8221;) with Craig-Hallum, as sales agent, pursuant to which we may offer and sell, from time to time, through Craig-Hallum, up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of shares (the &amp;#8220;Shares&amp;#8221;) of our common stock. Any Shares offered and sold in the offering will be issued pursuant to our effective shelf registration statement on Form S-3 (File No. 333-201907) and the related prospectus previously declared effective by the SEC on February 13, 2015, as supplemented by a prospectus supplement, dated June 7, 2016, that we filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;). The number of shares eligible for sale under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the ATM Agreement, we will pay Craig-Hallum a placement fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the gross sales price of the Shares, unless Craig-Hallum acts as principal, in which case we may sell Shares to Craig-Hallum as principal at a price to be agreed upon by us and Craig-Hallum. We will also reimburse Craig-Hallum for certain expenses incurred in connection with the ATM Agreement, and agreed to provide indemnification and contribution to Craig-Hallum with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The ATM Agreement was terminated during the fourth quarter of 2016 and at the time of termination we had sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,177,849&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares.&amp;#160; The average sales price per common share was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.42&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the aggregate net proceeds from the sales totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We did not sell any shares under the ATM Agreement during the three month periods ended March 31, 2017 and 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The sale of shares under the ATM Agreement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the 2012 Private Placement.  The exercise price of these warrants decreased to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.23&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share and the number of shares issuable upon exercise of the warrants increased from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,262,088&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,362,276&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  The &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,362,276&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants issued in the 2012 Private Placement expired in February 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Common Stock Warrants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we did not issue any warrants, no warrants were exercised and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,362,276&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants expired. During the three months ended March 31, 2016, we issued warrants to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,933,106&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock and no warrants were exercised. The warrants issued in the three months ended March 31, 2016 included &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,051,650&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants issued due to repricing requirements of the Private Placement and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,881,456&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants issued in connection with the January 2016 Offering.  Warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,334,011&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock were outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrant Holder&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Issue&amp;#160;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Underlying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Various Institutional Holders&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;441,655&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Affiliates of Third Security, LLC&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;250,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Various Institutional Holders&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;April 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;374,618&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Various Institutional Holders&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(3)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;February 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;714,780&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Various Institutional Holders&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(4)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;122,433&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Various Institutional Holders&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(5)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,161,972&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Affiliates of Third Security, LLC&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(6)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;161,026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Various Institutional Holders&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(6)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107,527&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,334,011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with an offering which was completed in January 2013. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with a private placement which was completed in October 2014.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with an offering which was completed in February 2015.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with an offering which was completed in July 2015.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were originally issued in connection with the offering in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:174%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Preferred Stock Series A.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s Board of Directors is authorized to issue up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. The authority of the Board of Directors includes, but is not limited to, the determination or fixing of the following with respect to shares of such class or any series thereof: (i)&amp;#160;the number of shares; (ii)&amp;#160;the dividend rate, whether dividends shall be cumulative and, if so, from which date; (iii)&amp;#160;whether shares are to be redeemable and, if so, the terms and amount of any sinking fund providing for the purchase or redemption of such shares; (iv)&amp;#160;whether shares shall be convertible and, if so, the terms and provisions thereof; (v)&amp;#160;what restrictions are to apply, if any, on the issue or reissue of any additional preferred stock; and (vi)&amp;#160;whether shares have voting rights. The preferred stock may be issued with a preference over the common stock as to the payment of dividends.  We have no current plans to issue any additional preferred stock. Classes of stock such as the preferred stock may be used, in certain circumstances, to create voting impediments on extraordinary corporate transactions or to frustrate persons seeking to effect a merger or otherwise to gain control of the Company. For the foregoing reasons, any additional preferred stock issued by the Company could have an adverse effect on the rights of the holders of the common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December&amp;#160;29, 2010, we entered into a transaction with the Third Security Investors, pursuant to the terms of a Series A Convertible Preferred Stock Purchase Agreement (the &amp;#8220;Series A Purchase Agreement&amp;#8221;), in which we: (i)&amp;#160;sold an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,586,205&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series A Preferred Stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.32&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share; and (ii)&amp;#160;issued Series A Warrants to purchase up to an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,293,102&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series A Preferred Stock having an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.32&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share (the sale of Series A Preferred Stock and issuance of the Series A Warrants hereafter referred to together as the &amp;#8220;Financing&amp;#8221;). The Series A Warrants may be exercised at any time from December&amp;#160;29, 2010 until December&amp;#160;28, 2015 and contain a &amp;#8220;cashless exercise&amp;#8221; feature.  The gross proceeds from the Series A financing were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  The &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of costs incurred to complete the Series A financing were recorded as a reduction in the value of the Series A Preferred Stock.  We used the net proceeds from the financing to acquire the FAMILION family of genetic tests from PGxHealth, a subsidiary of Clinical Data, Inc. Until the November 2011 modifications, the Series A Preferred Stock met the definition of mandatorily redeemable stock as it was preferred capital stock that was redeemable at the option of the holder through December 2015 and was reported outside of equity. The Series A Preferred Stock was to be accreted to its redemption value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Until the November 2011 modifications, the Series A Warrants did not qualify to be treated as equity and, accordingly, were recorded as a liability.  A preferred stock anti-dilution feature is embedded within the Series A Preferred Stock that met the definition of a derivative.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Series A financing, we filed a Certificate of Designation of Series A Convertible Preferred Stock (the &amp;#8220;Series A Certificate of Designation&amp;#8221;) with the Secretary of State of the State of Delaware, designating &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,879,307&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our preferred stock as Series A Preferred Stock. As of December 31, 2013, the Series A Preferred Stock, including the Series A Preferred Stock issuable upon exercise of the Series A Warrants, was convertible into shares of our common stock at a rate of 4-for-1, which conversion rate is subject to further adjustment as set forth in the Series A Certificate of Designation. Giving effect to the reverse split of our stock in January 2014, the conversion rate was adjusted to 1-for-3. Certain rights of the holders of the Series A Preferred Stock are senior to the rights of the holders of our common stock. The Series A Preferred Stock has a liquidation preference equal to its original price per share, plus any accrued and unpaid dividends thereon. The holders of the Series A Preferred Stock are entitled to receive quarterly dividends, which accrue at the rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the original price per share per annum, whether or not declared, and which shall compound annually and shall be cumulative. In any calendar quarter in which we have positive distributable cash flow as defined in the Series A Purchase Agreement, we are required to pay from funds legally available a cash dividend in the amount equal to the lesser of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of such distributable cash flow or the aggregate amount of dividends accrued on the Series A Preferred Stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Generally, the holders of the Series A Preferred Stock are entitled to vote together with the holders of common stock, as a single group, on an as-converted basis. However, the Series A Certificate of Designation provides that we shall not perform some activities, subject to certain exceptions, without the affirmative vote of a majority of the holders of the outstanding shares of Series A Preferred Stock.  The holders of the Series A Preferred Stock, along with the holders of the Series B Preferred Stock, also are entitled to elect or appoint, as a single group, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;directors of the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Series A financing, we also entered into a registration rights agreement with the Third Security Investors (the &amp;#8220;Registration Rights Agreement&amp;#8221;). Pursuant to the terms of the Registration Rights Agreement, the Company has granted certain demand, &amp;#8220;piggyback&amp;#8221; and S-3 registration rights covering the resale of the shares of common stock underlying the Series A Preferred Stock issued pursuant to the Series A Purchase Agreement and issuable upon exercise of the Series A Warrants and all shares of common stock issuable upon any dividend or other distribution with respect thereto.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2011, we entered into a transaction with the Third Security Investors, pursuant to an Agreement Regarding Preferred Stock (the &amp;#8220;Amendment Agreement&amp;#8221;), in which the Third Security Investors agreed to (i) waive their rights to enforce the anti-dilution and redemption features of the Series A Preferred Stock and (ii) at the next annual stockholders&amp;#8217; meeting, vote to amend the Series A Certificate of Designation to remove the anti-dilution and redemption features of the Series A Preferred Stock.  In exchange, the Company issued shares of common stock to the Third Security Investors having an aggregate market value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As a result of the Amendment Agreement, the values of the Series A Preferred Stock and Series A Warrants, including the Series A Preferred Stock conversion feature and Series A Warrant liability, were reclassified into stockholders&amp;#8217; equity as of the date of the Amendment Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Preferred Stock Series B.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On March 5, 2014, we entered into a Series B Convertible Preferred Stock Purchase Agreement (the &amp;#8220;Series B Purchase Agreement&amp;#8221;) with affiliates of Third Security, LLC (the &amp;#8220;2014 Third Security Investors&amp;#8221;), pursuant to which we, in a private placement, sold and issued an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,443,297&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our Series B Preferred Stock, par value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.01&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share (the &amp;#8220;Series B Preferred Stock&amp;#8221;), at a price per share of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.85&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for an aggregate purchase price of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  Each share of Series B Preferred Stock issued pursuant to the Series B Purchase Agreement was initially convertible into shares of our common stock at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-for-1, which conversion rate was subject to further adjustment as set forth in the Certificate of Designation of Series B Convertible Preferred Stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Series B financing, we also entered into a Registration Rights Agreement, dated March 5, 2014, with the 2014 Third Security Investors, pursuant to which we granted certain demand, &amp;#8220;piggy-back&amp;#8221; and S-3 registrations rights covering the resale of the shares of common stock underlying the Series B Preferred Stock issued pursuant to the Series B Purchase Agreement and all shares of common stock issuable upon any dividend or other distribution with respect thereto.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Series B financing required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement.  The exercise price of the warrants decreased from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.96&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.73&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share and the number of shares issuable upon exercise of the warrants increased from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,097,600&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,212,665&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Conversion of Preferred Stock - Series A and Series B.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 6, 2016, the Company entered into a Conversion Agreement (the &amp;#8220;Conversion Agreement&amp;#8221;) with the holders (the &amp;#8220;Preferred Holders&amp;#8221;) of all of the Company&amp;#8217;s outstanding shares of Series A Convertible Preferred Stock, par value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.01&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share (the &amp;#8220;Series A Preferred Stock&amp;#8221;), and Series B Preferred Stock, pursuant to which, among other things, the Preferred Holders: (a) elected to convert all of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock into shares of our  common stock, in each case in accordance with the terms thereof, and (b) agreed that all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock would be paid by the Company in shares of our common stock at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share of our common stock (collectively, the &amp;#8220;Conversion&amp;#8221;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The outstanding shares of Series A Preferred Stock were convertible into shares of our common stock at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-for-3, and the outstanding shares of Series B Preferred Stock were convertible into shares of our common stock at a rate of 1-for-1. Prior to the entry into the Conversion Agreement, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,586,205&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series A Preferred Stock outstanding, which were converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;862,057&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,443,297&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series B Preferred Stock outstanding, which were converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,443,297&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock, for an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,305,354&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock issued upon conversion of the Series A Preferred Stock and Series B Preferred Stock (the &amp;#8220;Conversion Shares&amp;#8221;). At the time of the entry into the Conversion Agreement, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.7&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million in accrued and unpaid dividends on the outstanding shares of Series A Preferred Stock, which were converted, in accordance with the Conversion Agreement, into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,681,590&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.8&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million in accrued and unpaid dividends on the outstanding shares of Series B Preferred Stock, which were converted, in accordance with the terms of the Conversion Agreement, into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;793,235&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock, for an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,474,825&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock issued pursuant to the accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock. Therefore, in connection with the full conversion of the Series A Preferred Stock and Series B Preferred Stock, plus the conversion of all accrued and unpaid dividends thereon, we issued an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,780,179&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock to the Preferred Holders on January 6, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Following the conversion of the shares of Series A Preferred Stock and Series B Preferred Stock into common stock, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series A Preferred Stock or Series B Preferred Stock remain outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Preferred Stock Dividends.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; undeclared dividends for the three months ended March 31, 2017. For the three months ended March 31, 2016, we had undeclared dividends.  In accordance with the FASB&amp;#8217;s Accounting Standards Codification Topic 260-10-45-11, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Earnings per Share&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8221;, these dividends were added to the net loss per share calculation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2017Q1YTD" id="Fact-B11F8FC376C2539E94A12ABC5E62E46F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;SUBSEQUENT EVENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On April 13, 2017, Transgenomic completed the sale of an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.15 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of promissory notes (the &amp;#8220;Bridge Notes&amp;#8221;) in a bridge financing pursuant to a securities purchase agreement (the &amp;#8220;Purchase Agreement&amp;#8221;). Transgenomic may receive additional investments of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in connection with the bridge financing. The financing is intended to help facilitate the completion of Transgenomic&amp;#8217;s merger with Precipio, which is expected to close during the second quarter of 2017. Transgenomic received net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,031,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the sale of the Bridge Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Bridge Notes have an annual interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-day maturity. Transgenomic may repay the Bridge Notes at any time in cash upon payment of a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; premium. In connection with the issuance of the Bridge Notes, Transgenomic issued warrants (the &amp;#8220;Bridge Warrants&amp;#8221;) to acquire &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.15 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Transgenomic common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, subject to anti-dilution protection. The Purchase Agreement provides certain piggyback registration rights for the holders of the Bridge Warrants for a period of six months after the closing of the bridge financing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As part of the bridge financing, Transgenomic agreed to loan &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the net proceeds from the sale of the Bridge Notes to Precipio pursuant to a promissory note (the &amp;#8220;Precipio Note&amp;#8221;) with an original principal amount of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$561,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon substantially the same terms and conditions as the Bridge Notes. The payment of the Precipio Note is subordinated to the payment by Precipio of its secured &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; bank debt pursuant to a subordination agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Aegis Capital Corp. acted as placement agent for the bridge financing and received a placement agent fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$84,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and warrants (the &amp;#8220;Aegis Warrants&amp;#8221;) to acquire &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;168,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Transgenomic common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. The Aegis Warrants are identical to the Bridge Warrants except that the Aegis Warrants do not have anti-dilution protection.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>tbio-20170331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.transgenomic.com/20170331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:tbio="http://www.transgenomic.com/20170331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tbio-20170331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tbio-20170331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tbio-20170331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tbio-20170331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="BusinessDescription" roleURI="http://www.transgenomic.com/role/BusinessDescription">
        <link:definition>2101100 - Disclosure - BUSINESS DESCRIPTION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessDescriptionDetails" roleURI="http://www.transgenomic.com/role/BusinessDescriptionDetails">
        <link:definition>2401401 - Disclosure - BUSINESS DESCRIPTION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParentheticals" roleURI="http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheetsParentheticals">
        <link:definition>1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.transgenomic.com/role/Contingencies">
        <link:definition>2108100 - Disclosure - CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.transgenomic.com/role/ContingenciesDetails">
        <link:definition>2408401 - Disclosure - CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.transgenomic.com/role/Debt">
        <link:definition>2107100 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtConvertiblePromissoryNotesDetails" roleURI="http://www.transgenomic.com/role/DebtConvertiblePromissoryNotesDetails">
        <link:definition>2407404 - Disclosure - DEBT (Convertible Promissory Notes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtRevolvingLineAndTermLoanDetails" roleURI="http://www.transgenomic.com/role/DebtRevolvingLineAndTermLoanDetails">
        <link:definition>2407403 - Disclosure - DEBT (Revolving Line and Term Loan) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleOfDebtDetails" roleURI="http://www.transgenomic.com/role/DebtScheduleOfDebtDetails">
        <link:definition>2407402 - Disclosure - DEBT (Schedule of Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.transgenomic.com/role/DebtTables">
        <link:definition>2307301 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperations" roleURI="http://www.transgenomic.com/role/DiscontinuedOperations">
        <link:definition>2105100 - Disclosure - DISCONTINUED OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsRevenuesAndNetIncomeLossDetails" roleURI="http://www.transgenomic.com/role/DiscontinuedOperationsRevenuesAndNetIncomeLossDetails">
        <link:definition>2405402 - Disclosure - DISCONTINUED OPERATIONS (Revenues and Net Income (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsTables" roleURI="http://www.transgenomic.com/role/DiscontinuedOperationsTables">
        <link:definition>2305301 - Disclosure - DISCONTINUED OPERATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.transgenomic.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - DOCUMENT AND ENTITY INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://www.transgenomic.com/role/FairValue">
        <link:definition>2111100 - Disclosure - FAIR VALUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueDetails" roleURI="http://www.transgenomic.com/role/FairValueDetails">
        <link:definition>2411402 - Disclosure - FAIR VALUE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://www.transgenomic.com/role/FairValueTables">
        <link:definition>2311301 - Disclosure - FAIR VALUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.transgenomic.com/role/IncomeTaxes">
        <link:definition>2109100 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.transgenomic.com/role/IncomeTaxesDetails">
        <link:definition>2409401 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptions" roleURI="http://www.transgenomic.com/role/StockOptions">
        <link:definition>2112100 - Disclosure - STOCK OPTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsStockAppreciationRightsDetails" roleURI="http://www.transgenomic.com/role/StockOptionsStockAppreciationRightsDetails">
        <link:definition>2412403 - Disclosure - STOCK OPTIONS (Stock Appreciation Rights) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsStockOptionsDetails" roleURI="http://www.transgenomic.com/role/StockOptionsStockOptionsDetails">
        <link:definition>2412402 - Disclosure - STOCK OPTIONS (Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsTables" roleURI="http://www.transgenomic.com/role/StockOptionsTables">
        <link:definition>2312301 - Disclosure - STOCK OPTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.transgenomic.com/role/StockholdersEquity">
        <link:definition>2110100 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockDetails" roleURI="http://www.transgenomic.com/role/StockholdersEquityCommonStockDetails">
        <link:definition>2410402 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockWarrantsDetails" roleURI="http://www.transgenomic.com/role/StockholdersEquityCommonStockWarrantsDetails">
        <link:definition>2410403 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityConversionOfPreferredStockDetails" roleURI="http://www.transgenomic.com/role/StockholdersEquityConversionOfPreferredStockDetails">
        <link:definition>2410406 - Disclosure - STOCKHOLDERS' EQUITY (Conversion of Preferred Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityPreferredStockDividendsDetails" roleURI="http://www.transgenomic.com/role/StockholdersEquityPreferredStockDividendsDetails">
        <link:definition>2410407 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Dividends) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityPreferredStockSeriesADetails" roleURI="http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesADetails">
        <link:definition>2410404 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Series A) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityPreferredStockSeriesBDetails" roleURI="http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesBDetails">
        <link:definition>2410405 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Series B) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.transgenomic.com/role/StockholdersEquityTables">
        <link:definition>2310301 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.transgenomic.com/role/SubsequentEvents">
        <link:definition>2114100 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.transgenomic.com/role/SubsequentEventsDetails">
        <link:definition>2414401 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails">
        <link:definition>2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNarrativesDetails" roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesNarrativesDetails">
        <link:definition>2402402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails">
        <link:definition>2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedConsolidatedStatementsOfCashFlowsParentheticals" roleURI="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsParentheticals">
        <link:definition>1005001 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICALS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedConsolidatedStatementsOfOperations" roleURI="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="tbio_A2012WarrantLiabilityMember" name="A2012WarrantLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_A2016WarrantLiabilityMember" name="A2016WarrantLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_A2016WarrantMember" name="A2016WarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_AdditionalNotePrivatePlacementMember" name="AdditionalNotePrivatePlacementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_AdditionalNotesMember" name="AdditionalNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_AdditionalShorttermLoanMaximumAmountAuthorized" name="AdditionalShorttermLoanMaximumAmountAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="tbio_AegisCorpMember" name="AegisCorpMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_AffiliatesofThirdSecurityLLCJanuary2018Member" name="AffiliatesofThirdSecurityLLCJanuary2018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_AffiliatesofThirdSecurityLLCJanuary2021Member" name="AffiliatesofThirdSecurityLLCJanuary2021Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_AgentNoteMember" name="AgentNoteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_AttheMarketOfferingAgreementMember" name="AttheMarketOfferingAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_CPAGlobalMember" name="CPAGlobalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_CashPaymentPortionofStockWarrantsExercised" name="CashPaymentPortionofStockWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" name="ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights" name="ClassofWarrantorRightExchangePriceofWarrantsorRights" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment" name="ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_ClassofWarrantorRightExerciseTerm1" name="ClassofWarrantorRightExerciseTerm1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired" name="ClassofWarrantorRightNumberofIssuedWarrantsExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_ConcentrationOfCashPolicyPolicyTextBlock" name="ConcentrationOfCashPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote" name="ConvertibleNotesNumberOfSecuritiesCalledByNote" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="tbio_CraigHallumCapitalGroupLLCMember" name="CraigHallumCapitalGroupLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_DebtConversionConvertedInstrumentInterest" name="DebtConversionConvertedInstrumentInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease" name="DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_DebtInstrumentDebtDefaultPeriod" name="DebtInstrumentDebtDefaultPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_DebtInstrumentFutureDebtExtinguishmentCosts" name="DebtInstrumentFutureDebtExtinguishmentCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors" name="DebtInstrumentNumberofAdditionalAccreditedInvestors" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="tbio_DebtInstrumentPremiumFeePercentage" name="DebtInstrumentPremiumFeePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="tbio_DebtInstrumentPrepaymentPenaltyPercent" name="DebtInstrumentPrepaymentPenaltyPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_DelinquentAccountsPayable" name="DelinquentAccountsPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense" name="DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense" name="DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="tbio_DividendsPreferredStockCashNotDeclared" name="DividendsPreferredStockCashNotDeclared" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="tbio_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_EdgeBioSystemsInc.Member" name="EdgeBioSystemsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_EquityIncentivePlan2006Member" name="EquityIncentivePlan2006Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_GainLossOnStockWarrantsRevaluation" name="GainLossOnStockWarrantsRevaluation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_GeneticAssaysandPlatformsandPatientTestingMember" name="GeneticAssaysandPlatformsandPatientTestingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_InitialFairValueofWarrantsIssued" name="InitialFairValueofWarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="tbio_InterestIncomeAndExpenseNet" name="InterestIncomeAndExpenseNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="tbio_LoantoRelatedPartyPercentage" name="LoantoRelatedPartyPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="tbio_LossContingencyDeferredPayment" name="LossContingencyDeferredPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="tbio_MountSinaiMember" name="MountSinaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_NumberOfDirectors" name="NumberOfDirectors" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="tbio_OfferingMember" name="OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_OtherIncomeExpense" name="OtherIncomeExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds" name="PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares" name="PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_PercentageofInitialNote" name="PercentageofInitialNote" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="tbio_PharmacogenomicServicesMember" name="PharmacogenomicServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_PlacementFees" name="PlacementFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="tbio_PlacementFeesPercentageofGrossSalesPrice" name="PlacementFeesPercentageofGrossSalesPrice" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent" name="PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="tbio_PrecipioMember" name="PrecipioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_PreferredStockDividendRateCompoundPercentageMaximum" name="PreferredStockDividendRateCompoundPercentageMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_ProceedsFromtheSalesofDebtInstrument" name="ProceedsFromtheSalesofDebtInstrument" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet" name="ProceedsfromIssuanceofCommonStockandWarrantsNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes" name="Proceedsfromissuanceofcommonstockandconvertiblenotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent" name="RequiredCumulativePaymentonPrincipalPerAmendmentPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="tbio_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_ScienceParkDevelopmentCorporationMember" name="ScienceParkDevelopmentCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_SecurityPurchaseAgreementMember" name="SecurityPurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember" name="SeriesA1ConvertiblePreferredStockandWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_SeriesA1WarrantMember" name="SeriesA1WarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_SeriesAWarrantsMember" name="SeriesAWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="tbio_SmithMember" name="SmithMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_StockIssuanceCostsReimbursableExpenses" name="StockIssuanceCostsReimbursableExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="tbio_StockWarrantExchangeAmount" name="StockWarrantExchangeAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="tbio_StockWarrantsSettledwithCash" name="StockWarrantsSettledwithCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="tbio_StockholdersEquityNoteConversionRatio" name="StockholdersEquityNoteConversionRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_StockholdersEquityNoteReverseStockSplitConversionRatio" name="StockholdersEquityNoteReverseStockSplitConversionRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="tbio_TermLoanMember" name="TermLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_ThirdSecurityLlcAndAffiliatesMember" name="ThirdSecurityLlcAndAffiliatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_TotalGainsOrLossesAbstract" name="TotalGainsOrLossesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_UNMCMember" name="UNMCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_VariousInstitutionalHoldersApril2020Member" name="VariousInstitutionalHoldersApril2020Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_VariousInstitutionalHoldersDecember2020OneMember" name="VariousInstitutionalHoldersDecember2020OneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_VariousInstitutionalHoldersFebruary2020Member" name="VariousInstitutionalHoldersFebruary2020Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_VariousInstitutionalHoldersJanuary2018Member" name="VariousInstitutionalHoldersJanuary2018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_VariousInstitutionalHoldersJanuary2021OneMember" name="VariousInstitutionalHoldersJanuary2021OneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_VariousInstitutionalHoldersJanuary2021TwoMember" name="VariousInstitutionalHoldersJanuary2021TwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_VendorIIMember" name="VendorIIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_VendorMember" name="VendorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_WallStreetJournalPrimeRateMember" name="WallStreetJournalPrimeRateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_WarrantyHoldersAndIssuanceAxis" name="WarrantyHoldersAndIssuanceAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="tbio_WarrantyHoldersAndIssuanceDomain" name="WarrantyHoldersAndIssuanceDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="tbio_WorkingCapitalDeficiency" name="WorkingCapitalDeficiency" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="tbio_XIFINInc.Member" name="XIFINInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>tbio-20170331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.transgenomic.com/role/BusinessDescription" xlink:href="tbio-20170331.xsd#BusinessDescription" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/BusinessDescriptionDetails" xlink:href="tbio-20170331.xsd#BusinessDescriptionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheets" xlink:href="tbio-20170331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:href="tbio-20170331.xsd#CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/Contingencies" xlink:href="tbio-20170331.xsd#Contingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/ContingenciesDetails" xlink:href="tbio-20170331.xsd#ContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/Debt" xlink:href="tbio-20170331.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DebtConvertiblePromissoryNotesDetails" xlink:href="tbio-20170331.xsd#DebtConvertiblePromissoryNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DebtRevolvingLineAndTermLoanDetails" xlink:href="tbio-20170331.xsd#DebtRevolvingLineAndTermLoanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DebtScheduleOfDebtDetails" xlink:href="tbio-20170331.xsd#DebtScheduleOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DebtTables" xlink:href="tbio-20170331.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DiscontinuedOperations" xlink:href="tbio-20170331.xsd#DiscontinuedOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DiscontinuedOperationsRevenuesAndNetIncomeLossDetails" xlink:href="tbio-20170331.xsd#DiscontinuedOperationsRevenuesAndNetIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DiscontinuedOperationsTables" xlink:href="tbio-20170331.xsd#DiscontinuedOperationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DocumentAndEntityInformation" xlink:href="tbio-20170331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/FairValue" xlink:href="tbio-20170331.xsd#FairValue" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/FairValueDetails" xlink:href="tbio-20170331.xsd#FairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/FairValueTables" xlink:href="tbio-20170331.xsd#FairValueTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/IncomeTaxes" xlink:href="tbio-20170331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/IncomeTaxesDetails" xlink:href="tbio-20170331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockOptions" xlink:href="tbio-20170331.xsd#StockOptions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockOptionsStockAppreciationRightsDetails" xlink:href="tbio-20170331.xsd#StockOptionsStockAppreciationRightsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockOptionsStockOptionsDetails" xlink:href="tbio-20170331.xsd#StockOptionsStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockOptionsTables" xlink:href="tbio-20170331.xsd#StockOptionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquity" xlink:href="tbio-20170331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityCommonStockDetails" xlink:href="tbio-20170331.xsd#StockholdersEquityCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:href="tbio-20170331.xsd#StockholdersEquityCommonStockWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityConversionOfPreferredStockDetails" xlink:href="tbio-20170331.xsd#StockholdersEquityConversionOfPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityPreferredStockDividendsDetails" xlink:href="tbio-20170331.xsd#StockholdersEquityPreferredStockDividendsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesADetails" xlink:href="tbio-20170331.xsd#StockholdersEquityPreferredStockSeriesADetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesBDetails" xlink:href="tbio-20170331.xsd#StockholdersEquityPreferredStockSeriesBDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityTables" xlink:href="tbio-20170331.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SubsequentEvents" xlink:href="tbio-20170331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SubsequentEventsDetails" xlink:href="tbio-20170331.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tbio-20170331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:href="tbio-20170331.xsd#SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesNarrativesDetails" xlink:href="tbio-20170331.xsd#SummaryOfSignificantAccountingPoliciesNarrativesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tbio-20170331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:href="tbio-20170331.xsd#SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:href="tbio-20170331.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsParentheticals" xlink:href="tbio-20170331.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlowsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:href="tbio-20170331.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/BusinessDescription" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/BusinessDescriptionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_ed9fae98-3ae1-7659-630e-7314e2eeb5de" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_ed9fae98-3ae1-7659-630e-7314e2eeb5de" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_27e98f68-fe6c-3420-5b5a-861a4dc60800" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AdditionalPaidInCapital_27e98f68-fe6c-3420-5b5a-861a4dc60800" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e20e4396-1ab7-d9ec-b779-e1a72ae620da" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e20e4396-1ab7-d9ec-b779-e1a72ae620da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_fdc0ed61-91fa-946a-6107-cae34d7fdf9d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_fdc0ed61-91fa-946a-6107-cae34d7fdf9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/Contingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/ContingenciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/DebtConvertiblePromissoryNotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/DebtRevolvingLineAndTermLoanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/DebtScheduleOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_3d1ff4d2-78b4-0876-a2bf-23c555b4696e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_3d1ff4d2-78b4-0876-a2bf-23c555b4696e" xlink:to="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_898d9dde-51c0-10b5-4600-dc6b12c399c4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_3d1ff4d2-78b4-0876-a2bf-23c555b4696e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_898d9dde-51c0-10b5-4600-dc6b12c399c4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/DiscontinuedOperations" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/DiscontinuedOperationsRevenuesAndNetIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f834d2c-e90e-21df-1140-46d28f006205" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c456ee30-018f-7f2e-ff1b-e572f3b88321" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f834d2c-e90e-21df-1140-46d28f006205" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c456ee30-018f-7f2e-ff1b-e572f3b88321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_65664b1f-a797-e2f8-8ddd-5d998f0986e7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c456ee30-018f-7f2e-ff1b-e572f3b88321" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_65664b1f-a797-e2f8-8ddd-5d998f0986e7" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense" xlink:label="loc_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense_c964e847-c837-1a18-9a0f-94cabe12ddcf" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_65664b1f-a797-e2f8-8ddd-5d998f0986e7" xlink:to="loc_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense_c964e847-c837-1a18-9a0f-94cabe12ddcf" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense" xlink:label="loc_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense_3c9d528c-1c82-abc4-1ec5-94cabdbc9b90" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_65664b1f-a797-e2f8-8ddd-5d998f0986e7" xlink:to="loc_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense_3c9d528c-1c82-abc4-1ec5-94cabdbc9b90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_457e6fb3-208a-452c-2c3a-b218f2f684b1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_65664b1f-a797-e2f8-8ddd-5d998f0986e7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_457e6fb3-208a-452c-2c3a-b218f2f684b1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9e4f1252-47bf-7ba6-fed7-01b1b8bd5d22" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_457e6fb3-208a-452c-2c3a-b218f2f684b1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9e4f1252-47bf-7ba6-fed7-01b1b8bd5d22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8712fd20-5d5a-b470-c9c7-0fe02bd6250a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_457e6fb3-208a-452c-2c3a-b218f2f684b1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8712fd20-5d5a-b470-c9c7-0fe02bd6250a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc155cc8-6ee1-5ea7-d824-9c91dc052636" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c456ee30-018f-7f2e-ff1b-e572f3b88321" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc155cc8-6ee1-5ea7-d824-9c91dc052636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_dd0a6efc-12cc-d6c2-cd8c-0b8c52628140" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f834d2c-e90e-21df-1140-46d28f006205" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_dd0a6efc-12cc-d6c2-cd8c-0b8c52628140" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/DiscontinuedOperationsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/FairValue" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/FairValueDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/FairValueTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/StockOptions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/StockOptionsStockAppreciationRightsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/StockOptionsStockOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/StockOptionsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityCommonStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityConversionOfPreferredStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityPreferredStockDividendsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesADetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesBDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/SubsequentEventsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesNarrativesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_24485696-f982-096a-ee6a-f5e510cdb21c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_24485696-f982-096a-ee6a-f5e510cdb21c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_44a700f6-fd76-d81b-18cc-566e56087517" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_44a700f6-fd76-d81b-18cc-566e56087517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_9ae738f0-5b10-fcbb-98fe-43bb46377ad9" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_9ae738f0-5b10-fcbb-98fe-43bb46377ad9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_24372e3a-d7cf-aeb5-3e3e-92a986bb9251" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_24372e3a-d7cf-aeb5-3e3e-92a986bb9251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f727506e-917a-c7f2-effd-742269ec6604" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f727506e-917a-c7f2-effd-742269ec6604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="loc_us-gaap_GainLossOnContractTermination_6b526f92-8799-0a22-cfdd-6c589a578636" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_GainLossOnContractTermination_6b526f92-8799-0a22-cfdd-6c589a578636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_ad8bf556-b7c8-7821-188c-b2f20d2a1601" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_ad8bf556-b7c8-7821-188c-b2f20d2a1601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_51b81a6f-f6af-160e-e526-5abd0f450976" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_51b81a6f-f6af-160e-e526-5abd0f450976" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5d4a5cdc-af3d-5a6b-4771-61ef2a3cbcb0" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5d4a5cdc-af3d-5a6b-4771-61ef2a3cbcb0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_e0f76ffa-e5a2-315e-fb9f-0e3dc9ccc4ca" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_e0f76ffa-e5a2-315e-fb9f-0e3dc9ccc4ca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503015f3-ea26-0d7a-c655-6d6aff0c5fab" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503015f3-ea26-0d7a-c655-6d6aff0c5fab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_6497c9ca-b570-d510-eb1e-c94e7a7aedb4" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_6497c9ca-b570-d510-eb1e-c94e7a7aedb4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d8c0a214-0b0d-1fc8-686b-ed5eca49895f" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d8c0a214-0b0d-1fc8-686b-ed5eca49895f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2341918a-c49e-5d4b-79f6-51d4e80ea39b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2341918a-c49e-5d4b-79f6-51d4e80ea39b" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsParentheticals" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_11a7c554-b3e3-7a3c-a81e-5c5ff89c25e9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_11a7c554-b3e3-7a3c-a81e-5c5ff89c25e9" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_ad8bf556-b7c8-7821-188c-b2f20d2a1601" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_ad8bf556-b7c8-7821-188c-b2f20d2a1601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_ad8bf556-b7c8-7821-188c-b2f20d2a1601" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:to="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_f7eb5dbc-6802-ae51-de6b-9a44f4241080" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:to="loc_us-gaap_SalesRevenueNet_f7eb5dbc-6802-ae51-de6b-9a44f4241080" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_368e9778-4d12-f736-79b9-637804de9992" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_368e9778-4d12-f736-79b9-637804de9992" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_OtherIncomeExpense" xlink:label="loc_tbio_OtherIncomeExpense_4ad7300b-237c-82a9-1da0-94cabdd01228" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:to="loc_tbio_OtherIncomeExpense_4ad7300b-237c-82a9-1da0-94cabdd01228" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_InterestIncomeAndExpenseNet" xlink:label="loc_tbio_InterestIncomeAndExpenseNet_e4a1216b-a474-58e8-0f45-94cabe150921" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tbio_OtherIncomeExpense_4ad7300b-237c-82a9-1da0-94cabdd01228" xlink:to="loc_tbio_InterestIncomeAndExpenseNet_e4a1216b-a474-58e8-0f45-94cabe150921" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_GainLossOnStockWarrantsRevaluation" xlink:label="loc_tbio_GainLossOnStockWarrantsRevaluation_7d1e7a9a-aabd-3d19-b2db-94cabdc11cdf" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tbio_OtherIncomeExpense_4ad7300b-237c-82a9-1da0-94cabdd01228" xlink:to="loc_tbio_GainLossOnStockWarrantsRevaluation_7d1e7a9a-aabd-3d19-b2db-94cabdc11cdf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_ad8bf556-b7c8-7821-188c-b2f20d2a1601" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f834d2c-e90e-21df-1140-46d28f006205" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f834d2c-e90e-21df-1140-46d28f006205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_887cbdfa-41ea-fa5b-a522-ded45c1dacc2" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_11a7c554-b3e3-7a3c-a81e-5c5ff89c25e9" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_887cbdfa-41ea-fa5b-a522-ded45c1dacc2" xlink:type="arc" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>tbio-20170331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.transgenomic.com/role/BusinessDescription" xlink:href="tbio-20170331.xsd#BusinessDescription" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/BusinessDescriptionDetails" xlink:href="tbio-20170331.xsd#BusinessDescriptionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheets" xlink:href="tbio-20170331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:href="tbio-20170331.xsd#CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/Contingencies" xlink:href="tbio-20170331.xsd#Contingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/ContingenciesDetails" xlink:href="tbio-20170331.xsd#ContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/Debt" xlink:href="tbio-20170331.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DebtConvertiblePromissoryNotesDetails" xlink:href="tbio-20170331.xsd#DebtConvertiblePromissoryNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DebtRevolvingLineAndTermLoanDetails" xlink:href="tbio-20170331.xsd#DebtRevolvingLineAndTermLoanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DebtScheduleOfDebtDetails" xlink:href="tbio-20170331.xsd#DebtScheduleOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DebtTables" xlink:href="tbio-20170331.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DiscontinuedOperations" xlink:href="tbio-20170331.xsd#DiscontinuedOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DiscontinuedOperationsRevenuesAndNetIncomeLossDetails" xlink:href="tbio-20170331.xsd#DiscontinuedOperationsRevenuesAndNetIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DiscontinuedOperationsTables" xlink:href="tbio-20170331.xsd#DiscontinuedOperationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DocumentAndEntityInformation" xlink:href="tbio-20170331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/FairValue" xlink:href="tbio-20170331.xsd#FairValue" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/FairValueDetails" xlink:href="tbio-20170331.xsd#FairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/FairValueTables" xlink:href="tbio-20170331.xsd#FairValueTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/IncomeTaxes" xlink:href="tbio-20170331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/IncomeTaxesDetails" xlink:href="tbio-20170331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockOptions" xlink:href="tbio-20170331.xsd#StockOptions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockOptionsStockAppreciationRightsDetails" xlink:href="tbio-20170331.xsd#StockOptionsStockAppreciationRightsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockOptionsStockOptionsDetails" xlink:href="tbio-20170331.xsd#StockOptionsStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockOptionsTables" xlink:href="tbio-20170331.xsd#StockOptionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquity" xlink:href="tbio-20170331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityCommonStockDetails" xlink:href="tbio-20170331.xsd#StockholdersEquityCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:href="tbio-20170331.xsd#StockholdersEquityCommonStockWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityConversionOfPreferredStockDetails" xlink:href="tbio-20170331.xsd#StockholdersEquityConversionOfPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityPreferredStockDividendsDetails" xlink:href="tbio-20170331.xsd#StockholdersEquityPreferredStockDividendsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesADetails" xlink:href="tbio-20170331.xsd#StockholdersEquityPreferredStockSeriesADetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesBDetails" xlink:href="tbio-20170331.xsd#StockholdersEquityPreferredStockSeriesBDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityTables" xlink:href="tbio-20170331.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SubsequentEvents" xlink:href="tbio-20170331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SubsequentEventsDetails" xlink:href="tbio-20170331.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tbio-20170331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:href="tbio-20170331.xsd#SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesNarrativesDetails" xlink:href="tbio-20170331.xsd#SummaryOfSignificantAccountingPoliciesNarrativesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tbio-20170331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:href="tbio-20170331.xsd#SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:href="tbio-20170331.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsParentheticals" xlink:href="tbio-20170331.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlowsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:href="tbio-20170331.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/BusinessDescription" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/BusinessDescriptionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_08FD9FB320DA85D89DACFDA2FDA8B34E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_08FD9FB320DA85D89DACFDA2FDA8B34E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9342AE83BFDCCA2DDF1BFDA2FDA8DC0A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_08FD9FB320DA85D89DACFDA2FDA8B34E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9342AE83BFDCCA2DDF1BFDA2FDA8DC0A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9342AE83BFDCCA2DDF1BFDA2FDA8DC0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_08FD9FB320DA85D89DACFDA2FDA8B34E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9342AE83BFDCCA2DDF1BFDA2FDA8DC0A" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PrecipioMember" xlink:label="loc_tbio_PrecipioMember_959B456802F9B2F53F01FDA2FDA8CAF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9342AE83BFDCCA2DDF1BFDA2FDA8DC0A" xlink:to="loc_tbio_PrecipioMember_959B456802F9B2F53F01FDA2FDA8CAF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_AC91D8594230C6D032EDFDA2FDA8CF67" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:to="loc_dei_LegalEntityAxis_AC91D8594230C6D032EDFDA2FDA8CF67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_56E0FC8AAC6960671D1BFDA2FDA8281B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_AC91D8594230C6D032EDFDA2FDA8CF67" xlink:to="loc_dei_EntityDomain_56E0FC8AAC6960671D1BFDA2FDA8281B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_56E0FC8AAC6960671D1BFDA2FDA8281B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_AC91D8594230C6D032EDFDA2FDA8CF67" xlink:to="loc_dei_EntityDomain_56E0FC8AAC6960671D1BFDA2FDA8281B" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PrecipioMember" xlink:label="loc_tbio_PrecipioMember_ADAFC117DDE8C39EC5B6FDA2FDA8ED0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_56E0FC8AAC6960671D1BFDA2FDA8281B" xlink:to="loc_tbio_PrecipioMember_ADAFC117DDE8C39EC5B6FDA2FDA8ED0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_FB2003453BD54A472620FDA2FDA838CC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_FB2003453BD54A472620FDA2FDA838CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2DCE938F71896187FC87FDA2FDA8188C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FB2003453BD54A472620FDA2FDA838CC" xlink:to="loc_us-gaap_ClassOfStockDomain_2DCE938F71896187FC87FDA2FDA8188C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2DCE938F71896187FC87FDA2FDA8188C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FB2003453BD54A472620FDA2FDA838CC" xlink:to="loc_us-gaap_ClassOfStockDomain_2DCE938F71896187FC87FDA2FDA8188C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1F74755E3C90EAE55644FDA2FDA8C49E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2DCE938F71896187FC87FDA2FDA8188C" xlink:to="loc_us-gaap_CommonStockMember_1F74755E3C90EAE55644FDA2FDA8C49E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_5C4DB431943C1359EBBFFDA2FDA81978" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2DCE938F71896187FC87FDA2FDA8188C" xlink:to="loc_us-gaap_PreferredStockMember_5C4DB431943C1359EBBFFDA2FDA81978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_D4CAAF49D7494D09947CFDA2FDA80A26" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:to="loc_us-gaap_RangeAxis_D4CAAF49D7494D09947CFDA2FDA80A26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_4A2C867BE142151FB0AEFDA2FDA80469_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_D4CAAF49D7494D09947CFDA2FDA80A26" xlink:to="loc_us-gaap_RangeMember_4A2C867BE142151FB0AEFDA2FDA80469_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_4A2C867BE142151FB0AEFDA2FDA80469" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_D4CAAF49D7494D09947CFDA2FDA80A26" xlink:to="loc_us-gaap_RangeMember_4A2C867BE142151FB0AEFDA2FDA80469" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_A3E1D33883AD9A78351FFDA2FDA81A54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_4A2C867BE142151FB0AEFDA2FDA80469" xlink:to="loc_us-gaap_MaximumMember_A3E1D33883AD9A78351FFDA2FDA81A54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_BD52437AAD7E683DA1F4FDA2FDA8492E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_4A2C867BE142151FB0AEFDA2FDA80469" xlink:to="loc_us-gaap_MinimumMember_BD52437AAD7E683DA1F4FDA2FDA8492E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_C6BFB90ACDC8135E709FFDA2FDA81933" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_C6BFB90ACDC8135E709FFDA2FDA81933" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WorkingCapitalDeficiency" xlink:label="loc_tbio_WorkingCapitalDeficiency_44FA6D5BB99005AF64B2FDA2FDA86683" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:to="loc_tbio_WorkingCapitalDeficiency_44FA6D5BB99005AF64B2FDA2FDA86683" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_AEBA0CBE0BB2A142689EFDA2FDA86F17" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_AEBA0CBE0BB2A142689EFDA2FDA86F17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_0CE818CB955DEAED1CD3FDA2FDA83D5A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_0CE818CB955DEAED1CD3FDA2FDA83D5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_A3D168EF234F49E40B6DFDA2FDA87153" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_A3D168EF234F49E40B6DFDA2FDA87153" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockholdersEquityNoteReverseStockSplitConversionRatio" xlink:label="loc_tbio_StockholdersEquityNoteReverseStockSplitConversionRatio_226D2A7366491587835FFDA2FDA82811" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:to="loc_tbio_StockholdersEquityNoteReverseStockSplitConversionRatio_226D2A7366491587835FFDA2FDA82811" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/Contingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_794A1791C39094C01ED3FE284701A509" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:to="loc_us-gaap_LossContingenciesTable_794A1791C39094C01ED3FE284701A509" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_7712BBB49D2E2663B528FE284701094B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_794A1791C39094C01ED3FE284701A509" xlink:to="loc_us-gaap_LitigationCaseAxis_7712BBB49D2E2663B528FE284701094B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationCaseAxis_7712BBB49D2E2663B528FE284701094B" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationCaseAxis_7712BBB49D2E2663B528FE284701094B" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_UNMCMember" xlink:label="loc_tbio_UNMCMember_D184C1A38071F5C69627FE2847012537" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:to="loc_tbio_UNMCMember_D184C1A38071F5C69627FE2847012537" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_MountSinaiMember" xlink:label="loc_tbio_MountSinaiMember_16E370EB8EA33B3D6A01FE2847011F04" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:to="loc_tbio_MountSinaiMember_16E370EB8EA33B3D6A01FE2847011F04" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SmithMember" xlink:label="loc_tbio_SmithMember_84BE32A93402A72A1D24FE284701666D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:to="loc_tbio_SmithMember_84BE32A93402A72A1D24FE284701666D" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_XIFINInc.Member" xlink:label="loc_tbio_XIFINInc.Member_5C2A8E3A1B867410A239FE284701D5F2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:to="loc_tbio_XIFINInc.Member_5C2A8E3A1B867410A239FE284701D5F2" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ScienceParkDevelopmentCorporationMember" xlink:label="loc_tbio_ScienceParkDevelopmentCorporationMember_E85EDA555642964F7F26FE284701967D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:to="loc_tbio_ScienceParkDevelopmentCorporationMember_E85EDA555642964F7F26FE284701967D" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_CPAGlobalMember" xlink:label="loc_tbio_CPAGlobalMember_C5298113F43077631E65FE2847013E07" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:to="loc_tbio_CPAGlobalMember_C5298113F43077631E65FE2847013E07" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_EdgeBioSystemsInc.Member" xlink:label="loc_tbio_EdgeBioSystemsInc.Member_333456E834882AD25099FE284701794E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:to="loc_tbio_EdgeBioSystemsInc.Member_333456E834882AD25099FE284701794E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1BA93A9D803C9462A9AFFE28AA4CE8F6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_794A1791C39094C01ED3FE284701A509" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1BA93A9D803C9462A9AFFE28AA4CE8F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_D8832AF800381F4D07B4FE28AC12348D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1BA93A9D803C9462A9AFFE28AA4CE8F6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_D8832AF800381F4D07B4FE28AC12348D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_D8832AF800381F4D07B4FE28AC12348D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1BA93A9D803C9462A9AFFE28AA4CE8F6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_D8832AF800381F4D07B4FE28AC12348D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_01E16122048407576433FE292DAEF3A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_D8832AF800381F4D07B4FE28AC12348D" xlink:to="loc_us-gaap_SubsequentEventMember_01E16122048407576433FE292DAEF3A7" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DelinquentAccountsPayable" xlink:label="loc_tbio_DelinquentAccountsPayable_ED03BFA643F099E01A4AFE2847016277" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:to="loc_tbio_DelinquentAccountsPayable_ED03BFA643F099E01A4AFE2847016277" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_CAE6273AE35BACF04150FE2847018A38" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_CAE6273AE35BACF04150FE2847018A38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_828A59321A550D8D3A67FE2847016A1F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_828A59321A550D8D3A67FE2847016A1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_024B789388731B12AE87FE284701714E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_024B789388731B12AE87FE284701714E" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_LossContingencyDeferredPayment" xlink:label="loc_tbio_LossContingencyDeferredPayment_3291D351928EA8AB0491FE28470158B0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:to="loc_tbio_LossContingencyDeferredPayment_3291D351928EA8AB0491FE28470158B0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/DebtConvertiblePromissoryNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_87EF020B392261BB79340D52F1BB12EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_us-gaap_DebtInstrumentTable_87EF020B392261BB79340D52F1BB12EA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_DD04219A656ED2DB9A300D52F1BBF01E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_87EF020B392261BB79340D52F1BB12EA" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_DD04219A656ED2DB9A300D52F1BBF01E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FFA38C7D092B8A4A45930D52F1BB6CE6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DD04219A656ED2DB9A300D52F1BBF01E" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_FFA38C7D092B8A4A45930D52F1BB6CE6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FFA38C7D092B8A4A45930D52F1BB6CE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DD04219A656ED2DB9A300D52F1BBF01E" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_FFA38C7D092B8A4A45930D52F1BB6CE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_8C0333FC0B0F742631110D52F1BBF9F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_FFA38C7D092B8A4A45930D52F1BB6CE6" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_8C0333FC0B0F742631110D52F1BBF9F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B81A29C7196A73C651F80D89BD7752BB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_87EF020B392261BB79340D52F1BB12EA" xlink:to="loc_us-gaap_DebtInstrumentAxis_B81A29C7196A73C651F80D89BD7752BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_457221C3687733F4D11C0D89BD86CA37_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_B81A29C7196A73C651F80D89BD7752BB" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_457221C3687733F4D11C0D89BD86CA37_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_457221C3687733F4D11C0D89BD86CA37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_B81A29C7196A73C651F80D89BD7752BB" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_457221C3687733F4D11C0D89BD86CA37" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AdditionalNotesMember" xlink:label="loc_tbio_AdditionalNotesMember_BFC70A70DFE30478D22D0D8ADD539F43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_457221C3687733F4D11C0D89BD86CA37" xlink:to="loc_tbio_AdditionalNotesMember_BFC70A70DFE30478D22D0D8ADD539F43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_11D9E3B62E0FAAD9920A0D52F1BBFCDE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_87EF020B392261BB79340D52F1BB12EA" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_11D9E3B62E0FAAD9920A0D52F1BBFCDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_386EABD08A6F7C5A86930D52F1BB84B5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_11D9E3B62E0FAAD9920A0D52F1BBFCDE" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_386EABD08A6F7C5A86930D52F1BB84B5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_386EABD08A6F7C5A86930D52F1BB84B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_11D9E3B62E0FAAD9920A0D52F1BBFCDE" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_386EABD08A6F7C5A86930D52F1BB84B5" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AgentNoteMember" xlink:label="loc_tbio_AgentNoteMember_B8A440DF68F97BE7F4FF0D52F1BB3088" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_386EABD08A6F7C5A86930D52F1BB84B5" xlink:to="loc_tbio_AgentNoteMember_B8A440DF68F97BE7F4FF0D52F1BB3088" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AdditionalNotePrivatePlacementMember" xlink:label="loc_tbio_AdditionalNotePrivatePlacementMember_BDCED2B8D4CE99ED08C40D52F1BC51A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_386EABD08A6F7C5A86930D52F1BB84B5" xlink:to="loc_tbio_AdditionalNotePrivatePlacementMember_BDCED2B8D4CE99ED08C40D52F1BC51A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_D067386479A6EA34F9D50D52F1BC78A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_D067386479A6EA34F9D50D52F1BC78A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_59BA1E82151B935A5B680D52F1BC0998" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_59BA1E82151B935A5B680D52F1BC0998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_CB9F8E474953E69267760D52F1BC6355" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_CB9F8E474953E69267760D52F1BC6355" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors" xlink:label="loc_tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors_B14EB4F814D8219F196F0D52F1BC8864" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors_B14EB4F814D8219F196F0D52F1BC8864" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PercentageofInitialNote" xlink:label="loc_tbio_PercentageofInitialNote_6E32D24E8890F063B1640D52F1BC4D9B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_tbio_PercentageofInitialNote_6E32D24E8890F063B1640D52F1BC4D9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4237E5FF5F522E66912B0D52F1BCE739" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4237E5FF5F522E66912B0D52F1BCE739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_0393A4479C663E6F90350D52F1BC2EE4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_us-gaap_LongTermDebt_0393A4479C663E6F90350D52F1BC2EE4" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentDebtDefaultPeriod" xlink:label="loc_tbio_DebtInstrumentDebtDefaultPeriod_2C5A87365AF3348237A90D62620F1240" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_tbio_DebtInstrumentDebtDefaultPeriod_2C5A87365AF3348237A90D62620F1240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_3E9B5CA503FE272AD1010D52F1BC965A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_3E9B5CA503FE272AD1010D52F1BC965A" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent" xlink:label="loc_tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_BEF393BD9A93A7235CE80D857BAEDE75" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_BEF393BD9A93A7235CE80D857BAEDE75" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent" xlink:label="loc_tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_D26C4C57E8FE431374BC0D9508E91AA5" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_D26C4C57E8FE431374BC0D9508E91AA5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/DebtRevolvingLineAndTermLoanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:to="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_0906F2941C5140445AD3F99435A3C71C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:to="loc_us-gaap_CreditFacilityAxis_0906F2941C5140445AD3F99435A3C71C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_70B4A2FEA4E065F0ABABF99435A34A4A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_0906F2941C5140445AD3F99435A3C71C" xlink:to="loc_us-gaap_CreditFacilityDomain_70B4A2FEA4E065F0ABABF99435A34A4A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_70B4A2FEA4E065F0ABABF99435A34A4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_0906F2941C5140445AD3F99435A3C71C" xlink:to="loc_us-gaap_CreditFacilityDomain_70B4A2FEA4E065F0ABABF99435A34A4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_3D6B4D5EE5D24EBBBAB3F99435A33177" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_70B4A2FEA4E065F0ABABF99435A34A4A" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_3D6B4D5EE5D24EBBBAB3F99435A33177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E8CFEEE0BDFF52D83786F99435A33FB7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E8CFEEE0BDFF52D83786F99435A33FB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E8CFEEE0BDFF52D83786F99435A33FB7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E8CFEEE0BDFF52D83786F99435A33FB7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_269B1013E088307350CDF99435A3F42E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4" xlink:to="loc_us-gaap_LineOfCreditMember_269B1013E088307350CDF99435A3F42E" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_TermLoanMember" xlink:label="loc_tbio_TermLoanMember_6C57E1EC15B158087595F99435A4B86A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4" xlink:to="loc_tbio_TermLoanMember_6C57E1EC15B158087595F99435A4B86A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_3C61FBF083A5D87B771CF99435A4B932" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_3C61FBF083A5D87B771CF99435A4B932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_29EDA996064EE9C9C2DFF99435A44274" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_29EDA996064EE9C9C2DFF99435A44274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_7002F71E6E3CFEFFE69CF99435A40F33_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_29EDA996064EE9C9C2DFF99435A44274" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_7002F71E6E3CFEFFE69CF99435A40F33_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_7002F71E6E3CFEFFE69CF99435A40F33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_29EDA996064EE9C9C2DFF99435A44274" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_7002F71E6E3CFEFFE69CF99435A40F33" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ThirdSecurityLlcAndAffiliatesMember" xlink:label="loc_tbio_ThirdSecurityLlcAndAffiliatesMember_6300BC7AB349A5DE3569F99435A456B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7002F71E6E3CFEFFE69CF99435A40F33" xlink:to="loc_tbio_ThirdSecurityLlcAndAffiliatesMember_6300BC7AB349A5DE3569F99435A456B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4D503A975E5329E9743FF99435A40008" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:to="loc_dei_LegalEntityAxis_4D503A975E5329E9743FF99435A40008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8A97C2951879C202B097F99435A4BC2B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4D503A975E5329E9743FF99435A40008" xlink:to="loc_dei_EntityDomain_8A97C2951879C202B097F99435A4BC2B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8A97C2951879C202B097F99435A4BC2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4D503A975E5329E9743FF99435A40008" xlink:to="loc_dei_EntityDomain_8A97C2951879C202B097F99435A4BC2B" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PrecipioMember" xlink:label="loc_tbio_PrecipioMember_63B9F574EA41FF300AC2F99435A46D31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8A97C2951879C202B097F99435A4BC2B" xlink:to="loc_tbio_PrecipioMember_63B9F574EA41FF300AC2F99435A46D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_EBB7779F986493FCCD39F99435A475B1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_EBB7779F986493FCCD39F99435A475B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_EBB7779F986493FCCD39F99435A475B1" xlink:to="loc_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_EBB7779F986493FCCD39F99435A475B1" xlink:to="loc_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="loc_us-gaap_ConvertibleCommonStockMember_8774692473B1B2DDFC15F99435A405E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731" xlink:to="loc_us-gaap_ConvertibleCommonStockMember_8774692473B1B2DDFC15F99435A405E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_92B4AC166897CFE88224F99435A46C04" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_92B4AC166897CFE88224F99435A46C04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_47254065B2513BCA14EDF99435A4ADAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_47254065B2513BCA14EDF99435A4ADAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_F07F53E359E80D7EC164F99435A49E65" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_F07F53E359E80D7EC164F99435A49E65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_E4DFE054E144426BEC4FF99435A5F1C9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_E4DFE054E144426BEC4FF99435A5F1C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1EF339EE5030DBBCE93CF99435A5747C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1EF339EE5030DBBCE93CF99435A5747C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_C6F49B728771C80ECDA0F99435A55C0A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:to="loc_us-gaap_SharePrice_C6F49B728771C80ECDA0F99435A55C0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_86BAF934F4193C007AA9F99435A54D82" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_86BAF934F4193C007AA9F99435A54D82" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtConversionConvertedInstrumentInterest" xlink:label="loc_tbio_DebtConversionConvertedInstrumentInterest_B929999A8FFDBCEB3DF3F99435A54ED1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:to="loc_tbio_DebtConversionConvertedInstrumentInterest_B929999A8FFDBCEB3DF3F99435A54ED1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/DebtScheduleOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_A3AC88A9938945FA0060E9708A2174C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_DebtInstrumentTable_A3AC88A9938945FA0060E9708A2174C3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_CC059F51A8849DF39DCEE9708A212EB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A3AC88A9938945FA0060E9708A2174C3" xlink:to="loc_us-gaap_CreditFacilityAxis_CC059F51A8849DF39DCEE9708A212EB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_98A17E920C1A1230BBF6E9708A21D42F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_CC059F51A8849DF39DCEE9708A212EB8" xlink:to="loc_us-gaap_CreditFacilityDomain_98A17E920C1A1230BBF6E9708A21D42F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_98A17E920C1A1230BBF6E9708A21D42F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_CC059F51A8849DF39DCEE9708A212EB8" xlink:to="loc_us-gaap_CreditFacilityDomain_98A17E920C1A1230BBF6E9708A21D42F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_DE9182867A2FDD342CDAE9708A212D28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_98A17E920C1A1230BBF6E9708A21D42F" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_DE9182867A2FDD342CDAE9708A212D28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E308D768B1F33539E831E9708A21B9FF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A3AC88A9938945FA0060E9708A2174C3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E308D768B1F33539E831E9708A21B9FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2D57F1A795DFE9C4EEC3E9708A211274_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E308D768B1F33539E831E9708A21B9FF" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2D57F1A795DFE9C4EEC3E9708A211274_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2D57F1A795DFE9C4EEC3E9708A211274" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E308D768B1F33539E831E9708A21B9FF" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2D57F1A795DFE9C4EEC3E9708A211274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_2216BFADE99ADFE2F486E9708A21ECDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2D57F1A795DFE9C4EEC3E9708A211274" xlink:to="loc_us-gaap_LineOfCreditMember_2216BFADE99ADFE2F486E9708A21ECDC" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_TermLoanMember" xlink:label="loc_tbio_TermLoanMember_14C8E57AE7BC7D0D98E7E9708A212DE3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2D57F1A795DFE9C4EEC3E9708A211274" xlink:to="loc_tbio_TermLoanMember_14C8E57AE7BC7D0D98E7E9708A212DE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_AF450348C77A05953262E9708A21C42F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2D57F1A795DFE9C4EEC3E9708A211274" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_AF450348C77A05953262E9708A21C42F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_8778F3460A797A010706E9708A2117EB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A3AC88A9938945FA0060E9708A2174C3" xlink:to="loc_us-gaap_VariableRateAxis_8778F3460A797A010706E9708A2117EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_DCCA6B2A810062322A9AE9708A219B90_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_8778F3460A797A010706E9708A2117EB" xlink:to="loc_us-gaap_VariableRateDomain_DCCA6B2A810062322A9AE9708A219B90_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_DCCA6B2A810062322A9AE9708A219B90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_8778F3460A797A010706E9708A2117EB" xlink:to="loc_us-gaap_VariableRateDomain_DCCA6B2A810062322A9AE9708A219B90" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WallStreetJournalPrimeRateMember" xlink:label="loc_tbio_WallStreetJournalPrimeRateMember_1C25840BA562B55A66C6E9708A217152" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_DCCA6B2A810062322A9AE9708A219B90" xlink:to="loc_tbio_WallStreetJournalPrimeRateMember_1C25840BA562B55A66C6E9708A217152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_4F5D10C3EE1D44F39DABE9708A2122E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_4F5D10C3EE1D44F39DABE9708A2122E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_27A1BF5D9742B734B22BE9708A22DEFC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_LongTermDebtCurrent_27A1BF5D9742B734B22BE9708A22DEFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_42B65531057083411225E9708A22FCAA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_42B65531057083411225E9708A22FCAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_FB1795C6FB1BED6F17A5E9708A22E266" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_FB1795C6FB1BED6F17A5E9708A22E266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0BAE3944153261E29DEFE9708A22BA33" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0BAE3944153261E29DEFE9708A22BA33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_AF6ACDFAA91089D03195E9708A221D61" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_AF6ACDFAA91089D03195E9708A221D61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_D0CDD5DA93BCBE713A70E9708A22DC14" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_D0CDD5DA93BCBE713A70E9708A22DC14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_6596FB699EA02C70E0D6E9708A22A909" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_6596FB699EA02C70E0D6E9708A22A909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_BB30E706EAF51D7F2469E9708A2236EB" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_BB30E706EAF51D7F2469E9708A2236EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_8E341A9E8BC980F50F35E9708A2201F7" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_8E341A9E8BC980F50F35E9708A2201F7" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentFutureDebtExtinguishmentCosts" xlink:label="loc_tbio_DebtInstrumentFutureDebtExtinguishmentCosts_7E79E84CC0B197F9E3F0E9708A221B02" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_tbio_DebtInstrumentFutureDebtExtinguishmentCosts_7E79E84CC0B197F9E3F0E9708A221B02" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentPrepaymentPenaltyPercent" xlink:label="loc_tbio_DebtInstrumentPrepaymentPenaltyPercent_F93C840AC73B33C6E232E9708A22567C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_tbio_DebtInstrumentPrepaymentPenaltyPercent_F93C840AC73B33C6E232E9708A22567C" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease" xlink:label="loc_tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease_18566916BD0A720EC743E9708A2276C7" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease_18566916BD0A720EC743E9708A2276C7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/DiscontinuedOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/DiscontinuedOperationsRevenuesAndNetIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8131CEB7ECD9B9ECFA631C26775BF177" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8131CEB7ECD9B9ECFA631C26775BF177" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_D400ACF6839EF9FBD0401C26775BA4E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8131CEB7ECD9B9ECFA631C26775BF177" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_D400ACF6839EF9FBD0401C26775BA4E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_07996FE250E9F548691A1C26775BFEF4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_D400ACF6839EF9FBD0401C26775BA4E1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_07996FE250E9F548691A1C26775BFEF4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_07996FE250E9F548691A1C26775BFEF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_D400ACF6839EF9FBD0401C26775BA4E1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_07996FE250E9F548691A1C26775BFEF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_F02566B8A1CDB144308D1C26775BA319" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_07996FE250E9F548691A1C26775BFEF4" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_F02566B8A1CDB144308D1C26775BA319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_41B2A31C953F2FC07B1D1C26775B7ECF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8131CEB7ECD9B9ECFA631C26775BF177" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_41B2A31C953F2FC07B1D1C26775B7ECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_EF99DACFEAB718C93A741C26775BEA4C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_41B2A31C953F2FC07B1D1C26775B7ECF" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_EF99DACFEAB718C93A741C26775BEA4C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_EF99DACFEAB718C93A741C26775BEA4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_41B2A31C953F2FC07B1D1C26775B7ECF" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_EF99DACFEAB718C93A741C26775BEA4C" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_GeneticAssaysandPlatformsandPatientTestingMember" xlink:label="loc_tbio_GeneticAssaysandPlatformsandPatientTestingMember_05551864FACF5825970C1C26775B9044" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_EF99DACFEAB718C93A741C26775BEA4C" xlink:to="loc_tbio_GeneticAssaysandPlatformsandPatientTestingMember_05551864FACF5825970C1C26775B9044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_35A56375BE94F9F0D0BD1C26775B6297" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_35A56375BE94F9F0D0BD1C26775B6297" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_C67AB91D5A559730B7DA1C26775BC289" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_C67AB91D5A559730B7DA1C26775BC289" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_F3B245D989E75AC6F30B1C26775B5ABE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_F3B245D989E75AC6F30B1C26775B5ABE" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense" xlink:label="loc_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense_9D1CFE30C80ECF8181431C26775B53C9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense_9D1CFE30C80ECF8181431C26775B53C9" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense" xlink:label="loc_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense_3F9309E2946A40CC5F371C26775C6E0C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense_3F9309E2946A40CC5F371C26775C6E0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_FAE55C2E7EDD65AA78881C26775C75FB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_FAE55C2E7EDD65AA78881C26775C75FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6DBAC20CA4B6A6F6FBF71C26775C152B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6DBAC20CA4B6A6F6FBF71C26775C152B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_C906F295B088C131D31E1C26775CB77F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_C906F295B088C131D31E1C26775CB77F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_2B7C4633146466F3132D1C26775CD47B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_2B7C4633146466F3132D1C26775CD47B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_C386ABC9DD02DAE58E3D1C26775CC726" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_C386ABC9DD02DAE58E3D1C26775CC726" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_33741C0BD4E1DF1FB3291C2B33712D31" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_33741C0BD4E1DF1FB3291C2B33712D31" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/DiscontinuedOperationsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/FairValue" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/FairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_88AECF3B218AE09C0AA3F8A8305F4457" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_88AECF3B218AE09C0AA3F8A8305F4457" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_7BFF78F5F813C52FDFD1F8A8305F2D9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_88AECF3B218AE09C0AA3F8A8305F4457" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_7BFF78F5F813C52FDFD1F8A8305F2D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_7BFF78F5F813C52FDFD1F8A8305F2D9F" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_7BFF78F5F813C52FDFD1F8A8305F2D9F" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_A2012WarrantLiabilityMember" xlink:label="loc_tbio_A2012WarrantLiabilityMember_61274625DAFB77C7C1A4F8A8305F2070" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014" xlink:to="loc_tbio_A2012WarrantLiabilityMember_61274625DAFB77C7C1A4F8A8305F2070" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_A2016WarrantLiabilityMember" xlink:label="loc_tbio_A2016WarrantLiabilityMember_5ECC6F4D7766C8B1088CF8A8305F98EF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014" xlink:to="loc_tbio_A2016WarrantLiabilityMember_5ECC6F4D7766C8B1088CF8A8305F98EF" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_9BCEEF5762F45E97E74AF8A8305F8326" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:to="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_9BCEEF5762F45E97E74AF8A8305F8326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_AC1F9F8FADEF00EAF4EEF8A8305F90A1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_AC1F9F8FADEF00EAF4EEF8A8305F90A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_95D9E0E07184ADE3CE6AF8A8305FFFA8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:to="loc_us-gaap_SharePrice_95D9E0E07184ADE3CE6AF8A8305FFFA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_3D6D189FAE167058E716F8A8305FA83F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_3D6D189FAE167058E716F8A8305FA83F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BD30836400D5D21345BBF8A83060373A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BD30836400D5D21345BBF8A83060373A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767E63F28D5E2EEC112FF8A83060BA10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767E63F28D5E2EEC112FF8A83060BA10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_F7180AD919679FCABB56F8A83060BCC5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_F7180AD919679FCABB56F8A83060BCC5" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_TotalGainsOrLossesAbstract" xlink:label="loc_tbio_TotalGainsOrLossesAbstract_64E35FD2C42019E77F45F8A830657A2D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E" xlink:to="loc_tbio_TotalGainsOrLossesAbstract_64E35FD2C42019E77F45F8A830657A2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1D784943C372C67DEA87F8A83065E25F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tbio_TotalGainsOrLossesAbstract_64E35FD2C42019E77F45F8A830657A2D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1D784943C372C67DEA87F8A83065E25F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/FairValueTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/StockOptions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/StockOptionsStockAppreciationRightsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FA3EC23F2FB8B248FD42FDF1A00F61D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6DF3D70DFF3E8D0D8674FDF1A00FCBB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FA3EC23F2FB8B248FD42FDF1A00F61D9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6DF3D70DFF3E8D0D8674FDF1A00FCBB7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1B3BE95E42C0C4CAEA58FDF1A00FCBCD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6DF3D70DFF3E8D0D8674FDF1A00FCBB7" xlink:to="loc_us-gaap_AwardTypeAxis_1B3BE95E42C0C4CAEA58FDF1A00FCBCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_722DE36115F6B847BB93FDF1A00FAE67_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1B3BE95E42C0C4CAEA58FDF1A00FCBCD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_722DE36115F6B847BB93FDF1A00FAE67_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_722DE36115F6B847BB93FDF1A00FAE67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1B3BE95E42C0C4CAEA58FDF1A00FCBCD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_722DE36115F6B847BB93FDF1A00FAE67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_AC1E1FD9AA259B46B1B3FDF1A00F5E59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_722DE36115F6B847BB93FDF1A00FAE67" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_AC1E1FD9AA259B46B1B3FDF1A00F5E59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_763EF179280064F0895FFDF1A00F3082" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FA3EC23F2FB8B248FD42FDF1A00F61D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_763EF179280064F0895FFDF1A00F3082" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_4360F12B0598F5D914D3FDF1A00F3C8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_763EF179280064F0895FFDF1A00F3082" xlink:to="loc_tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_4360F12B0598F5D914D3FDF1A00F3C8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FD8B4BCB104DE67120ADFDF1A010C0F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FA3EC23F2FB8B248FD42FDF1A00F61D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FD8B4BCB104DE67120ADFDF1A010C0F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_115EFEA5F7F3CB3EBEABFDF1A010CB2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FD8B4BCB104DE67120ADFDF1A010C0F5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_115EFEA5F7F3CB3EBEABFDF1A010CB2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_E1C32DBB1AD370A34D74FDF1A010D45B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FA3EC23F2FB8B248FD42FDF1A00F61D9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_E1C32DBB1AD370A34D74FDF1A010D45B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_FDE66F72CA6D63447260FDF1A0105F34" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FA3EC23F2FB8B248FD42FDF1A00F61D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_FDE66F72CA6D63447260FDF1A0105F34" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/StockOptionsStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F1A2BEF43778C8E3FC23E97089D0431E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F1A2BEF43778C8E3FC23E97089D0431E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8D573AFB1774DF09E5D7E97089D0E915" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F1A2BEF43778C8E3FC23E97089D0431E" xlink:to="loc_us-gaap_AwardTypeAxis_8D573AFB1774DF09E5D7E97089D0E915" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E1D213561DABD7AF9B85E97089D0B0B1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8D573AFB1774DF09E5D7E97089D0E915" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E1D213561DABD7AF9B85E97089D0B0B1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E1D213561DABD7AF9B85E97089D0B0B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8D573AFB1774DF09E5D7E97089D0E915" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E1D213561DABD7AF9B85E97089D0B0B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F5B467B1DBB809D77B19E97089D04385" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E1D213561DABD7AF9B85E97089D0B0B1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_F5B467B1DBB809D77B19E97089D04385" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_110795FDDD57918167CAE97089D14A02" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F1A2BEF43778C8E3FC23E97089D0431E" xlink:to="loc_us-gaap_PlanNameAxis_110795FDDD57918167CAE97089D14A02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E03008731366CAA3C04DE97089D1A60C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_110795FDDD57918167CAE97089D14A02" xlink:to="loc_us-gaap_PlanNameDomain_E03008731366CAA3C04DE97089D1A60C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E03008731366CAA3C04DE97089D1A60C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_110795FDDD57918167CAE97089D14A02" xlink:to="loc_us-gaap_PlanNameDomain_E03008731366CAA3C04DE97089D1A60C" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_EquityIncentivePlan2006Member" xlink:label="loc_tbio_EquityIncentivePlan2006Member_200434173A6BAB7F1FC6E97089D181B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_E03008731366CAA3C04DE97089D1A60C" xlink:to="loc_tbio_EquityIncentivePlan2006Member_200434173A6BAB7F1FC6E97089D181B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9688A779E36B78976D78E97089D1C19E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9688A779E36B78976D78E97089D1C19E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4873A0B672D28BAD8D77E97089D1E451" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4873A0B672D28BAD8D77E97089D1E451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0E1925642A2252F33980E97089D1E3B2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0E1925642A2252F33980E97089D1E3B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_F94395364C22834E83DAE97089D1817E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_F94395364C22834E83DAE97089D1817E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C2C9233362DFB3A0AC61E97089D19FA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C2C9233362DFB3A0AC61E97089D19FA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E1EE996B9A03AA00A59EE97089D1FACE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E1EE996B9A03AA00A59EE97089D1FACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_098155652C041C21BF5AE97089D196FC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_098155652C041C21BF5AE97089D196FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_BFC11917445D4967E368E97089D1A2B8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_BFC11917445D4967E368E97089D1A2B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32859C42ECD2BE9C14A0E97089D259C5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32859C42ECD2BE9C14A0E97089D259C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5F26EA2A82E7B09A8510E97089D2C714" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5F26EA2A82E7B09A8510E97089D2C714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_53931938E679D65912B8E9DAB9F889AA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_53931938E679D65912B8E9DAB9F889AA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/StockOptionsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceAxis" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceAxis_F99037AF17F67AF15AFA0CE49E680609" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:to="loc_tbio_WarrantyHoldersAndIssuanceAxis_F99037AF17F67AF15AFA0CE49E680609" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceDomain" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceDomain_F5EC0EF35B81C3A3AADE0CE49E682233_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceAxis_F99037AF17F67AF15AFA0CE49E680609" xlink:to="loc_tbio_WarrantyHoldersAndIssuanceDomain_F5EC0EF35B81C3A3AADE0CE49E682233_default" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceDomain" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceDomain_F5EC0EF35B81C3A3AADE0CE49E682233" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceAxis_F99037AF17F67AF15AFA0CE49E680609" xlink:to="loc_tbio_WarrantyHoldersAndIssuanceDomain_F5EC0EF35B81C3A3AADE0CE49E682233" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SecurityPurchaseAgreementMember" xlink:label="loc_tbio_SecurityPurchaseAgreementMember_BCB5F473AF4189309D480CE49E684725" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_F5EC0EF35B81C3A3AADE0CE49E682233" xlink:to="loc_tbio_SecurityPurchaseAgreementMember_BCB5F473AF4189309D480CE49E684725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_D3573EAE419EEC10A7C00CE49E687A8E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_D3573EAE419EEC10A7C00CE49E687A8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_AC869EB47EE7F15E00290CE49E68CB32_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_D3573EAE419EEC10A7C00CE49E687A8E" xlink:to="loc_us-gaap_ClassOfStockDomain_AC869EB47EE7F15E00290CE49E68CB32_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_AC869EB47EE7F15E00290CE49E68CB32" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_D3573EAE419EEC10A7C00CE49E687A8E" xlink:to="loc_us-gaap_ClassOfStockDomain_AC869EB47EE7F15E00290CE49E68CB32" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember" xlink:label="loc_tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember_5B69A2A7353C8FD194CF0CE49E686DA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_AC869EB47EE7F15E00290CE49E68CB32" xlink:to="loc_tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember_5B69A2A7353C8FD194CF0CE49E686DA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_19F7B71F655C8B5E8A230CE49E69ED19" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_AC869EB47EE7F15E00290CE49E68CB32" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_19F7B71F655C8B5E8A230CE49E69ED19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DDB5770E874953AD8E650CE49E692B50" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_AC869EB47EE7F15E00290CE49E68CB32" xlink:to="loc_us-gaap_CommonStockMember_DDB5770E874953AD8E650CE49E692B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_96B565D09D9B3BA844CB0CE49E695A36" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_96B565D09D9B3BA844CB0CE49E695A36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7BB8C8D825358C2486BB0CE49E692EFA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_96B565D09D9B3BA844CB0CE49E695A36" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7BB8C8D825358C2486BB0CE49E692EFA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7BB8C8D825358C2486BB0CE49E692EFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_96B565D09D9B3BA844CB0CE49E695A36" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7BB8C8D825358C2486BB0CE49E692EFA" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_A2016WarrantMember" xlink:label="loc_tbio_A2016WarrantMember_DE57F763325150B093C10CE49E69864A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7BB8C8D825358C2486BB0CE49E692EFA" xlink:to="loc_tbio_A2016WarrantMember_DE57F763325150B093C10CE49E69864A" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SeriesA1WarrantMember" xlink:label="loc_tbio_SeriesA1WarrantMember_A5BF271C086D1545E4120CE49E69F985" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7BB8C8D825358C2486BB0CE49E692EFA" xlink:to="loc_tbio_SeriesA1WarrantMember_A5BF271C086D1545E4120CE49E69F985" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SeriesAWarrantsMember" xlink:label="loc_tbio_SeriesAWarrantsMember_204E551728830B7966240CE49E696F55" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7BB8C8D825358C2486BB0CE49E692EFA" xlink:to="loc_tbio_SeriesAWarrantsMember_204E551728830B7966240CE49E696F55" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AttheMarketOfferingAgreementMember" xlink:label="loc_tbio_AttheMarketOfferingAgreementMember_05987039D226947B96570CE49E69BA76" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7BB8C8D825358C2486BB0CE49E692EFA" xlink:to="loc_tbio_AttheMarketOfferingAgreementMember_05987039D226947B96570CE49E69BA76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_23080CBE2F4F6756D0950CE49E69155D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:to="loc_us-gaap_CounterpartyNameAxis_23080CBE2F4F6756D0950CE49E69155D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_23080CBE2F4F6756D0950CE49E69155D" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_23080CBE2F4F6756D0950CE49E69155D" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_CraigHallumCapitalGroupLLCMember" xlink:label="loc_tbio_CraigHallumCapitalGroupLLCMember_5925CE01BC84458F89B10CE49E69FE60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3" xlink:to="loc_tbio_CraigHallumCapitalGroupLLCMember_5925CE01BC84458F89B10CE49E69FE60" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VendorMember" xlink:label="loc_tbio_VendorMember_F824A074A52AAE2F236F0CE49E69147A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3" xlink:to="loc_tbio_VendorMember_F824A074A52AAE2F236F0CE49E69147A" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VendorIIMember" xlink:label="loc_tbio_VendorIIMember_C24A823388C108E6FED60CE49E69C871" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3" xlink:to="loc_tbio_VendorIIMember_C24A823388C108E6FED60CE49E69C871" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_617AB5EA043BB99937840CE49E6AA5B5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:to="loc_us-gaap_RangeAxis_617AB5EA043BB99937840CE49E6AA5B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1F243389DBB5CF5246F00CE49E6AC0BE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_617AB5EA043BB99937840CE49E6AA5B5" xlink:to="loc_us-gaap_RangeMember_1F243389DBB5CF5246F00CE49E6AC0BE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1F243389DBB5CF5246F00CE49E6AC0BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_617AB5EA043BB99937840CE49E6AA5B5" xlink:to="loc_us-gaap_RangeMember_1F243389DBB5CF5246F00CE49E6AC0BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10B0E0417E78C8C441B70CE49E6ACFA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1F243389DBB5CF5246F00CE49E6AC0BE" xlink:to="loc_us-gaap_MaximumMember_10B0E0417E78C8C441B70CE49E6ACFA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_D382525760D9CD0B7B7B0CE49E6AA90C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:to="loc_us-gaap_StatementScenarioAxis_D382525760D9CD0B7B7B0CE49E6AA90C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_1BC14D8A9A869AAE90440CE49E6A6DCD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_D382525760D9CD0B7B7B0CE49E6AA90C" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_1BC14D8A9A869AAE90440CE49E6A6DCD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_1BC14D8A9A869AAE90440CE49E6A6DCD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_D382525760D9CD0B7B7B0CE49E6AA90C" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_1BC14D8A9A869AAE90440CE49E6A6DCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_16920D13F3788EF085D50CE49E6A24CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_1BC14D8A9A869AAE90440CE49E6A6DCD" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_16920D13F3788EF085D50CE49E6A24CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6BAD22E09BE6AA9EAE940CE49E6AB837" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6BAD22E09BE6AA9EAE940CE49E6AB837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7DA37A8EE585A0F32A90CE49E6AA070_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6BAD22E09BE6AA9EAE940CE49E6AB837" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7DA37A8EE585A0F32A90CE49E6AA070_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7DA37A8EE585A0F32A90CE49E6AA070" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6BAD22E09BE6AA9EAE940CE49E6AB837" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7DA37A8EE585A0F32A90CE49E6AA070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_584CDE94AF94857C6ABA0CE49E6ADDA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7DA37A8EE585A0F32A90CE49E6AA070" xlink:to="loc_us-gaap_PrivatePlacementMember_584CDE94AF94857C6ABA0CE49E6ADDA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_557759EF0DBF65E9F3260CE49E6A2451" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_557759EF0DBF65E9F3260CE49E6A2451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_AD06E29A334CA809C1B70CE49E6A4AD9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_AD06E29A334CA809C1B70CE49E6A4AD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6615B9033459430643F00CE49E6A0E4C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6615B9033459430643F00CE49E6A0E4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E2803968FEC2F3D001250CE49E6AEE22" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E2803968FEC2F3D001250CE49E6AEE22" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_InitialFairValueofWarrantsIssued" xlink:label="loc_tbio_InitialFairValueofWarrantsIssued_A010D6CD31038663E1D30CE49E6AD5DA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_InitialFairValueofWarrantsIssued_A010D6CD31038663E1D30CE49E6AD5DA" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet" xlink:label="loc_tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet_B24BF8AD3823D21A73980CE49E6B3CD7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet_B24BF8AD3823D21A73980CE49E6B3CD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_8F9CA6D86893954E96910CE49E6B2945" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_8F9CA6D86893954E96910CE49E6B2945" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6B15164DFB23C33AEE560CE49E6BE9C8" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6B15164DFB23C33AEE560CE49E6BE9C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_F2ACEF297C062A6E677C0CE49E6B50AC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_Dividends_F2ACEF297C062A6E677C0CE49E6B50AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_BE62BF7AFBF983CD34110CE49E6B8464" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_BE62BF7AFBF983CD34110CE49E6B8464" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_D97999A5644A2EE034900CE49E6BBE87" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_D97999A5644A2EE034900CE49E6BBE87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3C9CC536EC01D74183C50CE49E6BB3F0" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3C9CC536EC01D74183C50CE49E6BB3F0" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassofWarrantorRightExerciseTerm1" xlink:label="loc_tbio_ClassofWarrantorRightExerciseTerm1_26F088A358E9EC87D0120CE49E6B8394" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_ClassofWarrantorRightExerciseTerm1_26F088A358E9EC87D0120CE49E6B8394" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockWarrantExchangeAmount" xlink:label="loc_tbio_StockWarrantExchangeAmount_7A7ACA3E735C5EB93B530CE49E6B7C61" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_StockWarrantExchangeAmount_7A7ACA3E735C5EB93B530CE49E6B7C61" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment" xlink:label="loc_tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment_478A733D04BD5309D8B30CE49E6B895E" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment_478A733D04BD5309D8B30CE49E6B895E" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights" xlink:label="loc_tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights_CD4F4CF723AECB7289E80CE49E6B7404" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights_CD4F4CF723AECB7289E80CE49E6B7404" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_CashPaymentPortionofStockWarrantsExercised" xlink:label="loc_tbio_CashPaymentPortionofStockWarrantsExercised_96981F744B4178361C060CE49E6B6BD7" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_CashPaymentPortionofStockWarrantsExercised_96981F744B4178361C060CE49E6B6BD7" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockWarrantsSettledwithCash" xlink:label="loc_tbio_StockWarrantsSettledwithCash_4EF6BA197799AAB1EB910CE49E6BFD64" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_StockWarrantsSettledwithCash_4EF6BA197799AAB1EB910CE49E6BFD64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_E401B8DB81246EE1BB540CE49E6BEE54" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_E401B8DB81246EE1BB540CE49E6BEE54" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds" xlink:label="loc_tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds_94FAF8420589BBAB3E680CE49E6B15E0" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds_94FAF8420589BBAB3E680CE49E6B15E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_9FAAD738CED5FC9F796E0CE49E6B0578" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_SharePrice_9FAAD738CED5FC9F796E0CE49E6B0578" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares" xlink:label="loc_tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares_9CF9AAE4F8305482FE640CE49E6C31C2" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares_9CF9AAE4F8305482FE640CE49E6C31C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_C59EC960D55B8C937BE50CE49E6C3631" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_C59EC960D55B8C937BE50CE49E6C3631" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockIssuanceCostsReimbursableExpenses" xlink:label="loc_tbio_StockIssuanceCostsReimbursableExpenses_CAC4DC87359C8DBAAFF80CE49E6C502B" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_StockIssuanceCostsReimbursableExpenses_CAC4DC87359C8DBAAFF80CE49E6C502B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement_EB5E6FC74766506ACAE20CE49E6C4023" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement_EB5E6FC74766506ACAE20CE49E6C4023" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1D3A22B06F3B6B0A33D60CE49E6CDB8F" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1D3A22B06F3B6B0A33D60CE49E6CDB8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_46B0C3C9D8829F637FF30CE49E6CF97D" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_46B0C3C9D8829F637FF30CE49E6CF97D" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PlacementFeesPercentageofGrossSalesPrice" xlink:label="loc_tbio_PlacementFeesPercentageofGrossSalesPrice_6725CD7F667CFE0679EF0CE49E6CE550" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_PlacementFeesPercentageofGrossSalesPrice_6725CD7F667CFE0679EF0CE49E6CE550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1BE997650C968FEBDB3D0CE49E6C8348" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_CommonStockSharesIssued_1BE997650C968FEBDB3D0CE49E6C8348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9C323911DCE7897244040CE49E6C90F6" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9C323911DCE7897244040CE49E6C90F6" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockholdersEquityNoteConversionRatio" xlink:label="loc_tbio_StockholdersEquityNoteConversionRatio_9E06EA32C379325691390CE49E6CDC73" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_StockholdersEquityNoteConversionRatio_9E06EA32C379325691390CE49E6CDC73" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_BCACBA6160B268C61DCAF864D9AD39D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_20838CC8354CAC80596EF864D99DF2AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_BCACBA6160B268C61DCAF864D9AD39D3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_20838CC8354CAC80596EF864D99DF2AC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceAxis" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceAxis_32C6F0E5F7CA8B8AD5FEF864D9AD4E73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_20838CC8354CAC80596EF864D99DF2AC" xlink:to="loc_tbio_WarrantyHoldersAndIssuanceAxis_32C6F0E5F7CA8B8AD5FEF864D9AD4E73" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceDomain" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceAxis_32C6F0E5F7CA8B8AD5FEF864D9AD4E73" xlink:to="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292_default" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceDomain" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceAxis_32C6F0E5F7CA8B8AD5FEF864D9AD4E73" xlink:to="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersJanuary2018Member" xlink:label="loc_tbio_VariousInstitutionalHoldersJanuary2018Member_EA77125991AB12F0DD06F864D9AD190C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="loc_tbio_VariousInstitutionalHoldersJanuary2018Member_EA77125991AB12F0DD06F864D9AD190C" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AffiliatesofThirdSecurityLLCJanuary2018Member" xlink:label="loc_tbio_AffiliatesofThirdSecurityLLCJanuary2018Member_10250DCD19246BC38A98F864D9ADE770" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="loc_tbio_AffiliatesofThirdSecurityLLCJanuary2018Member_10250DCD19246BC38A98F864D9ADE770" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersApril2020Member" xlink:label="loc_tbio_VariousInstitutionalHoldersApril2020Member_221E901F173036A38F42F864D9AD35ED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="loc_tbio_VariousInstitutionalHoldersApril2020Member_221E901F173036A38F42F864D9AD35ED" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersFebruary2020Member" xlink:label="loc_tbio_VariousInstitutionalHoldersFebruary2020Member_00EB76114B081FB32FB3F864D9AD3D5E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="loc_tbio_VariousInstitutionalHoldersFebruary2020Member_00EB76114B081FB32FB3F864D9AD3D5E" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersDecember2020OneMember" xlink:label="loc_tbio_VariousInstitutionalHoldersDecember2020OneMember_137D9F7AD169D6E38764F864D9ADA55A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="loc_tbio_VariousInstitutionalHoldersDecember2020OneMember_137D9F7AD169D6E38764F864D9ADA55A" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersJanuary2021OneMember" xlink:label="loc_tbio_VariousInstitutionalHoldersJanuary2021OneMember_D4459DEA92D97356D8FAF864D9ADDA7F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="loc_tbio_VariousInstitutionalHoldersJanuary2021OneMember_D4459DEA92D97356D8FAF864D9ADDA7F" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AffiliatesofThirdSecurityLLCJanuary2021Member" xlink:label="loc_tbio_AffiliatesofThirdSecurityLLCJanuary2021Member_49A330F8AE829C841B53F864D9AD2881" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="loc_tbio_AffiliatesofThirdSecurityLLCJanuary2021Member_49A330F8AE829C841B53F864D9AD2881" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersJanuary2021TwoMember" xlink:label="loc_tbio_VariousInstitutionalHoldersJanuary2021TwoMember_B4827F0E66E751828CF4F864D9ADBE5A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="loc_tbio_VariousInstitutionalHoldersJanuary2021TwoMember_B4827F0E66E751828CF4F864D9ADBE5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_EB2DBC6F5FD1F8561C34F864D9AD191A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_20838CC8354CAC80596EF864D99DF2AC" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_EB2DBC6F5FD1F8561C34F864D9AD191A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_EB2DBC6F5FD1F8561C34F864D9AD191A" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_EB2DBC6F5FD1F8561C34F864D9AD191A" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_FFA6626469636ADD68D7F864D9AD0292" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710" xlink:to="loc_us-gaap_PrivatePlacementMember_FFA6626469636ADD68D7F864D9AD0292" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_OfferingMember" xlink:label="loc_tbio_OfferingMember_0B94FB93F9CFC02BAD12F864D9ADF752" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710" xlink:to="loc_tbio_OfferingMember_0B94FB93F9CFC02BAD12F864D9ADF752" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired" xlink:label="loc_tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired_B3D292C77B7DEE7E823DF865D30D6E13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BCACBA6160B268C61DCAF864D9AD39D3" xlink:to="loc_tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired_B3D292C77B7DEE7E823DF865D30D6E13" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_BA0802240838C4F9B52CF864D9AD0786" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BCACBA6160B268C61DCAF864D9AD39D3" xlink:to="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_BA0802240838C4F9B52CF864D9AD0786" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_DDCFC3052050DF1B4F4DF864D9ADEDF0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BCACBA6160B268C61DCAF864D9AD39D3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_DDCFC3052050DF1B4F4DF864D9ADEDF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22AB4F356AE64962A675F864D9ADF51C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_BCACBA6160B268C61DCAF864D9AD39D3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22AB4F356AE64962A675F864D9ADF51C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityConversionOfPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaap_ConversionOfStockTable_55B43033EF586C5B8476F8C18F09FA54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_ConversionOfStockTable_55B43033EF586C5B8476F8C18F09FA54" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_AAAB466F7450A57BE2BCF8C18F0914E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_55B43033EF586C5B8476F8C18F09FA54" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_AAAB466F7450A57BE2BCF8C18F0914E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B5EA5379EE4177569054F8C18F09C235_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_AAAB466F7450A57BE2BCF8C18F0914E2" xlink:to="loc_us-gaap_EquityComponentDomain_B5EA5379EE4177569054F8C18F09C235_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B5EA5379EE4177569054F8C18F09C235" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_AAAB466F7450A57BE2BCF8C18F0914E2" xlink:to="loc_us-gaap_EquityComponentDomain_B5EA5379EE4177569054F8C18F09C235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_FBAF2CA0D94BACD2E6B6F8C18F09A410" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B5EA5379EE4177569054F8C18F09C235" xlink:to="loc_us-gaap_PreferredStockMember_FBAF2CA0D94BACD2E6B6F8C18F09A410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_8178C7708F918C176D85F8C18F09A72C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B5EA5379EE4177569054F8C18F09C235" xlink:to="loc_us-gaap_CommonStockMember_8178C7708F918C176D85F8C18F09A72C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A29468257E126CA804E1F8C18F09608C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_55B43033EF586C5B8476F8C18F09FA54" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A29468257E126CA804E1F8C18F09608C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_87280F60FE5167096D05F8C18F09D1E4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A29468257E126CA804E1F8C18F09608C" xlink:to="loc_us-gaap_ClassOfStockDomain_87280F60FE5167096D05F8C18F09D1E4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_87280F60FE5167096D05F8C18F09D1E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A29468257E126CA804E1F8C18F09608C" xlink:to="loc_us-gaap_ClassOfStockDomain_87280F60FE5167096D05F8C18F09D1E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_274322DDB516BD8EFF46F8C18F09DE45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_87280F60FE5167096D05F8C18F09D1E4" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_274322DDB516BD8EFF46F8C18F09DE45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_7129EE8FC9D06E3BBF63F8C18F09CA78" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_87280F60FE5167096D05F8C18F09D1E4" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_7129EE8FC9D06E3BBF63F8C18F09CA78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_94180AF6E25704452099F8C18F0A5728" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_94180AF6E25704452099F8C18F0A5728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6F6BCF6F72765E652954F8C18F0A73E8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6F6BCF6F72765E652954F8C18F0A73E8" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockholdersEquityNoteConversionRatio" xlink:label="loc_tbio_StockholdersEquityNoteConversionRatio_55D50AF42334ED7D4DC5F8C18F0A4DF3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_tbio_StockholdersEquityNoteConversionRatio_55D50AF42334ED7D4DC5F8C18F0A4DF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_409B96AED495C9CF17DBF8C18F0A0E28" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_409B96AED495C9CF17DBF8C18F0A0E28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_63583B3BBF3A173DE222F8C18F0A954A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_63583B3BBF3A173DE222F8C18F0A954A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockDividendsShares" xlink:label="loc_us-gaap_CommonStockDividendsShares_31F5410EF0C97FB28529F8C18F0ABE9D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_CommonStockDividendsShares_31F5410EF0C97FB28529F8C18F0ABE9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockDividendsShares" xlink:label="loc_us-gaap_StockDividendsShares_F051A15CE70E69F81827F8C18F0A4990" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_StockDividendsShares_F051A15CE70E69F81827F8C18F0A4990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_716CE248F39CDD8CD1ECF8C18F0ABB61" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_SharesIssued_716CE248F39CDD8CD1ECF8C18F0ABB61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_99C11C666C792D792181F8C18F0A7DFB" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_99C11C666C792D792181F8C18F0A7DFB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityPreferredStockDividendsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_5A031D19CA0A88A74242F8B156479144" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_209C3FFB2E87C91D0A6BF8B1564630CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_5A031D19CA0A88A74242F8B156479144" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_209C3FFB2E87C91D0A6BF8B1564630CD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_C04A4458C0FEACEB2064F8B15701B7EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_209C3FFB2E87C91D0A6BF8B1564630CD" xlink:to="loc_us-gaap_StatementClassOfStockAxis_C04A4458C0FEACEB2064F8B15701B7EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1D3FD536846990D1B9F0F8B1570122A7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C04A4458C0FEACEB2064F8B15701B7EE" xlink:to="loc_us-gaap_ClassOfStockDomain_1D3FD536846990D1B9F0F8B1570122A7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1D3FD536846990D1B9F0F8B1570122A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C04A4458C0FEACEB2064F8B15701B7EE" xlink:to="loc_us-gaap_ClassOfStockDomain_1D3FD536846990D1B9F0F8B1570122A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_077D5D9323D101390A4AF8B157543D55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1D3FD536846990D1B9F0F8B1570122A7" xlink:to="loc_us-gaap_PreferredStockMember_077D5D9323D101390A4AF8B157543D55" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DividendsPreferredStockCashNotDeclared" xlink:label="loc_tbio_DividendsPreferredStockCashNotDeclared_76BF69921F45864CE6A1F8A7AD4CB347" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5A031D19CA0A88A74242F8B156479144" xlink:to="loc_tbio_DividendsPreferredStockCashNotDeclared_76BF69921F45864CE6A1F8A7AD4CB347" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesADetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_BDACA856422DF2BECEC5F89321D43AB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_BDACA856422DF2BECEC5F89321D43AB5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_CD31711393080966D0B5F89321D4FC8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_BDACA856422DF2BECEC5F89321D43AB5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_CD31711393080966D0B5F89321D4FC8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_CD31711393080966D0B5F89321D4FC8E" xlink:to="loc_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_CD31711393080966D0B5F89321D4FC8E" xlink:to="loc_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_65B350A8A0317A498FCBF89321D4F3D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE" xlink:to="loc_us-gaap_PreferredStockMember_65B350A8A0317A498FCBF89321D4F3D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_F4FB5CD53F0CA1804C1EF89381FCB288" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE" xlink:to="loc_us-gaap_CommonStockMember_F4FB5CD53F0CA1804C1EF89381FCB288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_AD903EF05C295788DEF3F89321D4FD9D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_BDACA856422DF2BECEC5F89321D43AB5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_AD903EF05C295788DEF3F89321D4FD9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A7FA0752CC1E411316C0F89321D5E28D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_AD903EF05C295788DEF3F89321D4FD9D" xlink:to="loc_us-gaap_ClassOfStockDomain_A7FA0752CC1E411316C0F89321D5E28D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A7FA0752CC1E411316C0F89321D5E28D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_AD903EF05C295788DEF3F89321D4FD9D" xlink:to="loc_us-gaap_ClassOfStockDomain_A7FA0752CC1E411316C0F89321D5E28D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_D8B40C5962EF319AECBEF89321D5A269" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A7FA0752CC1E411316C0F89321D5E28D" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_D8B40C5962EF319AECBEF89321D5A269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_A376625546574BA8EBB3F8933C6CB5B8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_BDACA856422DF2BECEC5F89321D43AB5" xlink:to="loc_us-gaap_RangeAxis_A376625546574BA8EBB3F8933C6CB5B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_299654020A41FBDC98BBF8933CDED30E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_A376625546574BA8EBB3F8933C6CB5B8" xlink:to="loc_us-gaap_RangeMember_299654020A41FBDC98BBF8933CDED30E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_299654020A41FBDC98BBF8933CDED30E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_A376625546574BA8EBB3F8933C6CB5B8" xlink:to="loc_us-gaap_RangeMember_299654020A41FBDC98BBF8933CDED30E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_90ABF490A7A1137488A7F8933E0D05C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_299654020A41FBDC98BBF8933CDED30E" xlink:to="loc_us-gaap_MinimumMember_90ABF490A7A1137488A7F8933E0D05C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B4A8B5402489B7EE0351F89321D5F8B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_B4A8B5402489B7EE0351F89321D5F8B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_45501EF938DF6B2BE5CBF89321D5A490" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_45501EF938DF6B2BE5CBF89321D5A490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5B45FAD27B46CFDA3F69F89321D51D4B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5B45FAD27B46CFDA3F69F89321D51D4B" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote" xlink:label="loc_tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote_76C8303CE2B4EBA88D79F89321D6D427" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote_76C8303CE2B4EBA88D79F89321D6D427" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes" xlink:label="loc_tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes_B13477710B0ABFC4BF2BF89338B6A1DD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes_B13477710B0ABFC4BF2BF89338B6A1DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6C206152D9FDBE32D167F89321D595BD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6C206152D9FDBE32D167F89321D595BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_7DD017678FE0484E712BF89339CDF98E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_7DD017678FE0484E712BF89339CDF98E" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PreferredStockDividendRateCompoundPercentageMaximum" xlink:label="loc_tbio_PreferredStockDividendRateCompoundPercentageMaximum_7F5CA36515D2B00DBF47F8933A18D96E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_tbio_PreferredStockDividendRateCompoundPercentageMaximum_7F5CA36515D2B00DBF47F8933A18D96E" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_NumberOfDirectors" xlink:label="loc_tbio_NumberOfDirectors_D5C820E68337C3ED7EBBF8933A533F42" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_tbio_NumberOfDirectors_D5C820E68337C3ED7EBBF8933A533F42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_950D41B97D4B32BAA28BF89381FCC2E1" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_950D41B97D4B32BAA28BF89381FCC2E1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesBDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_C1424369FF8B394200E6FDF1A02AD30D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_C1424369FF8B394200E6FDF1A02AD30D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_D3AE46BDFD68C9570EB9FDF1A02ABD9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C1424369FF8B394200E6FDF1A02AD30D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_D3AE46BDFD68C9570EB9FDF1A02ABD9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_26226CD5589D684ADC98FDF1A02AAE19_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_D3AE46BDFD68C9570EB9FDF1A02ABD9A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_26226CD5589D684ADC98FDF1A02AAE19_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_26226CD5589D684ADC98FDF1A02AAE19" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_D3AE46BDFD68C9570EB9FDF1A02ABD9A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_26226CD5589D684ADC98FDF1A02AAE19" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ThirdSecurityLlcAndAffiliatesMember" xlink:label="loc_tbio_ThirdSecurityLlcAndAffiliatesMember_01A1E68160C6E89EC7D3FDF1A02A1580" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_26226CD5589D684ADC98FDF1A02AAE19" xlink:to="loc_tbio_ThirdSecurityLlcAndAffiliatesMember_01A1E68160C6E89EC7D3FDF1A02A1580" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceAxis" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceAxis_91631225B5A31FF9EAA8FDF1A02A0D85" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C1424369FF8B394200E6FDF1A02AD30D" xlink:to="loc_tbio_WarrantyHoldersAndIssuanceAxis_91631225B5A31FF9EAA8FDF1A02A0D85" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceDomain" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceDomain_ABCB07EAC79134B71FEDFDF1A02AD8BA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceAxis_91631225B5A31FF9EAA8FDF1A02A0D85" xlink:to="loc_tbio_WarrantyHoldersAndIssuanceDomain_ABCB07EAC79134B71FEDFDF1A02AD8BA_default" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceDomain" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceDomain_ABCB07EAC79134B71FEDFDF1A02AD8BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceAxis_91631225B5A31FF9EAA8FDF1A02A0D85" xlink:to="loc_tbio_WarrantyHoldersAndIssuanceDomain_ABCB07EAC79134B71FEDFDF1A02AD8BA" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ThirdSecurityLlcAndAffiliatesMember" xlink:label="loc_tbio_ThirdSecurityLlcAndAffiliatesMember_D03A485A36BA021915B4FDF1A02A9381" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_ABCB07EAC79134B71FEDFDF1A02AD8BA" xlink:to="loc_tbio_ThirdSecurityLlcAndAffiliatesMember_D03A485A36BA021915B4FDF1A02A9381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_420109801F58EC0713E1FDF1A02AFF48" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C1424369FF8B394200E6FDF1A02AD30D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_420109801F58EC0713E1FDF1A02AFF48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_37437E3C458D1B36FAFAFDF1A02A395F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_420109801F58EC0713E1FDF1A02AFF48" xlink:to="loc_us-gaap_EquityComponentDomain_37437E3C458D1B36FAFAFDF1A02A395F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_37437E3C458D1B36FAFAFDF1A02A395F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_420109801F58EC0713E1FDF1A02AFF48" xlink:to="loc_us-gaap_EquityComponentDomain_37437E3C458D1B36FAFAFDF1A02A395F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_DA8BAD8A8DF0128B7599FDF1A02ADA27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_37437E3C458D1B36FAFAFDF1A02A395F" xlink:to="loc_us-gaap_PreferredStockMember_DA8BAD8A8DF0128B7599FDF1A02ADA27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11C2284492C721FBBCF7FDF1A02A3D49" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C1424369FF8B394200E6FDF1A02AD30D" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11C2284492C721FBBCF7FDF1A02A3D49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_E9C6E8F8C879B8A2728DFDF1A02AF085_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11C2284492C721FBBCF7FDF1A02A3D49" xlink:to="loc_us-gaap_ClassOfStockDomain_E9C6E8F8C879B8A2728DFDF1A02AF085_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_E9C6E8F8C879B8A2728DFDF1A02AF085" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11C2284492C721FBBCF7FDF1A02A3D49" xlink:to="loc_us-gaap_ClassOfStockDomain_E9C6E8F8C879B8A2728DFDF1A02AF085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_3A40F726A489DA137F04FDF1A02A59C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_E9C6E8F8C879B8A2728DFDF1A02AF085" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_3A40F726A489DA137F04FDF1A02A59C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D1991E8DB0C642A3594BFDF1A02A0678" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D1991E8DB0C642A3594BFDF1A02A0678" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4770312D725F6AE8DFF0FDF1A02A1FB0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4770312D725F6AE8DFF0FDF1A02A1FB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_6234B884C5621E0445BDFDF1A02A780E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:to="loc_us-gaap_SharePrice_6234B884C5621E0445BDFDF1A02A780E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_FCD263996959636084AEFDF1A02A3600" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_FCD263996959636084AEFDF1A02A3600" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockholdersEquityNoteConversionRatio" xlink:label="loc_tbio_StockholdersEquityNoteConversionRatio_543F724866A52EEA504BFDF1A02A78CF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:to="loc_tbio_StockholdersEquityNoteConversionRatio_543F724866A52EEA504BFDF1A02A78CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_815FC92B34C13C7A854DFE11E2AECCB9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_815FC92B34C13C7A854DFE11E2AECCB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E8B9A725CB9D5FB6C718FE19FE4F76B2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E8B9A725CB9D5FB6C718FE19FE4F76B2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_C81DE6CBA703D0B7D63D0CE49DD0A86C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_C81DE6CBA703D0B7D63D0CE49DD0A86C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_E33EFD29BC1ABE56D7B10CE49DD0C58A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C81DE6CBA703D0B7D63D0CE49DD0A86C" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_E33EFD29BC1ABE56D7B10CE49DD0C58A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_E33EFD29BC1ABE56D7B10CE49DD0C58A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C81DE6CBA703D0B7D63D0CE49DD0A86C" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_E33EFD29BC1ABE56D7B10CE49DD0C58A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2DEC441387BFD13F21570CE49DD0C521" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_E33EFD29BC1ABE56D7B10CE49DD0C58A" xlink:to="loc_us-gaap_SubsequentEventMember_2DEC441387BFD13F21570CE49DD0C521" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_80405FC43A261EA7DD380CE49DD0714B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_80405FC43A261EA7DD380CE49DD0714B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_33960ECBAE207F4F40760CE49DD1EEA6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_80405FC43A261EA7DD380CE49DD0714B" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_33960ECBAE207F4F40760CE49DD1EEA6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_33960ECBAE207F4F40760CE49DD1EEA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_80405FC43A261EA7DD380CE49DD0714B" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_33960ECBAE207F4F40760CE49DD1EEA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_D91F96F014DAEC9213F20CE49DD11260" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_33960ECBAE207F4F40760CE49DD1EEA6" xlink:to="loc_us-gaap_BridgeLoanMember_D91F96F014DAEC9213F20CE49DD11260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5A1859C351619AD5648D0CE49DD15CE8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40" xlink:to="loc_dei_LegalEntityAxis_5A1859C351619AD5648D0CE49DD15CE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_13BEEE97E6412E14A85A0CE49DD15F9B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5A1859C351619AD5648D0CE49DD15CE8" xlink:to="loc_dei_EntityDomain_13BEEE97E6412E14A85A0CE49DD15F9B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_13BEEE97E6412E14A85A0CE49DD15F9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5A1859C351619AD5648D0CE49DD15CE8" xlink:to="loc_dei_EntityDomain_13BEEE97E6412E14A85A0CE49DD15F9B" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PrecipioMember" xlink:label="loc_tbio_PrecipioMember_3053E7BCED4F7989FA810CE49DD136BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_13BEEE97E6412E14A85A0CE49DD15F9B" xlink:to="loc_tbio_PrecipioMember_3053E7BCED4F7989FA810CE49DD136BF" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AegisCorpMember" xlink:label="loc_tbio_AegisCorpMember_34A10592FD9A8F6753C30CE49DD1AD37" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_13BEEE97E6412E14A85A0CE49DD15F9B" xlink:to="loc_tbio_AegisCorpMember_34A10592FD9A8F6753C30CE49DD1AD37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_22ABEEFD82702A28D66C0CE49DD13B94" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_22ABEEFD82702A28D66C0CE49DD13B94" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AdditionalShorttermLoanMaximumAmountAuthorized" xlink:label="loc_tbio_AdditionalShorttermLoanMaximumAmountAuthorized_5C12CE79F9C3A8EAB0C30CE49DD28CF8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_tbio_AdditionalShorttermLoanMaximumAmountAuthorized_5C12CE79F9C3A8EAB0C30CE49DD28CF8" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ProceedsFromtheSalesofDebtInstrument" xlink:label="loc_tbio_ProceedsFromtheSalesofDebtInstrument_C9BFD350F7E1BA02A1A70CE49DD2CCDB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_tbio_ProceedsFromtheSalesofDebtInstrument_C9BFD350F7E1BA02A1A70CE49DD2CCDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_C95DF94AE5450103BED00CE49DD2705F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_C95DF94AE5450103BED00CE49DD2705F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_679DA1D54B6E2790A5350CE49DD2A630" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_us-gaap_DebtInstrumentTerm_679DA1D54B6E2790A5350CE49DD2A630" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentPremiumFeePercentage" xlink:label="loc_tbio_DebtInstrumentPremiumFeePercentage_D3F0CFAB4D158FDB17170CE49DD29B7B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_tbio_DebtInstrumentPremiumFeePercentage_D3F0CFAB4D158FDB17170CE49DD29B7B" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_353A109C40CCE6B237550CE49DD24543" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_353A109C40CCE6B237550CE49DD24543" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_B460F71D780F2794EE130CE49DD28CCB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_B460F71D780F2794EE130CE49DD28CCB" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_LoantoRelatedPartyPercentage" xlink:label="loc_tbio_LoantoRelatedPartyPercentage_F899E5A568EE88A102360CE49DD29292" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_tbio_LoantoRelatedPartyPercentage_F899E5A568EE88A102360CE49DD29292" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaap_SecuredDebt_AE3BAD65377E5FBB71C60CE49DD23646" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_us-gaap_SecuredDebt_AE3BAD65377E5FBB71C60CE49DD23646" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PlacementFees" xlink:label="loc_tbio_PlacementFees_BE9EBC64BCAF76FFF5D80CE49DD21157" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_tbio_PlacementFees_BE9EBC64BCAF76FFF5D80CE49DD21157" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesNarrativesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5089D56CCB0E4A883D56F922467FA42E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:to="loc_us-gaap_RangeAxis_5089D56CCB0E4A883D56F922467FA42E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_ECB65DA9E1B3C54E03D8F922467FBC33_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5089D56CCB0E4A883D56F922467FA42E" xlink:to="loc_us-gaap_RangeMember_ECB65DA9E1B3C54E03D8F922467FBC33_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_ECB65DA9E1B3C54E03D8F922467FBC33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5089D56CCB0E4A883D56F922467FA42E" xlink:to="loc_us-gaap_RangeMember_ECB65DA9E1B3C54E03D8F922467FBC33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_DD81EABAEEFBEDB73961F922467F61C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_ECB65DA9E1B3C54E03D8F922467FBC33" xlink:to="loc_us-gaap_MaximumMember_DD81EABAEEFBEDB73961F922467F61C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9297D8BE4142ADE4CDEFF922467FECCC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9297D8BE4142ADE4CDEFF922467FECCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4A15998F5AA3217F4525F922467FEFCD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9297D8BE4142ADE4CDEFF922467FECCC" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4A15998F5AA3217F4525F922467FEFCD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4A15998F5AA3217F4525F922467FEFCD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9297D8BE4142ADE4CDEFF922467FECCC" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4A15998F5AA3217F4525F922467FEFCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F0BF88F9C31197693E11F922467F43FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4A15998F5AA3217F4525F922467FEFCD" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F0BF88F9C31197693E11F922467F43FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_C956E160001919D22EC9F922467F0565" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:to="loc_us-gaap_TitleOfIndividualAxis_C956E160001919D22EC9F922467F0565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0B9EF6860F9506DB6202F922467F3D65_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_C956E160001919D22EC9F922467F0565" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0B9EF6860F9506DB6202F922467F3D65_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0B9EF6860F9506DB6202F922467F3D65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_C956E160001919D22EC9F922467F0565" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0B9EF6860F9506DB6202F922467F3D65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember_FD211E4274C3E06025B7F922467F20F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0B9EF6860F9506DB6202F922467F3D65" xlink:to="loc_us-gaap_ExecutiveOfficerMember_FD211E4274C3E06025B7F922467F20F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1C53D83FA3AAE59E4757F922467FE107" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1C53D83FA3AAE59E4757F922467FE107" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_B71D3ABCF305669CA5EAF922467FC672_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1C53D83FA3AAE59E4757F922467FE107" xlink:to="loc_us-gaap_SegmentDomain_B71D3ABCF305669CA5EAF922467FC672_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_B71D3ABCF305669CA5EAF922467FC672" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1C53D83FA3AAE59E4757F922467FE107" xlink:to="loc_us-gaap_SegmentDomain_B71D3ABCF305669CA5EAF922467FC672" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PharmacogenomicServicesMember" xlink:label="loc_tbio_PharmacogenomicServicesMember_5DE0360C1FACCA9DF398F922467FDC07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_B71D3ABCF305669CA5EAF922467FC672" xlink:to="loc_tbio_PharmacogenomicServicesMember_5DE0360C1FACCA9DF398F922467FDC07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_A0585D0F80AE5CAC64B4F922467F00B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_OtherAssetsCurrent_A0585D0F80AE5CAC64B4F922467F00B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_D2FFBA0BC33B7AB10858F922467F73FF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_D2FFBA0BC33B7AB10858F922467F73FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_1110FD9027EE78B52971F922467F92E4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_1110FD9027EE78B52971F922467F92E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9108391CED427E49AB3BF922467FCC7D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9108391CED427E49AB3BF922467FCC7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_E86611F32DB00FA5E24DF922467F5D79" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_E86611F32DB00FA5E24DF922467F5D79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_055EAACFE10737EF6E66F922467F539A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_ShareBasedCompensation_055EAACFE10737EF6E66F922467F539A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1A167671C855305387CAF922467F559B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1A167671C855305387CAF922467F559B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_034D726B5125DE47B2A4F922467F7D62" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_034D726B5125DE47B2A4F922467F7D62" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_3676D7AECE76789AA3D4F922467F027C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_3676D7AECE76789AA3D4F922467F027C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_B11641F5826BC154EA4EF922467F96D7" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_DeferredRevenueCurrent_B11641F5826BC154EA4EF922467F96D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8C4C8FF1829D3DEBE19BF922467FE615" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8C4C8FF1829D3DEBE19BF922467FE615" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsParentheticals" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_7E647D837158F0D51DFB1C2677A50A44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_StatementTable_7E647D837158F0D51DFB1C2677A50A44" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_B02DC4865E3F275D25551C2677A5437C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7E647D837158F0D51DFB1C2677A50A44" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_B02DC4865E3F275D25551C2677A5437C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_B02DC4865E3F275D25551C2677A5437C" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_B02DC4865E3F275D25551C2677A5437C" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_9D652B2C01CAB032004C1C2677A55A53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_9D652B2C01CAB032004C1C2677A55A53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_FC3DC7C5A67B75CB83FE1C2677A50C2C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_FC3DC7C5A67B75CB83FE1C2677A50C2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_073F6101FC718C7F32B91C2677A58192" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_SalesRevenueNet_073F6101FC718C7F32B91C2677A58192" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_19F90F8EDE6124AF7E191C2677A54EDF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_19F90F8EDE6124AF7E191C2677A54EDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_21A07CE8535969A40D061C2677A540AE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_GrossProfit_21A07CE8535969A40D061C2677A540AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_FAA64CD333E6B2B1AE2E1C2677A50D7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_FAA64CD333E6B2B1AE2E1C2677A50D7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_08A87CCE718140E13A701C2677A6A7E5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_08A87CCE718140E13A701C2677A6A7E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_388AE4CD72637733B41E1C2677A6125D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C" xlink:to="loc_us-gaap_OperatingExpenses_388AE4CD72637733B41E1C2677A6125D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8A3147A9D4364507BC991C2677A61CDE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_OperatingIncomeLoss_8A3147A9D4364507BC991C2677A61CDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_InterestIncomeAndExpenseNet" xlink:label="loc_tbio_InterestIncomeAndExpenseNet_7C71CAE3177D8E9F98891C2677A609FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9" xlink:to="loc_tbio_InterestIncomeAndExpenseNet_7C71CAE3177D8E9F98891C2677A609FE" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_GainLossOnStockWarrantsRevaluation" xlink:label="loc_tbio_GainLossOnStockWarrantsRevaluation_FAE545525B5452B55A0B1C2677A6ED1B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9" xlink:to="loc_tbio_GainLossOnStockWarrantsRevaluation_FAE545525B5452B55A0B1C2677A6ED1B" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_OtherIncomeExpense" xlink:label="loc_tbio_OtherIncomeExpense_432D356ADE70C59274BC1C2677A6909E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9" xlink:to="loc_tbio_OtherIncomeExpense_432D356ADE70C59274BC1C2677A6909E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_A0D7F492A438962BCD351C2677A66929" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_A0D7F492A438962BCD351C2677A66929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_15C7C6057CB8AE73260D1C2677A61F22" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_15C7C6057CB8AE73260D1C2677A61F22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_C9B6428D211E9D978A7A1C2677A66363" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_C9B6428D211E9D978A7A1C2677A66363" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_783B740A282FC3F82CB71C2677A6A8BC" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_783B740A282FC3F82CB71C2677A6A8BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DA96A300DAEE1749BF9A1C2677A66E15" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_NetIncomeLoss_DA96A300DAEE1749BF9A1C2677A66E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_765A737FB2243BDD31161C2677A69C3C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_765A737FB2243BDD31161C2677A69C3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_41AFA31A3B5C550749341C2677A6D8BF" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_41AFA31A3B5C550749341C2677A6D8BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_47941E60731BE162FFBC1C2677A786A1" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_47941E60731BE162FFBC1C2677A786A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D25F1D95C8167F465EE01C2677A7AAD3" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D25F1D95C8167F465EE01C2677A7AAD3" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>tbio-20170331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_7E46942E912F6E3546D7F99435A3C51D_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_7E46942E912F6E3546D7F99435A3C51D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7E46942E912F6E3546D7F99435A3C51D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7E46942E912F6E3546D7F99435A3C51D" xlink:to="lab_us-gaap_DebtDisclosureAbstract_7E46942E912F6E3546D7F99435A3C51D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:to="lab_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_0906F2941C5140445AD3F99435A3C71C_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_0906F2941C5140445AD3F99435A3C71C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_0906F2941C5140445AD3F99435A3C71C_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_0906F2941C5140445AD3F99435A3C71C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_0906F2941C5140445AD3F99435A3C71C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_0906F2941C5140445AD3F99435A3C71C" xlink:to="lab_us-gaap_CreditFacilityAxis_0906F2941C5140445AD3F99435A3C71C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_70B4A2FEA4E065F0ABABF99435A34A4A_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_70B4A2FEA4E065F0ABABF99435A34A4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_70B4A2FEA4E065F0ABABF99435A34A4A_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_70B4A2FEA4E065F0ABABF99435A34A4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_70B4A2FEA4E065F0ABABF99435A34A4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_70B4A2FEA4E065F0ABABF99435A34A4A" xlink:to="lab_us-gaap_CreditFacilityDomain_70B4A2FEA4E065F0ABABF99435A34A4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_3D6B4D5EE5D24EBBBAB3F99435A33177_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember_3D6B4D5EE5D24EBBBAB3F99435A33177" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_3D6B4D5EE5D24EBBBAB3F99435A33177_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember_3D6B4D5EE5D24EBBBAB3F99435A33177" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_3D6B4D5EE5D24EBBBAB3F99435A33177" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember_3D6B4D5EE5D24EBBBAB3F99435A33177" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember_3D6B4D5EE5D24EBBBAB3F99435A33177" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_E8CFEEE0BDFF52D83786F99435A33FB7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_E8CFEEE0BDFF52D83786F99435A33FB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_E8CFEEE0BDFF52D83786F99435A33FB7_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_E8CFEEE0BDFF52D83786F99435A33FB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E8CFEEE0BDFF52D83786F99435A33FB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E8CFEEE0BDFF52D83786F99435A33FB7" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_E8CFEEE0BDFF52D83786F99435A33FB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditMember_269B1013E088307350CDF99435A3F42E_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_269B1013E088307350CDF99435A3F42E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_269B1013E088307350CDF99435A3F42E_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_269B1013E088307350CDF99435A3F42E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_269B1013E088307350CDF99435A3F42E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember_269B1013E088307350CDF99435A3F42E" xlink:to="lab_us-gaap_LineOfCreditMember_269B1013E088307350CDF99435A3F42E" xlink:type="arc" />
    <link:label id="lab_tbio_TermLoanMember_6C57E1EC15B158087595F99435A4B86A_terseLabel_en-US" xlink:label="lab_tbio_TermLoanMember_6C57E1EC15B158087595F99435A4B86A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_tbio_TermLoanMember_6C57E1EC15B158087595F99435A4B86A_label_en-US" xlink:label="lab_tbio_TermLoanMember_6C57E1EC15B158087595F99435A4B86A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_tbio_TermLoanMember_6C57E1EC15B158087595F99435A4B86A_documentation_en-US" xlink:label="lab_tbio_TermLoanMember_6C57E1EC15B158087595F99435A4B86A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_TermLoanMember" xlink:label="loc_tbio_TermLoanMember_6C57E1EC15B158087595F99435A4B86A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_TermLoanMember_6C57E1EC15B158087595F99435A4B86A" xlink:to="lab_tbio_TermLoanMember_6C57E1EC15B158087595F99435A4B86A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_3C61FBF083A5D87B771CF99435A4B932_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_3C61FBF083A5D87B771CF99435A4B932" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_3C61FBF083A5D87B771CF99435A4B932_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_3C61FBF083A5D87B771CF99435A4B932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_3C61FBF083A5D87B771CF99435A4B932" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember_3C61FBF083A5D87B771CF99435A4B932" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember_3C61FBF083A5D87B771CF99435A4B932" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_29EDA996064EE9C9C2DFF99435A44274_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_29EDA996064EE9C9C2DFF99435A44274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_29EDA996064EE9C9C2DFF99435A44274_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_29EDA996064EE9C9C2DFF99435A44274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_29EDA996064EE9C9C2DFF99435A44274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_29EDA996064EE9C9C2DFF99435A44274" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis_29EDA996064EE9C9C2DFF99435A44274" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_7002F71E6E3CFEFFE69CF99435A40F33_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_7002F71E6E3CFEFFE69CF99435A40F33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_7002F71E6E3CFEFFE69CF99435A40F33_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_7002F71E6E3CFEFFE69CF99435A40F33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_7002F71E6E3CFEFFE69CF99435A40F33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7002F71E6E3CFEFFE69CF99435A40F33" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain_7002F71E6E3CFEFFE69CF99435A40F33" xlink:type="arc" />
    <link:label id="lab_tbio_ThirdSecurityLlcAndAffiliatesMember_6300BC7AB349A5DE3569F99435A456B9_terseLabel_en-US" xlink:label="lab_tbio_ThirdSecurityLlcAndAffiliatesMember_6300BC7AB349A5DE3569F99435A456B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third Security LLC and affiliates</link:label>
    <link:label id="lab_tbio_ThirdSecurityLlcAndAffiliatesMember_6300BC7AB349A5DE3569F99435A456B9_label_en-US" xlink:label="lab_tbio_ThirdSecurityLlcAndAffiliatesMember_6300BC7AB349A5DE3569F99435A456B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third Security LLC And Affiliates [Member]</link:label>
    <link:label id="lab_tbio_ThirdSecurityLlcAndAffiliatesMember_6300BC7AB349A5DE3569F99435A456B9_documentation_en-US" xlink:label="lab_tbio_ThirdSecurityLlcAndAffiliatesMember_6300BC7AB349A5DE3569F99435A456B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Third Security LLC And Affiliates [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ThirdSecurityLlcAndAffiliatesMember" xlink:label="loc_tbio_ThirdSecurityLlcAndAffiliatesMember_6300BC7AB349A5DE3569F99435A456B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_ThirdSecurityLlcAndAffiliatesMember_6300BC7AB349A5DE3569F99435A456B9" xlink:to="lab_tbio_ThirdSecurityLlcAndAffiliatesMember_6300BC7AB349A5DE3569F99435A456B9" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_4D503A975E5329E9743FF99435A40008_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_4D503A975E5329E9743FF99435A40008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_4D503A975E5329E9743FF99435A40008_label_en-US" xlink:label="lab_dei_LegalEntityAxis_4D503A975E5329E9743FF99435A40008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4D503A975E5329E9743FF99435A40008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_4D503A975E5329E9743FF99435A40008" xlink:to="lab_dei_LegalEntityAxis_4D503A975E5329E9743FF99435A40008" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_8A97C2951879C202B097F99435A4BC2B_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_8A97C2951879C202B097F99435A4BC2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_8A97C2951879C202B097F99435A4BC2B_label_en-US" xlink:label="lab_dei_EntityDomain_8A97C2951879C202B097F99435A4BC2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8A97C2951879C202B097F99435A4BC2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_8A97C2951879C202B097F99435A4BC2B" xlink:to="lab_dei_EntityDomain_8A97C2951879C202B097F99435A4BC2B" xlink:type="arc" />
    <link:label id="lab_tbio_PrecipioMember_63B9F574EA41FF300AC2F99435A46D31_terseLabel_en-US" xlink:label="lab_tbio_PrecipioMember_63B9F574EA41FF300AC2F99435A46D31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Precipio</link:label>
    <link:label id="lab_tbio_PrecipioMember_63B9F574EA41FF300AC2F99435A46D31_label_en-US" xlink:label="lab_tbio_PrecipioMember_63B9F574EA41FF300AC2F99435A46D31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Precipio [Member]</link:label>
    <link:label id="lab_tbio_PrecipioMember_63B9F574EA41FF300AC2F99435A46D31_documentation_en-US" xlink:label="lab_tbio_PrecipioMember_63B9F574EA41FF300AC2F99435A46D31" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Precipio [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PrecipioMember" xlink:label="loc_tbio_PrecipioMember_63B9F574EA41FF300AC2F99435A46D31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_PrecipioMember_63B9F574EA41FF300AC2F99435A46D31" xlink:to="lab_tbio_PrecipioMember_63B9F574EA41FF300AC2F99435A46D31" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_EBB7779F986493FCCD39F99435A475B1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_EBB7779F986493FCCD39F99435A475B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_EBB7779F986493FCCD39F99435A475B1_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_EBB7779F986493FCCD39F99435A475B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_EBB7779F986493FCCD39F99435A475B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_EBB7779F986493FCCD39F99435A475B1" xlink:to="lab_us-gaap_StatementClassOfStockAxis_EBB7779F986493FCCD39F99435A475B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731" xlink:to="lab_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleCommonStockMember_8774692473B1B2DDFC15F99435A405E5_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleCommonStockMember_8774692473B1B2DDFC15F99435A405E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Common Stock</link:label>
    <link:label id="lab_us-gaap_ConvertibleCommonStockMember_8774692473B1B2DDFC15F99435A405E5_label_en-US" xlink:label="lab_us-gaap_ConvertibleCommonStockMember_8774692473B1B2DDFC15F99435A405E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="loc_us-gaap_ConvertibleCommonStockMember_8774692473B1B2DDFC15F99435A405E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleCommonStockMember_8774692473B1B2DDFC15F99435A405E5" xlink:to="lab_us-gaap_ConvertibleCommonStockMember_8774692473B1B2DDFC15F99435A405E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_92B4AC166897CFE88224F99435A46C04_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_92B4AC166897CFE88224F99435A46C04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_92B4AC166897CFE88224F99435A46C04_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_92B4AC166897CFE88224F99435A46C04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_92B4AC166897CFE88224F99435A46C04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_92B4AC166897CFE88224F99435A46C04" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_92B4AC166897CFE88224F99435A46C04" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:to="lab_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_47254065B2513BCA14EDF99435A4ADAC_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_47254065B2513BCA14EDF99435A4ADAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_47254065B2513BCA14EDF99435A4ADAC_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_47254065B2513BCA14EDF99435A4ADAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_47254065B2513BCA14EDF99435A4ADAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_47254065B2513BCA14EDF99435A4ADAC" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_47254065B2513BCA14EDF99435A4ADAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_F07F53E359E80D7EC164F99435A49E65_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_F07F53E359E80D7EC164F99435A49E65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_F07F53E359E80D7EC164F99435A49E65_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_F07F53E359E80D7EC164F99435A49E65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_F07F53E359E80D7EC164F99435A49E65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_F07F53E359E80D7EC164F99435A49E65" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_F07F53E359E80D7EC164F99435A49E65" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_E4DFE054E144426BEC4FF99435A5F1C9_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_E4DFE054E144426BEC4FF99435A5F1C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment to lenders to support the amount advanced</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_E4DFE054E144426BEC4FF99435A5F1C9_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_E4DFE054E144426BEC4FF99435A5F1C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Lines of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_E4DFE054E144426BEC4FF99435A5F1C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_E4DFE054E144426BEC4FF99435A5F1C9" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_E4DFE054E144426BEC4FF99435A5F1C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1EF339EE5030DBBCE93CF99435A5747C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1EF339EE5030DBBCE93CF99435A5747C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares converted (shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1EF339EE5030DBBCE93CF99435A5747C_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1EF339EE5030DBBCE93CF99435A5747C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1EF339EE5030DBBCE93CF99435A5747C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1EF339EE5030DBBCE93CF99435A5747C" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1EF339EE5030DBBCE93CF99435A5747C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_C6F49B728771C80ECDA0F99435A55C0A_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_C6F49B728771C80ECDA0F99435A55C0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_C6F49B728771C80ECDA0F99435A55C0A_label_en-US" xlink:label="lab_us-gaap_SharePrice_C6F49B728771C80ECDA0F99435A55C0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_C6F49B728771C80ECDA0F99435A55C0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_C6F49B728771C80ECDA0F99435A55C0A" xlink:to="lab_us-gaap_SharePrice_C6F49B728771C80ECDA0F99435A55C0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_86BAF934F4193C007AA9F99435A54D82_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_86BAF934F4193C007AA9F99435A54D82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible promissory notes</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_86BAF934F4193C007AA9F99435A54D82_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_86BAF934F4193C007AA9F99435A54D82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_86BAF934F4193C007AA9F99435A54D82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_86BAF934F4193C007AA9F99435A54D82" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_86BAF934F4193C007AA9F99435A54D82" xlink:type="arc" />
    <link:label id="lab_tbio_DebtConversionConvertedInstrumentInterest_B929999A8FFDBCEB3DF3F99435A54ED1_terseLabel_en-US" xlink:label="lab_tbio_DebtConversionConvertedInstrumentInterest_B929999A8FFDBCEB3DF3F99435A54ED1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion, converted Instrument, interest</link:label>
    <link:label id="lab_tbio_DebtConversionConvertedInstrumentInterest_B929999A8FFDBCEB3DF3F99435A54ED1_label_en-US" xlink:label="lab_tbio_DebtConversionConvertedInstrumentInterest_B929999A8FFDBCEB3DF3F99435A54ED1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Interest</link:label>
    <link:label id="lab_tbio_DebtConversionConvertedInstrumentInterest_B929999A8FFDBCEB3DF3F99435A54ED1_documentation_en-US" xlink:label="lab_tbio_DebtConversionConvertedInstrumentInterest_B929999A8FFDBCEB3DF3F99435A54ED1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Interest</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtConversionConvertedInstrumentInterest" xlink:label="loc_tbio_DebtConversionConvertedInstrumentInterest_B929999A8FFDBCEB3DF3F99435A54ED1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_DebtConversionConvertedInstrumentInterest_B929999A8FFDBCEB3DF3F99435A54ED1" xlink:to="lab_tbio_DebtConversionConvertedInstrumentInterest_B929999A8FFDBCEB3DF3F99435A54ED1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_996BAE26DC744D8C1C5D94CAF0A6730C_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2BC9CF23044356F8BFF9BDC19CEEDD08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2BC9CF23044356F8BFF9BDC19CEEDD08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2BC9CF23044356F8BFF9BDC19CEEDD08" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2BC9CF23044356F8BFF9BDC19CEEDD08" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_A87D58232DABE2CC1D0694CAF0A6ECB4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_2ED98220D68355139FC54B713A4B42C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DISCONTINUED OPERATIONS</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_A87D58232DABE2CC1D0694CAF0A6ECB4_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_2ED98220D68355139FC54B713A4B42C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_2ED98220D68355139FC54B713A4B42C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_2ED98220D68355139FC54B713A4B42C7" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_2ED98220D68355139FC54B713A4B42C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_D114AE088CADD402640194CAF21F027F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_DB011DFCC7D15CA391B3956A944081A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_D114AE088CADD402640194CAF21F027F_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_DB011DFCC7D15CA391B3956A944081A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_DB011DFCC7D15CA391B3956A944081A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_DB011DFCC7D15CA391B3956A944081A7" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_DB011DFCC7D15CA391B3956A944081A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_C821636FD421A212130CF9224670AD24_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_C821636FD421A212130CF9224670AD24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_C821636FD421A212130CF9224670AD24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C821636FD421A212130CF9224670AD24" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_C821636FD421A212130CF9224670AD24" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_5089D56CCB0E4A883D56F922467FA42E_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_5089D56CCB0E4A883D56F922467FA42E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_5089D56CCB0E4A883D56F922467FA42E_label_en-US" xlink:label="lab_us-gaap_RangeAxis_5089D56CCB0E4A883D56F922467FA42E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5089D56CCB0E4A883D56F922467FA42E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_5089D56CCB0E4A883D56F922467FA42E" xlink:to="lab_us-gaap_RangeAxis_5089D56CCB0E4A883D56F922467FA42E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_ECB65DA9E1B3C54E03D8F922467FBC33_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_ECB65DA9E1B3C54E03D8F922467FBC33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_ECB65DA9E1B3C54E03D8F922467FBC33_label_en-US" xlink:label="lab_us-gaap_RangeMember_ECB65DA9E1B3C54E03D8F922467FBC33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_ECB65DA9E1B3C54E03D8F922467FBC33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_ECB65DA9E1B3C54E03D8F922467FBC33" xlink:to="lab_us-gaap_RangeMember_ECB65DA9E1B3C54E03D8F922467FBC33" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_DD81EABAEEFBEDB73961F922467F61C9_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_DD81EABAEEFBEDB73961F922467F61C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_DD81EABAEEFBEDB73961F922467F61C9_label_en-US" xlink:label="lab_us-gaap_MaximumMember_DD81EABAEEFBEDB73961F922467F61C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_DD81EABAEEFBEDB73961F922467F61C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_DD81EABAEEFBEDB73961F922467F61C9" xlink:to="lab_us-gaap_MaximumMember_DD81EABAEEFBEDB73961F922467F61C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9297D8BE4142ADE4CDEFF922467FECCC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_9297D8BE4142ADE4CDEFF922467FECCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9297D8BE4142ADE4CDEFF922467FECCC_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_9297D8BE4142ADE4CDEFF922467FECCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9297D8BE4142ADE4CDEFF922467FECCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9297D8BE4142ADE4CDEFF922467FECCC" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_9297D8BE4142ADE4CDEFF922467FECCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4A15998F5AA3217F4525F922467FEFCD_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_4A15998F5AA3217F4525F922467FEFCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4A15998F5AA3217F4525F922467FEFCD_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_4A15998F5AA3217F4525F922467FEFCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4A15998F5AA3217F4525F922467FEFCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4A15998F5AA3217F4525F922467FEFCD" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_4A15998F5AA3217F4525F922467FEFCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F0BF88F9C31197693E11F922467F43FB_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F0BF88F9C31197693E11F922467F43FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F0BF88F9C31197693E11F922467F43FB_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F0BF88F9C31197693E11F922467F43FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F0BF88F9C31197693E11F922467F43FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F0BF88F9C31197693E11F922467F43FB" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F0BF88F9C31197693E11F922467F43FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_C956E160001919D22EC9F922467F0565_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_C956E160001919D22EC9F922467F0565" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_C956E160001919D22EC9F922467F0565_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_C956E160001919D22EC9F922467F0565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_C956E160001919D22EC9F922467F0565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_C956E160001919D22EC9F922467F0565" xlink:to="lab_us-gaap_TitleOfIndividualAxis_C956E160001919D22EC9F922467F0565" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0B9EF6860F9506DB6202F922467F3D65_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0B9EF6860F9506DB6202F922467F3D65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0B9EF6860F9506DB6202F922467F3D65_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0B9EF6860F9506DB6202F922467F3D65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0B9EF6860F9506DB6202F922467F3D65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0B9EF6860F9506DB6202F922467F3D65" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0B9EF6860F9506DB6202F922467F3D65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExecutiveOfficerMember_FD211E4274C3E06025B7F922467F20F0_terseLabel_en-US" xlink:label="lab_us-gaap_ExecutiveOfficerMember_FD211E4274C3E06025B7F922467F20F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Officers</link:label>
    <link:label id="lab_us-gaap_ExecutiveOfficerMember_FD211E4274C3E06025B7F922467F20F0_label_en-US" xlink:label="lab_us-gaap_ExecutiveOfficerMember_FD211E4274C3E06025B7F922467F20F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember_FD211E4274C3E06025B7F922467F20F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExecutiveOfficerMember_FD211E4274C3E06025B7F922467F20F0" xlink:to="lab_us-gaap_ExecutiveOfficerMember_FD211E4274C3E06025B7F922467F20F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_1C53D83FA3AAE59E4757F922467FE107_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_1C53D83FA3AAE59E4757F922467FE107" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business segments</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_1C53D83FA3AAE59E4757F922467FE107_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_1C53D83FA3AAE59E4757F922467FE107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1C53D83FA3AAE59E4757F922467FE107" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1C53D83FA3AAE59E4757F922467FE107" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis_1C53D83FA3AAE59E4757F922467FE107" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentDomain_B71D3ABCF305669CA5EAF922467FC672_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain_B71D3ABCF305669CA5EAF922467FC672" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_B71D3ABCF305669CA5EAF922467FC672_label_en-US" xlink:label="lab_us-gaap_SegmentDomain_B71D3ABCF305669CA5EAF922467FC672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_B71D3ABCF305669CA5EAF922467FC672" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain_B71D3ABCF305669CA5EAF922467FC672" xlink:to="lab_us-gaap_SegmentDomain_B71D3ABCF305669CA5EAF922467FC672" xlink:type="arc" />
    <link:label id="lab_tbio_PharmacogenomicServicesMember_5DE0360C1FACCA9DF398F922467FDC07_terseLabel_en-US" xlink:label="lab_tbio_PharmacogenomicServicesMember_5DE0360C1FACCA9DF398F922467FDC07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmacogenomic Services</link:label>
    <link:label id="lab_tbio_PharmacogenomicServicesMember_5DE0360C1FACCA9DF398F922467FDC07_label_en-US" xlink:label="lab_tbio_PharmacogenomicServicesMember_5DE0360C1FACCA9DF398F922467FDC07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmacogenomic services [Member]</link:label>
    <link:label id="lab_tbio_PharmacogenomicServicesMember_5DE0360C1FACCA9DF398F922467FDC07_documentation_en-US" xlink:label="lab_tbio_PharmacogenomicServicesMember_5DE0360C1FACCA9DF398F922467FDC07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmacogenomic services [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PharmacogenomicServicesMember" xlink:label="loc_tbio_PharmacogenomicServicesMember_5DE0360C1FACCA9DF398F922467FDC07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_PharmacogenomicServicesMember_5DE0360C1FACCA9DF398F922467FDC07" xlink:to="lab_tbio_PharmacogenomicServicesMember_5DE0360C1FACCA9DF398F922467FDC07" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_A0585D0F80AE5CAC64B4F922467F00B0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_A0585D0F80AE5CAC64B4F922467F00B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_A0585D0F80AE5CAC64B4F922467F00B0_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_A0585D0F80AE5CAC64B4F922467F00B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_A0585D0F80AE5CAC64B4F922467F00B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_A0585D0F80AE5CAC64B4F922467F00B0" xlink:to="lab_us-gaap_OtherAssetsCurrent_A0585D0F80AE5CAC64B4F922467F00B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_D2FFBA0BC33B7AB10858F922467F73FF_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_D2FFBA0BC33B7AB10858F922467F73FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current prepaid expense</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_D2FFBA0BC33B7AB10858F922467F73FF_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_D2FFBA0BC33B7AB10858F922467F73FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_D2FFBA0BC33B7AB10858F922467F73FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_D2FFBA0BC33B7AB10858F922467F73FF" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_D2FFBA0BC33B7AB10858F922467F73FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_1110FD9027EE78B52971F922467F92E4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_1110FD9027EE78B52971F922467F92E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_1110FD9027EE78B52971F922467F92E4_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_1110FD9027EE78B52971F922467F92E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_1110FD9027EE78B52971F922467F92E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent_1110FD9027EE78B52971F922467F92E4" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent_1110FD9027EE78B52971F922467F92E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9108391CED427E49AB3BF922467FCC7D_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9108391CED427E49AB3BF922467FCC7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9108391CED427E49AB3BF922467FCC7D_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9108391CED427E49AB3BF922467FCC7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9108391CED427E49AB3BF922467FCC7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9108391CED427E49AB3BF922467FCC7D" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9108391CED427E49AB3BF922467FCC7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_E86611F32DB00FA5E24DF922467F5D79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_E86611F32DB00FA5E24DF922467F5D79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, unvested options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_E86611F32DB00FA5E24DF922467F5D79_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_E86611F32DB00FA5E24DF922467F5D79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_E86611F32DB00FA5E24DF922467F5D79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_E86611F32DB00FA5E24DF922467F5D79" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_E86611F32DB00FA5E24DF922467F5D79" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_055EAACFE10737EF6E66F922467F539A_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_055EAACFE10737EF6E66F922467F539A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_055EAACFE10737EF6E66F922467F539A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_055EAACFE10737EF6E66F922467F539A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_055EAACFE10737EF6E66F922467F539A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_055EAACFE10737EF6E66F922467F539A" xlink:to="lab_us-gaap_ShareBasedCompensation_055EAACFE10737EF6E66F922467F539A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1A167671C855305387CAF922467F559B_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1A167671C855305387CAF922467F559B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense related to unvested stock awards, not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1A167671C855305387CAF922467F559B_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1A167671C855305387CAF922467F559B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1A167671C855305387CAF922467F559B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1A167671C855305387CAF922467F559B" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1A167671C855305387CAF922467F559B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_034D726B5125DE47B2A4F922467F7D62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_034D726B5125DE47B2A4F922467F7D62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested stock options, unrecognized compensation expense weighted average recognition period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_034D726B5125DE47B2A4F922467F7D62_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_034D726B5125DE47B2A4F922467F7D62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_034D726B5125DE47B2A4F922467F7D62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_034D726B5125DE47B2A4F922467F7D62" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_034D726B5125DE47B2A4F922467F7D62" xlink:type="arc" />
    <link:label id="lab_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_3676D7AECE76789AA3D4F922467F027C_verboseLabel_en-US" xlink:label="lab_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_3676D7AECE76789AA3D4F922467F027C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock rights issued (in shares)</link:label>
    <link:label id="lab_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_3676D7AECE76789AA3D4F922467F027C_label_en-US" xlink:label="lab_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_3676D7AECE76789AA3D4F922467F027C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Issued Warrants or Rights</link:label>
    <link:label id="lab_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_3676D7AECE76789AA3D4F922467F027C_documentation_en-US" xlink:label="lab_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_3676D7AECE76789AA3D4F922467F027C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Issued Warrants or Rights</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_3676D7AECE76789AA3D4F922467F027C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_3676D7AECE76789AA3D4F922467F027C" xlink:to="lab_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_3676D7AECE76789AA3D4F922467F027C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_B11641F5826BC154EA4EF922467F96D7_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_B11641F5826BC154EA4EF922467F96D7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_B11641F5826BC154EA4EF922467F96D7_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_B11641F5826BC154EA4EF922467F96D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_B11641F5826BC154EA4EF922467F96D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_B11641F5826BC154EA4EF922467F96D7" xlink:to="lab_us-gaap_DeferredRevenueCurrent_B11641F5826BC154EA4EF922467F96D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8C4C8FF1829D3DEBE19BF922467FE615_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8C4C8FF1829D3DEBE19BF922467FE615" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, warrants and conversion rights, common stock callable and antidilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8C4C8FF1829D3DEBE19BF922467FE615_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8C4C8FF1829D3DEBE19BF922467FE615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8C4C8FF1829D3DEBE19BF922467FE615" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8C4C8FF1829D3DEBE19BF922467FE615" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8C4C8FF1829D3DEBE19BF922467FE615" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_70FACE28AD2FFDE25E2494CAF2AC93B2_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_DD5004B8426D5136A698085502356FB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DD5004B8426D5136A698085502356FB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DD5004B8426D5136A698085502356FB2" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_DD5004B8426D5136A698085502356FB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_25B2E4F2A2B8565B63BC94CAF2AC4B0D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B6AA521CE6D45042BA32A328068E9BBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of changes in fair value of liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_25B2E4F2A2B8565B63BC94CAF2AC4B0D_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B6AA521CE6D45042BA32A328068E9BBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B6AA521CE6D45042BA32A328068E9BBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B6AA521CE6D45042BA32A328068E9BBD" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B6AA521CE6D45042BA32A328068E9BBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6E37A7E1893A85592E55FDA2FDA85039_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6E37A7E1893A85592E55FDA2FDA85039" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6E37A7E1893A85592E55FDA2FDA85039" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6E37A7E1893A85592E55FDA2FDA85039" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6E37A7E1893A85592E55FDA2FDA85039" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_08FD9FB320DA85D89DACFDA2FDA8B34E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_08FD9FB320DA85D89DACFDA2FDA8B34E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_08FD9FB320DA85D89DACFDA2FDA8B34E_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_08FD9FB320DA85D89DACFDA2FDA8B34E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_08FD9FB320DA85D89DACFDA2FDA8B34E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_08FD9FB320DA85D89DACFDA2FDA8B34E" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_08FD9FB320DA85D89DACFDA2FDA8B34E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9342AE83BFDCCA2DDF1BFDA2FDA8DC0A_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9342AE83BFDCCA2DDF1BFDA2FDA8DC0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9342AE83BFDCCA2DDF1BFDA2FDA8DC0A_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9342AE83BFDCCA2DDF1BFDA2FDA8DC0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9342AE83BFDCCA2DDF1BFDA2FDA8DC0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9342AE83BFDCCA2DDF1BFDA2FDA8DC0A" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9342AE83BFDCCA2DDF1BFDA2FDA8DC0A" xlink:type="arc" />
    <link:label id="lab_tbio_PrecipioMember_959B456802F9B2F53F01FDA2FDA8CAF6_verboseLabel_en-US" xlink:label="lab_tbio_PrecipioMember_959B456802F9B2F53F01FDA2FDA8CAF6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Precipio</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PrecipioMember" xlink:label="loc_tbio_PrecipioMember_959B456802F9B2F53F01FDA2FDA8CAF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_PrecipioMember_959B456802F9B2F53F01FDA2FDA8CAF6" xlink:to="lab_tbio_PrecipioMember_959B456802F9B2F53F01FDA2FDA8CAF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_1F74755E3C90EAE55644FDA2FDA8C49E_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_1F74755E3C90EAE55644FDA2FDA8C49E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_1F74755E3C90EAE55644FDA2FDA8C49E_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_1F74755E3C90EAE55644FDA2FDA8C49E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1F74755E3C90EAE55644FDA2FDA8C49E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_1F74755E3C90EAE55644FDA2FDA8C49E" xlink:to="lab_us-gaap_CommonStockMember_1F74755E3C90EAE55644FDA2FDA8C49E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_5C4DB431943C1359EBBFFDA2FDA81978_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_5C4DB431943C1359EBBFFDA2FDA81978" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_5C4DB431943C1359EBBFFDA2FDA81978_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_5C4DB431943C1359EBBFFDA2FDA81978" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_5C4DB431943C1359EBBFFDA2FDA81978" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_5C4DB431943C1359EBBFFDA2FDA81978" xlink:to="lab_us-gaap_PreferredStockMember_5C4DB431943C1359EBBFFDA2FDA81978" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_BD52437AAD7E683DA1F4FDA2FDA8492E_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_BD52437AAD7E683DA1F4FDA2FDA8492E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_BD52437AAD7E683DA1F4FDA2FDA8492E_label_en-US" xlink:label="lab_us-gaap_MinimumMember_BD52437AAD7E683DA1F4FDA2FDA8492E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_BD52437AAD7E683DA1F4FDA2FDA8492E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_BD52437AAD7E683DA1F4FDA2FDA8492E" xlink:to="lab_us-gaap_MinimumMember_BD52437AAD7E683DA1F4FDA2FDA8492E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_C6BFB90ACDC8135E709FFDA2FDA81933_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_C6BFB90ACDC8135E709FFDA2FDA81933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_C6BFB90ACDC8135E709FFDA2FDA81933_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_C6BFB90ACDC8135E709FFDA2FDA81933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_C6BFB90ACDC8135E709FFDA2FDA81933" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_C6BFB90ACDC8135E709FFDA2FDA81933" xlink:to="lab_us-gaap_NumberOfOperatingSegments_C6BFB90ACDC8135E709FFDA2FDA81933" xlink:type="arc" />
    <link:label id="lab_tbio_WorkingCapitalDeficiency_44FA6D5BB99005AF64B2FDA2FDA86683_terseLabel_en-US" xlink:label="lab_tbio_WorkingCapitalDeficiency_44FA6D5BB99005AF64B2FDA2FDA86683" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_tbio_WorkingCapitalDeficiency_44FA6D5BB99005AF64B2FDA2FDA86683_label_en-US" xlink:label="lab_tbio_WorkingCapitalDeficiency_44FA6D5BB99005AF64B2FDA2FDA86683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Working Capital (Deficiency)</link:label>
    <link:label id="lab_tbio_WorkingCapitalDeficiency_44FA6D5BB99005AF64B2FDA2FDA86683_documentation_en-US" xlink:label="lab_tbio_WorkingCapitalDeficiency_44FA6D5BB99005AF64B2FDA2FDA86683" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Working Capital (Deficiency)</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WorkingCapitalDeficiency" xlink:label="loc_tbio_WorkingCapitalDeficiency_44FA6D5BB99005AF64B2FDA2FDA86683" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_WorkingCapitalDeficiency_44FA6D5BB99005AF64B2FDA2FDA86683" xlink:to="lab_tbio_WorkingCapitalDeficiency_44FA6D5BB99005AF64B2FDA2FDA86683" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_AEBA0CBE0BB2A142689EFDA2FDA86F17_verboseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_AEBA0CBE0BB2A142689EFDA2FDA86F17" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares converted, shares</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_AEBA0CBE0BB2A142689EFDA2FDA86F17_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_AEBA0CBE0BB2A142689EFDA2FDA86F17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_AEBA0CBE0BB2A142689EFDA2FDA86F17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1_AEBA0CBE0BB2A142689EFDA2FDA86F17" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1_AEBA0CBE0BB2A142689EFDA2FDA86F17" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_0CE818CB955DEAED1CD3FDA2FDA83D5A_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_0CE818CB955DEAED1CD3FDA2FDA83D5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of shares owned after transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_0CE818CB955DEAED1CD3FDA2FDA83D5A_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_0CE818CB955DEAED1CD3FDA2FDA83D5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_0CE818CB955DEAED1CD3FDA2FDA83D5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_0CE818CB955DEAED1CD3FDA2FDA83D5A" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_0CE818CB955DEAED1CD3FDA2FDA83D5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_A3D168EF234F49E40B6DFDA2FDA87153_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_A3D168EF234F49E40B6DFDA2FDA87153" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt settled with issuance of preferred stock and warrants</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_A3D168EF234F49E40B6DFDA2FDA87153_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_A3D168EF234F49E40B6DFDA2FDA87153" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_A3D168EF234F49E40B6DFDA2FDA87153" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1_A3D168EF234F49E40B6DFDA2FDA87153" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1_A3D168EF234F49E40B6DFDA2FDA87153" xlink:type="arc" />
    <link:label id="lab_tbio_StockholdersEquityNoteReverseStockSplitConversionRatio_226D2A7366491587835FFDA2FDA82811_terseLabel_en-US" xlink:label="lab_tbio_StockholdersEquityNoteReverseStockSplitConversionRatio_226D2A7366491587835FFDA2FDA82811" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split ratio</link:label>
    <link:label id="lab_tbio_StockholdersEquityNoteReverseStockSplitConversionRatio_226D2A7366491587835FFDA2FDA82811_label_en-US" xlink:label="lab_tbio_StockholdersEquityNoteReverseStockSplitConversionRatio_226D2A7366491587835FFDA2FDA82811" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Reverse Stock Split, Conversion Ratio</link:label>
    <link:label id="lab_tbio_StockholdersEquityNoteReverseStockSplitConversionRatio_226D2A7366491587835FFDA2FDA82811_documentation_en-US" xlink:label="lab_tbio_StockholdersEquityNoteReverseStockSplitConversionRatio_226D2A7366491587835FFDA2FDA82811" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Reverse Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockholdersEquityNoteReverseStockSplitConversionRatio" xlink:label="loc_tbio_StockholdersEquityNoteReverseStockSplitConversionRatio_226D2A7366491587835FFDA2FDA82811" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_StockholdersEquityNoteReverseStockSplitConversionRatio_226D2A7366491587835FFDA2FDA82811" xlink:to="lab_tbio_StockholdersEquityNoteReverseStockSplitConversionRatio_226D2A7366491587835FFDA2FDA82811" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F6DD17B20ED0EEE3E53294CAF1DE799F_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_409AA232C0EF5937A51CA8A14A22D6E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_409AA232C0EF5937A51CA8A14A22D6E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_409AA232C0EF5937A51CA8A14A22D6E0" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_409AA232C0EF5937A51CA8A14A22D6E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_06AB1C1727BFC6F0854C94CAF1DE21B8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_C67D546757D05A819B77C3E6861F9FDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK OPTIONS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_06AB1C1727BFC6F0854C94CAF1DE21B8_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_C67D546757D05A819B77C3E6861F9FDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_C67D546757D05A819B77C3E6861F9FDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_C67D546757D05A819B77C3E6861F9FDD" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_C67D546757D05A819B77C3E6861F9FDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_B15EDBC35FECC976C423F8A7AD4C8213_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_B15EDBC35FECC976C423F8A7AD4C8213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_B15EDBC35FECC976C423F8A7AD4C8213" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_B15EDBC35FECC976C423F8A7AD4C8213" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_B15EDBC35FECC976C423F8A7AD4C8213" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_209C3FFB2E87C91D0A6BF8B1564630CD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_209C3FFB2E87C91D0A6BF8B1564630CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_209C3FFB2E87C91D0A6BF8B1564630CD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_209C3FFB2E87C91D0A6BF8B1564630CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_209C3FFB2E87C91D0A6BF8B1564630CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_209C3FFB2E87C91D0A6BF8B1564630CD" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_209C3FFB2E87C91D0A6BF8B1564630CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_5A031D19CA0A88A74242F8B156479144_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_5A031D19CA0A88A74242F8B156479144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_5A031D19CA0A88A74242F8B156479144_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_5A031D19CA0A88A74242F8B156479144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_5A031D19CA0A88A74242F8B156479144" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_5A031D19CA0A88A74242F8B156479144" xlink:to="lab_us-gaap_ClassOfStockLineItems_5A031D19CA0A88A74242F8B156479144" xlink:type="arc" />
    <link:label id="lab_tbio_DividendsPreferredStockCashNotDeclared_76BF69921F45864CE6A1F8A7AD4CB347_terseLabel_en-US" xlink:label="lab_tbio_DividendsPreferredStockCashNotDeclared_76BF69921F45864CE6A1F8A7AD4CB347" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative undeclared dividends, preferred stock</link:label>
    <link:label id="lab_tbio_DividendsPreferredStockCashNotDeclared_76BF69921F45864CE6A1F8A7AD4CB347_label_en-US" xlink:label="lab_tbio_DividendsPreferredStockCashNotDeclared_76BF69921F45864CE6A1F8A7AD4CB347" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Preferred Stock, Cash, Not Declared</link:label>
    <link:label id="lab_tbio_DividendsPreferredStockCashNotDeclared_76BF69921F45864CE6A1F8A7AD4CB347_documentation_en-US" xlink:label="lab_tbio_DividendsPreferredStockCashNotDeclared_76BF69921F45864CE6A1F8A7AD4CB347" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividends, Preferred Stock, Cash, Not Declared</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DividendsPreferredStockCashNotDeclared" xlink:label="loc_tbio_DividendsPreferredStockCashNotDeclared_76BF69921F45864CE6A1F8A7AD4CB347" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_DividendsPreferredStockCashNotDeclared_76BF69921F45864CE6A1F8A7AD4CB347" xlink:to="lab_tbio_DividendsPreferredStockCashNotDeclared_76BF69921F45864CE6A1F8A7AD4CB347" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6FA723D2B2A52EF6AB7B94CAF11BAFEA_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_B60B3547757D5294980957A5A9DC0AA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6FA723D2B2A52EF6AB7B94CAF11BAFEA_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_B60B3547757D5294980957A5A9DC0AA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_B60B3547757D5294980957A5A9DC0AA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_B60B3547757D5294980957A5A9DC0AA7" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_B60B3547757D5294980957A5A9DC0AA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_CD31711393080966D0B5F89321D4FC8E_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_CD31711393080966D0B5F89321D4FC8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_CD31711393080966D0B5F89321D4FC8E_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_CD31711393080966D0B5F89321D4FC8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_CD31711393080966D0B5F89321D4FC8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_CD31711393080966D0B5F89321D4FC8E" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_CD31711393080966D0B5F89321D4FC8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE" xlink:to="lab_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_65B350A8A0317A498FCBF89321D4F3D1_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_65B350A8A0317A498FCBF89321D4F3D1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_65B350A8A0317A498FCBF89321D4F3D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_65B350A8A0317A498FCBF89321D4F3D1" xlink:to="lab_us-gaap_PreferredStockMember_65B350A8A0317A498FCBF89321D4F3D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_D8B40C5962EF319AECBEF89321D5A269_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_D8B40C5962EF319AECBEF89321D5A269" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_D8B40C5962EF319AECBEF89321D5A269_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_D8B40C5962EF319AECBEF89321D5A269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_D8B40C5962EF319AECBEF89321D5A269" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_D8B40C5962EF319AECBEF89321D5A269" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_D8B40C5962EF319AECBEF89321D5A269" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_B4A8B5402489B7EE0351F89321D5F8B2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_B4A8B5402489B7EE0351F89321D5F8B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_B4A8B5402489B7EE0351F89321D5F8B2_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_B4A8B5402489B7EE0351F89321D5F8B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B4A8B5402489B7EE0351F89321D5F8B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_B4A8B5402489B7EE0351F89321D5F8B2" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_B4A8B5402489B7EE0351F89321D5F8B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_45501EF938DF6B2BE5CBF89321D5A490_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_45501EF938DF6B2BE5CBF89321D5A490" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Private placement, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_45501EF938DF6B2BE5CBF89321D5A490_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_45501EF938DF6B2BE5CBF89321D5A490" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_45501EF938DF6B2BE5CBF89321D5A490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_45501EF938DF6B2BE5CBF89321D5A490" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_45501EF938DF6B2BE5CBF89321D5A490" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5B45FAD27B46CFDA3F69F89321D51D4B_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5B45FAD27B46CFDA3F69F89321D51D4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrant, exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5B45FAD27B46CFDA3F69F89321D51D4B_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5B45FAD27B46CFDA3F69F89321D51D4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5B45FAD27B46CFDA3F69F89321D51D4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5B45FAD27B46CFDA3F69F89321D51D4B" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5B45FAD27B46CFDA3F69F89321D51D4B" xlink:type="arc" />
    <link:label id="lab_tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote_76C8303CE2B4EBA88D79F89321D6D427_terseLabel_en-US" xlink:label="lab_tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote_76C8303CE2B4EBA88D79F89321D6D427" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes, number of securities called by note</link:label>
    <link:label id="lab_tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote_76C8303CE2B4EBA88D79F89321D6D427_label_en-US" xlink:label="lab_tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote_76C8303CE2B4EBA88D79F89321D6D427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible notes, Number of Securities Called by Note</link:label>
    <link:label id="lab_tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote_76C8303CE2B4EBA88D79F89321D6D427_documentation_en-US" xlink:label="lab_tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote_76C8303CE2B4EBA88D79F89321D6D427" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible notes, Number of Securities Called by Note</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote" xlink:label="loc_tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote_76C8303CE2B4EBA88D79F89321D6D427" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote_76C8303CE2B4EBA88D79F89321D6D427" xlink:to="lab_tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote_76C8303CE2B4EBA88D79F89321D6D427" xlink:type="arc" />
    <link:label id="lab_tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes_B13477710B0ABFC4BF2BF89338B6A1DD_terseLabel_en-US" xlink:label="lab_tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes_B13477710B0ABFC4BF2BF89338B6A1DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock and convertible notes</link:label>
    <link:label id="lab_tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes_B13477710B0ABFC4BF2BF89338B6A1DD_label_en-US" xlink:label="lab_tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes_B13477710B0ABFC4BF2BF89338B6A1DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock and convertible notes</link:label>
    <link:label id="lab_tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes_B13477710B0ABFC4BF2BF89338B6A1DD_documentation_en-US" xlink:label="lab_tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes_B13477710B0ABFC4BF2BF89338B6A1DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock and convertible notes</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes" xlink:label="loc_tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes_B13477710B0ABFC4BF2BF89338B6A1DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes_B13477710B0ABFC4BF2BF89338B6A1DD" xlink:to="lab_tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes_B13477710B0ABFC4BF2BF89338B6A1DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_6C206152D9FDBE32D167F89321D595BD_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_6C206152D9FDBE32D167F89321D595BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_6C206152D9FDBE32D167F89321D595BD_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_6C206152D9FDBE32D167F89321D595BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6C206152D9FDBE32D167F89321D595BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_6C206152D9FDBE32D167F89321D595BD" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_6C206152D9FDBE32D167F89321D595BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_7DD017678FE0484E712BF89339CDF98E_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage_7DD017678FE0484E712BF89339CDF98E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, dividend rate (percentage)</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_7DD017678FE0484E712BF89339CDF98E_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage_7DD017678FE0484E712BF89339CDF98E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_7DD017678FE0484E712BF89339CDF98E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePercentage_7DD017678FE0484E712BF89339CDF98E" xlink:to="lab_us-gaap_PreferredStockDividendRatePercentage_7DD017678FE0484E712BF89339CDF98E" xlink:type="arc" />
    <link:label id="lab_tbio_PreferredStockDividendRateCompoundPercentageMaximum_7F5CA36515D2B00DBF47F8933A18D96E_terseLabel_en-US" xlink:label="lab_tbio_PreferredStockDividendRateCompoundPercentageMaximum_7F5CA36515D2B00DBF47F8933A18D96E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, compound dividend rate maximum (percentage)</link:label>
    <link:label id="lab_tbio_PreferredStockDividendRateCompoundPercentageMaximum_7F5CA36515D2B00DBF47F8933A18D96E_label_en-US" xlink:label="lab_tbio_PreferredStockDividendRateCompoundPercentageMaximum_7F5CA36515D2B00DBF47F8933A18D96E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Dividend Rate, Compound Percentage Maximum</link:label>
    <link:label id="lab_tbio_PreferredStockDividendRateCompoundPercentageMaximum_7F5CA36515D2B00DBF47F8933A18D96E_documentation_en-US" xlink:label="lab_tbio_PreferredStockDividendRateCompoundPercentageMaximum_7F5CA36515D2B00DBF47F8933A18D96E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock, Dividend Rate, Compound Percentage Maximum</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PreferredStockDividendRateCompoundPercentageMaximum" xlink:label="loc_tbio_PreferredStockDividendRateCompoundPercentageMaximum_7F5CA36515D2B00DBF47F8933A18D96E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_PreferredStockDividendRateCompoundPercentageMaximum_7F5CA36515D2B00DBF47F8933A18D96E" xlink:to="lab_tbio_PreferredStockDividendRateCompoundPercentageMaximum_7F5CA36515D2B00DBF47F8933A18D96E" xlink:type="arc" />
    <link:label id="lab_tbio_NumberOfDirectors_D5C820E68337C3ED7EBBF8933A533F42_terseLabel_en-US" xlink:label="lab_tbio_NumberOfDirectors_D5C820E68337C3ED7EBBF8933A533F42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of directors</link:label>
    <link:label id="lab_tbio_NumberOfDirectors_D5C820E68337C3ED7EBBF8933A533F42_label_en-US" xlink:label="lab_tbio_NumberOfDirectors_D5C820E68337C3ED7EBBF8933A533F42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Directors</link:label>
    <link:label id="lab_tbio_NumberOfDirectors_D5C820E68337C3ED7EBBF8933A533F42_documentation_en-US" xlink:label="lab_tbio_NumberOfDirectors_D5C820E68337C3ED7EBBF8933A533F42" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Directors</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_NumberOfDirectors" xlink:label="loc_tbio_NumberOfDirectors_D5C820E68337C3ED7EBBF8933A533F42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_NumberOfDirectors_D5C820E68337C3ED7EBBF8933A533F42" xlink:to="lab_tbio_NumberOfDirectors_D5C820E68337C3ED7EBBF8933A533F42" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_950D41B97D4B32BAA28BF89381FCC2E1_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_950D41B97D4B32BAA28BF89381FCC2E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption value adjustment</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_950D41B97D4B32BAA28BF89381FCC2E1_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_950D41B97D4B32BAA28BF89381FCC2E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value, Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_950D41B97D4B32BAA28BF89381FCC2E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_950D41B97D4B32BAA28BF89381FCC2E1" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_950D41B97D4B32BAA28BF89381FCC2E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1FA89DC83D2C2071D9ADF99435E43B38_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1FA89DC83D2C2071D9ADF99435E43B38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1FA89DC83D2C2071D9ADF99435E43B38_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1FA89DC83D2C2071D9ADF99435E43B38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1FA89DC83D2C2071D9ADF99435E43B38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1FA89DC83D2C2071D9ADF99435E43B38" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1FA89DC83D2C2071D9ADF99435E43B38" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_3F6C867C60E57FA7BBDFF99435E44558_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_3F6C867C60E57FA7BBDFF99435E44558" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_3F6C867C60E57FA7BBDFF99435E44558_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_3F6C867C60E57FA7BBDFF99435E44558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_3F6C867C60E57FA7BBDFF99435E44558" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_3F6C867C60E57FA7BBDFF99435E44558" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_3F6C867C60E57FA7BBDFF99435E44558" xlink:type="arc" />
    <link:label id="lab_tbio_RisksAndUncertaintiesPolicyTextBlock_464684861CFFAB54AFD0F99435E444CB_terseLabel_en-US" xlink:label="lab_tbio_RisksAndUncertaintiesPolicyTextBlock_464684861CFFAB54AFD0F99435E444CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:label id="lab_tbio_RisksAndUncertaintiesPolicyTextBlock_464684861CFFAB54AFD0F99435E444CB_label_en-US" xlink:label="lab_tbio_RisksAndUncertaintiesPolicyTextBlock_464684861CFFAB54AFD0F99435E444CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Policy Text Block]</link:label>
    <link:label id="lab_tbio_RisksAndUncertaintiesPolicyTextBlock_464684861CFFAB54AFD0F99435E444CB_documentation_en-US" xlink:label="lab_tbio_RisksAndUncertaintiesPolicyTextBlock_464684861CFFAB54AFD0F99435E444CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Policy Text Block]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_tbio_RisksAndUncertaintiesPolicyTextBlock_464684861CFFAB54AFD0F99435E444CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_RisksAndUncertaintiesPolicyTextBlock_464684861CFFAB54AFD0F99435E444CB" xlink:to="lab_tbio_RisksAndUncertaintiesPolicyTextBlock_464684861CFFAB54AFD0F99435E444CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_259B1D3010B23E0E0CC7F99435E4F19C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_259B1D3010B23E0E0CC7F99435E4F19C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_259B1D3010B23E0E0CC7F99435E4F19C_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_259B1D3010B23E0E0CC7F99435E4F19C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_259B1D3010B23E0E0CC7F99435E4F19C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_259B1D3010B23E0E0CC7F99435E4F19C" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_259B1D3010B23E0E0CC7F99435E4F19C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9984F63EC18D8A2664DDF99435E4AD36_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9984F63EC18D8A2664DDF99435E4AD36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9984F63EC18D8A2664DDF99435E4AD36_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9984F63EC18D8A2664DDF99435E4AD36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9984F63EC18D8A2664DDF99435E4AD36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9984F63EC18D8A2664DDF99435E4AD36" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9984F63EC18D8A2664DDF99435E4AD36" xlink:type="arc" />
    <link:label id="lab_tbio_ConcentrationOfCashPolicyPolicyTextBlock_196FD2D4005ED4058FB4F99435E488B2_terseLabel_en-US" xlink:label="lab_tbio_ConcentrationOfCashPolicyPolicyTextBlock_196FD2D4005ED4058FB4F99435E488B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Cash</link:label>
    <link:label id="lab_tbio_ConcentrationOfCashPolicyPolicyTextBlock_196FD2D4005ED4058FB4F99435E488B2_label_en-US" xlink:label="lab_tbio_ConcentrationOfCashPolicyPolicyTextBlock_196FD2D4005ED4058FB4F99435E488B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of Cash Policy [Policy Text Block]</link:label>
    <link:label id="lab_tbio_ConcentrationOfCashPolicyPolicyTextBlock_196FD2D4005ED4058FB4F99435E488B2_documentation_en-US" xlink:label="lab_tbio_ConcentrationOfCashPolicyPolicyTextBlock_196FD2D4005ED4058FB4F99435E488B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration of Cash Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ConcentrationOfCashPolicyPolicyTextBlock" xlink:label="loc_tbio_ConcentrationOfCashPolicyPolicyTextBlock_196FD2D4005ED4058FB4F99435E488B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_ConcentrationOfCashPolicyPolicyTextBlock_196FD2D4005ED4058FB4F99435E488B2" xlink:to="lab_tbio_ConcentrationOfCashPolicyPolicyTextBlock_196FD2D4005ED4058FB4F99435E488B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7F16BE17EE177ECB1E45F99435E5A87D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7F16BE17EE177ECB1E45F99435E5A87D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7F16BE17EE177ECB1E45F99435E5A87D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7F16BE17EE177ECB1E45F99435E5A87D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7F16BE17EE177ECB1E45F99435E5A87D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7F16BE17EE177ECB1E45F99435E5A87D" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7F16BE17EE177ECB1E45F99435E5A87D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_E9A730000038DC698D01F99435E5485A_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_E9A730000038DC698D01F99435E5485A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Sales Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_E9A730000038DC698D01F99435E5485A_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_E9A730000038DC698D01F99435E5485A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_E9A730000038DC698D01F99435E5485A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_E9A730000038DC698D01F99435E5485A" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_E9A730000038DC698D01F99435E5485A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_7A2B5B5F2A2258BE86F3F99435E51523_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_7A2B5B5F2A2258BE86F3F99435E51523" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_7A2B5B5F2A2258BE86F3F99435E51523_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_7A2B5B5F2A2258BE86F3F99435E51523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7A2B5B5F2A2258BE86F3F99435E51523" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_7A2B5B5F2A2258BE86F3F99435E51523" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_7A2B5B5F2A2258BE86F3F99435E51523" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BABBA85E8B02D73EFAE2F99435E5673F_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BABBA85E8B02D73EFAE2F99435E5673F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BABBA85E8B02D73EFAE2F99435E5673F_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BABBA85E8B02D73EFAE2F99435E5673F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BABBA85E8B02D73EFAE2F99435E5673F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BABBA85E8B02D73EFAE2F99435E5673F" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BABBA85E8B02D73EFAE2F99435E5673F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_B8EC1FB220FEB16362EF94CAF206E187_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E4373E3AA12D575BB060DC0027829017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_B8EC1FB220FEB16362EF94CAF206E187_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E4373E3AA12D575BB060DC0027829017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E4373E3AA12D575BB060DC0027829017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E4373E3AA12D575BB060DC0027829017" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E4373E3AA12D575BB060DC0027829017" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_8D573AFB1774DF09E5D7E97089D0E915_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_8D573AFB1774DF09E5D7E97089D0E915" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_8D573AFB1774DF09E5D7E97089D0E915_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_8D573AFB1774DF09E5D7E97089D0E915" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8D573AFB1774DF09E5D7E97089D0E915" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_8D573AFB1774DF09E5D7E97089D0E915" xlink:to="lab_us-gaap_AwardTypeAxis_8D573AFB1774DF09E5D7E97089D0E915" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E1D213561DABD7AF9B85E97089D0B0B1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E1D213561DABD7AF9B85E97089D0B0B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E1D213561DABD7AF9B85E97089D0B0B1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E1D213561DABD7AF9B85E97089D0B0B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E1D213561DABD7AF9B85E97089D0B0B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E1D213561DABD7AF9B85E97089D0B0B1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E1D213561DABD7AF9B85E97089D0B0B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_F5B467B1DBB809D77B19E97089D04385_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_F5B467B1DBB809D77B19E97089D04385" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_F5B467B1DBB809D77B19E97089D04385_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_F5B467B1DBB809D77B19E97089D04385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F5B467B1DBB809D77B19E97089D04385" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_F5B467B1DBB809D77B19E97089D04385" xlink:to="lab_us-gaap_EmployeeStockOptionMember_F5B467B1DBB809D77B19E97089D04385" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_110795FDDD57918167CAE97089D14A02_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_110795FDDD57918167CAE97089D14A02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_110795FDDD57918167CAE97089D14A02_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_110795FDDD57918167CAE97089D14A02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_110795FDDD57918167CAE97089D14A02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_110795FDDD57918167CAE97089D14A02" xlink:to="lab_us-gaap_PlanNameAxis_110795FDDD57918167CAE97089D14A02" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_E03008731366CAA3C04DE97089D1A60C_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_E03008731366CAA3C04DE97089D1A60C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_E03008731366CAA3C04DE97089D1A60C_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_E03008731366CAA3C04DE97089D1A60C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E03008731366CAA3C04DE97089D1A60C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_E03008731366CAA3C04DE97089D1A60C" xlink:to="lab_us-gaap_PlanNameDomain_E03008731366CAA3C04DE97089D1A60C" xlink:type="arc" />
    <link:label id="lab_tbio_EquityIncentivePlan2006Member_200434173A6BAB7F1FC6E97089D181B6_terseLabel_en-US" xlink:label="lab_tbio_EquityIncentivePlan2006Member_200434173A6BAB7F1FC6E97089D181B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2006</link:label>
    <link:label id="lab_tbio_EquityIncentivePlan2006Member_200434173A6BAB7F1FC6E97089D181B6_label_en-US" xlink:label="lab_tbio_EquityIncentivePlan2006Member_200434173A6BAB7F1FC6E97089D181B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2006 [Member]</link:label>
    <link:label id="lab_tbio_EquityIncentivePlan2006Member_200434173A6BAB7F1FC6E97089D181B6_documentation_en-US" xlink:label="lab_tbio_EquityIncentivePlan2006Member_200434173A6BAB7F1FC6E97089D181B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2006 [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_EquityIncentivePlan2006Member" xlink:label="loc_tbio_EquityIncentivePlan2006Member_200434173A6BAB7F1FC6E97089D181B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_EquityIncentivePlan2006Member_200434173A6BAB7F1FC6E97089D181B6" xlink:to="lab_tbio_EquityIncentivePlan2006Member_200434173A6BAB7F1FC6E97089D181B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9688A779E36B78976D78E97089D1C19E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9688A779E36B78976D78E97089D1C19E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9688A779E36B78976D78E97089D1C19E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9688A779E36B78976D78E97089D1C19E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9688A779E36B78976D78E97089D1C19E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9688A779E36B78976D78E97089D1C19E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9688A779E36B78976D78E97089D1C19E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4873A0B672D28BAD8D77E97089D1E451_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4873A0B672D28BAD8D77E97089D1E451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4873A0B672D28BAD8D77E97089D1E451_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4873A0B672D28BAD8D77E97089D1E451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4873A0B672D28BAD8D77E97089D1E451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4873A0B672D28BAD8D77E97089D1E451" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4873A0B672D28BAD8D77E97089D1E451" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0E1925642A2252F33980E97089D1E3B2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0E1925642A2252F33980E97089D1E3B2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0E1925642A2252F33980E97089D1E3B2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0E1925642A2252F33980E97089D1E3B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0E1925642A2252F33980E97089D1E3B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0E1925642A2252F33980E97089D1E3B2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0E1925642A2252F33980E97089D1E3B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_210938FF7FE295E5F1EDE97089D1B844_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_210938FF7FE295E5F1EDE97089D1B844" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_210938FF7FE295E5F1EDE97089D1B844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_210938FF7FE295E5F1EDE97089D1B844" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_210938FF7FE295E5F1EDE97089D1B844" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_F94395364C22834E83DAE97089D1817E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_F94395364C22834E83DAE97089D1817E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_F94395364C22834E83DAE97089D1817E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_F94395364C22834E83DAE97089D1817E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_F94395364C22834E83DAE97089D1817E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_F94395364C22834E83DAE97089D1817E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_F94395364C22834E83DAE97089D1817E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C2C9233362DFB3A0AC61E97089D19FA6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C2C9233362DFB3A0AC61E97089D19FA6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C2C9233362DFB3A0AC61E97089D19FA6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C2C9233362DFB3A0AC61E97089D19FA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C2C9233362DFB3A0AC61E97089D19FA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C2C9233362DFB3A0AC61E97089D19FA6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C2C9233362DFB3A0AC61E97089D19FA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E1EE996B9A03AA00A59EE97089D1FACE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E1EE996B9A03AA00A59EE97089D1FACE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E1EE996B9A03AA00A59EE97089D1FACE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E1EE996B9A03AA00A59EE97089D1FACE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E1EE996B9A03AA00A59EE97089D1FACE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E1EE996B9A03AA00A59EE97089D1FACE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E1EE996B9A03AA00A59EE97089D1FACE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_098155652C041C21BF5AE97089D196FC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_098155652C041C21BF5AE97089D196FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_098155652C041C21BF5AE97089D196FC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_098155652C041C21BF5AE97089D196FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_098155652C041C21BF5AE97089D196FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_098155652C041C21BF5AE97089D196FC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_098155652C041C21BF5AE97089D196FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_428EA25167C4245AF22EE97089D1628B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_428EA25167C4245AF22EE97089D1628B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_428EA25167C4245AF22EE97089D1628B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_428EA25167C4245AF22EE97089D1628B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_428EA25167C4245AF22EE97089D1628B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_BFC11917445D4967E368E97089D1A2B8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_BFC11917445D4967E368E97089D1A2B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_BFC11917445D4967E368E97089D1A2B8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_BFC11917445D4967E368E97089D1A2B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_BFC11917445D4967E368E97089D1A2B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_BFC11917445D4967E368E97089D1A2B8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_BFC11917445D4967E368E97089D1A2B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32859C42ECD2BE9C14A0E97089D259C5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32859C42ECD2BE9C14A0E97089D259C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, expected to vest, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32859C42ECD2BE9C14A0E97089D259C5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32859C42ECD2BE9C14A0E97089D259C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32859C42ECD2BE9C14A0E97089D259C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32859C42ECD2BE9C14A0E97089D259C5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32859C42ECD2BE9C14A0E97089D259C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5F26EA2A82E7B09A8510E97089D2C714_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5F26EA2A82E7B09A8510E97089D2C714" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, expected to vest, outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5F26EA2A82E7B09A8510E97089D2C714_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5F26EA2A82E7B09A8510E97089D2C714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5F26EA2A82E7B09A8510E97089D2C714" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5F26EA2A82E7B09A8510E97089D2C714" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5F26EA2A82E7B09A8510E97089D2C714" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_53931938E679D65912B8E9DAB9F889AA_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_53931938E679D65912B8E9DAB9F889AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, expected to vest remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_53931938E679D65912B8E9DAB9F889AA_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_53931938E679D65912B8E9DAB9F889AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_53931938E679D65912B8E9DAB9F889AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_53931938E679D65912B8E9DAB9F889AA" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_53931938E679D65912B8E9DAB9F889AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_3F274008BD9D0552CE00F99435F09DAE_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_3F274008BD9D0552CE00F99435F09DAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3F274008BD9D0552CE00F99435F09DAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3F274008BD9D0552CE00F99435F09DAE" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_3F274008BD9D0552CE00F99435F09DAE" xlink:type="arc" />
    <link:label id="lab_tbio_WarrantyHoldersAndIssuanceAxis_32C6F0E5F7CA8B8AD5FEF864D9AD4E73_terseLabel_en-US" xlink:label="lab_tbio_WarrantyHoldersAndIssuanceAxis_32C6F0E5F7CA8B8AD5FEF864D9AD4E73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warranty Holders and Issuance [Axis]</link:label>
    <link:label id="lab_tbio_WarrantyHoldersAndIssuanceAxis_32C6F0E5F7CA8B8AD5FEF864D9AD4E73_label_en-US" xlink:label="lab_tbio_WarrantyHoldersAndIssuanceAxis_32C6F0E5F7CA8B8AD5FEF864D9AD4E73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warranty Holders and Issuance [Axis]</link:label>
    <link:label id="lab_tbio_WarrantyHoldersAndIssuanceAxis_32C6F0E5F7CA8B8AD5FEF864D9AD4E73_documentation_en-US" xlink:label="lab_tbio_WarrantyHoldersAndIssuanceAxis_32C6F0E5F7CA8B8AD5FEF864D9AD4E73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warranty Holders and Issuance [Axis]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceAxis" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceAxis_32C6F0E5F7CA8B8AD5FEF864D9AD4E73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceAxis_32C6F0E5F7CA8B8AD5FEF864D9AD4E73" xlink:to="lab_tbio_WarrantyHoldersAndIssuanceAxis_32C6F0E5F7CA8B8AD5FEF864D9AD4E73" xlink:type="arc" />
    <link:label id="lab_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292_terseLabel_en-US" xlink:label="lab_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warranty Holders and Issuance [Domain]</link:label>
    <link:label id="lab_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292_label_en-US" xlink:label="lab_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warranty Holders and Issuance [Domain]</link:label>
    <link:label id="lab_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292_documentation_en-US" xlink:label="lab_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warranty Holders and Issuance [Domain]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceDomain" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="lab_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:type="arc" />
    <link:label id="lab_tbio_VariousInstitutionalHoldersJanuary2018Member_EA77125991AB12F0DD06F864D9AD190C_terseLabel_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersJanuary2018Member_EA77125991AB12F0DD06F864D9AD190C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2018</link:label>
    <link:label id="lab_tbio_VariousInstitutionalHoldersJanuary2018Member_EA77125991AB12F0DD06F864D9AD190C_label_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersJanuary2018Member_EA77125991AB12F0DD06F864D9AD190C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2018 [Member]</link:label>
    <link:label id="lab_tbio_VariousInstitutionalHoldersJanuary2018Member_EA77125991AB12F0DD06F864D9AD190C_documentation_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersJanuary2018Member_EA77125991AB12F0DD06F864D9AD190C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2018 [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersJanuary2018Member" xlink:label="loc_tbio_VariousInstitutionalHoldersJanuary2018Member_EA77125991AB12F0DD06F864D9AD190C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_VariousInstitutionalHoldersJanuary2018Member_EA77125991AB12F0DD06F864D9AD190C" xlink:to="lab_tbio_VariousInstitutionalHoldersJanuary2018Member_EA77125991AB12F0DD06F864D9AD190C" xlink:type="arc" />
    <link:label id="lab_tbio_AffiliatesofThirdSecurityLLCJanuary2018Member_10250DCD19246BC38A98F864D9ADE770_terseLabel_en-US" xlink:label="lab_tbio_AffiliatesofThirdSecurityLLCJanuary2018Member_10250DCD19246BC38A98F864D9ADE770" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of Third Security, LLC; January 2018</link:label>
    <link:label id="lab_tbio_AffiliatesofThirdSecurityLLCJanuary2018Member_10250DCD19246BC38A98F864D9ADE770_label_en-US" xlink:label="lab_tbio_AffiliatesofThirdSecurityLLCJanuary2018Member_10250DCD19246BC38A98F864D9ADE770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliates of Third Security, LLC; January 2018 [Member]</link:label>
    <link:label id="lab_tbio_AffiliatesofThirdSecurityLLCJanuary2018Member_10250DCD19246BC38A98F864D9ADE770_documentation_en-US" xlink:label="lab_tbio_AffiliatesofThirdSecurityLLCJanuary2018Member_10250DCD19246BC38A98F864D9ADE770" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliates of Third Security, LLC; January 2018 [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AffiliatesofThirdSecurityLLCJanuary2018Member" xlink:label="loc_tbio_AffiliatesofThirdSecurityLLCJanuary2018Member_10250DCD19246BC38A98F864D9ADE770" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_AffiliatesofThirdSecurityLLCJanuary2018Member_10250DCD19246BC38A98F864D9ADE770" xlink:to="lab_tbio_AffiliatesofThirdSecurityLLCJanuary2018Member_10250DCD19246BC38A98F864D9ADE770" xlink:type="arc" />
    <link:label id="lab_tbio_VariousInstitutionalHoldersApril2020Member_221E901F173036A38F42F864D9AD35ED_terseLabel_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersApril2020Member_221E901F173036A38F42F864D9AD35ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; April 2020</link:label>
    <link:label id="lab_tbio_VariousInstitutionalHoldersApril2020Member_221E901F173036A38F42F864D9AD35ED_label_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersApril2020Member_221E901F173036A38F42F864D9AD35ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; April 2020 [Member]</link:label>
    <link:label id="lab_tbio_VariousInstitutionalHoldersApril2020Member_221E901F173036A38F42F864D9AD35ED_documentation_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersApril2020Member_221E901F173036A38F42F864D9AD35ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; April 2020 [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersApril2020Member" xlink:label="loc_tbio_VariousInstitutionalHoldersApril2020Member_221E901F173036A38F42F864D9AD35ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_VariousInstitutionalHoldersApril2020Member_221E901F173036A38F42F864D9AD35ED" xlink:to="lab_tbio_VariousInstitutionalHoldersApril2020Member_221E901F173036A38F42F864D9AD35ED" xlink:type="arc" />
    <link:label id="lab_tbio_VariousInstitutionalHoldersFebruary2020Member_00EB76114B081FB32FB3F864D9AD3D5E_terseLabel_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersFebruary2020Member_00EB76114B081FB32FB3F864D9AD3D5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; February 2020</link:label>
    <link:label id="lab_tbio_VariousInstitutionalHoldersFebruary2020Member_00EB76114B081FB32FB3F864D9AD3D5E_label_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersFebruary2020Member_00EB76114B081FB32FB3F864D9AD3D5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; February 2020 [Member]</link:label>
    <link:label id="lab_tbio_VariousInstitutionalHoldersFebruary2020Member_00EB76114B081FB32FB3F864D9AD3D5E_documentation_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersFebruary2020Member_00EB76114B081FB32FB3F864D9AD3D5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; February 2020 [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersFebruary2020Member" xlink:label="loc_tbio_VariousInstitutionalHoldersFebruary2020Member_00EB76114B081FB32FB3F864D9AD3D5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_VariousInstitutionalHoldersFebruary2020Member_00EB76114B081FB32FB3F864D9AD3D5E" xlink:to="lab_tbio_VariousInstitutionalHoldersFebruary2020Member_00EB76114B081FB32FB3F864D9AD3D5E" xlink:type="arc" />
    <link:label id="lab_tbio_VariousInstitutionalHoldersDecember2020OneMember_137D9F7AD169D6E38764F864D9ADA55A_terseLabel_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersDecember2020OneMember_137D9F7AD169D6E38764F864D9ADA55A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; December 2020</link:label>
    <link:label id="lab_tbio_VariousInstitutionalHoldersDecember2020OneMember_137D9F7AD169D6E38764F864D9ADA55A_label_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersDecember2020OneMember_137D9F7AD169D6E38764F864D9ADA55A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; December 2020 One [Member]</link:label>
    <link:label id="lab_tbio_VariousInstitutionalHoldersDecember2020OneMember_137D9F7AD169D6E38764F864D9ADA55A_documentation_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersDecember2020OneMember_137D9F7AD169D6E38764F864D9ADA55A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; December 2020 One [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersDecember2020OneMember" xlink:label="loc_tbio_VariousInstitutionalHoldersDecember2020OneMember_137D9F7AD169D6E38764F864D9ADA55A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_VariousInstitutionalHoldersDecember2020OneMember_137D9F7AD169D6E38764F864D9ADA55A" xlink:to="lab_tbio_VariousInstitutionalHoldersDecember2020OneMember_137D9F7AD169D6E38764F864D9ADA55A" xlink:type="arc" />
    <link:label id="lab_tbio_VariousInstitutionalHoldersJanuary2021OneMember_D4459DEA92D97356D8FAF864D9ADDA7F_terseLabel_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersJanuary2021OneMember_D4459DEA92D97356D8FAF864D9ADDA7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2021</link:label>
    <link:label id="lab_tbio_VariousInstitutionalHoldersJanuary2021OneMember_D4459DEA92D97356D8FAF864D9ADDA7F_label_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersJanuary2021OneMember_D4459DEA92D97356D8FAF864D9ADDA7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2021 One [Member]</link:label>
    <link:label id="lab_tbio_VariousInstitutionalHoldersJanuary2021OneMember_D4459DEA92D97356D8FAF864D9ADDA7F_documentation_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersJanuary2021OneMember_D4459DEA92D97356D8FAF864D9ADDA7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2021 One [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersJanuary2021OneMember" xlink:label="loc_tbio_VariousInstitutionalHoldersJanuary2021OneMember_D4459DEA92D97356D8FAF864D9ADDA7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_VariousInstitutionalHoldersJanuary2021OneMember_D4459DEA92D97356D8FAF864D9ADDA7F" xlink:to="lab_tbio_VariousInstitutionalHoldersJanuary2021OneMember_D4459DEA92D97356D8FAF864D9ADDA7F" xlink:type="arc" />
    <link:label id="lab_tbio_AffiliatesofThirdSecurityLLCJanuary2021Member_49A330F8AE829C841B53F864D9AD2881_terseLabel_en-US" xlink:label="lab_tbio_AffiliatesofThirdSecurityLLCJanuary2021Member_49A330F8AE829C841B53F864D9AD2881" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of Third Security, LLC; January 2021</link:label>
    <link:label id="lab_tbio_AffiliatesofThirdSecurityLLCJanuary2021Member_49A330F8AE829C841B53F864D9AD2881_label_en-US" xlink:label="lab_tbio_AffiliatesofThirdSecurityLLCJanuary2021Member_49A330F8AE829C841B53F864D9AD2881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliates of Third Security, LLC; January 2021 [Member]</link:label>
    <link:label id="lab_tbio_AffiliatesofThirdSecurityLLCJanuary2021Member_49A330F8AE829C841B53F864D9AD2881_documentation_en-US" xlink:label="lab_tbio_AffiliatesofThirdSecurityLLCJanuary2021Member_49A330F8AE829C841B53F864D9AD2881" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliates of Third Security, LLC; January 2021 [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AffiliatesofThirdSecurityLLCJanuary2021Member" xlink:label="loc_tbio_AffiliatesofThirdSecurityLLCJanuary2021Member_49A330F8AE829C841B53F864D9AD2881" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_AffiliatesofThirdSecurityLLCJanuary2021Member_49A330F8AE829C841B53F864D9AD2881" xlink:to="lab_tbio_AffiliatesofThirdSecurityLLCJanuary2021Member_49A330F8AE829C841B53F864D9AD2881" xlink:type="arc" />
    <link:label id="lab_tbio_VariousInstitutionalHoldersJanuary2021TwoMember_B4827F0E66E751828CF4F864D9ADBE5A_terseLabel_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersJanuary2021TwoMember_B4827F0E66E751828CF4F864D9ADBE5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2021</link:label>
    <link:label id="lab_tbio_VariousInstitutionalHoldersJanuary2021TwoMember_B4827F0E66E751828CF4F864D9ADBE5A_label_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersJanuary2021TwoMember_B4827F0E66E751828CF4F864D9ADBE5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2021 Two [Member]</link:label>
    <link:label id="lab_tbio_VariousInstitutionalHoldersJanuary2021TwoMember_B4827F0E66E751828CF4F864D9ADBE5A_documentation_en-US" xlink:label="lab_tbio_VariousInstitutionalHoldersJanuary2021TwoMember_B4827F0E66E751828CF4F864D9ADBE5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2021 Two [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersJanuary2021TwoMember" xlink:label="loc_tbio_VariousInstitutionalHoldersJanuary2021TwoMember_B4827F0E66E751828CF4F864D9ADBE5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_VariousInstitutionalHoldersJanuary2021TwoMember_B4827F0E66E751828CF4F864D9ADBE5A" xlink:to="lab_tbio_VariousInstitutionalHoldersJanuary2021TwoMember_B4827F0E66E751828CF4F864D9ADBE5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_EB2DBC6F5FD1F8561C34F864D9AD191A_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_EB2DBC6F5FD1F8561C34F864D9AD191A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_EB2DBC6F5FD1F8561C34F864D9AD191A_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_EB2DBC6F5FD1F8561C34F864D9AD191A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_EB2DBC6F5FD1F8561C34F864D9AD191A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_EB2DBC6F5FD1F8561C34F864D9AD191A" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_EB2DBC6F5FD1F8561C34F864D9AD191A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrivatePlacementMember_FFA6626469636ADD68D7F864D9AD0292_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember_FFA6626469636ADD68D7F864D9AD0292" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_FFA6626469636ADD68D7F864D9AD0292_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember_FFA6626469636ADD68D7F864D9AD0292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_FFA6626469636ADD68D7F864D9AD0292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_FFA6626469636ADD68D7F864D9AD0292" xlink:to="lab_us-gaap_PrivatePlacementMember_FFA6626469636ADD68D7F864D9AD0292" xlink:type="arc" />
    <link:label id="lab_tbio_OfferingMember_0B94FB93F9CFC02BAD12F864D9ADF752_terseLabel_en-US" xlink:label="lab_tbio_OfferingMember_0B94FB93F9CFC02BAD12F864D9ADF752" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering</link:label>
    <link:label id="lab_tbio_OfferingMember_0B94FB93F9CFC02BAD12F864D9ADF752_label_en-US" xlink:label="lab_tbio_OfferingMember_0B94FB93F9CFC02BAD12F864D9ADF752" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering [Member]</link:label>
    <link:label id="lab_tbio_OfferingMember_0B94FB93F9CFC02BAD12F864D9ADF752_documentation_en-US" xlink:label="lab_tbio_OfferingMember_0B94FB93F9CFC02BAD12F864D9ADF752" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Offering [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_OfferingMember" xlink:label="loc_tbio_OfferingMember_0B94FB93F9CFC02BAD12F864D9ADF752" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_OfferingMember_0B94FB93F9CFC02BAD12F864D9ADF752" xlink:to="lab_tbio_OfferingMember_0B94FB93F9CFC02BAD12F864D9ADF752" xlink:type="arc" />
    <link:label id="lab_tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired_B3D292C77B7DEE7E823DF865D30D6E13_terseLabel_en-US" xlink:label="lab_tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired_B3D292C77B7DEE7E823DF865D30D6E13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of stock warrants expired (shares)</link:label>
    <link:label id="lab_tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired_B3D292C77B7DEE7E823DF865D30D6E13_label_en-US" xlink:label="lab_tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired_B3D292C77B7DEE7E823DF865D30D6E13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Issued Warrants Expired</link:label>
    <link:label id="lab_tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired_B3D292C77B7DEE7E823DF865D30D6E13_documentation_en-US" xlink:label="lab_tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired_B3D292C77B7DEE7E823DF865D30D6E13" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Issued Warrants Expired</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired" xlink:label="loc_tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired_B3D292C77B7DEE7E823DF865D30D6E13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired_B3D292C77B7DEE7E823DF865D30D6E13" xlink:to="lab_tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired_B3D292C77B7DEE7E823DF865D30D6E13" xlink:type="arc" />
    <link:label id="lab_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_BA0802240838C4F9B52CF864D9AD0786_terseLabel_en-US" xlink:label="lab_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_BA0802240838C4F9B52CF864D9AD0786" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants issued (in shares)</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_BA0802240838C4F9B52CF864D9AD0786" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_BA0802240838C4F9B52CF864D9AD0786" xlink:to="lab_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_BA0802240838C4F9B52CF864D9AD0786" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_DDCFC3052050DF1B4F4DF864D9ADEDF0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_DDCFC3052050DF1B4F4DF864D9ADEDF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Shares</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_DDCFC3052050DF1B4F4DF864D9ADEDF0_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_DDCFC3052050DF1B4F4DF864D9ADEDF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_DDCFC3052050DF1B4F4DF864D9ADEDF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_DDCFC3052050DF1B4F4DF864D9ADEDF0" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_DDCFC3052050DF1B4F4DF864D9ADEDF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22AB4F356AE64962A675F864D9ADF51C_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22AB4F356AE64962A675F864D9ADF51C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22AB4F356AE64962A675F864D9ADF51C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22AB4F356AE64962A675F864D9ADF51C" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22AB4F356AE64962A675F864D9ADF51C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockTable_55B43033EF586C5B8476F8C18F09FA54_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockTable_55B43033EF586C5B8476F8C18F09FA54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockTable_55B43033EF586C5B8476F8C18F09FA54_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockTable_55B43033EF586C5B8476F8C18F09FA54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaap_ConversionOfStockTable_55B43033EF586C5B8476F8C18F09FA54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockTable_55B43033EF586C5B8476F8C18F09FA54" xlink:to="lab_us-gaap_ConversionOfStockTable_55B43033EF586C5B8476F8C18F09FA54" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_7129EE8FC9D06E3BBF63F8C18F09CA78_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_7129EE8FC9D06E3BBF63F8C18F09CA78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B preferred stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_7129EE8FC9D06E3BBF63F8C18F09CA78_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_7129EE8FC9D06E3BBF63F8C18F09CA78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_7129EE8FC9D06E3BBF63F8C18F09CA78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_7129EE8FC9D06E3BBF63F8C18F09CA78" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_7129EE8FC9D06E3BBF63F8C18F09CA78" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="lab_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_94180AF6E25704452099F8C18F0A5728_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_94180AF6E25704452099F8C18F0A5728" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_94180AF6E25704452099F8C18F0A5728_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_94180AF6E25704452099F8C18F0A5728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_94180AF6E25704452099F8C18F0A5728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_94180AF6E25704452099F8C18F0A5728" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_94180AF6E25704452099F8C18F0A5728" xlink:type="arc" />
    <link:label id="lab_tbio_StockholdersEquityNoteConversionRatio_55D50AF42334ED7D4DC5F8C18F0A4DF3_terseLabel_en-US" xlink:label="lab_tbio_StockholdersEquityNoteConversionRatio_55D50AF42334ED7D4DC5F8C18F0A4DF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_tbio_StockholdersEquityNoteConversionRatio_55D50AF42334ED7D4DC5F8C18F0A4DF3_label_en-US" xlink:label="lab_tbio_StockholdersEquityNoteConversionRatio_55D50AF42334ED7D4DC5F8C18F0A4DF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Conversion Ratio</link:label>
    <link:label id="lab_tbio_StockholdersEquityNoteConversionRatio_55D50AF42334ED7D4DC5F8C18F0A4DF3_documentation_en-US" xlink:label="lab_tbio_StockholdersEquityNoteConversionRatio_55D50AF42334ED7D4DC5F8C18F0A4DF3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Conversion Ratio</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockholdersEquityNoteConversionRatio" xlink:label="loc_tbio_StockholdersEquityNoteConversionRatio_55D50AF42334ED7D4DC5F8C18F0A4DF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_StockholdersEquityNoteConversionRatio_55D50AF42334ED7D4DC5F8C18F0A4DF3" xlink:to="lab_tbio_StockholdersEquityNoteConversionRatio_55D50AF42334ED7D4DC5F8C18F0A4DF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_63583B3BBF3A173DE222F8C18F0A954A_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_63583B3BBF3A173DE222F8C18F0A954A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_63583B3BBF3A173DE222F8C18F0A954A_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_63583B3BBF3A173DE222F8C18F0A954A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_63583B3BBF3A173DE222F8C18F0A954A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_63583B3BBF3A173DE222F8C18F0A954A" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_63583B3BBF3A173DE222F8C18F0A954A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockDividendsShares_31F5410EF0C97FB28529F8C18F0ABE9D_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsShares_31F5410EF0C97FB28529F8C18F0ABE9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock dividend (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsShares_31F5410EF0C97FB28529F8C18F0ABE9D_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsShares_31F5410EF0C97FB28529F8C18F0ABE9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Dividends, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockDividendsShares" xlink:label="loc_us-gaap_CommonStockDividendsShares_31F5410EF0C97FB28529F8C18F0ABE9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsShares_31F5410EF0C97FB28529F8C18F0ABE9D" xlink:to="lab_us-gaap_CommonStockDividendsShares_31F5410EF0C97FB28529F8C18F0ABE9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockDividendsShares_F051A15CE70E69F81827F8C18F0A4990_terseLabel_en-US" xlink:label="lab_us-gaap_StockDividendsShares_F051A15CE70E69F81827F8C18F0A4990" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock dividends (shares)</link:label>
    <link:label id="lab_us-gaap_StockDividendsShares_F051A15CE70E69F81827F8C18F0A4990_label_en-US" xlink:label="lab_us-gaap_StockDividendsShares_F051A15CE70E69F81827F8C18F0A4990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Dividends, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockDividendsShares" xlink:label="loc_us-gaap_StockDividendsShares_F051A15CE70E69F81827F8C18F0A4990" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockDividendsShares_F051A15CE70E69F81827F8C18F0A4990" xlink:to="lab_us-gaap_StockDividendsShares_F051A15CE70E69F81827F8C18F0A4990" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_716CE248F39CDD8CD1ECF8C18F0ABB61_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_716CE248F39CDD8CD1ECF8C18F0ABB61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares, issued (shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_716CE248F39CDD8CD1ECF8C18F0ABB61_label_en-US" xlink:label="lab_us-gaap_SharesIssued_716CE248F39CDD8CD1ECF8C18F0ABB61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_716CE248F39CDD8CD1ECF8C18F0ABB61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_716CE248F39CDD8CD1ECF8C18F0ABB61" xlink:to="lab_us-gaap_SharesIssued_716CE248F39CDD8CD1ECF8C18F0ABB61" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_99C11C666C792D792181F8C18F0A7DFB_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_99C11C666C792D792181F8C18F0A7DFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_99C11C666C792D792181F8C18F0A7DFB_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_99C11C666C792D792181F8C18F0A7DFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_99C11C666C792D792181F8C18F0A7DFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_99C11C666C792D792181F8C18F0A7DFB" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_99C11C666C792D792181F8C18F0A7DFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_92FDCEE184A572C717B894CAF0849B11_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_6B119FABBB225AC5AB89DCF91908C3AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_92FDCEE184A572C717B894CAF0849B11_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_6B119FABBB225AC5AB89DCF91908C3AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_6B119FABBB225AC5AB89DCF91908C3AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_6B119FABBB225AC5AB89DCF91908C3AB" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_6B119FABBB225AC5AB89DCF91908C3AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_3889EDD8FC3174CBA64694CAF276448E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_0166C78B261A5483AD74443649F8B0A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BUSINESS DESCRIPTION</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_3889EDD8FC3174CBA64694CAF276448E_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_0166C78B261A5483AD74443649F8B0A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_0166C78B261A5483AD74443649F8B0A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_0166C78B261A5483AD74443649F8B0A5" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_0166C78B261A5483AD74443649F8B0A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_D3AE46BDFD68C9570EB9FDF1A02ABD9A_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_D3AE46BDFD68C9570EB9FDF1A02ABD9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_D3AE46BDFD68C9570EB9FDF1A02ABD9A_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_D3AE46BDFD68C9570EB9FDF1A02ABD9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_D3AE46BDFD68C9570EB9FDF1A02ABD9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_D3AE46BDFD68C9570EB9FDF1A02ABD9A" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_D3AE46BDFD68C9570EB9FDF1A02ABD9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_26226CD5589D684ADC98FDF1A02AAE19_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_26226CD5589D684ADC98FDF1A02AAE19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_26226CD5589D684ADC98FDF1A02AAE19_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_26226CD5589D684ADC98FDF1A02AAE19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_26226CD5589D684ADC98FDF1A02AAE19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_26226CD5589D684ADC98FDF1A02AAE19" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_26226CD5589D684ADC98FDF1A02AAE19" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_FCD263996959636084AEFDF1A02A3600_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_FCD263996959636084AEFDF1A02A3600" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Private placement, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_FCD263996959636084AEFDF1A02A3600_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_FCD263996959636084AEFDF1A02A3600" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_FCD263996959636084AEFDF1A02A3600" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_FCD263996959636084AEFDF1A02A3600" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_FCD263996959636084AEFDF1A02A3600" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E8B9A725CB9D5FB6C718FE19FE4F76B2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E8B9A725CB9D5FB6C718FE19FE4F76B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrant, common stock called (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E8B9A725CB9D5FB6C718FE19FE4F76B2_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E8B9A725CB9D5FB6C718FE19FE4F76B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E8B9A725CB9D5FB6C718FE19FE4F76B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E8B9A725CB9D5FB6C718FE19FE4F76B2" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E8B9A725CB9D5FB6C718FE19FE4F76B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_AC3FE7858E0884EC4BD394CAF2A398A7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6569B60C751D5652BF7E1F880E46D5B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of discontinued operations impact on income statement and balance sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_AC3FE7858E0884EC4BD394CAF2A398A7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6569B60C751D5652BF7E1F880E46D5B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6569B60C751D5652BF7E1F880E46D5B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6569B60C751D5652BF7E1F880E46D5B1" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6569B60C751D5652BF7E1F880E46D5B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_A2FACA901FEB704202730D52F2331173_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_A2FACA901FEB704202730D52F2331173" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense for intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_A2FACA901FEB704202730D52F2331173_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_A2FACA901FEB704202730D52F2331173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_A2FACA901FEB704202730D52F2331173" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_A2FACA901FEB704202730D52F2331173" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_A2FACA901FEB704202730D52F2331173" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_334500717AADAD75AF860D52F233AE61_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_334500717AADAD75AF860D52F233AE61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining amortization expense, 2017</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_334500717AADAD75AF860D52F233AE61_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_334500717AADAD75AF860D52F233AE61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_334500717AADAD75AF860D52F233AE61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_334500717AADAD75AF860D52F233AE61" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_334500717AADAD75AF860D52F233AE61" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5813607B7959646376F70D52F233BE58_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5813607B7959646376F70D52F233BE58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense, 2018</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5813607B7959646376F70D52F233BE58_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5813607B7959646376F70D52F233BE58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5813607B7959646376F70D52F233BE58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5813607B7959646376F70D52F233BE58" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5813607B7959646376F70D52F233BE58" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_17CB8F8BE0A9080AA09E0D52F233235A_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_17CB8F8BE0A9080AA09E0D52F233235A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense, 2019 (less than)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_17CB8F8BE0A9080AA09E0D52F233235A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_17CB8F8BE0A9080AA09E0D52F233235A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_17CB8F8BE0A9080AA09E0D52F233235A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_17CB8F8BE0A9080AA09E0D52F233235A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_17CB8F8BE0A9080AA09E0D52F233235A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_BA5FEBF3BB8383EF75040D52F23365CC_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_BA5FEBF3BB8383EF75040D52F23365CC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense, 2020 (less than)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_BA5FEBF3BB8383EF75040D52F23365CC_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_BA5FEBF3BB8383EF75040D52F23365CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_BA5FEBF3BB8383EF75040D52F23365CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_BA5FEBF3BB8383EF75040D52F23365CC" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_BA5FEBF3BB8383EF75040D52F23365CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EBDE5401BF768D6935810D52F2335DF6_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EBDE5401BF768D6935810D52F2335DF6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense, 2021 (less than)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EBDE5401BF768D6935810D52F2335DF6_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EBDE5401BF768D6935810D52F2335DF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EBDE5401BF768D6935810D52F2335DF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EBDE5401BF768D6935810D52F2335DF6" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EBDE5401BF768D6935810D52F2335DF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_AC1E1FD9AA259B46B1B3FDF1A00F5E59_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember_AC1E1FD9AA259B46B1B3FDF1A00F5E59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SARs</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_AC1E1FD9AA259B46B1B3FDF1A00F5E59_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember_AC1E1FD9AA259B46B1B3FDF1A00F5E59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_AC1E1FD9AA259B46B1B3FDF1A00F5E59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember_AC1E1FD9AA259B46B1B3FDF1A00F5E59" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember_AC1E1FD9AA259B46B1B3FDF1A00F5E59" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_763EF179280064F0895FFDF1A00F3082_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_763EF179280064F0895FFDF1A00F3082" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of SARs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_763EF179280064F0895FFDF1A00F3082_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_763EF179280064F0895FFDF1A00F3082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_763EF179280064F0895FFDF1A00F3082" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_763EF179280064F0895FFDF1A00F3082" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_763EF179280064F0895FFDF1A00F3082" xlink:type="arc" />
    <link:label id="lab_tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_4360F12B0598F5D914D3FDF1A00F3C8F_terseLabel_en-US" xlink:label="lab_tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_4360F12B0598F5D914D3FDF1A00F3C8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_4360F12B0598F5D914D3FDF1A00F3C8F_label_en-US" xlink:label="lab_tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_4360F12B0598F5D914D3FDF1A00F3C8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Number</link:label>
    <link:label id="lab_tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_4360F12B0598F5D914D3FDF1A00F3C8F_documentation_en-US" xlink:label="lab_tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_4360F12B0598F5D914D3FDF1A00F3C8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Number</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_4360F12B0598F5D914D3FDF1A00F3C8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_4360F12B0598F5D914D3FDF1A00F3C8F" xlink:to="lab_tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_4360F12B0598F5D914D3FDF1A00F3C8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FD8B4BCB104DE67120ADFDF1A010C0F5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FD8B4BCB104DE67120ADFDF1A010C0F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FD8B4BCB104DE67120ADFDF1A010C0F5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FD8B4BCB104DE67120ADFDF1A010C0F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FD8B4BCB104DE67120ADFDF1A010C0F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FD8B4BCB104DE67120ADFDF1A010C0F5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FD8B4BCB104DE67120ADFDF1A010C0F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_115EFEA5F7F3CB3EBEABFDF1A010CB2F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_115EFEA5F7F3CB3EBEABFDF1A010CB2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_115EFEA5F7F3CB3EBEABFDF1A010CB2F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_115EFEA5F7F3CB3EBEABFDF1A010CB2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_115EFEA5F7F3CB3EBEABFDF1A010CB2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_115EFEA5F7F3CB3EBEABFDF1A010CB2F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_115EFEA5F7F3CB3EBEABFDF1A010CB2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_E1C32DBB1AD370A34D74FDF1A010D45B_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_E1C32DBB1AD370A34D74FDF1A010D45B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock appreciation rights, aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_E1C32DBB1AD370A34D74FDF1A010D45B_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_E1C32DBB1AD370A34D74FDF1A010D45B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_E1C32DBB1AD370A34D74FDF1A010D45B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_E1C32DBB1AD370A34D74FDF1A010D45B" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_E1C32DBB1AD370A34D74FDF1A010D45B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_AF450348C77A05953262E9708A21C42F_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_AF450348C77A05953262E9708A21C42F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible promissory notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_AF450348C77A05953262E9708A21C42F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember_AF450348C77A05953262E9708A21C42F" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember_AF450348C77A05953262E9708A21C42F" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_8778F3460A797A010706E9708A2117EB_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_8778F3460A797A010706E9708A2117EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_8778F3460A797A010706E9708A2117EB_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_8778F3460A797A010706E9708A2117EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_8778F3460A797A010706E9708A2117EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_8778F3460A797A010706E9708A2117EB" xlink:to="lab_us-gaap_VariableRateAxis_8778F3460A797A010706E9708A2117EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_DCCA6B2A810062322A9AE9708A219B90_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_DCCA6B2A810062322A9AE9708A219B90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_DCCA6B2A810062322A9AE9708A219B90_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_DCCA6B2A810062322A9AE9708A219B90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_DCCA6B2A810062322A9AE9708A219B90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_DCCA6B2A810062322A9AE9708A219B90" xlink:to="lab_us-gaap_VariableRateDomain_DCCA6B2A810062322A9AE9708A219B90" xlink:type="arc" />
    <link:label id="lab_tbio_WallStreetJournalPrimeRateMember_1C25840BA562B55A66C6E9708A217152_terseLabel_en-US" xlink:label="lab_tbio_WallStreetJournalPrimeRateMember_1C25840BA562B55A66C6E9708A217152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wall Street Journal prime rate</link:label>
    <link:label id="lab_tbio_WallStreetJournalPrimeRateMember_1C25840BA562B55A66C6E9708A217152_label_en-US" xlink:label="lab_tbio_WallStreetJournalPrimeRateMember_1C25840BA562B55A66C6E9708A217152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wall Street Journal Prime Rate [Member]</link:label>
    <link:label id="lab_tbio_WallStreetJournalPrimeRateMember_1C25840BA562B55A66C6E9708A217152_documentation_en-US" xlink:label="lab_tbio_WallStreetJournalPrimeRateMember_1C25840BA562B55A66C6E9708A217152" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Wall Street Journal Prime Rate [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WallStreetJournalPrimeRateMember" xlink:label="loc_tbio_WallStreetJournalPrimeRateMember_1C25840BA562B55A66C6E9708A217152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_WallStreetJournalPrimeRateMember_1C25840BA562B55A66C6E9708A217152" xlink:to="lab_tbio_WallStreetJournalPrimeRateMember_1C25840BA562B55A66C6E9708A217152" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_4F5D10C3EE1D44F39DABE9708A2122E6_totalLabel_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations_4F5D10C3EE1D44F39DABE9708A2122E6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_4F5D10C3EE1D44F39DABE9708A2122E6_label_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations_4F5D10C3EE1D44F39DABE9708A2122E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt and Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_4F5D10C3EE1D44F39DABE9708A2122E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_4F5D10C3EE1D44F39DABE9708A2122E6" xlink:to="lab_us-gaap_DebtAndCapitalLeaseObligations_4F5D10C3EE1D44F39DABE9708A2122E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_27A1BF5D9742B734B22BE9708A22DEFC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_27A1BF5D9742B734B22BE9708A22DEFC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_27A1BF5D9742B734B22BE9708A22DEFC_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_27A1BF5D9742B734B22BE9708A22DEFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_27A1BF5D9742B734B22BE9708A22DEFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_27A1BF5D9742B734B22BE9708A22DEFC" xlink:to="lab_us-gaap_LongTermDebtCurrent_27A1BF5D9742B734B22BE9708A22DEFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_42B65531057083411225E9708A22FCAA_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_42B65531057083411225E9708A22FCAA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net of current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_42B65531057083411225E9708A22FCAA_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_42B65531057083411225E9708A22FCAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_42B65531057083411225E9708A22FCAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_42B65531057083411225E9708A22FCAA" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_42B65531057083411225E9708A22FCAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_FB1795C6FB1BED6F17A5E9708A22E266_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_FB1795C6FB1BED6F17A5E9708A22E266" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Annual interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_FB1795C6FB1BED6F17A5E9708A22E266_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_FB1795C6FB1BED6F17A5E9708A22E266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_FB1795C6FB1BED6F17A5E9708A22E266" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_FB1795C6FB1BED6F17A5E9708A22E266" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_FB1795C6FB1BED6F17A5E9708A22E266" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0BAE3944153261E29DEFE9708A22BA33_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0BAE3944153261E29DEFE9708A22BA33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0BAE3944153261E29DEFE9708A22BA33_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0BAE3944153261E29DEFE9708A22BA33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0BAE3944153261E29DEFE9708A22BA33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0BAE3944153261E29DEFE9708A22BA33" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0BAE3944153261E29DEFE9708A22BA33" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_AF6ACDFAA91089D03195E9708A221D61_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_AF6ACDFAA91089D03195E9708A221D61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_AF6ACDFAA91089D03195E9708A221D61_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_AF6ACDFAA91089D03195E9708A221D61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_AF6ACDFAA91089D03195E9708A221D61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_AF6ACDFAA91089D03195E9708A221D61" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_AF6ACDFAA91089D03195E9708A221D61" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_D0CDD5DA93BCBE713A70E9708A22DC14_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_D0CDD5DA93BCBE713A70E9708A22DC14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment fee amount</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_D0CDD5DA93BCBE713A70E9708A22DC14_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_D0CDD5DA93BCBE713A70E9708A22DC14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Commitment Fee Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_D0CDD5DA93BCBE713A70E9708A22DC14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_D0CDD5DA93BCBE713A70E9708A22DC14" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_D0CDD5DA93BCBE713A70E9708A22DC14" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_6596FB699EA02C70E0D6E9708A22A909_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_6596FB699EA02C70E0D6E9708A22A909" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment fee (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_6596FB699EA02C70E0D6E9708A22A909_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_6596FB699EA02C70E0D6E9708A22A909" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_6596FB699EA02C70E0D6E9708A22A909" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_6596FB699EA02C70E0D6E9708A22A909" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_6596FB699EA02C70E0D6E9708A22A909" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_BB30E706EAF51D7F2469E9708A2236EB_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_BB30E706EAF51D7F2469E9708A2236EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_BB30E706EAF51D7F2469E9708A2236EB_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_BB30E706EAF51D7F2469E9708A2236EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_BB30E706EAF51D7F2469E9708A2236EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_BB30E706EAF51D7F2469E9708A2236EB" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_BB30E706EAF51D7F2469E9708A2236EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_8E341A9E8BC980F50F35E9708A2201F7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_8E341A9E8BC980F50F35E9708A2201F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_8E341A9E8BC980F50F35E9708A2201F7_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_8E341A9E8BC980F50F35E9708A2201F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_8E341A9E8BC980F50F35E9708A2201F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_8E341A9E8BC980F50F35E9708A2201F7" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_8E341A9E8BC980F50F35E9708A2201F7" xlink:type="arc" />
    <link:label id="lab_tbio_DebtInstrumentFutureDebtExtinguishmentCosts_7E79E84CC0B197F9E3F0E9708A221B02_terseLabel_en-US" xlink:label="lab_tbio_DebtInstrumentFutureDebtExtinguishmentCosts_7E79E84CC0B197F9E3F0E9708A221B02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future debt extinguishment costs</link:label>
    <link:label id="lab_tbio_DebtInstrumentFutureDebtExtinguishmentCosts_7E79E84CC0B197F9E3F0E9708A221B02_label_en-US" xlink:label="lab_tbio_DebtInstrumentFutureDebtExtinguishmentCosts_7E79E84CC0B197F9E3F0E9708A221B02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Future Debt Extinguishment Costs</link:label>
    <link:label id="lab_tbio_DebtInstrumentFutureDebtExtinguishmentCosts_7E79E84CC0B197F9E3F0E9708A221B02_documentation_en-US" xlink:label="lab_tbio_DebtInstrumentFutureDebtExtinguishmentCosts_7E79E84CC0B197F9E3F0E9708A221B02" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Future Debt Extinguishment Costs</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentFutureDebtExtinguishmentCosts" xlink:label="loc_tbio_DebtInstrumentFutureDebtExtinguishmentCosts_7E79E84CC0B197F9E3F0E9708A221B02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_DebtInstrumentFutureDebtExtinguishmentCosts_7E79E84CC0B197F9E3F0E9708A221B02" xlink:to="lab_tbio_DebtInstrumentFutureDebtExtinguishmentCosts_7E79E84CC0B197F9E3F0E9708A221B02" xlink:type="arc" />
    <link:label id="lab_tbio_DebtInstrumentPrepaymentPenaltyPercent_F93C840AC73B33C6E232E9708A22567C_terseLabel_en-US" xlink:label="lab_tbio_DebtInstrumentPrepaymentPenaltyPercent_F93C840AC73B33C6E232E9708A22567C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment penalty percentage of outstanding balance (as a percent)</link:label>
    <link:label id="lab_tbio_DebtInstrumentPrepaymentPenaltyPercent_F93C840AC73B33C6E232E9708A22567C_label_en-US" xlink:label="lab_tbio_DebtInstrumentPrepaymentPenaltyPercent_F93C840AC73B33C6E232E9708A22567C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Penalty Percent</link:label>
    <link:label id="lab_tbio_DebtInstrumentPrepaymentPenaltyPercent_F93C840AC73B33C6E232E9708A22567C_documentation_en-US" xlink:label="lab_tbio_DebtInstrumentPrepaymentPenaltyPercent_F93C840AC73B33C6E232E9708A22567C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Penalty Percent</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentPrepaymentPenaltyPercent" xlink:label="loc_tbio_DebtInstrumentPrepaymentPenaltyPercent_F93C840AC73B33C6E232E9708A22567C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_DebtInstrumentPrepaymentPenaltyPercent_F93C840AC73B33C6E232E9708A22567C" xlink:to="lab_tbio_DebtInstrumentPrepaymentPenaltyPercent_F93C840AC73B33C6E232E9708A22567C" xlink:type="arc" />
    <link:label id="lab_tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease_18566916BD0A720EC743E9708A2276C7_terseLabel_en-US" xlink:label="lab_tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease_18566916BD0A720EC743E9708A2276C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in interest rate in case of debt default (as a percent)</link:label>
    <link:label id="lab_tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease_18566916BD0A720EC743E9708A2276C7_label_en-US" xlink:label="lab_tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease_18566916BD0A720EC743E9708A2276C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Default, Interest Rate, Stated Percentage Increase</link:label>
    <link:label id="lab_tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease_18566916BD0A720EC743E9708A2276C7_documentation_en-US" xlink:label="lab_tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease_18566916BD0A720EC743E9708A2276C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Default, Interest Rate, Stated Percentage Increase</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease" xlink:label="loc_tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease_18566916BD0A720EC743E9708A2276C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease_18566916BD0A720EC743E9708A2276C7" xlink:to="lab_tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease_18566916BD0A720EC743E9708A2276C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_B81A29C7196A73C651F80D89BD7752BB_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_B81A29C7196A73C651F80D89BD7752BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_B81A29C7196A73C651F80D89BD7752BB_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_B81A29C7196A73C651F80D89BD7752BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B81A29C7196A73C651F80D89BD7752BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_B81A29C7196A73C651F80D89BD7752BB" xlink:to="lab_us-gaap_DebtInstrumentAxis_B81A29C7196A73C651F80D89BD7752BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_457221C3687733F4D11C0D89BD86CA37_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_457221C3687733F4D11C0D89BD86CA37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_457221C3687733F4D11C0D89BD86CA37_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_457221C3687733F4D11C0D89BD86CA37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_457221C3687733F4D11C0D89BD86CA37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_457221C3687733F4D11C0D89BD86CA37" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_457221C3687733F4D11C0D89BD86CA37" xlink:type="arc" />
    <link:label id="lab_tbio_AdditionalNotesMember_BFC70A70DFE30478D22D0D8ADD539F43_terseLabel_en-US" xlink:label="lab_tbio_AdditionalNotesMember_BFC70A70DFE30478D22D0D8ADD539F43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Notes</link:label>
    <link:label id="lab_tbio_AdditionalNotesMember_BFC70A70DFE30478D22D0D8ADD539F43_label_en-US" xlink:label="lab_tbio_AdditionalNotesMember_BFC70A70DFE30478D22D0D8ADD539F43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Notes [Member]</link:label>
    <link:label id="lab_tbio_AdditionalNotesMember_BFC70A70DFE30478D22D0D8ADD539F43_documentation_en-US" xlink:label="lab_tbio_AdditionalNotesMember_BFC70A70DFE30478D22D0D8ADD539F43" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Notes [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AdditionalNotesMember" xlink:label="loc_tbio_AdditionalNotesMember_BFC70A70DFE30478D22D0D8ADD539F43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_AdditionalNotesMember_BFC70A70DFE30478D22D0D8ADD539F43" xlink:to="lab_tbio_AdditionalNotesMember_BFC70A70DFE30478D22D0D8ADD539F43" xlink:type="arc" />
    <link:label id="lab_tbio_AgentNoteMember_B8A440DF68F97BE7F4FF0D52F1BB3088_terseLabel_en-US" xlink:label="lab_tbio_AgentNoteMember_B8A440DF68F97BE7F4FF0D52F1BB3088" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agent Note</link:label>
    <link:label id="lab_tbio_AgentNoteMember_B8A440DF68F97BE7F4FF0D52F1BB3088_label_en-US" xlink:label="lab_tbio_AgentNoteMember_B8A440DF68F97BE7F4FF0D52F1BB3088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agent Note [Member]</link:label>
    <link:label id="lab_tbio_AgentNoteMember_B8A440DF68F97BE7F4FF0D52F1BB3088_documentation_en-US" xlink:label="lab_tbio_AgentNoteMember_B8A440DF68F97BE7F4FF0D52F1BB3088" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agent Note [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AgentNoteMember" xlink:label="loc_tbio_AgentNoteMember_B8A440DF68F97BE7F4FF0D52F1BB3088" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_AgentNoteMember_B8A440DF68F97BE7F4FF0D52F1BB3088" xlink:to="lab_tbio_AgentNoteMember_B8A440DF68F97BE7F4FF0D52F1BB3088" xlink:type="arc" />
    <link:label id="lab_tbio_AdditionalNotePrivatePlacementMember_BDCED2B8D4CE99ED08C40D52F1BC51A5_verboseLabel_en-US" xlink:label="lab_tbio_AdditionalNotePrivatePlacementMember_BDCED2B8D4CE99ED08C40D52F1BC51A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional notes</link:label>
    <link:label id="lab_tbio_AdditionalNotePrivatePlacementMember_BDCED2B8D4CE99ED08C40D52F1BC51A5_label_en-US" xlink:label="lab_tbio_AdditionalNotePrivatePlacementMember_BDCED2B8D4CE99ED08C40D52F1BC51A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Note Private Placement [Member]</link:label>
    <link:label id="lab_tbio_AdditionalNotePrivatePlacementMember_BDCED2B8D4CE99ED08C40D52F1BC51A5_documentation_en-US" xlink:label="lab_tbio_AdditionalNotePrivatePlacementMember_BDCED2B8D4CE99ED08C40D52F1BC51A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Note Private Placement [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AdditionalNotePrivatePlacementMember" xlink:label="loc_tbio_AdditionalNotePrivatePlacementMember_BDCED2B8D4CE99ED08C40D52F1BC51A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_AdditionalNotePrivatePlacementMember_BDCED2B8D4CE99ED08C40D52F1BC51A5" xlink:to="lab_tbio_AdditionalNotePrivatePlacementMember_BDCED2B8D4CE99ED08C40D52F1BC51A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_59BA1E82151B935A5B680D52F1BC0998_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_59BA1E82151B935A5B680D52F1BC0998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_59BA1E82151B935A5B680D52F1BC0998" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_59BA1E82151B935A5B680D52F1BC0998" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_59BA1E82151B935A5B680D52F1BC0998" xlink:type="arc" />
    <link:label id="lab_tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors_B14EB4F814D8219F196F0D52F1BC8864_terseLabel_en-US" xlink:label="lab_tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors_B14EB4F814D8219F196F0D52F1BC8864" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional accredited investors</link:label>
    <link:label id="lab_tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors_B14EB4F814D8219F196F0D52F1BC8864_label_en-US" xlink:label="lab_tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors_B14EB4F814D8219F196F0D52F1BC8864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Additional Accredited Investors</link:label>
    <link:label id="lab_tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors_B14EB4F814D8219F196F0D52F1BC8864_documentation_en-US" xlink:label="lab_tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors_B14EB4F814D8219F196F0D52F1BC8864" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Additional Accredited Investors</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors" xlink:label="loc_tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors_B14EB4F814D8219F196F0D52F1BC8864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors_B14EB4F814D8219F196F0D52F1BC8864" xlink:to="lab_tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors_B14EB4F814D8219F196F0D52F1BC8864" xlink:type="arc" />
    <link:label id="lab_tbio_PercentageofInitialNote_6E32D24E8890F063B1640D52F1BC4D9B_terseLabel_en-US" xlink:label="lab_tbio_PercentageofInitialNote_6E32D24E8890F063B1640D52F1BC4D9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of initial note</link:label>
    <link:label id="lab_tbio_PercentageofInitialNote_6E32D24E8890F063B1640D52F1BC4D9B_label_en-US" xlink:label="lab_tbio_PercentageofInitialNote_6E32D24E8890F063B1640D52F1BC4D9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Initial Note</link:label>
    <link:label id="lab_tbio_PercentageofInitialNote_6E32D24E8890F063B1640D52F1BC4D9B_documentation_en-US" xlink:label="lab_tbio_PercentageofInitialNote_6E32D24E8890F063B1640D52F1BC4D9B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of Initial Note</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PercentageofInitialNote" xlink:label="loc_tbio_PercentageofInitialNote_6E32D24E8890F063B1640D52F1BC4D9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_PercentageofInitialNote_6E32D24E8890F063B1640D52F1BC4D9B" xlink:to="lab_tbio_PercentageofInitialNote_6E32D24E8890F063B1640D52F1BC4D9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_0393A4479C663E6F90350D52F1BC2EE4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_0393A4479C663E6F90350D52F1BC2EE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_0393A4479C663E6F90350D52F1BC2EE4_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_0393A4479C663E6F90350D52F1BC2EE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_0393A4479C663E6F90350D52F1BC2EE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_0393A4479C663E6F90350D52F1BC2EE4" xlink:to="lab_us-gaap_LongTermDebt_0393A4479C663E6F90350D52F1BC2EE4" xlink:type="arc" />
    <link:label id="lab_tbio_DebtInstrumentDebtDefaultPeriod_2C5A87365AF3348237A90D62620F1240_terseLabel_en-US" xlink:label="lab_tbio_DebtInstrumentDebtDefaultPeriod_2C5A87365AF3348237A90D62620F1240" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, default period</link:label>
    <link:label id="lab_tbio_DebtInstrumentDebtDefaultPeriod_2C5A87365AF3348237A90D62620F1240_label_en-US" xlink:label="lab_tbio_DebtInstrumentDebtDefaultPeriod_2C5A87365AF3348237A90D62620F1240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Default, Period</link:label>
    <link:label id="lab_tbio_DebtInstrumentDebtDefaultPeriod_2C5A87365AF3348237A90D62620F1240_documentation_en-US" xlink:label="lab_tbio_DebtInstrumentDebtDefaultPeriod_2C5A87365AF3348237A90D62620F1240" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Default, Period</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentDebtDefaultPeriod" xlink:label="loc_tbio_DebtInstrumentDebtDefaultPeriod_2C5A87365AF3348237A90D62620F1240" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_DebtInstrumentDebtDefaultPeriod_2C5A87365AF3348237A90D62620F1240" xlink:to="lab_tbio_DebtInstrumentDebtDefaultPeriod_2C5A87365AF3348237A90D62620F1240" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_3E9B5CA503FE272AD1010D52F1BC965A_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent_3E9B5CA503FE272AD1010D52F1BC965A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_3E9B5CA503FE272AD1010D52F1BC965A_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent_3E9B5CA503FE272AD1010D52F1BC965A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_3E9B5CA503FE272AD1010D52F1BC965A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent_3E9B5CA503FE272AD1010D52F1BC965A" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent_3E9B5CA503FE272AD1010D52F1BC965A" xlink:type="arc" />
    <link:label id="lab_tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_BEF393BD9A93A7235CE80D857BAEDE75_terseLabel_en-US" xlink:label="lab_tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_BEF393BD9A93A7235CE80D857BAEDE75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Required cumulative principal payment, percent</link:label>
    <link:label id="lab_tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_BEF393BD9A93A7235CE80D857BAEDE75_label_en-US" xlink:label="lab_tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_BEF393BD9A93A7235CE80D857BAEDE75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Required Cumulative Payment on Principal Per Amendment, Percent</link:label>
    <link:label id="lab_tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_BEF393BD9A93A7235CE80D857BAEDE75_documentation_en-US" xlink:label="lab_tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_BEF393BD9A93A7235CE80D857BAEDE75" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Required Cumulative Payment on Principal Per Amendment, Percent</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent" xlink:label="loc_tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_BEF393BD9A93A7235CE80D857BAEDE75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_BEF393BD9A93A7235CE80D857BAEDE75" xlink:to="lab_tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_BEF393BD9A93A7235CE80D857BAEDE75" xlink:type="arc" />
    <link:label id="lab_tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_D26C4C57E8FE431374BC0D9508E91AA5_terseLabel_en-US" xlink:label="lab_tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_D26C4C57E8FE431374BC0D9508E91AA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion of principal required by deferred maturity date, percent</link:label>
    <link:label id="lab_tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_D26C4C57E8FE431374BC0D9508E91AA5_label_en-US" xlink:label="lab_tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_D26C4C57E8FE431374BC0D9508E91AA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion of Principal Required to Be Paid Prior to Deferred Maturity Date, Percent</link:label>
    <link:label id="lab_tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_D26C4C57E8FE431374BC0D9508E91AA5_documentation_en-US" xlink:label="lab_tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_D26C4C57E8FE431374BC0D9508E91AA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Portion of Principal Required to Be Paid Prior to Deferred Maturity Date, Percent</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent" xlink:label="loc_tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_D26C4C57E8FE431374BC0D9508E91AA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_D26C4C57E8FE431374BC0D9508E91AA5" xlink:to="lab_tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_D26C4C57E8FE431374BC0D9508E91AA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_88AECF3B218AE09C0AA3F8A8305F4457_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_88AECF3B218AE09C0AA3F8A8305F4457" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_88AECF3B218AE09C0AA3F8A8305F4457_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_88AECF3B218AE09C0AA3F8A8305F4457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_88AECF3B218AE09C0AA3F8A8305F4457" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_88AECF3B218AE09C0AA3F8A8305F4457" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_88AECF3B218AE09C0AA3F8A8305F4457" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_7BFF78F5F813C52FDFD1F8A8305F2D9F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_7BFF78F5F813C52FDFD1F8A8305F2D9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_7BFF78F5F813C52FDFD1F8A8305F2D9F_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_7BFF78F5F813C52FDFD1F8A8305F2D9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_7BFF78F5F813C52FDFD1F8A8305F2D9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_7BFF78F5F813C52FDFD1F8A8305F2D9F" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis_7BFF78F5F813C52FDFD1F8A8305F2D9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014" xlink:type="arc" />
    <link:label id="lab_tbio_A2012WarrantLiabilityMember_61274625DAFB77C7C1A4F8A8305F2070_terseLabel_en-US" xlink:label="lab_tbio_A2012WarrantLiabilityMember_61274625DAFB77C7C1A4F8A8305F2070" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2012 Warrant Liability</link:label>
    <link:label id="lab_tbio_A2012WarrantLiabilityMember_61274625DAFB77C7C1A4F8A8305F2070_label_en-US" xlink:label="lab_tbio_A2012WarrantLiabilityMember_61274625DAFB77C7C1A4F8A8305F2070" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2012 Warrant Liability [Member]</link:label>
    <link:label id="lab_tbio_A2012WarrantLiabilityMember_61274625DAFB77C7C1A4F8A8305F2070_documentation_en-US" xlink:label="lab_tbio_A2012WarrantLiabilityMember_61274625DAFB77C7C1A4F8A8305F2070" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2012 Warrant Liability [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_A2012WarrantLiabilityMember" xlink:label="loc_tbio_A2012WarrantLiabilityMember_61274625DAFB77C7C1A4F8A8305F2070" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_A2012WarrantLiabilityMember_61274625DAFB77C7C1A4F8A8305F2070" xlink:to="lab_tbio_A2012WarrantLiabilityMember_61274625DAFB77C7C1A4F8A8305F2070" xlink:type="arc" />
    <link:label id="lab_tbio_A2016WarrantLiabilityMember_5ECC6F4D7766C8B1088CF8A8305F98EF_terseLabel_en-US" xlink:label="lab_tbio_A2016WarrantLiabilityMember_5ECC6F4D7766C8B1088CF8A8305F98EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Warrant Liability</link:label>
    <link:label id="lab_tbio_A2016WarrantLiabilityMember_5ECC6F4D7766C8B1088CF8A8305F98EF_label_en-US" xlink:label="lab_tbio_A2016WarrantLiabilityMember_5ECC6F4D7766C8B1088CF8A8305F98EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Warrant Liability [Member]</link:label>
    <link:label id="lab_tbio_A2016WarrantLiabilityMember_5ECC6F4D7766C8B1088CF8A8305F98EF_documentation_en-US" xlink:label="lab_tbio_A2016WarrantLiabilityMember_5ECC6F4D7766C8B1088CF8A8305F98EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Warrant Liability [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_A2016WarrantLiabilityMember" xlink:label="loc_tbio_A2016WarrantLiabilityMember_5ECC6F4D7766C8B1088CF8A8305F98EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_A2016WarrantLiabilityMember_5ECC6F4D7766C8B1088CF8A8305F98EF" xlink:to="lab_tbio_A2016WarrantLiabilityMember_5ECC6F4D7766C8B1088CF8A8305F98EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_AC1F9F8FADEF00EAF4EEF8A8305F90A1_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_AC1F9F8FADEF00EAF4EEF8A8305F90A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_AC1F9F8FADEF00EAF4EEF8A8305F90A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_AC1F9F8FADEF00EAF4EEF8A8305F90A1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_AC1F9F8FADEF00EAF4EEF8A8305F90A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_3D6D189FAE167058E716F8A8305FA83F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_3D6D189FAE167058E716F8A8305FA83F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_3D6D189FAE167058E716F8A8305FA83F_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_3D6D189FAE167058E716F8A8305FA83F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_3D6D189FAE167058E716F8A8305FA83F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_3D6D189FAE167058E716F8A8305FA83F" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_3D6D189FAE167058E716F8A8305FA83F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BD30836400D5D21345BBF8A83060373A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BD30836400D5D21345BBF8A83060373A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BD30836400D5D21345BBF8A83060373A_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BD30836400D5D21345BBF8A83060373A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BD30836400D5D21345BBF8A83060373A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BD30836400D5D21345BBF8A83060373A" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BD30836400D5D21345BBF8A83060373A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767E63F28D5E2EEC112FF8A83060BA10_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767E63F28D5E2EEC112FF8A83060BA10" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767E63F28D5E2EEC112FF8A83060BA10_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767E63F28D5E2EEC112FF8A83060BA10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767E63F28D5E2EEC112FF8A83060BA10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767E63F28D5E2EEC112FF8A83060BA10" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767E63F28D5E2EEC112FF8A83060BA10" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_F7180AD919679FCABB56F8A83060BCC5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_F7180AD919679FCABB56F8A83060BCC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_F7180AD919679FCABB56F8A83060BCC5_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_F7180AD919679FCABB56F8A83060BCC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_F7180AD919679FCABB56F8A83060BCC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_F7180AD919679FCABB56F8A83060BCC5" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_F7180AD919679FCABB56F8A83060BCC5" xlink:type="arc" />
    <link:label id="lab_tbio_TotalGainsOrLossesAbstract_64E35FD2C42019E77F45F8A830657A2D_terseLabel_en-US" xlink:label="lab_tbio_TotalGainsOrLossesAbstract_64E35FD2C42019E77F45F8A830657A2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total (gains) or losses:</link:label>
    <link:label id="lab_tbio_TotalGainsOrLossesAbstract_64E35FD2C42019E77F45F8A830657A2D_label_en-US" xlink:label="lab_tbio_TotalGainsOrLossesAbstract_64E35FD2C42019E77F45F8A830657A2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total gains or losses [Abstract]</link:label>
    <link:label id="lab_tbio_TotalGainsOrLossesAbstract_64E35FD2C42019E77F45F8A830657A2D_documentation_en-US" xlink:label="lab_tbio_TotalGainsOrLossesAbstract_64E35FD2C42019E77F45F8A830657A2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total gains or losses [Abstract]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_TotalGainsOrLossesAbstract" xlink:label="loc_tbio_TotalGainsOrLossesAbstract_64E35FD2C42019E77F45F8A830657A2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_TotalGainsOrLossesAbstract_64E35FD2C42019E77F45F8A830657A2D" xlink:to="lab_tbio_TotalGainsOrLossesAbstract_64E35FD2C42019E77F45F8A830657A2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1D784943C372C67DEA87F8A83065E25F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1D784943C372C67DEA87F8A83065E25F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Recognized in earnings</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1D784943C372C67DEA87F8A83065E25F_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1D784943C372C67DEA87F8A83065E25F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1D784943C372C67DEA87F8A83065E25F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1D784943C372C67DEA87F8A83065E25F" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1D784943C372C67DEA87F8A83065E25F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DC7C313EFC58C0CBB8B1F8A83065FB17_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DC7C313EFC58C0CBB8B1F8A83065FB17" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DC7C313EFC58C0CBB8B1F8A83065FB17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DC7C313EFC58C0CBB8B1F8A83065FB17" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DC7C313EFC58C0CBB8B1F8A83065FB17" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_116DB9A01C41AF73684EFDF1A0186076_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_116DB9A01C41AF73684EFDF1A0186076" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of stock option activity</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_116DB9A01C41AF73684EFDF1A0186076_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_116DB9A01C41AF73684EFDF1A0186076" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_116DB9A01C41AF73684EFDF1A0186076" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_116DB9A01C41AF73684EFDF1A0186076" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_116DB9A01C41AF73684EFDF1A0186076" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1D3C85F0E80111A3055BE88E44773EA7_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_1D3C85F0E80111A3055BE88E44773EA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1D3C85F0E80111A3055BE88E44773EA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1D3C85F0E80111A3055BE88E44773EA7" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_1D3C85F0E80111A3055BE88E44773EA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1C6FB0312EA9806AB6ACE88E44774146_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_1C6FB0312EA9806AB6ACE88E44774146" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1C6FB0312EA9806AB6ACE88E44774146_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_1C6FB0312EA9806AB6ACE88E44774146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1C6FB0312EA9806AB6ACE88E44774146" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_1C6FB0312EA9806AB6ACE88E44774146" xlink:to="lab_us-gaap_PreferredStockSharesIssued_1C6FB0312EA9806AB6ACE88E44774146" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_026A14AFAD693789BA63E88E4477E1AC_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_026A14AFAD693789BA63E88E4477E1AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_026A14AFAD693789BA63E88E4477E1AC_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_026A14AFAD693789BA63E88E4477E1AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_026A14AFAD693789BA63E88E4477E1AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_026A14AFAD693789BA63E88E4477E1AC" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_026A14AFAD693789BA63E88E4477E1AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_F267C1DE0BC6503996E0E88E4477BCA5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_F267C1DE0BC6503996E0E88E4477BCA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_F267C1DE0BC6503996E0E88E4477BCA5_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_F267C1DE0BC6503996E0E88E4477BCA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F267C1DE0BC6503996E0E88E4477BCA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_F267C1DE0BC6503996E0E88E4477BCA5" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_F267C1DE0BC6503996E0E88E4477BCA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5C8CC01799F2534C70E1E88E44775BD3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_5C8CC01799F2534C70E1E88E44775BD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5C8CC01799F2534C70E1E88E44775BD3_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_5C8CC01799F2534C70E1E88E44775BD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_5C8CC01799F2534C70E1E88E44775BD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_5C8CC01799F2534C70E1E88E44775BD3" xlink:to="lab_us-gaap_CommonStockSharesIssued_5C8CC01799F2534C70E1E88E44775BD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1C108CE2B0F388C7D030E88E44777209_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1C108CE2B0F388C7D030E88E44777209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1C108CE2B0F388C7D030E88E44777209_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1C108CE2B0F388C7D030E88E44777209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1C108CE2B0F388C7D030E88E44777209" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_1C108CE2B0F388C7D030E88E44777209" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1C108CE2B0F388C7D030E88E44777209" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_473533F657853FB4433FFDB27F22F0EB_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_473533F657853FB4433FFDB27F22F0EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_473533F657853FB4433FFDB27F22F0EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_473533F657853FB4433FFDB27F22F0EB" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_473533F657853FB4433FFDB27F22F0EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_56D4BD3AB392CF77AD28FDB27F22D93A_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_56D4BD3AB392CF77AD28FDB27F22D93A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_56D4BD3AB392CF77AD28FDB27F22D93A_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_56D4BD3AB392CF77AD28FDB27F22D93A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_56D4BD3AB392CF77AD28FDB27F22D93A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_56D4BD3AB392CF77AD28FDB27F22D93A" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_56D4BD3AB392CF77AD28FDB27F22D93A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9C8D0505F701A2AF7B2394CAF21D64E1_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_6EBE366C65B65EEB9558E0EEF0D0B6FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6EBE366C65B65EEB9558E0EEF0D0B6FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6EBE366C65B65EEB9558E0EEF0D0B6FA" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_6EBE366C65B65EEB9558E0EEF0D0B6FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_89EDFF8913372F82AB5194CAF21EE675_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_F272AEAEF2355DA69B80B149757AEA2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_89EDFF8913372F82AB5194CAF21EE675_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_F272AEAEF2355DA69B80B149757AEA2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_F272AEAEF2355DA69B80B149757AEA2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_F272AEAEF2355DA69B80B149757AEA2F" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_F272AEAEF2355DA69B80B149757AEA2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_DCE121D5B19FF2D88E0B94CAF29B1432_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_D487EE2045A95627B2A8EAB485CECC3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stockholders' equity, including warrants and rights</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_DCE121D5B19FF2D88E0B94CAF29B1432_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_D487EE2045A95627B2A8EAB485CECC3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_D487EE2045A95627B2A8EAB485CECC3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_D487EE2045A95627B2A8EAB485CECC3B" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_D487EE2045A95627B2A8EAB485CECC3B" xlink:type="arc" />
    <link:label id="lab_tbio_DocumentAndEntityInformationAbstract_8AC37BF644537DDB4F7C94CD8E555F24_label_en-US" xlink:label="lab_tbio_DocumentAndEntityInformationAbstract_34B5D89B17EF57029DCAA249BFD4E699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_tbio_DocumentAndEntityInformationAbstract_8AC37BF644537DDB4F7C94CD8E555F24_documentation_en-US" xlink:label="lab_tbio_DocumentAndEntityInformationAbstract_34B5D89B17EF57029DCAA249BFD4E699" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DocumentAndEntityInformationAbstract" xlink:label="loc_tbio_DocumentAndEntityInformationAbstract_34B5D89B17EF57029DCAA249BFD4E699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_DocumentAndEntityInformationAbstract_34B5D89B17EF57029DCAA249BFD4E699" xlink:to="lab_tbio_DocumentAndEntityInformationAbstract_34B5D89B17EF57029DCAA249BFD4E699" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_6248E55EDAF42F6A0E9094CD8E55DE32_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_C55CF6EC186D5240A87568965591834A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_6248E55EDAF42F6A0E9094CD8E55DE32_label_en-US" xlink:label="lab_dei_EntityRegistrantName_C55CF6EC186D5240A87568965591834A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_C55CF6EC186D5240A87568965591834A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_C55CF6EC186D5240A87568965591834A" xlink:to="lab_dei_EntityRegistrantName_C55CF6EC186D5240A87568965591834A" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_11B279BBFD6E5DB3E79394CD8E55A35C_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_175C97256C5158379E5CA07C952FB5F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_11B279BBFD6E5DB3E79394CD8E55A35C_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_175C97256C5158379E5CA07C952FB5F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_175C97256C5158379E5CA07C952FB5F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_175C97256C5158379E5CA07C952FB5F7" xlink:to="lab_dei_EntityCentralIndexKey_175C97256C5158379E5CA07C952FB5F7" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_D0557FB64A4953F3EAD694CD8E55F028_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_3F377F9D64F85BCBA2E9C43B5142E59F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_D0557FB64A4953F3EAD694CD8E55F028_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_3F377F9D64F85BCBA2E9C43B5142E59F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_3F377F9D64F85BCBA2E9C43B5142E59F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_3F377F9D64F85BCBA2E9C43B5142E59F" xlink:to="lab_dei_CurrentFiscalYearEndDate_3F377F9D64F85BCBA2E9C43B5142E59F" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_4B4718116B096CDB5FFE94CD8E55117C_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_6A8C067E7D6E52EA8F4658B7DFC26E27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_4B4718116B096CDB5FFE94CD8E55117C_label_en-US" xlink:label="lab_dei_EntityFilerCategory_6A8C067E7D6E52EA8F4658B7DFC26E27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_6A8C067E7D6E52EA8F4658B7DFC26E27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_6A8C067E7D6E52EA8F4658B7DFC26E27" xlink:to="lab_dei_EntityFilerCategory_6A8C067E7D6E52EA8F4658B7DFC26E27" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_C33B73A52ED807F05CCB94CD8E5516BB_terseLabel_en-US" xlink:label="lab_dei_DocumentType_D21B17F24F1D5DBB909FDBE786D2F565" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_C33B73A52ED807F05CCB94CD8E5516BB_label_en-US" xlink:label="lab_dei_DocumentType_D21B17F24F1D5DBB909FDBE786D2F565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_D21B17F24F1D5DBB909FDBE786D2F565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_D21B17F24F1D5DBB909FDBE786D2F565" xlink:to="lab_dei_DocumentType_D21B17F24F1D5DBB909FDBE786D2F565" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_F2599E4BC610EF81508D94CD8E556D99_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_9723D07E056355A7B52BFC0747847F30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_F2599E4BC610EF81508D94CD8E556D99_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_9723D07E056355A7B52BFC0747847F30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_9723D07E056355A7B52BFC0747847F30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_9723D07E056355A7B52BFC0747847F30" xlink:to="lab_dei_DocumentPeriodEndDate_9723D07E056355A7B52BFC0747847F30" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_8DA073D5BA739FDB42FA94CD8E559CD9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_DA26FEDD3F7257B6B57A881E2A254DE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8DA073D5BA739FDB42FA94CD8E559CD9_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_DA26FEDD3F7257B6B57A881E2A254DE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_DA26FEDD3F7257B6B57A881E2A254DE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_DA26FEDD3F7257B6B57A881E2A254DE9" xlink:to="lab_dei_DocumentFiscalYearFocus_DA26FEDD3F7257B6B57A881E2A254DE9" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A91FCCEEF26E5EEE403294CD8E56CAC4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_DB73AB1F477051BB985C0573B0E58F73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A91FCCEEF26E5EEE403294CD8E56CAC4_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_DB73AB1F477051BB985C0573B0E58F73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_DB73AB1F477051BB985C0573B0E58F73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_DB73AB1F477051BB985C0573B0E58F73" xlink:to="lab_dei_DocumentFiscalPeriodFocus_DB73AB1F477051BB985C0573B0E58F73" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_A4D4531118F1D3F686DD94CD8E563483_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_4E9F2A103815509F96AA1EEEC369176E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_A4D4531118F1D3F686DD94CD8E563483_label_en-US" xlink:label="lab_dei_AmendmentFlag_4E9F2A103815509F96AA1EEEC369176E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_4E9F2A103815509F96AA1EEEC369176E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_4E9F2A103815509F96AA1EEEC369176E" xlink:to="lab_dei_AmendmentFlag_4E9F2A103815509F96AA1EEEC369176E" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8AD7125A9BC1AA93A9C394CD8E563A91_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_16692DEA1DEF5D84B1AF898A82887BA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8AD7125A9BC1AA93A9C394CD8E563A91_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_16692DEA1DEF5D84B1AF898A82887BA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_16692DEA1DEF5D84B1AF898A82887BA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_16692DEA1DEF5D84B1AF898A82887BA5" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_16692DEA1DEF5D84B1AF898A82887BA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8131CEB7ECD9B9ECFA631C26775BF177_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8131CEB7ECD9B9ECFA631C26775BF177" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8131CEB7ECD9B9ECFA631C26775BF177_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8131CEB7ECD9B9ECFA631C26775BF177" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8131CEB7ECD9B9ECFA631C26775BF177" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8131CEB7ECD9B9ECFA631C26775BF177" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8131CEB7ECD9B9ECFA631C26775BF177" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_D400ACF6839EF9FBD0401C26775BA4E1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis_D400ACF6839EF9FBD0401C26775BA4E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_D400ACF6839EF9FBD0401C26775BA4E1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis_D400ACF6839EF9FBD0401C26775BA4E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_D400ACF6839EF9FBD0401C26775BA4E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_D400ACF6839EF9FBD0401C26775BA4E1" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis_D400ACF6839EF9FBD0401C26775BA4E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_07996FE250E9F548691A1C26775BFEF4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain_07996FE250E9F548691A1C26775BFEF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_07996FE250E9F548691A1C26775BFEF4_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain_07996FE250E9F548691A1C26775BFEF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_07996FE250E9F548691A1C26775BFEF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_07996FE250E9F548691A1C26775BFEF4" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain_07996FE250E9F548691A1C26775BFEF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_F02566B8A1CDB144308D1C26775BA319_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember_F02566B8A1CDB144308D1C26775BA319" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_F02566B8A1CDB144308D1C26775BA319_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember_F02566B8A1CDB144308D1C26775BA319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_F02566B8A1CDB144308D1C26775BA319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember_F02566B8A1CDB144308D1C26775BA319" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember_F02566B8A1CDB144308D1C26775BA319" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_41B2A31C953F2FC07B1D1C26775B7ECF_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_41B2A31C953F2FC07B1D1C26775B7ECF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_41B2A31C953F2FC07B1D1C26775B7ECF_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_41B2A31C953F2FC07B1D1C26775B7ECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_41B2A31C953F2FC07B1D1C26775B7ECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_41B2A31C953F2FC07B1D1C26775B7ECF" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_41B2A31C953F2FC07B1D1C26775B7ECF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_EF99DACFEAB718C93A741C26775BEA4C_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_EF99DACFEAB718C93A741C26775BEA4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_EF99DACFEAB718C93A741C26775BEA4C_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_EF99DACFEAB718C93A741C26775BEA4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_EF99DACFEAB718C93A741C26775BEA4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_EF99DACFEAB718C93A741C26775BEA4C" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_EF99DACFEAB718C93A741C26775BEA4C" xlink:type="arc" />
    <link:label id="lab_tbio_GeneticAssaysandPlatformsandPatientTestingMember_05551864FACF5825970C1C26775B9044_terseLabel_en-US" xlink:label="lab_tbio_GeneticAssaysandPlatformsandPatientTestingMember_05551864FACF5825970C1C26775B9044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genetic Assays and Platforms and Patient Testing</link:label>
    <link:label id="lab_tbio_GeneticAssaysandPlatformsandPatientTestingMember_05551864FACF5825970C1C26775B9044_label_en-US" xlink:label="lab_tbio_GeneticAssaysandPlatformsandPatientTestingMember_05551864FACF5825970C1C26775B9044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genetic Assays and Platforms and Patient Testing [Member]</link:label>
    <link:label id="lab_tbio_GeneticAssaysandPlatformsandPatientTestingMember_05551864FACF5825970C1C26775B9044_documentation_en-US" xlink:label="lab_tbio_GeneticAssaysandPlatformsandPatientTestingMember_05551864FACF5825970C1C26775B9044" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genetic Assays and Platforms and Patient Testing [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_GeneticAssaysandPlatformsandPatientTestingMember" xlink:label="loc_tbio_GeneticAssaysandPlatformsandPatientTestingMember_05551864FACF5825970C1C26775B9044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_GeneticAssaysandPlatformsandPatientTestingMember_05551864FACF5825970C1C26775B9044" xlink:to="lab_tbio_GeneticAssaysandPlatformsandPatientTestingMember_05551864FACF5825970C1C26775B9044" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_35A56375BE94F9F0D0BD1C26775B6297_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_35A56375BE94F9F0D0BD1C26775B6297" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_35A56375BE94F9F0D0BD1C26775B6297_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_35A56375BE94F9F0D0BD1C26775B6297" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_35A56375BE94F9F0D0BD1C26775B6297" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_35A56375BE94F9F0D0BD1C26775B6297" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_35A56375BE94F9F0D0BD1C26775B6297" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_C67AB91D5A559730B7DA1C26775BC289_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_C67AB91D5A559730B7DA1C26775BC289" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_C67AB91D5A559730B7DA1C26775BC289_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_C67AB91D5A559730B7DA1C26775BC289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_C67AB91D5A559730B7DA1C26775BC289" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_C67AB91D5A559730B7DA1C26775BC289" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_C67AB91D5A559730B7DA1C26775BC289" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_F3B245D989E75AC6F30B1C26775B5ABE_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_F3B245D989E75AC6F30B1C26775B5ABE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit (loss)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_F3B245D989E75AC6F30B1C26775B5ABE_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_F3B245D989E75AC6F30B1C26775B5ABE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gross Profit (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_F3B245D989E75AC6F30B1C26775B5ABE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_F3B245D989E75AC6F30B1C26775B5ABE" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_F3B245D989E75AC6F30B1C26775B5ABE" xlink:type="arc" />
    <link:label id="lab_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense_9D1CFE30C80ECF8181431C26775B53C9_terseLabel_en-US" xlink:label="lab_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense_9D1CFE30C80ECF8181431C26775B53C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense_9D1CFE30C80ECF8181431C26775B53C9_label_en-US" xlink:label="lab_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense_9D1CFE30C80ECF8181431C26775B53C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Selling, General And Administrative Expense</link:label>
    <link:label id="lab_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense_9D1CFE30C80ECF8181431C26775B53C9_documentation_en-US" xlink:label="lab_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense_9D1CFE30C80ECF8181431C26775B53C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Selling, General And Administrative Expense</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense" xlink:label="loc_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense_9D1CFE30C80ECF8181431C26775B53C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense_9D1CFE30C80ECF8181431C26775B53C9" xlink:to="lab_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense_9D1CFE30C80ECF8181431C26775B53C9" xlink:type="arc" />
    <link:label id="lab_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense_3F9309E2946A40CC5F371C26775C6E0C_terseLabel_en-US" xlink:label="lab_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense_3F9309E2946A40CC5F371C26775C6E0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense_3F9309E2946A40CC5F371C26775C6E0C_label_en-US" xlink:label="lab_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense_3F9309E2946A40CC5F371C26775C6E0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development Expense</link:label>
    <link:label id="lab_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense_3F9309E2946A40CC5F371C26775C6E0C_documentation_en-US" xlink:label="lab_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense_3F9309E2946A40CC5F371C26775C6E0C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development Expense</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense" xlink:label="loc_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense_3F9309E2946A40CC5F371C26775C6E0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense_3F9309E2946A40CC5F371C26775C6E0C" xlink:to="lab_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense_3F9309E2946A40CC5F371C26775C6E0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_FAE55C2E7EDD65AA78881C26775C75FB_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_FAE55C2E7EDD65AA78881C26775C75FB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income (loss) from discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_FAE55C2E7EDD65AA78881C26775C75FB_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_FAE55C2E7EDD65AA78881C26775C75FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_FAE55C2E7EDD65AA78881C26775C75FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_FAE55C2E7EDD65AA78881C26775C75FB" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_FAE55C2E7EDD65AA78881C26775C75FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_6DBAC20CA4B6A6F6FBF71C26775C152B_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_6DBAC20CA4B6A6F6FBF71C26775C152B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on settlement of liability</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_6DBAC20CA4B6A6F6FBF71C26775C152B_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_6DBAC20CA4B6A6F6FBF71C26775C152B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6DBAC20CA4B6A6F6FBF71C26775C152B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6DBAC20CA4B6A6F6FBF71C26775C152B" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_6DBAC20CA4B6A6F6FBF71C26775C152B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_C906F295B088C131D31E1C26775CB77F_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_C906F295B088C131D31E1C26775CB77F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from discontinued operations before income taxes</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_C906F295B088C131D31E1C26775CB77F_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_C906F295B088C131D31E1C26775CB77F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_C906F295B088C131D31E1C26775CB77F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_C906F295B088C131D31E1C26775CB77F" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_C906F295B088C131D31E1C26775CB77F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_2B7C4633146466F3132D1C26775CD47B_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_2B7C4633146466F3132D1C26775CD47B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_2B7C4633146466F3132D1C26775CD47B_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_2B7C4633146466F3132D1C26775CD47B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_2B7C4633146466F3132D1C26775CD47B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_2B7C4633146466F3132D1C26775CD47B" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_2B7C4633146466F3132D1C26775CD47B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_C386ABC9DD02DAE58E3D1C26775CC726_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_C386ABC9DD02DAE58E3D1C26775CC726" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from discontinued operations, net of taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_C386ABC9DD02DAE58E3D1C26775CC726_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_C386ABC9DD02DAE58E3D1C26775CC726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_C386ABC9DD02DAE58E3D1C26775CC726" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_C386ABC9DD02DAE58E3D1C26775CC726" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_C386ABC9DD02DAE58E3D1C26775CC726" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_33741C0BD4E1DF1FB3291C2B33712D31_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_33741C0BD4E1DF1FB3291C2B33712D31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_33741C0BD4E1DF1FB3291C2B33712D31_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_33741C0BD4E1DF1FB3291C2B33712D31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_33741C0BD4E1DF1FB3291C2B33712D31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_33741C0BD4E1DF1FB3291C2B33712D31" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_33741C0BD4E1DF1FB3291C2B33712D31" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_794A1791C39094C01ED3FE284701A509_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_794A1791C39094C01ED3FE284701A509" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_794A1791C39094C01ED3FE284701A509_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_794A1791C39094C01ED3FE284701A509" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_794A1791C39094C01ED3FE284701A509" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_794A1791C39094C01ED3FE284701A509" xlink:to="lab_us-gaap_LossContingenciesTable_794A1791C39094C01ED3FE284701A509" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationCaseAxis_7712BBB49D2E2663B528FE284701094B_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationCaseAxis_7712BBB49D2E2663B528FE284701094B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationCaseAxis_7712BBB49D2E2663B528FE284701094B_label_en-US" xlink:label="lab_us-gaap_LitigationCaseAxis_7712BBB49D2E2663B528FE284701094B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_7712BBB49D2E2663B528FE284701094B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationCaseAxis_7712BBB49D2E2663B528FE284701094B" xlink:to="lab_us-gaap_LitigationCaseAxis_7712BBB49D2E2663B528FE284701094B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC_label_en-US" xlink:label="lab_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:to="lab_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:type="arc" />
    <link:label id="lab_tbio_UNMCMember_D184C1A38071F5C69627FE2847012537_terseLabel_en-US" xlink:label="lab_tbio_UNMCMember_D184C1A38071F5C69627FE2847012537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UNMC</link:label>
    <link:label id="lab_tbio_UNMCMember_D184C1A38071F5C69627FE2847012537_label_en-US" xlink:label="lab_tbio_UNMCMember_D184C1A38071F5C69627FE2847012537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNMC [Member]</link:label>
    <link:label id="lab_tbio_UNMCMember_D184C1A38071F5C69627FE2847012537_documentation_en-US" xlink:label="lab_tbio_UNMCMember_D184C1A38071F5C69627FE2847012537" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UNMC [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_UNMCMember" xlink:label="loc_tbio_UNMCMember_D184C1A38071F5C69627FE2847012537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_UNMCMember_D184C1A38071F5C69627FE2847012537" xlink:to="lab_tbio_UNMCMember_D184C1A38071F5C69627FE2847012537" xlink:type="arc" />
    <link:label id="lab_tbio_MountSinaiMember_16E370EB8EA33B3D6A01FE2847011F04_terseLabel_en-US" xlink:label="lab_tbio_MountSinaiMember_16E370EB8EA33B3D6A01FE2847011F04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mount Sinai</link:label>
    <link:label id="lab_tbio_MountSinaiMember_16E370EB8EA33B3D6A01FE2847011F04_label_en-US" xlink:label="lab_tbio_MountSinaiMember_16E370EB8EA33B3D6A01FE2847011F04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mount Sinai [Member]</link:label>
    <link:label id="lab_tbio_MountSinaiMember_16E370EB8EA33B3D6A01FE2847011F04_documentation_en-US" xlink:label="lab_tbio_MountSinaiMember_16E370EB8EA33B3D6A01FE2847011F04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mount Sinai [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_MountSinaiMember" xlink:label="loc_tbio_MountSinaiMember_16E370EB8EA33B3D6A01FE2847011F04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_MountSinaiMember_16E370EB8EA33B3D6A01FE2847011F04" xlink:to="lab_tbio_MountSinaiMember_16E370EB8EA33B3D6A01FE2847011F04" xlink:type="arc" />
    <link:label id="lab_tbio_SmithMember_84BE32A93402A72A1D24FE284701666D_terseLabel_en-US" xlink:label="lab_tbio_SmithMember_84BE32A93402A72A1D24FE284701666D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Smith</link:label>
    <link:label id="lab_tbio_SmithMember_84BE32A93402A72A1D24FE284701666D_label_en-US" xlink:label="lab_tbio_SmithMember_84BE32A93402A72A1D24FE284701666D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Smith [Member]</link:label>
    <link:label id="lab_tbio_SmithMember_84BE32A93402A72A1D24FE284701666D_documentation_en-US" xlink:label="lab_tbio_SmithMember_84BE32A93402A72A1D24FE284701666D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Smith [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SmithMember" xlink:label="loc_tbio_SmithMember_84BE32A93402A72A1D24FE284701666D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_SmithMember_84BE32A93402A72A1D24FE284701666D" xlink:to="lab_tbio_SmithMember_84BE32A93402A72A1D24FE284701666D" xlink:type="arc" />
    <link:label id="lab_tbio_XIFINInc.Member_5C2A8E3A1B867410A239FE284701D5F2_terseLabel_en-US" xlink:label="lab_tbio_XIFINInc.Member_5C2A8E3A1B867410A239FE284701D5F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">XIFIN, Inc.</link:label>
    <link:label id="lab_tbio_XIFINInc.Member_5C2A8E3A1B867410A239FE284701D5F2_label_en-US" xlink:label="lab_tbio_XIFINInc.Member_5C2A8E3A1B867410A239FE284701D5F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">XIFIN, Inc. [Member]</link:label>
    <link:label id="lab_tbio_XIFINInc.Member_5C2A8E3A1B867410A239FE284701D5F2_documentation_en-US" xlink:label="lab_tbio_XIFINInc.Member_5C2A8E3A1B867410A239FE284701D5F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">XIFIN, Inc. [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_XIFINInc.Member" xlink:label="loc_tbio_XIFINInc.Member_5C2A8E3A1B867410A239FE284701D5F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_XIFINInc.Member_5C2A8E3A1B867410A239FE284701D5F2" xlink:to="lab_tbio_XIFINInc.Member_5C2A8E3A1B867410A239FE284701D5F2" xlink:type="arc" />
    <link:label id="lab_tbio_ScienceParkDevelopmentCorporationMember_E85EDA555642964F7F26FE284701967D_terseLabel_en-US" xlink:label="lab_tbio_ScienceParkDevelopmentCorporationMember_E85EDA555642964F7F26FE284701967D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Science Park Development Corporation</link:label>
    <link:label id="lab_tbio_ScienceParkDevelopmentCorporationMember_E85EDA555642964F7F26FE284701967D_label_en-US" xlink:label="lab_tbio_ScienceParkDevelopmentCorporationMember_E85EDA555642964F7F26FE284701967D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Science Park Development Corporation [Member]</link:label>
    <link:label id="lab_tbio_ScienceParkDevelopmentCorporationMember_E85EDA555642964F7F26FE284701967D_documentation_en-US" xlink:label="lab_tbio_ScienceParkDevelopmentCorporationMember_E85EDA555642964F7F26FE284701967D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Science Park Development Corporation [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ScienceParkDevelopmentCorporationMember" xlink:label="loc_tbio_ScienceParkDevelopmentCorporationMember_E85EDA555642964F7F26FE284701967D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_ScienceParkDevelopmentCorporationMember_E85EDA555642964F7F26FE284701967D" xlink:to="lab_tbio_ScienceParkDevelopmentCorporationMember_E85EDA555642964F7F26FE284701967D" xlink:type="arc" />
    <link:label id="lab_tbio_CPAGlobalMember_C5298113F43077631E65FE2847013E07_terseLabel_en-US" xlink:label="lab_tbio_CPAGlobalMember_C5298113F43077631E65FE2847013E07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CPA Global</link:label>
    <link:label id="lab_tbio_CPAGlobalMember_C5298113F43077631E65FE2847013E07_label_en-US" xlink:label="lab_tbio_CPAGlobalMember_C5298113F43077631E65FE2847013E07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CPA Global [Member]</link:label>
    <link:label id="lab_tbio_CPAGlobalMember_C5298113F43077631E65FE2847013E07_documentation_en-US" xlink:label="lab_tbio_CPAGlobalMember_C5298113F43077631E65FE2847013E07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CPA Global [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_CPAGlobalMember" xlink:label="loc_tbio_CPAGlobalMember_C5298113F43077631E65FE2847013E07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_CPAGlobalMember_C5298113F43077631E65FE2847013E07" xlink:to="lab_tbio_CPAGlobalMember_C5298113F43077631E65FE2847013E07" xlink:type="arc" />
    <link:label id="lab_tbio_EdgeBioSystemsInc.Member_333456E834882AD25099FE284701794E_terseLabel_en-US" xlink:label="lab_tbio_EdgeBioSystemsInc.Member_333456E834882AD25099FE284701794E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Edge BioSystems, Inc.</link:label>
    <link:label id="lab_tbio_EdgeBioSystemsInc.Member_333456E834882AD25099FE284701794E_label_en-US" xlink:label="lab_tbio_EdgeBioSystemsInc.Member_333456E834882AD25099FE284701794E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Edge BioSystems, Inc. [Member]</link:label>
    <link:label id="lab_tbio_EdgeBioSystemsInc.Member_333456E834882AD25099FE284701794E_documentation_en-US" xlink:label="lab_tbio_EdgeBioSystemsInc.Member_333456E834882AD25099FE284701794E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Edge BioSystems, Inc. [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_EdgeBioSystemsInc.Member" xlink:label="loc_tbio_EdgeBioSystemsInc.Member_333456E834882AD25099FE284701794E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_EdgeBioSystemsInc.Member_333456E834882AD25099FE284701794E" xlink:to="lab_tbio_EdgeBioSystemsInc.Member_333456E834882AD25099FE284701794E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_1BA93A9D803C9462A9AFFE28AA4CE8F6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_1BA93A9D803C9462A9AFFE28AA4CE8F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_1BA93A9D803C9462A9AFFE28AA4CE8F6_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_1BA93A9D803C9462A9AFFE28AA4CE8F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1BA93A9D803C9462A9AFFE28AA4CE8F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1BA93A9D803C9462A9AFFE28AA4CE8F6" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_1BA93A9D803C9462A9AFFE28AA4CE8F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_D8832AF800381F4D07B4FE28AC12348D_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_D8832AF800381F4D07B4FE28AC12348D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_D8832AF800381F4D07B4FE28AC12348D_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_D8832AF800381F4D07B4FE28AC12348D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_D8832AF800381F4D07B4FE28AC12348D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_D8832AF800381F4D07B4FE28AC12348D" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_D8832AF800381F4D07B4FE28AC12348D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_01E16122048407576433FE292DAEF3A7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_01E16122048407576433FE292DAEF3A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_01E16122048407576433FE292DAEF3A7_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_01E16122048407576433FE292DAEF3A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_01E16122048407576433FE292DAEF3A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_01E16122048407576433FE292DAEF3A7" xlink:to="lab_us-gaap_SubsequentEventMember_01E16122048407576433FE292DAEF3A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:to="lab_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:type="arc" />
    <link:label id="lab_tbio_DelinquentAccountsPayable_ED03BFA643F099E01A4AFE2847016277_terseLabel_en-US" xlink:label="lab_tbio_DelinquentAccountsPayable_ED03BFA643F099E01A4AFE2847016277" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Delinquent accounts payable</link:label>
    <link:label id="lab_tbio_DelinquentAccountsPayable_ED03BFA643F099E01A4AFE2847016277_label_en-US" xlink:label="lab_tbio_DelinquentAccountsPayable_ED03BFA643F099E01A4AFE2847016277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Delinquent Accounts Payable</link:label>
    <link:label id="lab_tbio_DelinquentAccountsPayable_ED03BFA643F099E01A4AFE2847016277_documentation_en-US" xlink:label="lab_tbio_DelinquentAccountsPayable_ED03BFA643F099E01A4AFE2847016277" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Delinquent Accounts Payable</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DelinquentAccountsPayable" xlink:label="loc_tbio_DelinquentAccountsPayable_ED03BFA643F099E01A4AFE2847016277" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_DelinquentAccountsPayable_ED03BFA643F099E01A4AFE2847016277" xlink:to="lab_tbio_DelinquentAccountsPayable_ED03BFA643F099E01A4AFE2847016277" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_CAE6273AE35BACF04150FE2847018A38_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_CAE6273AE35BACF04150FE2847018A38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Damages sought in a lawsuit</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_CAE6273AE35BACF04150FE2847018A38_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_CAE6273AE35BACF04150FE2847018A38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_CAE6273AE35BACF04150FE2847018A38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue_CAE6273AE35BACF04150FE2847018A38" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue_CAE6273AE35BACF04150FE2847018A38" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_828A59321A550D8D3A67FE2847016A1F_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_828A59321A550D8D3A67FE2847016A1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_828A59321A550D8D3A67FE2847016A1F_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_828A59321A550D8D3A67FE2847016A1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_828A59321A550D8D3A67FE2847016A1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_828A59321A550D8D3A67FE2847016A1F" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue_828A59321A550D8D3A67FE2847016A1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_024B789388731B12AE87FE284701714E_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue_024B789388731B12AE87FE284701714E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrual of possible loss in a lawsuit</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_024B789388731B12AE87FE284701714E_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue_024B789388731B12AE87FE284701714E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_024B789388731B12AE87FE284701714E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue_024B789388731B12AE87FE284701714E" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue_024B789388731B12AE87FE284701714E" xlink:type="arc" />
    <link:label id="lab_tbio_LossContingencyDeferredPayment_3291D351928EA8AB0491FE28470158B0_terseLabel_en-US" xlink:label="lab_tbio_LossContingencyDeferredPayment_3291D351928EA8AB0491FE28470158B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred loss payment</link:label>
    <link:label id="lab_tbio_LossContingencyDeferredPayment_3291D351928EA8AB0491FE28470158B0_label_en-US" xlink:label="lab_tbio_LossContingencyDeferredPayment_3291D351928EA8AB0491FE28470158B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Deferred Payment</link:label>
    <link:label id="lab_tbio_LossContingencyDeferredPayment_3291D351928EA8AB0491FE28470158B0_documentation_en-US" xlink:label="lab_tbio_LossContingencyDeferredPayment_3291D351928EA8AB0491FE28470158B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Deferred Payment</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_LossContingencyDeferredPayment" xlink:label="loc_tbio_LossContingencyDeferredPayment_3291D351928EA8AB0491FE28470158B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_LossContingencyDeferredPayment_3291D351928EA8AB0491FE28470158B0" xlink:to="lab_tbio_LossContingencyDeferredPayment_3291D351928EA8AB0491FE28470158B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_E68FBCF37B94426A3459F994083F08FA_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_E68FBCF37B94426A3459F994083F08FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_E68FBCF37B94426A3459F994083F08FA_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_E68FBCF37B94426A3459F994083F08FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_E68FBCF37B94426A3459F994083F08FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_E68FBCF37B94426A3459F994083F08FA" xlink:to="lab_us-gaap_AssetsAbstract_E68FBCF37B94426A3459F994083F08FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6A48FCEC519A62743614F994083F4BE7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_6A48FCEC519A62743614F994083F4BE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6A48FCEC519A62743614F994083F4BE7_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_6A48FCEC519A62743614F994083F4BE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6A48FCEC519A62743614F994083F4BE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6A48FCEC519A62743614F994083F4BE7" xlink:to="lab_us-gaap_AssetsCurrentAbstract_6A48FCEC519A62743614F994083F4BE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C533AA389AFDBEB7CB3BF994083F08C7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C533AA389AFDBEB7CB3BF994083F08C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C533AA389AFDBEB7CB3BF994083F08C7_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C533AA389AFDBEB7CB3BF994083F08C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C533AA389AFDBEB7CB3BF994083F08C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C533AA389AFDBEB7CB3BF994083F08C7" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C533AA389AFDBEB7CB3BF994083F08C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_19324F25440592A1A773F994083FABB5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_19324F25440592A1A773F994083FABB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_19324F25440592A1A773F994083FABB5_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_19324F25440592A1A773F994083FABB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_19324F25440592A1A773F994083FABB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_19324F25440592A1A773F994083FABB5" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_19324F25440592A1A773F994083FABB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_94A2E567CBC71B35078DF994083FEB67_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_94A2E567CBC71B35078DF994083FEB67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_94A2E567CBC71B35078DF994083FEB67_label_en-US" xlink:label="lab_us-gaap_InventoryNet_94A2E567CBC71B35078DF994083FEB67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_94A2E567CBC71B35078DF994083FEB67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_94A2E567CBC71B35078DF994083FEB67" xlink:to="lab_us-gaap_InventoryNet_94A2E567CBC71B35078DF994083FEB67" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_4EEDE65D7F29B6AC2648F994083FAA38_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_4EEDE65D7F29B6AC2648F994083FAA38" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_4EEDE65D7F29B6AC2648F994083FAA38_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_4EEDE65D7F29B6AC2648F994083FAA38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4EEDE65D7F29B6AC2648F994083FAA38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_4EEDE65D7F29B6AC2648F994083FAA38" xlink:to="lab_us-gaap_AssetsCurrent_4EEDE65D7F29B6AC2648F994083FAA38" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_EDF3FB7927C5991F52DDF994083F8E8A_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_EDF3FB7927C5991F52DDF994083F8E8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_EDF3FB7927C5991F52DDF994083F8E8A_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_EDF3FB7927C5991F52DDF994083F8E8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_EDF3FB7927C5991F52DDF994083F8E8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_EDF3FB7927C5991F52DDF994083F8E8A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_EDF3FB7927C5991F52DDF994083F8E8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_3D84D2D3CABF6AFE200EF994083F2DA9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_3D84D2D3CABF6AFE200EF994083F2DA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_3D84D2D3CABF6AFE200EF994083F2DA9_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_3D84D2D3CABF6AFE200EF994083F2DA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_3D84D2D3CABF6AFE200EF994083F2DA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3D84D2D3CABF6AFE200EF994083F2DA9" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_3D84D2D3CABF6AFE200EF994083F2DA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D57DE0D85DE4BC100390F994083FAD60_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D57DE0D85DE4BC100390F994083FAD60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D57DE0D85DE4BC100390F994083FAD60_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D57DE0D85DE4BC100390F994083FAD60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D57DE0D85DE4BC100390F994083FAD60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D57DE0D85DE4BC100390F994083FAD60" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D57DE0D85DE4BC100390F994083FAD60" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2B967A76DC3CB4A00A0AF994083FA753_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_2B967A76DC3CB4A00A0AF994083FA753" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2B967A76DC3CB4A00A0AF994083FA753_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_2B967A76DC3CB4A00A0AF994083FA753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2B967A76DC3CB4A00A0AF994083FA753" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_2B967A76DC3CB4A00A0AF994083FA753" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_2B967A76DC3CB4A00A0AF994083FA753" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_89B080BB6F2915B220A3F994083F3668_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_89B080BB6F2915B220A3F994083F3668" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_89B080BB6F2915B220A3F994083F3668_label_en-US" xlink:label="lab_us-gaap_Assets_89B080BB6F2915B220A3F994083F3668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_89B080BB6F2915B220A3F994083F3668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_89B080BB6F2915B220A3F994083F3668" xlink:to="lab_us-gaap_Assets_89B080BB6F2915B220A3F994083F3668" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4F3991124886A9697531F994083FCC9C_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4F3991124886A9697531F994083FCC9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4F3991124886A9697531F994083FCC9C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4F3991124886A9697531F994083FCC9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4F3991124886A9697531F994083FCC9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4F3991124886A9697531F994083FCC9C" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4F3991124886A9697531F994083FCC9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_F1524990CC1B939CC496F994083FBA51_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_F1524990CC1B939CC496F994083FBA51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_F1524990CC1B939CC496F994083FBA51_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_F1524990CC1B939CC496F994083FBA51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_F1524990CC1B939CC496F994083FBA51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F1524990CC1B939CC496F994083FBA51" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_F1524990CC1B939CC496F994083FBA51" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_C4F42AF69343C16E2AFAF994083F047D_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_C4F42AF69343C16E2AFAF994083F047D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current maturities of long-term debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_C4F42AF69343C16E2AFAF994083F047D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_C4F42AF69343C16E2AFAF994083F047D" xlink:to="lab_us-gaap_LongTermDebtCurrent_C4F42AF69343C16E2AFAF994083F047D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_263C08D0E0EF529127D5F994083F9635_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_263C08D0E0EF529127D5F994083F9635" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_263C08D0E0EF529127D5F994083F9635_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_263C08D0E0EF529127D5F994083F9635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_263C08D0E0EF529127D5F994083F9635" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_263C08D0E0EF529127D5F994083F9635" xlink:to="lab_us-gaap_AccountsPayableCurrent_263C08D0E0EF529127D5F994083F9635" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7D6AEA74FD027825BE1BF994083F4065_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7D6AEA74FD027825BE1BF994083F4065" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7D6AEA74FD027825BE1BF994083F4065_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7D6AEA74FD027825BE1BF994083F4065" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7D6AEA74FD027825BE1BF994083F4065" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7D6AEA74FD027825BE1BF994083F4065" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7D6AEA74FD027825BE1BF994083F4065" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5096C5EEE075DB6E1285F994083F56FF_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_5096C5EEE075DB6E1285F994083F56FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5096C5EEE075DB6E1285F994083F56FF_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_5096C5EEE075DB6E1285F994083F56FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5096C5EEE075DB6E1285F994083F56FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5096C5EEE075DB6E1285F994083F56FF" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_5096C5EEE075DB6E1285F994083F56FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_A57E1503EB885BC20150F994083F42AF_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_A57E1503EB885BC20150F994083F42AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_A57E1503EB885BC20150F994083F42AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_A57E1503EB885BC20150F994083F42AF" xlink:to="lab_us-gaap_DeferredRevenueCurrent_A57E1503EB885BC20150F994083F42AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_B802919466B98026F301F994083FDD03_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_B802919466B98026F301F994083FDD03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_B802919466B98026F301F994083FDD03_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_B802919466B98026F301F994083FDD03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_B802919466B98026F301F994083FDD03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_B802919466B98026F301F994083FDD03" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_B802919466B98026F301F994083FDD03" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_87F1F7E0D9432980D4ACF994083F68BE_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_87F1F7E0D9432980D4ACF994083F68BE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_87F1F7E0D9432980D4ACF994083F68BE_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_87F1F7E0D9432980D4ACF994083F68BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_87F1F7E0D9432980D4ACF994083F68BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_87F1F7E0D9432980D4ACF994083F68BE" xlink:to="lab_us-gaap_LiabilitiesCurrent_87F1F7E0D9432980D4ACF994083F68BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_B03D69180761086F9331F994083F4EA8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_B03D69180761086F9331F994083F4EA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LONG TERM LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_B03D69180761086F9331F994083F4EA8_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_B03D69180761086F9331F994083F4EA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_B03D69180761086F9331F994083F4EA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_B03D69180761086F9331F994083F4EA8" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_B03D69180761086F9331F994083F4EA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_5D6CCD53A531E54B8A29F994083FC614_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_5D6CCD53A531E54B8A29F994083FC614" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_5D6CCD53A531E54B8A29F994083FC614_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_5D6CCD53A531E54B8A29F994083FC614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_5D6CCD53A531E54B8A29F994083FC614" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_5D6CCD53A531E54B8A29F994083FC614" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_5D6CCD53A531E54B8A29F994083FC614" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6B3A5451437A2CE628C6F994083F4D8D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_6B3A5451437A2CE628C6F994083F4D8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6B3A5451437A2CE628C6F994083F4D8D_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_6B3A5451437A2CE628C6F994083F4D8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6B3A5451437A2CE628C6F994083F4D8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_6B3A5451437A2CE628C6F994083F4D8D" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_6B3A5451437A2CE628C6F994083F4D8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_7256A8A07B14161E4A9BF994083FF72E_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_7256A8A07B14161E4A9BF994083FF72E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_7256A8A07B14161E4A9BF994083FF72E_label_en-US" xlink:label="lab_us-gaap_Liabilities_7256A8A07B14161E4A9BF994083FF72E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_7256A8A07B14161E4A9BF994083FF72E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_7256A8A07B14161E4A9BF994083FF72E" xlink:to="lab_us-gaap_Liabilities_7256A8A07B14161E4A9BF994083FF72E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_44EB7C882112E542011FF994083FCEE2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_44EB7C882112E542011FF994083FCEE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; DEFICIT:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_44EB7C882112E542011FF994083FCEE2_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_44EB7C882112E542011FF994083FCEE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_44EB7C882112E542011FF994083FCEE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44EB7C882112E542011FF994083FCEE2" xlink:to="lab_us-gaap_StockholdersEquityAbstract_44EB7C882112E542011FF994083FCEE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_44953D59CDEDC759BEA7F994083F0FC8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_44953D59CDEDC759BEA7F994083F0FC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.01 par value, 15,000,000 shares authorized, 214,705 shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_44953D59CDEDC759BEA7F994083F0FC8_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_44953D59CDEDC759BEA7F994083F0FC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_44953D59CDEDC759BEA7F994083F0FC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_44953D59CDEDC759BEA7F994083F0FC8" xlink:to="lab_us-gaap_PreferredStockValue_44953D59CDEDC759BEA7F994083F0FC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_8610DB1B1D514A2BB424F994083F0469_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_8610DB1B1D514A2BB424F994083F0469" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value, 150,000,000 shares authorized, 26,863,062 shares at March 31, 2017 and 26,446,927 shares at December 31, 2016 issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_8610DB1B1D514A2BB424F994083F0469_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_8610DB1B1D514A2BB424F994083F0469" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_8610DB1B1D514A2BB424F994083F0469" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_8610DB1B1D514A2BB424F994083F0469" xlink:to="lab_us-gaap_CommonStockValue_8610DB1B1D514A2BB424F994083F0469" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_C6BE7F738F66B0C20FB4F994083F7139_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_C6BE7F738F66B0C20FB4F994083F7139" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_C6BE7F738F66B0C20FB4F994083F7139_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_C6BE7F738F66B0C20FB4F994083F7139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_C6BE7F738F66B0C20FB4F994083F7139" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_C6BE7F738F66B0C20FB4F994083F7139" xlink:to="lab_us-gaap_AdditionalPaidInCapital_C6BE7F738F66B0C20FB4F994083F7139" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_420C73C4A717F5189DABF994083FD76F_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_420C73C4A717F5189DABF994083FD76F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_420C73C4A717F5189DABF994083FD76F_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_420C73C4A717F5189DABF994083FD76F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_420C73C4A717F5189DABF994083FD76F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_420C73C4A717F5189DABF994083FD76F" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_420C73C4A717F5189DABF994083FD76F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_A565470082F3FC267E41F994083F587D_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_A565470082F3FC267E41F994083F587D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_A565470082F3FC267E41F994083F587D_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_A565470082F3FC267E41F994083F587D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A565470082F3FC267E41F994083F587D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_A565470082F3FC267E41F994083F587D" xlink:to="lab_us-gaap_StockholdersEquity_A565470082F3FC267E41F994083F587D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_592CCA24C3A563353587F994083F4B58_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_592CCA24C3A563353587F994083F4B58" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_592CCA24C3A563353587F994083F4B58_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_592CCA24C3A563353587F994083F4B58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_592CCA24C3A563353587F994083F4B58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_592CCA24C3A563353587F994083F4B58" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_592CCA24C3A563353587F994083F4B58" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_9A2454F12C64BB6A93630CE49DD04BFA_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_9A2454F12C64BB6A93630CE49DD04BFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9A2454F12C64BB6A93630CE49DD04BFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9A2454F12C64BB6A93630CE49DD04BFA" xlink:to="lab_us-gaap_SubsequentEventsAbstract_9A2454F12C64BB6A93630CE49DD04BFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40" xlink:to="lab_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_80405FC43A261EA7DD380CE49DD0714B_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_80405FC43A261EA7DD380CE49DD0714B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_80405FC43A261EA7DD380CE49DD0714B_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_80405FC43A261EA7DD380CE49DD0714B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_80405FC43A261EA7DD380CE49DD0714B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_80405FC43A261EA7DD380CE49DD0714B" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis_80405FC43A261EA7DD380CE49DD0714B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_33960ECBAE207F4F40760CE49DD1EEA6_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_33960ECBAE207F4F40760CE49DD1EEA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_33960ECBAE207F4F40760CE49DD1EEA6_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_33960ECBAE207F4F40760CE49DD1EEA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_33960ECBAE207F4F40760CE49DD1EEA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_33960ECBAE207F4F40760CE49DD1EEA6" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain_33960ECBAE207F4F40760CE49DD1EEA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BridgeLoanMember_D91F96F014DAEC9213F20CE49DD11260_terseLabel_en-US" xlink:label="lab_us-gaap_BridgeLoanMember_D91F96F014DAEC9213F20CE49DD11260" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:label id="lab_us-gaap_BridgeLoanMember_D91F96F014DAEC9213F20CE49DD11260_label_en-US" xlink:label="lab_us-gaap_BridgeLoanMember_D91F96F014DAEC9213F20CE49DD11260" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_D91F96F014DAEC9213F20CE49DD11260" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember_D91F96F014DAEC9213F20CE49DD11260" xlink:to="lab_us-gaap_BridgeLoanMember_D91F96F014DAEC9213F20CE49DD11260" xlink:type="arc" />
    <link:label id="lab_tbio_AegisCorpMember_34A10592FD9A8F6753C30CE49DD1AD37_terseLabel_en-US" xlink:label="lab_tbio_AegisCorpMember_34A10592FD9A8F6753C30CE49DD1AD37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aegis Corp</link:label>
    <link:label id="lab_tbio_AegisCorpMember_34A10592FD9A8F6753C30CE49DD1AD37_label_en-US" xlink:label="lab_tbio_AegisCorpMember_34A10592FD9A8F6753C30CE49DD1AD37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aegis Corp [Member]</link:label>
    <link:label id="lab_tbio_AegisCorpMember_34A10592FD9A8F6753C30CE49DD1AD37_documentation_en-US" xlink:label="lab_tbio_AegisCorpMember_34A10592FD9A8F6753C30CE49DD1AD37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aegis Corp [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AegisCorpMember" xlink:label="loc_tbio_AegisCorpMember_34A10592FD9A8F6753C30CE49DD1AD37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_AegisCorpMember_34A10592FD9A8F6753C30CE49DD1AD37" xlink:to="lab_tbio_AegisCorpMember_34A10592FD9A8F6753C30CE49DD1AD37" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="lab_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:type="arc" />
    <link:label id="lab_tbio_AdditionalShorttermLoanMaximumAmountAuthorized_5C12CE79F9C3A8EAB0C30CE49DD28CF8_terseLabel_en-US" xlink:label="lab_tbio_AdditionalShorttermLoanMaximumAmountAuthorized_5C12CE79F9C3A8EAB0C30CE49DD28CF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum additional bridge loan amount</link:label>
    <link:label id="lab_tbio_AdditionalShorttermLoanMaximumAmountAuthorized_5C12CE79F9C3A8EAB0C30CE49DD28CF8_label_en-US" xlink:label="lab_tbio_AdditionalShorttermLoanMaximumAmountAuthorized_5C12CE79F9C3A8EAB0C30CE49DD28CF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Short-term Loan, Maximum Amount Authorized</link:label>
    <link:label id="lab_tbio_AdditionalShorttermLoanMaximumAmountAuthorized_5C12CE79F9C3A8EAB0C30CE49DD28CF8_documentation_en-US" xlink:label="lab_tbio_AdditionalShorttermLoanMaximumAmountAuthorized_5C12CE79F9C3A8EAB0C30CE49DD28CF8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Short-term Loan, Maximum Amount Authorized</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AdditionalShorttermLoanMaximumAmountAuthorized" xlink:label="loc_tbio_AdditionalShorttermLoanMaximumAmountAuthorized_5C12CE79F9C3A8EAB0C30CE49DD28CF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_AdditionalShorttermLoanMaximumAmountAuthorized_5C12CE79F9C3A8EAB0C30CE49DD28CF8" xlink:to="lab_tbio_AdditionalShorttermLoanMaximumAmountAuthorized_5C12CE79F9C3A8EAB0C30CE49DD28CF8" xlink:type="arc" />
    <link:label id="lab_tbio_ProceedsFromtheSalesofDebtInstrument_C9BFD350F7E1BA02A1A70CE49DD2CCDB_terseLabel_en-US" xlink:label="lab_tbio_ProceedsFromtheSalesofDebtInstrument_C9BFD350F7E1BA02A1A70CE49DD2CCDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sales of debt instrument</link:label>
    <link:label id="lab_tbio_ProceedsFromtheSalesofDebtInstrument_C9BFD350F7E1BA02A1A70CE49DD2CCDB_label_en-US" xlink:label="lab_tbio_ProceedsFromtheSalesofDebtInstrument_C9BFD350F7E1BA02A1A70CE49DD2CCDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From the Sales of Debt Instrument</link:label>
    <link:label id="lab_tbio_ProceedsFromtheSalesofDebtInstrument_C9BFD350F7E1BA02A1A70CE49DD2CCDB_documentation_en-US" xlink:label="lab_tbio_ProceedsFromtheSalesofDebtInstrument_C9BFD350F7E1BA02A1A70CE49DD2CCDB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From the Sales of Debt Instrument</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ProceedsFromtheSalesofDebtInstrument" xlink:label="loc_tbio_ProceedsFromtheSalesofDebtInstrument_C9BFD350F7E1BA02A1A70CE49DD2CCDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_ProceedsFromtheSalesofDebtInstrument_C9BFD350F7E1BA02A1A70CE49DD2CCDB" xlink:to="lab_tbio_ProceedsFromtheSalesofDebtInstrument_C9BFD350F7E1BA02A1A70CE49DD2CCDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTerm_679DA1D54B6E2790A5350CE49DD2A630_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_679DA1D54B6E2790A5350CE49DD2A630" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_679DA1D54B6E2790A5350CE49DD2A630_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_679DA1D54B6E2790A5350CE49DD2A630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_679DA1D54B6E2790A5350CE49DD2A630" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm_679DA1D54B6E2790A5350CE49DD2A630" xlink:to="lab_us-gaap_DebtInstrumentTerm_679DA1D54B6E2790A5350CE49DD2A630" xlink:type="arc" />
    <link:label id="lab_tbio_DebtInstrumentPremiumFeePercentage_D3F0CFAB4D158FDB17170CE49DD29B7B_terseLabel_en-US" xlink:label="lab_tbio_DebtInstrumentPremiumFeePercentage_D3F0CFAB4D158FDB17170CE49DD29B7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, premium rate (percentage)</link:label>
    <link:label id="lab_tbio_DebtInstrumentPremiumFeePercentage_D3F0CFAB4D158FDB17170CE49DD29B7B_label_en-US" xlink:label="lab_tbio_DebtInstrumentPremiumFeePercentage_D3F0CFAB4D158FDB17170CE49DD29B7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Premium Fee, Percentage</link:label>
    <link:label id="lab_tbio_DebtInstrumentPremiumFeePercentage_D3F0CFAB4D158FDB17170CE49DD29B7B_documentation_en-US" xlink:label="lab_tbio_DebtInstrumentPremiumFeePercentage_D3F0CFAB4D158FDB17170CE49DD29B7B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Premium Fee, Percentage</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentPremiumFeePercentage" xlink:label="loc_tbio_DebtInstrumentPremiumFeePercentage_D3F0CFAB4D158FDB17170CE49DD29B7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_DebtInstrumentPremiumFeePercentage_D3F0CFAB4D158FDB17170CE49DD29B7B" xlink:to="lab_tbio_DebtInstrumentPremiumFeePercentage_D3F0CFAB4D158FDB17170CE49DD29B7B" xlink:type="arc" />
    <link:label id="lab_tbio_LoantoRelatedPartyPercentage_F899E5A568EE88A102360CE49DD29292_terseLabel_en-US" xlink:label="lab_tbio_LoantoRelatedPartyPercentage_F899E5A568EE88A102360CE49DD29292" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of loan to related party</link:label>
    <link:label id="lab_tbio_LoantoRelatedPartyPercentage_F899E5A568EE88A102360CE49DD29292_label_en-US" xlink:label="lab_tbio_LoantoRelatedPartyPercentage_F899E5A568EE88A102360CE49DD29292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan to Related Party Percentage</link:label>
    <link:label id="lab_tbio_LoantoRelatedPartyPercentage_F899E5A568EE88A102360CE49DD29292_documentation_en-US" xlink:label="lab_tbio_LoantoRelatedPartyPercentage_F899E5A568EE88A102360CE49DD29292" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan to Related Party Percentage</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_LoantoRelatedPartyPercentage" xlink:label="loc_tbio_LoantoRelatedPartyPercentage_F899E5A568EE88A102360CE49DD29292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_LoantoRelatedPartyPercentage_F899E5A568EE88A102360CE49DD29292" xlink:to="lab_tbio_LoantoRelatedPartyPercentage_F899E5A568EE88A102360CE49DD29292" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebt_AE3BAD65377E5FBB71C60CE49DD23646_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebt_AE3BAD65377E5FBB71C60CE49DD23646" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebt_AE3BAD65377E5FBB71C60CE49DD23646_label_en-US" xlink:label="lab_us-gaap_SecuredDebt_AE3BAD65377E5FBB71C60CE49DD23646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaap_SecuredDebt_AE3BAD65377E5FBB71C60CE49DD23646" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebt_AE3BAD65377E5FBB71C60CE49DD23646" xlink:to="lab_us-gaap_SecuredDebt_AE3BAD65377E5FBB71C60CE49DD23646" xlink:type="arc" />
    <link:label id="lab_tbio_PlacementFees_BE9EBC64BCAF76FFF5D80CE49DD21157_terseLabel_en-US" xlink:label="lab_tbio_PlacementFees_BE9EBC64BCAF76FFF5D80CE49DD21157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Placement fees</link:label>
    <link:label id="lab_tbio_PlacementFees_BE9EBC64BCAF76FFF5D80CE49DD21157_label_en-US" xlink:label="lab_tbio_PlacementFees_BE9EBC64BCAF76FFF5D80CE49DD21157" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Placement Fees</link:label>
    <link:label id="lab_tbio_PlacementFees_BE9EBC64BCAF76FFF5D80CE49DD21157_documentation_en-US" xlink:label="lab_tbio_PlacementFees_BE9EBC64BCAF76FFF5D80CE49DD21157" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Placement Fees</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PlacementFees" xlink:label="loc_tbio_PlacementFees_BE9EBC64BCAF76FFF5D80CE49DD21157" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_PlacementFees_BE9EBC64BCAF76FFF5D80CE49DD21157" xlink:to="lab_tbio_PlacementFees_BE9EBC64BCAF76FFF5D80CE49DD21157" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_0658A5C35B030AFDA7F325ACF5F36035_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_E840CD3B290D5780B9DD269B6191E4C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_0658A5C35B030AFDA7F325ACF5F36035_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_E840CD3B290D5780B9DD269B6191E4C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_E840CD3B290D5780B9DD269B6191E4C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_E840CD3B290D5780B9DD269B6191E4C6" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_E840CD3B290D5780B9DD269B6191E4C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_DEA9917934A57A9098692FD9E2DAE247_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2527483ABAC750D680413315A15E9283" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_DEA9917934A57A9098692FD9E2DAE247_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2527483ABAC750D680413315A15E9283" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2527483ABAC750D680413315A15E9283" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2527483ABAC750D680413315A15E9283" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2527483ABAC750D680413315A15E9283" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9C30E6C9A65F0872BDF7FDA118EF4A3E_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9C30E6C9A65F0872BDF7FDA118EF4A3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS USED IN OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9C30E6C9A65F0872BDF7FDA118EF4A3E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9C30E6C9A65F0872BDF7FDA118EF4A3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9C30E6C9A65F0872BDF7FDA118EF4A3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9C30E6C9A65F0872BDF7FDA118EF4A3E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9C30E6C9A65F0872BDF7FDA118EF4A3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_B9DFA13C99EA0645892BFDA118EFF375_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_B9DFA13C99EA0645892BFDA118EFF375" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET LOSS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_B9DFA13C99EA0645892BFDA118EFF375_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_B9DFA13C99EA0645892BFDA118EFF375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_B9DFA13C99EA0645892BFDA118EFF375" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_B9DFA13C99EA0645892BFDA118EFF375" xlink:to="lab_us-gaap_NetIncomeLoss_B9DFA13C99EA0645892BFDA118EFF375" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6C2ACD0E88EED12142F8FDA118EFA841_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6C2ACD0E88EED12142F8FDA118EFA841" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less income (loss) from discontinued operations, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6C2ACD0E88EED12142F8FDA118EFA841" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6C2ACD0E88EED12142F8FDA118EFA841" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6C2ACD0E88EED12142F8FDA118EFA841" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_20328C4AC840DFDC0E1AFDA118EFB534_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_20328C4AC840DFDC0E1AFDA118EFB534" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_20328C4AC840DFDC0E1AFDA118EFB534_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_20328C4AC840DFDC0E1AFDA118EFB534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_20328C4AC840DFDC0E1AFDA118EFB534" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_20328C4AC840DFDC0E1AFDA118EFB534" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations_20328C4AC840DFDC0E1AFDA118EFB534" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B9FCB53722387D8409A7FDA118EFF9B9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B9FCB53722387D8409A7FDA118EFF9B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash flows used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B9FCB53722387D8409A7FDA118EFF9B9_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B9FCB53722387D8409A7FDA118EFF9B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B9FCB53722387D8409A7FDA118EFF9B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B9FCB53722387D8409A7FDA118EFF9B9" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B9FCB53722387D8409A7FDA118EFF9B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_CBC37B2C0C244A3219A8FDA118EF3D03_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_CBC37B2C0C244A3219A8FDA118EF3D03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_CBC37B2C0C244A3219A8FDA118EF3D03_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_CBC37B2C0C244A3219A8FDA118EF3D03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_CBC37B2C0C244A3219A8FDA118EF3D03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_CBC37B2C0C244A3219A8FDA118EF3D03" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_CBC37B2C0C244A3219A8FDA118EF3D03" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_E83E820F5E4E0F37B0AAFDA118EFA99A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_E83E820F5E4E0F37B0AAFDA118EFA99A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation and change in liability of stock appreciation rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_E83E820F5E4E0F37B0AAFDA118EFA99A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_E83E820F5E4E0F37B0AAFDA118EFA99A" xlink:to="lab_us-gaap_ShareBasedCompensation_E83E820F5E4E0F37B0AAFDA118EFA99A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_A97718E4D2C7FBCEEA54FDA118EF4217_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_A97718E4D2C7FBCEEA54FDA118EF4217" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Provision for losses on doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_A97718E4D2C7FBCEEA54FDA118EF4217_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_A97718E4D2C7FBCEEA54FDA118EF4217" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for Doubtful Accounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_A97718E4D2C7FBCEEA54FDA118EF4217" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts_A97718E4D2C7FBCEEA54FDA118EF4217" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts_A97718E4D2C7FBCEEA54FDA118EF4217" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_B4C0C94454182D5EB1E0FDA118EF707E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_B4C0C94454182D5EB1E0FDA118EF707E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant revaluation</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_B4C0C94454182D5EB1E0FDA118EF707E_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_B4C0C94454182D5EB1E0FDA118EF707E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_B4C0C94454182D5EB1E0FDA118EF707E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_B4C0C94454182D5EB1E0FDA118EF707E" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_B4C0C94454182D5EB1E0FDA118EF707E" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnContractTermination_0879A28C4C19B362827EFDA1191D621A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnContractTermination_0879A28C4C19B362827EFDA1191D621A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on settlement of lease termination</link:label>
    <link:label id="lab_us-gaap_GainLossOnContractTermination_0879A28C4C19B362827EFDA1191D621A_label_en-US" xlink:label="lab_us-gaap_GainLossOnContractTermination_0879A28C4C19B362827EFDA1191D621A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Contract Termination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="loc_us-gaap_GainLossOnContractTermination_0879A28C4C19B362827EFDA1191D621A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnContractTermination_0879A28C4C19B362827EFDA1191D621A" xlink:to="lab_us-gaap_GainLossOnContractTermination_0879A28C4C19B362827EFDA1191D621A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_8ACA1ADD76B8413AFEF6FDA118EF53D0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_8ACA1ADD76B8413AFEF6FDA118EF53D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred interest</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_8ACA1ADD76B8413AFEF6FDA118EF53D0_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_8ACA1ADD76B8413AFEF6FDA118EF53D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_8ACA1ADD76B8413AFEF6FDA118EF53D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_8ACA1ADD76B8413AFEF6FDA118EF53D0" xlink:to="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_8ACA1ADD76B8413AFEF6FDA118EF53D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429F12C7F75B087BE63BFDA118EF1D14_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429F12C7F75B087BE63BFDA118EF1D14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429F12C7F75B087BE63BFDA118EF1D14_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429F12C7F75B087BE63BFDA118EF1D14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429F12C7F75B087BE63BFDA118EF1D14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429F12C7F75B087BE63BFDA118EF1D14" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429F12C7F75B087BE63BFDA118EF1D14" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_D9056F1362699FAD1D7FFDA118EF5139_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_D9056F1362699FAD1D7FFDA118EF5139" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_D9056F1362699FAD1D7FFDA118EF5139_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_D9056F1362699FAD1D7FFDA118EF5139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_D9056F1362699FAD1D7FFDA118EF5139" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_D9056F1362699FAD1D7FFDA118EF5139" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_D9056F1362699FAD1D7FFDA118EF5139" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_E2127E0DA59C7C6C7AA2FDA118EFF48B_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_E2127E0DA59C7C6C7AA2FDA118EFF48B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_E2127E0DA59C7C6C7AA2FDA118EFF48B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_E2127E0DA59C7C6C7AA2FDA118EFF48B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_E2127E0DA59C7C6C7AA2FDA118EFF48B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_E2127E0DA59C7C6C7AA2FDA118EFF48B" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_E2127E0DA59C7C6C7AA2FDA118EFF48B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_49C4323CB5C4EB2B87F4FDA118EF20F4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_49C4323CB5C4EB2B87F4FDA118EF20F4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_49C4323CB5C4EB2B87F4FDA118EF20F4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_49C4323CB5C4EB2B87F4FDA118EF20F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_49C4323CB5C4EB2B87F4FDA118EF20F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_49C4323CB5C4EB2B87F4FDA118EF20F4" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_49C4323CB5C4EB2B87F4FDA118EF20F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_BC351E36E4D99A288160FDA118EF8DAF_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_BC351E36E4D99A288160FDA118EF8DAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_BC351E36E4D99A288160FDA118EF8DAF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_BC351E36E4D99A288160FDA118EF8DAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_BC351E36E4D99A288160FDA118EF8DAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_BC351E36E4D99A288160FDA118EF8DAF" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_BC351E36E4D99A288160FDA118EF8DAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_B6E6DAB75C1699BDE8A0FDA118EF6193_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_B6E6DAB75C1699BDE8A0FDA118EF6193" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_B6E6DAB75C1699BDE8A0FDA118EF6193_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_B6E6DAB75C1699BDE8A0FDA118EF6193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_B6E6DAB75C1699BDE8A0FDA118EF6193" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_B6E6DAB75C1699BDE8A0FDA118EF6193" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_B6E6DAB75C1699BDE8A0FDA118EF6193" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9886ABD82DB8CD7D4F22FDA118EF46F5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9886ABD82DB8CD7D4F22FDA118EF46F5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities, continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9886ABD82DB8CD7D4F22FDA118EF46F5_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9886ABD82DB8CD7D4F22FDA118EF46F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9886ABD82DB8CD7D4F22FDA118EF46F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9886ABD82DB8CD7D4F22FDA118EF46F5" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9886ABD82DB8CD7D4F22FDA118EF46F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_71D3407EF73196D4CB6CFDA118EFEEC9_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_71D3407EF73196D4CB6CFDA118EFEEC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities, discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_71D3407EF73196D4CB6CFDA118EFEEC9_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_71D3407EF73196D4CB6CFDA118EFEEC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_71D3407EF73196D4CB6CFDA118EFEEC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_71D3407EF73196D4CB6CFDA118EFEEC9" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_71D3407EF73196D4CB6CFDA118EFEEC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_D4142B3F5A0D90F87023FDA118EF86AE_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_D4142B3F5A0D90F87023FDA118EF86AE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_D4142B3F5A0D90F87023FDA118EF86AE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_D4142B3F5A0D90F87023FDA118EF86AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_D4142B3F5A0D90F87023FDA118EF86AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_D4142B3F5A0D90F87023FDA118EF86AE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_D4142B3F5A0D90F87023FDA118EF86AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_74C666BBFFC25211CB71FDA118EFC2FB_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_74C666BBFFC25211CB71FDA118EFC2FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS USED IN INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_74C666BBFFC25211CB71FDA118EFC2FB_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_74C666BBFFC25211CB71FDA118EFC2FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_74C666BBFFC25211CB71FDA118EFC2FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_74C666BBFFC25211CB71FDA118EFC2FB" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_74C666BBFFC25211CB71FDA118EFC2FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FFC4546BE5FE28252AEFDA118EFD2CB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FFC4546BE5FE28252AEFDA118EFD2CB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FFC4546BE5FE28252AEFDA118EFD2CB_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FFC4546BE5FE28252AEFDA118EFD2CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FFC4546BE5FE28252AEFDA118EFD2CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FFC4546BE5FE28252AEFDA118EFD2CB" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FFC4546BE5FE28252AEFDA118EFD2CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6FB6B921ED92C047A6D7FDA118EF02DE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6FB6B921ED92C047A6D7FDA118EF02DE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in other assets</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6FB6B921ED92C047A6D7FDA118EF02DE_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6FB6B921ED92C047A6D7FDA118EF02DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6FB6B921ED92C047A6D7FDA118EF02DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6FB6B921ED92C047A6D7FDA118EF02DE" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6FB6B921ED92C047A6D7FDA118EF02DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_D7973622C7FF70DF8BFBFDA118EF8135_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_D7973622C7FF70DF8BFBFDA118EF8135" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_D7973622C7FF70DF8BFBFDA118EF8135_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_D7973622C7FF70DF8BFBFDA118EF8135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_D7973622C7FF70DF8BFBFDA118EF8135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_D7973622C7FF70DF8BFBFDA118EF8135" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_D7973622C7FF70DF8BFBFDA118EF8135" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2139C0D1502C64605C47FDA118EF0301_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2139C0D1502C64605C47FDA118EF0301" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS (USED IN) PROVIDED BY FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2139C0D1502C64605C47FDA118EF0301_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2139C0D1502C64605C47FDA118EF0301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2139C0D1502C64605C47FDA118EF0301" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2139C0D1502C64605C47FDA118EF0301" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2139C0D1502C64605C47FDA118EF0301" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_0EBC89A22866C591BEF8FDA118EF26A3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_0EBC89A22866C591BEF8FDA118EF26A3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on capital lease obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_0EBC89A22866C591BEF8FDA118EF26A3_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_0EBC89A22866C591BEF8FDA118EF26A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_0EBC89A22866C591BEF8FDA118EF26A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_0EBC89A22866C591BEF8FDA118EF26A3" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_0EBC89A22866C591BEF8FDA118EF26A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_135FC295F1395691853EFDA118EFC8C6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_135FC295F1395691853EFDA118EFC8C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of preferred stock and warrants, net of costs of $219</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_135FC295F1395691853EFDA118EFC8C6_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_135FC295F1395691853EFDA118EFC8C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_135FC295F1395691853EFDA118EFC8C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_135FC295F1395691853EFDA118EFC8C6" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_135FC295F1395691853EFDA118EFC8C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_F4066A20F65E221A5949FDA118EFB1C3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_F4066A20F65E221A5949FDA118EFB1C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_F4066A20F65E221A5949FDA118EFB1C3_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_F4066A20F65E221A5949FDA118EFB1C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_F4066A20F65E221A5949FDA118EFB1C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable_F4066A20F65E221A5949FDA118EFB1C3" xlink:to="lab_us-gaap_ProceedsFromNotesPayable_F4066A20F65E221A5949FDA118EFB1C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_F4E0CD4DE52597C09804FDA118EFE066_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable_F4E0CD4DE52597C09804FDA118EFE066" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_F4E0CD4DE52597C09804FDA118EFE066_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable_F4E0CD4DE52597C09804FDA118EFE066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_F4E0CD4DE52597C09804FDA118EFE066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable_F4E0CD4DE52597C09804FDA118EFE066" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable_F4E0CD4DE52597C09804FDA118EFE066" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BB378B75B95365C74E30FDA118EFD079_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BB378B75B95365C74E30FDA118EFD079" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BB378B75B95365C74E30FDA118EFD079_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BB378B75B95365C74E30FDA118EFD079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BB378B75B95365C74E30FDA118EFD079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BB378B75B95365C74E30FDA118EFD079" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BB378B75B95365C74E30FDA118EFD079" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EEE2DD276E4E9FDD28B3FDA118EFF07E_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EEE2DD276E4E9FDD28B3FDA118EFF07E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET CHANGE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EEE2DD276E4E9FDD28B3FDA118EFF07E_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EEE2DD276E4E9FDD28B3FDA118EFF07E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EEE2DD276E4E9FDD28B3FDA118EFF07E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EEE2DD276E4E9FDD28B3FDA118EFF07E" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EEE2DD276E4E9FDD28B3FDA118EFF07E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D81BF647F445FA73E42DFDA118EF467D_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D81BF647F445FA73E42DFDA118EF467D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D81BF647F445FA73E42DFDA118EF467D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D81BF647F445FA73E42DFDA118EF467D" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D81BF647F445FA73E42DFDA118EF467D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_EAB82FE2A5AF6B32E361FDA118EFA897_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_EAB82FE2A5AF6B32E361FDA118EFA897" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EAB82FE2A5AF6B32E361FDA118EFA897" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EAB82FE2A5AF6B32E361FDA118EFA897" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_EAB82FE2A5AF6B32E361FDA118EFA897" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_BB2FA33502956641E5B4FDA118EF415E_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_BB2FA33502956641E5B4FDA118EF415E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_BB2FA33502956641E5B4FDA118EF415E_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_BB2FA33502956641E5B4FDA118EF415E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_BB2FA33502956641E5B4FDA118EF415E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_BB2FA33502956641E5B4FDA118EF415E" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_BB2FA33502956641E5B4FDA118EF415E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_3EC5176A95BAE854E86BFDA118EF59D9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_3EC5176A95BAE854E86BFDA118EF59D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaid_3EC5176A95BAE854E86BFDA118EF59D9_label_en-US" xlink:label="lab_us-gaap_InterestPaid_3EC5176A95BAE854E86BFDA118EF59D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_3EC5176A95BAE854E86BFDA118EF59D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_3EC5176A95BAE854E86BFDA118EF59D9" xlink:to="lab_us-gaap_InterestPaid_3EC5176A95BAE854E86BFDA118EF59D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38B778A234D160A85A7BFDA118EF6405_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38B778A234D160A85A7BFDA118EF6405" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38B778A234D160A85A7BFDA118EF6405_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38B778A234D160A85A7BFDA118EF6405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38B778A234D160A85A7BFDA118EF6405" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38B778A234D160A85A7BFDA118EF6405" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38B778A234D160A85A7BFDA118EF6405" xlink:type="arc" />
    <link:label id="lab_tbio_InitialFairValueofWarrantsIssued_4E408600DD53D3DF1646FDA118EF353A_terseLabel_en-US" xlink:label="lab_tbio_InitialFairValueofWarrantsIssued_4E408600DD53D3DF1646FDA118EF353A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial valuation of warrant issued in conjunction with Private Placement</link:label>
    <link:label id="lab_tbio_InitialFairValueofWarrantsIssued_4E408600DD53D3DF1646FDA118EF353A_label_en-US" xlink:label="lab_tbio_InitialFairValueofWarrantsIssued_4E408600DD53D3DF1646FDA118EF353A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Fair Value of Warrants Issued</link:label>
    <link:label id="lab_tbio_InitialFairValueofWarrantsIssued_4E408600DD53D3DF1646FDA118EF353A_documentation_en-US" xlink:label="lab_tbio_InitialFairValueofWarrantsIssued_4E408600DD53D3DF1646FDA118EF353A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Fair Value of Warrants Issued</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_InitialFairValueofWarrantsIssued" xlink:label="loc_tbio_InitialFairValueofWarrantsIssued_4E408600DD53D3DF1646FDA118EF353A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_InitialFairValueofWarrantsIssued_4E408600DD53D3DF1646FDA118EF353A" xlink:to="lab_tbio_InitialFairValueofWarrantsIssued_4E408600DD53D3DF1646FDA118EF353A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_275F1E8B433EA7A8709E94CAF170CB83_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9080C77C233F56BF9F9E5A7CFD0ED530" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_275F1E8B433EA7A8709E94CAF170CB83_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9080C77C233F56BF9F9E5A7CFD0ED530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9080C77C233F56BF9F9E5A7CFD0ED530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9080C77C233F56BF9F9E5A7CFD0ED530" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9080C77C233F56BF9F9E5A7CFD0ED530" xlink:type="arc" />
    <link:label id="lab_tbio_SecurityPurchaseAgreementMember_BCB5F473AF4189309D480CE49E684725_terseLabel_en-US" xlink:label="lab_tbio_SecurityPurchaseAgreementMember_BCB5F473AF4189309D480CE49E684725" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Purchase Agreement</link:label>
    <link:label id="lab_tbio_SecurityPurchaseAgreementMember_BCB5F473AF4189309D480CE49E684725_label_en-US" xlink:label="lab_tbio_SecurityPurchaseAgreementMember_BCB5F473AF4189309D480CE49E684725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Purchase Agreement [Member]</link:label>
    <link:label id="lab_tbio_SecurityPurchaseAgreementMember_BCB5F473AF4189309D480CE49E684725_documentation_en-US" xlink:label="lab_tbio_SecurityPurchaseAgreementMember_BCB5F473AF4189309D480CE49E684725" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Security Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SecurityPurchaseAgreementMember" xlink:label="loc_tbio_SecurityPurchaseAgreementMember_BCB5F473AF4189309D480CE49E684725" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_SecurityPurchaseAgreementMember_BCB5F473AF4189309D480CE49E684725" xlink:to="lab_tbio_SecurityPurchaseAgreementMember_BCB5F473AF4189309D480CE49E684725" xlink:type="arc" />
    <link:label id="lab_tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember_5B69A2A7353C8FD194CF0CE49E686DA5_terseLabel_en-US" xlink:label="lab_tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember_5B69A2A7353C8FD194CF0CE49E686DA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-1 Convertible Preferred Stock and Warrants</link:label>
    <link:label id="lab_tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember_5B69A2A7353C8FD194CF0CE49E686DA5_label_en-US" xlink:label="lab_tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember_5B69A2A7353C8FD194CF0CE49E686DA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A-1 Convertible Preferred Stock and Warrants [Member]</link:label>
    <link:label id="lab_tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember_5B69A2A7353C8FD194CF0CE49E686DA5_documentation_en-US" xlink:label="lab_tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember_5B69A2A7353C8FD194CF0CE49E686DA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A-1 Convertible Preferred Stock and Warrants [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember" xlink:label="loc_tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember_5B69A2A7353C8FD194CF0CE49E686DA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember_5B69A2A7353C8FD194CF0CE49E686DA5" xlink:to="lab_tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember_5B69A2A7353C8FD194CF0CE49E686DA5" xlink:type="arc" />
    <link:label id="lab_tbio_A2016WarrantMember_DE57F763325150B093C10CE49E69864A_terseLabel_en-US" xlink:label="lab_tbio_A2016WarrantMember_DE57F763325150B093C10CE49E69864A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Warrant</link:label>
    <link:label id="lab_tbio_A2016WarrantMember_DE57F763325150B093C10CE49E69864A_label_en-US" xlink:label="lab_tbio_A2016WarrantMember_DE57F763325150B093C10CE49E69864A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Warrant [Member]</link:label>
    <link:label id="lab_tbio_A2016WarrantMember_DE57F763325150B093C10CE49E69864A_documentation_en-US" xlink:label="lab_tbio_A2016WarrantMember_DE57F763325150B093C10CE49E69864A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Warrant [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_A2016WarrantMember" xlink:label="loc_tbio_A2016WarrantMember_DE57F763325150B093C10CE49E69864A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_A2016WarrantMember_DE57F763325150B093C10CE49E69864A" xlink:to="lab_tbio_A2016WarrantMember_DE57F763325150B093C10CE49E69864A" xlink:type="arc" />
    <link:label id="lab_tbio_SeriesA1WarrantMember_A5BF271C086D1545E4120CE49E69F985_terseLabel_en-US" xlink:label="lab_tbio_SeriesA1WarrantMember_A5BF271C086D1545E4120CE49E69F985" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-1 Warrant</link:label>
    <link:label id="lab_tbio_SeriesA1WarrantMember_A5BF271C086D1545E4120CE49E69F985_label_en-US" xlink:label="lab_tbio_SeriesA1WarrantMember_A5BF271C086D1545E4120CE49E69F985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A-1 Warrant [Member]</link:label>
    <link:label id="lab_tbio_SeriesA1WarrantMember_A5BF271C086D1545E4120CE49E69F985_documentation_en-US" xlink:label="lab_tbio_SeriesA1WarrantMember_A5BF271C086D1545E4120CE49E69F985" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A-1 Warrant [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SeriesA1WarrantMember" xlink:label="loc_tbio_SeriesA1WarrantMember_A5BF271C086D1545E4120CE49E69F985" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_SeriesA1WarrantMember_A5BF271C086D1545E4120CE49E69F985" xlink:to="lab_tbio_SeriesA1WarrantMember_A5BF271C086D1545E4120CE49E69F985" xlink:type="arc" />
    <link:label id="lab_tbio_SeriesAWarrantsMember_204E551728830B7966240CE49E696F55_terseLabel_en-US" xlink:label="lab_tbio_SeriesAWarrantsMember_204E551728830B7966240CE49E696F55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Warrants</link:label>
    <link:label id="lab_tbio_SeriesAWarrantsMember_204E551728830B7966240CE49E696F55_label_en-US" xlink:label="lab_tbio_SeriesAWarrantsMember_204E551728830B7966240CE49E696F55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Warrants [Member]</link:label>
    <link:label id="lab_tbio_SeriesAWarrantsMember_204E551728830B7966240CE49E696F55_documentation_en-US" xlink:label="lab_tbio_SeriesAWarrantsMember_204E551728830B7966240CE49E696F55" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Warrants [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SeriesAWarrantsMember" xlink:label="loc_tbio_SeriesAWarrantsMember_204E551728830B7966240CE49E696F55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_SeriesAWarrantsMember_204E551728830B7966240CE49E696F55" xlink:to="lab_tbio_SeriesAWarrantsMember_204E551728830B7966240CE49E696F55" xlink:type="arc" />
    <link:label id="lab_tbio_AttheMarketOfferingAgreementMember_05987039D226947B96570CE49E69BA76_terseLabel_en-US" xlink:label="lab_tbio_AttheMarketOfferingAgreementMember_05987039D226947B96570CE49E69BA76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At the Market Offering Agreement</link:label>
    <link:label id="lab_tbio_AttheMarketOfferingAgreementMember_05987039D226947B96570CE49E69BA76_label_en-US" xlink:label="lab_tbio_AttheMarketOfferingAgreementMember_05987039D226947B96570CE49E69BA76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At the Market Offering Agreement [Member]</link:label>
    <link:label id="lab_tbio_AttheMarketOfferingAgreementMember_05987039D226947B96570CE49E69BA76_documentation_en-US" xlink:label="lab_tbio_AttheMarketOfferingAgreementMember_05987039D226947B96570CE49E69BA76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At the Market Offering Agreement [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AttheMarketOfferingAgreementMember" xlink:label="loc_tbio_AttheMarketOfferingAgreementMember_05987039D226947B96570CE49E69BA76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_AttheMarketOfferingAgreementMember_05987039D226947B96570CE49E69BA76" xlink:to="lab_tbio_AttheMarketOfferingAgreementMember_05987039D226947B96570CE49E69BA76" xlink:type="arc" />
    <link:label id="lab_us-gaap_CounterpartyNameAxis_23080CBE2F4F6756D0950CE49E69155D_terseLabel_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_23080CBE2F4F6756D0950CE49E69155D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_us-gaap_CounterpartyNameAxis_23080CBE2F4F6756D0950CE49E69155D_label_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_23080CBE2F4F6756D0950CE49E69155D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_23080CBE2F4F6756D0950CE49E69155D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CounterpartyNameAxis_23080CBE2F4F6756D0950CE49E69155D" xlink:to="lab_us-gaap_CounterpartyNameAxis_23080CBE2F4F6756D0950CE49E69155D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3" xlink:to="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3" xlink:type="arc" />
    <link:label id="lab_tbio_CraigHallumCapitalGroupLLCMember_5925CE01BC84458F89B10CE49E69FE60_terseLabel_en-US" xlink:label="lab_tbio_CraigHallumCapitalGroupLLCMember_5925CE01BC84458F89B10CE49E69FE60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Craig-Hallum Capital Group LLC</link:label>
    <link:label id="lab_tbio_CraigHallumCapitalGroupLLCMember_5925CE01BC84458F89B10CE49E69FE60_label_en-US" xlink:label="lab_tbio_CraigHallumCapitalGroupLLCMember_5925CE01BC84458F89B10CE49E69FE60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Craig-Hallum Capital Group LLC [Member]</link:label>
    <link:label id="lab_tbio_CraigHallumCapitalGroupLLCMember_5925CE01BC84458F89B10CE49E69FE60_documentation_en-US" xlink:label="lab_tbio_CraigHallumCapitalGroupLLCMember_5925CE01BC84458F89B10CE49E69FE60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Craig-Hallum Capital Group LLC [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_CraigHallumCapitalGroupLLCMember" xlink:label="loc_tbio_CraigHallumCapitalGroupLLCMember_5925CE01BC84458F89B10CE49E69FE60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_CraigHallumCapitalGroupLLCMember_5925CE01BC84458F89B10CE49E69FE60" xlink:to="lab_tbio_CraigHallumCapitalGroupLLCMember_5925CE01BC84458F89B10CE49E69FE60" xlink:type="arc" />
    <link:label id="lab_tbio_VendorMember_F824A074A52AAE2F236F0CE49E69147A_terseLabel_en-US" xlink:label="lab_tbio_VendorMember_F824A074A52AAE2F236F0CE49E69147A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vendor I</link:label>
    <link:label id="lab_tbio_VendorMember_F824A074A52AAE2F236F0CE49E69147A_label_en-US" xlink:label="lab_tbio_VendorMember_F824A074A52AAE2F236F0CE49E69147A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vendor [Member]</link:label>
    <link:label id="lab_tbio_VendorMember_F824A074A52AAE2F236F0CE49E69147A_documentation_en-US" xlink:label="lab_tbio_VendorMember_F824A074A52AAE2F236F0CE49E69147A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vendor [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VendorMember" xlink:label="loc_tbio_VendorMember_F824A074A52AAE2F236F0CE49E69147A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_VendorMember_F824A074A52AAE2F236F0CE49E69147A" xlink:to="lab_tbio_VendorMember_F824A074A52AAE2F236F0CE49E69147A" xlink:type="arc" />
    <link:label id="lab_tbio_VendorIIMember_C24A823388C108E6FED60CE49E69C871_terseLabel_en-US" xlink:label="lab_tbio_VendorIIMember_C24A823388C108E6FED60CE49E69C871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vendor II</link:label>
    <link:label id="lab_tbio_VendorIIMember_C24A823388C108E6FED60CE49E69C871_label_en-US" xlink:label="lab_tbio_VendorIIMember_C24A823388C108E6FED60CE49E69C871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vendor II [Member]</link:label>
    <link:label id="lab_tbio_VendorIIMember_C24A823388C108E6FED60CE49E69C871_documentation_en-US" xlink:label="lab_tbio_VendorIIMember_C24A823388C108E6FED60CE49E69C871" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vendor II [Member]</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VendorIIMember" xlink:label="loc_tbio_VendorIIMember_C24A823388C108E6FED60CE49E69C871" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_VendorIIMember_C24A823388C108E6FED60CE49E69C871" xlink:to="lab_tbio_VendorIIMember_C24A823388C108E6FED60CE49E69C871" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_D382525760D9CD0B7B7B0CE49E6AA90C_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_D382525760D9CD0B7B7B0CE49E6AA90C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_D382525760D9CD0B7B7B0CE49E6AA90C_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_D382525760D9CD0B7B7B0CE49E6AA90C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_D382525760D9CD0B7B7B0CE49E6AA90C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_D382525760D9CD0B7B7B0CE49E6AA90C" xlink:to="lab_us-gaap_StatementScenarioAxis_D382525760D9CD0B7B7B0CE49E6AA90C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_1BC14D8A9A869AAE90440CE49E6A6DCD_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_1BC14D8A9A869AAE90440CE49E6A6DCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_1BC14D8A9A869AAE90440CE49E6A6DCD_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_1BC14D8A9A869AAE90440CE49E6A6DCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_1BC14D8A9A869AAE90440CE49E6A6DCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_1BC14D8A9A869AAE90440CE49E6A6DCD" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_1BC14D8A9A869AAE90440CE49E6A6DCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioPreviouslyReportedMember_16920D13F3788EF085D50CE49E6A24CA_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioPreviouslyReportedMember_16920D13F3788EF085D50CE49E6A24CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Previously Reported</link:label>
    <link:label id="lab_us-gaap_ScenarioPreviouslyReportedMember_16920D13F3788EF085D50CE49E6A24CA_label_en-US" xlink:label="lab_us-gaap_ScenarioPreviouslyReportedMember_16920D13F3788EF085D50CE49E6A24CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Previously Reported [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_16920D13F3788EF085D50CE49E6A24CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioPreviouslyReportedMember_16920D13F3788EF085D50CE49E6A24CA" xlink:to="lab_us-gaap_ScenarioPreviouslyReportedMember_16920D13F3788EF085D50CE49E6A24CA" xlink:type="arc" />
    <link:label id="lab_tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet_B24BF8AD3823D21A73980CE49E6B3CD7_terseLabel_en-US" xlink:label="lab_tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet_B24BF8AD3823D21A73980CE49E6B3CD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from the issuance of stock warrants</link:label>
    <link:label id="lab_tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet_B24BF8AD3823D21A73980CE49E6B3CD7_label_en-US" xlink:label="lab_tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet_B24BF8AD3823D21A73980CE49E6B3CD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock and Warrants, Net</link:label>
    <link:label id="lab_tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet_B24BF8AD3823D21A73980CE49E6B3CD7_documentation_en-US" xlink:label="lab_tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet_B24BF8AD3823D21A73980CE49E6B3CD7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock and Warrants, Net</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet" xlink:label="loc_tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet_B24BF8AD3823D21A73980CE49E6B3CD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet_B24BF8AD3823D21A73980CE49E6B3CD7" xlink:to="lab_tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet_B24BF8AD3823D21A73980CE49E6B3CD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_Dividends_F2ACEF297C062A6E677C0CE49E6B50AC_terseLabel_en-US" xlink:label="lab_us-gaap_Dividends_F2ACEF297C062A6E677C0CE49E6B50AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_Dividends_F2ACEF297C062A6E677C0CE49E6B50AC_label_en-US" xlink:label="lab_us-gaap_Dividends_F2ACEF297C062A6E677C0CE49E6B50AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_F2ACEF297C062A6E677C0CE49E6B50AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends_F2ACEF297C062A6E677C0CE49E6B50AC" xlink:to="lab_us-gaap_Dividends_F2ACEF297C062A6E677C0CE49E6B50AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_BE62BF7AFBF983CD34110CE49E6B8464_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_BE62BF7AFBF983CD34110CE49E6B8464" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, number of securities called by each warrant or right (per right)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_BE62BF7AFBF983CD34110CE49E6B8464_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_BE62BF7AFBF983CD34110CE49E6B8464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_BE62BF7AFBF983CD34110CE49E6B8464" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_BE62BF7AFBF983CD34110CE49E6B8464" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_BE62BF7AFBF983CD34110CE49E6B8464" xlink:type="arc" />
    <link:label id="lab_tbio_ClassofWarrantorRightExerciseTerm1_26F088A358E9EC87D0120CE49E6B8394_terseLabel_en-US" xlink:label="lab_tbio_ClassofWarrantorRightExerciseTerm1_26F088A358E9EC87D0120CE49E6B8394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, exercise term</link:label>
    <link:label id="lab_tbio_ClassofWarrantorRightExerciseTerm1_26F088A358E9EC87D0120CE49E6B8394_label_en-US" xlink:label="lab_tbio_ClassofWarrantorRightExerciseTerm1_26F088A358E9EC87D0120CE49E6B8394" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Term1</link:label>
    <link:label id="lab_tbio_ClassofWarrantorRightExerciseTerm1_26F088A358E9EC87D0120CE49E6B8394_documentation_en-US" xlink:label="lab_tbio_ClassofWarrantorRightExerciseTerm1_26F088A358E9EC87D0120CE49E6B8394" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Term1</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassofWarrantorRightExerciseTerm1" xlink:label="loc_tbio_ClassofWarrantorRightExerciseTerm1_26F088A358E9EC87D0120CE49E6B8394" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_ClassofWarrantorRightExerciseTerm1_26F088A358E9EC87D0120CE49E6B8394" xlink:to="lab_tbio_ClassofWarrantorRightExerciseTerm1_26F088A358E9EC87D0120CE49E6B8394" xlink:type="arc" />
    <link:label id="lab_tbio_StockWarrantExchangeAmount_7A7ACA3E735C5EB93B530CE49E6B7C61_terseLabel_en-US" xlink:label="lab_tbio_StockWarrantExchangeAmount_7A7ACA3E735C5EB93B530CE49E6B7C61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock warrant exchange amount</link:label>
    <link:label id="lab_tbio_StockWarrantExchangeAmount_7A7ACA3E735C5EB93B530CE49E6B7C61_label_en-US" xlink:label="lab_tbio_StockWarrantExchangeAmount_7A7ACA3E735C5EB93B530CE49E6B7C61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Warrant Exchange Amount</link:label>
    <link:label id="lab_tbio_StockWarrantExchangeAmount_7A7ACA3E735C5EB93B530CE49E6B7C61_documentation_en-US" xlink:label="lab_tbio_StockWarrantExchangeAmount_7A7ACA3E735C5EB93B530CE49E6B7C61" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Warrant Exchange Amount</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockWarrantExchangeAmount" xlink:label="loc_tbio_StockWarrantExchangeAmount_7A7ACA3E735C5EB93B530CE49E6B7C61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_StockWarrantExchangeAmount_7A7ACA3E735C5EB93B530CE49E6B7C61" xlink:to="lab_tbio_StockWarrantExchangeAmount_7A7ACA3E735C5EB93B530CE49E6B7C61" xlink:type="arc" />
    <link:label id="lab_tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment_478A733D04BD5309D8B30CE49E6B895E_terseLabel_en-US" xlink:label="lab_tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment_478A733D04BD5309D8B30CE49E6B895E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise period not subject to cash payment</link:label>
    <link:label id="lab_tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment_478A733D04BD5309D8B30CE49E6B895E_label_en-US" xlink:label="lab_tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment_478A733D04BD5309D8B30CE49E6B895E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Period Not Subject to Cash Payment</link:label>
    <link:label id="lab_tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment_478A733D04BD5309D8B30CE49E6B895E_documentation_en-US" xlink:label="lab_tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment_478A733D04BD5309D8B30CE49E6B895E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Period Not Subject to Cash Payment</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment" xlink:label="loc_tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment_478A733D04BD5309D8B30CE49E6B895E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment_478A733D04BD5309D8B30CE49E6B895E" xlink:to="lab_tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment_478A733D04BD5309D8B30CE49E6B895E" xlink:type="arc" />
    <link:label id="lab_tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights_CD4F4CF723AECB7289E80CE49E6B7404_terseLabel_en-US" xlink:label="lab_tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights_CD4F4CF723AECB7289E80CE49E6B7404" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share of stock warrants exchanged (usd per unit)</link:label>
    <link:label id="lab_tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights_CD4F4CF723AECB7289E80CE49E6B7404_label_en-US" xlink:label="lab_tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights_CD4F4CF723AECB7289E80CE49E6B7404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exchange Price of Warrants or Rights</link:label>
    <link:label id="lab_tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights_CD4F4CF723AECB7289E80CE49E6B7404_documentation_en-US" xlink:label="lab_tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights_CD4F4CF723AECB7289E80CE49E6B7404" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exchange Price of Warrants or Rights</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights" xlink:label="loc_tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights_CD4F4CF723AECB7289E80CE49E6B7404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights_CD4F4CF723AECB7289E80CE49E6B7404" xlink:to="lab_tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights_CD4F4CF723AECB7289E80CE49E6B7404" xlink:type="arc" />
    <link:label id="lab_tbio_CashPaymentPortionofStockWarrantsExercised_96981F744B4178361C060CE49E6B6BD7_terseLabel_en-US" xlink:label="lab_tbio_CashPaymentPortionofStockWarrantsExercised_96981F744B4178361C060CE49E6B6BD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payment for portion of stock warrants exercised</link:label>
    <link:label id="lab_tbio_CashPaymentPortionofStockWarrantsExercised_96981F744B4178361C060CE49E6B6BD7_label_en-US" xlink:label="lab_tbio_CashPaymentPortionofStockWarrantsExercised_96981F744B4178361C060CE49E6B6BD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Payment Portion of Stock Warrants Exercised</link:label>
    <link:label id="lab_tbio_CashPaymentPortionofStockWarrantsExercised_96981F744B4178361C060CE49E6B6BD7_documentation_en-US" xlink:label="lab_tbio_CashPaymentPortionofStockWarrantsExercised_96981F744B4178361C060CE49E6B6BD7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Payment Portion of Stock Warrants Exercised</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_CashPaymentPortionofStockWarrantsExercised" xlink:label="loc_tbio_CashPaymentPortionofStockWarrantsExercised_96981F744B4178361C060CE49E6B6BD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_CashPaymentPortionofStockWarrantsExercised_96981F744B4178361C060CE49E6B6BD7" xlink:to="lab_tbio_CashPaymentPortionofStockWarrantsExercised_96981F744B4178361C060CE49E6B6BD7" xlink:type="arc" />
    <link:label id="lab_tbio_StockWarrantsSettledwithCash_4EF6BA197799AAB1EB910CE49E6BFD64_terseLabel_en-US" xlink:label="lab_tbio_StockWarrantsSettledwithCash_4EF6BA197799AAB1EB910CE49E6BFD64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock warrants settled with cash</link:label>
    <link:label id="lab_tbio_StockWarrantsSettledwithCash_4EF6BA197799AAB1EB910CE49E6BFD64_label_en-US" xlink:label="lab_tbio_StockWarrantsSettledwithCash_4EF6BA197799AAB1EB910CE49E6BFD64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Warrants Settled with Cash</link:label>
    <link:label id="lab_tbio_StockWarrantsSettledwithCash_4EF6BA197799AAB1EB910CE49E6BFD64_documentation_en-US" xlink:label="lab_tbio_StockWarrantsSettledwithCash_4EF6BA197799AAB1EB910CE49E6BFD64" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Warrants Settled with Cash</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockWarrantsSettledwithCash" xlink:label="loc_tbio_StockWarrantsSettledwithCash_4EF6BA197799AAB1EB910CE49E6BFD64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_StockWarrantsSettledwithCash_4EF6BA197799AAB1EB910CE49E6BFD64" xlink:to="lab_tbio_StockWarrantsSettledwithCash_4EF6BA197799AAB1EB910CE49E6BFD64" xlink:type="arc" />
    <link:label id="lab_tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds_94FAF8420589BBAB3E680CE49E6B15E0_terseLabel_en-US" xlink:label="lab_tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds_94FAF8420589BBAB3E680CE49E6B15E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of stock issuance costs, percentage of gross offering proceeds</link:label>
    <link:label id="lab_tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds_94FAF8420589BBAB3E680CE49E6B15E0_label_en-US" xlink:label="lab_tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds_94FAF8420589BBAB3E680CE49E6B15E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs, Percentage of Gross Offering Proceeds</link:label>
    <link:label id="lab_tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds_94FAF8420589BBAB3E680CE49E6B15E0_documentation_en-US" xlink:label="lab_tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds_94FAF8420589BBAB3E680CE49E6B15E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs, Percentage of Gross Offering Proceeds</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds" xlink:label="loc_tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds_94FAF8420589BBAB3E680CE49E6B15E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds_94FAF8420589BBAB3E680CE49E6B15E0" xlink:to="lab_tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds_94FAF8420589BBAB3E680CE49E6B15E0" xlink:type="arc" />
    <link:label id="lab_tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares_9CF9AAE4F8305482FE640CE49E6C31C2_terseLabel_en-US" xlink:label="lab_tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares_9CF9AAE4F8305482FE640CE49E6C31C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of stock Issuance costs, warrant right to purchase common stock (shares)</link:label>
    <link:label id="lab_tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares_9CF9AAE4F8305482FE640CE49E6C31C2_label_en-US" xlink:label="lab_tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares_9CF9AAE4F8305482FE640CE49E6C31C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs, Warrant Right To Purchase Common Stock Shares</link:label>
    <link:label id="lab_tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares_9CF9AAE4F8305482FE640CE49E6C31C2_documentation_en-US" xlink:label="lab_tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares_9CF9AAE4F8305482FE640CE49E6C31C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs, Warrant Right To Purchase Common Stock Shares</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares" xlink:label="loc_tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares_9CF9AAE4F8305482FE640CE49E6C31C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares_9CF9AAE4F8305482FE640CE49E6C31C2" xlink:to="lab_tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares_9CF9AAE4F8305482FE640CE49E6C31C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_C59EC960D55B8C937BE50CE49E6C3631_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_C59EC960D55B8C937BE50CE49E6C3631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_C59EC960D55B8C937BE50CE49E6C3631_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_C59EC960D55B8C937BE50CE49E6C3631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_C59EC960D55B8C937BE50CE49E6C3631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_C59EC960D55B8C937BE50CE49E6C3631" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_C59EC960D55B8C937BE50CE49E6C3631" xlink:type="arc" />
    <link:label id="lab_tbio_StockIssuanceCostsReimbursableExpenses_CAC4DC87359C8DBAAFF80CE49E6C502B_terseLabel_en-US" xlink:label="lab_tbio_StockIssuanceCostsReimbursableExpenses_CAC4DC87359C8DBAAFF80CE49E6C502B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursable expenses</link:label>
    <link:label id="lab_tbio_StockIssuanceCostsReimbursableExpenses_CAC4DC87359C8DBAAFF80CE49E6C502B_label_en-US" xlink:label="lab_tbio_StockIssuanceCostsReimbursableExpenses_CAC4DC87359C8DBAAFF80CE49E6C502B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs, Reimbursable Expenses</link:label>
    <link:label id="lab_tbio_StockIssuanceCostsReimbursableExpenses_CAC4DC87359C8DBAAFF80CE49E6C502B_documentation_en-US" xlink:label="lab_tbio_StockIssuanceCostsReimbursableExpenses_CAC4DC87359C8DBAAFF80CE49E6C502B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs, Reimbursable Expenses</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockIssuanceCostsReimbursableExpenses" xlink:label="loc_tbio_StockIssuanceCostsReimbursableExpenses_CAC4DC87359C8DBAAFF80CE49E6C502B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_StockIssuanceCostsReimbursableExpenses_CAC4DC87359C8DBAAFF80CE49E6C502B" xlink:to="lab_tbio_StockIssuanceCostsReimbursableExpenses_CAC4DC87359C8DBAAFF80CE49E6C502B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement_EB5E6FC74766506ACAE20CE49E6C4023_terseLabel_en-US" xlink:label="lab_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement_EB5E6FC74766506ACAE20CE49E6C4023" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partners' capital account, units, sold in private placement (units)</link:label>
    <link:label id="lab_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement_EB5E6FC74766506ACAE20CE49E6C4023_label_en-US" xlink:label="lab_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement_EB5E6FC74766506ACAE20CE49E6C4023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partners' Capital Account, Units, Sold in Private Placement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement_EB5E6FC74766506ACAE20CE49E6C4023" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement_EB5E6FC74766506ACAE20CE49E6C4023" xlink:to="lab_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement_EB5E6FC74766506ACAE20CE49E6C4023" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1D3A22B06F3B6B0A33D60CE49E6CDB8F_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1D3A22B06F3B6B0A33D60CE49E6CDB8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued for services (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1D3A22B06F3B6B0A33D60CE49E6CDB8F_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1D3A22B06F3B6B0A33D60CE49E6CDB8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1D3A22B06F3B6B0A33D60CE49E6CDB8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1D3A22B06F3B6B0A33D60CE49E6CDB8F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1D3A22B06F3B6B0A33D60CE49E6CDB8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_46B0C3C9D8829F637FF30CE49E6CF97D_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_46B0C3C9D8829F637FF30CE49E6CF97D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued for services</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_46B0C3C9D8829F637FF30CE49E6CF97D_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_46B0C3C9D8829F637FF30CE49E6CF97D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_46B0C3C9D8829F637FF30CE49E6CF97D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_46B0C3C9D8829F637FF30CE49E6CF97D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_46B0C3C9D8829F637FF30CE49E6CF97D" xlink:type="arc" />
    <link:label id="lab_tbio_PlacementFeesPercentageofGrossSalesPrice_6725CD7F667CFE0679EF0CE49E6CE550_terseLabel_en-US" xlink:label="lab_tbio_PlacementFeesPercentageofGrossSalesPrice_6725CD7F667CFE0679EF0CE49E6CE550" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Placement fees, percentage of gross sales price</link:label>
    <link:label id="lab_tbio_PlacementFeesPercentageofGrossSalesPrice_6725CD7F667CFE0679EF0CE49E6CE550_label_en-US" xlink:label="lab_tbio_PlacementFeesPercentageofGrossSalesPrice_6725CD7F667CFE0679EF0CE49E6CE550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Placement Fees, Percentage of Gross Sales Price</link:label>
    <link:label id="lab_tbio_PlacementFeesPercentageofGrossSalesPrice_6725CD7F667CFE0679EF0CE49E6CE550_documentation_en-US" xlink:label="lab_tbio_PlacementFeesPercentageofGrossSalesPrice_6725CD7F667CFE0679EF0CE49E6CE550" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Placement Fees, Percentage of Gross Sales Price</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PlacementFeesPercentageofGrossSalesPrice" xlink:label="loc_tbio_PlacementFeesPercentageofGrossSalesPrice_6725CD7F667CFE0679EF0CE49E6CE550" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_PlacementFeesPercentageofGrossSalesPrice_6725CD7F667CFE0679EF0CE49E6CE550" xlink:to="lab_tbio_PlacementFeesPercentageofGrossSalesPrice_6725CD7F667CFE0679EF0CE49E6CE550" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9C323911DCE7897244040CE49E6C90F6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9C323911DCE7897244040CE49E6C90F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9C323911DCE7897244040CE49E6C90F6_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9C323911DCE7897244040CE49E6C90F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9C323911DCE7897244040CE49E6C90F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9C323911DCE7897244040CE49E6C90F6" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9C323911DCE7897244040CE49E6C90F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_B71DBC04E225B7166D5EF9AF7FB0DBAA_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_B71DBC04E225B7166D5EF9AF7FB0DBAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_B71DBC04E225B7166D5EF9AF7FB0DBAA_label_en-US" xlink:label="lab_us-gaap_Depreciation_B71DBC04E225B7166D5EF9AF7FB0DBAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_B71DBC04E225B7166D5EF9AF7FB0DBAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_B71DBC04E225B7166D5EF9AF7FB0DBAA" xlink:to="lab_us-gaap_Depreciation_B71DBC04E225B7166D5EF9AF7FB0DBAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_8CBF104B130704A1F6EB1C2677A4BAC2_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_8CBF104B130704A1F6EB1C2677A4BAC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_8CBF104B130704A1F6EB1C2677A4BAC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_8CBF104B130704A1F6EB1C2677A4BAC2" xlink:to="lab_us-gaap_IncomeStatementAbstract_8CBF104B130704A1F6EB1C2677A4BAC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_7E647D837158F0D51DFB1C2677A50A44_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_7E647D837158F0D51DFB1C2677A50A44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_7E647D837158F0D51DFB1C2677A50A44_label_en-US" xlink:label="lab_us-gaap_StatementTable_7E647D837158F0D51DFB1C2677A50A44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_7E647D837158F0D51DFB1C2677A50A44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_7E647D837158F0D51DFB1C2677A50A44" xlink:to="lab_us-gaap_StatementTable_7E647D837158F0D51DFB1C2677A50A44" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_B02DC4865E3F275D25551C2677A5437C_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_B02DC4865E3F275D25551C2677A5437C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_B02DC4865E3F275D25551C2677A5437C_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_B02DC4865E3F275D25551C2677A5437C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_B02DC4865E3F275D25551C2677A5437C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_B02DC4865E3F275D25551C2677A5437C" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_B02DC4865E3F275D25551C2677A5437C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_9D652B2C01CAB032004C1C2677A55A53_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember_9D652B2C01CAB032004C1C2677A55A53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations</link:label>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_9D652B2C01CAB032004C1C2677A55A53_label_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember_9D652B2C01CAB032004C1C2677A55A53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_9D652B2C01CAB032004C1C2677A55A53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentContinuingOperationsMember_9D652B2C01CAB032004C1C2677A55A53" xlink:to="lab_us-gaap_SegmentContinuingOperationsMember_9D652B2C01CAB032004C1C2677A55A53" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="lab_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNet_073F6101FC718C7F32B91C2677A58192_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_073F6101FC718C7F32B91C2677A58192" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">NET SALES</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNet_073F6101FC718C7F32B91C2677A58192_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_073F6101FC718C7F32B91C2677A58192" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_073F6101FC718C7F32B91C2677A58192" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet_073F6101FC718C7F32B91C2677A58192" xlink:to="lab_us-gaap_SalesRevenueNet_073F6101FC718C7F32B91C2677A58192" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_19F90F8EDE6124AF7E191C2677A54EDF_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_19F90F8EDE6124AF7E191C2677A54EDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COST OF GOODS SOLD</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_19F90F8EDE6124AF7E191C2677A54EDF_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_19F90F8EDE6124AF7E191C2677A54EDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_19F90F8EDE6124AF7E191C2677A54EDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_19F90F8EDE6124AF7E191C2677A54EDF" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_19F90F8EDE6124AF7E191C2677A54EDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_21A07CE8535969A40D061C2677A540AE_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_21A07CE8535969A40D061C2677A540AE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit (loss)</link:label>
    <link:label id="lab_us-gaap_GrossProfit_21A07CE8535969A40D061C2677A540AE_label_en-US" xlink:label="lab_us-gaap_GrossProfit_21A07CE8535969A40D061C2677A540AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_21A07CE8535969A40D061C2677A540AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_21A07CE8535969A40D061C2677A540AE" xlink:to="lab_us-gaap_GrossProfit_21A07CE8535969A40D061C2677A540AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OPERATING EXPENSES:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C" xlink:to="lab_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_FAA64CD333E6B2B1AE2E1C2677A50D7C_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_FAA64CD333E6B2B1AE2E1C2677A50D7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_FAA64CD333E6B2B1AE2E1C2677A50D7C_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_FAA64CD333E6B2B1AE2E1C2677A50D7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_FAA64CD333E6B2B1AE2E1C2677A50D7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_FAA64CD333E6B2B1AE2E1C2677A50D7C" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_FAA64CD333E6B2B1AE2E1C2677A50D7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_08A87CCE718140E13A701C2677A6A7E5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_08A87CCE718140E13A701C2677A6A7E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_08A87CCE718140E13A701C2677A6A7E5_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_08A87CCE718140E13A701C2677A6A7E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_08A87CCE718140E13A701C2677A6A7E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_08A87CCE718140E13A701C2677A6A7E5" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_08A87CCE718140E13A701C2677A6A7E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_388AE4CD72637733B41E1C2677A6125D_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_388AE4CD72637733B41E1C2677A6125D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_388AE4CD72637733B41E1C2677A6125D_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_388AE4CD72637733B41E1C2677A6125D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_388AE4CD72637733B41E1C2677A6125D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_388AE4CD72637733B41E1C2677A6125D" xlink:to="lab_us-gaap_OperatingExpenses_388AE4CD72637733B41E1C2677A6125D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8A3147A9D4364507BC991C2677A61CDE_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_8A3147A9D4364507BC991C2677A61CDE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">OPERATING LOSS FROM CONTINUING OPERATIONS</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8A3147A9D4364507BC991C2677A61CDE_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_8A3147A9D4364507BC991C2677A61CDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8A3147A9D4364507BC991C2677A61CDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_8A3147A9D4364507BC991C2677A61CDE" xlink:to="lab_us-gaap_OperatingIncomeLoss_8A3147A9D4364507BC991C2677A61CDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER INCOME (EXPENSE):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9" xlink:type="arc" />
    <link:label id="lab_tbio_InterestIncomeAndExpenseNet_7C71CAE3177D8E9F98891C2677A609FE_terseLabel_en-US" xlink:label="lab_tbio_InterestIncomeAndExpenseNet_7C71CAE3177D8E9F98891C2677A609FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_tbio_InterestIncomeAndExpenseNet_7C71CAE3177D8E9F98891C2677A609FE_label_en-US" xlink:label="lab_tbio_InterestIncomeAndExpenseNet_7C71CAE3177D8E9F98891C2677A609FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income and (expense), net</link:label>
    <link:label id="lab_tbio_InterestIncomeAndExpenseNet_7C71CAE3177D8E9F98891C2677A609FE_documentation_en-US" xlink:label="lab_tbio_InterestIncomeAndExpenseNet_7C71CAE3177D8E9F98891C2677A609FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest income and (expense), net</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_InterestIncomeAndExpenseNet" xlink:label="loc_tbio_InterestIncomeAndExpenseNet_7C71CAE3177D8E9F98891C2677A609FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_InterestIncomeAndExpenseNet_7C71CAE3177D8E9F98891C2677A609FE" xlink:to="lab_tbio_InterestIncomeAndExpenseNet_7C71CAE3177D8E9F98891C2677A609FE" xlink:type="arc" />
    <link:label id="lab_tbio_GainLossOnStockWarrantsRevaluation_FAE545525B5452B55A0B1C2677A6ED1B_terseLabel_en-US" xlink:label="lab_tbio_GainLossOnStockWarrantsRevaluation_FAE545525B5452B55A0B1C2677A6ED1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant revaluation</link:label>
    <link:label id="lab_tbio_GainLossOnStockWarrantsRevaluation_FAE545525B5452B55A0B1C2677A6ED1B_label_en-US" xlink:label="lab_tbio_GainLossOnStockWarrantsRevaluation_FAE545525B5452B55A0B1C2677A6ED1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Stock Warrants Revaluation</link:label>
    <link:label id="lab_tbio_GainLossOnStockWarrantsRevaluation_FAE545525B5452B55A0B1C2677A6ED1B_documentation_en-US" xlink:label="lab_tbio_GainLossOnStockWarrantsRevaluation_FAE545525B5452B55A0B1C2677A6ED1B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_GainLossOnStockWarrantsRevaluation" xlink:label="loc_tbio_GainLossOnStockWarrantsRevaluation_FAE545525B5452B55A0B1C2677A6ED1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_GainLossOnStockWarrantsRevaluation_FAE545525B5452B55A0B1C2677A6ED1B" xlink:to="lab_tbio_GainLossOnStockWarrantsRevaluation_FAE545525B5452B55A0B1C2677A6ED1B" xlink:type="arc" />
    <link:label id="lab_tbio_OtherIncomeExpense_432D356ADE70C59274BC1C2677A6909E_totalLabel_en-US" xlink:label="lab_tbio_OtherIncomeExpense_432D356ADE70C59274BC1C2677A6909E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_tbio_OtherIncomeExpense_432D356ADE70C59274BC1C2677A6909E_label_en-US" xlink:label="lab_tbio_OtherIncomeExpense_432D356ADE70C59274BC1C2677A6909E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_tbio_OtherIncomeExpense_432D356ADE70C59274BC1C2677A6909E_documentation_en-US" xlink:label="lab_tbio_OtherIncomeExpense_432D356ADE70C59274BC1C2677A6909E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:loc xlink:href="tbio-20170331.xsd#tbio_OtherIncomeExpense" xlink:label="loc_tbio_OtherIncomeExpense_432D356ADE70C59274BC1C2677A6909E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tbio_OtherIncomeExpense_432D356ADE70C59274BC1C2677A6909E" xlink:to="lab_tbio_OtherIncomeExpense_432D356ADE70C59274BC1C2677A6909E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_A0D7F492A438962BCD351C2677A66929_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_A0D7F492A438962BCD351C2677A66929" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_A0D7F492A438962BCD351C2677A66929_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_A0D7F492A438962BCD351C2677A66929" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_A0D7F492A438962BCD351C2677A66929" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_A0D7F492A438962BCD351C2677A66929" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_A0D7F492A438962BCD351C2677A66929" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_15C7C6057CB8AE73260D1C2677A61F22_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_15C7C6057CB8AE73260D1C2677A61F22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAX EXPENSE (BENEFIT)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_15C7C6057CB8AE73260D1C2677A61F22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_15C7C6057CB8AE73260D1C2677A61F22" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_15C7C6057CB8AE73260D1C2677A61F22" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_C9B6428D211E9D978A7A1C2677A66363_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_C9B6428D211E9D978A7A1C2677A66363" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">LOSS FROM CONTINUING OPERATIONS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_C9B6428D211E9D978A7A1C2677A66363" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_C9B6428D211E9D978A7A1C2677A66363" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations_C9B6428D211E9D978A7A1C2677A66363" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_783B740A282FC3F82CB71C2677A6A8BC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_783B740A282FC3F82CB71C2677A6A8BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME (LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAXES</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_783B740A282FC3F82CB71C2677A6A8BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_783B740A282FC3F82CB71C2677A6A8BC" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_783B740A282FC3F82CB71C2677A6A8BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_765A737FB2243BDD31161C2677A69C3C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_765A737FB2243BDD31161C2677A69C3C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">PREFERRED STOCK DIVIDENDS</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_765A737FB2243BDD31161C2677A69C3C_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_765A737FB2243BDD31161C2677A69C3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_765A737FB2243BDD31161C2677A69C3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_765A737FB2243BDD31161C2677A69C3C" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_765A737FB2243BDD31161C2677A69C3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_41AFA31A3B5C550749341C2677A6D8BF_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_41AFA31A3B5C550749341C2677A6D8BF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET LOSS AVAILABLE TO COMMON STOCKHOLDERS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_41AFA31A3B5C550749341C2677A6D8BF_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_41AFA31A3B5C550749341C2677A6D8BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_41AFA31A3B5C550749341C2677A6D8BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_41AFA31A3B5C550749341C2677A6D8BF" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_41AFA31A3B5C550749341C2677A6D8BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_47941E60731BE162FFBC1C2677A786A1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_47941E60731BE162FFBC1C2677A786A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_47941E60731BE162FFBC1C2677A786A1_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_47941E60731BE162FFBC1C2677A786A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_47941E60731BE162FFBC1C2677A786A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_47941E60731BE162FFBC1C2677A786A1" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_47941E60731BE162FFBC1C2677A786A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D25F1D95C8167F465EE01C2677A7AAD3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D25F1D95C8167F465EE01C2677A7AAD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D25F1D95C8167F465EE01C2677A7AAD3_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D25F1D95C8167F465EE01C2677A7AAD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D25F1D95C8167F465EE01C2677A7AAD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D25F1D95C8167F465EE01C2677A7AAD3" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D25F1D95C8167F465EE01C2677A7AAD3" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>tbio-20170331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.transgenomic.com/role/BusinessDescription" xlink:href="tbio-20170331.xsd#BusinessDescription" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/BusinessDescriptionDetails" xlink:href="tbio-20170331.xsd#BusinessDescriptionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheets" xlink:href="tbio-20170331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:href="tbio-20170331.xsd#CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/Contingencies" xlink:href="tbio-20170331.xsd#Contingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/ContingenciesDetails" xlink:href="tbio-20170331.xsd#ContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/Debt" xlink:href="tbio-20170331.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DebtConvertiblePromissoryNotesDetails" xlink:href="tbio-20170331.xsd#DebtConvertiblePromissoryNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DebtRevolvingLineAndTermLoanDetails" xlink:href="tbio-20170331.xsd#DebtRevolvingLineAndTermLoanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DebtScheduleOfDebtDetails" xlink:href="tbio-20170331.xsd#DebtScheduleOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DebtTables" xlink:href="tbio-20170331.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DiscontinuedOperations" xlink:href="tbio-20170331.xsd#DiscontinuedOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DiscontinuedOperationsRevenuesAndNetIncomeLossDetails" xlink:href="tbio-20170331.xsd#DiscontinuedOperationsRevenuesAndNetIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DiscontinuedOperationsTables" xlink:href="tbio-20170331.xsd#DiscontinuedOperationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/DocumentAndEntityInformation" xlink:href="tbio-20170331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/FairValue" xlink:href="tbio-20170331.xsd#FairValue" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/FairValueDetails" xlink:href="tbio-20170331.xsd#FairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/FairValueTables" xlink:href="tbio-20170331.xsd#FairValueTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/IncomeTaxes" xlink:href="tbio-20170331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/IncomeTaxesDetails" xlink:href="tbio-20170331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockOptions" xlink:href="tbio-20170331.xsd#StockOptions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockOptionsStockAppreciationRightsDetails" xlink:href="tbio-20170331.xsd#StockOptionsStockAppreciationRightsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockOptionsStockOptionsDetails" xlink:href="tbio-20170331.xsd#StockOptionsStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockOptionsTables" xlink:href="tbio-20170331.xsd#StockOptionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquity" xlink:href="tbio-20170331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityCommonStockDetails" xlink:href="tbio-20170331.xsd#StockholdersEquityCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:href="tbio-20170331.xsd#StockholdersEquityCommonStockWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityConversionOfPreferredStockDetails" xlink:href="tbio-20170331.xsd#StockholdersEquityConversionOfPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityPreferredStockDividendsDetails" xlink:href="tbio-20170331.xsd#StockholdersEquityPreferredStockDividendsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesADetails" xlink:href="tbio-20170331.xsd#StockholdersEquityPreferredStockSeriesADetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesBDetails" xlink:href="tbio-20170331.xsd#StockholdersEquityPreferredStockSeriesBDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/StockholdersEquityTables" xlink:href="tbio-20170331.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SubsequentEvents" xlink:href="tbio-20170331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SubsequentEventsDetails" xlink:href="tbio-20170331.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tbio-20170331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:href="tbio-20170331.xsd#SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesNarrativesDetails" xlink:href="tbio-20170331.xsd#SummaryOfSignificantAccountingPoliciesNarrativesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tbio-20170331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:href="tbio-20170331.xsd#SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:href="tbio-20170331.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsParentheticals" xlink:href="tbio-20170331.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlowsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:href="tbio-20170331.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/BusinessDescription" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8FCB832DB0E250398D8F9F9D30B19C07" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_0166C78B261A5483AD74443649F8B0A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8FCB832DB0E250398D8F9F9D30B19C07" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_0166C78B261A5483AD74443649F8B0A5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/BusinessDescriptionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6E37A7E1893A85592E55FDA2FDA85039" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6E37A7E1893A85592E55FDA2FDA85039" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_08FD9FB320DA85D89DACFDA2FDA8B34E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_08FD9FB320DA85D89DACFDA2FDA8B34E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9342AE83BFDCCA2DDF1BFDA2FDA8DC0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_08FD9FB320DA85D89DACFDA2FDA8B34E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9342AE83BFDCCA2DDF1BFDA2FDA8DC0A" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PrecipioMember" xlink:label="loc_tbio_PrecipioMember_959B456802F9B2F53F01FDA2FDA8CAF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9342AE83BFDCCA2DDF1BFDA2FDA8DC0A" xlink:to="loc_tbio_PrecipioMember_959B456802F9B2F53F01FDA2FDA8CAF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_AC91D8594230C6D032EDFDA2FDA8CF67" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:to="loc_dei_LegalEntityAxis_AC91D8594230C6D032EDFDA2FDA8CF67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_56E0FC8AAC6960671D1BFDA2FDA8281B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_AC91D8594230C6D032EDFDA2FDA8CF67" xlink:to="loc_dei_EntityDomain_56E0FC8AAC6960671D1BFDA2FDA8281B" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_56E0FC8AAC6960671D1BFDA2FDA8281B" xlink:to="loc_tbio_PrecipioMember_959B456802F9B2F53F01FDA2FDA8CAF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_FB2003453BD54A472620FDA2FDA838CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_FB2003453BD54A472620FDA2FDA838CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2DCE938F71896187FC87FDA2FDA8188C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FB2003453BD54A472620FDA2FDA838CC" xlink:to="loc_us-gaap_ClassOfStockDomain_2DCE938F71896187FC87FDA2FDA8188C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1F74755E3C90EAE55644FDA2FDA8C49E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2DCE938F71896187FC87FDA2FDA8188C" xlink:to="loc_us-gaap_CommonStockMember_1F74755E3C90EAE55644FDA2FDA8C49E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_5C4DB431943C1359EBBFFDA2FDA81978" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2DCE938F71896187FC87FDA2FDA8188C" xlink:to="loc_us-gaap_PreferredStockMember_5C4DB431943C1359EBBFFDA2FDA81978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_D4CAAF49D7494D09947CFDA2FDA80A26" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:to="loc_us-gaap_RangeAxis_D4CAAF49D7494D09947CFDA2FDA80A26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_4A2C867BE142151FB0AEFDA2FDA80469" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_D4CAAF49D7494D09947CFDA2FDA80A26" xlink:to="loc_us-gaap_RangeMember_4A2C867BE142151FB0AEFDA2FDA80469" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_A3E1D33883AD9A78351FFDA2FDA81A54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_4A2C867BE142151FB0AEFDA2FDA80469" xlink:to="loc_us-gaap_MaximumMember_A3E1D33883AD9A78351FFDA2FDA81A54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_BD52437AAD7E683DA1F4FDA2FDA8492E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_4A2C867BE142151FB0AEFDA2FDA80469" xlink:to="loc_us-gaap_MinimumMember_BD52437AAD7E683DA1F4FDA2FDA8492E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AA24B948C0756B681E14FDA2FDA841F5" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_C6BFB90ACDC8135E709FFDA2FDA81933" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_C6BFB90ACDC8135E709FFDA2FDA81933" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WorkingCapitalDeficiency" xlink:label="loc_tbio_WorkingCapitalDeficiency_44FA6D5BB99005AF64B2FDA2FDA86683" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:to="loc_tbio_WorkingCapitalDeficiency_44FA6D5BB99005AF64B2FDA2FDA86683" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_AEBA0CBE0BB2A142689EFDA2FDA86F17" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_AEBA0CBE0BB2A142689EFDA2FDA86F17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_0CE818CB955DEAED1CD3FDA2FDA83D5A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_0CE818CB955DEAED1CD3FDA2FDA83D5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_A3D168EF234F49E40B6DFDA2FDA87153" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_A3D168EF234F49E40B6DFDA2FDA87153" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockholdersEquityNoteReverseStockSplitConversionRatio" xlink:label="loc_tbio_StockholdersEquityNoteReverseStockSplitConversionRatio_226D2A7366491587835FFDA2FDA82811" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BCC3159CB1B16A9F738BFDA2FDA896F3" xlink:to="loc_tbio_StockholdersEquityNoteReverseStockSplitConversionRatio_226D2A7366491587835FFDA2FDA82811" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_D6C88654C25C387E4DBDF994083F5500" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_E68FBCF37B94426A3459F994083F08FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D6C88654C25C387E4DBDF994083F5500" xlink:to="loc_us-gaap_AssetsAbstract_E68FBCF37B94426A3459F994083F08FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6A48FCEC519A62743614F994083F4BE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E68FBCF37B94426A3459F994083F08FA" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6A48FCEC519A62743614F994083F4BE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C533AA389AFDBEB7CB3BF994083F08C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6A48FCEC519A62743614F994083F4BE7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C533AA389AFDBEB7CB3BF994083F08C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_19324F25440592A1A773F994083FABB5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6A48FCEC519A62743614F994083F4BE7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_19324F25440592A1A773F994083FABB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_94A2E567CBC71B35078DF994083FEB67" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6A48FCEC519A62743614F994083F4BE7" xlink:to="loc_us-gaap_InventoryNet_94A2E567CBC71B35078DF994083FEB67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_0E29BA40531DEE574D2AF994083FAFFB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6A48FCEC519A62743614F994083F4BE7" xlink:to="loc_us-gaap_OtherAssetsCurrent_0E29BA40531DEE574D2AF994083FAFFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5C1A40DC3E2BE4EA5BD8F994083F0379" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6A48FCEC519A62743614F994083F4BE7" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5C1A40DC3E2BE4EA5BD8F994083F0379" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4EEDE65D7F29B6AC2648F994083FAA38" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6A48FCEC519A62743614F994083F4BE7" xlink:to="loc_us-gaap_AssetsCurrent_4EEDE65D7F29B6AC2648F994083FAA38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_EDF3FB7927C5991F52DDF994083F8E8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E68FBCF37B94426A3459F994083F08FA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_EDF3FB7927C5991F52DDF994083F8E8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_3D84D2D3CABF6AFE200EF994083F2DA9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E68FBCF37B94426A3459F994083F08FA" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_3D84D2D3CABF6AFE200EF994083F2DA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D57DE0D85DE4BC100390F994083FAD60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3D84D2D3CABF6AFE200EF994083F2DA9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D57DE0D85DE4BC100390F994083FAD60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2B967A76DC3CB4A00A0AF994083FA753" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3D84D2D3CABF6AFE200EF994083F2DA9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2B967A76DC3CB4A00A0AF994083FA753" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_89B080BB6F2915B220A3F994083F3668" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E68FBCF37B94426A3459F994083F08FA" xlink:to="loc_us-gaap_Assets_89B080BB6F2915B220A3F994083F3668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4F3991124886A9697531F994083FCC9C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D6C88654C25C387E4DBDF994083F5500" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4F3991124886A9697531F994083FCC9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_F1524990CC1B939CC496F994083FBA51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4F3991124886A9697531F994083FCC9C" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_F1524990CC1B939CC496F994083FBA51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_C4F42AF69343C16E2AFAF994083F047D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F1524990CC1B939CC496F994083FBA51" xlink:to="loc_us-gaap_LongTermDebtCurrent_C4F42AF69343C16E2AFAF994083F047D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_263C08D0E0EF529127D5F994083F9635" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F1524990CC1B939CC496F994083FBA51" xlink:to="loc_us-gaap_AccountsPayableCurrent_263C08D0E0EF529127D5F994083F9635" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7D6AEA74FD027825BE1BF994083F4065" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F1524990CC1B939CC496F994083FBA51" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7D6AEA74FD027825BE1BF994083F4065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5096C5EEE075DB6E1285F994083F56FF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F1524990CC1B939CC496F994083FBA51" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5096C5EEE075DB6E1285F994083F56FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_A57E1503EB885BC20150F994083F42AF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F1524990CC1B939CC496F994083FBA51" xlink:to="loc_us-gaap_DeferredRevenueCurrent_A57E1503EB885BC20150F994083F42AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_B802919466B98026F301F994083FDD03" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F1524990CC1B939CC496F994083FBA51" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_B802919466B98026F301F994083FDD03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_87F1F7E0D9432980D4ACF994083F68BE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F1524990CC1B939CC496F994083FBA51" xlink:to="loc_us-gaap_LiabilitiesCurrent_87F1F7E0D9432980D4ACF994083F68BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_B03D69180761086F9331F994083F4EA8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4F3991124886A9697531F994083FCC9C" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_B03D69180761086F9331F994083F4EA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_5D6CCD53A531E54B8A29F994083FC614" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_B03D69180761086F9331F994083F4EA8" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_5D6CCD53A531E54B8A29F994083FC614" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6B3A5451437A2CE628C6F994083F4D8D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_B03D69180761086F9331F994083F4EA8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6B3A5451437A2CE628C6F994083F4D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_7256A8A07B14161E4A9BF994083FF72E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4F3991124886A9697531F994083FCC9C" xlink:to="loc_us-gaap_Liabilities_7256A8A07B14161E4A9BF994083FF72E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_44EB7C882112E542011FF994083FCEE2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4F3991124886A9697531F994083FCC9C" xlink:to="loc_us-gaap_StockholdersEquityAbstract_44EB7C882112E542011FF994083FCEE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_44953D59CDEDC759BEA7F994083F0FC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44EB7C882112E542011FF994083FCEE2" xlink:to="loc_us-gaap_PreferredStockValue_44953D59CDEDC759BEA7F994083F0FC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_8610DB1B1D514A2BB424F994083F0469" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44EB7C882112E542011FF994083FCEE2" xlink:to="loc_us-gaap_CommonStockValue_8610DB1B1D514A2BB424F994083F0469" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_C6BE7F738F66B0C20FB4F994083F7139" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44EB7C882112E542011FF994083FCEE2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_C6BE7F738F66B0C20FB4F994083F7139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_420C73C4A717F5189DABF994083FD76F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44EB7C882112E542011FF994083FCEE2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_420C73C4A717F5189DABF994083FD76F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A565470082F3FC267E41F994083F587D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44EB7C882112E542011FF994083FCEE2" xlink:to="loc_us-gaap_StockholdersEquity_A565470082F3FC267E41F994083F587D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_592CCA24C3A563353587F994083F4B58" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4F3991124886A9697531F994083FCC9C" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_592CCA24C3A563353587F994083F4B58" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1D3C85F0E80111A3055BE88E44773EA7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_D6688DA4DBEB0B897F11E88E447756E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1D3C85F0E80111A3055BE88E44773EA7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_D6688DA4DBEB0B897F11E88E447756E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_04C8F3D99AC17AB7A942E88E4477D3BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1D3C85F0E80111A3055BE88E44773EA7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_04C8F3D99AC17AB7A942E88E4477D3BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1C6FB0312EA9806AB6ACE88E44774146" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1D3C85F0E80111A3055BE88E44773EA7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1C6FB0312EA9806AB6ACE88E44774146" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_F9411135EFB077DF5947E88E44777422" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1D3C85F0E80111A3055BE88E44773EA7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_F9411135EFB077DF5947E88E44777422" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_026A14AFAD693789BA63E88E4477E1AC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1D3C85F0E80111A3055BE88E44773EA7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_026A14AFAD693789BA63E88E4477E1AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F267C1DE0BC6503996E0E88E4477BCA5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1D3C85F0E80111A3055BE88E44773EA7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_F267C1DE0BC6503996E0E88E4477BCA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_5C8CC01799F2534C70E1E88E44775BD3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1D3C85F0E80111A3055BE88E44773EA7" xlink:to="loc_us-gaap_CommonStockSharesIssued_5C8CC01799F2534C70E1E88E44775BD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1C108CE2B0F388C7D030E88E44777209" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1D3C85F0E80111A3055BE88E44773EA7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1C108CE2B0F388C7D030E88E44777209" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_473533F657853FB4433FFDB27F22F0EB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_56D4BD3AB392CF77AD28FDB27F22D93A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_473533F657853FB4433FFDB27F22F0EB" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_56D4BD3AB392CF77AD28FDB27F22D93A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2A2AF7B0F7BC0562C697FE28470121A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_794A1791C39094C01ED3FE284701A509" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2A2AF7B0F7BC0562C697FE28470121A5" xlink:to="loc_us-gaap_LossContingenciesTable_794A1791C39094C01ED3FE284701A509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_7712BBB49D2E2663B528FE284701094B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_794A1791C39094C01ED3FE284701A509" xlink:to="loc_us-gaap_LitigationCaseAxis_7712BBB49D2E2663B528FE284701094B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseAxis_7712BBB49D2E2663B528FE284701094B" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_UNMCMember" xlink:label="loc_tbio_UNMCMember_D184C1A38071F5C69627FE2847012537" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:to="loc_tbio_UNMCMember_D184C1A38071F5C69627FE2847012537" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_MountSinaiMember" xlink:label="loc_tbio_MountSinaiMember_16E370EB8EA33B3D6A01FE2847011F04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:to="loc_tbio_MountSinaiMember_16E370EB8EA33B3D6A01FE2847011F04" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SmithMember" xlink:label="loc_tbio_SmithMember_84BE32A93402A72A1D24FE284701666D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:to="loc_tbio_SmithMember_84BE32A93402A72A1D24FE284701666D" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_XIFINInc.Member" xlink:label="loc_tbio_XIFINInc.Member_5C2A8E3A1B867410A239FE284701D5F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:to="loc_tbio_XIFINInc.Member_5C2A8E3A1B867410A239FE284701D5F2" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ScienceParkDevelopmentCorporationMember" xlink:label="loc_tbio_ScienceParkDevelopmentCorporationMember_E85EDA555642964F7F26FE284701967D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:to="loc_tbio_ScienceParkDevelopmentCorporationMember_E85EDA555642964F7F26FE284701967D" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_CPAGlobalMember" xlink:label="loc_tbio_CPAGlobalMember_C5298113F43077631E65FE2847013E07" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:to="loc_tbio_CPAGlobalMember_C5298113F43077631E65FE2847013E07" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_EdgeBioSystemsInc.Member" xlink:label="loc_tbio_EdgeBioSystemsInc.Member_333456E834882AD25099FE284701794E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4D27A83BE0B83311BAA0FE2847014EBC" xlink:to="loc_tbio_EdgeBioSystemsInc.Member_333456E834882AD25099FE284701794E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1BA93A9D803C9462A9AFFE28AA4CE8F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_794A1791C39094C01ED3FE284701A509" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1BA93A9D803C9462A9AFFE28AA4CE8F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_D8832AF800381F4D07B4FE28AC12348D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1BA93A9D803C9462A9AFFE28AA4CE8F6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_D8832AF800381F4D07B4FE28AC12348D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_01E16122048407576433FE292DAEF3A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_D8832AF800381F4D07B4FE28AC12348D" xlink:to="loc_us-gaap_SubsequentEventMember_01E16122048407576433FE292DAEF3A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_794A1791C39094C01ED3FE284701A509" xlink:to="loc_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DelinquentAccountsPayable" xlink:label="loc_tbio_DelinquentAccountsPayable_ED03BFA643F099E01A4AFE2847016277" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:to="loc_tbio_DelinquentAccountsPayable_ED03BFA643F099E01A4AFE2847016277" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_CAE6273AE35BACF04150FE2847018A38" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_CAE6273AE35BACF04150FE2847018A38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_828A59321A550D8D3A67FE2847016A1F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_828A59321A550D8D3A67FE2847016A1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_024B789388731B12AE87FE284701714E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_024B789388731B12AE87FE284701714E" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_LossContingencyDeferredPayment" xlink:label="loc_tbio_LossContingencyDeferredPayment_3291D351928EA8AB0491FE28470158B0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78A6EF9F840B72288152FE2847017F75" xlink:to="loc_tbio_LossContingencyDeferredPayment_3291D351928EA8AB0491FE28470158B0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F6D291C865D85527AD68E1E487F9AFB1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_DB011DFCC7D15CA391B3956A944081A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F6D291C865D85527AD68E1E487F9AFB1" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_DB011DFCC7D15CA391B3956A944081A7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/DebtConvertiblePromissoryNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6CF2FF7195DED86E8DE00D52F1BB9B80" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_87EF020B392261BB79340D52F1BB12EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6CF2FF7195DED86E8DE00D52F1BB9B80" xlink:to="loc_us-gaap_DebtInstrumentTable_87EF020B392261BB79340D52F1BB12EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_DD04219A656ED2DB9A300D52F1BBF01E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87EF020B392261BB79340D52F1BB12EA" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_DD04219A656ED2DB9A300D52F1BBF01E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FFA38C7D092B8A4A45930D52F1BB6CE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DD04219A656ED2DB9A300D52F1BBF01E" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_FFA38C7D092B8A4A45930D52F1BB6CE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_8C0333FC0B0F742631110D52F1BBF9F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_FFA38C7D092B8A4A45930D52F1BB6CE6" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_8C0333FC0B0F742631110D52F1BBF9F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B81A29C7196A73C651F80D89BD7752BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87EF020B392261BB79340D52F1BB12EA" xlink:to="loc_us-gaap_DebtInstrumentAxis_B81A29C7196A73C651F80D89BD7752BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_457221C3687733F4D11C0D89BD86CA37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_B81A29C7196A73C651F80D89BD7752BB" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_457221C3687733F4D11C0D89BD86CA37" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AdditionalNotesMember" xlink:label="loc_tbio_AdditionalNotesMember_BFC70A70DFE30478D22D0D8ADD539F43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_457221C3687733F4D11C0D89BD86CA37" xlink:to="loc_tbio_AdditionalNotesMember_BFC70A70DFE30478D22D0D8ADD539F43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_11D9E3B62E0FAAD9920A0D52F1BBFCDE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87EF020B392261BB79340D52F1BB12EA" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_11D9E3B62E0FAAD9920A0D52F1BBFCDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_386EABD08A6F7C5A86930D52F1BB84B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_11D9E3B62E0FAAD9920A0D52F1BBFCDE" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_386EABD08A6F7C5A86930D52F1BB84B5" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AgentNoteMember" xlink:label="loc_tbio_AgentNoteMember_B8A440DF68F97BE7F4FF0D52F1BB3088" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_386EABD08A6F7C5A86930D52F1BB84B5" xlink:to="loc_tbio_AgentNoteMember_B8A440DF68F97BE7F4FF0D52F1BB3088" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AdditionalNotePrivatePlacementMember" xlink:label="loc_tbio_AdditionalNotePrivatePlacementMember_BDCED2B8D4CE99ED08C40D52F1BC51A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_386EABD08A6F7C5A86930D52F1BB84B5" xlink:to="loc_tbio_AdditionalNotePrivatePlacementMember_BDCED2B8D4CE99ED08C40D52F1BC51A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87EF020B392261BB79340D52F1BB12EA" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_D067386479A6EA34F9D50D52F1BC78A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_D067386479A6EA34F9D50D52F1BC78A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_59BA1E82151B935A5B680D52F1BC0998" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_59BA1E82151B935A5B680D52F1BC0998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_CB9F8E474953E69267760D52F1BC6355" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_CB9F8E474953E69267760D52F1BC6355" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors" xlink:label="loc_tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors_B14EB4F814D8219F196F0D52F1BC8864" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors_B14EB4F814D8219F196F0D52F1BC8864" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PercentageofInitialNote" xlink:label="loc_tbio_PercentageofInitialNote_6E32D24E8890F063B1640D52F1BC4D9B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_tbio_PercentageofInitialNote_6E32D24E8890F063B1640D52F1BC4D9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4237E5FF5F522E66912B0D52F1BCE739" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4237E5FF5F522E66912B0D52F1BCE739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_0393A4479C663E6F90350D52F1BC2EE4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_us-gaap_LongTermDebt_0393A4479C663E6F90350D52F1BC2EE4" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentDebtDefaultPeriod" xlink:label="loc_tbio_DebtInstrumentDebtDefaultPeriod_2C5A87365AF3348237A90D62620F1240" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_tbio_DebtInstrumentDebtDefaultPeriod_2C5A87365AF3348237A90D62620F1240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_3E9B5CA503FE272AD1010D52F1BC965A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_3E9B5CA503FE272AD1010D52F1BC965A" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent" xlink:label="loc_tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_BEF393BD9A93A7235CE80D857BAEDE75" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_BEF393BD9A93A7235CE80D857BAEDE75" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent" xlink:label="loc_tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_D26C4C57E8FE431374BC0D9508E91AA5" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3356105A668655D904530D52F1BC340B" xlink:to="loc_tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_D26C4C57E8FE431374BC0D9508E91AA5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/DebtRevolvingLineAndTermLoanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7E46942E912F6E3546D7F99435A3C51D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7E46942E912F6E3546D7F99435A3C51D" xlink:to="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_0906F2941C5140445AD3F99435A3C71C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:to="loc_us-gaap_CreditFacilityAxis_0906F2941C5140445AD3F99435A3C71C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_70B4A2FEA4E065F0ABABF99435A34A4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_0906F2941C5140445AD3F99435A3C71C" xlink:to="loc_us-gaap_CreditFacilityDomain_70B4A2FEA4E065F0ABABF99435A34A4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_3D6B4D5EE5D24EBBBAB3F99435A33177" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_70B4A2FEA4E065F0ABABF99435A34A4A" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_3D6B4D5EE5D24EBBBAB3F99435A33177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E8CFEEE0BDFF52D83786F99435A33FB7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E8CFEEE0BDFF52D83786F99435A33FB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E8CFEEE0BDFF52D83786F99435A33FB7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_269B1013E088307350CDF99435A3F42E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4" xlink:to="loc_us-gaap_LineOfCreditMember_269B1013E088307350CDF99435A3F42E" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_TermLoanMember" xlink:label="loc_tbio_TermLoanMember_6C57E1EC15B158087595F99435A4B86A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4" xlink:to="loc_tbio_TermLoanMember_6C57E1EC15B158087595F99435A4B86A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_3C61FBF083A5D87B771CF99435A4B932" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B9A78BE0462BB4A5E236F99435A3BAD4" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_3C61FBF083A5D87B771CF99435A4B932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_29EDA996064EE9C9C2DFF99435A44274" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_29EDA996064EE9C9C2DFF99435A44274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_7002F71E6E3CFEFFE69CF99435A40F33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_29EDA996064EE9C9C2DFF99435A44274" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_7002F71E6E3CFEFFE69CF99435A40F33" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ThirdSecurityLlcAndAffiliatesMember" xlink:label="loc_tbio_ThirdSecurityLlcAndAffiliatesMember_6300BC7AB349A5DE3569F99435A456B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7002F71E6E3CFEFFE69CF99435A40F33" xlink:to="loc_tbio_ThirdSecurityLlcAndAffiliatesMember_6300BC7AB349A5DE3569F99435A456B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4D503A975E5329E9743FF99435A40008" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:to="loc_dei_LegalEntityAxis_4D503A975E5329E9743FF99435A40008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8A97C2951879C202B097F99435A4BC2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4D503A975E5329E9743FF99435A40008" xlink:to="loc_dei_EntityDomain_8A97C2951879C202B097F99435A4BC2B" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PrecipioMember" xlink:label="loc_tbio_PrecipioMember_63B9F574EA41FF300AC2F99435A46D31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8A97C2951879C202B097F99435A4BC2B" xlink:to="loc_tbio_PrecipioMember_63B9F574EA41FF300AC2F99435A46D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_EBB7779F986493FCCD39F99435A475B1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_EBB7779F986493FCCD39F99435A475B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_EBB7779F986493FCCD39F99435A475B1" xlink:to="loc_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="loc_us-gaap_ConvertibleCommonStockMember_8774692473B1B2DDFC15F99435A405E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731" xlink:to="loc_us-gaap_ConvertibleCommonStockMember_8774692473B1B2DDFC15F99435A405E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_92B4AC166897CFE88224F99435A46C04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1B9BA338D7C7070F8EAAF99435A46731" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_92B4AC166897CFE88224F99435A46C04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E92D1566C1B2D863C02AF99435A3644A" xlink:to="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_47254065B2513BCA14EDF99435A4ADAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_47254065B2513BCA14EDF99435A4ADAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_F07F53E359E80D7EC164F99435A49E65" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_F07F53E359E80D7EC164F99435A49E65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_E4DFE054E144426BEC4FF99435A5F1C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_E4DFE054E144426BEC4FF99435A5F1C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1EF339EE5030DBBCE93CF99435A5747C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1EF339EE5030DBBCE93CF99435A5747C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_C6F49B728771C80ECDA0F99435A55C0A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:to="loc_us-gaap_SharePrice_C6F49B728771C80ECDA0F99435A55C0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_86BAF934F4193C007AA9F99435A54D82" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_86BAF934F4193C007AA9F99435A54D82" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtConversionConvertedInstrumentInterest" xlink:label="loc_tbio_DebtConversionConvertedInstrumentInterest_B929999A8FFDBCEB3DF3F99435A54ED1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_83981FB45F358944FF95F99435A4FC86" xlink:to="loc_tbio_DebtConversionConvertedInstrumentInterest_B929999A8FFDBCEB3DF3F99435A54ED1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/DebtScheduleOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1BF0EBAEF75C89A9FD42E9708A213939" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_A3AC88A9938945FA0060E9708A2174C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1BF0EBAEF75C89A9FD42E9708A213939" xlink:to="loc_us-gaap_DebtInstrumentTable_A3AC88A9938945FA0060E9708A2174C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_CC059F51A8849DF39DCEE9708A212EB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A3AC88A9938945FA0060E9708A2174C3" xlink:to="loc_us-gaap_CreditFacilityAxis_CC059F51A8849DF39DCEE9708A212EB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_98A17E920C1A1230BBF6E9708A21D42F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_CC059F51A8849DF39DCEE9708A212EB8" xlink:to="loc_us-gaap_CreditFacilityDomain_98A17E920C1A1230BBF6E9708A21D42F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_DE9182867A2FDD342CDAE9708A212D28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_98A17E920C1A1230BBF6E9708A21D42F" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_DE9182867A2FDD342CDAE9708A212D28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E308D768B1F33539E831E9708A21B9FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A3AC88A9938945FA0060E9708A2174C3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E308D768B1F33539E831E9708A21B9FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2D57F1A795DFE9C4EEC3E9708A211274" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E308D768B1F33539E831E9708A21B9FF" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2D57F1A795DFE9C4EEC3E9708A211274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_2216BFADE99ADFE2F486E9708A21ECDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2D57F1A795DFE9C4EEC3E9708A211274" xlink:to="loc_us-gaap_LineOfCreditMember_2216BFADE99ADFE2F486E9708A21ECDC" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_TermLoanMember" xlink:label="loc_tbio_TermLoanMember_14C8E57AE7BC7D0D98E7E9708A212DE3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2D57F1A795DFE9C4EEC3E9708A211274" xlink:to="loc_tbio_TermLoanMember_14C8E57AE7BC7D0D98E7E9708A212DE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_AF450348C77A05953262E9708A21C42F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2D57F1A795DFE9C4EEC3E9708A211274" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_AF450348C77A05953262E9708A21C42F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_8778F3460A797A010706E9708A2117EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A3AC88A9938945FA0060E9708A2174C3" xlink:to="loc_us-gaap_VariableRateAxis_8778F3460A797A010706E9708A2117EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_DCCA6B2A810062322A9AE9708A219B90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_8778F3460A797A010706E9708A2117EB" xlink:to="loc_us-gaap_VariableRateDomain_DCCA6B2A810062322A9AE9708A219B90" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WallStreetJournalPrimeRateMember" xlink:label="loc_tbio_WallStreetJournalPrimeRateMember_1C25840BA562B55A66C6E9708A217152" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_DCCA6B2A810062322A9AE9708A219B90" xlink:to="loc_tbio_WallStreetJournalPrimeRateMember_1C25840BA562B55A66C6E9708A217152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A3AC88A9938945FA0060E9708A2174C3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_4F5D10C3EE1D44F39DABE9708A2122E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_4F5D10C3EE1D44F39DABE9708A2122E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_27A1BF5D9742B734B22BE9708A22DEFC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_LongTermDebtCurrent_27A1BF5D9742B734B22BE9708A22DEFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_42B65531057083411225E9708A22FCAA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_42B65531057083411225E9708A22FCAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_FB1795C6FB1BED6F17A5E9708A22E266" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_FB1795C6FB1BED6F17A5E9708A22E266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0BAE3944153261E29DEFE9708A22BA33" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0BAE3944153261E29DEFE9708A22BA33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_AF6ACDFAA91089D03195E9708A221D61" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_AF6ACDFAA91089D03195E9708A221D61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_D0CDD5DA93BCBE713A70E9708A22DC14" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_D0CDD5DA93BCBE713A70E9708A22DC14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_6596FB699EA02C70E0D6E9708A22A909" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_6596FB699EA02C70E0D6E9708A22A909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_BB30E706EAF51D7F2469E9708A2236EB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_BB30E706EAF51D7F2469E9708A2236EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_8E341A9E8BC980F50F35E9708A2201F7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_8E341A9E8BC980F50F35E9708A2201F7" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentFutureDebtExtinguishmentCosts" xlink:label="loc_tbio_DebtInstrumentFutureDebtExtinguishmentCosts_7E79E84CC0B197F9E3F0E9708A221B02" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_tbio_DebtInstrumentFutureDebtExtinguishmentCosts_7E79E84CC0B197F9E3F0E9708A221B02" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentPrepaymentPenaltyPercent" xlink:label="loc_tbio_DebtInstrumentPrepaymentPenaltyPercent_F93C840AC73B33C6E232E9708A22567C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_tbio_DebtInstrumentPrepaymentPenaltyPercent_F93C840AC73B33C6E232E9708A22567C" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease" xlink:label="loc_tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease_18566916BD0A720EC743E9708A2276C7" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_41C14E36DC7182FCB3BBE9708A21D9CE" xlink:to="loc_tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease_18566916BD0A720EC743E9708A2276C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_23B3D259CE175124A91FD73342C762DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_6B119FABBB225AC5AB89DCF91908C3AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_23B3D259CE175124A91FD73342C762DB" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_6B119FABBB225AC5AB89DCF91908C3AB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/DiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2BC9CF23044356F8BFF9BDC19CEEDD08" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_2ED98220D68355139FC54B713A4B42C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2BC9CF23044356F8BFF9BDC19CEEDD08" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_2ED98220D68355139FC54B713A4B42C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/DiscontinuedOperationsRevenuesAndNetIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6DCC202B33C32EC855521C26775AD87F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8131CEB7ECD9B9ECFA631C26775BF177" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6DCC202B33C32EC855521C26775AD87F" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8131CEB7ECD9B9ECFA631C26775BF177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_D400ACF6839EF9FBD0401C26775BA4E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8131CEB7ECD9B9ECFA631C26775BF177" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_D400ACF6839EF9FBD0401C26775BA4E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_07996FE250E9F548691A1C26775BFEF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_D400ACF6839EF9FBD0401C26775BA4E1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_07996FE250E9F548691A1C26775BFEF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_F02566B8A1CDB144308D1C26775BA319" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_07996FE250E9F548691A1C26775BFEF4" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_F02566B8A1CDB144308D1C26775BA319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_41B2A31C953F2FC07B1D1C26775B7ECF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8131CEB7ECD9B9ECFA631C26775BF177" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_41B2A31C953F2FC07B1D1C26775B7ECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_EF99DACFEAB718C93A741C26775BEA4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_41B2A31C953F2FC07B1D1C26775B7ECF" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_EF99DACFEAB718C93A741C26775BEA4C" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_GeneticAssaysandPlatformsandPatientTestingMember" xlink:label="loc_tbio_GeneticAssaysandPlatformsandPatientTestingMember_05551864FACF5825970C1C26775B9044" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_EF99DACFEAB718C93A741C26775BEA4C" xlink:to="loc_tbio_GeneticAssaysandPlatformsandPatientTestingMember_05551864FACF5825970C1C26775B9044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8131CEB7ECD9B9ECFA631C26775BF177" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_35A56375BE94F9F0D0BD1C26775B6297" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_35A56375BE94F9F0D0BD1C26775B6297" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_C67AB91D5A559730B7DA1C26775BC289" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_C67AB91D5A559730B7DA1C26775BC289" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_F3B245D989E75AC6F30B1C26775B5ABE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_F3B245D989E75AC6F30B1C26775B5ABE" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense" xlink:label="loc_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense_9D1CFE30C80ECF8181431C26775B53C9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense_9D1CFE30C80ECF8181431C26775B53C9" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense" xlink:label="loc_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense_3F9309E2946A40CC5F371C26775C6E0C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense_3F9309E2946A40CC5F371C26775C6E0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_FAE55C2E7EDD65AA78881C26775C75FB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_FAE55C2E7EDD65AA78881C26775C75FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6DBAC20CA4B6A6F6FBF71C26775C152B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6DBAC20CA4B6A6F6FBF71C26775C152B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_C906F295B088C131D31E1C26775CB77F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_C906F295B088C131D31E1C26775CB77F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_2B7C4633146466F3132D1C26775CD47B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_2B7C4633146466F3132D1C26775CD47B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_C386ABC9DD02DAE58E3D1C26775CC726" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_C386ABC9DD02DAE58E3D1C26775CC726" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_33741C0BD4E1DF1FB3291C2B33712D31" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A469FD3582F964F113B21C26775B0AC1" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_33741C0BD4E1DF1FB3291C2B33712D31" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/DiscontinuedOperationsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8101F8DAD2905C0FB026A03A803267EC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6569B60C751D5652BF7E1F880E46D5B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8101F8DAD2905C0FB026A03A803267EC" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6569B60C751D5652BF7E1F880E46D5B1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DocumentAndEntityInformationAbstract" xlink:label="loc_tbio_DocumentAndEntityInformationAbstract_34B5D89B17EF57029DCAA249BFD4E699" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_C55CF6EC186D5240A87568965591834A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_DocumentAndEntityInformationAbstract_34B5D89B17EF57029DCAA249BFD4E699" xlink:to="loc_dei_EntityRegistrantName_C55CF6EC186D5240A87568965591834A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_175C97256C5158379E5CA07C952FB5F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_DocumentAndEntityInformationAbstract_34B5D89B17EF57029DCAA249BFD4E699" xlink:to="loc_dei_EntityCentralIndexKey_175C97256C5158379E5CA07C952FB5F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_3F377F9D64F85BCBA2E9C43B5142E59F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_DocumentAndEntityInformationAbstract_34B5D89B17EF57029DCAA249BFD4E699" xlink:to="loc_dei_CurrentFiscalYearEndDate_3F377F9D64F85BCBA2E9C43B5142E59F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_6A8C067E7D6E52EA8F4658B7DFC26E27" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_DocumentAndEntityInformationAbstract_34B5D89B17EF57029DCAA249BFD4E699" xlink:to="loc_dei_EntityFilerCategory_6A8C067E7D6E52EA8F4658B7DFC26E27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_D21B17F24F1D5DBB909FDBE786D2F565" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_DocumentAndEntityInformationAbstract_34B5D89B17EF57029DCAA249BFD4E699" xlink:to="loc_dei_DocumentType_D21B17F24F1D5DBB909FDBE786D2F565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_9723D07E056355A7B52BFC0747847F30" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_DocumentAndEntityInformationAbstract_34B5D89B17EF57029DCAA249BFD4E699" xlink:to="loc_dei_DocumentPeriodEndDate_9723D07E056355A7B52BFC0747847F30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_DA26FEDD3F7257B6B57A881E2A254DE9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_DocumentAndEntityInformationAbstract_34B5D89B17EF57029DCAA249BFD4E699" xlink:to="loc_dei_DocumentFiscalYearFocus_DA26FEDD3F7257B6B57A881E2A254DE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_DB73AB1F477051BB985C0573B0E58F73" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_DocumentAndEntityInformationAbstract_34B5D89B17EF57029DCAA249BFD4E699" xlink:to="loc_dei_DocumentFiscalPeriodFocus_DB73AB1F477051BB985C0573B0E58F73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_4E9F2A103815509F96AA1EEEC369176E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_DocumentAndEntityInformationAbstract_34B5D89B17EF57029DCAA249BFD4E699" xlink:to="loc_dei_AmendmentFlag_4E9F2A103815509F96AA1EEEC369176E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_16692DEA1DEF5D84B1AF898A82887BA5" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_DocumentAndEntityInformationAbstract_34B5D89B17EF57029DCAA249BFD4E699" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_16692DEA1DEF5D84B1AF898A82887BA5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9B67A8FF72705E40AA1AF387B595341C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_B60B3547757D5294980957A5A9DC0AA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9B67A8FF72705E40AA1AF387B595341C" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_B60B3547757D5294980957A5A9DC0AA7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/FairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_C4AE42540E69103E9FE4F8A8305FF49B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_88AECF3B218AE09C0AA3F8A8305F4457" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C4AE42540E69103E9FE4F8A8305FF49B" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_88AECF3B218AE09C0AA3F8A8305F4457" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_7BFF78F5F813C52FDFD1F8A8305F2D9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_88AECF3B218AE09C0AA3F8A8305F4457" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_7BFF78F5F813C52FDFD1F8A8305F2D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_7BFF78F5F813C52FDFD1F8A8305F2D9F" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_A2012WarrantLiabilityMember" xlink:label="loc_tbio_A2012WarrantLiabilityMember_61274625DAFB77C7C1A4F8A8305F2070" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014" xlink:to="loc_tbio_A2012WarrantLiabilityMember_61274625DAFB77C7C1A4F8A8305F2070" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_A2016WarrantLiabilityMember" xlink:label="loc_tbio_A2016WarrantLiabilityMember_5ECC6F4D7766C8B1088CF8A8305F98EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_486563B4A875958410F7F8A8305FE014" xlink:to="loc_tbio_A2016WarrantLiabilityMember_5ECC6F4D7766C8B1088CF8A8305F98EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_88AECF3B218AE09C0AA3F8A8305F4457" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_9BCEEF5762F45E97E74AF8A8305F8326" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:to="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_9BCEEF5762F45E97E74AF8A8305F8326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_AC1F9F8FADEF00EAF4EEF8A8305F90A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_AC1F9F8FADEF00EAF4EEF8A8305F90A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_95D9E0E07184ADE3CE6AF8A8305FFFA8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:to="loc_us-gaap_SharePrice_95D9E0E07184ADE3CE6AF8A8305FFFA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_3D6D189FAE167058E716F8A8305FA83F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_3D6D189FAE167058E716F8A8305FA83F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BD30836400D5D21345BBF8A83060373A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BD30836400D5D21345BBF8A83060373A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E91901DE317462A9D37CF8A8305F8C72" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767E63F28D5E2EEC112FF8A83060BA10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767E63F28D5E2EEC112FF8A83060BA10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_F7180AD919679FCABB56F8A83060BCC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_F7180AD919679FCABB56F8A83060BCC5" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_TotalGainsOrLossesAbstract" xlink:label="loc_tbio_TotalGainsOrLossesAbstract_64E35FD2C42019E77F45F8A830657A2D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E" xlink:to="loc_tbio_TotalGainsOrLossesAbstract_64E35FD2C42019E77F45F8A830657A2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1D784943C372C67DEA87F8A83065E25F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_TotalGainsOrLossesAbstract_64E35FD2C42019E77F45F8A830657A2D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1D784943C372C67DEA87F8A83065E25F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DC7C313EFC58C0CBB8B1F8A83065FB17" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_669B37F47FAC2852E251F8A83060200E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DC7C313EFC58C0CBB8B1F8A83065FB17" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DD5004B8426D5136A698085502356FB2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B6AA521CE6D45042BA32A328068E9BBD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DD5004B8426D5136A698085502356FB2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B6AA521CE6D45042BA32A328068E9BBD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6EBE366C65B65EEB9558E0EEF0D0B6FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_F272AEAEF2355DA69B80B149757AEA2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6EBE366C65B65EEB9558E0EEF0D0B6FA" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_F272AEAEF2355DA69B80B149757AEA2F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6F7317DB3547537FB817E427930F4779" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2527483ABAC750D680413315A15E9283" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6F7317DB3547537FB817E427930F4779" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2527483ABAC750D680413315A15E9283" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/StockOptions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_409AA232C0EF5937A51CA8A14A22D6E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_C67D546757D05A819B77C3E6861F9FDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_409AA232C0EF5937A51CA8A14A22D6E0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_C67D546757D05A819B77C3E6861F9FDD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/StockOptionsStockAppreciationRightsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_22456E2EDBBDBB64147EFDF1A00FEFC8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6DF3D70DFF3E8D0D8674FDF1A00FCBB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_22456E2EDBBDBB64147EFDF1A00FEFC8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6DF3D70DFF3E8D0D8674FDF1A00FCBB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1B3BE95E42C0C4CAEA58FDF1A00FCBCD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6DF3D70DFF3E8D0D8674FDF1A00FCBB7" xlink:to="loc_us-gaap_AwardTypeAxis_1B3BE95E42C0C4CAEA58FDF1A00FCBCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_722DE36115F6B847BB93FDF1A00FAE67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1B3BE95E42C0C4CAEA58FDF1A00FCBCD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_722DE36115F6B847BB93FDF1A00FAE67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_AC1E1FD9AA259B46B1B3FDF1A00F5E59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_722DE36115F6B847BB93FDF1A00FAE67" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_AC1E1FD9AA259B46B1B3FDF1A00F5E59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FA3EC23F2FB8B248FD42FDF1A00F61D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6DF3D70DFF3E8D0D8674FDF1A00FCBB7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FA3EC23F2FB8B248FD42FDF1A00F61D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_763EF179280064F0895FFDF1A00F3082" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FA3EC23F2FB8B248FD42FDF1A00F61D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_763EF179280064F0895FFDF1A00F3082" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_4360F12B0598F5D914D3FDF1A00F3C8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_763EF179280064F0895FFDF1A00F3082" xlink:to="loc_tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_4360F12B0598F5D914D3FDF1A00F3C8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FD8B4BCB104DE67120ADFDF1A010C0F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FA3EC23F2FB8B248FD42FDF1A00F61D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FD8B4BCB104DE67120ADFDF1A010C0F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_115EFEA5F7F3CB3EBEABFDF1A010CB2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_FD8B4BCB104DE67120ADFDF1A010C0F5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_115EFEA5F7F3CB3EBEABFDF1A010CB2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_E1C32DBB1AD370A34D74FDF1A010D45B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FA3EC23F2FB8B248FD42FDF1A00F61D9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_E1C32DBB1AD370A34D74FDF1A010D45B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_FDE66F72CA6D63447260FDF1A0105F34" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FA3EC23F2FB8B248FD42FDF1A00F61D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_FDE66F72CA6D63447260FDF1A0105F34" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/StockOptionsStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8228577001457DC570E4E97089D05601" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F1A2BEF43778C8E3FC23E97089D0431E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8228577001457DC570E4E97089D05601" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F1A2BEF43778C8E3FC23E97089D0431E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8D573AFB1774DF09E5D7E97089D0E915" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F1A2BEF43778C8E3FC23E97089D0431E" xlink:to="loc_us-gaap_AwardTypeAxis_8D573AFB1774DF09E5D7E97089D0E915" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E1D213561DABD7AF9B85E97089D0B0B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8D573AFB1774DF09E5D7E97089D0E915" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E1D213561DABD7AF9B85E97089D0B0B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F5B467B1DBB809D77B19E97089D04385" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E1D213561DABD7AF9B85E97089D0B0B1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_F5B467B1DBB809D77B19E97089D04385" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_110795FDDD57918167CAE97089D14A02" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F1A2BEF43778C8E3FC23E97089D0431E" xlink:to="loc_us-gaap_PlanNameAxis_110795FDDD57918167CAE97089D14A02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E03008731366CAA3C04DE97089D1A60C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_110795FDDD57918167CAE97089D14A02" xlink:to="loc_us-gaap_PlanNameDomain_E03008731366CAA3C04DE97089D1A60C" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_EquityIncentivePlan2006Member" xlink:label="loc_tbio_EquityIncentivePlan2006Member_200434173A6BAB7F1FC6E97089D181B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_E03008731366CAA3C04DE97089D1A60C" xlink:to="loc_tbio_EquityIncentivePlan2006Member_200434173A6BAB7F1FC6E97089D181B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F1A2BEF43778C8E3FC23E97089D0431E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9688A779E36B78976D78E97089D1C19E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9688A779E36B78976D78E97089D1C19E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4873A0B672D28BAD8D77E97089D1E451" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4873A0B672D28BAD8D77E97089D1E451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0E1925642A2252F33980E97089D1E3B2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0E1925642A2252F33980E97089D1E3B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_210938FF7FE295E5F1EDE97089D1B844" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571B28C62E3AF72933BE97089D11F58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_210938FF7FE295E5F1EDE97089D1B844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_F94395364C22834E83DAE97089D1817E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_F94395364C22834E83DAE97089D1817E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C2C9233362DFB3A0AC61E97089D19FA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C2C9233362DFB3A0AC61E97089D19FA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E1EE996B9A03AA00A59EE97089D1FACE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E1EE996B9A03AA00A59EE97089D1FACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_098155652C041C21BF5AE97089D196FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_098155652C041C21BF5AE97089D196FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_428EA25167C4245AF22EE97089D1628B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30132B4DB38EB8DD8BEEE97089D19901" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_428EA25167C4245AF22EE97089D1628B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_BFC11917445D4967E368E97089D1A2B8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_BFC11917445D4967E368E97089D1A2B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32859C42ECD2BE9C14A0E97089D259C5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32859C42ECD2BE9C14A0E97089D259C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5F26EA2A82E7B09A8510E97089D2C714" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5F26EA2A82E7B09A8510E97089D2C714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_53931938E679D65912B8E9DAB9F889AA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CA0DB9A68E66A4889BFE97089D1573E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_53931938E679D65912B8E9DAB9F889AA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/StockOptionsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7883915DE733C8BAB473FDF1A0185150" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_116DB9A01C41AF73684EFDF1A0186076" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7883915DE733C8BAB473FDF1A0185150" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_116DB9A01C41AF73684EFDF1A0186076" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_D01703B11BB3548A86E7FF59EF47A15F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9080C77C233F56BF9F9E5A7CFD0ED530" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_D01703B11BB3548A86E7FF59EF47A15F" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9080C77C233F56BF9F9E5A7CFD0ED530" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_D447FD36A74F44EB355A0CE49E680A3D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_D447FD36A74F44EB355A0CE49E680A3D" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceAxis" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceAxis_F99037AF17F67AF15AFA0CE49E680609" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:to="loc_tbio_WarrantyHoldersAndIssuanceAxis_F99037AF17F67AF15AFA0CE49E680609" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceDomain" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceDomain_F5EC0EF35B81C3A3AADE0CE49E682233" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceAxis_F99037AF17F67AF15AFA0CE49E680609" xlink:to="loc_tbio_WarrantyHoldersAndIssuanceDomain_F5EC0EF35B81C3A3AADE0CE49E682233" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SecurityPurchaseAgreementMember" xlink:label="loc_tbio_SecurityPurchaseAgreementMember_BCB5F473AF4189309D480CE49E684725" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_F5EC0EF35B81C3A3AADE0CE49E682233" xlink:to="loc_tbio_SecurityPurchaseAgreementMember_BCB5F473AF4189309D480CE49E684725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_D3573EAE419EEC10A7C00CE49E687A8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_D3573EAE419EEC10A7C00CE49E687A8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_AC869EB47EE7F15E00290CE49E68CB32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_D3573EAE419EEC10A7C00CE49E687A8E" xlink:to="loc_us-gaap_ClassOfStockDomain_AC869EB47EE7F15E00290CE49E68CB32" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember" xlink:label="loc_tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember_5B69A2A7353C8FD194CF0CE49E686DA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_AC869EB47EE7F15E00290CE49E68CB32" xlink:to="loc_tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember_5B69A2A7353C8FD194CF0CE49E686DA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_19F7B71F655C8B5E8A230CE49E69ED19" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_AC869EB47EE7F15E00290CE49E68CB32" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_19F7B71F655C8B5E8A230CE49E69ED19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DDB5770E874953AD8E650CE49E692B50" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_AC869EB47EE7F15E00290CE49E68CB32" xlink:to="loc_us-gaap_CommonStockMember_DDB5770E874953AD8E650CE49E692B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_96B565D09D9B3BA844CB0CE49E695A36" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_96B565D09D9B3BA844CB0CE49E695A36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7BB8C8D825358C2486BB0CE49E692EFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_96B565D09D9B3BA844CB0CE49E695A36" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7BB8C8D825358C2486BB0CE49E692EFA" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_A2016WarrantMember" xlink:label="loc_tbio_A2016WarrantMember_DE57F763325150B093C10CE49E69864A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7BB8C8D825358C2486BB0CE49E692EFA" xlink:to="loc_tbio_A2016WarrantMember_DE57F763325150B093C10CE49E69864A" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SeriesA1WarrantMember" xlink:label="loc_tbio_SeriesA1WarrantMember_A5BF271C086D1545E4120CE49E69F985" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7BB8C8D825358C2486BB0CE49E692EFA" xlink:to="loc_tbio_SeriesA1WarrantMember_A5BF271C086D1545E4120CE49E69F985" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_SeriesAWarrantsMember" xlink:label="loc_tbio_SeriesAWarrantsMember_204E551728830B7966240CE49E696F55" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7BB8C8D825358C2486BB0CE49E692EFA" xlink:to="loc_tbio_SeriesAWarrantsMember_204E551728830B7966240CE49E696F55" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AttheMarketOfferingAgreementMember" xlink:label="loc_tbio_AttheMarketOfferingAgreementMember_05987039D226947B96570CE49E69BA76" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7BB8C8D825358C2486BB0CE49E692EFA" xlink:to="loc_tbio_AttheMarketOfferingAgreementMember_05987039D226947B96570CE49E69BA76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_23080CBE2F4F6756D0950CE49E69155D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:to="loc_us-gaap_CounterpartyNameAxis_23080CBE2F4F6756D0950CE49E69155D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_23080CBE2F4F6756D0950CE49E69155D" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_CraigHallumCapitalGroupLLCMember" xlink:label="loc_tbio_CraigHallumCapitalGroupLLCMember_5925CE01BC84458F89B10CE49E69FE60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3" xlink:to="loc_tbio_CraigHallumCapitalGroupLLCMember_5925CE01BC84458F89B10CE49E69FE60" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VendorMember" xlink:label="loc_tbio_VendorMember_F824A074A52AAE2F236F0CE49E69147A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3" xlink:to="loc_tbio_VendorMember_F824A074A52AAE2F236F0CE49E69147A" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VendorIIMember" xlink:label="loc_tbio_VendorIIMember_C24A823388C108E6FED60CE49E69C871" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_007CC080EAD89FF755070CE49E6926D3" xlink:to="loc_tbio_VendorIIMember_C24A823388C108E6FED60CE49E69C871" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_617AB5EA043BB99937840CE49E6AA5B5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:to="loc_us-gaap_RangeAxis_617AB5EA043BB99937840CE49E6AA5B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1F243389DBB5CF5246F00CE49E6AC0BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_617AB5EA043BB99937840CE49E6AA5B5" xlink:to="loc_us-gaap_RangeMember_1F243389DBB5CF5246F00CE49E6AC0BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10B0E0417E78C8C441B70CE49E6ACFA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1F243389DBB5CF5246F00CE49E6AC0BE" xlink:to="loc_us-gaap_MaximumMember_10B0E0417E78C8C441B70CE49E6ACFA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_D382525760D9CD0B7B7B0CE49E6AA90C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:to="loc_us-gaap_StatementScenarioAxis_D382525760D9CD0B7B7B0CE49E6AA90C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_1BC14D8A9A869AAE90440CE49E6A6DCD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_D382525760D9CD0B7B7B0CE49E6AA90C" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_1BC14D8A9A869AAE90440CE49E6A6DCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_16920D13F3788EF085D50CE49E6A24CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_1BC14D8A9A869AAE90440CE49E6A6DCD" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_16920D13F3788EF085D50CE49E6A24CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6BAD22E09BE6AA9EAE940CE49E6AB837" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6BAD22E09BE6AA9EAE940CE49E6AB837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7DA37A8EE585A0F32A90CE49E6AA070" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6BAD22E09BE6AA9EAE940CE49E6AB837" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7DA37A8EE585A0F32A90CE49E6AA070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_584CDE94AF94857C6ABA0CE49E6ADDA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7DA37A8EE585A0F32A90CE49E6AA070" xlink:to="loc_us-gaap_PrivatePlacementMember_584CDE94AF94857C6ABA0CE49E6ADDA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_96921EFAACEBA1FA4AC40CE49E68E6D9" xlink:to="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_557759EF0DBF65E9F3260CE49E6A2451" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_557759EF0DBF65E9F3260CE49E6A2451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_AD06E29A334CA809C1B70CE49E6A4AD9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_AD06E29A334CA809C1B70CE49E6A4AD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6615B9033459430643F00CE49E6A0E4C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6615B9033459430643F00CE49E6A0E4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E2803968FEC2F3D001250CE49E6AEE22" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E2803968FEC2F3D001250CE49E6AEE22" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_InitialFairValueofWarrantsIssued" xlink:label="loc_tbio_InitialFairValueofWarrantsIssued_A010D6CD31038663E1D30CE49E6AD5DA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_InitialFairValueofWarrantsIssued_A010D6CD31038663E1D30CE49E6AD5DA" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet" xlink:label="loc_tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet_B24BF8AD3823D21A73980CE49E6B3CD7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet_B24BF8AD3823D21A73980CE49E6B3CD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_8F9CA6D86893954E96910CE49E6B2945" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_8F9CA6D86893954E96910CE49E6B2945" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6B15164DFB23C33AEE560CE49E6BE9C8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6B15164DFB23C33AEE560CE49E6BE9C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_F2ACEF297C062A6E677C0CE49E6B50AC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_Dividends_F2ACEF297C062A6E677C0CE49E6B50AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_BE62BF7AFBF983CD34110CE49E6B8464" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_BE62BF7AFBF983CD34110CE49E6B8464" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_D97999A5644A2EE034900CE49E6BBE87" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_D97999A5644A2EE034900CE49E6BBE87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3C9CC536EC01D74183C50CE49E6BB3F0" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3C9CC536EC01D74183C50CE49E6BB3F0" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassofWarrantorRightExerciseTerm1" xlink:label="loc_tbio_ClassofWarrantorRightExerciseTerm1_26F088A358E9EC87D0120CE49E6B8394" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_ClassofWarrantorRightExerciseTerm1_26F088A358E9EC87D0120CE49E6B8394" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockWarrantExchangeAmount" xlink:label="loc_tbio_StockWarrantExchangeAmount_7A7ACA3E735C5EB93B530CE49E6B7C61" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_StockWarrantExchangeAmount_7A7ACA3E735C5EB93B530CE49E6B7C61" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment" xlink:label="loc_tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment_478A733D04BD5309D8B30CE49E6B895E" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment_478A733D04BD5309D8B30CE49E6B895E" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights" xlink:label="loc_tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights_CD4F4CF723AECB7289E80CE49E6B7404" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights_CD4F4CF723AECB7289E80CE49E6B7404" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_CashPaymentPortionofStockWarrantsExercised" xlink:label="loc_tbio_CashPaymentPortionofStockWarrantsExercised_96981F744B4178361C060CE49E6B6BD7" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_CashPaymentPortionofStockWarrantsExercised_96981F744B4178361C060CE49E6B6BD7" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockWarrantsSettledwithCash" xlink:label="loc_tbio_StockWarrantsSettledwithCash_4EF6BA197799AAB1EB910CE49E6BFD64" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_StockWarrantsSettledwithCash_4EF6BA197799AAB1EB910CE49E6BFD64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_E401B8DB81246EE1BB540CE49E6BEE54" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_E401B8DB81246EE1BB540CE49E6BEE54" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds" xlink:label="loc_tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds_94FAF8420589BBAB3E680CE49E6B15E0" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds_94FAF8420589BBAB3E680CE49E6B15E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_9FAAD738CED5FC9F796E0CE49E6B0578" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_SharePrice_9FAAD738CED5FC9F796E0CE49E6B0578" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares" xlink:label="loc_tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares_9CF9AAE4F8305482FE640CE49E6C31C2" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares_9CF9AAE4F8305482FE640CE49E6C31C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_C59EC960D55B8C937BE50CE49E6C3631" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_C59EC960D55B8C937BE50CE49E6C3631" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockIssuanceCostsReimbursableExpenses" xlink:label="loc_tbio_StockIssuanceCostsReimbursableExpenses_CAC4DC87359C8DBAAFF80CE49E6C502B" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_StockIssuanceCostsReimbursableExpenses_CAC4DC87359C8DBAAFF80CE49E6C502B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement_EB5E6FC74766506ACAE20CE49E6C4023" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement_EB5E6FC74766506ACAE20CE49E6C4023" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1D3A22B06F3B6B0A33D60CE49E6CDB8F" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1D3A22B06F3B6B0A33D60CE49E6CDB8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_46B0C3C9D8829F637FF30CE49E6CF97D" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_46B0C3C9D8829F637FF30CE49E6CF97D" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PlacementFeesPercentageofGrossSalesPrice" xlink:label="loc_tbio_PlacementFeesPercentageofGrossSalesPrice_6725CD7F667CFE0679EF0CE49E6CE550" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_PlacementFeesPercentageofGrossSalesPrice_6725CD7F667CFE0679EF0CE49E6CE550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1BE997650C968FEBDB3D0CE49E6C8348" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_CommonStockSharesIssued_1BE997650C968FEBDB3D0CE49E6C8348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9C323911DCE7897244040CE49E6C90F6" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9C323911DCE7897244040CE49E6C90F6" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockholdersEquityNoteConversionRatio" xlink:label="loc_tbio_StockholdersEquityNoteConversionRatio_9E06EA32C379325691390CE49E6CDC73" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_313A3F449ADA0D2451600CE49E6AFA47" xlink:to="loc_tbio_StockholdersEquityNoteConversionRatio_9E06EA32C379325691390CE49E6CDC73" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_E0D3CAD2FE2B35F985D3F864D99D4505" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_20838CC8354CAC80596EF864D99DF2AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_E0D3CAD2FE2B35F985D3F864D99D4505" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_20838CC8354CAC80596EF864D99DF2AC" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceAxis" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceAxis_32C6F0E5F7CA8B8AD5FEF864D9AD4E73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_20838CC8354CAC80596EF864D99DF2AC" xlink:to="loc_tbio_WarrantyHoldersAndIssuanceAxis_32C6F0E5F7CA8B8AD5FEF864D9AD4E73" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceDomain" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceAxis_32C6F0E5F7CA8B8AD5FEF864D9AD4E73" xlink:to="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersJanuary2018Member" xlink:label="loc_tbio_VariousInstitutionalHoldersJanuary2018Member_EA77125991AB12F0DD06F864D9AD190C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="loc_tbio_VariousInstitutionalHoldersJanuary2018Member_EA77125991AB12F0DD06F864D9AD190C" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AffiliatesofThirdSecurityLLCJanuary2018Member" xlink:label="loc_tbio_AffiliatesofThirdSecurityLLCJanuary2018Member_10250DCD19246BC38A98F864D9ADE770" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="loc_tbio_AffiliatesofThirdSecurityLLCJanuary2018Member_10250DCD19246BC38A98F864D9ADE770" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersApril2020Member" xlink:label="loc_tbio_VariousInstitutionalHoldersApril2020Member_221E901F173036A38F42F864D9AD35ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="loc_tbio_VariousInstitutionalHoldersApril2020Member_221E901F173036A38F42F864D9AD35ED" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersFebruary2020Member" xlink:label="loc_tbio_VariousInstitutionalHoldersFebruary2020Member_00EB76114B081FB32FB3F864D9AD3D5E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="loc_tbio_VariousInstitutionalHoldersFebruary2020Member_00EB76114B081FB32FB3F864D9AD3D5E" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersDecember2020OneMember" xlink:label="loc_tbio_VariousInstitutionalHoldersDecember2020OneMember_137D9F7AD169D6E38764F864D9ADA55A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="loc_tbio_VariousInstitutionalHoldersDecember2020OneMember_137D9F7AD169D6E38764F864D9ADA55A" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersJanuary2021OneMember" xlink:label="loc_tbio_VariousInstitutionalHoldersJanuary2021OneMember_D4459DEA92D97356D8FAF864D9ADDA7F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="loc_tbio_VariousInstitutionalHoldersJanuary2021OneMember_D4459DEA92D97356D8FAF864D9ADDA7F" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AffiliatesofThirdSecurityLLCJanuary2021Member" xlink:label="loc_tbio_AffiliatesofThirdSecurityLLCJanuary2021Member_49A330F8AE829C841B53F864D9AD2881" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="loc_tbio_AffiliatesofThirdSecurityLLCJanuary2021Member_49A330F8AE829C841B53F864D9AD2881" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_VariousInstitutionalHoldersJanuary2021TwoMember" xlink:label="loc_tbio_VariousInstitutionalHoldersJanuary2021TwoMember_B4827F0E66E751828CF4F864D9ADBE5A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_7CA35C069ED3F32CE42CF864D9AD0292" xlink:to="loc_tbio_VariousInstitutionalHoldersJanuary2021TwoMember_B4827F0E66E751828CF4F864D9ADBE5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_EB2DBC6F5FD1F8561C34F864D9AD191A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_20838CC8354CAC80596EF864D99DF2AC" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_EB2DBC6F5FD1F8561C34F864D9AD191A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_EB2DBC6F5FD1F8561C34F864D9AD191A" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_FFA6626469636ADD68D7F864D9AD0292" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710" xlink:to="loc_us-gaap_PrivatePlacementMember_FFA6626469636ADD68D7F864D9AD0292" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_OfferingMember" xlink:label="loc_tbio_OfferingMember_0B94FB93F9CFC02BAD12F864D9ADF752" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06DDA5B830E84A7BD053F864D9AD7710" xlink:to="loc_tbio_OfferingMember_0B94FB93F9CFC02BAD12F864D9ADF752" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_BCACBA6160B268C61DCAF864D9AD39D3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_20838CC8354CAC80596EF864D99DF2AC" xlink:to="loc_us-gaap_ClassOfStockLineItems_BCACBA6160B268C61DCAF864D9AD39D3" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired" xlink:label="loc_tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired_B3D292C77B7DEE7E823DF865D30D6E13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BCACBA6160B268C61DCAF864D9AD39D3" xlink:to="loc_tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired_B3D292C77B7DEE7E823DF865D30D6E13" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_BA0802240838C4F9B52CF864D9AD0786" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BCACBA6160B268C61DCAF864D9AD39D3" xlink:to="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_BA0802240838C4F9B52CF864D9AD0786" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_DDCFC3052050DF1B4F4DF864D9ADEDF0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BCACBA6160B268C61DCAF864D9AD39D3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_DDCFC3052050DF1B4F4DF864D9ADEDF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22AB4F356AE64962A675F864D9ADF51C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_BCACBA6160B268C61DCAF864D9AD39D3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22AB4F356AE64962A675F864D9ADF51C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityConversionOfPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_36D7042DF111D084694EF8C18F09C36A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaap_ConversionOfStockTable_55B43033EF586C5B8476F8C18F09FA54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_36D7042DF111D084694EF8C18F09C36A" xlink:to="loc_us-gaap_ConversionOfStockTable_55B43033EF586C5B8476F8C18F09FA54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_AAAB466F7450A57BE2BCF8C18F0914E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_55B43033EF586C5B8476F8C18F09FA54" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_AAAB466F7450A57BE2BCF8C18F0914E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B5EA5379EE4177569054F8C18F09C235" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_AAAB466F7450A57BE2BCF8C18F0914E2" xlink:to="loc_us-gaap_EquityComponentDomain_B5EA5379EE4177569054F8C18F09C235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_FBAF2CA0D94BACD2E6B6F8C18F09A410" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B5EA5379EE4177569054F8C18F09C235" xlink:to="loc_us-gaap_PreferredStockMember_FBAF2CA0D94BACD2E6B6F8C18F09A410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_8178C7708F918C176D85F8C18F09A72C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B5EA5379EE4177569054F8C18F09C235" xlink:to="loc_us-gaap_CommonStockMember_8178C7708F918C176D85F8C18F09A72C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A29468257E126CA804E1F8C18F09608C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_55B43033EF586C5B8476F8C18F09FA54" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A29468257E126CA804E1F8C18F09608C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_87280F60FE5167096D05F8C18F09D1E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A29468257E126CA804E1F8C18F09608C" xlink:to="loc_us-gaap_ClassOfStockDomain_87280F60FE5167096D05F8C18F09D1E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_274322DDB516BD8EFF46F8C18F09DE45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_87280F60FE5167096D05F8C18F09D1E4" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_274322DDB516BD8EFF46F8C18F09DE45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_7129EE8FC9D06E3BBF63F8C18F09CA78" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_87280F60FE5167096D05F8C18F09D1E4" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_7129EE8FC9D06E3BBF63F8C18F09CA78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_55B43033EF586C5B8476F8C18F09FA54" xlink:to="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_94180AF6E25704452099F8C18F0A5728" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_94180AF6E25704452099F8C18F0A5728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6F6BCF6F72765E652954F8C18F0A73E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6F6BCF6F72765E652954F8C18F0A73E8" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockholdersEquityNoteConversionRatio" xlink:label="loc_tbio_StockholdersEquityNoteConversionRatio_55D50AF42334ED7D4DC5F8C18F0A4DF3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_tbio_StockholdersEquityNoteConversionRatio_55D50AF42334ED7D4DC5F8C18F0A4DF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_409B96AED495C9CF17DBF8C18F0A0E28" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_409B96AED495C9CF17DBF8C18F0A0E28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_63583B3BBF3A173DE222F8C18F0A954A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_63583B3BBF3A173DE222F8C18F0A954A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockDividendsShares" xlink:label="loc_us-gaap_CommonStockDividendsShares_31F5410EF0C97FB28529F8C18F0ABE9D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_CommonStockDividendsShares_31F5410EF0C97FB28529F8C18F0ABE9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockDividendsShares" xlink:label="loc_us-gaap_StockDividendsShares_F051A15CE70E69F81827F8C18F0A4990" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_StockDividendsShares_F051A15CE70E69F81827F8C18F0A4990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_716CE248F39CDD8CD1ECF8C18F0ABB61" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_SharesIssued_716CE248F39CDD8CD1ECF8C18F0ABB61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_99C11C666C792D792181F8C18F0A7DFB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_A7FEFCC923372EA04794F8C18F0A74A2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_99C11C666C792D792181F8C18F0A7DFB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityPreferredStockDividendsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_B15EDBC35FECC976C423F8A7AD4C8213" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_209C3FFB2E87C91D0A6BF8B1564630CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_B15EDBC35FECC976C423F8A7AD4C8213" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_209C3FFB2E87C91D0A6BF8B1564630CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_C04A4458C0FEACEB2064F8B15701B7EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_209C3FFB2E87C91D0A6BF8B1564630CD" xlink:to="loc_us-gaap_StatementClassOfStockAxis_C04A4458C0FEACEB2064F8B15701B7EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1D3FD536846990D1B9F0F8B1570122A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C04A4458C0FEACEB2064F8B15701B7EE" xlink:to="loc_us-gaap_ClassOfStockDomain_1D3FD536846990D1B9F0F8B1570122A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_077D5D9323D101390A4AF8B157543D55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1D3FD536846990D1B9F0F8B1570122A7" xlink:to="loc_us-gaap_PreferredStockMember_077D5D9323D101390A4AF8B157543D55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_5A031D19CA0A88A74242F8B156479144" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_209C3FFB2E87C91D0A6BF8B1564630CD" xlink:to="loc_us-gaap_ClassOfStockLineItems_5A031D19CA0A88A74242F8B156479144" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DividendsPreferredStockCashNotDeclared" xlink:label="loc_tbio_DividendsPreferredStockCashNotDeclared_76BF69921F45864CE6A1F8A7AD4CB347" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5A031D19CA0A88A74242F8B156479144" xlink:to="loc_tbio_DividendsPreferredStockCashNotDeclared_76BF69921F45864CE6A1F8A7AD4CB347" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesADetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_2BAD379F625E01C3DB28F89321D33528" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_BDACA856422DF2BECEC5F89321D43AB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_2BAD379F625E01C3DB28F89321D33528" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_BDACA856422DF2BECEC5F89321D43AB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_CD31711393080966D0B5F89321D4FC8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_BDACA856422DF2BECEC5F89321D43AB5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_CD31711393080966D0B5F89321D4FC8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_CD31711393080966D0B5F89321D4FC8E" xlink:to="loc_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_65B350A8A0317A498FCBF89321D4F3D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE" xlink:to="loc_us-gaap_PreferredStockMember_65B350A8A0317A498FCBF89321D4F3D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_F4FB5CD53F0CA1804C1EF89381FCB288" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_89FB3A97C542BFD2746DF89321D410FE" xlink:to="loc_us-gaap_CommonStockMember_F4FB5CD53F0CA1804C1EF89381FCB288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_AD903EF05C295788DEF3F89321D4FD9D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_BDACA856422DF2BECEC5F89321D43AB5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_AD903EF05C295788DEF3F89321D4FD9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A7FA0752CC1E411316C0F89321D5E28D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_AD903EF05C295788DEF3F89321D4FD9D" xlink:to="loc_us-gaap_ClassOfStockDomain_A7FA0752CC1E411316C0F89321D5E28D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_D8B40C5962EF319AECBEF89321D5A269" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A7FA0752CC1E411316C0F89321D5E28D" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_D8B40C5962EF319AECBEF89321D5A269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_A376625546574BA8EBB3F8933C6CB5B8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_BDACA856422DF2BECEC5F89321D43AB5" xlink:to="loc_us-gaap_RangeAxis_A376625546574BA8EBB3F8933C6CB5B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_299654020A41FBDC98BBF8933CDED30E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_A376625546574BA8EBB3F8933C6CB5B8" xlink:to="loc_us-gaap_RangeMember_299654020A41FBDC98BBF8933CDED30E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_90ABF490A7A1137488A7F8933E0D05C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_299654020A41FBDC98BBF8933CDED30E" xlink:to="loc_us-gaap_MinimumMember_90ABF490A7A1137488A7F8933E0D05C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_BDACA856422DF2BECEC5F89321D43AB5" xlink:to="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B4A8B5402489B7EE0351F89321D5F8B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_B4A8B5402489B7EE0351F89321D5F8B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_45501EF938DF6B2BE5CBF89321D5A490" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_45501EF938DF6B2BE5CBF89321D5A490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5B45FAD27B46CFDA3F69F89321D51D4B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5B45FAD27B46CFDA3F69F89321D51D4B" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote" xlink:label="loc_tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote_76C8303CE2B4EBA88D79F89321D6D427" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote_76C8303CE2B4EBA88D79F89321D6D427" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes" xlink:label="loc_tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes_B13477710B0ABFC4BF2BF89338B6A1DD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes_B13477710B0ABFC4BF2BF89338B6A1DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6C206152D9FDBE32D167F89321D595BD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6C206152D9FDBE32D167F89321D595BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_7DD017678FE0484E712BF89339CDF98E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_7DD017678FE0484E712BF89339CDF98E" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PreferredStockDividendRateCompoundPercentageMaximum" xlink:label="loc_tbio_PreferredStockDividendRateCompoundPercentageMaximum_7F5CA36515D2B00DBF47F8933A18D96E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_tbio_PreferredStockDividendRateCompoundPercentageMaximum_7F5CA36515D2B00DBF47F8933A18D96E" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_NumberOfDirectors" xlink:label="loc_tbio_NumberOfDirectors_D5C820E68337C3ED7EBBF8933A533F42" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_tbio_NumberOfDirectors_D5C820E68337C3ED7EBBF8933A533F42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_950D41B97D4B32BAA28BF89381FCC2E1" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_742EAD8FD853A88977B2F89321D52449" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_950D41B97D4B32BAA28BF89381FCC2E1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesBDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_EFE1FD1203808E85F311FDF1A02AF78B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_C1424369FF8B394200E6FDF1A02AD30D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_EFE1FD1203808E85F311FDF1A02AF78B" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_C1424369FF8B394200E6FDF1A02AD30D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_D3AE46BDFD68C9570EB9FDF1A02ABD9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C1424369FF8B394200E6FDF1A02AD30D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_D3AE46BDFD68C9570EB9FDF1A02ABD9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_26226CD5589D684ADC98FDF1A02AAE19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_D3AE46BDFD68C9570EB9FDF1A02ABD9A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_26226CD5589D684ADC98FDF1A02AAE19" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ThirdSecurityLlcAndAffiliatesMember" xlink:label="loc_tbio_ThirdSecurityLlcAndAffiliatesMember_01A1E68160C6E89EC7D3FDF1A02A1580" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_26226CD5589D684ADC98FDF1A02AAE19" xlink:to="loc_tbio_ThirdSecurityLlcAndAffiliatesMember_01A1E68160C6E89EC7D3FDF1A02A1580" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceAxis" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceAxis_91631225B5A31FF9EAA8FDF1A02A0D85" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C1424369FF8B394200E6FDF1A02AD30D" xlink:to="loc_tbio_WarrantyHoldersAndIssuanceAxis_91631225B5A31FF9EAA8FDF1A02A0D85" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_WarrantyHoldersAndIssuanceDomain" xlink:label="loc_tbio_WarrantyHoldersAndIssuanceDomain_ABCB07EAC79134B71FEDFDF1A02AD8BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceAxis_91631225B5A31FF9EAA8FDF1A02A0D85" xlink:to="loc_tbio_WarrantyHoldersAndIssuanceDomain_ABCB07EAC79134B71FEDFDF1A02AD8BA" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tbio_WarrantyHoldersAndIssuanceDomain_ABCB07EAC79134B71FEDFDF1A02AD8BA" xlink:to="loc_tbio_ThirdSecurityLlcAndAffiliatesMember_01A1E68160C6E89EC7D3FDF1A02A1580" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_420109801F58EC0713E1FDF1A02AFF48" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C1424369FF8B394200E6FDF1A02AD30D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_420109801F58EC0713E1FDF1A02AFF48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_37437E3C458D1B36FAFAFDF1A02A395F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_420109801F58EC0713E1FDF1A02AFF48" xlink:to="loc_us-gaap_EquityComponentDomain_37437E3C458D1B36FAFAFDF1A02A395F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_DA8BAD8A8DF0128B7599FDF1A02ADA27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_37437E3C458D1B36FAFAFDF1A02A395F" xlink:to="loc_us-gaap_PreferredStockMember_DA8BAD8A8DF0128B7599FDF1A02ADA27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11C2284492C721FBBCF7FDF1A02A3D49" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C1424369FF8B394200E6FDF1A02AD30D" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11C2284492C721FBBCF7FDF1A02A3D49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_E9C6E8F8C879B8A2728DFDF1A02AF085" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11C2284492C721FBBCF7FDF1A02A3D49" xlink:to="loc_us-gaap_ClassOfStockDomain_E9C6E8F8C879B8A2728DFDF1A02AF085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_3A40F726A489DA137F04FDF1A02A59C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_E9C6E8F8C879B8A2728DFDF1A02AF085" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_3A40F726A489DA137F04FDF1A02A59C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C1424369FF8B394200E6FDF1A02AD30D" xlink:to="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D1991E8DB0C642A3594BFDF1A02A0678" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D1991E8DB0C642A3594BFDF1A02A0678" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4770312D725F6AE8DFF0FDF1A02A1FB0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4770312D725F6AE8DFF0FDF1A02A1FB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_6234B884C5621E0445BDFDF1A02A780E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:to="loc_us-gaap_SharePrice_6234B884C5621E0445BDFDF1A02A780E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_FCD263996959636084AEFDF1A02A3600" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_FCD263996959636084AEFDF1A02A3600" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_StockholdersEquityNoteConversionRatio" xlink:label="loc_tbio_StockholdersEquityNoteConversionRatio_543F724866A52EEA504BFDF1A02A78CF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:to="loc_tbio_StockholdersEquityNoteConversionRatio_543F724866A52EEA504BFDF1A02A78CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_815FC92B34C13C7A854DFE11E2AECCB9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_815FC92B34C13C7A854DFE11E2AECCB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E8B9A725CB9D5FB6C718FE19FE4F76B2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B6D709BE00949E814DFFFDF1A02A257C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E8B9A725CB9D5FB6C718FE19FE4F76B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_41209461197E5430877F5AE1C0C86C81" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_D487EE2045A95627B2A8EAB485CECC3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_41209461197E5430877F5AE1C0C86C81" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_D487EE2045A95627B2A8EAB485CECC3B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_23B0DE7B9FBF5FB7A6358453F7C4C9F5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_E840CD3B290D5780B9DD269B6191E4C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_23B0DE7B9FBF5FB7A6358453F7C4C9F5" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_E840CD3B290D5780B9DD269B6191E4C6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9A2454F12C64BB6A93630CE49DD04BFA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9A2454F12C64BB6A93630CE49DD04BFA" xlink:to="loc_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_C81DE6CBA703D0B7D63D0CE49DD0A86C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_C81DE6CBA703D0B7D63D0CE49DD0A86C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_E33EFD29BC1ABE56D7B10CE49DD0C58A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C81DE6CBA703D0B7D63D0CE49DD0A86C" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_E33EFD29BC1ABE56D7B10CE49DD0C58A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2DEC441387BFD13F21570CE49DD0C521" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_E33EFD29BC1ABE56D7B10CE49DD0C58A" xlink:to="loc_us-gaap_SubsequentEventMember_2DEC441387BFD13F21570CE49DD0C521" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_80405FC43A261EA7DD380CE49DD0714B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_80405FC43A261EA7DD380CE49DD0714B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_33960ECBAE207F4F40760CE49DD1EEA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_80405FC43A261EA7DD380CE49DD0714B" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_33960ECBAE207F4F40760CE49DD1EEA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_D91F96F014DAEC9213F20CE49DD11260" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_33960ECBAE207F4F40760CE49DD1EEA6" xlink:to="loc_us-gaap_BridgeLoanMember_D91F96F014DAEC9213F20CE49DD11260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5A1859C351619AD5648D0CE49DD15CE8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40" xlink:to="loc_dei_LegalEntityAxis_5A1859C351619AD5648D0CE49DD15CE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_13BEEE97E6412E14A85A0CE49DD15F9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5A1859C351619AD5648D0CE49DD15CE8" xlink:to="loc_dei_EntityDomain_13BEEE97E6412E14A85A0CE49DD15F9B" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PrecipioMember" xlink:label="loc_tbio_PrecipioMember_3053E7BCED4F7989FA810CE49DD136BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_13BEEE97E6412E14A85A0CE49DD15F9B" xlink:to="loc_tbio_PrecipioMember_3053E7BCED4F7989FA810CE49DD136BF" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AegisCorpMember" xlink:label="loc_tbio_AegisCorpMember_34A10592FD9A8F6753C30CE49DD1AD37" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_13BEEE97E6412E14A85A0CE49DD15F9B" xlink:to="loc_tbio_AegisCorpMember_34A10592FD9A8F6753C30CE49DD1AD37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_718E60C1B05A3AC42A610CE49DD06E40" xlink:to="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_22ABEEFD82702A28D66C0CE49DD13B94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_22ABEEFD82702A28D66C0CE49DD13B94" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_AdditionalShorttermLoanMaximumAmountAuthorized" xlink:label="loc_tbio_AdditionalShorttermLoanMaximumAmountAuthorized_5C12CE79F9C3A8EAB0C30CE49DD28CF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_tbio_AdditionalShorttermLoanMaximumAmountAuthorized_5C12CE79F9C3A8EAB0C30CE49DD28CF8" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ProceedsFromtheSalesofDebtInstrument" xlink:label="loc_tbio_ProceedsFromtheSalesofDebtInstrument_C9BFD350F7E1BA02A1A70CE49DD2CCDB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_tbio_ProceedsFromtheSalesofDebtInstrument_C9BFD350F7E1BA02A1A70CE49DD2CCDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_C95DF94AE5450103BED00CE49DD2705F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_C95DF94AE5450103BED00CE49DD2705F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_679DA1D54B6E2790A5350CE49DD2A630" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_us-gaap_DebtInstrumentTerm_679DA1D54B6E2790A5350CE49DD2A630" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_DebtInstrumentPremiumFeePercentage" xlink:label="loc_tbio_DebtInstrumentPremiumFeePercentage_D3F0CFAB4D158FDB17170CE49DD29B7B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_tbio_DebtInstrumentPremiumFeePercentage_D3F0CFAB4D158FDB17170CE49DD29B7B" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_353A109C40CCE6B237550CE49DD24543" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_353A109C40CCE6B237550CE49DD24543" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_B460F71D780F2794EE130CE49DD28CCB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_B460F71D780F2794EE130CE49DD28CCB" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_LoantoRelatedPartyPercentage" xlink:label="loc_tbio_LoantoRelatedPartyPercentage_F899E5A568EE88A102360CE49DD29292" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_tbio_LoantoRelatedPartyPercentage_F899E5A568EE88A102360CE49DD29292" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaap_SecuredDebt_AE3BAD65377E5FBB71C60CE49DD23646" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_us-gaap_SecuredDebt_AE3BAD65377E5FBB71C60CE49DD23646" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PlacementFees" xlink:label="loc_tbio_PlacementFees_BE9EBC64BCAF76FFF5D80CE49DD21157" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_D8D5C47C061073CC6F980CE49DD15EB9" xlink:to="loc_tbio_PlacementFees_BE9EBC64BCAF76FFF5D80CE49DD21157" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_CD72E7B930345E6D9AD2053555F8C3C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E4373E3AA12D575BB060DC0027829017" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CD72E7B930345E6D9AD2053555F8C3C9" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E4373E3AA12D575BB060DC0027829017" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4C3BBCF178C2268363EE0D52F233975F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_A2FACA901FEB704202730D52F2331173" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4C3BBCF178C2268363EE0D52F233975F" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_A2FACA901FEB704202730D52F2331173" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_334500717AADAD75AF860D52F233AE61" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4C3BBCF178C2268363EE0D52F233975F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_334500717AADAD75AF860D52F233AE61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5813607B7959646376F70D52F233BE58" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4C3BBCF178C2268363EE0D52F233975F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5813607B7959646376F70D52F233BE58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_17CB8F8BE0A9080AA09E0D52F233235A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4C3BBCF178C2268363EE0D52F233975F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_17CB8F8BE0A9080AA09E0D52F233235A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_BA5FEBF3BB8383EF75040D52F23365CC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4C3BBCF178C2268363EE0D52F233975F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_BA5FEBF3BB8383EF75040D52F23365CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EBDE5401BF768D6935810D52F2335DF6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4C3BBCF178C2268363EE0D52F233975F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EBDE5401BF768D6935810D52F2335DF6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesNarrativesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_C821636FD421A212130CF9224670AD24" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C821636FD421A212130CF9224670AD24" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5089D56CCB0E4A883D56F922467FA42E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:to="loc_us-gaap_RangeAxis_5089D56CCB0E4A883D56F922467FA42E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_ECB65DA9E1B3C54E03D8F922467FBC33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5089D56CCB0E4A883D56F922467FA42E" xlink:to="loc_us-gaap_RangeMember_ECB65DA9E1B3C54E03D8F922467FBC33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_DD81EABAEEFBEDB73961F922467F61C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_ECB65DA9E1B3C54E03D8F922467FBC33" xlink:to="loc_us-gaap_MaximumMember_DD81EABAEEFBEDB73961F922467F61C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9297D8BE4142ADE4CDEFF922467FECCC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9297D8BE4142ADE4CDEFF922467FECCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4A15998F5AA3217F4525F922467FEFCD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9297D8BE4142ADE4CDEFF922467FECCC" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4A15998F5AA3217F4525F922467FEFCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F0BF88F9C31197693E11F922467F43FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4A15998F5AA3217F4525F922467FEFCD" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_F0BF88F9C31197693E11F922467F43FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_C956E160001919D22EC9F922467F0565" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:to="loc_us-gaap_TitleOfIndividualAxis_C956E160001919D22EC9F922467F0565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0B9EF6860F9506DB6202F922467F3D65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_C956E160001919D22EC9F922467F0565" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0B9EF6860F9506DB6202F922467F3D65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember_FD211E4274C3E06025B7F922467F20F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0B9EF6860F9506DB6202F922467F3D65" xlink:to="loc_us-gaap_ExecutiveOfficerMember_FD211E4274C3E06025B7F922467F20F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1C53D83FA3AAE59E4757F922467FE107" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1C53D83FA3AAE59E4757F922467FE107" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_B71D3ABCF305669CA5EAF922467FC672" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1C53D83FA3AAE59E4757F922467FE107" xlink:to="loc_us-gaap_SegmentDomain_B71D3ABCF305669CA5EAF922467FC672" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_PharmacogenomicServicesMember" xlink:label="loc_tbio_PharmacogenomicServicesMember_5DE0360C1FACCA9DF398F922467FDC07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_B71D3ABCF305669CA5EAF922467FC672" xlink:to="loc_tbio_PharmacogenomicServicesMember_5DE0360C1FACCA9DF398F922467FDC07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD24F1AF7880BD7B8D40F922467F4701" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_A0585D0F80AE5CAC64B4F922467F00B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_OtherAssetsCurrent_A0585D0F80AE5CAC64B4F922467F00B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_D2FFBA0BC33B7AB10858F922467F73FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_D2FFBA0BC33B7AB10858F922467F73FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_1110FD9027EE78B52971F922467F92E4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_1110FD9027EE78B52971F922467F92E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9108391CED427E49AB3BF922467FCC7D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9108391CED427E49AB3BF922467FCC7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_E86611F32DB00FA5E24DF922467F5D79" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_E86611F32DB00FA5E24DF922467F5D79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_055EAACFE10737EF6E66F922467F539A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_ShareBasedCompensation_055EAACFE10737EF6E66F922467F539A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1A167671C855305387CAF922467F559B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1A167671C855305387CAF922467F559B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_034D726B5125DE47B2A4F922467F7D62" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_034D726B5125DE47B2A4F922467F7D62" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_3676D7AECE76789AA3D4F922467F027C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_3676D7AECE76789AA3D4F922467F027C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_B11641F5826BC154EA4EF922467F96D7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_DeferredRevenueCurrent_B11641F5826BC154EA4EF922467F96D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8C4C8FF1829D3DEBE19BF922467FE615" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6E07472E5AA55BD43F2BF922467FA641" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8C4C8FF1829D3DEBE19BF922467FE615" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_CE6B7C663FFC3B1CECD8F99435E44704" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1FA89DC83D2C2071D9ADF99435E43B38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CE6B7C663FFC3B1CECD8F99435E44704" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1FA89DC83D2C2071D9ADF99435E43B38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_3F6C867C60E57FA7BBDFF99435E44558" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CE6B7C663FFC3B1CECD8F99435E44704" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_3F6C867C60E57FA7BBDFF99435E44558" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_tbio_RisksAndUncertaintiesPolicyTextBlock_464684861CFFAB54AFD0F99435E444CB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CE6B7C663FFC3B1CECD8F99435E44704" xlink:to="loc_tbio_RisksAndUncertaintiesPolicyTextBlock_464684861CFFAB54AFD0F99435E444CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_259B1D3010B23E0E0CC7F99435E4F19C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CE6B7C663FFC3B1CECD8F99435E44704" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_259B1D3010B23E0E0CC7F99435E4F19C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9984F63EC18D8A2664DDF99435E4AD36" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CE6B7C663FFC3B1CECD8F99435E44704" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9984F63EC18D8A2664DDF99435E4AD36" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_ConcentrationOfCashPolicyPolicyTextBlock" xlink:label="loc_tbio_ConcentrationOfCashPolicyPolicyTextBlock_196FD2D4005ED4058FB4F99435E488B2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CE6B7C663FFC3B1CECD8F99435E44704" xlink:to="loc_tbio_ConcentrationOfCashPolicyPolicyTextBlock_196FD2D4005ED4058FB4F99435E488B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7F16BE17EE177ECB1E45F99435E5A87D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CE6B7C663FFC3B1CECD8F99435E44704" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7F16BE17EE177ECB1E45F99435E5A87D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_E9A730000038DC698D01F99435E5485A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CE6B7C663FFC3B1CECD8F99435E44704" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_E9A730000038DC698D01F99435E5485A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7A2B5B5F2A2258BE86F3F99435E51523" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CE6B7C663FFC3B1CECD8F99435E44704" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_7A2B5B5F2A2258BE86F3F99435E51523" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BABBA85E8B02D73EFAE2F99435E5673F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CE6B7C663FFC3B1CECD8F99435E44704" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_BABBA85E8B02D73EFAE2F99435E5673F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_EB291F4F6E98E0E132ADF99435D5077D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_B71DBC04E225B7166D5EF9AF7FB0DBAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EB291F4F6E98E0E132ADF99435D5077D" xlink:to="loc_us-gaap_Depreciation_B71DBC04E225B7166D5EF9AF7FB0DBAA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_07F0B8066EAECCCB5906FDA118EFE0D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9C30E6C9A65F0872BDF7FDA118EF4A3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_07F0B8066EAECCCB5906FDA118EFE0D0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9C30E6C9A65F0872BDF7FDA118EF4A3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_B9DFA13C99EA0645892BFDA118EFF375" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9C30E6C9A65F0872BDF7FDA118EF4A3E" xlink:to="loc_us-gaap_NetIncomeLoss_B9DFA13C99EA0645892BFDA118EFF375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6C2ACD0E88EED12142F8FDA118EFA841" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9C30E6C9A65F0872BDF7FDA118EF4A3E" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6C2ACD0E88EED12142F8FDA118EFA841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_20328C4AC840DFDC0E1AFDA118EFB534" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9C30E6C9A65F0872BDF7FDA118EF4A3E" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_20328C4AC840DFDC0E1AFDA118EFB534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B9FCB53722387D8409A7FDA118EFF9B9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9C30E6C9A65F0872BDF7FDA118EF4A3E" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B9FCB53722387D8409A7FDA118EFF9B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_CBC37B2C0C244A3219A8FDA118EF3D03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B9FCB53722387D8409A7FDA118EFF9B9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_CBC37B2C0C244A3219A8FDA118EF3D03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_E83E820F5E4E0F37B0AAFDA118EFA99A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B9FCB53722387D8409A7FDA118EFF9B9" xlink:to="loc_us-gaap_ShareBasedCompensation_E83E820F5E4E0F37B0AAFDA118EFA99A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_A97718E4D2C7FBCEEA54FDA118EF4217" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B9FCB53722387D8409A7FDA118EFF9B9" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_A97718E4D2C7FBCEEA54FDA118EF4217" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_B4C0C94454182D5EB1E0FDA118EF707E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B9FCB53722387D8409A7FDA118EFF9B9" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_B4C0C94454182D5EB1E0FDA118EF707E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="loc_us-gaap_GainLossOnContractTermination_0879A28C4C19B362827EFDA1191D621A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B9FCB53722387D8409A7FDA118EFF9B9" xlink:to="loc_us-gaap_GainLossOnContractTermination_0879A28C4C19B362827EFDA1191D621A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_8ACA1ADD76B8413AFEF6FDA118EF53D0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B9FCB53722387D8409A7FDA118EFF9B9" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_8ACA1ADD76B8413AFEF6FDA118EF53D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429F12C7F75B087BE63BFDA118EF1D14" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B9FCB53722387D8409A7FDA118EFF9B9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429F12C7F75B087BE63BFDA118EF1D14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_D9056F1362699FAD1D7FFDA118EF5139" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429F12C7F75B087BE63BFDA118EF1D14" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_D9056F1362699FAD1D7FFDA118EF5139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_E2127E0DA59C7C6C7AA2FDA118EFF48B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429F12C7F75B087BE63BFDA118EF1D14" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_E2127E0DA59C7C6C7AA2FDA118EFF48B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_49C4323CB5C4EB2B87F4FDA118EF20F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429F12C7F75B087BE63BFDA118EF1D14" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_49C4323CB5C4EB2B87F4FDA118EF20F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_BC351E36E4D99A288160FDA118EF8DAF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429F12C7F75B087BE63BFDA118EF1D14" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_BC351E36E4D99A288160FDA118EF8DAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_B6E6DAB75C1699BDE8A0FDA118EF6193" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429F12C7F75B087BE63BFDA118EF1D14" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_B6E6DAB75C1699BDE8A0FDA118EF6193" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9886ABD82DB8CD7D4F22FDA118EF46F5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9C30E6C9A65F0872BDF7FDA118EF4A3E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9886ABD82DB8CD7D4F22FDA118EF46F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_71D3407EF73196D4CB6CFDA118EFEEC9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9C30E6C9A65F0872BDF7FDA118EF4A3E" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_71D3407EF73196D4CB6CFDA118EFEEC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_D4142B3F5A0D90F87023FDA118EF86AE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9C30E6C9A65F0872BDF7FDA118EF4A3E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_D4142B3F5A0D90F87023FDA118EF86AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_74C666BBFFC25211CB71FDA118EFC2FB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_07F0B8066EAECCCB5906FDA118EFE0D0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_74C666BBFFC25211CB71FDA118EFC2FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FFC4546BE5FE28252AEFDA118EFD2CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_74C666BBFFC25211CB71FDA118EFC2FB" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FFC4546BE5FE28252AEFDA118EFD2CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6FB6B921ED92C047A6D7FDA118EF02DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_74C666BBFFC25211CB71FDA118EFC2FB" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6FB6B921ED92C047A6D7FDA118EF02DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_D7973622C7FF70DF8BFBFDA118EF8135" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_74C666BBFFC25211CB71FDA118EFC2FB" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_D7973622C7FF70DF8BFBFDA118EF8135" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2139C0D1502C64605C47FDA118EF0301" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_07F0B8066EAECCCB5906FDA118EFE0D0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2139C0D1502C64605C47FDA118EF0301" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_0EBC89A22866C591BEF8FDA118EF26A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2139C0D1502C64605C47FDA118EF0301" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_0EBC89A22866C591BEF8FDA118EF26A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_135FC295F1395691853EFDA118EFC8C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2139C0D1502C64605C47FDA118EF0301" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_135FC295F1395691853EFDA118EFC8C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_F4066A20F65E221A5949FDA118EFB1C3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2139C0D1502C64605C47FDA118EF0301" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_F4066A20F65E221A5949FDA118EFB1C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_F4E0CD4DE52597C09804FDA118EFE066" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2139C0D1502C64605C47FDA118EF0301" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_F4E0CD4DE52597C09804FDA118EFE066" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BB378B75B95365C74E30FDA118EFD079" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2139C0D1502C64605C47FDA118EF0301" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BB378B75B95365C74E30FDA118EFD079" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EEE2DD276E4E9FDD28B3FDA118EFF07E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_07F0B8066EAECCCB5906FDA118EFE0D0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_EEE2DD276E4E9FDD28B3FDA118EFF07E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D81BF647F445FA73E42DFDA118EF467D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_07F0B8066EAECCCB5906FDA118EFE0D0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D81BF647F445FA73E42DFDA118EF467D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EAB82FE2A5AF6B32E361FDA118EFA897" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_07F0B8066EAECCCB5906FDA118EFE0D0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EAB82FE2A5AF6B32E361FDA118EFA897" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_BB2FA33502956641E5B4FDA118EF415E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_07F0B8066EAECCCB5906FDA118EFE0D0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_BB2FA33502956641E5B4FDA118EF415E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_3EC5176A95BAE854E86BFDA118EF59D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_BB2FA33502956641E5B4FDA118EF415E" xlink:to="loc_us-gaap_InterestPaid_3EC5176A95BAE854E86BFDA118EF59D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38B778A234D160A85A7BFDA118EF6405" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_07F0B8066EAECCCB5906FDA118EFE0D0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38B778A234D160A85A7BFDA118EF6405" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_InitialFairValueofWarrantsIssued" xlink:label="loc_tbio_InitialFairValueofWarrantsIssued_4E408600DD53D3DF1646FDA118EF353A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38B778A234D160A85A7BFDA118EF6405" xlink:to="loc_tbio_InitialFairValueofWarrantsIssued_4E408600DD53D3DF1646FDA118EF353A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_F982E1DEF866EB899FE9FDA118EF5C10" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38B778A234D160A85A7BFDA118EF6405" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_F982E1DEF866EB899FE9FDA118EF5C10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_5BB25F34F420CAEFD8E3FDA118EFB6C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38B778A234D160A85A7BFDA118EF6405" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_5BB25F34F420CAEFD8E3FDA118EFB6C9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsParentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3F274008BD9D0552CE00F99435F09DAE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_88C33D62D4FFED11CC52F99435F04CA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3F274008BD9D0552CE00F99435F09DAE" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_88C33D62D4FFED11CC52F99435F04CA0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_8CBF104B130704A1F6EB1C2677A4BAC2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_7E647D837158F0D51DFB1C2677A50A44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8CBF104B130704A1F6EB1C2677A4BAC2" xlink:to="loc_us-gaap_StatementTable_7E647D837158F0D51DFB1C2677A50A44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_B02DC4865E3F275D25551C2677A5437C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7E647D837158F0D51DFB1C2677A50A44" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_B02DC4865E3F275D25551C2677A5437C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_B02DC4865E3F275D25551C2677A5437C" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_9D652B2C01CAB032004C1C2677A55A53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_9D652B2C01CAB032004C1C2677A55A53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_FC3DC7C5A67B75CB83FE1C2677A50C2C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_9B5FB11B8F502F0383881C2677A5CA68" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_FC3DC7C5A67B75CB83FE1C2677A50C2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7E647D837158F0D51DFB1C2677A50A44" xlink:to="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_073F6101FC718C7F32B91C2677A58192" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_SalesRevenueNet_073F6101FC718C7F32B91C2677A58192" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_19F90F8EDE6124AF7E191C2677A54EDF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_19F90F8EDE6124AF7E191C2677A54EDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_21A07CE8535969A40D061C2677A540AE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_GrossProfit_21A07CE8535969A40D061C2677A540AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_FAA64CD333E6B2B1AE2E1C2677A50D7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_FAA64CD333E6B2B1AE2E1C2677A50D7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_08A87CCE718140E13A701C2677A6A7E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_08A87CCE718140E13A701C2677A6A7E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_388AE4CD72637733B41E1C2677A6125D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_E8F0BF3711092657BCB91C2677A50F3C" xlink:to="loc_us-gaap_OperatingExpenses_388AE4CD72637733B41E1C2677A6125D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8A3147A9D4364507BC991C2677A61CDE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_OperatingIncomeLoss_8A3147A9D4364507BC991C2677A61CDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_InterestIncomeAndExpenseNet" xlink:label="loc_tbio_InterestIncomeAndExpenseNet_7C71CAE3177D8E9F98891C2677A609FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9" xlink:to="loc_tbio_InterestIncomeAndExpenseNet_7C71CAE3177D8E9F98891C2677A609FE" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_GainLossOnStockWarrantsRevaluation" xlink:label="loc_tbio_GainLossOnStockWarrantsRevaluation_FAE545525B5452B55A0B1C2677A6ED1B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9" xlink:to="loc_tbio_GainLossOnStockWarrantsRevaluation_FAE545525B5452B55A0B1C2677A6ED1B" xlink:type="arc" />
    <link:loc xlink:href="tbio-20170331.xsd#tbio_OtherIncomeExpense" xlink:label="loc_tbio_OtherIncomeExpense_432D356ADE70C59274BC1C2677A6909E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_393D7A2324307759AB0B1C2677A677E9" xlink:to="loc_tbio_OtherIncomeExpense_432D356ADE70C59274BC1C2677A6909E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_A0D7F492A438962BCD351C2677A66929" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_A0D7F492A438962BCD351C2677A66929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_15C7C6057CB8AE73260D1C2677A61F22" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_15C7C6057CB8AE73260D1C2677A61F22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_C9B6428D211E9D978A7A1C2677A66363" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_C9B6428D211E9D978A7A1C2677A66363" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_783B740A282FC3F82CB71C2677A6A8BC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_783B740A282FC3F82CB71C2677A6A8BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DA96A300DAEE1749BF9A1C2677A66E15" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_NetIncomeLoss_DA96A300DAEE1749BF9A1C2677A66E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_765A737FB2243BDD31161C2677A69C3C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_765A737FB2243BDD31161C2677A69C3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_41AFA31A3B5C550749341C2677A6D8BF" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_41AFA31A3B5C550749341C2677A6D8BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_47941E60731BE162FFBC1C2677A786A1" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_47941E60731BE162FFBC1C2677A786A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D25F1D95C8167F465EE01C2677A7AAD3" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EFF071E18200470D7DB81C2677A5FA4C" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D25F1D95C8167F465EE01C2677A7AAD3" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757644512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DOCUMENT AND ENTITY INFORMATION - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Apr. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TRANSGENOMIC INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001043961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,863,062<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764927664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">567<span></span>
</td>
<td class="nump">495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>OTHER ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">1,229<span></span>
</td>
<td class="nump">1,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities of long-term debt</a></td>
<td class="nump">7,368<span></span>
</td>
<td class="nump">7,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,509<span></span>
</td>
<td class="nump">6,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,398<span></span>
</td>
<td class="nump">3,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,529<span></span>
</td>
<td class="nump">1,529<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">21,129<span></span>
</td>
<td class="nump">19,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Common stock warrant liability</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">21,872<span></span>
</td>
<td class="nump">20,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; DEFICIT:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 15,000,000 shares authorized, 214,705 shares issued and outstanding</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 150,000,000 shares authorized, 26,863,062 shares at March 31, 2017 and 26,446,927 shares at December 31, 2016 issued and outstanding</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">206,342<span></span>
</td>
<td class="nump">205,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(227,255)<span></span>
</td>
<td class="num">(225,493)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(20,643)<span></span>
</td>
<td class="num">(19,350)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Liabilities and stockholders' equity</a></td>
<td class="nump">$ 1,229<span></span>
</td>
<td class="nump">$ 1,259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752768880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">214,705<span></span>
</td>
<td class="nump">214,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">214,705<span></span>
</td>
<td class="nump">214,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">26,863,062<span></span>
</td>
<td class="nump">26,446,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">26,863,062<span></span>
</td>
<td class="nump">26,446,927<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765545152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">NET SALES</a></td>
<td class="nump">$ 658,000<span></span>
</td>
<td class="nump">$ 236,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">COST OF GOODS SOLD</a></td>
<td class="nump">459,000<span></span>
</td>
<td class="nump">505,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="nump">199,000<span></span>
</td>
<td class="num">(269,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">1,620,000<span></span>
</td>
<td class="nump">1,704,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">134,000<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="nump">1,754,000<span></span>
</td>
<td class="nump">1,974,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS FROM CONTINUING OPERATIONS</a></td>
<td class="num">(1,555,000)<span></span>
</td>
<td class="num">(2,243,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_InterestIncomeAndExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(247,000)<span></span>
</td>
<td class="num">(169,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_GainLossOnStockWarrantsRevaluation', window );">Warrant revaluation</a></td>
<td class="num">(33,000)<span></span>
</td>
<td class="nump">321,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_OtherIncomeExpense', window );">Other Income (Expense)</a></td>
<td class="num">(280,000)<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES</a></td>
<td class="num">(1,835,000)<span></span>
</td>
<td class="num">(2,091,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">INCOME TAX EXPENSE (BENEFIT)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">LOSS FROM CONTINUING OPERATIONS</a></td>
<td class="num">(1,835,000)<span></span>
</td>
<td class="num">(2,091,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">INCOME (LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAXES</a></td>
<td class="nump">73,000<span></span>
</td>
<td class="num">(1,173,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(1,762,000)<span></span>
</td>
<td class="num">(3,264,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">PREFERRED STOCK DIVIDENDS</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(393,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS AVAILABLE TO COMMON STOCKHOLDERS</a></td>
<td class="num">$ (1,762,000)<span></span>
</td>
<td class="num">$ (3,657,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE)</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES)</a></td>
<td class="nump">26,779,835<span></span>
</td>
<td class="nump">20,323,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS AVAILABLE TO COMMON STOCKHOLDERS</a></td>
<td class="num">$ (1,835,000)<span></span>
</td>
<td class="num">$ (2,484,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE)</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS AVAILABLE TO COMMON STOCKHOLDERS</a></td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="num">$ (1,173,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE)</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_GainLossOnStockWarrantsRevaluation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_GainLossOnStockWarrantsRevaluation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_InterestIncomeAndExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest income and (expense), net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_InterestIncomeAndExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_OtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_OtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4613673-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764859184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS USED IN OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (1,762)<span></span>
</td>
<td class="num">$ (3,264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Less income (loss) from discontinued operations, net of tax</a></td>
<td class="nump">73<span></span>
</td>
<td class="num">(1,173)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations</a></td>
<td class="num">(1,835)<span></span>
</td>
<td class="num">(2,091)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation and change in liability of stock appreciation rights</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for losses on doubtful accounts</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant revaluation</a></td>
<td class="nump">33<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Loss on settlement of lease termination</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Deferred interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(55)<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(45)<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,967<span></span>
</td>
<td class="nump">1,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(587)<span></span>
</td>
<td class="num">(481)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities, continuing operations</a></td>
<td class="num">(130)<span></span>
</td>
<td class="num">(1,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by (used in) operating activities, discontinued operations</a></td>
<td class="nump">80<span></span>
</td>
<td class="num">(612)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(1,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS USED IN INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Change in other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS (USED IN) PROVIDED BY FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Principal payments on capital lease obligations</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Issuance of preferred stock and warrants, net of costs of $219</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(550)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows (used in) provided by financing activities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1,728<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET CHANGE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the period for interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_InitialFairValueofWarrantsIssued', window );">Initial valuation of warrant issued in conjunction with Private Placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Debt settled with issuance of preferred stock and warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_InitialFairValueofWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Fair Value of Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_InitialFairValueofWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4613673-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750952864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICALS)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="nump">$ 219<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6607742464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS DESCRIPTION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">BUSINESS DESCRIPTION</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BUSINESS DESCRIPTION</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Description</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transgenomic, Inc., and Subsidiary, (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, the &#8220;Company&#8221; or &#8220;Transgenomic&#8221;) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and integrated diseases through our proprietary molecular technologies and clinical and research services. A key goal is to bring our Multiplexed ICE COLD-PCR (&#8220;MX-ICP&#8221;) product to the clinical market through strategic partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring and treatment of cancer.</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MX-ICP is technology proprietary to Transgenomic. It is a reagent that improves the ability to detect genetic mutations. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital PCR. By enhancing the level of detection of genetic mutations and suppressing the normal or wild-type DNA, several benefits are provided.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, our operations were organized and reviewed by management along our major product lines and presented in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> business segments: Laboratory Services and Genetic Assays and Platforms. Beginning with the quarter ended September 30, 2015, our operations are now organized as </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> business segment, our Laboratory Services segment, and during the fourth quarter of 2015, we began including a portion of our Laboratory Services segment as discontinued operations, this has continued through March 31, 2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our current Laboratory Services business consists of our laboratory in Omaha, Nebraska, which is focused on providing genetic analytical services related to Oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing service technologies, including our proprietary MX-ICP technology. Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;) as a high complexity laboratory and is accredited by the College of American Pathologists.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed consolidated balance sheets, statements of operations and statements of cash flows for all periods presented reflect our former Genetic Assays and Platforms activities and Patient Testing business as discontinued operations (See Note 3 - &#8220;Discontinued Operations&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Going Concern</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America applicable for a going concern, which assume that we will realize our assets and discharge our liabilities in the ordinary course of business. We have incurred substantial operating losses and have used cash in our operating activities for the past few years. As of March 31, 2017, we had negative working capital of </font><font style="font-family:inherit;font-size:10pt;">$20.6 million</font><font style="font-family:inherit;font-size:10pt;"> and we were also not in compliance with our loan agreement due to the fact that events of default existed, including our failure to make certain required monthly interest payments to the lenders. The Company&#8217;s ability to continue as a going concern is dependent upon a combination of completing its planned merger with Precipio Diagnostics, LLC (&#8220;Precipio&#8221;), generating additional revenue, improving cash collections, potentially selling underutilized assets and/or product lines related to discontinued operations and, if needed, raising necessary financing to meet its obligations and pay its liabilities arising from normal business operations when they come due. Following the planned merger, Transgenomic will change its name to Precipio, Inc. (&#8220;New Precipio&#8221;). On February 17, 2017, Transgenomic received written notification from the staff of Nasdaq that, as a result of Transgenomic&#8217;s inability to maintain certain Nasdaq continued listing requirements, Nasdaq had determined to delist Transgenomic&#8217;s shares from Nasdaq.  Accordingly, trading in Transgenomic&#8217;s shares was suspended, and on February 22, 2017, Transgenomic&#8217;s shares began trading on the OTCQB exchange under the ticker &#8220;TBIO&#8221;.  As discussed below upon completion of the merger, the New Precipio common stock will be required to meet the Nasdaq listing standards.  As a result of the merger, New Precipio is expected to meet Nasdaq's initial listing requirements.  In addition, at the time of the merger the Company intends to execute a reverse stock split. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern for the next twelve months from the date of issuance of these condensed financial statements. These condensed consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. There is no assurance that the Company will complete the merger in a timely manner or at all. The merger agreement is subject to many closing conditions and termination rights. The Company also cannot be certain that additional financing, if needed, will be available on acceptable terms, or at all, and its failure to raise capital when needed could limit its ability to continue its operations.</font></div><div style="line-height:174%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Merger Agreement</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 12, 2016, Transgenomic, New Haven Labs Inc., a wholly owned subsidiary of Transgenomic (&#8220;Merger Sub&#8221; and, together with Transgenomic, the &#8220;Transgenomic Parties&#8221;), and Precipio entered into an Agreement and Plan of Merger (as amended by the Merger Agreement Amendment (as defined below) the &#8220;Merger Agreement&#8221;) pursuant to which Precipio will become a wholly owned subsidiary of Transgenomic (the &#8220;Merger&#8221;), on the terms and subject to the conditions set forth in the Merger Agreement. On February 2, 2017, Transgenomic, Merger Sub and Precipio entered into a First Amendment to Agreement and Plan of Merger (the &#8220;Merger Agreement Amendment&#8221;), which provided for, among other things, the revision of the exchange ratio set forth in the Merger Agreement, the waiver and removal of certain closing conditions and the authorization of certain actions taken by each of Transgenomic and Precipio since the date the Merger Agreement. The parties expect the Merger to close in the second quarter of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the effectiveness of the Merger (the &#8220;Effective Time&#8221;), (i)&#160;the outstanding common units of Precipio will be converted into the right to receive approximately </font><font style="font-family:inherit;font-size:10pt;">160.6 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of New Precipio (&#8220;New Precipio common stock&#8221;), together with cash in lieu of fractional units, which will result in Precipio common unit holders owning approximately </font><font style="font-family:inherit;font-size:10pt;">52%</font><font style="font-family:inherit;font-size:10pt;"> of the issued and outstanding shares of New Precipio common stock on a fully diluted basis, taking into account the issuance of shares of convertible preferred stock of New Precipio (&#8220;New Precipio preferred stock&#8221;) in the Merger and the private placement as discussed below (the &#8220;fully diluted New Precipio common stock&#8221;) and (ii)&#160;the outstanding preferred units of Precipio will be converted into the right to receive approximately </font><font style="font-family:inherit;font-size:10pt;">24.1 million</font><font style="font-family:inherit;font-size:10pt;"> shares of New Precipio preferred stock with an aggregate face amount equal to </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> (based upon the purchase price of the new preferred stock of New Precipio in the new preferred stock financing), which will result in the Precipio preferred unit holders owning approximately </font><font style="font-family:inherit;font-size:10pt;">8%</font><font style="font-family:inherit;font-size:10pt;"> of the fully diluted New Precipio common stock.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon completion of the merger, New Precipio will be required to meet the initial listing requirements to qualify its shares for listing and begin trading of its shares on Nasdaq. These initial listing requirements are more difficult to achieve than the continued listing requirements.&#160; Pursuant to the Merger Agreement, Transgenomic agreed to use its commercially reasonable efforts to cause the shares of Transgenomic common stock being issued in the merger to be approved for listing on Nasdaq at or prior to the effective time of the merger. Based on information currently available to Transgenomic, Transgenomic anticipates that its stock will be unable to meet the </font><font style="font-family:inherit;font-size:10pt;">$4.00</font><font style="font-family:inherit;font-size:10pt;"> (or, to the extent applicable, </font><font style="font-family:inherit;font-size:10pt;">$3.00</font><font style="font-family:inherit;font-size:10pt;">) minimum bid price initial listing requirement at the closing of the merger unless it effects a reverse stock split. On October 31, 2016, the stockholders of Transgenomic authorized the Transgenomic Board to effect a reverse stock split of the shares of Transgenomic common stock at a ratio of between one-for-ten to one-for-thirty, such ratio to be determined by our Board of Directors (the &#8220;Reverse Split Proposal&#8221;).  The Reverse Split Proposal was described in detail in our definitive proxy statement filed with the Securities and Exchange Commission on September 22, 2016, as supplemented on October 13, 2016.&#160; In addition, often times a reverse stock split will not result in a trading price for the affected common stock that is proportional to the ratio of the split.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750952864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are presented in conformity with GAAP. Supplemental cash flows from discontinued operations are presented in Note 3 - &#8220;Discontinued Operations&#8221;. We have evaluated events occurring subsequent to March 31, 2017 for potential recognition or disclosure in the condensed consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2016. The accompanying condensed consolidated financial statements as of and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 13, 2017. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2017.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risks and Uncertainties.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements.  The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise specified, book value approximates fair value. The common stock warrant liability is recorded at fair value.  See Note 8 - &#8220;Fair Value&#8221; for additional information.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents and Other Current Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less. Other current assets as of March 31, 2017 of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> include prepaid assets of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and other receivables of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Cash.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits.  We have not experienced any losses on such accounts as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense in continuing operations related to property and equipment was less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for each of the three month periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. Depreciation expense during each period includes depreciation related to equipment acquired under capital leases. </font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense for intangible assets was less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> during the three month periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. Amortization expense for intangible assets is expected to be </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for each of the years ending December 31, 2017, 2018 and less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for each of the years ending December 31, 2019, 2020 and 2021.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">-year contractual terms. Unvested awards as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> had vesting periods of up to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. None of the awards outstanding at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are subject to performance or market-based vesting conditions.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016, we recorded compensation expense for all stock awards of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, within selling, general and administrative expense. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the unrecognized compensation expense related to unvested stock awards was less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> year.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in our stock awards outstanding as of March 31, 2017 were fully vested stock appreciation rights (&#8220;SARs&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">to purchase </font><font style="font-family:inherit;font-size:10pt;">83,333</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. The SARs were issued solely to our executive officers and vested over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. </font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Sales Recognition.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:66px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is realized and earned when all of the following criteria are met:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persuasive evidence of an arrangement exists;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delivery has occurred or services have been rendered;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The seller&#8217;s price to the buyer is fixed or determinable; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collectability is reasonably assured.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In our Omaha, Nebraska laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year.  At each of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue were </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales from Patient Testing laboratories are reported as part of discontinued operations (See Note 3 - &#8220;Discontinued Operations&#8221;) and are recognized on an individual test basis and, since collectability is not reasonably assured, are recognized when cash is received. There are no deferred net sales associated with our Patient Testing services. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loss Per Share.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period.  Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to </font><font style="font-family:inherit;font-size:10pt;">4,425,218</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">12,970,881</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock have been excluded from the computation of diluted loss per share at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, because the effect is anti-dilutive due to the net loss.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers. This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year.  As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company adopted ASU No. 2016-09 as of January&#160;1, 2017. The adoption of this guidance does not have a material effect on the Company&#8217;s financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August&#160;2016, FASB issued ASU No.&#160;2016-15</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">Classification of Certain Cash Receipts and Cash Payments.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">ASU No.&#160;2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No.&#160;2016-15 is effective for fiscal years beginning after December&#160;15, 2017, and for interim periods within that fiscal year. We do not believe ASU No.&#160;2016-15 will have a material effect on our financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, FASB issued ASU No.&#160;2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business.  ASU No. 2017-01adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within those fiscal years. The Company does not believe ASU No. 2017-01 will have a material effect on its financial position and results of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6596995216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISCONTINUED OPERATIONS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DISCONTINUED OPERATIONS</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In March 2016, we halted testing services in our Patient Testing laboratory in New Haven, Connecticut. As a result of this action, as of December 31, 2015, our Patient Testing business met the criteria to be reported as discontinued operations. The related assets, liabilities, results of operations and cash flows for the Patient Testing business are classified as assets held for sale, liabilities held for sale and discontinued operations for all periods presented.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results of the discontinued operations consisted of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three months ended     March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,025</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss) from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on settlement of liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At March 31, 2017 and December 31, 2016, the Company had assets of the discontinued operations of less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> which were classified as assets held for sale in the condensed consolidated balance sheets.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721665-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=SL51724579-110230<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721663-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721659-107760<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721671-107760<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721677-107760<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1474-107760<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752799536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DEBT</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dollars&#160;in&#160;Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revolving Line of Credit</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term Loan</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible Promissory Notes </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,368</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,814</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,368</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,814</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net of current maturities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revolving Line of Credit.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6.25%</font><font style="font-family:inherit;font-size:10pt;"> or (b) the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wall Street Journal</font><font style="font-family:inherit;font-size:10pt;"> prime rate plus </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3%</font><font style="font-family:inherit;font-size:10pt;">. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;">6.75%</font><font style="font-family:inherit;font-size:10pt;">. As discussed below under </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Additional Terms</font><font style="font-family:inherit;font-size:10pt;">, the interest rate is subject to increase if there is a default under the Loan Agreement. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20,000</font><font style="font-family:inherit;font-size:10pt;"> on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line.  In addition, a fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum is payable quarterly on the unused portion of the Revolving Line.  The Revolving Line matures on November 1, 2017.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Term Loan.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">We received </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> under the Term Loan on the Effective Date.  Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">9.1%</font><font style="font-family:inherit;font-size:10pt;">.  As discussed below, the interest rate is subject to increase if there is a default under the Loan Agreement.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will pay the Lenders an additional final payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$120,000</font><font style="font-family:inherit;font-size:10pt;">, at maturity or prepayment of the Term Loan, which has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1%</font><font style="font-family:inherit;font-size:10pt;"> of the total outstanding balance under the Term Loan.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Additional Terms.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement contains affirmative and negative covenants.  Under the Loan Agreement, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders&#8217; consent.  Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of March 31, 2017, we were not in compliance with the Loan Agreement, as amended, due to the fact that events of default existed, including our failure to make certain required monthly interest payments.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. At March 31, 2017, our applicable interest rates have been increased by </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">   Convertible Promissory Notes. </font><font style="font-family:inherit;font-size:10pt;">The Notes accrue interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> per year and matured on December 31, 2016. </font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revolving Line and Term Loan.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 13, 2013 (the &#8220;Effective Date&#8221;), we entered into a Loan and Security Agreement with affiliates of Third Security, LLC, a related party, (the &#8220;Lenders&#8221;) for (a) a revolving line of credit (the &#8220;Revolving Line&#8221;) with borrowing availability of up to </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">, subject to reduction based on our eligible accounts receivable, and (b) a term loan (the &#8220;Term Loan&#8221; and, together with the Revolving Line, the &#8220;Loan Agreement&#8221;) of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">. From the Effective Date through 2015, there were a number of amendments to the Loan Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2016, we entered into an eighth amendment to the Loan Agreement (the &#8220;Eighth Amendment&#8221;). The Eighth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) extended the maturity date of the Loan Agreement until November 1, 2017, and (d) provided for the repayment of an overadvance of </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;"> previously provided by the Lenders to us pursuant to the Loan Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2016, the overadvance that existed at December 31, 2015 was repaid to the Lenders and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> was received from certain of the Lenders and another lender affiliate in connection with the equity offering made on January 6, 2016.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 6, 2016, we entered into a ninth amendment to the Loan Agreement (the &#8220;Ninth Amendment&#8221;). The Ninth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) amended the prepayment terms of the Loan Agreement, (c) provided for the reduction of amounts available under the Revolving Line upon the prepayment or repayment of certain amounts by us, (d) removed the minimum liquidity ratio and minimum net revenue financial covenants applicable to us under the Loan Agreement, (e) amended the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent of the Lenders, and (f) capitalized certain amounts owed by us to the Lenders and added such overdue amounts to the outstanding principal amount of the Revolving Line. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 2, 2017, we entered into a termination and tenth amendment to the Loan Agreement (the &#8220;Tenth Amendment&#8221;). The Tenth Amendment, among other things, (i) provides that the Lenders will waive specified events of default under the terms of the Loan Agreement until the effective time of the Merger (or the termination of the Merger Agreement in accordance with its terms), (ii) provides for the conversion of all outstanding indebtedness owed to the Lenders under the Loan Agreement (the &#8220;Outstanding Indebtedness&#8221;) into shares of Transgenomic common stock and preferred stock (collectively, the &#8220;Conversion Shares&#8221;) effective as of the closing date of the Merger and (iii) the termination of the Loan Documents (as defined in the Loan Agreement) and the termination and release of all security interests and liens of the Lenders in the Collateral (as defined in the Loan Agreement) in each case immediately following the conversion of the Outstanding Indebtedness into Conversion Shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effectiveness of certain provisions in the Tenth Amendment, including provisions relating to conversion of the Conversion Shares and termination of the Loan Documents, is conditioned on, among other things, the consummation of the Merger, and, in the event that the Merger is not consummated, these provisions in the Loan Agreement Amendment will terminate.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Tenth Amendment, the Lenders have agreed to convert the outstanding principal and accrued interest under the Loan Agreement into (i) approximately </font><font style="font-family:inherit;font-size:10pt;">10.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares of New Precipio common stock immediately prior to the effectiveness of the Merger at a price equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;"> per share and (ii) </font><font style="font-family:inherit;font-size:10pt;">24.1 million</font><font style="font-family:inherit;font-size:10pt;"> shares of New Precipio preferred stock. As of March 31, 2017, the outstanding amount owed under the Loan Agreement was approximately </font><font style="font-family:inherit;font-size:10pt;">$7.2 million</font><font style="font-family:inherit;font-size:10pt;"> of principal and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> of accrued interest. The issuance of the Conversion Shares is subject to the approval of the Transgenomic stockholders in accordance with NASDAQ Capital Market listing rules.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Promissory Notes.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 31, 2014, we entered into an Unsecured Convertible Promissory Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;) with an accredited investor (the &#8220;Investor&#8221;), pursuant to which we agreed to issue and sell to the Investor in a private placement an unsecured convertible promissory note (the &#8220;Initial Note&#8221;). We issued the Initial Note in the aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;"> to the Investor on December 31, 2014. Pursuant to the terms of the Initial Note, interest accrued at a rate of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> per year and the Initial Note was set to mature on December 31, 2016. The Initial Note has been converted in full into </font><font style="font-family:inherit;font-size:10pt;">502,786</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, in accordance with the terms of the Initial Note. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 15, 2015, we entered into the Note Purchase Agreement with </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> accredited investors (the &#8220;Additional Investors&#8221;) and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, notes (the &#8220;Additional Notes&#8221;) in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$925,000</font><font style="font-family:inherit;font-size:10pt;">.  We also issued, to our placement agent for the Notes, a convertible promissory note in an aggregate principal amount equal to </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> of the proceeds received by us, or </font><font style="font-family:inherit;font-size:10pt;">$46,250</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Agent Note&#8221;).  The Additional Notes and Agent Note have the same terms and conditions as the Initial Note.  As of December 31, 2016, </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;"> of the aggregate principal amount of the Additional Notes and Agent Note, and accrued interest thereon, had been converted into an aggregate of </font><font style="font-family:inherit;font-size:10pt;">281,023</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On the Maturity Date, the then outstanding aggregate amount owed on the Additional Notes and Agent Note of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, including accrued interest, became due. Pursuant to the terms of the Initial Note, our failure to pay any principal or interest within </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> days of the date such payment is due will constitute an event of default (the &#8220;Prospective Event of Default&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 10, 2017, the Additional Investors and our placement agent executed a waiver of the Prospective Event of Default, pursuant to which, they agreed to waive the Prospective Event of Default on the condition that the Company and the Additional Investors enter into definitive documentation evidencing the terms for an extended maturity date of the Additional Notes and the Agent Note on or before January 16, 2017 (the &#8220;Waiver Deadline&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2017, all but one Additional Investor exercised their conversion rights relating to their respective Additional Notes, including the Agent Note, and converted an aggregate principal amount of&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.4</font><font style="font-family:inherit;font-size:10pt;"> million, and accrued interest of less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, into </font><font style="font-family:inherit;font-size:10pt;">416,135</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. The Waiver Deadline was extended with respect to the remaining Additional Investor who did not exercise conversion rights (the &#8220;Non-Converting Investor&#8221;) so that the parties could continue to discuss a resolution of the Prospective Event of Default relating to such Non-Converting Investor&#8217;s Additional Note with an outstanding principal amount due of </font><font style="font-family:inherit;font-size:10pt;">$0.1</font><font style="font-family:inherit;font-size:10pt;"> million.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 17, 2017, the Non-Converting Investor agreed to extend the Maturity Date of its Additional Note pursuant to an amendment to the Additional Note (the &#8220;Amendment&#8221;). The Amendment provides that two-thirds of the outstanding principal amount of the Additional Note must be paid upon the earlier to occur of the close of the Company&#8217;s merger with Precipio Diagnostics, LLC or June 16, 2017 (such applicable date, the &#8220;Deferred Maturity Date&#8221;).&#160; The remaining one-third of the principal amount outstanding on the Additional Note must be paid on the six month anniversary of the Deferred Maturity Date (the &#8220;Extended Maturity Date&#8221;).</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750860528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">CONTINGENCIES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONTINGENCIES</font></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to a number of claims of various amounts that arise out of the normal course of our business.  In addition to the claims described in this Note, we are delinquent on the payment of outstanding accounts payable amounting to approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> with certain of our vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, the Board of Regents of the University of Nebraska (&#8220;UNMC&#8221;) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> owed by us to UNMC.  A </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. We and UNMC entered into a settlement agreement dated February 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> to UNMC in installments over a period of time. As of March 15, 2017, the initial payment due to UNMC under the settlement agreement is delinquent. We and UNMC are currently in discussions to extend the date of the initial payment due to UNMC.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, on April 13, 2016, Fox Chase Cancer Center (&#8220;Fox Chase&#8221;) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the &#8220;Court of Common Pleas&#8221;), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the &#8220;License Agreement&#8221;), as well as the assignment of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc. (&#8220;IDT&#8221;) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the &#8220;IDT Agreement&#8221;). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase&#8217;s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney&#8217;s fees.&#160; Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by us as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> On June 23, 2016, the Icahn School of Medicine at Mount Sinai (&#8220;Mount Sinai&#8221;) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> owed by us to Mount Sinai for services rendered. We and Mount Sinai entered into a settlement agreement dated October 27, 2016, which included, among other things, a mutual general release of claims, and our agreement to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> to Mount Sinai in installments over a period of time. A </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.  Effective as of February 1, 2017, we and Mount Sinai agreed to amend the terms of our settlement agreement to extend the date of the initial payment due to Mount Sinai.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 19, 2016, Todd Smith (&#8220;Smith&#8221;) filed a lawsuit against us in the District Court of Douglas County Nebraska, alleging breach of contract and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> owed by us to Smith for costs and damages arising from a breach of our obligations pursuant to a lease agreement between the parties.  On April 7, 2017, we entered into a settlement agreement with Smith related to the early termination of our lease for our Omaha, Nebraska facility. The agreement included, among other things, a mutual general release of claims, and our agreement to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> to Smith in installments over a period of time. A </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded and is reflected in accrued expenses at March 31, 2017. The accrued liability includes </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> recorded as a net loss on the settlement and is included in other expense in our condensed consolidated statements of operations for the three months ended March 31, 2017. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 21, 2017, XIFIN, Inc. (&#8220;XIFIN&#8221;) filed a lawsuit against us in the District Court for the Southern District of California alleging breach of written contract and seeking recovery of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.27 million</font><font style="font-family:inherit;font-size:10pt;"> owed by us to XIFIN for damages arising from a breach of our obligations pursuant to a Systems Services Agreement between us and XIFIN, dated as of February 22, 2013, as amended and restated on September 1, 2014. On April 5, 2017, the court clerk entered default against us. On May 5, 2017, XIFIN filed an application for entry of default judgment against us. A </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and Science Park Development Corporation (&#8220;SPDC&#8221;) entered into that certain Lease dated as of December 31, 2011, as modified by the First Amendment to Lease dated as of June 18, 2013, as further modified by a letter agreement dated as of February 2, 2015, as modified by the Second Amendment to Lease dated as of June 26, 2015 (the &#8220; SPDC Lease&#8221;).   In November 2016, SPDC alleged that we defaulted on our obligations under the SPDC Lease.  Specifically, SPDC alleges that we failed to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> in rental payments due under the SPDC Lease and that we vacated a portion of the leased premises in violation of the terms of the SPDC Lease.  We and SPDC entered into a settlement agreement dated March 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> to SPDC in installments over a period of time. This liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CPA Global provides us with certain patent management services.  On February 6, 2017, CPA Global claimed that we owe approximately </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> for certain patent maintenance services rendered.  CPA Global has not filed claims against us in connection with this allegation.  A liability of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 9, 2016, counsel for Edge BioSystems, Inc. (&#8220;EdgeBio&#8221;) sent a demand letter on behalf of EdgeBio to us in connection with the terms of that certain Asset Purchase Agreement dated September 8, 2015 (the &#8220;EdgeBio Agreement&#8221;). EdgeBio alleges, among other things, that certain customers of EdgeBio erroneously remitted payments to us, that such payments should have been paid to EdgeBio and that we failed to remit these funds to EdgeBio in violation of the terms of the EdgeBio Agreement.  On September 13, 2016, we received a demand for payment letter from EdgeBio&#8217;s counsel alleging that the balance due to EdgeBio is approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.  A liability of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 17, 2017, Jesse Campbell (&#8220;Campbell&#8221;) filed a lawsuit individually and on behalf of others similarly situated against us in the District Court for the District of Nebraska alleging we have a materially incomplete and misleading proxy relating to a potential merger and that the merger agreement&#8217;s deal protection provisions deter superior offers.&#160; As a result, he alleges that we have violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9 promulgated thereafter.&#160; Although we intend to defend the lawsuit, there can be no assurance regarding the ultimate outcome of this case.  Given the uncertainty of litigation, the legal standards that must be met for, among other things, class certification and success on the merits, we are unable to estimate the amount of loss, or range of possible loss, at this time that may result from this action. In the event that a settlement is reached related to these matters, the amount of such settlement may be material to our results of operations and financial condition and may have a material adverse impact on our liquidity.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750927824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCOME TAXES </font></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annually, we file U.S. Federal, state and foreign income tax returns.&#160; All U.S. Federal and most state loss carryforwards remain subject to adjustment in the event of an income tax examination.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense from continuing operations was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> for both the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016. We maintain a full valuation allowance on our net deferred tax assets,&#160;having concluded that we are not more likely than not going to realize the benefit of our deferred tax assets, including our net operating loss carryforwards.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750894720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCKHOLDERS&#8217; DEFICIT</font></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock.</font></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">150,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock authorized for issuance.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2016, we entered into a Securities Purchase Agreement (the &#8220;SPA&#8221;) with certain accredited investors (the &#8220;2016 Investors&#8221;), pursuant to which, on January 8, 2016, we sold to the 2016 Investors, and the 2016 Investors purchased from us (the &#8220;January 2016 Offering&#8221;), an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> of units (the &#8220;Units&#8221;) consisting of (a) an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,365,243</font><font style="font-family:inherit;font-size:10pt;"> shares (the &#8220;A-1 Preferred Shares&#8221;) of our Series A-1 Convertible Preferred Stock (the &#8220;A-1 Preferred&#8221;), and (b) warrants (the &#8220;2016 Warrants&#8221;) to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,773,929</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, with an initial value of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">. The gross amount of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> included </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> of cash proceeds and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> of debt settled with the issuance of preferred stock and warrants. Each Unit was sold to the 2016 Investors at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$0.93</font><font style="font-family:inherit;font-size:10pt;"> per Unit. The A-1 Preferred Shares are convertible into shares of our common stock at an initial rate of 1-for-1, which conversion rate is subject to further adjustment as set forth in our Certificate of Designation of Series A-1 Convertible Preferred Stock, which was filed with the Secretary of State of the State of Delaware on January 8, 2016 (the &#8220;Series A-1 Certificate of Designation&#8221;). We determined there was a beneficial conversion feature (&#8220;BCF&#8221;) in connection with this issuance and valued the BCF at </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">.&#160; The holders of the A-1 Preferred were able to convert at any time following the issuance.&#160; Accordingly, we recorded a dividend totaling </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> during 2016 related to this beneficial conversion, which was recorded against additional paid in capital. Pursuant to the terms of the Series A-1 Certificate of Designation, the holders of the A-1 Preferred Shares will generally be entitled to that number of votes as is equal to the product obtained by multiplying: (i) the number of whole shares of our common stock into which the A-1 Preferred may be converted as of the record date of such vote or consent, by (ii) </font><font style="font-family:inherit;font-size:10pt;">0.93</font><font style="font-family:inherit;font-size:10pt;">, rounded down to the nearest whole number. Therefore, every </font><font style="font-family:inherit;font-size:10pt;">1.075269</font><font style="font-family:inherit;font-size:10pt;"> shares of A-1 Preferred will generally initially be entitled to one vote. In May 2016, </font><font style="font-family:inherit;font-size:10pt;">2,150,538</font><font style="font-family:inherit;font-size:10pt;"> of the A-1 Preferred Shares were converted into </font><font style="font-family:inherit;font-size:10pt;">2,150,538</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. At March 31, 2017, there were </font><font style="font-family:inherit;font-size:10pt;">214,705</font><font style="font-family:inherit;font-size:10pt;"> A-1 Preferred Shares outstanding.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrants were immediately exercisable upon issuance, have a term of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years and have an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.21</font><font style="font-family:inherit;font-size:10pt;"> per share of our common stock. Each 2016 Warrant includes both cash and &#8220;cashless exercise&#8221; features and an exchange feature whereby the holder of the 2016 Warrant may exchange (the &#8220;Exchange Right&#8221;) all or any portion of the 2016 Warrant for a number of shares of our common stock equal to the quotient obtained by dividing the &#8220;Exchange Amount&#8221; by the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged (the &#8220;Exchange Price&#8221;). Under the 2016 Warrants, the &#8220;Exchange Amount&#8221; is based upon a Black Scholes option pricing model, and the aggregate Exchange Amount under all of the 2016 Warrants will be </font><font style="font-family:inherit;font-size:10pt;">$1.4</font><font style="font-family:inherit;font-size:10pt;"> million, subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged. Each 2016 Warrant provides that the number of shares that may be issued upon exercise of the Exchange Right is limited to the number of shares that may be purchased pursuant to the terms of the 2016 Warrant, unless we have previously obtained stockholder approval or approval from The Nasdaq Stock Market LLC to issue any additional shares of our common stock (the &#8220;Additional Shares&#8221;) pursuant to the Exchange Right (the &#8220;Required Approvals&#8221;). For any Exchange Right exercised more than </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days following the issuance of the 2016 Warrants, if we have not obtained either of the Required Approvals, we will be required to pay the 2016 Warrant holder an amount in cash for any Additional Shares that we cannot issue without the Required Approvals based on the Exchange Amount.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrants further provide that, to the extent the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged is less than </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, the Exchange Price will be deemed to be equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, and, in addition to issuing shares of our common stock based on this Exchange Price, we will be required to pay to the 2016 Warrant holder an amount in cash equal to the product obtained by multiplying (a) </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;"> minus the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the 2016 Warrant holder by the Company in such exchange at an Exchange Price equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">. Therefore, if the Required Approvals are obtained, based on the Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$1,436,882</font><font style="font-family:inherit;font-size:10pt;"> (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of the issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the 2016 Warrants will be </font><font style="font-family:inherit;font-size:10pt;">2,873,765</font><font style="font-family:inherit;font-size:10pt;">. In addition, if, for example, assuming an Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$1,436,882</font><font style="font-family:inherit;font-size:10pt;">, the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrants are exchanged is </font><font style="font-family:inherit;font-size:10pt;">$0.25</font><font style="font-family:inherit;font-size:10pt;">, we would be required to pay to the 2016 Warrant holders cash in an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$718,441</font><font style="font-family:inherit;font-size:10pt;"> in addition to issuing the 2016 Warrant holders </font><font style="font-family:inherit;font-size:10pt;">2,873,765</font><font style="font-family:inherit;font-size:10pt;"> shares. During the year ended December 31, 2016, </font><font style="font-family:inherit;font-size:10pt;">1,006,419</font><font style="font-family:inherit;font-size:10pt;"> of the 2016 Warrants were exchanged for </font><font style="font-family:inherit;font-size:10pt;">1,613,353</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock and cash due of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">. As of March 31, 2017 and December 31, 2016, the </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> due to a 2016 Investor is included in other current liabilities on our condensed consolidated balance sheet.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the terms of the SPA, we amended that certain Series A Warrant to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,161,972</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock previously issued by us to an affiliate of one of the 2016 Investors on July 7, 2015 (the &#8220;Original Warrant&#8221;), as previously reported by us on our Amendment No. 1 to Current Report on Form 8-K/A, filed with the SEC on July 7, 2015 (as so amended, the &#8220;Amended Warrant&#8221;). The Amended Warrant amends the Original Warrant to provide that the Amended Warrant is subject to the same terms and conditions as the 2016 Warrants and, therefore, includes both cash and &#8220;cashless exercise&#8221; features and an Exchange Right whereby the number of shares issuable pursuant to the Exchange Right is equal to the &#8220;Amended Warrant Exchange Amount&#8221;, which is based on a Black Scholes option pricing model, and will be </font><font style="font-family:inherit;font-size:10pt;">$941,197</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment to the extent that the risk-free U.S. treasury rate fluctuates between the date of issuance of the Amended Warrant and the date the Amended Warrant is exchanged. The Amended Warrant is exercisable for up to </font><font style="font-family:inherit;font-size:10pt;">1,161,972</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock in the event we have obtained either of the Required Approvals with respect to the Amended Warrant. In the event the Amended Warrant holder exercises the Amended Warrant more than </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days following the issuance of the Amended Warrant, if we have not obtained either of the Required Approvals, we will be required to pay the Amended Warrant holder an amount in cash for the shares of our common stock that we cannot issue under the Amended Warrant pursuant to such exercise without the Required Approvals based on the Amended Warrant Exchange Amount.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Amended Warrant also provides that, to the extent the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is less than </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, the Exchange Price will be deemed to be equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, and, in addition to issuing shares of our common stock based on this Exchange Price (assuming receipt of the Required Approvals), we will be required to pay to the Amended Warrant holder an amount in cash equal to the product obtained by multiplying (a) </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;"> minus the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the Amended Warrant holder by us in such exchange at an Exchange Price equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">. Therefore, if the Required Approvals are obtained, based on the Amended Warrant Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$941,197</font><font style="font-family:inherit;font-size:10pt;"> (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the issuance of the Amended Warrant and the date the Amended Warrant is exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the Amended Warrant will be </font><font style="font-family:inherit;font-size:10pt;">1,882,395</font><font style="font-family:inherit;font-size:10pt;">. In addition, if, for example, assuming an Amended Warrant Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$941,197</font><font style="font-family:inherit;font-size:10pt;">, the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is </font><font style="font-family:inherit;font-size:10pt;">$0.25</font><font style="font-family:inherit;font-size:10pt;">, we would be required to pay to the Amended Warrant holder cash in an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$470,599</font><font style="font-family:inherit;font-size:10pt;"> in addition to issuing the Amended Warrant holder </font><font style="font-family:inherit;font-size:10pt;">1,882,395</font><font style="font-family:inherit;font-size:10pt;"> shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with entering into the SPA, we also entered into a Registration Rights Agreement, dated January 8, 2016, with the 2016 Investors. Pursuant to the terms of the Registration Rights Agreement, we were required to file with the SEC a registration statement to register for resale the shares of our common stock issuable upon conversion of the A-1 Preferred Shares and the shares of our common stock issuable upon exercise of the 2016 Warrants and the Amended Warrant by January 25, 2016. We filed the required registration statement with the SEC on January 25, 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Craig-Hallum (the &#8220;Placement Agent&#8221;) served as the sole placement agent for the January 2016 Offering. In consideration for services rendered as the Placement Agent in the January 2016 Offering, we (1) paid to the Placement Agent cash commissions equal to approximately </font><font style="font-family:inherit;font-size:10pt;">$140,000</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">7.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross proceeds received in the January 2016 Offering, excluding any proceeds received from Third Security, LLC or any of its affiliates; (2) issued to the Placement Agent, for a price of </font><font style="font-family:inherit;font-size:10pt;">$50</font><font style="font-family:inherit;font-size:10pt;">, a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year warrant to purchase up to </font><font style="font-family:inherit;font-size:10pt;">107,527</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.21</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Agent Warrant&#8221;), which is subject to the same terms as the 2016 Warrants except that the Agent Warrant was not exercisable until July 8, 2016 and does not contain the Exchange Right; and (3) reimbursed the Placement Agent for reasonable out-of-pocket expenses, including fees paid to the Placement Agent&#8217;s legal counsel, incurred in connection with the January 2016 Offering, which reimbursable expenses did not exceed </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The January 2016 Offering and the payment of all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock in the form of shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">$1.00</font><font style="font-family:inherit;font-size:10pt;"> per share of our common stock discussed under &#8220;-Conversion of Preferred Stock&#8221; below required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale (the &#8220;2012 Private Placement&#8221;).  The exercise price of these warrants decreased to </font><font style="font-family:inherit;font-size:10pt;">$4.39</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">2,188,177</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">3,239,827</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 31, 2016, we issued to a vendor an aggregate of </font><font style="font-family:inherit;font-size:10pt;">78,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock and, on June 14, 2016, we issued to a second vendor an aggregate of </font><font style="font-family:inherit;font-size:10pt;">64,153</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. Such shares of common stock were issued to the vendors in lieu of an aggregate cash amount of approximately </font><font style="font-family:inherit;font-size:10pt;">$89,000</font><font style="font-family:inherit;font-size:10pt;"> owed by us to such vendors for services previously performed by such vendors. We issued the shares to the vendors in transactions exempt from registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The offering of the shares to the vendors did not involve a public offering, and no general solicitation or advertisement was made in connection with the offering of the shares to the vendors.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 7, 2016, we entered into an At the Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with Craig-Hallum, as sales agent, pursuant to which we may offer and sell, from time to time, through Craig-Hallum, up to </font><font style="font-family:inherit;font-size:10pt;">$3,500,000</font><font style="font-family:inherit;font-size:10pt;"> of shares (the &#8220;Shares&#8221;) of our common stock. Any Shares offered and sold in the offering will be issued pursuant to our effective shelf registration statement on Form S-3 (File No. 333-201907) and the related prospectus previously declared effective by the SEC on February 13, 2015, as supplemented by a prospectus supplement, dated June 7, 2016, that we filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The number of shares eligible for sale under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the ATM Agreement, we will pay Craig-Hallum a placement fee of </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> of the gross sales price of the Shares, unless Craig-Hallum acts as principal, in which case we may sell Shares to Craig-Hallum as principal at a price to be agreed upon by us and Craig-Hallum. We will also reimburse Craig-Hallum for certain expenses incurred in connection with the ATM Agreement, and agreed to provide indemnification and contribution to Craig-Hallum with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The ATM Agreement was terminated during the fourth quarter of 2016 and at the time of termination we had sold </font><font style="font-family:inherit;font-size:10pt;">1,177,849</font><font style="font-family:inherit;font-size:10pt;"> shares.&#160; The average sales price per common share was </font><font style="font-family:inherit;font-size:10pt;">$0.42</font><font style="font-family:inherit;font-size:10pt;"> and the aggregate net proceeds from the sales totaled </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">. We did not sell any shares under the ATM Agreement during the three month periods ended March 31, 2017 and 2016.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The sale of shares under the ATM Agreement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the 2012 Private Placement.  The exercise price of these warrants decreased to </font><font style="font-family:inherit;font-size:10pt;">$4.23</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">3,262,088</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">3,362,276</font><font style="font-family:inherit;font-size:10pt;">.  The </font><font style="font-family:inherit;font-size:10pt;">3,362,276</font><font style="font-family:inherit;font-size:10pt;"> warrants issued in the 2012 Private Placement expired in February 2017.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrants.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we did not issue any warrants, no warrants were exercised and </font><font style="font-family:inherit;font-size:10pt;">3,362,276</font><font style="font-family:inherit;font-size:10pt;"> warrants expired. During the three months ended March 31, 2016, we issued warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">2,933,106</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and no warrants were exercised. The warrants issued in the three months ended March 31, 2016 included </font><font style="font-family:inherit;font-size:10pt;">1,051,650</font><font style="font-family:inherit;font-size:10pt;"> warrants issued due to repricing requirements of the Private Placement and </font><font style="font-family:inherit;font-size:10pt;">1,881,456</font><font style="font-family:inherit;font-size:10pt;"> warrants issued in connection with the January 2016 Offering.  Warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">3,334,011</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were outstanding at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrant Holder</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issue&#160;Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">374,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,780</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.24</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.66</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,161,972</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,527</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,334,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in January 2013. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with a private placement which was completed in October 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in February 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in July 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were originally issued in connection with the offering in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table><div style="line-height:174%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock Series A.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Board of Directors is authorized to issue up to </font><font style="font-family:inherit;font-size:10pt;">15,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. The authority of the Board of Directors includes, but is not limited to, the determination or fixing of the following with respect to shares of such class or any series thereof: (i)&#160;the number of shares; (ii)&#160;the dividend rate, whether dividends shall be cumulative and, if so, from which date; (iii)&#160;whether shares are to be redeemable and, if so, the terms and amount of any sinking fund providing for the purchase or redemption of such shares; (iv)&#160;whether shares shall be convertible and, if so, the terms and provisions thereof; (v)&#160;what restrictions are to apply, if any, on the issue or reissue of any additional preferred stock; and (vi)&#160;whether shares have voting rights. The preferred stock may be issued with a preference over the common stock as to the payment of dividends.  We have no current plans to issue any additional preferred stock. Classes of stock such as the preferred stock may be used, in certain circumstances, to create voting impediments on extraordinary corporate transactions or to frustrate persons seeking to effect a merger or otherwise to gain control of the Company. For the foregoing reasons, any additional preferred stock issued by the Company could have an adverse effect on the rights of the holders of the common stock.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;29, 2010, we entered into a transaction with the Third Security Investors, pursuant to the terms of a Series A Convertible Preferred Stock Purchase Agreement (the &#8220;Series A Purchase Agreement&#8221;), in which we: (i)&#160;sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,586,205</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$2.32</font><font style="font-family:inherit;font-size:10pt;"> per share; and (ii)&#160;issued Series A Warrants to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,293,102</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock having an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.32</font><font style="font-family:inherit;font-size:10pt;"> per share (the sale of Series A Preferred Stock and issuance of the Series A Warrants hereafter referred to together as the &#8220;Financing&#8221;). The Series A Warrants may be exercised at any time from December&#160;29, 2010 until December&#160;28, 2015 and contain a &#8220;cashless exercise&#8221; feature.  The gross proceeds from the Series A financing were </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;">.  The </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> of costs incurred to complete the Series A financing were recorded as a reduction in the value of the Series A Preferred Stock.  We used the net proceeds from the financing to acquire the FAMILION family of genetic tests from PGxHealth, a subsidiary of Clinical Data, Inc. Until the November 2011 modifications, the Series A Preferred Stock met the definition of mandatorily redeemable stock as it was preferred capital stock that was redeemable at the option of the holder through December 2015 and was reported outside of equity. The Series A Preferred Stock was to be accreted to its redemption value of </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;">. Until the November 2011 modifications, the Series A Warrants did not qualify to be treated as equity and, accordingly, were recorded as a liability.  A preferred stock anti-dilution feature is embedded within the Series A Preferred Stock that met the definition of a derivative.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Series A financing, we filed a Certificate of Designation of Series A Convertible Preferred Stock (the &#8220;Series A Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware, designating </font><font style="font-family:inherit;font-size:10pt;">3,879,307</font><font style="font-family:inherit;font-size:10pt;"> shares of our preferred stock as Series A Preferred Stock. As of December 31, 2013, the Series A Preferred Stock, including the Series A Preferred Stock issuable upon exercise of the Series A Warrants, was convertible into shares of our common stock at a rate of 4-for-1, which conversion rate is subject to further adjustment as set forth in the Series A Certificate of Designation. Giving effect to the reverse split of our stock in January 2014, the conversion rate was adjusted to 1-for-3. Certain rights of the holders of the Series A Preferred Stock are senior to the rights of the holders of our common stock. The Series A Preferred Stock has a liquidation preference equal to its original price per share, plus any accrued and unpaid dividends thereon. The holders of the Series A Preferred Stock are entitled to receive quarterly dividends, which accrue at the rate of </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of the original price per share per annum, whether or not declared, and which shall compound annually and shall be cumulative. In any calendar quarter in which we have positive distributable cash flow as defined in the Series A Purchase Agreement, we are required to pay from funds legally available a cash dividend in the amount equal to the lesser of </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of such distributable cash flow or the aggregate amount of dividends accrued on the Series A Preferred Stock.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Generally, the holders of the Series A Preferred Stock are entitled to vote together with the holders of common stock, as a single group, on an as-converted basis. However, the Series A Certificate of Designation provides that we shall not perform some activities, subject to certain exceptions, without the affirmative vote of a majority of the holders of the outstanding shares of Series A Preferred Stock.  The holders of the Series A Preferred Stock, along with the holders of the Series B Preferred Stock, also are entitled to elect or appoint, as a single group, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#160;directors of the Company.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Series A financing, we also entered into a registration rights agreement with the Third Security Investors (the &#8220;Registration Rights Agreement&#8221;). Pursuant to the terms of the Registration Rights Agreement, the Company has granted certain demand, &#8220;piggyback&#8221; and S-3 registration rights covering the resale of the shares of common stock underlying the Series A Preferred Stock issued pursuant to the Series A Purchase Agreement and issuable upon exercise of the Series A Warrants and all shares of common stock issuable upon any dividend or other distribution with respect thereto.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2011, we entered into a transaction with the Third Security Investors, pursuant to an Agreement Regarding Preferred Stock (the &#8220;Amendment Agreement&#8221;), in which the Third Security Investors agreed to (i) waive their rights to enforce the anti-dilution and redemption features of the Series A Preferred Stock and (ii) at the next annual stockholders&#8217; meeting, vote to amend the Series A Certificate of Designation to remove the anti-dilution and redemption features of the Series A Preferred Stock.  In exchange, the Company issued shares of common stock to the Third Security Investors having an aggregate market value of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the Amendment Agreement, the values of the Series A Preferred Stock and Series A Warrants, including the Series A Preferred Stock conversion feature and Series A Warrant liability, were reclassified into stockholders&#8217; equity as of the date of the Amendment Agreement.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock Series B.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 5, 2014, we entered into a Series B Convertible Preferred Stock Purchase Agreement (the &#8220;Series B Purchase Agreement&#8221;) with affiliates of Third Security, LLC (the &#8220;2014 Third Security Investors&#8221;), pursuant to which we, in a private placement, sold and issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,443,297</font><font style="font-family:inherit;font-size:10pt;"> shares of our Series B Preferred Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Series B Preferred Stock&#8221;), at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$4.85</font><font style="font-family:inherit;font-size:10pt;"> for an aggregate purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">.  Each share of Series B Preferred Stock issued pursuant to the Series B Purchase Agreement was initially convertible into shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;">-for-1, which conversion rate was subject to further adjustment as set forth in the Certificate of Designation of Series B Convertible Preferred Stock.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Series B financing, we also entered into a Registration Rights Agreement, dated March 5, 2014, with the 2014 Third Security Investors, pursuant to which we granted certain demand, &#8220;piggy-back&#8221; and S-3 registrations rights covering the resale of the shares of common stock underlying the Series B Preferred Stock issued pursuant to the Series B Purchase Agreement and all shares of common stock issuable upon any dividend or other distribution with respect thereto.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Series B financing required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement.  The exercise price of the warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$12.96</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$11.73</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">1,097,600</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1,212,665</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Conversion of Preferred Stock - Series A and Series B.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2016, the Company entered into a Conversion Agreement (the &#8220;Conversion Agreement&#8221;) with the holders (the &#8220;Preferred Holders&#8221;) of all of the Company&#8217;s outstanding shares of Series A Convertible Preferred Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Series A Preferred Stock&#8221;), and Series B Preferred Stock, pursuant to which, among other things, the Preferred Holders: (a) elected to convert all of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock into shares of our  common stock, in each case in accordance with the terms thereof, and (b) agreed that all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock would be paid by the Company in shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">$1.00</font><font style="font-family:inherit;font-size:10pt;"> per share of our common stock (collectively, the &#8220;Conversion&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The outstanding shares of Series A Preferred Stock were convertible into shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;">-for-3, and the outstanding shares of Series B Preferred Stock were convertible into shares of our common stock at a rate of 1-for-1. Prior to the entry into the Conversion Agreement, there were </font><font style="font-family:inherit;font-size:10pt;">2,586,205</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock outstanding, which were converted into </font><font style="font-family:inherit;font-size:10pt;">862,057</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, and </font><font style="font-family:inherit;font-size:10pt;">1,443,297</font><font style="font-family:inherit;font-size:10pt;"> shares of Series B Preferred Stock outstanding, which were converted into </font><font style="font-family:inherit;font-size:10pt;">1,443,297</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, for an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,305,354</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock issued upon conversion of the Series A Preferred Stock and Series B Preferred Stock (the &#8220;Conversion Shares&#8221;). At the time of the entry into the Conversion Agreement, there were </font><font style="font-family:inherit;font-size:10pt;">$3.7</font><font style="font-family:inherit;font-size:10pt;"> million in accrued and unpaid dividends on the outstanding shares of Series A Preferred Stock, which were converted, in accordance with the Conversion Agreement, into </font><font style="font-family:inherit;font-size:10pt;">3,681,590</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, and </font><font style="font-family:inherit;font-size:10pt;">$0.8</font><font style="font-family:inherit;font-size:10pt;"> million in accrued and unpaid dividends on the outstanding shares of Series B Preferred Stock, which were converted, in accordance with the terms of the Conversion Agreement, into </font><font style="font-family:inherit;font-size:10pt;">793,235</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, for an aggregate of </font><font style="font-family:inherit;font-size:10pt;">4,474,825</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock issued pursuant to the accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock. Therefore, in connection with the full conversion of the Series A Preferred Stock and Series B Preferred Stock, plus the conversion of all accrued and unpaid dividends thereon, we issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;">6,780,179</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock to the Preferred Holders on January 6, 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following the conversion of the shares of Series A Preferred Stock and Series B Preferred Stock into common stock, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock or Series B Preferred Stock remain outstanding.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock Dividends.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> undeclared dividends for the three months ended March 31, 2017. For the three months ended March 31, 2016, we had undeclared dividends.  In accordance with the FASB&#8217;s Accounting Standards Codification Topic 260-10-45-11, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings per Share</font><font style="font-family:inherit;font-size:10pt;">&#8221;, these dividends were added to the net loss per share calculation.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750927824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FAIR VALUE</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FAIR VALUE</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities;</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2&#8212;Observable inputs other than those included in Level&#160;1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets;&#160;and</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3&#8212;Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our long term debt book value approximates fair market value due to the variable interest rate it bears. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrant Liabilities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2012 Warrant Liability</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2012 Warrant Liability represents the fair value of the </font><font style="font-family:inherit;font-size:10pt;">3.4 million</font><font style="font-family:inherit;font-size:10pt;"> warrants issued in February 2012 (as adjusted pursuant to the terms of the 2012 Warrants). We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated Statement of Operations. Management does not believe that this liability will be settled by a use of cash. The 2012 Warrants expired in February 2017 and, as such, the 2012 Warrant Liability no longer exists at March 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2012 Warrant Liability is considered a Level 3 financial instrument and is valued using a Monte Carlo simulation model.  This method is well suited to valuing options with non-standard features, such as anti-dilution protection.  A Monte Carlo simulation model uses repeated random sampling to simulate significant uncertainty in inputs.  Assumptions and inputs used in the valuation of the common stock warrants are broken down into four sections: Static Business Inputs; Static Technical Inputs; Simulated Business Inputs; and Simulated Technical Inputs.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 Warrant Liability</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrant Liability represents the fair value of the </font><font style="font-family:inherit;font-size:10pt;">1.8 million</font><font style="font-family:inherit;font-size:10pt;"> warrants issued in January 2016, of which, </font><font style="font-family:inherit;font-size:10pt;">0.8 million</font><font style="font-family:inherit;font-size:10pt;"> warrants remain outstanding as of March 31, 2017. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated Statement of Operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrant Liability is considered a Level 3 financial instrument and is valued using a binomial lattice simulation model.  This method is well suited to valuing options with non-standard features.  Assumptions and inputs used in the valuation of the common stock warrants include; our equity value, which was estimated using our stock price of </font><font style="font-family:inherit;font-size:10pt;">$0.56</font><font style="font-family:inherit;font-size:10pt;"> as of March 31, 2017; volatility of </font><font style="font-family:inherit;font-size:10pt;">115%</font><font style="font-family:inherit;font-size:10pt;">; and a risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">1.66%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2017 and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:  &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.6953125%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,446</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750955648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK OPTIONS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCK OPTIONS </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Options.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity under our 2006 Equity Incentive Plan (the "Plan") during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">738,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62,739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">675,287</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.73</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,957</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we did not grant any options to purchase shares of our common stock.  Options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">14,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock were granted during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">661,914</font><font style="font-family:inherit;font-size:10pt;"> options that were vested or expected to vest with an aggregate intrinsic value of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> with a remaining weighted average contractual life of </font><font style="font-family:inherit;font-size:10pt;">7.2</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Appreciation Rights (</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">SARs</font><font style="font-family:inherit;font-size:10pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">83,333</font><font style="font-family:inherit;font-size:10pt;"> outstanding and exercisable SARs shares were vested or expected to vest. All outstanding SARs were issued solely to our chief executive officer. The weighted-average exercise price of these SARs was </font><font style="font-family:inherit;font-size:10pt;">$4.32</font><font style="font-family:inherit;font-size:10pt;"> per share and the aggregate intrinsic value was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> with a remaining weighted average contractual life of </font><font style="font-family:inherit;font-size:10pt;">6.5</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750953728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUBSEQUENT EVENTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 13, 2017, Transgenomic completed the sale of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$1.15 million</font><font style="font-family:inherit;font-size:10pt;"> of promissory notes (the &#8220;Bridge Notes&#8221;) in a bridge financing pursuant to a securities purchase agreement (the &#8220;Purchase Agreement&#8221;). Transgenomic may receive additional investments of up to </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;"> in connection with the bridge financing. The financing is intended to help facilitate the completion of Transgenomic&#8217;s merger with Precipio, which is expected to close during the second quarter of 2017. Transgenomic received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$1,031,000</font><font style="font-family:inherit;font-size:10pt;"> from the sale of the Bridge Notes.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Bridge Notes have an annual interest rate of </font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;"> and a </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">-day maturity. Transgenomic may repay the Bridge Notes at any time in cash upon payment of a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> premium. In connection with the issuance of the Bridge Notes, Transgenomic issued warrants (the &#8220;Bridge Warrants&#8221;) to acquire </font><font style="font-family:inherit;font-size:10pt;">1.15 million</font><font style="font-family:inherit;font-size:10pt;"> shares of Transgenomic common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;"> per share, subject to anti-dilution protection. The Purchase Agreement provides certain piggyback registration rights for the holders of the Bridge Warrants for a period of six months after the closing of the bridge financing.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the bridge financing, Transgenomic agreed to loan </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of the net proceeds from the sale of the Bridge Notes to Precipio pursuant to a promissory note (the &#8220;Precipio Note&#8221;) with an original principal amount of up to </font><font style="font-family:inherit;font-size:10pt;">$561,500</font><font style="font-family:inherit;font-size:10pt;"> upon substantially the same terms and conditions as the Bridge Notes. The payment of the Precipio Note is subordinated to the payment by Precipio of its secured </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;"> bank debt pursuant to a subordination agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aegis Capital Corp. acted as placement agent for the bridge financing and received a placement agent fee of </font><font style="font-family:inherit;font-size:10pt;">$84,000</font><font style="font-family:inherit;font-size:10pt;"> and warrants (the &#8220;Aegis Warrants&#8221;) to acquire </font><font style="font-family:inherit;font-size:10pt;">168,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Transgenomic common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;"> per share. The Aegis Warrants are identical to the Bridge Warrants except that the Aegis Warrants do not have anti-dilution protection.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764990640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are presented in conformity with GAAP. Supplemental cash flows from discontinued operations are presented in Note 3 - &#8220;Discontinued Operations&#8221;. We have evaluated events occurring subsequent to March 31, 2017 for potential recognition or disclosure in the condensed consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2016. The accompanying condensed consolidated financial statements as of and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 13, 2017. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2017.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risks and Uncertainties.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements.  The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise specified, book value approximates fair value. The common stock warrant liability is recorded at fair value.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents and Other Current Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ConcentrationOfCashPolicyPolicyTextBlock', window );">Concentrations of Cash</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Cash.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">-year contractual terms. Unvested awards as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> had vesting periods of up to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. None of the awards outstanding at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are subject to performance or market-based vesting conditions.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Net Sales Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Sales Recognition.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:66px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is realized and earned when all of the following criteria are met:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persuasive evidence of an arrangement exists;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delivery has occurred or services have been rendered;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The seller&#8217;s price to the buyer is fixed or determinable; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collectability is reasonably assured.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In our Omaha, Nebraska laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year.  At each of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue were </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales from Patient Testing laboratories are reported as part of discontinued operations (See Note 3 - &#8220;Discontinued Operations&#8221;) and are recognized on an individual test basis and, since collectability is not reasonably assured, are recognized when cash is received. There are no deferred net sales associated with our Patient Testing services. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loss Per Share.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period.  Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers. This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year.  As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company adopted ASU No. 2016-09 as of January&#160;1, 2017. The adoption of this guidance does not have a material effect on the Company&#8217;s financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August&#160;2016, FASB issued ASU No.&#160;2016-15</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">Classification of Certain Cash Receipts and Cash Payments.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">ASU No.&#160;2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No.&#160;2016-15 is effective for fiscal years beginning after December&#160;15, 2017, and for interim periods within that fiscal year. We do not believe ASU No.&#160;2016-15 will have a material effect on our financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, FASB issued ASU No.&#160;2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business.  ASU No. 2017-01adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within those fiscal years. The Company does not believe ASU No. 2017-01 will have a material effect on its financial position and results of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_ConcentrationOfCashPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration of Cash Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_ConcentrationOfCashPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks and Uncertainties [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755317728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of discontinued operations impact on income statement and balance sheets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results of the discontinued operations consisted of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three months ended     March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,025</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss) from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on settlement of liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721665-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1474-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=SL51724579-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721663-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721659-107760<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721671-107760<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721677-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750980960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dollars&#160;in&#160;Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revolving Line of Credit</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term Loan</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible Promissory Notes </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,368</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,814</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,368</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,814</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net of current maturities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revolving Line of Credit.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6.25%</font><font style="font-family:inherit;font-size:10pt;"> or (b) the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wall Street Journal</font><font style="font-family:inherit;font-size:10pt;"> prime rate plus </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3%</font><font style="font-family:inherit;font-size:10pt;">. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;">6.75%</font><font style="font-family:inherit;font-size:10pt;">. As discussed below under </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Additional Terms</font><font style="font-family:inherit;font-size:10pt;">, the interest rate is subject to increase if there is a default under the Loan Agreement. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20,000</font><font style="font-family:inherit;font-size:10pt;"> on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line.  In addition, a fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum is payable quarterly on the unused portion of the Revolving Line.  The Revolving Line matures on November 1, 2017.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Term Loan.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">We received </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> under the Term Loan on the Effective Date.  Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">9.1%</font><font style="font-family:inherit;font-size:10pt;">.  As discussed below, the interest rate is subject to increase if there is a default under the Loan Agreement.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will pay the Lenders an additional final payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$120,000</font><font style="font-family:inherit;font-size:10pt;">, at maturity or prepayment of the Term Loan, which has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1%</font><font style="font-family:inherit;font-size:10pt;"> of the total outstanding balance under the Term Loan.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Additional Terms.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement contains affirmative and negative covenants.  Under the Loan Agreement, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders&#8217; consent.  Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of March 31, 2017, we were not in compliance with the Loan Agreement, as amended, due to the fact that events of default existed, including our failure to make certain required monthly interest payments.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. At March 31, 2017, our applicable interest rates have been increased by </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">   Convertible Promissory Notes. </font><font style="font-family:inherit;font-size:10pt;">The Notes accrue interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> per year and matured on December 31, 2016. </font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755373904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of stockholders' equity, including warrants and rights</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrant Holder</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issue&#160;Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">374,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,780</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.24</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.66</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,161,972</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,527</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,334,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in January 2013. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with a private placement which was completed in October 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in February 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in July 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were originally issued in connection with the offering in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755399536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of changes in fair value of liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2017 and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:  &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.6953125%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,446</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755356704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity under our 2006 Equity Incentive Plan (the "Plan") during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">738,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62,739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">675,287</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.73</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,957</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765642960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS DESCRIPTION (Details)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 02, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>operating_segments</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 29, 2015 </div>
<div>operating_segments</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | operating_segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WorkingCapitalDeficiency', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (20,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Debt settled with issuance of preferred stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_StockholdersEquityNoteReverseStockSplitConversionRatio', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_StockholdersEquityNoteReverseStockSplitConversionRatio', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=tbio_PrecipioMember', window );">Precipio | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted, shares | shares</a></td>
<td class="nump">160.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage of shares owned after transaction</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=tbio_PrecipioMember', window );">Precipio | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted, shares | shares</a></td>
<td class="nump">24.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage of shares owned after transaction</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Debt settled with issuance of preferred stock and warrants</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_StockholdersEquityNoteReverseStockSplitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity Note, Reverse Stock Split, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_StockholdersEquityNoteReverseStockSplitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_WorkingCapitalDeficiency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital (Deficiency)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_WorkingCapitalDeficiency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tbio_PrecipioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tbio_PrecipioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764642000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">$ 190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Current prepaid expense</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other current receivables</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation arrangement by share-based payment award, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="num">$ (24,000)<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock awards, not yet recognized</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested stock options, unrecognized compensation expense weighted average recognition period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights', window );">Common stock rights issued (in shares)</a></td>
<td class="nump">2,933,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options, warrants and conversion rights, common stock callable and antidilutive (in shares)</a></td>
<td class="nump">4,425,218<span></span>
</td>
<td class="nump">12,970,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=tbio_PharmacogenomicServicesMember', window );">Pharmacogenomic Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember', window );">Executive Officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, unvested options, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights', window );">Common stock rights issued (in shares)</a></td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, unvested options, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Issued Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=tbio_PharmacogenomicServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=tbio_PharmacogenomicServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750941216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765675760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Intangible Assets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remaining amortization expense, 2017</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Amortization expense, 2018</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Amortization expense, 2019 (less than)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Amortization expense, 2020 (less than)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Amortization expense, 2021 (less than)</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753404976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS (Revenues and Net Income (Loss)) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations, net of taxes</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="num">$ (1,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued operations | Genetic Assays and Platforms and Patient Testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Net sales</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss', window );">Gross profit (loss)</a></td>
<td class="nump">53<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="num">(65)<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax', window );">Operating income (loss) from discontinued operations</a></td>
<td class="nump">118<span></span>
</td>
<td class="num">(1,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on settlement of liability</a></td>
<td class="num">(45)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Income (loss) from discontinued operations before income taxes</a></td>
<td class="nump">73<span></span>
</td>
<td class="num">(1,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations, net of taxes</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="num">$ (1,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Selling, General And Administrative Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65896914&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=tbio_GeneticAssaysandPlatformsandPatientTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=tbio_GeneticAssaysandPlatformsandPatientTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765632880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Schedule of Debt) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">$ 7,368,000<span></span>
</td>
<td class="nump">$ 7,814,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="num">(7,368,000)<span></span>
</td>
<td class="num">(7,814,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current maturities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tbio_TermLoanMember', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Current interest rate (as a percent)</a></td>
<td class="nump">9.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_DebtInstrumentFutureDebtExtinguishmentCosts', window );">Future debt extinguishment costs</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_DebtInstrumentPrepaymentPenaltyPercent', window );">Prepayment penalty percentage of outstanding balance (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease', window );">Increase in interest rate in case of debt default (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 571,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">$ 3,243,000<span></span>
</td>
<td class="nump">$ 3,243,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate (as a percent)</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (as a percent)</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Commitment fee amount</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Line of credit | Wall Street Journal prime rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Default, Interest Rate, Stated Percentage Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_DebtInstrumentDebtDefaultInterestRateStatedPercentageIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_DebtInstrumentFutureDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Future Debt Extinguishment Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_DebtInstrumentFutureDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_DebtInstrumentPrepaymentPenaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_DebtInstrumentPrepaymentPenaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tbio_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tbio_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=tbio_WallStreetJournalPrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=tbio_WallStreetJournalPrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765414096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Revolving Line and Term Loan) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 02, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jan. 06, 2016</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Mar. 13, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 499,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=tbio_PrecipioMember', window );">Precipio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_DebtConversionConvertedInstrumentInterest', window );">Debt conversion, converted Instrument, interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=tbio_PrecipioMember', window );">Precipio | Convertible Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares converted (shares)</a></td>
<td class="nump">10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=tbio_PrecipioMember', window );">Precipio | Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares converted (shares)</a></td>
<td class="nump">24,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tbio_TermLoanMember', window );">Term loan | Third Security LLC and affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares converted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Payment to lenders to support the amount advanced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Line of credit | Third Security LLC and affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_DebtConversionConvertedInstrumentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Conversion, Converted Instrument, Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_DebtConversionConvertedInstrumentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tbio_PrecipioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tbio_PrecipioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tbio_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tbio_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=tbio_ThirdSecurityLlcAndAffiliatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=tbio_ThirdSecurityLlcAndAffiliatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6766510048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Convertible Promissory Notes) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 13, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 17, 2017</div></th>
<th class="th">
<div>Jan. 06, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 20, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 15, 2015 </div>
<div>investor</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 499,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tbio_AdditionalNotePrivatePlacementMember', window );">Additional notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors', window );">Number of additional accredited investors | investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares converted (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_DebtInstrumentDebtDefaultPeriod', window );">Debt instrument, default period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes payable | Agent Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 446,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares converted (shares) | shares</a></td>
<td class="nump">416,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_PercentageofInitialNote', window );">Percentage of initial note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes payable | Additional notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares converted (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes payable | Additional Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent', window );">Required cumulative principal payment, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent', window );">Portion of principal required by deferred maturity date, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_DebtInstrumentDebtDefaultPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Default, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_DebtInstrumentDebtDefaultPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Additional Accredited Investors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_DebtInstrumentNumberofAdditionalAccreditedInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_PercentageofInitialNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Initial Note</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_PercentageofInitialNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of Principal Required to Be Paid Prior to Deferred Maturity Date, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Required Cumulative Payment on Principal Per Amendment, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_RequiredCumulativePaymentonPrincipalPerAmendmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tbio_AdditionalNotePrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tbio_AdditionalNotePrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tbio_AgentNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tbio_AgentNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tbio_AdditionalNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tbio_AdditionalNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767324464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONTINGENCIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 07, 2017</div></th>
<th class="th"><div>Mar. 06, 2017</div></th>
<th class="th"><div>Feb. 21, 2017</div></th>
<th class="th"><div>Feb. 06, 2017</div></th>
<th class="th"><div>Dec. 19, 2016</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Oct. 27, 2016</div></th>
<th class="th"><div>Sep. 13, 2016</div></th>
<th class="th"><div>Jun. 23, 2016</div></th>
<th class="th"><div>Feb. 25, 2016</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_DelinquentAccountsPayable', window );">Delinquent accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=tbio_UNMCMember', window );">UNMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought in a lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Accrual of possible loss in a lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=tbio_MountSinaiMember', window );">Mount Sinai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought in a lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Accrual of possible loss in a lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=tbio_SmithMember', window );">Smith</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought in a lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_LossContingencyDeferredPayment', window );">Deferred loss payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=tbio_SmithMember', window );">Smith | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Accrual of possible loss in a lawsuit</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=tbio_XIFINInc.Member', window );">XIFIN, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought in a lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=tbio_ScienceParkDevelopmentCorporationMember', window );">Science Park Development Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought in a lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Accrual of possible loss in a lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=tbio_CPAGlobalMember', window );">CPA Global</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought in a lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=tbio_EdgeBioSystemsInc.Member', window );">Edge BioSystems, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought in a lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_DelinquentAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Delinquent Accounts Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_DelinquentAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_LossContingencyDeferredPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Deferred Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_LossContingencyDeferredPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=tbio_UNMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=tbio_UNMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=tbio_MountSinaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=tbio_MountSinaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=tbio_SmithMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=tbio_SmithMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=tbio_XIFINInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=tbio_XIFINInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=tbio_ScienceParkDevelopmentCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=tbio_ScienceParkDevelopmentCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=tbio_CPAGlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=tbio_CPAGlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=tbio_EdgeBioSystemsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=tbio_EdgeBioSystemsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765662384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773866416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Common Stock) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 14, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 08, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 06, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 29, 2010 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 31, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 07, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 07, 2015 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_InitialFairValueofWarrantsIssued', window );">Initial valuation of warrant issued in conjunction with Private Placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,827,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Debt settled with issuance of preferred stock and warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,705<span></span>
</td>
<td class="nump">214,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued for services | $</a></td>
<td class="nump">$ 89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,863,062<span></span>
</td>
<td class="nump">26,446,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,446,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tbio_CraigHallumCapitalGroupLLCMember', window );">Craig-Hallum Capital Group LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassofWarrantorRightExerciseTerm1', window );">Class of warrant or right, exercise term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds', window );">Payments of stock issuance costs, percentage of gross offering proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares', window );">Payments of stock Issuance costs, warrant right to purchase common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_StockIssuanceCostsReimbursableExpenses', window );">Reimbursable expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement', window );">Partners' capital account, units, sold in private placement (units)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,239,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tbio_CraigHallumCapitalGroupLLCMember', window );">Craig-Hallum Capital Group LLC | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement', window );">Partners' capital account, units, sold in private placement (units)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,188,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tbio_VendorMember', window );">Vendor I</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for services (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=tbio_VendorIIMember', window );">Vendor II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for services (shares)</a></td>
<td class="nump">64,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tbio_A2016WarrantMember', window );">2016 Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,006,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassofWarrantorRightExerciseTerm1', window );">Class of warrant or right, exercise term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_StockWarrantExchangeAmount', window );">Stock warrant exchange amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,436,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights', window );">Price per share of stock warrants exchanged (usd per unit) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tbio_SeriesA1WarrantMember', window );">Series A-1 Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment', window );">Exercise period not subject to cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tbio_AttheMarketOfferingAgreementMember', window );">At the Market Offering Agreement | Craig-Hallum Capital Group LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement', window );">Partners' capital account, units, sold in private placement (units)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,362,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_PlacementFeesPercentageofGrossSalesPrice', window );">Placement fees, percentage of gross sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,177,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,177,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tbio_AttheMarketOfferingAgreementMember', window );">At the Market Offering Agreement | Craig-Hallum Capital Group LLC | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement', window );">Partners' capital account, units, sold in private placement (units)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,262,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember', window );">Series A-1 Convertible Preferred Stock and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_StockholdersEquityNoteConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_StockholdersEquityNoteConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Craig-Hallum Capital Group LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | 2016 Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock warrant, common stock called (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,873,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,613,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_CashPaymentPortionofStockWarrantsExercised', window );">Cash payment for portion of stock warrants exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_StockWarrantsSettledwithCash', window );">Stock warrants settled with cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_SecurityPurchaseAgreementMember', window );">Security Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Private placement, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet', window );">Net proceeds from the issuance of stock warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_SecurityPurchaseAgreementMember', window );">Security Purchase Agreement | Series A Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock warrant, common stock called (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,161,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,161,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_StockWarrantExchangeAmount', window );">Stock warrant exchange amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 941,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment', window );">Exercise period not subject to cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights', window );">Price per share of stock warrants exchanged (usd per unit) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_SecurityPurchaseAgreementMember', window );">Security Purchase Agreement | Series A Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock warrant, common stock called (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,882,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_SecurityPurchaseAgreementMember', window );">Security Purchase Agreement | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Private placement, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,365,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (per right)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.075269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_SecurityPurchaseAgreementMember', window );">Security Purchase Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock warrant, common stock called (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,773,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (per right)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_SecurityPurchaseAgreementMember', window );">Security Purchase Agreement | Common Stock | Series A Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock warrant, common stock called (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,882,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_CashPaymentPortionofStockWarrantsExercised', window );">Cash payment for portion of stock warrants exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_CashPaymentPortionofStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Payment Portion of Stock Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_CashPaymentPortionofStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exchange Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_ClassofWarrantorRightExchangePriceofWarrantsorRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Period Not Subject to Cash Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_ClassofWarrantorRightExercisePeriodNotSubjecttoCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_ClassofWarrantorRightExerciseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Term1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_ClassofWarrantorRightExerciseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_InitialFairValueofWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Fair Value of Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_InitialFairValueofWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of Stock Issuance Costs, Percentage of Gross Offering Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_PaymentsofStockIssuanceCostsPercentageofGrossOfferingProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of Stock Issuance Costs, Warrant Right To Purchase Common Stock Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_PaymentsofStockIssuanceCostsWarrantRightToPurchaseCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_PlacementFeesPercentageofGrossSalesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Placement Fees, Percentage of Gross Sales Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_PlacementFeesPercentageofGrossSalesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Common Stock and Warrants, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_ProceedsfromIssuanceofCommonStockandWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_StockIssuanceCostsReimbursableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Reimbursable Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_StockIssuanceCostsReimbursableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_StockWarrantExchangeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Warrant Exchange Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_StockWarrantExchangeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_StockWarrantsSettledwithCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Warrants Settled with Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_StockWarrantsSettledwithCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_StockholdersEquityNoteConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity Note, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_StockholdersEquityNoteConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units sold in a private placement of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187171-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tbio_CraigHallumCapitalGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tbio_CraigHallumCapitalGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tbio_VendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tbio_VendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=tbio_VendorIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=tbio_VendorIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tbio_A2016WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tbio_A2016WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tbio_SeriesA1WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tbio_SeriesA1WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tbio_AttheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tbio_AttheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tbio_SeriesA1ConvertiblePreferredStockandWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_SecurityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_WarrantyHoldersAndIssuanceAxis=tbio_SecurityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tbio_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tbio_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765734080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired', window );">Class of stock warrants expired (shares)</a></td>
<td class="nump">3,362,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights', window );">Common stock warrants issued (in shares)</a></td>
<td class="nump">2,933,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Underlying Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,334,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights', window );">Common stock warrants issued (in shares)</a></td>
<td class="nump">1,051,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tbio_OfferingMember', window );">Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights', window );">Common stock warrants issued (in shares)</a></td>
<td class="nump">1,881,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersJanuary2018Member', window );">Various Institutional Holders; January 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Underlying Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_AffiliatesofThirdSecurityLLCJanuary2018Member', window );">Affiliates of Third Security, LLC; January 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Underlying Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersApril2020Member', window );">Various Institutional Holders; April 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Underlying Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersFebruary2020Member', window );">Various Institutional Holders; February 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Underlying Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersDecember2020OneMember', window );">Various Institutional Holders; December 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Underlying Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersJanuary2021OneMember', window );">Various Institutional Holders; January 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Underlying Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,161,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_AffiliatesofThirdSecurityLLCJanuary2021Member', window );">Affiliates of Third Security, LLC; January 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Underlying Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersJanuary2021TwoMember', window );">Various Institutional Holders; January 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Underlying Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Issued Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Issued Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_ClassofWarrantorRightNumberofIssuedWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tbio_OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tbio_OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersJanuary2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersJanuary2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_AffiliatesofThirdSecurityLLCJanuary2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_WarrantyHoldersAndIssuanceAxis=tbio_AffiliatesofThirdSecurityLLCJanuary2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersApril2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersApril2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersFebruary2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersFebruary2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersDecember2020OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersDecember2020OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersJanuary2021OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersJanuary2021OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_AffiliatesofThirdSecurityLLCJanuary2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_WarrantyHoldersAndIssuanceAxis=tbio_AffiliatesofThirdSecurityLLCJanuary2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersJanuary2021TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_WarrantyHoldersAndIssuanceAxis=tbio_VariousInstitutionalHoldersJanuary2021TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753986032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Preferred Stock Series A) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 29, 2010 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>Director </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 06, 2016 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes', window );">Proceeds from issuance of common stock and convertible notes | $</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_NumberOfDirectors', window );">Number of directors | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant, exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote', window );">Convertible notes, number of securities called by note | shares</a></td>
<td class="nump">1,293,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs | $</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred stock | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,879,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Private placement, net (in shares) | shares</a></td>
<td class="nump">2,586,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant, exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_PreferredStockDividendRateCompoundPercentageMaximum', window );">Preferred Stock, compound dividend rate maximum (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Redemption value adjustment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible notes, Number of Securities Called by Note</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_ConvertibleNotesNumberOfSecuritiesCalledByNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_NumberOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Directors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_NumberOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_PreferredStockDividendRateCompoundPercentageMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Dividend Rate, Compound Percentage Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_PreferredStockDividendRateCompoundPercentageMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and convertible notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_Proceedsfromissuanceofcommonstockandconvertiblenotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753486672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Preferred Stock Series B) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jan. 06, 2016</div></th>
<th class="th">
<div>Mar. 05, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 24, 2013 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_StockholdersEquityNoteConversionRatio', window );">Conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_StockholdersEquityNoteConversionRatio', window );">Conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_ThirdSecurityLlcAndAffiliatesMember', window );">Third Security LLC and affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant, exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock warrant, common stock called (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,212,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,097,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_ThirdSecurityLlcAndAffiliatesMember', window );">Third Security LLC and affiliates | Preferred Stock | Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Private placement, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,443,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Private placement, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_StockholdersEquityNoteConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tbio_ThirdSecurityLlcAndAffiliatesMember', window );">Third Security LLC and affiliates | Preferred Stock | Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_StockholdersEquityNoteConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_StockholdersEquityNoteConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity Note, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_StockholdersEquityNoteConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_WarrantyHoldersAndIssuanceAxis=tbio_ThirdSecurityLlcAndAffiliatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_WarrantyHoldersAndIssuanceAxis=tbio_ThirdSecurityLlcAndAffiliatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tbio_ThirdSecurityLlcAndAffiliatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tbio_ThirdSecurityLlcAndAffiliatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765989536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Conversion of Preferred Stock) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 06, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 29, 2010 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,705<span></span>
</td>
<td class="nump">214,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant, exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_StockholdersEquityNoteConversionRatio', window );">Conversion ratio</a></td>
<td class="nump">0.3333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Common stock dividend (shares)</a></td>
<td class="nump">3,681,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_StockholdersEquityNoteConversionRatio', window );">Conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_StockholdersEquityNoteConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted, shares</a></td>
<td class="nump">2,586,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends payable | $</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_StockholdersEquityNoteConversionRatio', window );">Conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted, shares</a></td>
<td class="nump">1,443,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends payable | $</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted, shares</a></td>
<td class="nump">2,305,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted, shares</a></td>
<td class="nump">862,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockDividendsShares', window );">Stock dividends (shares)</a></td>
<td class="nump">793,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, issued (shares)</a></td>
<td class="nump">6,780,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted, shares</a></td>
<td class="nump">1,443,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, issued (shares)</a></td>
<td class="nump">4,474,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_StockholdersEquityNoteConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity Note, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_StockholdersEquityNoteConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755294576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Preferred Stock Dividends) (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_DividendsPreferredStockCashNotDeclared', window );">Cumulative undeclared dividends, preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_DividendsPreferredStockCashNotDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividends, Preferred Stock, Cash, Not Declared</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_DividendsPreferredStockCashNotDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753483600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>Feb. 28, 2012</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights', window );">Common stock warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,933,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,334,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=tbio_A2012WarrantLiabilityMember', window );">2012 Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights', window );">Common stock warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_TotalGainsOrLossesAbstract', window );"><strong>Total (gains) or losses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Recognized in earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=tbio_A2016WarrantLiabilityMember', window );">2016 Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights', window );">Common stock warrants issued (in shares)</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_TotalGainsOrLossesAbstract', window );"><strong>Total (gains) or losses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Recognized in earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
<td class="nump">$ 1,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Issued Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_TotalGainsOrLossesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total gains or losses [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_TotalGainsOrLossesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tbio_A2012WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tbio_A2012WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tbio_A2016WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tbio_A2016WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754407040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS (Stock Options) (Details) - Employee Stock Option - Equity Incentive Plan 2006 - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">738,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(62,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">675,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">547,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">2.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share)</a></td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Stock options, expected to vest, outstanding (in shares)</a></td>
<td class="nump">661,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Stock options, expected to vest, outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Stock options, expected to vest remaining contractual term</a></td>
<td class="text">7 years 2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tbio_EquityIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tbio_EquityIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754617808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS (Stock Appreciation Rights) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested stock options, unrecognized compensation expense weighted average recognition period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SARs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of SARs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">83,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Stock appreciation rights, aggregate intrinsic value, outstanding | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested stock options, unrecognized compensation expense weighted average recognition period</a></td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765510368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 13, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights', window );">Common stock warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,933,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights', window );">Common stock warrants issued (in shares)</a></td>
<td class="nump">1,150,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant, exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Precipio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_LoantoRelatedPartyPercentage', window );">Percentage of loan to related party</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured debt</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Aegis Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights', window );">Common stock warrants issued (in shares)</a></td>
<td class="nump">168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant, exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bridge Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 1,150,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_AdditionalShorttermLoanMaximumAmountAuthorized', window );">Maximum additional bridge loan amount</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_ProceedsFromtheSalesofDebtInstrument', window );">Proceeds from the sales of debt instrument</a></td>
<td class="nump">$ 1,031,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate (as a percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_DebtInstrumentPremiumFeePercentage', window );">Debt instrument, premium rate (percentage)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tbio_PlacementFees', window );">Placement fees</a></td>
<td class="nump">$ 84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bridge Loan [Member] | Precipio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 561,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_AdditionalShorttermLoanMaximumAmountAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Short-term Loan, Maximum Amount Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_AdditionalShorttermLoanMaximumAmountAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Issued Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_DebtInstrumentPremiumFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Premium Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_DebtInstrumentPremiumFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_LoantoRelatedPartyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan to Related Party Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_LoantoRelatedPartyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_PlacementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Placement Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_PlacementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tbio_ProceedsFromtheSalesofDebtInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From the Sales of Debt Instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tbio_ProceedsFromtheSalesofDebtInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tbio_PrecipioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tbio_PrecipioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tbio_AegisCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tbio_AegisCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M]QP7C%Z5F:[T7/0MI%\HW@[M,1I[=/X74$L#!!0    ( ')TLDIOK$E@WP,
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M8QR)??+,N7D@6I"D5I)T36)\9/OTG\?!/#C/*!=,6RO3=LT4&$S;]4N(TSB
M)GQI$X9AO/43.Y&L#-;;"JZ90O.Z@L]"6956*C"[3E5]^X;8M6ZY<Z1"WLSZ
M_KQ0*K","C<R7B5+ZC0@^")4-Y%]-M2582!H-]9,,!7NXB]02P,$%     @
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MXV>8^KG%:&K^*UQ >'A0XFM46MCX1=5@G983BY<BV5LZN8KG./%?T]83Z)1
MYP2:>DF%HO(GYEB9&STBDV;?LW#%V8'ZV50A&$<1_WGQUD<O949O<W()1!/F
MF#!TB9D1Q+//)>A:B2/]/YW>K1-L5S5N(\'V'<%^G6"W2K"+!+MW!/<?FDR8
M?<2HB*'9IP]%R&*J$DP;]\FB2@\J[O(B.J_L XVW\@^>]OT;,RU7%IVU\W<;
M;Z#1VH&7LKGQ2]3Y)S8[ AH7S+VW35JTY#C=3V^(S ^Y_ M02P,$%     @
M<G2R2E)Y6.6P 0  T@,  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q]
M4]MNG# 0_17+'Q"S9INV*T#*IHI:J956J9H\>V$ *S9#;;.D?U_;L 2EJ"]X
M9CCGS,7C;$3S8EL 1UZUZFQ.6^?Z V.V;$$+>X,]=/Y/C48+YUW3,-L;$%4D
M:<5XDMPR+61'BRS&3J;(<'!*=G RQ Y:"_/G" K'G.[H-? HF]:% "NR7C3P
M$]RO_F2\QQ:52FKHK,2.&*AS>K<['/<!'P%/$D:[LDGHY(SX$IQO54Z34! H
M*%U0$/ZXP#TH%81\&;]G3;JD#,2U?55_B+W[7L["PCVJ9UFY-J>?**F@%H-R
MCSA^A;F?#Y3,S7^'"R@/#Y7X'"4J&[^D'*Q#/:OX4K1XG4[9Q7.<]:^T;0*?
M"?P=@4V)8N5?A!-%9G D9II]+\(5[P[<SZ8,P3B*^,\7;WWT4NSXYXQ=@M",
M.4X8OL8L".;5EQ1\*\61_T/GV_1TL\(TTM-U]C39%MAO"NRCP/Z_+6Y@TO=-
MLM5,-9@F;I,E)0Y=W.15=%G8.Q[OY T^;?L/81K967)&YV\VSK]&=.!+26[\
M"K7^@2V.@MH%\Z.WS;1FD^.PGU\06YYQ\1=02P,$%     @ <G2R2OFER0^S
M 0  T@,  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6Q]4V%OW" ,_2N(
M'U#N2-I5IR12K]7429MTZK3U,Y<X"2J$#,BE^_<S),W2+MH7P,;O^=F8;#3V
MQ;4 GKQJU;F<MM[W!\9<V8(6[LKTT.%-;:P6'DW;,-=;$%4$:<7X;G?#M) =
M+;+H.]DB,X-7LH.3)6[06MC?1U!FS.F>OCF>9-/ZX&!%UHL&OH/_T9\L6FQA
MJ:2&SDG3$0MU3N_VAV,:XF/ 3PFC6YU)J.1LS$LPOE0YW05!H*#T@4'@=H%[
M4"H0H8Q?,R==4@;@^OS&_CG6CK6<A8-[HYYEY=N<WE)202T&Y9_,^ AS/=>4
MS,5_A0LH# ]*,$=IE(LK*0?GC9Y94(H6K],NN[B/TTV:S+!M )\!? '<QCQL
M2A25/P@OBLR:D=BI][T(3[P_<.Q-&9RQ%?$.Q3OT7HI]PC-V"41SS'&*X>N8
M)8(A^Y*";Z4X\G_@?!N>;"I,(CQYIS#9)D@W"=)(D/ZWQ*V8]$,2MNJI!MO$
M:7*D-$,7)WGE70;VCL<W^1L^3?LW81O9.7(V'E\V]K\VQ@-*V5WA"+7XP19#
M0>W#\1.>[31FD^%-/_\@MGSCX@]02P,$%     @ <G2R2A/' S2U 0  T@,
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MAV<WCMEH!-M-/XC-W[CX!5!+ P04    " !R=+)*H#3.C+4!  #2 P  &0
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M?]G8_PK1@9>RN?(CU/@/-AL2*A>.-_YLQC$;#8?=](/8_(WSOU!+ P04
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M8_]+8SR@E-4%CE"-'VPR%)0^'*_Q;(<Q&PQOVO$'L>D;9Q]02P,$%     @
M<G2R2L3G<48P @  ; <  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M=57;CILP$/T5Q >L,>1"(D!*MJI:J96BK=H^.V02T!I,;2=L_[ZV82EUAQ=\
MX<PY,QY[)NN%?%45@ [>&MZJ/*RT[O:$J+*"AJDGT4%K_ER%;)@V2WDCJI/
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MPU7;Z=;,Y5#_AX46W=C;R-1@BS]02P,$%     @ <G2R2B:F##.R 0  T@,
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MZC66[W5WTN\&@E?Z%N/U5ZG5/U!+ P04    " !R=+)* Q1/1]D!  !D!
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M=J'VW(X\&TC6]M,<#7\IQ3]02P,$%     @ <G2R2LFLWE+[ @  (PP  !D
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M168<^]APH951+'T*I,^LY42@B19#<7^@X"S )EH,Q?V!LO_8O%C/%*G0VB<
ME)A5]08GZH)7.WU;J9VU.);ZJC28[6]$=U2?R-_A[77J>UKMLK)VGH54YWI]
M^MX*(;GBXM^HRN_5#:X?Y'PKFU>FWJOV&M,.I#AT5S2OOR<N_P%02P,$%
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M,#Y)\!7!GTL(%"&82P@5(?Q/@).$2!&BN818$>*1 ,%)0J((R5P/J2*D<PG
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M<=WO&O0GK=K;'9'@M"VS_ M02P,$%     @ <G2R2A#H"[S\ @  2PP  !D
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M360QMQT&#S X)=>8C8NA-+K&W$&8^!KS&<(DUYA[")/VF$#I[45C4#0V!&1
M0.(0)B @ 3$$=$ 0C8J\ZR"I@50&$BY"-%+[']!5)12LA#J54)K!!!%($,W?
MBQ@DB)T*2#8Z';<=)AKHG!"9@"D25V0T46,*$J3S168@039#9#97) IA*X:
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M(K.)K&QPR6D'@G0@KF]-3#J(/V[--KYAU!,R2F+7*69(;'M-/(HRRV.76'G
M H'.8TGFL23&&V=Y]!H63LI%_4<':H740A$2 POSE2*TYA"*A$5+1PN98U%B
M'T[JK=&,0[F"T(L  [L@[EA&&+T,,+Q^MC(:7V;S:W>0V6@Z9BNCL60VE_:
M1E</*(TN$\0,<4TR&EX6WS"@-)GL"C1W[!;R&(T>NX*]>R,:#ZIC.00:.["Q
MPV2^GH&-'42) -?:#31V8&/'!9_',D\,;,SX(G8$<NR_!'J1H\U HP<WH <T
M>G ->G U>D"C!\26:#?09H]QCK!TC2M-(% $6@T4=@/#1>((1',*Q"[+'?@
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M@?!DO98B(!8744M5=T<P*646;:4DBU*5'6],3( D*,%) C0 2BF'?_R<[6[
M!4AE994[)OI#M[-$X.(NYYQ[UN?\1U&4P9?U*BW^\P]/9;GYX?OOB_E3O(Z*
M3K:)4_AEF>7KJ(3_S!^_+S9Y'"V*IS@NUZOO^]WNR??K*$G_$&S3Y!_;>)QM
MT_(__S <]/_P7_]1)/_U'^5_7=R,'SY=7M\'H^N+ /YW<O^W8'+]X>;NT^A^
M<G,=' 7%4Y3'Q7]\7_[7?WR/[_![@^!3EI9/17"9+N)%]==/4=X)!KTPZ'=[
MI]4?1QO\L>O_\2*;;]=Q6@91NH"QRZ1\#28IKS')TN#_C&9%F4?S\O^IOBD/
MW\6/"3X!0UQ'Z[CZU/W=Z'KZ\?+ZYM-D# L=-XPRABGDT0H^O8B_!'^.7ZO/
MC;=YCM/\D!1S>.YO<93C5@0745G[YM%1KW\TZ#5\ZD.RBO-@#.\]9GGM.]-U
MM,+?[^)-EI=)^AB,L_4F2FL/ZHV[?]W49M#K'OVE\87;.$^R1>/LU5G^7__K
M?[4>F+T3'^"/-9*I/BG?]3[[E]INC>#5!;^^BAZKORZC55&;N3K+;+T&RIF6
MV?QS&$R)G(.;;5F40&.PH[6CO;F^N+R>7EX$\*_IS=7D8G0/__%^=#6Z'E\&
MTY\N+^^GP!@/TXO@X-UA\"Y(TN#^*=L6,%Y]U?%<L\))[5,/=W?$?-,IC/E#
M[>>H>")&F.,_XG]LD^=H!5M0^\AH/D?6+H(\GL?PT&P5AT$:E]7G)NDSO)[E
M29VA;\HG(+.YD'54%+'G,_37X"E>+0)@R:" V=08+"OA;-O'N<U!=N5P-+@V
M7-8&#]8[XYO[GR[OFO9GDL(1/B:PVL+_,JVI;2U-!W(U&;V?7$WN)Y>>4Y&U
M@43:YDD)>QEDRV"5I8]'99RO@T4\J\U$'] F>L73\?R>;V,X:&#N."U(UC4]
M$W_!1^HG>!$O8YC9 H@ 3GE;^X9[PJLDFB4KFG[[$;8\>'5S_3&XO[S[U+Y?
MS'\%\E_P$N4DF]6H-3G&LS2[N7.>+0],[V_&?_[IYNKB\F[ZO__OLW[O],?@
MXO+#9#RYK\WR-E?;5["@>-?M='MP7GD 3+<%?NH-PVZWB_\G=V(0;<LG8*9_
MQ@M@[]YQ>-H=JI^2HL"S0@+/6D2-M37>+W9;/WD2GIT,PNY)7_]:!B"NYT_Z
M[J4)P'/'QR?A>?_4>@[D4KR>P58KV;3GE$>+18+4"3N_B9+%$<B^>;1)X"0\
M]+I=;U=PI2R )Y;)/*FQ!9\@+?\I6RWBO%#'U/#"E3ELFJC]ZA])E-0I:C]Y
M?G [0L[_Z?)^,AY=30]!P+\+OF_0?J8EK(HN(^#\#TD:I?,$;[2L2'9H*34R
MT\<=',!6+K+5*LI!3,#!T*</=PY0(PP:B/^Z]]MR]E_QID4J;:^[E/[61;MO
MOVG%WE=W+]?[VIYK?;@>/5Q,[IG@?*0WO8?_0:U[&MQ\"&YN+^](V;:4BC:%
MNJ9%7%_>!]/1U>6T3OG3>_S"QYN;BVD W[^H/O$QSPK8^#Q;)F5PL(+_J'U:
MI@>2_O*OM[B8NH2?QJL5[$D8/,9IC&HSLF:T6"<IJ>)E\ER[C.[B(B9)A8\N
MX,):9:0$U+X.1!&1WGO9<.V9^5W=3*?!A[N;3[C;\)<'_*/97;]J 3; S:?+
MX$ 6=^A3,F(XY5+=NUY-XQ>YUN#J!;+V7M]\L4U2N.*![&4UM=W>L8;@_278
M9I=JUO>CO]9/W?RF3BPX>']Y#??>_5L_US#T ;YVR.]=3*;R*A"V>3,,D"J!
M]KQ3Q-]PC)J0N;O\< D:&+((7-TP^,\38*"+Q@&"T<^CR=7H_16L]P;6\.D3
MV*SVM5]]\?UH"H8?&KL7DZL'9$8:!N:MW_X)+H+@8'(=7-Q<78WN^$?Z:VW[
MZJ/]<CGY^!/\XVCT,VS%QTM^D?C<GEUP\W /4N#Z O<;O\6/><00V##I%ND_
M8T[(TKKB!_84/P<RK?FQ-XJE\6CZ4_#AZN:7_6T=ZY4''!W69;AS-+Z'T_1J
MB%<Q"*%$.(.$4+#,,]"D_0LC#L2;MXR^U(9">48OS_?9NM'B[]NB1,%3!&6&
MYE,&5_DJIB_@3/"O^&^RP):K[*4(M@7,!K8ATZ()+OKDF922VM(NX@T,FK#S
M@L3B&NWX?WI%!)FH1[.HJ%@"; ,^@:T3XX>U[HQ[P&IUM+$^DR>/3UZCZSDI
M\'<TW7!M>*/A[;N=E<LM"&VQ4;Q;BG=A7)8KK?6L8IAF@"HZJ#^^Q6AS)!$!
M6J,66E!1V4HV,7'!EF)?VU:/P;O+7&+%EJV+9I/A6IUUVRF'^Q&7'FN#6[^
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M8!^?[]#!BDVU9 DQ&X<W9AV[WQ.UB7TA*&O3!4G8^$L\WX+>$)%,PCN/UUO
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M0-G?W[ @@45W[LI$7 <9_,!C?-,60D:<F,2)%?,:,;.CNTK0875\HAK."5
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M!8K7H%EC4V=>*.EWUAV"]!N;W<<3NY#$0BG]TR-TJH/#^5EL4U+!'I;WDI&
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M%VGE?J-D;3'FB89.N?4L*H7/2;8M5J]._Z"*/ :C>U.Q7ZIT8A4D+ FNS,7
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MT[3'MZ/@XRJ;$:R,A#ZWA1NBV9!7RVIX:;4-L*],O=W6H+1S%FUG+]6V]8Y
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M<,7)UI^=@FUF@&.; 21LX1)L5)A.B@M5.<'J..:X57MF"\ J4Z5JWVJANU%
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ML]0KT$HM]2U[=OC=42-C>S+P1GBD/J8+34K<42)4,]HDCX^OL\CD)U-2]='
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M)R5MH"J4_N?6\=XZ+>?X#63U+$FS-3X)S%^BK?#;">QO*2+E''YDM#56S\0
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MU&DW$?+2DBF10PSPXV-&"I-U4Y-K7;$QW!73!VJE*8OC3&R0F>@-!V6[$&6
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MX!155-V9+=;!$/;V%P/N^=VJ92<1PM[^BA-2,=N6]Q]OT2]02P,$%     @
M<G2R2F%I :., P  6QL   \   !X;"]W;W)K8F]O:RYX;6S%F5USHC 4AO]*
MAIMM;U8A:C^F=@8!NYE5< UTMI<(L3(%X@1J=__]!ARGL:5G]B9Z(Y^&9Y+A
M?7+"W1L7+RO.7]"?(B^KL;&IZ^UMKU<E&U;$U7>^9:6\LN:BB&MY*)Y[U5:P
M.*TVC-5%WK/Z_5&OB+/2N+\[M+40O?N[9N<Q8V_5^_GF$,5)G>U8&*_&1M^0
M]_64&]M&#]L]T:WX'R:^7F<)<WGR6K"RWD,)EL=UQLMJDVTK Y5QP<:&&SC1
MW/-#9/LNDEL2/B'B3X/EW Y)X!NH?31)QX8I]^NXEO_9956VRIF!Q&TF+PB2
MF@VX/D@G\%W/IYZ+Y!X-9L2U0WDPL6>V[WA(@;0 2.N<D%B!Q  DU@L9^7;D
MDG /^1E7@1P D(-S0@X5R"$ .3PGY$B!' &0([V0DX@2WZ,4N1YUEF3QX96^
M LBN])+1:#ZWET\HF")*'GPR)8[=I)#C!)%,(07R&H"\U@OI$BJ'-"1^) <W
M6'C+-A.I G<#P-UHAO,FH1K/?2B?^]JS3_;2@^<[Q%.[QP2EH=D:Q'>"N8="
M^_<Q$^0(4[,D:!@X/W\$,]=;TF_(^Q5)WZILD!I,S6Z8VF2)'NU9I&K A#Q@
M:A9!VUORQ?OXUIE0[IN:@Y]&$RH'KIDS>8_R]P@,RGI3<]B#D6I>J9A0\)N:
MD_^+4$47<@J<LTK%A*+?U)W],EX/3)<J%!3YIN;,[XJ/+D@+DH&E60;O.=*)
M!BG!TJR$HT#II ,+",URZ)JMH0N7U7&6'U-"FK T:P*,&6N@8D+NL'2[ \14
MBP@+LHFEW280IEI&6)!;+,UN^3*TEVS'RE<5$W*+I=LM;6A3V5+ZFC/$U\AE
MJ_KR\!*IF)!;K).X178=SW=9^8QF6<E07*8H9*) ,Q43LHUU@@H#73B\W#%1
M-\]&"\&+K*JX^(M\KJYH0+[!IRP^.O,20\[!)RQ#NND@Y^ S%"3-F!<%+Q&M
M54QPV4JW="!,K$H'0]+!IRA8/F$N!%LS(5BJ8D+2P;JE V%B53H8D@[67=!\
M,>A-'E794?Y TL&ZE[+ WKQ6,2'I8,W24:?E72D$F0:?HJYYGY?3FB<O*-BV
M]TE[J\O2D&D&FDW3B6EOMX(EF;Q;Q82,,]!=Y7Q<H>@<\ &DG4&KG=[A^U/*
MUG**DOJR^4J>3^(\60C4;/8K:H-A4Q:O7_/<D>>"<L;C]HM1T\;A8]?]/U!+
M P04    " !R=+)*Y2$PY+ !   #&@  &@   'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QSQ=G!3L) $,;Q5R%] )>961$->/+B57V!IBR44-JFNT9]>VLO
ME@3Z>2"?EY(&,O,_-+]LRNHE5'G:-W4L]VV<?1ZK.JZS,J7VP;E8E.&8QYNF
M#77_S;;ICGGJ;[N=:_/BD.^"T_E\X;KQC.QQ-9XY>]ZLL^YY(]GL+>]V(:TS
M]UFYCZ8[Q#*$%-WP(3?]@OXG7VWXR_IFN]T7X:DIWH^A3F<J?A=D[GR03@<I
M/<BF@XP>Y*>#/#WH=CKHEAZTF Y:T(/NIH/NZ$'+Z: E/>A^.NB>'B1S(..<
MGX2PYFLM@&OA>RT ;.&++8!LX9LM &WAJRV ;>&[+0!NX<LM@&[AVRT ;^'K
MK4!OY>NM0&_]A[,V.FSS]5:@M_+U5J"W\O56H+?R]5:@M_+U5J"W\O56H+?R
M]5:@M_+U-J"W\?4VH+?Q]3:@M_W#NQ+TLH2OMP&]C:^W ;V-K[<!O8VOMP&]
MC:^W ;V-K[<!O8VOMP=Z>[[>'NCM^7I[H+?GZ^U'>L<R[\+F-77[>A>O77(R
M_&+-".Z8OJIP_8QAZL7](Z53OR6XX7KU)V68^A/A3O[S>?P&4$L#!!0    (
M ')TLDHPE#3!KP$  $ :   3    6T-O;G1E;G1?5'EP97-=+GAM;,V9WV["
M(!2'7\7T=K$(=.Y/U)MMMYO)]@*L/;6-;2& 3M]^M.J2F2YQ49/?32D<..>#
MDN^FDX^M(3?8U%7CIE'AO7EDS*4%U<K%VE 3(KFVM?*A:Q?,J'2I%L3$:#1F
MJ6X\-7[HVQS1;/),N5I5?O"T&V]33R-E3%6FRI>Z8>LF.THZW">,+57='%>4
MQMV$"='@91.RN# VC4+41>R$"L<+VWY8][8F:\N,_H6F\[Q,*=/IJ@Y+8F<L
MJ<P51+ZN8E<H2]F[MV6SV//.E?6OJ@Z)V:9BOR;$U^/PVXKZ ;K()2O[<"VH
MKU07V#WY604/MR'5EH;&AJCU9<_V M(\1!UK)UYRB]1>G8RRDXJ'U-?[L%_:
M+KOWO@/_"3K6->>=^N4X! B'!.%(0#AN03C&(!QW(!SW(!P/(!Q\A *"8E2.
MHE2.XE2.(E6.8E6.HE6.XE6.(E:.8E:!8E:!8E:!8E:!8E:!8E:!8E:!8E:!
M8E:!8E:!8E:)8E:)8E:)8E:)8E:)8E:)8E:)8E:)8E:)8E:)8M8$Q:P)BEF3
M*YJU:^-:E<U?))]:+P_U6??C:/8-4$L! A0#%     @ <G2R2A\CSP/
M$P(   L              ( !     %]R96QS+RYR96QS4$L! A0#%     @
M<G2R2F;S"V""    L0   !               ( !Z0   &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " !R=+)*M;\C:O     K @  $0
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M965T-"YX;6Q02P$"% ,4    " !R=+)*8$2=/WL$  #3%@  &
M    @ $H%@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
M<G2R2GGP:6R[ 0  U ,  !@              ( !V1H  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ')TLDI2>5CEL $  -(#   8
M          "  <H<  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " !R=+)*^:7)#[,!  #2 P  &               @ &P'@  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ <G2R2A/' S2U 0  T@,
M !@              ( !F2   'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( ')TLDJ@-,Z,M0$  -(#   9              "  80B  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ <G2R2FP4^#2S
M 0  T@,  !D              ( !<"0  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " !R=+)*+\H\U+0!  #2 P  &0
M@ %:)@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( ')T
MLDH8VPN7M0$  -(#   9              "  44H  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ <G2R2J"1+\RS 0  T@,  !D
M         ( !,2H  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " !R=+)*,$^#0+0!  #2 P  &0              @ $;+   >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ')TLDH_Y)FJM@$  -(#
M   9              "  08N  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ <G2R2L3G<48P @  ; <  !D              ( !\R\
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !R=+)*)J8,
M,[(!  #2 P  &0              @ %:,@  >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( ')TLDHOUJ0AMP$  -(#   9
M  "  4,T  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
M<G2R2NAL@X"W 0  T@,  !D              ( !,38  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " !R=+)*LCFS2;8!  #2 P  &0
M            @ $?.   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( ')TLDI=Y[KEMP$  -(#   9              "  0PZ  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ <G2R2AHDX(') @
M)@L  !D              ( !^CL  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " !R=+)*@W3DDB<#  !6#0  &0              @ 'Z
M/@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( ')TLDH#
M%$]'V0$  &0$   9              "  5A"  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ <G2R2@+1VX\< @  7@8  !D
M     ( !:$0  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ')TLDIX%FA:J0,  %83   9              "
M 3]4  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ <G2R
M2IKHOOC9 0  7@0  !D              ( !'U@  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " !R=+)*$;TR W$'  !8+0  &0
M        @ $O6@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( ')TLDI.:@)IG0,  *(1   9              "  ==A  !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ <G2R2A#H"[S\ @  2PP
M !D              ( !JV4  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " !R=+)*%UAJBMT"  #%"P  &0              @ '>:
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( ')TLDI^5WA1
MJ0,  &$1   9              "  ?)K  !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ <G2R2I6E'W"G 0  F0,  !D
M ( !TF\  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !R
M=+)*5 ^5"%4#  "7#@  &0              @ &P<0  >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( ')TLDIM>#C/N@(  (D)   9
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M  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( ')TLDK1:">X:0(
M ,D-   -              "  7KS  !X;"]S='EL97,N>&UL4$L! A0#%
M  @ <G2R2F%I :., P  6QL   \              ( !#O8  'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( ')TLDKE(3#DL $   ,:   :
M  "  <?Y  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M ')TLDHPE#3!KP$  $ :   3              "  :_[  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     S #, UPT  (_]      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>178</ContextCount>
  <ElementCount>237</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - DOCUMENT AND ENTITY INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/DocumentAndEntityInformation</Role>
      <ShortName>DOCUMENT AND ENTITY INFORMATION</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005001 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICALS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsParentheticals</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICALS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - BUSINESS DESCRIPTION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/BusinessDescription</Role>
      <ShortName>BUSINESS DESCRIPTION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - DISCONTINUED OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/DiscontinuedOperations</Role>
      <ShortName>DISCONTINUED OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/Contingencies</Role>
      <ShortName>CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - FAIR VALUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/FairValue</Role>
      <ShortName>FAIR VALUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - STOCK OPTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/StockOptions</Role>
      <ShortName>STOCK OPTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - DISCONTINUED OPERATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>DISCONTINUED OPERATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/DiscontinuedOperations</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/DebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/Debt</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/StockholdersEquity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - FAIR VALUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/FairValueTables</Role>
      <ShortName>FAIR VALUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/FairValue</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - STOCK OPTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/StockOptionsTables</Role>
      <ShortName>STOCK OPTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/StockOptions</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - BUSINESS DESCRIPTION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/BusinessDescriptionDetails</Role>
      <ShortName>BUSINESS DESCRIPTION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/BusinessDescription</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesNarrativesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - DISCONTINUED OPERATIONS (Revenues and Net Income (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/DiscontinuedOperationsRevenuesAndNetIncomeLossDetails</Role>
      <ShortName>DISCONTINUED OPERATIONS (Revenues and Net Income (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/DiscontinuedOperationsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - DEBT (Schedule of Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/DebtScheduleOfDebtDetails</Role>
      <ShortName>DEBT (Schedule of Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/DebtTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - DEBT (Revolving Line and Term Loan) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/DebtRevolvingLineAndTermLoanDetails</Role>
      <ShortName>DEBT (Revolving Line and Term Loan) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/DebtTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - DEBT (Convertible Promissory Notes) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.transgenomic.com/role/DebtConvertiblePromissoryNotesDetails</Role>
      <ShortName>DEBT (Convertible Promissory Notes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/DebtTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/ContingenciesDetails</Role>
      <ShortName>CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/Contingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2409401 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/StockholdersEquityCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Common Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/StockholdersEquityTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/StockholdersEquityCommonStockWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/StockholdersEquityTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Series A) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesADetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Preferred Stock Series A) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/StockholdersEquityTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Series B) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesBDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Preferred Stock Series B) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/StockholdersEquityTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - STOCKHOLDERS' EQUITY (Conversion of Preferred Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/StockholdersEquityConversionOfPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Conversion of Preferred Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/StockholdersEquityTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2410407 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Dividends) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/StockholdersEquityPreferredStockDividendsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Preferred Stock Dividends) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/StockholdersEquityTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - FAIR VALUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/FairValueDetails</Role>
      <ShortName>FAIR VALUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/FairValueTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - STOCK OPTIONS (Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/StockOptionsStockOptionsDetails</Role>
      <ShortName>STOCK OPTIONS (Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/StockOptionsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - STOCK OPTIONS (Stock Appreciation Rights) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/StockOptionsStockAppreciationRightsDetails</Role>
      <ShortName>STOCK OPTIONS (Stock Appreciation Rights) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/StockOptionsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="tbio-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2414401 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.transgenomic.com/role/SubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.transgenomic.com/role/SubsequentEvents</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tbio-20170331.xml</File>
    <File>tbio-20170331.xsd</File>
    <File>tbio-20170331_cal.xml</File>
    <File>tbio-20170331_def.xml</File>
    <File>tbio-20170331_lab.xml</File>
    <File>tbio-20170331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>58
<FILENAME>0001043961-17-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001043961-17-000009-xbrl.zip
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M4I2>,!<B>&&(-"*)U%A,+:"#*E$*=8R2W). / ,= ZAD.,,:0(L/GD8"8%R
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M[<,2(</U+"^<-OV2];)1IVV&P];#$$0 EFITW1_<Y3_#PVD_@JFH3 U?T$7
M#O;)6MAY$HPYF'3CL97&1Z\)4HJ5%W3AS*2IU3K \LOS\E<N/Z>",84,\B$
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M:RH!L2$$6<A3S@57E@A&G:?P>X4L9M7*1 FODMX:.<T%.[L( [_N 49K=;_
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MJG;%D=Z1S"]9.^M\RS-[V6@GF:+(B%36B]2))$BO**8R.L.DTX;@TBT<,JW
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M1(-,AH!@C2E%I5,;8*[@U\KZN8*,=;8J1N0CAD]V6G,+?I4D(P6AO3&VJI0
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M@\<7']M-XTI[6;\R8G[@WK]>/H]_[Z9U>O"1:M,I2NJR;:TV3-G 45!&P3_
M#&NFP!WZ0I9BWG]7+XAQ%^Y/0GP$;Q0?@'\L0.-"8!"B ,@4@)E *3W":0#;
M*O'AMP2?N 3_W@(C.!ZFDM/.:#Q)4\V>OQ]TNB ^M/%2K()X5T-T9ZCB'F(J
M ^%)2!X58F IZ2KQL;=+^_B%B0\<2BZW),%/O8IB[L+9O(DB)>Z%\8*#)$T*
M>8*A$L*=5-2]6@>%>+E"C-G7P707;U9# L)C$N+ZH "D"8M"\$G_"#%8$;U*
M@N0M82]7@EMX$:H<1%(!(8I2=U:66C1@(:T/R',6XTOU(G6D1W"-/9PNWUL:
MG!.6<\N%38)TR0AJ+KE9V0;_9?N1!1G^_E=%P^2"$B(74X>02)$"%,BUA7#8
M<F]TQ)846Z^<@@SK%A4_[^5=ZJQPDCN5!K!A0Y0,V$+4Y3BE0A23;8M.G-#C
MD_O17/1HJG"ET 0!L6BM$9%[PF&_*,LA7A0Z&D?3,*O5\S;29>MC7*Q&KF$4
MAI)P</MI5K3&8(7S]LHDS:IE3AAE'#XM2W(4TRP+D-6;".!*<!PU5\X9Q2(Q
MDCC$(\A[I8"/3@L//@W!!1T!VQLN4.KTQ)U7*%V,141*H=7*B(F\I>0U2&ZO
M):=:((:19]XJ%PV2)*:9;=(($B-S<N7(K*,4/IVTEF%)^+31&SEKKERD#']$
M\/\ U&0*]!$#A\0(DYHBC%8:5O)6'U>L^FY^FRD)< N\^R0!:L>\PT9Y1#B7
MCNC4XTY;QQGL?^+-2@'BM_*XP-:[>:^$A6+>O=PHAHB :,:9 K!#"#9.*R$%
M%ZGPV7B[&I_2XXI/%T367'N)_3AXGL;7F*"M$H$+0)Q"2NTPQLA8#Z'N:@>O
MCU5-]W'=J(#-!4;<8D<U\QPPIW;<81)2C^S @E@3P!Y9-K1F>\P#C6KVR&#8
MZEQ;YHQGCJ0:8A(9YMYX:E?:S,F(P:,5ZYZD%16 '$DX5A ,(*PB"R$2+P53
M5N+XK-):/;DKM-JWR\^>JN5T*B 3L348AS3H2A,2DO_B&GE/Y6* /BMMK&$T
MMY'<RUV&G:QR5-'Y$"27%L."1$NM==18"GA"B26K_%AX^S;UC12;T,.!%J6X
MSXXXY[5F6F*0L"],%"@8'E)Y#5+6$>*CI(3BRE7  FNY*?"J+[?7L01UKR>N
M@3%6$DR14=(J+EFTTC@: C$Z<FUT99]5E:;9;4KM'-%2'5L^35 :+(7@QDJ.
MO;-*,XQ(RNL*:I;NR,U$GBZH01!T]")_KE2%Q(;(Z(621G$7TCT*0L#^N$@8
M8<A4:3'24FR$XL<ATF?(78 %B"P:@R4+G IM/9@)[+P2RF*M9)5$"2;B1)24
M_T9_'7<?Y'&8\37A$(F2(Y%N#1&>2CPY0A"?.P\F)"K)3]B3/C>^W,)B2Z2T
M!0>)M1$\2F&]QP(@C0)(P\12+_?'59"2:K([J#S\*B!Q')MA/TL8C<**68$#
MP9QBHP6-,94#P@HB$JLNH1T<YWP:CX:C5B]=NMA8GU\XU8^>TY0W%<* N>!I
MUC!AZ?*,=H;**DA!*64(;SH!72#IR>0?O%R6>NN"U30U6>3>&&V=T9@*$M+X
M.EL)M'BAZOC$A+*Y"!:X=X9$'TT$J6BG@PX$:>=PNB^W=-G]<2,(@*>;3G2>
M1RA-U+5Z9[C2:9*=A!\(AEWDA<$888<X%E4SZZED8O%ZZFE(9,M25>U=D$++
M&+CATDB-K8XT*.*5@OBEJDTNH&Y&-Z6WCDXNVU2?TH"=T,)BA2G':5"$) H)
MIQ'L*^6J,GX2,ZF.TZ8T4U"JK0Z.!9?,"5>IKCX"7.(!C"]$8:@J5F L35P[
M69G4*A-52J)@G2:2,\Z<-0P)B1Q./0"T#)7[IQ9V/V:YU"C])$Y1*Y$D--F5
MO%DAPA);B-I].CM;,]KG,&)9S!D]SOBS#[..*0_Y)U;GC1Z?V7!EE^H@ R7
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M>W3PKX4*CYB:ER9 JS>YQ>>QAK"JMN5ZJ@VJ"Y2NI8S!AQCJ,D*7MN60NR#
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M8(89ZV8-%O#E;2JQ""7Q6.,G3;/&5<-N9H0+<JR)="<+J/9+#PKGD+!YR*;
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MHAM>I-%T"^IE 9QN7U?7U1H+<N*R^(;17CVIUOH(&F4:M<=_]A-4%G67E=)
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M\2;'/?5[^(:GGTO$?:HTK1#OC$LJKF[W0[#-3_AF?+>3'\5KP!N(&"%/ZVS
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MWV4_'.I>P'MME2R"74];/,&2ZKG+0F2?0CPJ6I%@_Y956B2FT/U)6#5)( 9
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M=>L5 CX_W(+5!32..] =6(?0>-ZE^*%>/-&:NRO]']0^W "F+"R@2?)'D?I
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M[_0+K2,35>\)5L>I;CH)G8W_57@)YD5'6'L[> DM4$C/PSG:!)E4WE)]J)U
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MQ(E6OUNUI\\PC&UU7RI::#T7]_$Z,E4Q=BZ4='5BG&@,H(A@DRNB'=05K<(
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MOSLD:=_N=-3SNO%LBTR#M^A\'G3.YS;)CQ9M7..P>/0*-ZVCME92V^DZ\GR
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M-,#&[7'A! 1^?QMB-"F\1Z)'H.FY'HB[GH'..R*M8X$%)'[@Y)W@D+;#29%
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MBB 2@!,%<\#Q7(X?<[]1]EJ6.Y+@[@?L7IU#-MOY0\$+!(<BZDZ9U1LR5[^
M&Y[&64JHS6MR\;H,O/85M]C4//$Y6WH!J5Y[ <_D?AQ<&J5=B90)W#V7@PGC
M7M9.6V.D(!$FH,BCR$H^%)?.,X1PW;&@;?%VS+,2.7YA'M4;X!ZW) JE'"4P
MDJX0?5%8FXM1HBQ^WBN6W"*$^IWEOK6UR,!69L]W/]MNWN<COR@>,V$?V#5C
MHUH452A@2%$?568]>ZNU[90_0<=$'PB#4HV?+.O;K"E=EA7=H.*O;]E>+#7M
MG92ZQ7XG/:#V)9LHDD#*\YQC)\?]@6G\(JZN;G "M9F)!=DK16H7_+9K5O"$
M[HWA+V2I'C1,069@,BYCLM8=%H7BMV056G5\&(2J!!&O9O46Q8/D8N&S4 KT
M"MT@BY86?1OX)@F./*FD:FU>7!)12O&\N""=I$P2*=A\(86G'Y-6TYYQ6115
M7IP+J8K)K5+T&C'^/%XUYBL"!>/RO2I*H5PH\!Y!H,XPP89OO"@+!K]$)P!.
M&D60ZXE]R>6)4&6TM9B]ZE.EP;Q&)LXP%U&\6DZ^<O$0"C4/?5Y4=DYDI(N\
MY:P.6(7,0E**XPV1)3Z3[9M45$C#&R*LP1IAWP7-H9M_%Q8&B*5>"#2.#;HK
M6/SET==P[3G&B35]_\&X7B&)" 8"572Y6OOA V/<1R(N&7X68:@<_U50:@Q'
MY2--QJ"E[OB5A)CC+B5?7ZEHB$=,/BOZ$G=8R("7ZJHRA7M!DD3I=>&A2M"!
M9M(1IQA_PU\0HV)[' ["<E%AXIL+T.5I)$2+E#Z2T#G0R@B&7"6*HBLBU'U*
M$%'9^5S4<I1RH40' NZ(3D2Y:6NIY4@W>"E;D!LR[H@FIK*Q.!;FF_HEYZ"8
M1"%YHZ9^;B5^.!PN/'C_,HB1TW0)7\II@0N4"F%2?.38&K_4ZU!CA&N*PYZ7
M6'=AR)J85!@.37UO+< )_4:(LPKRT[,N/<NJ.XR\-"O'8ZY'WDH,'F6JG95%
M;EF\+3(P0%(M4O=(R.#,VJP1@@CK.,(EV\>W(R#B@JV(KE^D^#PJD;W-*2[N
MU9+<(S*U3DHJDFXL*QK(*O:U,A@+2.:#JR;:'/8:=%G]+'/D42DDB^94)Q!;
MM(#K0I^^D\<%X<EQ'[3G&0)PO%D(NF^.7,B#QQQ23?MC@%3G.2L@^URPA9>;
M2W8V KI/<J6-HP,W*3H8W4TQ%L/G#BO$5635*#;]_2WCW@@UL)<7CA= 27BZ
M !$HE2QASKS#"!"E[<?O:6ZBWF-DS,4<55MP1[3S5,[<&1D5<4^&4$HL*O?R
M,<Y$MXX^SJQH3[53?ZE"1ZK*7HX7F:W[E*94T\EP:LU&@]EL<#KNGYZ=70VO
MSD[/+J87%Q?CB_.KO;5AY*F?FU>I-'(S_;C9N.KKI_/_^<>G7RXNO]PH^-2X
MN+RZ/K_^^F(_SQX6UJRC:E\GLPF/SGD0D.C]Y3&D@SV(?2N\SRE>N@H2>=D5
M3%BPVD]%_V@4?%\803V7\#,'B^3SO@8+.UJ+^J F*1+^%B6CYIX;+95T=BU.
M:HW[)CR!_U]WI+H0I;934$41I5P1B,3,!M""'5+;VP(^Y4AM8N9E1]!_&%&R
M*P7FE*XMG^7]]--EQ+CELM&PY?-I(4))R$J:1(";8&"/][[ R]\AX)KR"-0*
M^EK^61W,Q OR&:M1$-)$R"$7,546$8/"DC9:<413-$<H_SZ[?2^R)=+-J55V
MJR[.$*]:+F%WEK+&>5Z+'QA9"T/],-!=GQQ+1@4(W,H+_@U_6SC/8A^I(_O]
MQHKUI&28P\G8'(STEB\H+^_TV,+6E"*7DQRSQ=6*[)H;1IFO^/@YY3 E5+%0
M>94DVM;ARV3B&D?S]WE^5"47R'[CA3FI=2)XH:]&3L R3TZ&YFPP:SI=B1?>
MX3F]=/LB3RS3PRY6;ZJWVCS92\L(4Z;R](B6LG9V=4'7_/K:10^O!8^-<9@;
MM_AV N7+L3GF"B1)H;&9Q"ZBK8\0"@+F8**!X&.,43JW!DI5JJ14KZ0P^&?G
M?)Y57]2U,S--@A53!G$YG">JY"D/0BI2DV#%ENQ%7'DN"R(ATZQC (G'EJSM
MI*:2XA->K!;>6Z01N6_RAH:(K6/LZ1G"7V01HA(:OV#89"GSX^XF].6$\#@W
MV]U%+$&\@*,E61(0RW^X8#[60&(5*&8362GSJ9VXJBFXOU7<Z<U;YJ*58<Q9
MP&  D8LBMW+!L%=+,>7L[/RJF+%&Y>(#5FB7Z,4Y#U!A'Y3@'&3!^]K228%P
M1YH;AV3.,R)@X262YU2D9[K31<G70&*"HCFU/O!^%WD=&54HJ-] CU6$UK7_
M4*SP9QMTG06O!"8AFO0P2#NW3*:O$XT6@B%>7$U6*HOD"U[:V.9#[1!%K7$H
M<$+EWGN&:EA3.B$6:\UX:!=VX&']K:<JI!1Y-?-T036;D;X.YYSG]M]1*S6;
M%ZM6B^7R*R& !^:B2>;\P5BE?N*M?71;?S".O/<\T2,;"]L+LFWRD.0EW\'-
MV6-;E7DF7PO9>'RKL^1#ZG>"$Q?9_3%U;X7Y'7DP)RVDH4VMF$84IN0]<</[
M($^/QCU*Q([Q'13WLD"L,Q-;?T>:;"RKUS\9#R;:P6])HA2)+K]]7"(_3 S%
MHZ,$5)&"/-%UV=9$A\]XJ.F^Q%8>8Y%*JD38;5S#MF)WITFI.*&IMJ+7LQIK
M9)[T7YP;P-=2>1#*7:&&V@4=GG=M,&N@-6W!BA?U$5<KYGK<'20N7.47NB1F
M,&6 #56>-MR_\.ZT%D?,BKS;0:F&O$[C?:#IPE1^NZF2L<DR4\\KOWLW#]&'
M*3L=*M@8?T?5<.7J%:0LP;1(L*6[6+S=M439]R@W0 'G$$5*S\(T4,5G[Y:-
M@JR']A<D].+5:2QP&!$ZI=3_/,NT,#SOVI[CD2U(I !U_DQ#?KE9Q3H$8K-2
MX!73/"5_B;I-8@,P%HLOSCWW\5X#,<,$>HS.\PN5-M;[\# #.LR+=6ZLE.H!
M\WFX]1OY&3]>-*-^HRY$Y?%B\PFK1&Q,KF5B<]LX\VU8SHV#4"86-S5IW;B>
M5>@R/W=3Y[Z]T@=$>R2EDF5)WHA[(KHX<:2'$84U8JH6NV*IBS.D BE*?C+V
M.CY>8%L>NJ3S%6_RIP#WR/Q?^"GV<TCHFFIRCU<?U:*MJG]F<YOD/E=2#?=?
M9'13)2>R5/!LKAO<1'\16%UDPFQ<X,47B^R,5$-=#?-TLZTCYP&,]3;+29V\
M"31$$DS>A5E'[,X+TQ@[GDO&CO,$"A[/ /.>1(O\-\5+4-]]M&/7_E.XPW_E
MUX1_^>4<IT'+-GAF;6;R;1$V&\[T_*T*1WUYP:6-+ _VA8D&8Z=B"7&1XZ^$
MX"P-(X_+Y3VY]=5 GVD*M8(DC&O<$)6T;QK>HG -*CMS<1U+O+2Y7^2^D (F
MDG_&V(3]L"EZ)?'(7IZ&S(]<B(W>.%U.V!@%MP.<&"<?=#?)?N:;<RK>S2\)
MRP[H[@_H2O^KD(QTEN:&8-^_TO>::%XPUL.[9I%H"89D#.9BM%UV,<A@6.M6
M0.5WJ*0:YV8I]ZDF1;VH5]@63JBX!=OE3/@$4?,41QT%MENVO8";@C3^'GS#
MW83S]R4TNI/-(-#.EI,2!H#,/_5$:^;,Y.'QH!)CM)4'"OY(KTYY$J:4I&=N
M55L:+6ES-)R8T^E #S4>B?P;F[*%T?,\#^]PT?'^</VC^.9)V/X]%\$K^YNW
M2E>[DS>Y;QX!H.+&1X/VV<"<G@S-DXD>OR%YFJ481THV>5?(;P"3?692\;05
MY:('AT*QYIY$9XFJD"&TY3/H.5RN4^5EAMV5:BS*X@7%C"/=.3 GUM0<C31Y
M_6K02.T*6\B+0O[T#*7-'C6RY G&Y8:LN@)#EMGO3\R1I2D&5NVA8@5601&C
M:>X3:V@.QXUW/\H+=;@Z4]8 CVA.63NMZJNU4;XWOPK?SG7(:EEV,5T*9:Q:
MHS<DZU/DSQ<J9N1E#%QL>.<6"QH4ZOIV#H.F' ;7E D>1K),CLB7*J9W?#XE
M-24N1'"\*//(9>Y')KWWEA-K32QS=J()0F\1*XH;5EA08":EL5S98@$$+5:F
M],TMY1"&HEH5;SX^WO""?I+UFL0VEE*48W466<5?/@_!1W3)A= ]WA"T<'KG
M@NN^T OXX!46:I\>_\^/<*+E%+G+\\U94F)D?A.F[ <6!%$Q9Y&$6'Q K;!3
M7C#1C>*CXJD+I?>+!@W!0GLEJ564M10M?''/*FT0D20@S$*]<<62I:%&%3=,
MF)W-E5)>4_W^E]&_,E.E#V=FX>X>^=(;O)J-@'=GNIJIOL3 35X2N-J@[;)Y
M6T&\2NRJBCV\N)"&0)7D]+4/WY_$%!8V%@1,LI#&SN$,+I)$]4YYDJ6M(ILX
M_T;5=@N7EF3;N/*APXT=E5;28/2H9F.K T@DD^LIHS*2E&8Q_?*G5-$H/)$B
M2/N4Z-,C8K(#ETU&HS;$I!^'Q3#]_J)1VR1R%Y!J> 4-!*00GPK?IRCN4R_F
MWN\2O=I9U'4!K!>PFKX85LUY<;OHK4>O'E%[^CQD.@']=XUE:87X>PAAE3^O
MU4ZS,-IC#F?[#V(=).$V&=)Z#+<<8DRK1G3O):HU.NF;XYFF8,J6J%;-&EO(
MGC*NU9E"S57B*U_5I=HN2"IT^:K@:$<;J53ZY0M;>G'"*P1Q+1#GI5],@P=-
M-JNO2.]NT1W]R'W.1[YU+VY8J9R-SN2B+QE[)BC#Y 4VJ:\%_@58 74 T)WM
ML\<\!\5N2\I%Z6VWW*3"WGG<<A)X=09+F:\!;V;E:+("QK\SX6$G-"*WJF9/
M-KSPY>$ZQFR(,<\CVUL>_\/V?0!IY:C,9^QSPJN"+UDQP$$M4_@E7Z(PO >[
MSA['?G5)YA"KK%5$B(A*^+BB_B(O%"X[L41(8U'^A=)<) :L')MX],AZS^]Q
M"Q8O#T"J%GD!6( B)IDIU$2A)&NDKXR9:>A*3CCI]?^B-:>"EZ+)*JC(GI6/
MG!;O#<;A[T/%V^)2!]:R$R7 'DRZS"%2]C$\@?))QB)CL*,&[TO&<NG\37'=
M3/,E07W^HI9=M#RF/)_[VBBW'E37/S'' TVF]*.%70[IHNC&'2228971\BS4
MN2567!4<!BYD:\6%4/@$E<S@'8V4B\)!XOD\9"Y+Q2!&R.KV8A%;VPLJ3'C>
M,N]H^!Z8W%O- 8T)I%"6TAPAB4ZY#*^+'X>+XS4<(N/=E8*8%;I'++ %S1:Y
M+_>*&AGX8&!A?9 41O%IE#3BH+.BLDR]LJ$-EPNA><J9&2Y,A&\;RC1M0D:;
M+GD^LNI@5"G44TD=&6B674^P$"/V17.<*!4U6=. Z%66W8FE@R3++2I7]\.7
MQ!_/-OXH^&T1\NOZCTC!K*J5+M&GJU3KUCORU!XJC>D6,T5/%<EX?%XPCDK;
M4[CO36UD<S..#!69_T%URQ6'J')5M#"3K&RB$#=*A9_L3P*(B)-1&W8--E,X
MI8HEJ["B%N, /?=W>&J99"MF'E%NQ:9N@Y$P<"SGY&)),/*7:W/^CWI#34XE
MI?VK8)_Z_*%*PS7?^D NDT"DEND-3&LZ-:T333A%U_X/S<%P9DXUP:<7-/KK
M-(/RWB=>)BE/:;YGBF%B&W<@\<.HF231DVD3I;.K$L]Y\>,T8 8VI*U<J'#W
M-[G>R<BTFD^T[QDW&%>MJ27.*^L4+$^^9(K(^AY+29NHR^=YEYF3OPGWPW2F
MCQ+">S4'F!=S$RLL>'"4E%V0YXA'^'OJ&^0GE+N5>RHW-Z[0_@2D_0HL%9+H
M!8]BGDJEE H_=6A;K=EPJ!:VKZAJJ;Y2M*E@!A'S/=GRB$=<<1(T'Y'/0ZN[
M$4;#Z,A^CTZ(K$9@83[ ,C_"7GUA2^HF"\]?4%OBU%_R*H88_!8U5:B!2N'S
ML0>G9$?J%,2SO(\CJD5RKAJ^?2^:JH02D(H)5>^T-%>\X"[TJ>S3.IW#D-GK
M/",V"&6M./3\ 6"2;=RQT"G5)XV%8Q?V>V6[K,ZBVFE671W^O=;A1RE^4EN$
M/\"Z<W@XHJ9*9NC4%^(__?IK_M>"$YDW!5=<T,2@B'QC[D.NJ+./4\(J,T0Z
M1(U@NX/Q3M* BI\B]<!_,20=A>FR_ 6-_JH?AN989W^*'-YN"*?:BO"EHH#!
M0U9:#S=(F)A4WEG8'QG/R7P)(7_7I>8A>0.H^);YB[K8C;Q6<7,\-(ZN, Z&
M%S"&P^$Q4-"L?_(^P_"R1.M:-+--"SH"#!*0:9BQFWU7W!T00:',;K*&IFA[
MCL22@LRCF7#Y:ZO#YW_,0H0%ZI;YN!5W0=3=^)+"JD:#T='\_='X?5-:1K3A
M*ALZ(/>7GLR')Z-021A6.2L[SY+?C^HVB29F,.S/0G!?!W"8*9?'U[VSW@3_
M*$^R"[@U)6'S"FZ%F'/A)/-<3<P8*83H;"7*MF#ZH/.P-Q@W$0KBLEQU0@CQ
ME)7[*B[/H1[?^$+@>&N;G+*RT#H&&X3P1Y&?E6<*2V,HKXOB]?1YGB%LXR:+
MFF<<Q%+/4&4 PJ2T^Y2(D#FHBU]1FVUGWM['',BE4Z9K4WP^RO4OI+Q5D#?R
M%!>[DLB;IS+-IC"5\H41.2WEMJGJ(5<OH=:*,BFSE5_G>6B9J!NIHJZ],B.K
M>GXP4N+KIG#'F W5SR<]YN87\!<AUK@R_@3=F'#-D45B1"2'4!%RGWB?:!(O
MRPA@H"=VAQXQ<SK26JBZ7!7?QJ;C2U80*^@LE""(?(:X57K@7;\WTG1=;+."
M9L"2/-3-P>NM7!@5WM<6+M)_A1^[.0A+D20Q!N$%7*D#)PK! BP'S07G!50K
M6X)RL%11%$![^D]G #XF> ADY@"T[D3W'CBI#GY\UX#'0&/SFO8&/(;F8#(P
M^U--1>WU!3R&,*W!R4235",Z:N',GL8/B$8]@4'54./)R_NP)N'Z@S65;5@;
M 6S\1WR\MI]LEK&B:4&#Z@45Q.Q LYA5ZB=I(1%2J7J(C?2R5,A:AB2MG@,Y
MJ=ZUC$VF<N:US@H[2XXQT56=L8^H\20K)VOK[]84NPM.+I3;4L!3)6HJ!-Y4
M'9OEZVF*@:.CR^IK6G)=8UX>:Z@Y0.XPJQ&.C^Z3YGZ$EMD?6^9$UP75\JI$
MM:D<9@GTA1(_<R)MZ@)M)([W;2QS-&Y.H^V<< >*^O<JNFXDI RL/1R9?4M3
M0N>VH+'2"D=;F[HF1:^.U,'9\Q1I_MK+73MU:EUYI]"'OE]J0X\_JX,&8;2R
M_2+$P&>R@1-"\0[8S>*9O[WKOZ.?X[7MR)\K]N&KMP+:^<CNC2_AR@[*,[_W
MW.3VPVS6&UC3D_%??IIC>[OHV E]WU['[(/\APIV<$7*S*+L7^ARQ/D$?WLW
M>V=$X3W_MY4]^V/BYO^,*D<02^#S&L[^\E-AH/P#E8.6W[=>^/KP^WY^^J97
M_\3//T)0E&#@V+Z@X7F8).%*DCO_Z8.U_D:I":[Q?_KT?S\5F!CQO,JAZL]B
M!/57$7$V_N;192ABH\QG.;].GR?VIM) NN>B9A[Z+A]'9NG_@YPH6V5AY3E5
M;^G^MRR$B2S\\/[#K>>"=/T>88 G[$^K2<ZAO(TFB>X:L5N^J_]B=D=Y'>7M
M@_(NT3#F7:8[@NL(KGF"HZP-*F>UJYVQU^F)[+".%SI>V(?P%96 V\@)O&?F
MC@?]/#O#=OY84E-P-*W#Z,/_<1S&%HOO<.PZV>2?=H2)F)06Z"6IB-AR>V)3
MLCR+$>&].%W7["YLTD];?#,GZX0&.;+>TV1@H.P4=;!T>P[UP&1A>S9NFYQY
M^=8-^M9FK/_P-ZVCME92FQ+XV$RZ./S-ZZCNY51' VC=N=$( YB;%?4.?]LZ
M>FNEE/MA5E4N0B=8/VQ,?IH5M,*(<44!K%>/RSM1T;;].1R4W=%.V_;G\#!S
M1T-MVY]&$?"@IK+:P>Q.1SVO&\^VR#1XB\[G0>=\;I/\:-'&-0Z+1Z]PTSIJ
M:R6UG:XCSP<8/= &A%JT=1W-M1%X#T]&YJ0+=73TMC>H/NI<SZ\!D0\[MW-G
MN.O U]K"GAWMM&U_FJ4=I<:"/L#<$5';]J=1^'MBC<R3:4<];X%ZF@"S@]Y@
M9_]0YW<^/)0[ZOS.;9(?+=JXP\'%+=JT Z$VE XMVK5F2>V".8PJWG5^YT["
M[0UX6X.!.1IV%SLZ&;<7G&[U)IL%M#JG\Z'!\7'G=.ZL]E:!ZXYVMK#T:R.<
M/-&YHL]T1T"O3_@T@'M-:V*9LY/-[@8'LS\'0C^O40!5=[CO_,VOZD+?I/,Y
MMT* M&_C&H?%.]O(![1I!T)M;\H?TP20;M'F'0C)M6_CFH7> +S[@T[$=?3V
M:M#Z88/R0_$Z-P/(.S'1MOTY''C=T<X;<OIT7N>NTG#3T+A_8HX'F]V).NKJ
M5%LK@&Z+;(;#(K5NX[J-ZS:NV[ANX[J-V_?&"1!-C1@W$'1KL&]]H]%V[FI'
MCF]NXQ3(_",U,:UZ_KG^T7ED.#ZSH[^]"\* O?OQ41^GLDVU_=WII$:EDZII
M8%]\!Q_2NMO/6>*3.L66EZC.K-PYUJB;8GW_5MJ1)S8!;:KC)RSQ*5ST6,O?
MPLD76O4^YZ1E)>R7^@]?M,(*^M9)S5]O6<Q*;=GK.WG;@1&*WMW&_:WGW,*;
M,3; 7OLLX:\HM7N'O<W6UT\52!WC'"+C##K&*3&.L8Z\.VQGO_9MAZT8?+"&
M@3XY2<AO3UJC[8W9._YYK?PS[/CGR8I'J=YCC3O&>9N,,^H8Y^F(+?4[IGG+
M3#-^FTP31M[2"VP?J+^>?Y);EC.0RBPFL);+![(!SKGUKRL6T<3X),8R=["?
M)AU#ODV&G+Q-AMS.A=^3C>HVZF3TEX)#TJKQ2&K:.?XC/O[!2^ +#A_I<\1@
M-R)8^$T2.G\8-_ N,.OI]G7OXG6E-0VJUT2_\D#P!<F'X4"SDQ7(PSB'\[2#
M!^[=G@ZLDY]BXRRT(Q=OW%UX$1!(&,5 -8:=)K<@S?\#.Y"$G(R,=(W_WMB!
MYTP&A'V_7]U.Z#G#&?&M'?%[@^OLY&(Z.2#<,$#-9*Q"8(B8#M(T%E&X,A*0
MP+@D_*_)V2).@?1=%L.QV,@L\.@Z!%;"_]+(+'#@0ZBH*&K!_TEO_9G":2Y
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M&4N;F):"=YD)+V(&\%*D*V\<SP?CR'[/8_<RNY]V6#VGIR4A;)ULE3E=2O+
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MY*%YAT/_N#'VW__[KS_B.-X'_-^__W]02P,$%     @ <G2R2C.?BUF&$
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MG5<0V/8Z?]S>F,KHK<\_:9IJ!,1=4R8T;\=X"\3GBM+G[25":PGW?;O;:TO
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M-WR4:YP^X2OYOD]YG!A5(WG&IFSC>7Y+KH$\BHGQ+(]N!5U%=E'Y,Q64[=%
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MB45/D-46C,>=++]Y%^'=&4?'F'^D><(<1A81)X0$'C"L(2NM)F)E_5NASH(
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MQATGU(15)[G>")VWQ/]1AOT,S?9AV%T:7,_G?/XIY%/]$FR9)I8Z1Z-?6^M
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MM-[ TOL/@C4S'MW>!KN.>\.;(C. # 0S91?5?K$8'.J92*2),I Q$4PF[X1
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M(70T68;#BE0^*BZ,.F^PQ$;_*-#YL<TU.!,'?[)?PK7W7/C %H@-1=YZ"PN
MD)5]OLUX4?CZ<))R3&1;@+<OB[I%\%Y2?3:6M_/O3HA@E&%-E.!44D$@\+S
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M)=7J'I[KFE@;-D4,* (46 \U\<26%W&V0>'#GE-:Z\:LM0S0H"+1>]UNA%3
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M=%3IGC!,!=;1_L(*<FP=0JB@/.R((\J9[5! .D!J ']T2<71ESS.=THP])1
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MA)&7[3*Z*2)7FLEG)<#. VJ0I%P(ZSPN)=DVB(X9L"AP8VNO(4K7XGY5W"O
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M.IR8MS:7T$Q!6]^_UUTJ='LRT0-BO5FIZ8_H\"R *1[(-/GJX,LO5;HES"#
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M9R*,M%)(Z"+PQ2#7(.8+C%M.^@-M1&D=^FVD=6AF.9#: 2")= (2Z[VW'BJ
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MJM)=2D%[0M V/+7C,HOW,G>3B"$:NWD<=M"<ZY)PPZ%1#D/.K7#AK"I$*<A
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MNKVM=JW)/EU*DR2*LR!*0BS+)%%.P.&8IP\9-#QRJ6_(M:Z<G!;LP'6CQOC
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M7EFW',/F0O1JK!?/K$J.9T557=!Z+=<XA<Z]K[;ENBR.:2M) Q"',:=1 %
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MSX>[15$K+:4=<7NP<JOYMW+_Y0G&YB'(YJ%+AZW+]KM629RP..1!2B$+&",
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MAL*(AW$4^7$6DH!@C#J3),]!6WB-#+FO]S>[E58]N/JJ6&" 942E8IPU%(O
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MUYM5_2Y/:);S L4^QRS(B1^2@.#.+J6%TJ*I/6N.YZ .HR??!T^@]-82IKS
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MZJ9\J592R9CX!YN?DX2&A!8^2U/&BB ,HI"G'3Z21H%.%CD$+N=YYT6Y7HO
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ML")0OS'-@BW'BMW=Q;IZ@P00&QM<*LCVP#3"U%N":Y-;[ZJ[N[:#Z-V<C%>
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M__YOW9^(_W<_79?_^[_]?U!+ P04    " !R=+)*EZ\4O9]L  !+7@4 %0
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MZ=Z1"]S0U'0B=EUI_OUT]'4ZFZZFZZONWAZB5W!DJKXB(1X'CPTB(@13DLE
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MYPY823 *<EFB3"$5$SJFY 7OW_YA&ZNL6$S/P)233D4/MDLTP)9)* !G$(B
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M%5.864,KEOMH:B43EI%?LTOE1_-@GV>E\[Y"=.F>%@G&E$% %6."46HE(+1
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M&>N5DA (:0&&LAQTT+*8X-H+BLINWKK%8WW6?-SL[FZZ6B?HI<<S)2N^(;'
M6$NMDE@;[3C$BH/2#0T*^#X"N6N[::V@?$Z6_7W^L$PG1>;P"UDJ6;K:[TP8
ME<'-8%(Z!9 )^ !;;-\A)4%,WN4%W1G:)!/;P+TK;EXMLG&:3I8^()>G[XWF
MX_0IH_3(I<3'&R=:8^#R(PCE*;3<(\)D(35F4<=U%W2=:%VV-0[P.?8WGL:
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M(6(&=D[;@.;W<*DA@#NCU,/7Y70R'2T>/X]*DWQL$MO7)F%:680<D'H]\ER
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M,RMH*1-',0N9'F[0-$N26#0[]V2>K^*J>C&OVR0*2<($HMQ!Q(P2@#A8R,B
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M'3K7/%5Z(PS'M3NOL-&.7EG ],4)>A[L$Z9D_/BFL^XS>PR0&RV\T Y$HR.
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M!+;((,!AJG9:(8 U[E+%;(+JHP\JO+X"? B<Q[)Q<;>QCB\ZWQUOM.964[.
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M"@ 1              "  0    !T8FEO+3(P,3<P,S,Q+GAM;%!+ 0(4 Q0
M   ( ')TLDHSGXM9AA    6E   1              "  8#_  !T8FEO+3(P
M,3<P,S,Q+GAS9%!+ 0(4 Q0    ( ')TLDKZ8$B5&Q4  '+B   5
M      "  340 0!T8FEO+3(P,3<P,S,Q7V-A;"YX;6Q02P$"% ,4    " !R
M=+)*<[-BVG!1  #/]@, %0              @ &#)0$ =&)I;RTR,#$W,#,S
M,5]D968N>&UL4$L! A0#%     @ <G2R2K;O)9D.J   89\( !4
M     ( !)G<! '1B:6\M,C Q-S S,S%?;&%B+GAM;%!+ 0(4 Q0    ( ')T
MLDJ7KQ2]GVP  $M>!0 5              "  6<? @!T8FEO+3(P,3<P,S,Q
>7W!R92YX;6Q02P4&      8 !@"* 0  .8P"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
